6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O another/O section/O of/O the/O label/O [/O see/O Warnings/O and/O Precautions/O (/O 5/O )/O ]/O :/O Non/B-AdverseReaction -/I-AdverseReaction infectious/O pneumonitis/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Angioedema/B-AdverseReaction with/O concomitant/O use/O of/O ACE/O inhibitors/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Oral/B-AdverseReaction ulceration/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Renal/B-AdverseReaction failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Impaired/B-AdverseReaction wound/I-AdverseReaction healing/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O the/O adverse/O reaction/O rates/O observed/O can/O not/O be/O directly/O compared/O to/O rates/O in/O other/O trials/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
EXCERPT/O :/O Advanced/O HR+/O BC/O ,/O advanced/O PNET/O ,/O advanced/O RCC/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 30/O %/O )/O include/O stomatitis/B-AdverseReaction ,/O infections/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O edema/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O fever/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O headache/B-AdverseReaction and/O decreased/B-AdverseReaction appetite/I-AdverseReaction ./O
(/O 6.1/O ,/O 6.2/O ,/O 6.3/O )/O Renal/O angiomyolipoma/O with/O TSC/O :/O Most/O common/O adverse/O reaction/O (/O incidence/O 30/O %/O )/O is/O stomatitis/B-AdverseReaction ./O
(/O 6.4/O )/O SEGA/O with/O TSC/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 30/O %/O )/O are/O stomatitis/B-AdverseReaction and/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
(/O 6.5/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Novartis/O Pharmaceuticals/O Corporation/O at/O 1/O -/O 888/O -/O 669/O -/O 6682/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Study/O Experience/O in/O Advanced/O Hormone/O Receptor/O -/O Positive/O ,/O HER2-Negative/O Breast/O Cancer/O The/O efficacy/O and/O safety/O of/O AFINITOR/O (/O 10/O mg/O day/O )/O plus/O exemestane/O (/O 25/O mg/O day/O )/O (/O n=485/O )/O versus/O placebo/O plus/O exemestane/O (/O 25/O mg/O day/O )/O (/O n=239/O )/O was/O evaluated/O in/O a/O randomized/O ,/O controlled/O trial/O in/O patients/O with/O advanced/O or/O metastatic/O hormone/O receptor/O -/O positive/O ,/O HER2-negative/O breast/O cancer/O ./O
The/O median/O age/O of/O patients/O was/O 61/O years/O (/O range/O 28/O -/O 93/O years/O )/O ,/O and/O 75/O %/O were/O Caucasian/O ./O
Safety/O results/O are/O based/O on/O a/O median/O follow/O -/O up/O of/O approximately/O 13/O months/O ./O
The/O most/O common/O adverse/O reactions/O (/O incidence/O 30/O %/O )/O were/O stomatitis/B-AdverseReaction ,/O infections/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O and/O decreased/B-AdverseReaction appetite/I-AdverseReaction ./O
The/O most/O common/O Grade/B-Severity 3/4/I-Severity adverse/O reactions/O (/O incidence/O 2/O %/O )/O were/O stomatitis/B-AdverseReaction ,/O infections/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O pneumonitis/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O incidence/O 50/O %/O )/O were/O hypercholesterolemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O increased/B-AdverseReaction aspartate/I-AdverseReaction transaminase/I-AdverseReaction (/O AST/O )/O ,/O anemia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O increased/B-AdverseReaction alanine/I-AdverseReaction transaminase/I-AdverseReaction (/O ALT/O )/O ,/O and/O hypertriglyceridemia/B-AdverseReaction ./O
The/O most/O common/O Grade/O 3/4/O laboratory/O abnormalities/O (/O incidence/O 3/O %/O )/O were/O lymphopenia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O decreased/B-AdverseReaction potassium/I-AdverseReaction ,/O increased/B-AdverseReaction AST/I-AdverseReaction ,/O increased/B-AdverseReaction ALT/I-AdverseReaction ,/O and/O thrombocytopenia/B-AdverseReaction ./O
Fatal/B-AdverseReaction adverse/O reactions/O occurred/O more/O frequently/O in/O patients/O who/O received/O AFINITOR/O plus/O exemestane/O (/O 2/O %/O )/O compared/O to/O patients/O on/O the/O placebo/O plus/O exemestane/O arm/O (/O 0.4/O %/O )/O ./O
The/O rates/O of/O treatment/O -/O emergent/O adverse/O events/O resulting/O in/O permanent/O discontinuation/O were/O 24/O %/O and/O 5/O %/O for/O the/O AFINITOR/O plus/O exemestane/O and/O placebo/O plus/O exemestane/O treatment/O groups/O ,/O respectively/O ./O
Dose/O adjustments/O (/O interruptions/O or/O reductions/O )/O were/O more/O frequent/O among/O patients/O in/O the/O AFINITOR/O plus/O exemestane/O arm/O than/O in/O the/O placebo/O plus/O exemestane/O arm/O (/O 63/O %/O versus/O 14/O %/O )/O ./O
Table/O 2/O compares/O the/O incidence/O of/O treatment/O -/O emergent/O adverse/O reactions/O reported/O with/O an/O incidence/O of/O 10/O %/O for/O patients/O receiving/O AFINITOR/O 10/O mg/O daily/O versus/O placebo/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Reported/O 10/O %/O of/O Patients/O with/O Advanced/O HR+/O BC/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O 160/O patients/O (/O 33.2/O %/O )/O were/O exposed/O to/O AFINITOR/O therapy/O for/O a/O period/O of/O 32/O weeks/O a/O Exemestane/O (/O 25/O mg/O day/O )/O b/O Includes/O stomatitis/B-AdverseReaction ,/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ,/O aphthous/B-AdverseReaction stomatitis/I-AdverseReaction ,/O glossodynia/B-AdverseReaction ,/O gingival/B-AdverseReaction pain/I-AdverseReaction ,/O glossitis/B-AdverseReaction and/O lip/B-AdverseReaction ulceration/I-AdverseReaction c/O Includes/O all/O preferred/O terms/O within/O the/O '/O infections/O and/O infestations/O '/O system/O organ/O class/O ,/O the/O most/O common/O being/O nasopharyngitis/B-AdverseReaction (/O 10/O %/O )/O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 10/O %/O )/O ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 5/O %/O )/O ,/O pneumonia/B-AdverseReaction (/O 4/O %/O )/O ,/O bronchitis/B-AdverseReaction (/O 4/O %/O )/O ,/O cystitis/B-AdverseReaction (/O 3/O %/O )/O ,/O sinusitis/B-AdverseReaction (/O 3/O %/O )/O ,/O and/O also/O including/O candidiasis/B-AdverseReaction (/O 1/O %/O )/O ,/O and/O sepsis/B-AdverseReaction (/O 1/O %/O )/O ,/O and/O hepatitis/B-AdverseReaction C/I-AdverseReaction (/O 1/O %/O )/O ./O
d/O Includes/O pneumonitis/B-AdverseReaction ,/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction ,/O lung/B-AdverseReaction infiltration/I-AdverseReaction ,/O and/O pulmonary/B-AdverseReaction fibrosis/I-AdverseReaction e/O Exposure/O to/O AFINITOR/O or/O placebo/O AFINITOR/O (/O 10/O mg/O day/O )/O +/O exemestane/O a/O N=482/O Placebo/O +/O exemestane/O a/O N=238/O All/O grades/O Grade/O 3/O Grade/O 4/O All/O grades/O Grade/O 3/O Grade/O 4/O %/O %/O %/O %/O %/O %/O Any/O adverse/O reaction/O 100/O 41/O 9/O 90/O 22/O 5/O Gastrointestinal/O disorders/O Stomatitis/B-AdverseReaction b/O 67/O 8/O 0/O 11/O 0.8/O 0/O Diarrhea/B-AdverseReaction 33/O 2/O 0.2/O 18/O 0.8/O 0/O Nausea/B-AdverseReaction 29/O 0.2/O 0.2/O 28/O 1/O 0/O Vomiting/B-AdverseReaction 17/O 0.8/O 0.2/O 12/O 0.8/O 0/O Constipation/B-AdverseReaction 14/O 0.4/O 0/O 13/O 0.4/O 0/O Dry/B-AdverseReaction mouth/I-AdverseReaction 11/O 0/O 0/O 7/O 0/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 36/O 4/O 0.4/O 27/O 1/O 0/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 19/O 1/O 0/O 6/O 0.4/O 0/O Pyrexia/B-AdverseReaction 15/O 0.2/O 0/O 7/O 0.4/O 0/O Asthenia/B-AdverseReaction 13/O 2/O 0.2/O 4/O 0/O 0/O Infections/O and/O infestations/O Infections/B-AdverseReaction c/O 50/O 4/O 1/O 25/O 2/O 0/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 25/O 1/O 0/O 6/O 0/O 0/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 30/O 1/O 0/O 12/O 0.4/O 0/O Hyperglycemia/B-AdverseReaction 14/O 5/O 0.4/O 2/O 0.4/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 20/O 0.8/O 0/O 17/O 0/O 0/O Back/B-AdverseReaction pain/I-AdverseReaction 14/O 0.2/O 0/O 10/O 0.8/O 0/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 9/O 0.4/O 0/O 11/O 2/O 0/O Nervous/O system/O disorders/O Dysgeusia/B-AdverseReaction 22/O 0.2/O 0/O 6/O 0/O 0/O Headache/B-AdverseReaction 21/O 0.4/O 0/O 14/O 0/O 0/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 13/O 0.2/O 0/O 8/O 0/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 24/O 0.6/O 0/O 12/O 0/O 0/O Dyspnea/B-AdverseReaction 21/O 4/O 0.2/O 11/O 0.8/O 0.4/O Epistaxis/B-AdverseReaction 17/O 0/O 0/O 1/O 0/O 0/O Pneumonitis/B-AdverseReaction d/O 19/O 4/O 0.2/O 0.4/O 0/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 39/O 1/O 0/O 6/O 0/O 0/O Pruritus/B-AdverseReaction 13/O 0.2/O 0/O 5/O 0/O 0/O Alopecia/B-AdverseReaction 10/O 0/O 0/O 5/O 0/O 0/O Vascular/O disorders/O Hot/B-AdverseReaction flush/I-AdverseReaction 6/O 0/O 0/O 14/O 0/O 0/O Median/O duration/O of/O treatment/O e/O 23.9/O weeks/O 13.4/O weeks/O Key/O observed/O laboratory/O abnormalities/O are/O presented/O in/O Table/O 3/O ./O
Table/O 3/O :/O Key/O Laboratory/O Abnormalities/O Reported/O in/O 10/O %/O of/O Patients/O with/O Advanced/O HR+/O BC/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O a/O Exemestane/O (/O 25/O mg/O day/O )/O b/O Reflects/O corresponding/O adverse/O drug/O reaction/O reports/O of/O anemia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O and/O thrombocytopenia/B-AdverseReaction (/O collectively/O as/O pancytopenia/B-AdverseReaction )/O ,/O which/O occurred/O at/O lower/O frequency/O ./O
Laboratory/O parameter/O AFINITOR/O (/O 10/O mg/O day/O )/O +/O exemestane/O a/O N=482/O Placebo/O +/O exemestane/O a/O N=238/O All/O grades/O Grade/O 3/O Grade/O 4/O All/O grades/O Grade/O 3/O Grade/O 4/O %/O %/O %/O %/O %/O %/O Hematology/O b/O Hemoglobin/B-AdverseReaction decreased/I-AdverseReaction 68/O 6/O 0.6/O 40/O 0.8/O 0.4/O WBC/B-AdverseReaction decreased/I-AdverseReaction 58/O 1/O 0/O 28/O 5/O 0.8/O Platelets/B-AdverseReaction decreased/I-AdverseReaction 54/O 3/O 0.2/O 5/O 0/O 0.4/O Lymphocytes/B-AdverseReaction decreased/I-AdverseReaction 54/O 11/O 0.6/O 37/O 5/O 0.8/O Neutrophils/B-AdverseReaction decreased/I-AdverseReaction 31/O 2/O 0/O 11/O 0.8/O 0.8/O Clinical/O chemistry/O Glucose/B-AdverseReaction increased/I-AdverseReaction 69/O 9/O 0.4/O 44/O 0.8/O 0.4/O Cholesterol/B-AdverseReaction increased/I-AdverseReaction 70/O 0.6/O 0.2/O 38/O 0.8/O 0.8/O Aspartate/O transaminase/O (/O AST/O )/O increased/O 69/O 4/O 0.2/O 45/O 3/O 0.4/O Alanine/O transaminase/O (/O ALT/O )/O increased/O 51/O 4/O 0.2/O 29/O 5/O 0/O Triglycerides/B-AdverseReaction increased/I-AdverseReaction 50/O 0.8/O 0/O 26/O 0/O 0/O Albumin/B-AdverseReaction decreased/I-AdverseReaction 33/O 0.8/O 0/O 16/O 0.8/O 0/O Potassium/B-AdverseReaction decreased/I-AdverseReaction 29/O 4/O 0.2/O 7/O 1/O 0/O Creatinine/B-AdverseReaction increased/I-AdverseReaction 24/O 2/O 0.2/O 13/O 0/O 0/O 6.2/O Clinical/O Study/O Experience/O in/O Advanced/O Pancreatic/O Neuroendocrine/O Tumors/O In/O a/O randomized/O ,/O controlled/O trial/O of/O AFINITOR/O (/O n=204/O )/O versus/O placebo/O (/O n=203/O )/O in/O patients/O with/O advanced/O PNET/O the/O median/O age/O of/O patients/O was/O 58/O years/O (/O range/O 20/O -/O 87/O )/O ,/O 79/O %/O were/O Caucasian/O ,/O and/O 55/O %/O were/O male/O ./O
Patients/O on/O the/O placebo/O arm/O could/O cross/O over/O to/O open/O -/O label/O AFINITOR/O upon/O disease/O progression/O ./O
The/O most/O common/O adverse/O reactions/O (/O incidence/O 30/O %/O )/O were/O stomatitis/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O edema/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O fever/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
The/O most/O common/O Grade/B-Severity 3/I-Severity -/O 4/O adverse/O reactions/O (/O incidence/O 5/O %/O )/O were/O stomatitis/B-AdverseReaction and/O diarrhea/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O incidence/O 50/O %/O )/O were/O decreased/B-AdverseReaction hemoglobin/I-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O alkaline/B-AdverseReaction phosphatase/I-AdverseReaction increased/I-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O bicarbonate/B-AdverseReaction decreased/I-AdverseReaction ,/O and/O increased/B-AdverseReaction aspartate/I-AdverseReaction transaminase/I-AdverseReaction (/O AST/O )/O ./O
The/O most/O common/O Grade/B-Severity 3/I-Severity -/O 4/O laboratory/O abnormalities/O (/O incidence/O 3/O %/O )/O were/O hyperglycemia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O decreased/B-AdverseReaction hemoglobin/I-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O increased/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O increased/B-AdverseReaction aspartate/I-AdverseReaction transaminase/I-AdverseReaction (/O AST/O )/O ,/O potassium/B-AdverseReaction decreased/I-AdverseReaction ,/O and/O thrombocytopenia/B-AdverseReaction ./O
Deaths/B-AdverseReaction during/O double/O -/O blind/O treatment/O where/O an/O adverse/O event/O was/O the/O primary/O cause/O occurred/O in/O seven/O patients/O on/O AFINITOR/O and/O one/O patient/O on/O placebo/O ./O
Causes/O of/O death/B-AdverseReaction on/O the/O AFINITOR/O arm/O included/O one/O case/O of/O each/O of/O the/O following/O :/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction ,/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O death/B-AdverseReaction (/O cause/O unknown/O )/O ,/O hepatic/B-AdverseReaction failure/I-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O and/O sepsis/B-AdverseReaction ./O
There/O was/O one/O death/B-AdverseReaction due/O to/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction on/O the/O placebo/B-Factor arm/O ./O
After/O cross/O -/O over/O to/O open/O -/O label/O AFINITOR/O ,/O there/O were/O three/O additional/O deaths/B-AdverseReaction ,/O one/O due/O to/O hypoglycemia/B-AdverseReaction and/O cardiac/B-AdverseReaction arrest/I-AdverseReaction in/O a/O patient/O with/O insulinoma/O ,/O one/O due/O to/O myocardial/B-AdverseReaction infarction/I-AdverseReaction with/O congestive/B-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction ,/O and/O the/O other/O due/O to/O sudden/B-AdverseReaction death/I-AdverseReaction ./O
The/O rates/O of/O treatment/O -/O emergent/O adverse/O events/O resulting/O in/O permanent/O discontinuation/O were/O 20/O %/O and/O 6/O %/O for/O the/O AFINITOR/O and/O placebo/O treatment/O groups/O ,/O respectively/O ./O
Dose/O delay/O or/O reduction/O was/O necessary/O in/O 61/O %/O of/O everolimus/O patients/O and/O 29/O %/O of/O placebo/O patients/O ./O
Grade/B-Severity 3/I-Severity -/O 4/O renal/B-AdverseReaction failure/I-AdverseReaction occurred/O in/O six/O patients/O in/O the/O everolimus/O arm/O and/O three/O patients/O in/O the/O placebo/O arm/O ./O
Thrombotic/B-AdverseReaction events/I-AdverseReaction included/O five/O patients/O with/O pulmonary/B-AdverseReaction embolus/I-AdverseReaction in/O the/O everolimus/O arm/O and/O one/O in/O the/O placebo/O arm/O as/O well/O as/O three/O patients/O with/O thrombosis/B-AdverseReaction in/O the/O everolimus/O arm/O and/O two/O in/O the/O placebo/O arm/O ./O
Table/O 4/O compares/O the/O incidence/O of/O treatment/O -/O emergent/O adverse/O reactions/O reported/O with/O an/O incidence/O of/O 10/O %/O for/O patients/O receiving/O AFINITOR/O 10/O mg/O daily/O versus/O placebo/O ./O
Table/O 4/O :/O Adverse/O Reactions/O Reported/O 10/O %/O of/O Patients/O with/O Advanced/O PNET/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O a/O Includes/O stomatitis/B-AdverseReaction ,/O aphthous/B-AdverseReaction stomatitis/I-AdverseReaction ,/O gingival/B-AdverseReaction pain/I-AdverseReaction swelling/O ulceration/O ,/O glossitis/B-AdverseReaction ,/O glossodynia/B-AdverseReaction ,/O lip/B-AdverseReaction ulceration/I-AdverseReaction ,/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ,/O tongue/B-AdverseReaction ulceration/I-AdverseReaction ,/O and/O mucosal/B-AdverseReaction inflammation/I-AdverseReaction ./O
b/O Includes/O diarrhea/B-AdverseReaction ,/O enteritis/B-AdverseReaction ,/O enterocolitis/B-AdverseReaction ,/O colitis/B-AdverseReaction ,/O defecation/B-AdverseReaction urgency/I-AdverseReaction ,/O and/O steatorrhea/B-AdverseReaction ./O
c/O Includes/O pneumonitis/B-AdverseReaction ,/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction ,/O pulmonary/B-AdverseReaction fibrosis/I-AdverseReaction and/O restrictive/B-AdverseReaction pulmonary/I-AdverseReaction disease/I-AdverseReaction ./O
AFINITOR/O N=204/O Placebo/O N=203/O All/O grades/O Grade/O 3/O Grade/O 4/O All/O grades/O Grade/O 3/O Grade/O 4/O %/O %/O %/O %/O %/O %/O Any/O adverse/O reaction/O 100/O 49/O 13/O 98/O 32/O 8/O Gastrointestinal/O disorders/O Stomatitis/B-AdverseReaction a/O 70/O 7/O 0/O 20/O 0/O 0/O Diarrhea/B-AdverseReaction b/O 50/O 5/O 0.5/O 25/O 3/O 0/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 36/O 4/O 0/O 32/O 6/O 1/O Nausea/B-AdverseReaction 32/O 2/O 0/O 33/O 2/O 0/O Vomiting/B-AdverseReaction 29/O 1/O 0/O 21/O 2/O 0/O Constipation/B-AdverseReaction 14/O 0/O 0/O 13/O 0.5/O 0/O Dry/B-AdverseReaction mouth/I-AdverseReaction 11/O 0/O 0/O 4/O 0/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction malaise/B-AdverseReaction 45/O 3/O 0.5/O 27/O 2/O 0.5/O Edema/O (/O general/O and/O peripheral/O )/O 39/O 1/O 0.5/O 12/O 1/O 0/O Fever/B-AdverseReaction 31/O 0.5/O 0.5/O 13/O 0.5/O 0/O Asthenia/B-AdverseReaction 19/O 3/O 0/O 20/O 3/O 0/O Infections/O and/O infestations/O Nasopharyngitis/B-AdverseReaction rhinitis/B-AdverseReaction URI/B-AdverseReaction 25/O 0/O 0/O 13/O 0/O 0/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 16/O 0/O 0/O 6/O 0.5/O 0/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 28/O 0.5/O 0/O 11/O 0/O 0/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 30/O 1/O 0/O 18/O 1/O 0/O Diabetes/B-AdverseReaction mellitus/I-AdverseReaction 10/O 2/O 0/O 0.5/O 0/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 15/O 1/O 0.5/O 7/O 0.5/O 0/O Back/B-AdverseReaction pain/I-AdverseReaction 15/O 1/O 0/O 11/O 1/O 0/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 14/O 0.5/O 0/O 6/O 1/O 0/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 10/O 0/O 0/O 4/O 0/O 0/O Nervous/O system/O disorders/O Headache/B-AdverseReaction migraine/B-AdverseReaction 30/O 0.5/O 0/O 15/O 1/O 0/O Dysgeusia/B-AdverseReaction 19/O 0/O 0/O 5/O 0/O 0/O Dizziness/B-AdverseReaction 12/O 0.5/O 0/O 7/O 0/O 0/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 14/O 0/O 0/O 8/O 0/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction productive/B-AdverseReaction cough/I-AdverseReaction 25/O 0.5/O 0/O 13/O 0/O 0/O Epistaxis/B-AdverseReaction 22/O 0/O 0/O 1/O 0/O 0/O Dyspnea/B-AdverseReaction dyspnea/B-AdverseReaction exertional/I-AdverseReaction 20/O 2/O 0.5/O 7/O 0.5/O 0/O Pneumonitis/B-AdverseReaction c/O 17/O 3/O 0.5/O 0/O 0/O 0/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 11/O 0/O 0/O 6/O 0/O 0/O Skin/O and/O subcutaneous/O disorders/O Rash/B-AdverseReaction 59/O 0.5/O 0/O 19/O 0/O 0/O Nail/B-AdverseReaction disorders/I-AdverseReaction 22/O 0.5/O 0/O 2/O 0/O 0/O Pruritus/B-AdverseReaction pruritus/B-AdverseReaction generalized/I-AdverseReaction 21/O 0/O 0/O 13/O 0/O 0/O Dry/B-AdverseReaction skin/I-AdverseReaction xeroderma/B-AdverseReaction 13/O 0/O 0/O 6/O 0/O 0/O Vascular/O disorders/O Hypertension/B-AdverseReaction 13/O 1/O 0/O 6/O 1/O 0/O Median/O duration/O of/O treatment/O (/O wks/O )/O 37/O 16/O In/O female/O patients/O aged/O 18/O to/O 55/O years/O ,/O irregular/B-AdverseReaction menstruation/I-AdverseReaction occurred/O in/O 5/O of/O 46/O (/O 11/O %/O )/O AFINITOR/O -/O treated/O females/O and/O none/O of/O the/O 33/O females/O in/O the/O placebo/O group/O ./O
Key/O observed/O laboratory/O abnormalities/O are/O presented/O in/O Table/O 5/O ./O
Table/O 5/O :/O Key/O Laboratory/O Abnormalities/O Reported/O in/O 10/O %/O of/O Patients/O with/O Advanced/O PNET/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O Laboratory/O parameter/O AFINITOR/O N=204/O Placebo/O N=203/O All/O grades/O Grade/O 3/O -/O 4/O All/O grades/O Grade/O 3/O -/O 4/O %/O %/O %/O %/O Hematology/O Hemoglobin/B-AdverseReaction decreased/I-AdverseReaction 86/O 15/O 63/O 1/O Lymphocytes/B-AdverseReaction decreased/I-AdverseReaction 45/O 16/O 22/O 4/O Platelets/B-AdverseReaction decreased/I-AdverseReaction 45/O 3/O 11/O 0/O WBC/B-AdverseReaction decreased/I-AdverseReaction 43/O 2/O 13/O 0/O Neutrophils/B-AdverseReaction decreased/I-AdverseReaction 30/O 4/O 17/O 2/O Clinical/O chemistry/O Alkaline/B-AdverseReaction phosphatase/I-AdverseReaction increased/I-AdverseReaction 74/O 8/O 66/O 8/O Glucose/B-AdverseReaction (/I-AdverseReaction fasting/I-AdverseReaction )/O increased/O 75/O 17/O 53/O 6/O Cholesterol/B-AdverseReaction increased/I-AdverseReaction 66/O 0.5/O 22/O 0/O Bicarbonate/B-AdverseReaction decreased/I-AdverseReaction 56/O 0/O 40/O 0/O Aspartate/O transaminase/O (/O AST/O )/O increased/O 56/O 4/O 41/O 4/O Alanine/O transaminase/O (/O ALT/O )/O increased/O 48/O 2/O 35/O 2/O Phosphate/B-AdverseReaction decreased/I-AdverseReaction 40/O 10/O 14/O 3/O Triglycerides/B-AdverseReaction increased/I-AdverseReaction 39/O 0/O 10/O 0/O Calcium/B-AdverseReaction decreased/I-AdverseReaction 37/O 0.5/O 12/O 0/O Potassium/B-AdverseReaction decreased/I-AdverseReaction 23/O 4/O 5/O 0/O Creatinine/B-AdverseReaction increased/I-AdverseReaction 19/O 2/O 14/O 0/O Sodium/B-AdverseReaction decreased/I-AdverseReaction 16/O 1/O 16/O 1/O Albumin/B-AdverseReaction decreased/I-AdverseReaction 13/O 1/O 8/O 0/O Bilirubin/B-AdverseReaction increased/I-AdverseReaction 10/O 1/O 14/O 2/O Potassium/B-AdverseReaction increased/I-AdverseReaction 7/O 0/O 10/O 0.5/O 6.3/O Clinical/O Study/O Experience/O in/O Advanced/O Renal/O Cell/O Carcinoma/O The/O data/O described/O below/O reflect/O exposure/O to/O AFINITOR/O (/O n=274/O )/O and/O placebo/O (/O n=137/O )/O in/O a/O randomized/O ,/O controlled/O trial/O in/O patients/O with/O metastatic/O renal/O cell/O carcinoma/O who/O received/O prior/O treatment/O with/O sunitinib/O and/or/O sorafenib/O ./O
The/O median/O age/O of/O patients/O was/O 61/O years/O (/O range/O 27/O -/O 85/O )/O ,/O 88/O %/O were/O Caucasian/O ,/O and/O 78/O %/O were/O male/O ./O
The/O median/O duration/O of/O blinded/O study/O treatment/O was/O 141/O days/O (/O range/O 19/O -/O 451/O days/O )/O for/O patients/O receiving/O AFINITOR/O and/O 60/O days/O (/O range/O 21/O -/O 295/O days/O )/O for/O those/O receiving/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O (/O incidence/O 30/O %/O )/O were/O stomatitis/B-AdverseReaction ,/O infections/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction ./O
The/O most/O common/O Grade/B-Severity 3/I-Severity -/O 4/O adverse/O reactions/O (/O incidence/O 3/O %/O )/O were/O infections/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O dehydration/B-AdverseReaction ,/O pneumonitis/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O asthenia/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O incidence/O 50/O %/O )/O were/O anemia/B-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O hypertriglyceridemia/O ,/O hyperglycemia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O and/O increased/B-AdverseReaction creatinine/I-AdverseReaction ./O
The/O most/O common/O Grade/B-Severity 3/I-Severity -/O 4/O laboratory/O abnormalities/O (/O incidence/O 3/O %/O )/O were/O lymphopenia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O and/O hypercholesterolemia/B-AdverseReaction ./O
Deaths/B-AdverseReaction due/O to/O acute/B-AdverseReaction respiratory/I-AdverseReaction failure/I-AdverseReaction (/O 0.7/O %/O )/O ,/O infection/B-AdverseReaction (/O 0.7/O %/O )/O ,/O and/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction (/O 0.4/O %/O )/O were/O observed/O on/O the/O AFINITOR/O arm/O but/O none/O on/O the/O placebo/O arm/O ./O
The/O rates/O of/O treatment/O -/O emergent/O adverse/O events/O (/O irrespective/O of/O causality/O )/O resulting/O in/O permanent/O discontinuation/O were/O 14/O %/O and/O 3/O %/O for/O the/O AFINITOR/O and/O placebo/O treatment/O groups/O ,/O respectively/O ./O
The/O most/O common/O adverse/O reactions/O (/O irrespective/O of/O causality/O )/O leading/O to/O treatment/O discontinuation/O were/O pneumonitis/B-AdverseReaction and/O dyspnea/B-AdverseReaction ./O
Infections/B-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O and/O pneumonitis/B-AdverseReaction were/O the/O most/O common/O reasons/O for/O treatment/O delay/O or/O dose/O reduction/O ./O
The/O most/O common/O medical/O interventions/O required/O during/O AFINITOR/O treatment/O were/O for/O infections/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O and/O stomatitis/B-AdverseReaction ./O
Table/O 6/O compares/O the/O incidence/O of/O treatment/O -/O emergent/O adverse/O reactions/O reported/O with/O an/O incidence/O of/O 10/O %/O for/O patients/O receiving/O AFINITOR/O 10/O mg/O daily/O versus/O placebo/O ./O
Within/O each/O MedDRA/O system/O organ/O class/O ,/O the/O adverse/O reactions/O are/O presented/O in/O order/O of/O decreasing/O frequency/O ./O
Table/O 6/O :/O Adverse/O Reactions/O Reported/O in/O at/O Least/O 10/O %/O of/O Patients/O with/O RCC/O and/O at/O a/O Higher/O Rate/O in/O the/O AFINITOR/O Arm/O than/O in/O the/O Placebo/O Arm/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O a/O Stomatitis/B-AdverseReaction (/O including/O aphthous/B-AdverseReaction stomatitis/I-AdverseReaction )/O ,/O and/O mouth/O and/O tongue/B-AdverseReaction ulceration/I-AdverseReaction ./O
b/O Includes/O all/O preferred/O terms/O within/O the/O '/O infections/O and/O infestations/O '/O system/O organ/O class/O ,/O the/O most/O common/O being/O nasopharyngitis/B-AdverseReaction (/O 6/O %/O )/O ,/O pneumonia/B-AdverseReaction (/O 6/O %/O )/O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 5/O %/O )/O ,/O bronchitis/B-AdverseReaction (/O 4/O %/O )/O ,/O and/O sinusitis/B-AdverseReaction (/O 3/O %/O )/O ,/O and/O also/O including/O aspergillosis/B-AdverseReaction (/O 1/O %/O )/O ,/O candidiasis/B-AdverseReaction (/O 1/O %/O )/O ,/O and/O sepsis/B-AdverseReaction (/O 1/O %/O )/O ./O
c/O Includes/O pneumonitis/B-AdverseReaction ,/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction ,/O lung/B-AdverseReaction infiltration/I-AdverseReaction ,/O pulmonary/B-AdverseReaction alveolar/I-AdverseReaction hemorrhage/I-AdverseReaction ,/O pulmonary/B-AdverseReaction toxicity/I-AdverseReaction ,/O and/O alveolitis/B-AdverseReaction ./O
AFINITOR/O 10/O mg/O day/O N=274/O Placebo/O N=137/O All/O grades/O Grade/O 3/O Grade/O 4/O All/O grades/O Grade/O 3/O Grade/O 4/O %/O %/O %/O %/O %/O %/O Any/O a/O dverse/O r/O eaction/O 97/O 52/O 13/O 93/O 23/O 5/O Gastrointestinal/O d/O isorders/O Stomatitis/B-AdverseReaction a/O 44/O 4/O 1/O 8/O 0/O 0/O Diarrhea/B-AdverseReaction 30/O 1/O 0/O 7/O 0/O 0/O Nausea/B-AdverseReaction 26/O 1/O 0/O 19/O 0/O 0/O Vomiting/B-AdverseReaction 20/O 2/O 0/O 12/O 0/O 0/O Infections/O and/O i/O nfestations/O b/O 37/O 7/O 3/O 18/O 1/O 0/O General/O d/O isorders/O and/O a/O dministration/O s/O ite/O c/O onditions/O Asthenia/B-AdverseReaction 33/O 3/O 1/O 23/O 4/O 0/O Fatigue/B-AdverseReaction 31/O 5/O 0/O 27/O 3/O 1/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 25/O 1/O 0/O 8/O 1/O 0/O Pyrexia/B-AdverseReaction 20/O 1/O 0/O 9/O 0/O 0/O Mucosal/B-AdverseReaction inflammation/I-AdverseReaction 19/O 1/O 0/O 1/O 0/O 0/O Respiratory/O ,/O t/O horacic/O and/O m/O ediastinal/O d/O isorders/O Cough/B-AdverseReaction 30/O 1/O 0/O 16/O 0/O 0/O Dyspnea/B-AdverseReaction 24/O 6/O 1/O 15/O 3/O 0/O Epistaxis/B-AdverseReaction 18/O 0/O 0/O 0/O 0/O 0/O Pneumonitis/B-AdverseReaction c/O 14/O 4/O 0/O 0/O 0/O 0/O Skin/O and/O s/O ubcutaneous/O t/O issue/O d/O isorders/O Rash/B-AdverseReaction 29/O 1/O 0/O 7/O 0/O 0/O Pruritus/B-AdverseReaction 14/O 1/O 0/O 7/O 0/O 0/O Dry/B-AdverseReaction skin/I-AdverseReaction 13/O 1/O 0/O 5/O 0/O 0/O Metabolism/O and/O n/O utrition/O d/O isorders/O Anorexia/B-AdverseReaction 25/O 1/O 0/O 14/O 1/O 0/O Nervous/O s/O ystem/O d/O isorders/O Headache/B-AdverseReaction 19/O 1/O 1/O 9/O 1/O 0/O Dysgeusia/B-AdverseReaction 10/O 0/O 0/O 2/O 0/O 0/O Musculoskeletal/O and/O c/O onnective/O t/O issue/O d/O isorders/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 10/O 1/O 0/O 7/O 0/O 0/O Medi/O an/O d/O uration/O of/O t/O reatment/O (/O d/O )/O 141/O 60/O Other/O notable/O adverse/O reactions/O occurring/O more/O frequently/O with/O AFINITOR/O than/O with/O placebo/O ,/O but/O with/O an/O incidence/O of/O 10/O %/O include/O :/O Gastrointestinal/O disorders/O :/O Abdominal/B-AdverseReaction pain/I-AdverseReaction (/O 9/O %/O )/O ,/O dry/B-AdverseReaction mouth/I-AdverseReaction (/O 8/O %/O )/O ,/O hemorrhoids/B-AdverseReaction (/O 5/O %/O )/O ,/O dysphagia/B-AdverseReaction (/O 4/O %/O )/O General/O disorders/O and/O administration/O site/O conditions/O :/O Weight/B-AdverseReaction decreased/I-AdverseReaction (/O 9/O %/O )/O ,/O chest/B-AdverseReaction pain/I-AdverseReaction (/O 5/O %/O )/O ,/O chills/B-AdverseReaction (/O 4/O %/O )/O ,/O impaired/B-AdverseReaction wound/I-AdverseReaction healing/I-AdverseReaction (/O 1/O %/O )/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O Pleural/B-AdverseReaction effusion/I-AdverseReaction (/O 7/O %/O )/O ,/O pharyngolaryngeal/B-AdverseReaction pain/I-AdverseReaction (/O 4/O %/O )/O ,/O rhinorrhea/B-AdverseReaction (/O 3/O %/O )/O Skin/O and/O subcutaneous/O tissue/O disorders/O :/O Hand/B-AdverseReaction -/I-AdverseReaction foot/O syndrome/O (/O reported/O as/O palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O )/O (/O 5/O %/O )/O ,/O nail/B-AdverseReaction disorder/I-AdverseReaction (/O 5/O %/O )/O ,/O erythema/B-AdverseReaction (/O 4/O %/O )/O ,/O onychoclasis/B-AdverseReaction (/O 4/O %/O )/O ,/O skin/B-AdverseReaction lesion/I-AdverseReaction (/O 4/O %/O )/O ,/O acneiform/B-AdverseReaction dermatitis/I-AdverseReaction (/O 3/O %/O )/O ,/O angioedema/B-AdverseReaction (/O 1/O %/O )/O Metabolism/O and/O nutrition/O disorders/O :/O Exacerbation/O of/O pre/O -/O existing/O diabetes/O mellitus/O (/O 2/O %/O )/O ,/O new/B-AdverseReaction onset/I-AdverseReaction of/I-AdverseReaction diabetes/I-AdverseReaction mellitus/I-AdverseReaction (/O 1/O %/O )/O Psychiatric/O disorders/O :/O Insomnia/B-AdverseReaction (/O 9/O %/O )/O Nervous/O system/O disorders/O :/O Dizziness/B-AdverseReaction (/O 7/O %/O )/O ,/O paresthesia/B-AdverseReaction (/O 5/O %/O )/O Eye/O disorders/O :/O Eyelid/B-AdverseReaction edema/I-AdverseReaction (/O 4/O %/O )/O ,/O conjunctivitis/B-AdverseReaction (/O 2/O %/O )/O Vascular/O disorders/O :/O Hypertension/B-AdverseReaction (/O 4/O %/O )/O ,/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction (/O 1/O %/O )/O Renal/O and/O urinary/O disorders/O :/O Renal/B-AdverseReaction failure/I-AdverseReaction (/O 3/O %/O )/O Cardiac/O disorders/O :/O Tachycardia/B-AdverseReaction (/O 3/O %/O )/O ,/O congestive/B-AdverseReaction cardiac/I-AdverseReaction failure/I-AdverseReaction (/O 1/O %/O )/O Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O Jaw/B-AdverseReaction pain/I-AdverseReaction (/O 3/O %/O )/O Hematologic/O disorders/O :/O Hemorrhage/B-AdverseReaction (/O 3/O %/O )/O Key/O laboratory/O abnormalities/O are/O presented/O in/O Table/O 7/O ./O
Table/O 7/O :/O Key/O Laboratory/O Abnormalities/O Reported/O in/O Patients/O with/O RCC/O at/O a/O Higher/O Rate/O in/O the/O AFINITOR/O Arm/O than/O the/O Placebo/O Arm/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O a/O Reflects/O corresponding/O adverse/O drug/O reaction/O reports/O of/O anemia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O and/O thrombocytopenia/B-AdverseReaction (/O collectively/O pancytopenia/B-AdverseReaction )/O ,/O which/O occurred/O at/O lower/O frequency/O ./O
Laboratory/O p/O arameter/O AFINITOR/O 10/O mg/O day/O N=274/O Placebo/O N=137/O All/O grades/O Grade/O 3/O Grade/O 4/O All/O grades/O Grade/O 3/O Grade/O 4/O %/O %/O %/O %/O %/O %/O Hematology/O a/O Hemoglobin/B-AdverseReaction decreased/I-AdverseReaction 92/O 12/O 1/O 79/O 5/O 1/O Lymphocytes/B-AdverseReaction decreased/I-AdverseReaction 51/O 16/O 2/O 28/O 5/O 0/O Platelets/B-AdverseReaction decreased/I-AdverseReaction 23/O 1/O 0/O 2/O 0/O 1/O Neutrophils/B-AdverseReaction decreased/I-AdverseReaction 14/O 0/O 1/O 4/O 0/O 0/O Clinical/O c/O hemistry/O Cholesterol/B-AdverseReaction increased/I-AdverseReaction 77/O 4/O 0/O 35/O 0/O 0/O Triglycerides/B-AdverseReaction increased/I-AdverseReaction 73/O 1/O 0/O 34/O 0/O 0/O Glucose/B-AdverseReaction increased/I-AdverseReaction 57/O 15/O 1/O 25/O 1/O 0/O Creatinine/B-AdverseReaction increased/I-AdverseReaction 50/O 1/O 0/O 34/O 0/O 0/O Phosphate/B-AdverseReaction decreased/I-AdverseReaction 37/O 6/O 0/O 8/O 0/O 0/O Aspartate/O transaminase/O (/O AST/O )/O increased/O 25/O 1/O 1/O 7/O 0/O 0/O Alanine/O transaminase/O (/O ALT/O )/O increased/O 21/O 1/O 0/O 4/O 0/O 0/O Bilirubin/B-AdverseReaction increased/I-AdverseReaction 3/O 1/O 1/O 2/O 0/O 0/O 6.4/O Clinical/O Study/O Experience/O in/O Renal/O Angiomyolipoma/O with/O Tuberous/O Sclerosis/O Complex/O The/O data/O described/O below/O are/O based/O on/O a/O randomized/O (/O 2:1/O )/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trial/O of/O AFINITOR/O in/O 118/O patients/O with/O renal/O angiomyolipoma/O as/O a/O feature/O of/O TSC/O (/O n=113/O )/O or/O sporadic/O lymphangioleiomyomatosis/O (/O n=5/O )/O ./O
The/O median/O age/O of/O patients/O was/O 31/O years/O (/O range/O 18/O to/O 61/O years/O )/O ,/O 89/O %/O were/O Caucasian/O ,/O and/O 34/O %/O were/O male/O ./O
The/O median/O duration/O of/O blinded/O study/O treatment/O was/O 48/O weeks/O (/O range/O 2/O to/O 115/O weeks/O )/O for/O patients/O receiving/O AFINITOR/O and/O 45/O weeks/O (/O range/O 9/O to/O 115/O weeks/O )/O for/O those/O receiving/O placebo/O ./O
The/O most/O common/O adverse/O reaction/O reported/O for/O AFINITOR/O (/O incidence/O 30/O %/O )/O was/O stomatitis/B-AdverseReaction ./O
The/O most/O common/O Grade/O 3/O -/O 4/O adverse/O reactions/O (/O incidence/O 2/O %/O )/O were/O stomatitis/B-AdverseReaction and/O amenorrhea/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O incidence/O 50/O %/O )/O were/O hypercholesterolemia/B-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction ,/O and/O anemia/B-AdverseReaction ./O
The/O most/O common/O Grade/O 3/O -/O 4/O laboratory/O abnormality/O (/O incidence/O 3/O %/O )/O was/O hypophosphatemia/B-AdverseReaction ./O
The/O rate/O of/O adverse/O reactions/O resulting/O in/O permanent/O discontinuation/O was/O 3.8/O %/O in/O the/O AFINITOR/O -/O treated/O patients/O ./O
Adverse/O reactions/O leading/O to/O permanent/O discontinuation/O in/O the/O AFINITOR/O arm/O were/O hypersensitivity/B-AdverseReaction angioedema/B-AdverseReaction bronchospasm/B-AdverseReaction ,/O convulsion/B-AdverseReaction ,/O and/O hypophosphatemia/B-AdverseReaction ./O
Dose/O adjustments/O (/O interruptions/O or/O reductions/O )/O due/O to/O adverse/O reactions/O occurred/O in/O 52/O %/O of/O AFINITOR/O -/O treated/O patients/O ./O
The/O most/O common/O adverse/O reaction/O leading/O to/O AFINITOR/O dose/O adjustment/O was/O stomatitis/B-AdverseReaction ./O
Table/O 8/O compares/O the/O incidence/O of/O adverse/O reactions/O reported/O with/O an/O incidence/O of/O 10/O %/O for/O patients/O receiving/O AFINITOR/O and/O occurring/O more/O frequently/O with/O AFINITOR/O than/O with/O placebo/O ./O
Laboratory/O abnormalities/O are/O described/O separately/O in/O Table/O 9/O ./O
Table/O 8/O :/O Adverse/O Reactions/O Reported/O in/O 10/O %/O of/O AFINITOR/O -/O treated/O Patients/O with/O Renal/O Angiomyolipoma/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O a/O Includes/O stomatitis/B-AdverseReaction ,/O aphthous/B-AdverseReaction stomatitis/I-AdverseReaction ,/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ,/O gingival/B-AdverseReaction pain/I-AdverseReaction ,/O glossitis/B-AdverseReaction ,/O and/O glossodynia/B-AdverseReaction ./O
AFINITOR/O N=79/O Placebo/O N=39/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O Any/O adverse/O reaction/O 100/O 25/O 5/O 97/O 8/O 5/O Gastrointestinal/O disorders/O Stomatitis/B-AdverseReaction a/O 78/O 6/O 0/O 23/O 0/O 0/O Vomiting/B-AdverseReaction 15/O 0/O 0/O 5/O 0/O 0/O Diarrhea/B-AdverseReaction 14/O 0/O 0/O 5/O 0/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Peripheral/B-AdverseReaction edema/I-AdverseReaction 13/O 0/O 0/O 8/O 0/O 0/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 11/O 0/O 0/O 5/O 0/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 13/O 0/O 0/O 5/O 0/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 20/O 0/O 0/O 13/O 0/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Acne/B-AdverseReaction 22/O 0/O 0/O 5/O 0/O 0/O Amenorrhea/B-AdverseReaction occurred/O in/O 15/O %/O of/O AFINITOR/O -/O treated/O females/O (/O 8/O of/O 52/O )/O and/O 4/O %/O (/O 1/O of/O 26/O )/O of/O females/O in/O the/O placebo/O group/O ./O
Other/O adverse/O reactions/O involving/O the/O female/O reproductive/O system/O were/O menorrhagia/B-AdverseReaction (/O 10/O %/O )/O ,/O menstrual/B-AdverseReaction irregularities/I-AdverseReaction (/O 10/O %/O )/O ,/O and/O vaginal/B-AdverseReaction hemorrhage/I-AdverseReaction (/O 8/O %/O )/O ./O
The/O following/O additional/O adverse/O reactions/O occurred/O in/O less/O than/O 10/O %/O of/O AFINITOR/O -treated/O patients/O :/O epistaxis/B-AdverseReaction (/O 9/O %/O )/O ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction (/O 6/O %/O )/O ,/O otitis/B-AdverseReaction media/I-AdverseReaction (/O 6/O %/O )/O ,/O depression/B-AdverseReaction (/O 5/O %/O )/O ,/O abnormal/B-AdverseReaction taste/I-AdverseReaction (/O 5/O %/O )/O ,/O increased/O blood/O luteinizing/O hormone/O (/O LH/O )/O levels/O (/O 4/O %/O )/O ,/O increased/O blood/O follicle/O stimulating/O hormone/O (/O FSH/O )/O levels/O (/O 3/O %/O )/O ,/O hypersensitivity/B-AdverseReaction (/O 3/O %/O )/O ,/O ovarian/B-AdverseReaction cyst/I-AdverseReaction (/O 3/O %/O )/O ,/O pneumonitis/B-AdverseReaction (/O 1/O %/O )/O ,/O and/O angioedema/B-AdverseReaction (/O 1/O %/O )/O ./O
Table/O 9/O :/O Key/O Laboratory/O Abnormalities/O Reported/O in/O AFINITOR/O -/O treated/O Patients/O with/O Renal/O Angiomyolipoma/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O AFINITOR/O N=79/O Placebo/O N=39/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O Hematology/O Anemia/O 61/O 0/O 0/O 49/O 0/O 0/O Leucopenia/B-AdverseReaction 37/O 0/O 0/O 21/O 0/O 0/O Neutropenia/B-AdverseReaction 25/O 0/O 1/O 26/O 0/O 0/O Lymphopenia/B-AdverseReaction 20/O 1/O 0/O 8/O 0/O 0/O Thrombocytopenia/B-AdverseReaction 19/O 0/O 0/O 3/O 0/O 0/O Clinical/O chemistry/O Hypercholesterolemia/B-AdverseReaction 85/O 1/O 0/O 46/O 0/O 0/O Hypertriglyceridemia/B-AdverseReaction 52/O 0/O 0/O 10/O 0/O 0/O Hypophosphatemia/B-AdverseReaction 49/O 5/O 0/O 15/O 0/O 0/O Alkaline/B-AdverseReaction phosphatase/I-AdverseReaction increased/I-AdverseReaction 32/O 1/O 0/O 10/O 0/O 0/O Elevated/B-AdverseReaction aspartate/I-AdverseReaction transaminase/I-AdverseReaction (/O AST/O )/O 23/O 1/O 0/O 8/O 0/O 0/O Elevated/B-AdverseReaction alanine/I-AdverseReaction transaminase/I-AdverseReaction (/O ALT/O )/O 20/O 1/O 0/O 15/O 0/O 0/O Fasting/B-AdverseReaction hyperglycemia/I-AdverseReaction 14/O 0/O 0/O 8/O 0/O 0/O 6.5/O Clinical/O Study/O Experience/O in/O Subependymal/O Giant/O Cell/O Astrocytoma/O with/O Tuberous/O Sclerosis/O Complex/O The/O data/O described/O below/O are/O based/O on/O a/O randomized/O (/O 2:1/O )/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trial/O (/O Study/O 1/O )/O of/O AFINITOR/O in/O 117/O patients/O with/O subependymal/O giant/O cell/O astrocytoma/O (/O SEGA/O )/O and/O tuberous/O sclerosis/O complex/O (/O TSC/O )/O ./O
The/O median/O age/O of/O patients/O was/O 9.5/O years/O (/O range/O 0.8/O to/O 26/O years/O )/O ,/O 93/O %/O were/O Caucasian/O ,/O and/O 57/O %/O were/O male/O ./O
The/O median/O duration/O of/O blinded/O study/O treatment/O was/O 52/O weeks/O (/O range/O 24/O to/O 89/O weeks/O )/O for/O patients/O receiving/O AFINITOR/O and/O 47/O weeks/O (/O range/O 14/O to/O 88/O weeks/O )/O for/O those/O receiving/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O reported/O for/O AFINITOR/O (/O incidence/O 30/O %/O )/O were/O stomatitis/B-AdverseReaction and/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
The/O most/O common/O Grade/B-Severity 3/I-Severity -/O 4/O adverse/O reactions/O (/O incidence/O 2/O %/O )/O were/O stomatitis/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O gastroenteritis/B-AdverseReaction ,/O aggression/B-AdverseReaction ,/O agitation/B-AdverseReaction ,/O and/O amenorrhea/B-AdverseReaction ./O
The/O most/O common/O key/O laboratory/O abnormalities/O (/O incidence/O 50/O %/O )/O were/O hypercholesterolemia/B-AdverseReaction and/O elevated/B-AdverseReaction partial/I-AdverseReaction thromboplastin/I-AdverseReaction time/I-AdverseReaction ./O
The/O most/O common/O Grade/B-Severity 3/I-Severity -/O 4/O laboratory/O abnormality/O (/O incidence/O 3/O %/O )/O was/O neutropenia/B-AdverseReaction ./O
There/O were/O no/O adverse/O reactions/O resulting/O in/O permanent/O discontinuation/O ./O
Dose/O adjustments/O (/O interruptions/O or/O reductions/O )/O due/O to/O adverse/O reactions/O occurred/O in/O 55/O %/O of/O AFINITOR/O -/O treated/O patients/O ./O
The/O most/O common/O adverse/O reaction/O leading/O to/O AFINITOR/O dose/O adjustment/O was/O stomatitis/B-AdverseReaction ./O
Table/O 10/O compares/O the/O incidence/O of/O adverse/O reactions/O reported/O with/O an/O incidence/O of/O 10/O %/O for/O patients/O receiving/O AFINITOR/O and/O occurring/O more/O frequently/O with/O AFINITOR/O than/O with/O placebo/O ./O
Laboratory/O abnormalities/O are/O described/O separately/O in/O Table/O 11/O ./O
Table/O 10/O :/O Adverse/O Reactions/O Reported/O in/O 10/O %/O of/O AFINITOR/O -/O treated/O Patients/O with/O SEGA/O in/O Study/O 1/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O a/O Includes/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O and/O lip/B-AdverseReaction ulceration/I-AdverseReaction b/O Includes/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O and/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction viral/I-AdverseReaction c/O Includes/O gastroenteritis/B-AdverseReaction ,/O gastroenteritis/B-AdverseReaction viral/I-AdverseReaction ,/O and/O gastrointestinal/B-AdverseReaction infection/I-AdverseReaction d/O Includes/O agitation/B-AdverseReaction ,/O anxiety/B-AdverseReaction ,/O panic/B-AdverseReaction attack/I-AdverseReaction ,/O aggression/B-AdverseReaction ,/O abnormal/B-AdverseReaction behavior/I-AdverseReaction ,/O and/O obsessive/B-AdverseReaction compulsive/I-AdverseReaction disorder/I-AdverseReaction e/O Includes/O rash/B-AdverseReaction ,/O rash/B-AdverseReaction generalized/I-AdverseReaction ,/O rash/B-AdverseReaction macular/I-AdverseReaction ,/O rash/B-AdverseReaction maculo/I-AdverseReaction -/O papular/O ,/O rash/B-AdverseReaction papular/I-AdverseReaction ,/O dermatitis/B-AdverseReaction allergic/I-AdverseReaction ,/O and/O urticaria/B-AdverseReaction AFINITOR/O N=78/O Placebo/O N=39/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O Any/O adverse/O reaction/O 97/O 36/O 3/O 92/O 23/O 3/O Gastrointestinal/O disorders/O Stomatitis/B-AdverseReaction a/O 62/O 9/O 0/O 26/O 3/O 0/O Vomiting/B-AdverseReaction 22/O 1/O 0/O 13/O 0/O 0/O Diarrhea/B-AdverseReaction 17/O 0/O 0/O 5/O 0/O 0/O Constipation/B-AdverseReaction 10/O 0/O 0/O 3/O 0/O 0/O Infections/O and/O infestations/O Respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction b/O 31/O 1/O 1/O 23/O 0/O 0/O Gastroenteritis/B-AdverseReaction c/O 10/O 4/O 1/O 3/O 0/O 0/O Pharyngitis/O streptococcal/O 10/O 0/O 0/O 3/O 0/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Pyrexia/B-AdverseReaction 23/O 6/O 0/O 18/O 3/O 0/O Fatigue/B-AdverseReaction 14/O 0/O 0/O 3/O 0/O 0/O Psychiatric/O disorders/O Anxiety/B-AdverseReaction ,/O aggression/B-AdverseReaction or/O other/O behavioral/B-AdverseReaction disturbance/I-AdverseReaction d/O 21/O 5/O 0/O 3/O 0/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction e/O 21/O 0/O 0/O 8/O 0/O 0/O Acne/B-AdverseReaction 10/O 0/O 0/O 5/O 0/O 0/O Amenorrhea/B-AdverseReaction occurred/O in/O 17/O %/O of/O AFINITOR/O -/O treated/O females/O aged/O 10/O to/O 55/O years/O (/O 3/O of/O 18/O )/O and/O none/O of/O the/O females/O in/O the/O placebo/O group/O ./O
For/O this/O same/O group/O of/O AFINITOR/O -/O treated/O females/O ,/O the/O following/O menstrual/B-AdverseReaction abnormalities/I-AdverseReaction were/O reported/O :/O dysmenorrhea/B-AdverseReaction (/O 6/O %/O )/O ,/O menorrhagia/B-AdverseReaction (/O 6/O %/O )/O ,/O metrorrhagia/B-AdverseReaction (/O 6/O %/O )/O ,/O and/O unspecified/B-AdverseReaction menstrual/I-AdverseReaction irregularity/I-AdverseReaction (/O 6/O %/O )/O ./O
The/O following/O additional/O adverse/O reactions/O occurred/O in/O less/O than/O 10/O %/O of/O AFINITOR/O -/O treated/O patients/O :/O nausea/B-AdverseReaction (/O 8/O %/O )/O ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction (/O 8/O %/O )/O ,/O insomnia/B-AdverseReaction (/O 6/O %/O )/O ,/O pneumonia/B-AdverseReaction (/O 6/O %/O )/O ,/O epistaxis/B-AdverseReaction (/O 5/O %/O )/O ,/O hypersensitivity/B-AdverseReaction (/O 3/O %/O )/O ,/O increased/O blood/O luteinizing/O hormone/O (/O LH/O )/O levels/O (/O 1/O %/O )/O and/O pneumonitis/B-AdverseReaction (/O 1/O %/O )/O ./O
Table/O 11/O :/O Key/O Laboratory/O Abnormalities/O Reported/O in/O AFINITOR/O -/O treated/O Patients/O with/O SEGA/O in/O Study/O 1/O Grading/O according/O to/O CTCAE/O Version/O 3.0/O AFINITOR/O N=78/O Placebo/O N=39/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O All/O grades/O %/O Grade/O 3/O %/O Grade/O 4/O %/O Hematology/O Elevated/B-AdverseReaction partial/I-AdverseReaction thromboplastin/I-AdverseReaction time/I-AdverseReaction 72/O 3/O 0/O 44/O 5/O 0/O Neutropenia/B-AdverseReaction 46/O 9/O 0/O 41/O 3/O 0/O Anemia/B-AdverseReaction 41/O 0/O 0/O 21/O 0/O 0/O Clinical/O chemistry/O Hypercholesterolemia/B-AdverseReaction 81/O 0/O 0/O 39/O 0/O 0/O Elevated/B-AdverseReaction aspartate/I-AdverseReaction transaminase/I-AdverseReaction (/O AST/O )/O 33/O 0/O 0/O 0/O 0/O 0/O Hypertriglyceridemia/B-AdverseReaction 27/O 0/O 0/O 15/O 0/O 0/O Elevated/B-AdverseReaction alanine/I-AdverseReaction transaminase/I-AdverseReaction (/O ALT/O )/O 18/O 0/O 0/O 3/O 0/O 0/O Hypophosphatemia/B-AdverseReaction 9/O 1/O 0/O 3/O 0/O 0/O Longer/O -/O term/O follow/O -/O up/O of/O 34.2/O months/O (/O range/O 4.7/O to/O 47.1/O months/O )/O from/O a/O non/O -/O randomized/O ,/O open/O -/O label/O ,/O 28-patient/O trial/O resulted/O in/O the/O following/O additional/O notable/O adverse/O reactions/O and/O key/O laboratory/O abnormalities/O :/O cellulitis/B-AdverseReaction (/O 29/O %/O )/O ,/O hyperglycemia/B-AdverseReaction (/O 25/O %/O )/O ,/O and/O elevated/B-AdverseReaction creatinine/I-AdverseReaction (/O 14/O %/O )/O ./O
6.6/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O AFINITOR/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O :/O acute/B-AdverseReaction pancreatitis/I-AdverseReaction ,/O cholecystitis/B-AdverseReaction ,/O cholelithiasis/B-AdverseReaction ,/O arterial/B-AdverseReaction thrombotic/I-AdverseReaction events/I-AdverseReaction and/O reflex/B-AdverseReaction sympathetic/I-AdverseReaction dystrophy/I-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Non/B-AdverseReaction -/I-AdverseReaction infectious/O pneumonitis/O :/O Monitor/O for/O clinical/O symptoms/O or/O radiological/O changes/O ;/O fatal/B-AdverseReaction cases/O have/O occurred/O ./O
Manage/O by/O dose/O reduction/O or/O discontinuation/O until/O symptoms/O resolve/O ,/O and/O consider/O use/O of/O corticosteroids/O ./O
(/O 5.1/O )/O Infections/B-AdverseReaction :/O Increased/O risk/B-Factor of/O infections/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ./O
Monitor/O for/O signs/O and/O symptoms/O ,/O and/O treat/O promptly/O ./O
(/O 5.2/O )/O Angioedema/B-AdverseReaction :/O Patients/O taking/O concomitant/O ACE/O inhibitor/O therapy/O may/O be/O at/O increased/O risk/O for/O angioedema/O ./O
(/O 5.3/O )/O Oral/B-AdverseReaction ulceration/I-AdverseReaction :/O Mouth/B-AdverseReaction ulcers/I-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O and/O oral/B-AdverseReaction mucositis/I-AdverseReaction are/O common/O ./O
Management/O includes/O mouthwashes/O and/O topical/O treatments/O ./O
(/O 5.4/O )/O Renal/B-AdverseReaction failure/I-AdverseReaction :/O Cases/O of/O renal/B-AdverseReaction failure/I-AdverseReaction (/O including/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction )/O ,/O some/O with/O a/O fatal/B-AdverseReaction outcome/O ,/O have/O been/O observed/O ./O
(/O 5.5/O )/O Impaired/B-AdverseReaction wound/I-AdverseReaction healing/I-AdverseReaction :/O Increased/O risk/B-Factor of/O wound/B-AdverseReaction -/I-AdverseReaction related/O complications/O ./O
Monitor/O signs/O and/O symptoms/O ./O
Exercise/O caution/O in/O the/O peri/O -/O surgical/O period/O ./O
(/O 5.6/O )/O Laboratory/O test/O alterations/O :/O Elevations/B-AdverseReaction of/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction ,/O urinary/O protein/O ,/O blood/O glucose/O ,/O and/O lipids/O may/O occur/O ./O
Decreases/B-AdverseReaction in/I-AdverseReaction hemoglobin/I-AdverseReaction ,/O neutrophils/O ,/O and/O platelets/O may/B-Factor also/O occur/O ./O
Monitor/O renal/O function/O ,/O blood/O glucose/O ,/O lipids/O ,/O and/O hematologic/O parameters/O prior/O to/O treatment/O and/O periodically/O thereafter/O ./O
(/O 5.8/O )/O Vaccinations/O :/O Avoid/O live/O vaccines/O and/O close/O contact/O with/O those/O who/O have/O received/O live/O vaccines/O ./O
(/O 5.11/O )/O Embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicity/O :/O Fetal/B-AdverseReaction harm/I-AdverseReaction can/B-Factor occur/O when/O administered/O to/O a/O pregnant/O woman/O ./O
Apprise/O women/O of/O potential/O harm/O to/O the/O fetus/O ./O
(/O 5.12/O ,/O 8.1/O )/O 5.1/O Non/O -/O infectious/O Pneumonitis/O Non/B-AdverseReaction -/I-AdverseReaction infectious/O pneumonitis/O is/O a/O class/O effect/O of/O rapamycin/O derivatives/O ,/O including/O AFINITOR/O ./O
Non/B-AdverseReaction -/I-AdverseReaction infectious/O pneumonitis/O was/O reported/O in/O up/O to/O 19/O %/O of/O patients/O treated/O with/O AFINITOR/O in/O clinical/O trials/O ./O
The/O incidence/O of/O Common/O Terminology/O Criteria/O (/O CTC/O )/O Grade/B-Severity 3/I-Severity and/O 4/O non/B-AdverseReaction -/I-AdverseReaction infectious/O pneumonitis/O was/O up/O to/O 4.0/O %/O and/O up/O to/O 0.2/O %/O ,/O respectively/O [/O see/O Adverse/O Reactions/O (/O 6.1/O ,/O 6.2/O ,/O 6.3/O ,/O 6.4/O ,/O 6.5/O )/O ]/O ./O
Fatal/B-AdverseReaction outcomes/O have/O been/O observed/O ./O
Consider/B-Factor a/O diagnosis/O of/O non/O -/O infectious/O pneumonitis/O in/O patients/O presenting/O with/O non/O -/O specific/O respiratory/O signs/O and/O symptoms/O such/O as/O hypoxia/O ,/O pleural/O effusion/O ,/O cough/O ,/O or/O dyspnea/O ,/O and/O in/O whom/O infectious/O ,/O neoplastic/O ,/O and/O other/O causes/O have/O been/O excluded/O by/O means/O of/O appropriate/O investigations/O ./O
Opportunistic/O infections/O such/O as/O pneumocystis/O jiroveci/O pneumonia/O (/O PJP/O )/O should/O be/O considered/O in/O the/O differential/O diagnosis/O ./O
Advise/O patients/O to/O report/O promptly/O any/O new/O or/O worsening/O respiratory/O symptoms/O ./O
Patients/O who/O develop/O radiological/O changes/O suggestive/O of/O non/O -/O infectious/O pneumonitis/O and/O have/O few/O or/O no/O symptoms/O may/O continue/O AFINITOR/O therapy/O without/O dose/O alteration/O ./O
Imaging/O appears/O to/O overestimate/O the/O incidence/O of/O clinical/O pneumonitis/O ./O
If/O symptoms/O are/O moderate/O ,/O consider/O interrupting/O therapy/O until/O symptoms/O improve/O ./O
The/O use/O of/O corticosteroids/O may/O be/O indicated/B-Factor ./O
AFINITOR/O may/O be/O reintroduced/O at/O a/O daily/O dose/O approximately/O 50/O %/O lower/O than/O the/O dose/O previously/O administered/O [/O see/O Table/O 1/O in/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
For/O cases/O of/O Grade/O 3/O non/O -/O infectious/O pneumonitis/O interrupt/O AFINITOR/O until/O resolution/O to/O less/O than/O or/O equal/O to/O Grade/O 1/O ./O
AFINITOR/O may/O be/O re/O -/O introduced/O at/O a/O daily/O dose/O approximately/O 50/O %/O lower/O than/O the/O dose/O previously/O administered/O depending/O on/O the/O individual/O clinical/O circumstances/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
If/O toxicity/O recurs/O at/O Grade/O 3/O ,/O consider/O discontinuation/O of/O AFINITOR/O ./O
For/O cases/O of/O Grade/O 4/O non/O -/O infectious/O pneumonitis/O ,/O discontinue/O AFINITOR/O ./O
Corticosteroids/O may/O be/O indicated/O until/O clinical/O symptoms/O resolve/O ./O
For/O patients/O who/O require/O use/O of/O corticosteroids/O for/O treatment/O of/O non/O -/O infectious/O pneumonitis/O ,/O prophylaxis/O for/O PJP/O may/O be/O considered/O ./O
The/O development/O of/O pneumonitis/B-AdverseReaction has/O been/O reported/O even/O at/O a/O reduced/O dose/O ./O
5.2/O Infections/O AFINITOR/O has/O immunosuppressive/O properties/O and/O may/B-Factor predispose/O patients/O to/O bacterial/O ,/O fungal/O ,/O viral/O ,/O or/O protozoal/B-AdverseReaction infections/I-AdverseReaction ,/O including/O infections/B-AdverseReaction with/I-AdverseReaction opportunistic/I-AdverseReaction pathogens/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O ,/O 6.2/O ,/O 6.3/O ,/O 6.4/O ,/O 6.5/O )/O ]/O ./O
Localized/O and/O systemic/O infections/O ,/O including/O pneumonia/B-AdverseReaction ,/O mycobacterial/B-AdverseReaction infections/I-AdverseReaction ,/O other/O bacterial/B-AdverseReaction infections/I-AdverseReaction ,/O invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction ,/O such/O as/O aspergillosis/B-AdverseReaction ,/O candidiasis/B-AdverseReaction ,/O or/O pneumocystis/B-AdverseReaction jiroveci/I-AdverseReaction pneumonia/I-AdverseReaction (/O PJP/B-AdverseReaction )/O and/O viral/B-AdverseReaction infections/I-AdverseReaction including/O reactivation/B-AdverseReaction of/I-AdverseReaction hepatitis/I-AdverseReaction B/I-AdverseReaction virus/I-AdverseReaction have/O occurred/O in/O patients/O taking/O AFINITOR/O ./O
Some/O of/O these/O infections/B-AdverseReaction have/O been/O severe/B-Severity (/O e.g./O ,/O leading/O to/O sepsis/B-AdverseReaction ,/O respiratory/O or/O hepatic/B-AdverseReaction failure/I-AdverseReaction )/O or/O fatal/B-AdverseReaction ./O
Physicians/O and/O patients/O should/O be/O aware/O of/O the/O increased/O risk/O of/O infection/O with/O AFINITOR/O ./O
Complete/O treatment/O of/O pre/O -/O existing/O invasive/O fungal/O infections/O prior/O to/O starting/O treatment/O with/O AFINITOR/O ./O
While/O taking/O AFINITOR/O ,/O be/O vigilant/O for/O signs/O and/O symptoms/O of/O infection/O ;/O if/O a/O diagnosis/O of/O an/O infection/O is/O made/O ,/O institute/O appropriate/O treatment/O promptly/O and/O consider/O interruption/O or/O discontinuation/O of/O AFINITOR/O ./O
If/O a/O diagnosis/O of/O invasive/O systemic/O fungal/O infection/O is/O made/O ,/O discontinue/O AFINITOR/O and/O treat/O with/O appropriate/O antifungal/O therapy/O ./O
Pneumocystis/B-AdverseReaction jiroveci/I-AdverseReaction pneumonia/I-AdverseReaction ,/O some/O with/O a/O fatal/B-AdverseReaction outcome/O ,/O has/O been/O reported/O in/O patients/O who/O received/O everolimus/O ./O
This/O may/O be/O associated/O with/O concomitant/O use/O of/O corticosteroids/O or/O other/O immunosuppressive/O agents/O ./O
Prophylaxis/O for/O PJP/O should/O be/O considered/O when/O concomitant/O use/O of/O corticosteroids/O or/O other/O immunosuppressive/O agents/O are/O required/O ./O
5.3/O Angioedema/O with/O Concomitant/O Use/O of/O Angiotensin/O -/O Converting/O Enzyme/O (/O ACE/O )/O Inhibitors/O Patients/O taking/O concomitant/O ACE/O inhibitor/O therapy/O may/O be/O at/O increased/O risk/B-Factor for/O angioedema/B-AdverseReaction (/O e.g./O ,/O swelling/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction airways/I-AdverseReaction or/O tongue/O ,/O with/O or/O without/O respiratory/B-AdverseReaction impairment/I-AdverseReaction )/O ./O
In/O a/O pooled/O analysis/O of/O randomized/O double/O -/O blind/O oncology/O clinical/O trials/O ,/O the/O incidence/O of/O angioedema/B-AdverseReaction in/O patients/O taking/O everolimus/O with/O an/O ACE/O inhibitor/O was/O 6.8/O %/O compared/O to/O 1.3/O %/O in/O the/O control/O arm/O with/O an/O ACE/O inhibitor/O ./O
5.4/O Oral/O Ulceration/O Mouth/B-AdverseReaction ulcers/I-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O and/O oral/B-AdverseReaction mucositis/I-AdverseReaction have/O occurred/O in/O patients/O treated/O with/O AFINITOR/O at/O an/O incidence/O ranging/O from/O 44%-78/O %/O across/O the/O clinical/O trial/O experience/O ./O
Grade/B-Severity 3/I-Severity or/O 4/O stomatitis/B-AdverseReaction was/O reported/O in/O 4%-9/O %/O of/O patients/O [/O see/O Adverse/O Reactions/O (/O 6.1/O ,/O 6.2/O ,/O 6.3/O ,/O 6.4/O ,/O 6.5/O )/O ]/O ./O
In/O such/O cases/O ,/O topical/O treatments/O are/O recommended/O ,/O but/O alcohol-/O ,/O hydrogen/O peroxide-/O ,/O iodine-/O ,/O or/O thyme-/O containing/O mouthwashes/O should/O be/O avoided/O as/O they/O may/O exacerbate/O the/O condition/O ./O
Antifungal/O agents/O should/O not/O be/O used/O unless/O fungal/O infection/O has/O been/O diagnosed/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
5.5/O Renal/O Failure/O Cases/O of/O renal/B-AdverseReaction failure/I-AdverseReaction (/O including/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction )/O ,/O some/O with/O a/O fatal/B-AdverseReaction outcome/O ,/O have/O been/O observed/O in/O patients/O treated/O with/O AFINITOR/O [/O see/O Laboratory/O Tests/O and/O Monitoring/O (/O 5.8/O )/O ]/O ./O
5.6/O Impaired/O Wound/O Healing/O Everolimus/O delays/B-AdverseReaction wound/I-AdverseReaction healing/I-AdverseReaction and/O increases/O the/O occurrence/O of/O wound/B-AdverseReaction -/I-AdverseReaction related/O complications/O like/O wound/B-AdverseReaction dehiscence/I-AdverseReaction ,/O wound/B-AdverseReaction infection/I-AdverseReaction ,/O incisional/B-AdverseReaction hernia/I-AdverseReaction ,/O lymphocele/B-AdverseReaction ,/O and/O seroma/B-AdverseReaction ./O
These/O wound/O -/O related/O complications/O may/O require/O surgical/O intervention/O ./O
Exercise/O caution/O with/O the/O use/O of/O AFINITOR/O in/O the/O peri/O -/O surgical/O period/O ./O
5.7/O Geriatric/O Patients/O In/O the/O randomized/O advanced/O hormone/O receptor/O -/O positive/O ,/O HER2-negative/O breast/O cancer/O study/O ,/O the/O incidence/O of/O deaths/B-AdverseReaction due/O to/O any/O cause/O within/O 28/O days/O of/O the/O last/O AFINITOR/O dose/O was/O 6/O %/O in/O patients/O 65/O years/O of/O age/O compared/O to/O 2/O %/O in/O patients/O 65/O years/O of/O age/O ./O
Adverse/O reactions/O leading/O to/O permanent/O treatment/O discontinuation/O occurred/O in/O 33/O %/O of/O patients/O 65/O years/O of/O age/O compared/O to/O 17/O %/O in/O patients/O 65/O years/O of/O age/O ./O
Careful/O monitoring/O and/O appropriate/O dose/O adjustments/O for/O adverse/O reactions/O are/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ,/O Use/O in/O Specific/O Populations/O (/O 8.5/O )/O ]/O ./O
5.8/O Laboratory/O Tests/O and/O Monitoring/O Renal/O Function/O Elevations/B-AdverseReaction of/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O proteinuria/B-AdverseReaction have/O been/O reported/O in/O patients/O taking/O AFINITOR/O [/O see/O Adverse/O Reactions/O (/O 6.1/O ,/O 6.2/O ,/O 6.3/O ,/O 6.4/O ,/O 6.5/O )/O ]/O ./O
Monitoring/O of/O renal/O function/O ,/O including/O measurement/O of/O blood/O urea/O nitrogen/O (/O BUN/O )/O ,/O urinary/O protein/O ,/O or/O serum/O creatinine/O ,/O is/O recommended/O prior/O to/O the/O start/O of/O AFINITOR/O therapy/O and/O periodically/O thereafter/O ./O
Renal/O function/O of/O patients/O should/O be/O monitored/O particularly/O where/O patients/O have/O additional/O risk/O factors/O that/O may/O further/O impair/O renal/O function/O ./O
Blood/O Glucose/O and/O Lipids/O Hyperglycemia/B-AdverseReaction ,/O hyperlipidemia/B-AdverseReaction ,/O and/O hypertriglyceridemia/B-AdverseReaction have/O been/O reported/O in/O patients/O taking/O AFINITOR/O [/O see/O Adverse/O Reactions/O (/O 6.1/O ,/O 6.2/O ,/O 6.3/O ,/O 6.4/O ,/O 6.5/O )/O ]/O ./O
Monitoring/O of/O fasting/O serum/O glucose/O and/O lipid/O profile/O is/O recommended/O prior/O to/O the/O start/O of/O AFINITOR/O therapy/O and/O periodically/O thereafter/O as/O well/O as/O management/O with/O appropriate/O medical/O therapy/O ./O
More/O frequent/O monitoring/O is/O recommended/O when/O AFINITOR/O is/O co/O -/O administered/O with/O other/O drugs/O that/O may/O induce/O hyperglycemia/O ./O
When/O possible/O ,/O optimal/O glucose/O and/O lipid/O control/O should/O be/O achieved/O before/O starting/O a/O patient/O on/O AFINITOR/O ./O
Hematologic/O Parameters/O Decreased/B-AdverseReaction hemoglobin/I-AdverseReaction ,/O lymphocytes/O ,/O neutrophils/O ,/O and/O platelets/O have/O been/O reported/O in/O patients/O taking/O AFINITOR/O [/O see/O Adverse/O Reactions/O (/O 6.1/O ,/O 6.2/O ,/O 6.3/O ,/O 6.4/O ,/O 6.5/O )/O ]/O ./O
Monitoring/O of/O complete/O blood/O count/O is/O recommended/O prior/O to/O the/O start/O of/O AFINITOR/O therapy/O and/O periodically/O thereafter/O ./O
5.9/O Drug/O -/O drug/O Interactions/O Due/O to/O significant/O increases/O in/O exposure/O of/O everolimus/O ,/O co/O -/O administration/O with/O strong/O CYP3A4/O PgP/O inhibitors/O should/O be/O avoided/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O ,/O 2.5/O )/O and/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
A/O reduction/O of/O the/O AFINITOR/O dose/O is/O recommended/O when/O co/O -/O administered/O with/O a/O moderate/O CYP3A4/O PgP/O inhibitor/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O ,/O 2.5/O )/O and/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
An/O increase/O in/O the/O AFINITOR/O dose/O is/O recommended/O when/O co/O -/O administered/O with/O a/O strong/O CYP3A4/O PgP/O inducer/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O ,/O 2.5/O )/O and/O Drug/O Interactions/O (/O 7.2/O )/O ]/O ./O
5.10/O Hepatic/O Impairment/O Exposure/O to/O everolimus/O was/O increased/O in/O patients/O with/O hepatic/B-AdverseReaction impairment/I-AdverseReaction [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
For/O advanced/O HR+/O BC/O ,/O advanced/O PNET/O ,/O advanced/O RCC/O ,/O and/O renal/O angiomyolipoma/O with/O TSC/O patients/O with/O severe/B-Severity hepatic/B-AdverseReaction impairment/I-AdverseReaction (/O Child/O -/O Pugh/O class/O C/O )/O ,/O AFINITOR/O may/O be/O used/O at/O a/O reduced/O dose/O if/O the/O desired/O benefit/O outweighs/O the/O risk/O ./O
For/O patients/O with/O mild/O (/O Child/O -/O Pugh/O class/O A/O )/O or/O moderate/O (/O Child/O -/O Pugh/O class/O B/O )/O hepatic/O impairment/O ,/O a/O dose/O reduction/O is/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
For/O patients/O with/O SEGA/O and/O mild/O or/O moderate/O hepatic/O impairment/O ,/O adjust/O the/O dose/O of/O AFINITOR/O Tablets/O or/O AFINITOR/O DISPERZ/O based/O on/O therapeutic/O drug/O monitoring/O ./O
For/O patients/O with/O SEGA/O and/O severe/O hepatic/O impairment/O ,/O reduce/O the/O starting/O dose/O of/O AFINITOR/O Tablets/O or/O AFINITOR/O DISPERZ/O by/O approximately/O 50/O %/O and/O adjust/O subsequent/O doses/O based/O on/O therapeutic/O drug/O monitoring/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O ,/O 2.5/O )/O ]/O ./O
5.11/O Vaccinations/O During/O AFINITOR/O treatment/O ,/O avoid/O the/O use/O of/O live/O vaccines/O and/O avoid/O close/O contact/O with/O individuals/O who/O have/O received/O live/O vaccines/O (/O e.g./O ,/O intranasal/O influenza/O ,/O measles/O ,/O mumps/O ,/O rubella/O ,/O oral/O polio/O ,/O BCG/O ,/O yellow/O fever/O ,/O varicella/O ,/O and/O TY21a/O typhoid/O vaccines/O )/O ./O
For/O pediatric/O patients/O with/O SEGA/O that/O do/O not/O require/O immediate/O treatment/O ,/O complete/O the/O recommended/O childhood/O series/O of/O live/O virus/O vaccinations/O according/O to/O American/O Council/O on/O Immunization/O Practices/O (/O ACIP/O )/O guidelines/O prior/O to/O the/O start/O of/O therapy/O ./O
An/O accelerated/O vaccination/O schedule/O may/O be/O appropriate/O ./O
5.12/O Embryo/O -/O fetal/O Toxicity/O Based/O on/O the/O mechanism/O of/O action/O ,/O AFINITOR/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Everolimus/O caused/O embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicities/O in/O animals/B-Animal at/O maternal/O exposures/O that/O were/O lower/O than/O human/O exposures/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O a/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
Advise/O female/O patients/O of/O reproductive/O potential/O to/O avoid/O becoming/O pregnant/O and/O to/O use/O highly/O effective/O contraception/O while/O using/O AFINITOR/O and/O for/O up/O to/O 8/O weeks/O after/O ending/O treatment/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O Because/O clinical/O studies/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O studies/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O following/O adverse/O reactions/O are/O described/O in/O more/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O of/O the/O label/O :/O Seizures/B-AdverseReaction ,/O Anaphylaxis/B-AdverseReaction ,/O and/O Urinary/B-AdverseReaction Tract/I-AdverseReaction Infections/I-AdverseReaction ./O
EXCERPT/O :/O The/O most/O common/O adverse/O events/O (/O incidence/O 2/O %/O and/O at/O a/O rate/O greater/O than/O the/O placebo/O rate/O )/O for/O AMPYRA/O were/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O balance/B-AdverseReaction disorder/I-AdverseReaction ,/O multiple/B-AdverseReaction sclerosis/I-AdverseReaction relapse/I-AdverseReaction ,/O paresthesia/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O and/O pharyngolaryngeal/B-AdverseReaction pain/I-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Acorda/O Therapeutics/O at/O 1/O -/O 800/O -/O 367/O -/O 5109/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Controlled/O Clinical/O Trials/O Experience/O In/O three/O placebo/O -/O controlled/O clinical/O trials/O of/O up/O to/O 14/O weeks/O duration/O ,/O 4/O %/O (/O 15/400/O )/O of/O patients/O treated/O with/O AMPYRA/O 10/O mg/O twice/O daily/O experienced/O one/O or/O more/O treatment/O emergent/O adverse/O events/O leading/O to/O discontinuation/O ,/O compared/O to/O 2/O %/O (/O 5/238/O )/O of/O placebo/O -/O treated/O patients/O ./O
The/O treatment/O emergent/O adverse/O events/O leading/O to/O discontinuation/O of/O at/O least/O 2/O patients/O treated/O with/O AMPYRA/O and/O that/O led/O to/O discontinuation/O more/O frequently/O compared/O to/O placebo/O were/O headache/B-AdverseReaction (/O AMPYRA/O 0.5/O %/O ,/O placebo/O 0/O %/O )/O ,/O balance/B-AdverseReaction disorder/I-AdverseReaction (/O AMPYRA/O 0.5/O %/O ,/O placebo/O 0/O %/O )/O ,/O dizziness/B-AdverseReaction (/O AMPYRA/O 0.5/O %/O ,/O placebo/O 0/O %/O )/O ,/O and/O confusional/B-AdverseReaction state/I-AdverseReaction (/O AMPYRA/O 0.3/O %/O ,/O placebo/O 0/O %/O )/O ./O
Table/O 1/O lists/O adverse/O reactions/O that/O occurred/O in/O 2/O %/O of/O patients/O treated/O with/O AMPYRA/O 10/O mg/O twice/O daily/O ,/O and/O more/O frequently/O than/O in/O placebo/O -/O treated/O patients/O ,/O in/O controlled/O clinical/O trials/O ./O
Table/O 1/O :/O Adverse/O reactions/O with/O an/O incidence/O 2/O %/O of/O AMPYRA/O treated/O MS/O patients/O ,/O and/O more/O frequent/O with/O AMPYRA/O compared/O to/O placebo/O in/O controlled/O clinical/O trials/O Adverse/O Reaction/O Placebo(N=238/O )/O AMPYRA10/O mg/O twice/O daily(N=400/O )/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 8/O %/O 12/O %/O Insomnia/B-AdverseReaction 4/O %/O 9/O %/O Dizziness/B-AdverseReaction 4/O %/O 7/O %/O Headache/B-AdverseReaction 4/O %/O 7/O %/O Nausea/B-AdverseReaction 3/O %/O 7/O %/O Asthenia/B-AdverseReaction 4/O %/O 7/O %/O Back/B-AdverseReaction pain/I-AdverseReaction 2/O %/O 5/O %/O Balance/B-AdverseReaction disorder/I-AdverseReaction 1/O %/O 5/O %/O Multiple/B-AdverseReaction sclerosis/I-AdverseReaction relapse/I-AdverseReaction 3/O %/O 4/O %/O Paresthesia/B-AdverseReaction 3/O %/O 4/O %/O Nasopharyngitis/B-AdverseReaction 2/O %/O 4/O %/O Constipation/B-AdverseReaction 2/O %/O 3/O %/O Dyspepsia/B-AdverseReaction 1/O %/O 2/O %/O Pharyngolaryngeal/B-AdverseReaction pain/I-AdverseReaction 1/O %/O 2/O %/O 6.2/O Other/O Adverse/O Reactions/O AMPYRA/O has/O been/O evaluated/O in/O a/O total/O of/O 1,952/O subjects/O ,/O including/O 917/O MS/O patients/O ./O
A/O total/O of/O 741/O patients/O have/O been/O treated/O with/O AMPYRA/O for/O over/O six/O months/O ,/O 501/O for/O over/O one/O year/O and/O 352/O for/O over/O two/O years/O ./O
The/O experience/O in/O open/O -/O label/O clinical/O trials/O is/O consistent/O with/O the/O safety/O profile/O observed/O in/O the/O placebo/O -/O controlled/O clinical/O trials/O ./O
As/O in/O controlled/O clinical/O trials/O ,/O a/O dose/O -/O dependent/O increase/O in/O the/O incidence/O of/O seizures/B-AdverseReaction has/O been/O observed/O in/O open/O -/O label/O clinical/O trials/O with/O AMPYRA/O in/O patients/O with/O MS/O as/O follows/O :/O AMPYRA/O 10/O mg/O twice/O daily/O 0.41/O per/O 100/O person/O -/O years/O (/O 95/O %/O confidence/O interval/O 0.13/O -/O 0.96/O )/O ;/O dalfampridine/O 15/O mg/O twice/O daily/O 1.7/O per/O 100/O person/O -/O years/O (/O 95/O %/O confidence/O interval/O 0.21/O -/O 6.28/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O AMPYRA/O can/B-Factor cause/O seizures/B-AdverseReaction ;/O the/O risk/B-Factor of/O seizures/B-AdverseReaction increases/O with/O increasing/O AMPYRA/O doses/O ;/O discontinue/O AMPYRA/O and/O do/O not/O restart/O if/O a/O seizure/O occurs/O (/O 5.1/O )/O AMPYRA/O should/O not/O be/O taken/O with/O other/O forms/O of/O 4-aminopyridine/O (/O 4-AP/O ,/O fampridine/O )/O ,/O since/O the/O active/O ingredient/O is/O the/O same/O (/O 5.3/O )/O AMPYRA/O can/B-Factor cause/O anaphylaxis/B-AdverseReaction ./O
Discontinue/O and/O do/O not/O restart/O AMPYRA/O if/O this/O occurs/O (/O 5.4/O )/O 5.1/O Seizures/O AMPYRA/O can/B-Factor cause/O seizures/B-AdverseReaction ./O
Increased/O incidence/O of/O seizures/B-AdverseReaction has/O been/O observed/O at/O 20/O mg/O twice/O daily/O in/O controlled/O clinical/O studies/O of/O 9/O -/O 14/O weeks/O duration/O with/O dalfampridine/O in/O patients/O with/O MS/O ./O
In/O open/O label/O extension/O trials/O in/O MS/O patients/O ,/O the/O incidence/O of/O seizures/B-AdverseReaction during/O treatment/O with/O dalfampridine/O 15/O mg/O twice/O daily/O (/O 1.7/100PY/O )/O was/O over/O 4/O times/O higher/O than/O the/O incidence/O during/O treatment/O with/O 10/O mg/O twice/O daily/O (/O 0.4/100PY/O )/O ./O
In/O the/O post/O -/O marketing/O period/O seizures/B-AdverseReaction have/O been/O reported/O ./O
The/O majority/O of/O seizures/B-AdverseReaction occurred/O at/O the/O recommended/O dose/O and/O in/O patients/O without/O a/O history/O of/O seizures/O ,/O and/O generally/O within/O days/O to/O weeks/O of/O starting/O therapy/O ./O
AMPYRA/O has/O not/O been/O evaluated/O in/O patients/O with/O a/O history/O of/O seizures/O or/O with/O evidence/O of/O epileptiform/O activity/O on/O an/O EEG/O ,/O as/O these/O patients/O were/O excluded/O from/O clinical/O trials/O ./O
The/O risk/O of/O seizures/O in/O patients/O with/O epileptiform/O activity/O on/O an/O EEG/O is/O unknown/O ,/O and/O could/O be/O substantially/O higher/O than/O that/O observed/O in/O AMPYRA/O clinical/O studies/O ./O
AMPYRA/O should/O be/O discontinued/O and/O not/O restarted/O in/O patients/O who/O experience/O a/O seizure/O while/O on/O treatment/O ./O
AMPYRA/O is/O contraindicated/O in/O patients/O with/O a/O history/O of/O seizures/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.2/O Renal/O Impairment/O AMPYRA/O is/O eliminated/O through/O the/O kidneys/O primarily/O as/O unchanged/O drug/O [/O see/O Clinical/O Pharmacology/O (/O 12.4/O )/O ]/O ./O
Because/O patients/O with/O moderate/O to/O severe/O renal/O impairment/O (/O CrCl/O 50mL/O min/O )/O would/O require/O a/O dose/O lower/O than/O 10/O mg/O twice/O daily/O and/O no/O strength/O smaller/O than/O 10/O mg/O is/O available/O ,/O AMPYRA/O is/O contraindicated/O in/O these/O patients/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
In/O patients/O with/O mild/O renal/O impairment/O (/O CrCl/O 51/O -/O 80/O mL/O min/O )/O ,/O AMPYRA/O plasma/O levels/O may/O approach/O those/O seen/O at/O a/O dose/O of/O 15/O mg/O twice/O daily/O ,/O a/O dose/O that/O may/B-Factor be/O associated/O with/O an/O increased/O risk/O of/O seizures/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5.3/O Concurrent/O Treatment/O with/O Other/O Forms/O of/O 4-Aminopyridine/O AMPYRA/O should/O not/O be/O taken/O with/O other/O forms/O of/O 4-aminopyridine/O (/O 4-AP/O ,/O fampridine/O )/O since/O the/O active/O ingredient/O is/O the/O same/O ./O
Patients/O should/O discontinue/O use/O of/O any/O product/O containing/O 4-aminopyridine/O prior/O to/O initiating/O treatment/O with/O AMPYRA/O in/O order/O to/O reduce/O the/O potential/O for/O dose/O -/O related/O adverse/O reactions/O ./O
5.4/O Anaphylaxis/O AMPYRA/O can/B-Factor cause/O anaphylaxis/B-AdverseReaction and/O severe/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction ./O
Signs/O and/O symptoms/O have/O included/O respiratory/B-AdverseReaction compromise/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O and/O angioedema/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction throat/I-AdverseReaction and/O or/O tongue/O ./O
Patients/O should/O be/O informed/O of/O the/O signs/O and/O symptoms/O of/O anaphylaxis/O and/O instructed/O to/O discontinue/O AMPYRA/O and/O seek/O immediate/O medical/O care/O should/O these/O signs/O and/O symptoms/O occur/O (/O 17.3/O )/O ./O
5.5/O Urinary/O Tract/O Infections/O Urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction (/O UTIs/B-AdverseReaction )/O were/O reported/O more/O frequently/O as/O adverse/O reactions/O in/O controlled/O studies/O in/O patients/O receiving/O AMPYRA/O 10/O mg/O twice/O daily/O (/O 12/O %/O )/O as/O compared/O to/O placebo/O (/O 8/O %/O )/O ./O
UTIs/O in/O AMPYRA/O -/O treated/O patients/O should/O be/O evaluated/O and/O treated/O as/O clinically/O indicated/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O reported/O adverse/O reaction/O was/O headache/B-AdverseReaction ,/O occurring/O in/O 2/O %/O of/O patients/O ,/O followed/O by/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O blood/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O all/O occurring/O in/O 1/O %/O of/O patients/O (/O 6/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Eli/O Lilly/O and/O Company/O at/O 1/O -/O 800-LillyRx/O (/O 1/O -/O 800/O -/O 545/O -/O 5979/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
In/O clinical/O studies/O ,/O 555/O patients/O were/O exposed/O to/O Amyvid/O ./O
Amyvid/O caused/O no/O serious/O adverse/O reactions/O in/O the/O studies/O and/O the/O reported/O adverse/O reactions/O were/O predominantly/O mild/O to/O moderate/O in/O severity/O ./O
The/O adverse/O reactions/O reported/O in/O more/O than/O one/O subject/O within/O the/O studies/O are/O shown/O in/O Table/O 2/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Reported/O in/O Clinical/O Trials/O (/O N=555/O patients/O )/O a/O Includes/O the/O terms/O blood/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction and/O hypertension/B-AdverseReaction ./O
b/O Includes/O the/O terms/O injection/B-AdverseReaction site/I-AdverseReaction haemorrhage/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction irritation/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ./O
c/O Includes/O the/O terms/O feeling/B-AdverseReaction cold/I-AdverseReaction and/O chills/B-AdverseReaction ./O
Adverse/O Reactions/O N/O (/O Percent/O of/O patients/O )/O Headache/B-AdverseReaction 10/O (/O 1.8/O %/O )/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 4/O (/O 0.7/O %/O )/O Blood/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction a/O 4/O (/O 0.7/O %/O )/O Nausea/B-AdverseReaction 4/O (/O 0.7/O %/O )/O Fatigue/B-AdverseReaction 3/O (/O 0.5/O %/O )/O Injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction b/O 3/O (/O 0.5/O %/O )/O Anxiety/B-AdverseReaction 2/O (/O 0.4/O %/O )/O Back/B-AdverseReaction pain/I-AdverseReaction 2/O (/O 0.4/O %/O )/O Claustrophobia/B-AdverseReaction 2/O (/O 0.4/O %/O )/O Dizziness/B-AdverseReaction 2/O (/O 0.4/O %/O )/O Feeling/B-AdverseReaction cold/I-AdverseReaction c/O 2/O (/O 0.4/O %/O )/O Insomnia/B-AdverseReaction 2/O (/O 0.4/O %/O )/O Neck/B-AdverseReaction pain/I-AdverseReaction 2/O (/O 0.4/O %/O )/O Other/O adverse/O reactions/O occurred/O at/O lower/O frequencies/O and/O included/O infusion/B-AdverseReaction site/I-AdverseReaction rash/I-AdverseReaction ,/O dysgeusia/B-AdverseReaction ,/O pruritis/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O and/O flushing/B-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Image/O interpretation/O errors/O (/O especially/O false/O negatives/O )/O have/O been/O observed/O (/O 5.1/O )/O ./O
Radiation/B-AdverseReaction risk/I-AdverseReaction :/O Amyvid/O ,/O similar/O to/O all/O radiopharmaceuticals/O ,/O contributes/O to/O a/O patient/O 's/O long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O ./O
Ensure/O safe/O handling/O to/O protect/O patients/O and/O health/O care/O workers/O from/O unintentional/O radiation/O exposure/O (/O 2.1/O ,/O 5.2/O )/O ./O
5.1/O Risk/O for/O Image/O Misinterpretation/O and/O other/O Errors/O Errors/O may/O occur/O in/O the/O Amyvid/O estimation/O of/O brain/O neuritic/O plaque/O density/O during/O image/O interpretation/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Image/O interpretation/O should/O be/O performed/O independently/O of/O the/O patient/O 's/O clinical/O information/O ./O
The/O use/O of/O clinical/O information/O in/O the/O interpretation/O of/O Amyvid/O images/O has/O not/O been/O evaluated/O and/O may/O lead/O to/O errors/O ./O
Other/O errors/O may/O be/O due/O to/O extensive/O brain/O atrophy/O that/O limits/O the/O ability/O to/O distinguish/O gray/O and/O white/O matter/O on/O the/O Amyvid/O scan/O as/O well/O as/O motion/O artifacts/O that/O distort/O the/O image/O ./O
Amyvid/O scan/O results/O are/O indicative/O of/O the/O brain/O neuritic/O amyloid/O plaque/O content/O only/O at/O the/O time/O of/O image/O acquisition/O and/O a/O negative/O scan/O result/O does/O not/O preclude/O the/O development/O of/O brain/O amyloid/O in/O the/O future/O ./O
5.2/O Radiation/O Risk/O Amyvid/O ,/O similar/O to/O other/O radiopharmaceuticals/O ,/O contributes/O to/O a/O patient/O 's/O overall/O long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O ./O
Long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O is/O associated/O with/O an/O increased/O risk/B-Factor of/O cancer/B-AdverseReaction ./O
Ensure/O safe/O handling/O to/O protect/O patients/O and/O health/O care/O workers/O from/O unintentional/O radiation/O exposure/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O described/O in/O more/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O of/O the/O label/O :/O Suicidal/B-AdverseReaction Behavior/I-AdverseReaction and/O Ideation/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Serious/B-Severity Dermatologic/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Drug/B-AdverseReaction Reaction/I-AdverseReaction with/I-AdverseReaction Eosinophilia/I-AdverseReaction and/I-AdverseReaction Systemic/I-AdverseReaction Symptoms/I-AdverseReaction (/O DRESS)/Multiorgan/B-AdverseReaction Hypersensitivity/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Anaphylactic/B-AdverseReaction Reactions/I-AdverseReaction and/O Angioedema/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Hyponatremia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Neurological/B-AdverseReaction Adverse/I-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Drug/B-AdverseReaction Induced/I-AdverseReaction Liver/I-AdverseReaction Injury/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Abnormal/B-AdverseReaction Thyroid/I-AdverseReaction Function/I-AdverseReaction Tests/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O in/O patients/O receiving/O APTIOM/O (/O 4/O %/O and/O 2/O %/O greater/O than/O placebo/O )/O :/O dizziness/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O vertigo/B-AdverseReaction ,/O ataxia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O and/O tremor/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Sunovion/O at/O 1/O -/O 877/O -/O 737/O -/O 7226/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
In/O monotherapy/O trials/O in/O patients/O with/O partial/O -/O onset/O seizures/O [/O Study/O 1/O and/O Study/O 2/O ,/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ,/O 365/O patients/O received/O APTIOM/O ,/O of/O whom/O 225/O were/O treated/O for/O longer/O than/O 12/O months/O and/O 134/O for/O longer/O than/O 24/O months/O ./O
Of/O the/O patients/O in/O those/O trials/O ,/O 95/O %/O were/O between/O 18/O and/O 65/O years/O old/O ;/O 48/O %/O were/O male/O ,/O and/O 84/O %/O were/O Caucasian/O ./O
Across/O controlled/O and/O uncontrolled/O trials/O in/O patients/O receiving/O adjunctive/O therapy/O for/O partial/O -/O onset/O seizures/O ,/O 1195/O patients/O received/O APTIOM/O ,/O of/O whom/O 586/O were/O treated/O for/O longer/O than/O 6/O months/O and/O 462/O for/O longer/O than/O 12/O months/O ./O
In/O the/O placebo/O controlled/O adjunctive/O therapy/O trials/O in/O patients/O with/O partial/O -/O onset/O seizures/O (/O Study/O 3/O ,/O Study/O 4/O and/O Study/O 5/O )/O ,/O 1021/O patients/O received/O APTIOM/O ./O
Of/O the/O patients/O in/O those/O trials/O ,/O approximately/O 95/O %/O were/O between/O 18/O and/O 60/O years/O old/O ,/O approximately/O 50/O %/O were/O male/O ,/O and/O approximately/O 80/O %/O were/O Caucasian/O ./O
Monotherapy/O Historical/O Control/O Trials/O In/O the/O monotherapy/O epilepsy/O trials/O (/O Study/O 1/O and/O Study/O 2/O )/O ,/O 13/O %/O of/O patients/O randomized/O to/O receive/O APTIOM/O at/O the/O recommended/O doses/O of/O 1200/O mg/O and/O 1600/O mg/O once/O daily/O discontinued/O from/O the/O trials/O as/O a/O result/O of/O an/O adverse/O event/O ./O
The/O adverse/O reaction/O most/O commonly/O (/O 1/O %/O on/O APTIOM/O )/O leading/O to/O discontinuation/O was/O hyponatremia/B-AdverseReaction ./O
Adverse/O reactions/O observed/O in/O these/O studies/O were/O generally/O similar/O to/O those/O observed/O and/O attributed/O to/O drug/O in/O adjunctive/O placebo/O -/O controlled/O studies/O ./O
Because/O these/O studies/O did/O not/O include/O a/O placebo/O control/O group/O ,/O causality/O could/O not/O be/O established/O ./O
Dizziness/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O and/O fatigue/B-AdverseReaction were/O all/O reported/O at/O lower/O incidences/O during/O the/O AED/O Withdrawal/O Phase/O and/O Monotherapy/O Phase/O compared/O with/O the/O Titration/O Phase/O ./O
Adjunctive/O Therapy/O Controlled/O Trials/O In/O the/O controlled/O adjunctive/O therapy/O epilepsy/O trials/O (/O Study/O 3/O ,/O Study/O 4/O ,/O and/O Study/O 5/O )/O ,/O the/O rate/O of/O discontinuation/O as/O a/O result/O of/O any/O adverse/O reaction/O was/O 14/O %/O for/O the/O 800/O mg/O dose/O ,/O 25/O %/O for/O the/O 1200/O mg/O dose/O ,/O and/O 7/O %/O in/O subjects/O randomized/O to/O placebo/O ./O
The/O adverse/O reactions/O most/O commonly/O (/O 1/O %/O in/O any/O APTIOM/O treatment/O group/O ,/O and/O greater/O than/O placebo/O )/O leading/O to/O discontinuation/O ,/O in/O descending/O order/O of/O frequency/O ,/O were/O dizziness/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O ataxia/B-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O vertigo/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O dysarthria/B-AdverseReaction ,/O and/O tremor/B-AdverseReaction ./O
The/O most/O frequently/O reported/O adverse/O reactions/O in/O patients/O receiving/O APTIOM/O at/O doses/O of/O 800/O mg/O or/O 1200/O mg/O (/O 4/O %/O and/O 2/O %/O greater/O than/O placebo/O )/O were/O dizziness/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O vertigo/B-AdverseReaction ,/O ataxia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O and/O tremor/B-AdverseReaction ./O
Table/O 3/O gives/O the/O incidence/O of/O adverse/O reactions/O that/O occurred/O in/O 2/O %/O of/O subjects/O with/O partial/O -/O onset/O seizures/O in/O any/O APTIOM/O treatment/O group/O and/O for/O which/O the/O incidence/O was/O greater/O than/O placebo/O during/O the/O controlled/O clinical/O trials/O ./O
Adverse/O reactions/O during/O titration/O were/O less/O frequent/O for/O patients/O who/O began/O therapy/O at/O an/O initial/O dose/O of/O 400/O mg/O for/O 1/O week/O and/O then/O increased/O to/O 800/O mg/O compared/O to/O patients/O who/O initiated/O therapy/O at/O 800/O mg/O ./O
Table/O 3/O :/O Adverse/O Reactions/O Incidence/O in/O Pooled/O Controlled/O Clinical/O Trials/O of/O Adjunctive/O Therapy/O in/O Adults/O (/O Events/O 2/O %/O of/O Patients/O in/O the/O APTIOM/O 800/O mg/O or/O 1200/O mg/O Dose/O Group/O and/O More/O Frequent/O Than/O in/O the/O Placebo/O Group/O )/O Placebo/O APTIOM/O 800/O mg/O 1200/O mg/O (/O N=426/O )/O %/O (/O N=415/O )/O %/O (/O N=410/O )/O %/O Ear/O and/O labyrinth/O disorders/O Vertigo/B-AdverseReaction 1/O 2/O 6/O Eye/O disorders/O Diplopia/B-AdverseReaction Blurred/B-AdverseReaction vision/I-AdverseReaction Visual/B-AdverseReaction impairment/I-AdverseReaction 211/O 962/O 1151/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction Vomiting/B-AdverseReaction Diarrhea/B-AdverseReaction Constipation/B-AdverseReaction Abdominal/B-AdverseReaction pain/I-AdverseReaction Gastritis/B-AdverseReaction 53311<1/O 1064222/O 1610222<1/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction Asthenia/B-AdverseReaction Gait/B-AdverseReaction disturbance/I-AdverseReaction Peripheral/B-AdverseReaction edema/I-AdverseReaction 42<11/O 4222/O 7321/O Infections/O and/O Infestations/O Urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction 1/O 2/O 2/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Fall/B-AdverseReaction 1/O 3/O 1/O Metabolism/O and/O nutrition/O disorders/O Hyponatremia/B-AdverseReaction 1/O 2/O 2/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction Somnolence/B-AdverseReaction Headache/B-AdverseReaction Ataxia/B-AdverseReaction Balance/B-AdverseReaction disorder/I-AdverseReaction Tremor/B-AdverseReaction Dysarthria/B-AdverseReaction Memory/B-AdverseReaction impairment/I-AdverseReaction Nystagmus/B-AdverseReaction 9892<110<1<1/O 201113432111/O 281815634222/O Psychiatric/O disorders/O Depression/B-AdverseReaction Insomnia/B-AdverseReaction 21/O 12/O 32/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 1/O 2/O 1/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 1/O 1/O 3/O Vascular/O disorders/O Hypertension/B-AdverseReaction 1/O 1/O 2/O Other/O Adverse/O Reactions/O with/O APTIOM/O Use/O Compared/O to/O placebo/O ,/O APTIOM/O use/O was/O associated/O with/O slightly/O higher/O frequencies/O of/O decreases/O in/O hemoglobin/O and/O hematocrit/O ,/O increases/O in/O total/O cholesterol/O ,/O triglycerides/O ,/O and/O LDL/O ,/O and/O increases/O in/O creatine/O phosphokinase/O ./O
Adverse/O Reactions/O Based/O on/O Gender/O and/O Race/O No/O significant/O gender/O differences/O were/O noted/O in/O the/O incidence/O of/O adverse/O reactions/O ./O
Although/O there/O were/O few/O non/O -/O Caucasian/O patients/O ,/O no/O differences/O in/O the/O incidences/O of/O adverse/O reactions/O compared/O to/O Caucasian/O patients/O were/O observed/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Suicidal/B-AdverseReaction Behavior/I-AdverseReaction and/O Ideation/O :/O Monitor/O for/O suicidal/O thoughts/O or/O behavior/O ./O
(/O 5.1/O )/O Serious/B-Severity Dermatologic/B-AdverseReaction Reactions/I-AdverseReaction ,/O Drug/B-AdverseReaction Reaction/I-AdverseReaction with/I-AdverseReaction Eosinophilia/I-AdverseReaction and/I-AdverseReaction Systemic/I-AdverseReaction Symptoms/I-AdverseReaction (/O DRESS/B-AdverseReaction )/O ,/O Anaphylactic/B-AdverseReaction Reactions/I-AdverseReaction and/O Angioedema/B-AdverseReaction :/O Monitor/O and/O discontinue/O if/O another/O cause/O can/O not/O be/O established/O ./O
(/O 5.2/O ,/O 5.3/O ,/O 5.4/O )/O Hyponatremia/B-AdverseReaction :/O Monitor/O sodium/O levels/O in/O patients/O at/O risk/O or/O patients/O experiencing/O hyponatremia/O symptoms/O ./O
(/O 5.5/O )/O Neurological/B-AdverseReaction Adverse/I-AdverseReaction Reactions/I-AdverseReaction :/O Monitor/O for/O dizziness/O ,/O disturbance/O in/O gait/O and/O coordination/O ,/O somnolence/O ,/O fatigue/O ,/O cognitive/O dysfunction/O ,/O and/O visual/O changes/O ./O
Use/O caution/O when/O driving/O or/O operating/O machinery/O ./O
(/O 5.6/O )/O Withdrawal/O of/O APTIOM/O :/O Withdraw/O APTIOM/O gradually/O to/O minimize/O the/O risk/O of/O increased/O seizure/O frequency/O and/O status/O epilepticus/O ./O
(/O 2.6/O ,/O 5.7/O )/O Drug/B-AdverseReaction Induced/I-AdverseReaction Liver/I-AdverseReaction Injury/I-AdverseReaction :/O Discontinue/O APTIOM/O in/O patients/O with/O jaundice/O or/O evidence/O of/O significant/O liver/O injury/O ./O
(/O 5.8/O )/O 5.1/O Suicidal/O Behavior/O and/O Ideation/O Antiepileptic/O drugs/O (/O AEDs/O )/O ,/O including/O APTIOM/O ,/O increase/O the/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O in/O patients/O taking/O these/O drugs/O for/O any/O indication/O ./O
Patients/O treated/O with/O any/O AED/O for/O any/O indication/O should/O be/O monitored/O for/O the/O emergence/O or/O worsening/O of/O depression/O ,/O suicidal/O thoughts/O or/O behavior/O ,/O and/or/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ./O
Pooled/O analyses/O of/O 199/O placebo/O -/O controlled/O clinical/O trials/O (/O mono-/O and/O adjunctive/O therapy/O )/O of/O 11/O different/O AEDs/O showed/O that/O patients/O randomized/O to/O one/O of/O the/O AEDs/O had/O approximately/O twice/O the/O risk/O (/O adjusted/O Relative/O Risk/O 1.8/O ,/O 95/O %/O confidence/O interval/O [/O CI/O ]/O :/O 1.2/O ,/O 2.7/O )/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O compared/O to/O patients/O randomized/O to/O placebo/O ./O
In/O these/O trials/O ,/O which/O had/O a/O median/O treatment/O duration/O of/O 12/O weeks/O ,/O the/O estimated/O incidence/O of/O suicidal/B-AdverseReaction behavior/I-AdverseReaction or/O ideation/O among/O 27,863/O AED/O -/O treated/O patients/O was/O 0.43/O %/O ,/O compared/O to/O 0.24/O %/O among/O 16,029/O placebo/O -/O treated/O patients/O ,/O representing/O an/O increase/O of/O approximately/O one/O case/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O for/O every/O 530/O patients/O treated/O ./O
There/O were/O four/O suicides/B-AdverseReaction in/O drug/O -/O treated/O patients/O in/O the/O trials/O and/O none/O in/O placebo/O -/O treated/O patients/O ,/O but/O the/O number/B-Factor of/I-Factor events/I-Factor is/I-Factor too/I-Factor small/I-Factor to/I-Factor allow/I-Factor any/I-Factor conclusion/I-Factor about/O drug/O effect/O on/O suicide/B-AdverseReaction ./O
The/O increased/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O with/O AEDs/O was/O observed/O as/O early/O as/O one/O week/O after/O starting/O treatment/O with/O AEDs/O and/O persisted/O for/O the/O duration/O of/O treatment/O assessed/O ./O
Because/O most/O trials/O included/O in/O the/O analysis/O did/O not/O extend/O beyond/O 24/O weeks/O ,/O the/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O beyond/O 24/O weeks/O could/O not/O be/O assessed/O ./O
The/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O generally/O consistent/O among/O drugs/O in/O the/O data/O analyzed/O ./O
The/O finding/O of/O increased/O risk/O with/O AEDs/O of/O varying/O mechanisms/O of/O action/O and/O across/O a/O range/O of/O indications/O suggests/O that/O the/O risk/O applies/O to/O all/O AEDs/O used/O for/O any/O indication/O ./O
The/O risk/O did/O not/O vary/O substantially/O by/O age/O (/O 5/O -/O 100/O years/O )/O in/O the/O clinical/O trials/O analyzed/O ./O
Table/O 2/O shows/O absolute/O and/O relative/O risk/O by/O indication/O for/O all/O evaluated/O AEDs/O ./O
Table/O 2/O :/O Risk/B-Factor of/O Suicidal/B-AdverseReaction Thoughts/I-AdverseReaction or/O Behaviors/O by/O Indication/O for/O Antiepileptic/O Drugs/O in/O the/O Pooled/O Analysis/O Indication/O Placebo/O Patients/O with/O Events/O Per/O 1000/O Patients/O Drug/O Patients/O with/O Events/O Per/O 1000/O Patients/O Relative/O Risk/O :/O Incidence/O of/O Events/O in/O Drug/O Patients/O Incidence/O in/O Placebo/O Patients/O Risk/O Differences/O :/O Additional/O Drug/O Patients/O with/O Events/O Per/O 1000/O Patients/O Epilepsy/O 1.0/O 3.4/O 3.5/O 2.4/O Psychiatric/O 5.7/O 8.5/O 1.5/O 2.9/O Other/O 1.0/O 1.8/O 1.9/O 0.9/O Total/O 2.4/O 4.3/O 1.8/O 1.9/O The/O relative/O risk/O for/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O higher/O in/O clinical/O trials/O in/O patients/O with/O epilepsy/O than/O in/O clinical/O trials/O in/O patients/O with/O psychiatric/O or/O other/O conditions/O ,/O but/O the/O absolute/O risk/O differences/O were/O similar/O for/O epilepsy/O and/O psychiatric/O indications/O ./O
Anyone/O considering/O prescribing/O APTIOM/O or/O any/O other/O AED/O must/O balance/O this/O risk/O with/O the/O risk/O of/O untreated/O illness/O ./O
Epilepsy/O and/O many/O other/O illnesses/B-Negation for/I-Negation which/I-Negation AEDs/I-Negation are/I-Negation prescribed/I-Negation are/O themselves/O associated/O with/O morbidity/B-AdverseReaction and/O mortality/B-AdverseReaction and/O an/O increased/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction and/O behavior/O ./O
Should/O suicidal/O thoughts/O and/O behavior/O emerge/O during/O treatment/O ,/O the/O prescriber/O needs/O to/O consider/O whether/O the/O emergence/O of/O these/O symptoms/O in/O any/O given/O patient/O may/O be/O related/O to/O the/O illness/O being/O treated/O ./O
Patients/O ,/O their/O caregivers/O ,/O and/O families/O should/O be/O informed/O that/O AEDs/O increase/O the/O risk/O of/O suicidal/O thoughts/O and/O behavior/O and/O should/O be/O advised/O of/O the/O need/O to/O be/O alert/O for/O the/O emergence/O or/O worsening/O of/O the/O signs/O and/O symptoms/O of/O depression/O ;/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ;/O or/O the/O emergence/O of/O suicidal/O thoughts/O ,/O behavior/O ,/O or/O thoughts/O about/O self/O -/O harm/O ./O
Behaviors/O of/O concern/O should/O be/O reported/O immediately/O to/O healthcare/O providers/O ./O
5.2/O Serious/O Dermatologic/O Reactions/O Serious/O dermatologic/B-AdverseReaction reactions/I-AdverseReaction including/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O Syndrome/O (/O SJS/B-AdverseReaction )/O have/O been/O reported/O in/O association/O with/O APTIOM/O use/O ./O
Serious/B-Severity and/O sometimes/O fatal/B-AdverseReaction dermatologic/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction (/O TEN/B-AdverseReaction )/O and/O SJS/B-AdverseReaction ,/O have/O been/O reported/O in/O patients/O using/O oxcarbazepine/B-DrugClass or/O carbamazepine/O which/O are/O chemically/O related/O to/O APTIOM/O ./O
The/O reporting/O rate/O of/O these/O reactions/O associated/O with/O oxcarbazepine/O use/O exceeds/O the/O background/O incidence/O rate/O estimates/O by/O a/O factor/O of/O 3-/O to/O 10-fold/O ./O
Risk/O factors/O for/O development/O of/O serious/B-Severity dermatologic/B-AdverseReaction reactions/I-AdverseReaction with/O APTIOM/O use/O have/O not/B-Negation been/O identified/O ./O
If/O a/O patient/O develops/O a/O dermatologic/O reaction/O while/O taking/O APTIOM/O ,/O discontinue/O APTIOM/O use/O ,/O unless/O the/O reaction/O is/O clearly/O not/O drug/O -/O related/O ./O
Patients/O with/O a/O prior/O dermatologic/O reaction/O with/O either/O oxcarbazepine/O or/O APTIOM/O should/O not/O be/O treated/O with/O APTIOM/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.3/O Drug/O Reaction/O with/O Eosinophilia/O and/O Systemic/O Symptoms/O (/O DRESS)/Multiorgan/O Hypersensitivity/O Drug/B-AdverseReaction Reaction/I-AdverseReaction with/I-AdverseReaction Eosinophilia/I-AdverseReaction and/I-AdverseReaction Systemic/I-AdverseReaction Symptoms/I-AdverseReaction (/O DRESS/B-AdverseReaction )/O ,/O also/O known/O as/O Multiorgan/B-AdverseReaction Hypersensitivity/I-AdverseReaction ,/O has/O been/O reported/O in/O patients/O taking/O APTIOM/O ./O
DRESS/B-AdverseReaction may/O be/O fatal/B-AdverseReaction or/O life/B-Severity -/O threatening/O ./O
DRESS/B-AdverseReaction typically/O ,/O although/O not/O exclusively/O ,/O presents/O with/O fever/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/or/O lymphadenopathy/B-AdverseReaction ,/O in/O association/O with/O other/O organ/O system/O involvement/O ,/O such/O as/O hepatitis/B-AdverseReaction ,/O nephritis/B-AdverseReaction ,/O hematological/B-AdverseReaction abnormalities/I-AdverseReaction ,/O myocarditis/B-AdverseReaction ,/O or/O myositis/B-AdverseReaction sometimes/O resembling/O an/O acute/O viral/O infection/O ./O
Eosinophilia/B-AdverseReaction is/O often/O present/O ./O
Because/O this/O disorder/O is/O variable/O in/O its/O expression/O ,/O other/O organ/O systems/O not/O noted/O here/O may/O be/O involved/O ./O
It/O is/O important/O to/O note/O that/O early/O manifestations/O of/O hypersensitivity/B-AdverseReaction ,/O such/O as/O fever/B-AdverseReaction or/O lymphadenopathy/B-AdverseReaction ,/O may/O be/O present/O even/O though/O rash/B-AdverseReaction is/O not/B-Negation evident/I-Negation ./O
If/O such/O signs/O or/O symptoms/O are/O present/O ,/O the/O patient/O should/O be/O evaluated/O immediately/O ./O
APTIOM/O should/O be/O discontinued/O and/O not/O be/O resumed/O if/O an/O alternative/O etiology/O for/O the/O signs/O or/O symptoms/O can/O not/O be/O established/O ./O
Patients/O with/O a/O prior/O DRESS/O reaction/O with/O either/O oxcarbazepine/O or/O APTIOM/O should/O not/O be/O treated/O with/O APTIOM/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.4/O Anaphylactic/O Reactions/O and/O Angioedema/O Rare/O cases/O of/O anaphylaxis/B-AdverseReaction and/O angioedema/B-AdverseReaction have/O been/O reported/O in/O patients/O taking/O APTIOM/O ./O
Anaphylaxis/B-AdverseReaction and/O angioedema/B-AdverseReaction associated/O with/O laryngeal/B-AdverseReaction edema/I-AdverseReaction can/B-Factor be/O fatal/B-AdverseReaction ./O
If/O a/O patient/O develops/O any/O of/O these/O reactions/O after/O treatment/O with/O APTIOM/O ,/O the/O drug/O should/O be/O discontinued/O ./O
Patients/O with/O a/O prior/O anaphylactic/O -/O type/O reaction/O with/O either/O oxcarbazepine/O or/O APTIOM/O should/O not/O be/O treated/O with/O APTIOM/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.5/O Hyponatremia/O Clinically/O significant/O hyponatremia/B-AdverseReaction (/O sodium/O 125/O mEq/O L/O )/O can/O develop/O in/O patients/O taking/O APTIOM/O ./O
In/O the/O controlled/O adjunctive/O epilepsy/O trials/O ,/O 4/415/O patients/O (/O 1.0/O %/O )/O treated/O with/O 800/O mg/O and/O 6/410/O (/O 1.5/O %/O )/O patients/O treated/O with/O 1200/O mg/O of/O APTIOM/O had/O at/O least/O one/O serum/O sodium/O value/O less/O than/O 125/O mEq/O L/O ,/O compared/O to/O none/O of/O the/O patients/O assigned/O to/O placebo/O ./O
A/O higher/O percentage/O of/O APTIOM/O -/O treated/O patients/O (/O 5.1/O %/O )/O than/O placebo/O -/O treated/O patients/O (/O 0.7/O %/O )/O experienced/O decreases/B-AdverseReaction in/I-AdverseReaction sodium/I-AdverseReaction values/I-AdverseReaction of/O more/O than/O 10/B-Severity mEq/I-Severity L./O These/O effects/O were/O dose/O -/O related/O and/O generally/O appeared/O within/O the/O first/O 8/O weeks/O of/O treatment/O (/O as/O early/O as/O after/O 3/O days/O )/O ./O
Serious/O ,/O life/B-Severity -/O threatening/O complications/O were/O reported/O with/O APTIOM/O -/O associated/O hyponatremia/B-AdverseReaction (/O as/O low/O as/O 112/B-Severity mEq/I-Severity L/O )/O including/O seizures/B-AdverseReaction ,/O severe/B-Severity nausea/B-AdverseReaction vomiting/B-AdverseReaction leading/O to/O dehydration/B-AdverseReaction ,/O severe/B-Severity gait/B-AdverseReaction instability/I-AdverseReaction ,/O and/O injury/B-AdverseReaction ./O
Some/O patients/O required/O hospitalization/O and/O discontinuation/O of/O APTIOM/O ./O
Concurrent/O hypochloremia/B-AdverseReaction was/O also/O present/O in/O patients/O with/O hyponatremia/B-AdverseReaction ./O
Depending/O on/O the/O severity/O of/O hyponatremia/O ,/O the/O dose/O of/O APTIOM/O may/O need/O to/O be/O reduced/O or/O discontinued/O ./O
Hyponatremia/B-AdverseReaction was/O also/O observed/O in/O monotherapy/O trials/O ./O
Measurement/O of/O serum/O sodium/O and/O chloride/O levels/O should/O be/O considered/O during/O maintenance/O treatment/O with/O APTIOM/O ,/O particularly/O if/O the/O patient/O is/O receiving/O other/O medications/O known/O to/O decrease/O serum/O sodium/O levels/O and/O should/O be/O performed/O if/O symptoms/O of/O hyponatremia/O develop/O (/O e.g./O ,/O nausea/O vomiting/O ,/O malaise/O ,/O headache/O ,/O lethargy/O ,/O confusion/O ,/O irritability/O ,/O muscle/O weakness/O spasms/O ,/O obtundation/O ,/O or/O increase/O in/O seizure/O frequency/O or/O severity/O )/O ./O
5.6/O Neurological/O Adverse/O Reactions/O Dizziness/O and/O Disturbance/O in/O Gait/O and/O Coordination/O APTIOM/O causes/O dose/O -/O related/O increases/O in/O adverse/O reactions/O related/O to/O dizziness/B-AdverseReaction and/O disturbance/B-AdverseReaction in/I-AdverseReaction gait/I-AdverseReaction and/O coordination/O (/O dizziness/B-AdverseReaction ,/O ataxia/B-AdverseReaction ,/O vertigo/B-AdverseReaction ,/O balance/B-AdverseReaction disorder/I-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O nystagmus/B-AdverseReaction ,/O and/O abnormal/B-AdverseReaction coordination/I-AdverseReaction )/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O controlled/O adjunctive/O epilepsy/O trials/O ,/O these/O events/O were/O reported/O in/O 26/O %/O and/O 38/O %/O of/O patients/O randomized/O to/O receive/O APTIOM/O at/O doses/O of/O 800/O mg/O and/O 1200/O mg/O day/O ,/O respectively/O ,/O compared/O to/O 12/O %/O of/O placebo/O -/O treated/O patients/O ./O
Events/O related/O to/O dizziness/B-AdverseReaction and/O disturbance/B-AdverseReaction in/I-AdverseReaction gait/I-AdverseReaction and/O coordination/O were/O more/O often/O serious/O in/O APTIOM/O -/O treated/O patients/O than/O in/O placebo/O -/O treated/O patients/O (/O 2/O %/O vs./O 0/O %/O )/O ,/O and/O more/O often/O led/O to/O study/O withdrawal/O in/O APTIOM/O -/O treated/O patients/O than/O in/O placebo/O -/O treated/O patients/O (/O 9/O %/O vs./O 0.7/O %/O )/O ./O
There/O was/O an/O increased/O risk/O of/O these/O adverse/O reactions/O during/O the/O titration/O period/O (/O compared/O to/O the/O maintenance/O period/O )/O and/O there/O also/O may/O be/O an/O increased/O risk/O of/O these/O adverse/O reactions/O in/O patients/O 60/O years/O of/O age/O and/O older/O compared/O to/O younger/O adults/O ./O
Nausea/B-AdverseReaction and/O vomiting/B-AdverseReaction also/O occurred/O with/O these/O events/O ./O
Dizziness/B-AdverseReaction and/O disturbance/B-AdverseReaction in/I-AdverseReaction gait/I-AdverseReaction and/O coordination/O were/O also/O observed/O in/O monotherapy/O trials/O ./O
The/O incidence/O of/O dizziness/B-AdverseReaction was/O greater/O with/O the/O concomitant/O use/O of/O APTIOM/O and/O carbamazepine/O compared/O to/O the/O use/O of/O APTIOM/O without/O carbamazepine/O (/O up/O to/O 37/O %/O vs./O 19/O %/O ,/O respectively/O )/O ./O
Therefore/O ,/O consider/O dosage/O modifications/O of/O both/O APTIOM/O and/O carbamazepine/O if/O these/O drugs/O are/O used/O concomitantly/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Somnolence/O and/O Fatigue/O APTIOM/O causes/O dose/O -/O dependent/O increases/O in/O somnolence/B-AdverseReaction and/O fatigue/B-AdverseReaction -/O related/O adverse/O reactions/O (/O fatigue/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O malaise/B-AdverseReaction ,/O hypersomnia/B-AdverseReaction ,/O sedation/B-AdverseReaction ,/O and/O lethargy/B-AdverseReaction )/O ./O
In/O the/O controlled/O adjunctive/O epilepsy/O trials/O ,/O these/O events/O were/O reported/O in/O 13/O %/O of/O placebo/O patients/O ,/O 16/O %/O of/O patients/O randomized/O to/O receive/O 800/O mg/O day/O APTIOM/O ,/O and/O 28/O %/O of/O patients/O randomized/O to/O receive/O 1200/O mg/O day/O APTIOM/O ./O
Somnolence/B-AdverseReaction and/O fatigue/B-AdverseReaction -/I-AdverseReaction related/O events/O were/O serious/O in/O 0.3/O %/O of/O APTIOM/O -/O treated/O patients/O (/O and/O 0/O placebo/O patients/O )/O and/O led/O to/O discontinuation/O in/O 3/O %/O of/O APTIOM/O -/O treated/O patients/O (/O and/O 0.7/O %/O of/O placebo/O -/O treated/O patients/O )/O ./O
Somnolence/B-AdverseReaction and/O fatigue/B-AdverseReaction were/O also/O observed/O in/O monotherapy/O trials/O ./O
Cognitive/O Dysfunction/O APTIOM/O causes/O dose/O -/O dependent/O increases/O in/O cognitive/B-AdverseReaction dysfunction/I-AdverseReaction -/O related/O events/O (/O memory/B-AdverseReaction impairment/I-AdverseReaction ,/O disturbance/B-AdverseReaction in/I-AdverseReaction attention/I-AdverseReaction ,/O amnesia/B-AdverseReaction ,/O confusional/B-AdverseReaction state/I-AdverseReaction ,/O aphasia/B-AdverseReaction ,/O speech/B-AdverseReaction disorder/I-AdverseReaction ,/O slowness/B-AdverseReaction of/I-AdverseReaction thought/I-AdverseReaction ,/O disorientation/B-AdverseReaction ,/O and/O psychomotor/B-AdverseReaction retardation/I-AdverseReaction )/O ./O
In/O the/O controlled/O adjunctive/O epilepsy/O trials/O ,/O these/O events/O were/O reported/O in/O 1/O %/O of/O placebo/O patients/O ,/O 4/O %/O of/O patients/O randomized/O to/O receive/O 800/O mg/O day/O APTIOM/O ,/O and/O 7/O %/O of/O patients/O randomized/O to/O receive/O 1200/O mg/O day/O APTIOM/O ./O
Cognitive/B-AdverseReaction dysfunction/I-AdverseReaction -/O related/O events/O were/O serious/B-Severity in/O 0.2/O %/O of/O APTIOM/O -/O treated/O patients/O (/O and/O 0.2/O %/O of/O placebo/O patients/O )/O and/O led/O to/O discontinuation/O in/O 1/O %/O of/O APTIOM/O -/O treated/O patients/O (/O and/O 0.5/O %/O of/O placebo/O -/O treated/O patients/O )/O ./O
Cognitive/B-AdverseReaction dysfunction/I-AdverseReaction events/O were/O also/O observed/O in/O monotherapy/O trials/O ./O
Visual/O Changes/O APTIOM/O causes/O dose/O -/O dependent/O increases/O in/O events/O related/O to/O visual/B-AdverseReaction changes/I-AdverseReaction including/O diplopia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O and/O impaired/B-AdverseReaction vision/I-AdverseReaction ./O
In/O the/O controlled/O adjunctive/O epilepsy/O trials/O ,/O these/O events/O were/O reported/O in/O 16/O %/O of/O patients/O randomized/O to/O receive/O APTIOM/O compared/O to/O 6/O %/O of/O placebo/O patients/O ./O
Eye/B-AdverseReaction events/I-AdverseReaction were/O serious/B-Severity in/O 0.7/O %/O of/O APTIOM/O -/O treated/O patients/O (/O and/O 0/O placebo/O patients/O )/O and/O led/O to/O discontinuation/O in/O 4/O %/O of/O APTIOM/O -/O treated/O patients/O (/O and/O 0.2/O %/O of/O placebo/O -/O treated/O patients/O )/O ./O
There/O was/O an/O increased/O risk/O of/O these/O adverse/O reactions/O during/O the/O titration/O period/O (/O compared/O to/O the/O maintenance/O period/O )/O and/O also/O in/O patients/O 60/O years/O of/O age/O and/O older/O (/O compared/O to/O younger/O adults/O )/O ./O
The/O incidence/O of/O diplopia/B-AdverseReaction was/O greater/O with/O the/O concomitant/O use/O of/O APTIOM/O and/O carbamazepine/O compared/O to/O the/O use/O of/O APTIOM/O without/O carbamazepine/O (/O up/O to/O 16/O %/O vs./O 6/O %/O ,/O respectively/O )/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Events/O related/O to/O visual/B-AdverseReaction changes/I-AdverseReaction were/O also/O observed/O in/O monotherapy/O trials/O ./O
Hazardous/O Activities/O Prescribers/O should/O advise/O patients/O against/O engaging/O in/O hazardous/O activities/O requiring/O mental/O alertness/O ,/O such/O as/O operating/O motor/O vehicles/O or/O dangerous/O machinery/O ,/O until/O the/O effect/O of/O APTIOM/O is/O known/O ./O
5.7/O Withdrawal/O of/O AEDs/O As/O with/O all/O antiepileptic/O drugs/O ,/O APTIOM/O should/O be/O withdrawn/O gradually/O because/O of/O the/O risk/O of/O increased/O seizure/O frequency/O and/O status/O epilepticus/O ./O
5.8/O Drug/O Induced/O Liver/O Injury/O Hepatic/O effects/O ,/O ranging/O from/O mild/B-Severity to/I-Severity moderate/B-Severity elevations/B-AdverseReaction in/I-AdverseReaction transaminases/I-AdverseReaction (/O 3/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity )/O to/O rare/O cases/O with/O concomitant/O elevations/B-AdverseReaction of/I-AdverseReaction total/I-AdverseReaction bilirubin/I-AdverseReaction (/O 2/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity )/O have/O been/O reported/O with/O APTIOM/O use/O ./O
Baseline/O evaluations/O of/O liver/O laboratory/O tests/O are/O recommended/O ./O
The/O combination/O of/O transaminase/B-AdverseReaction elevations/I-AdverseReaction and/O elevated/B-AdverseReaction bilirubin/I-AdverseReaction without/O evidence/O of/O obstruction/O is/O generally/O recognized/O as/O an/O important/O predictor/O of/O severe/B-Severity liver/B-AdverseReaction injury/I-AdverseReaction ./O
APTIOM/O should/O be/O discontinued/O in/O patients/O with/O jaundice/O or/O other/O evidence/O of/O significant/O liver/O injury/O (/O e.g./O ,/O laboratory/O evidence/O )/O ./O
5.9/O Abnormal/O Thyroid/O Function/O Tests/O Dose/O -/O dependent/O decreases/O in/O serum/O T3/O and/O T4/O (/O free/O and/O total/O )/O values/O have/O been/O observed/O in/O patients/O taking/O APTIOM/O ./O
These/O changes/O were/O not/B-Negation associated/O with/O other/O abnormal/B-AdverseReaction thyroid/I-AdverseReaction function/I-AdverseReaction tests/O suggesting/O hypothyroidism/B-AdverseReaction ./O
Abnormal/O thyroid/O function/O tests/O should/O be/O clinically/O evaluated/O ./O
6/O ADVERSE/O REACTIONS/O L/O ong/O -/O acting/O beta/O 2/O -adrenergic/O agonists/O ,/O such/O as/O A/O RCAPTA/O NEOHALER/O ,/O increase/O the/O risk/B-Factor of/O asthma/B-AdverseReaction -/O related/O death/B-AdverseReaction ./O
ARCAPTA/O NEOHALER/O is/O not/O indicated/O for/O the/O treatment/O of/O asthma/O [/O See/O B/O oxed/O Warning/O and/O W/O arning/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 2/O %/O and/O more/O common/O than/O placebo/O )/O are/O cough/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O headache/B-AdverseReaction and/O nausea/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Novartis/O Pharmaceuticals/O Corporation/O at/O 1/O -/O 888/O -/O 669/O -/O 6682/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O in/O Chronic/O Obstructive/O Pulmonary/O Disease/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O ARCAPTA/O NEOHALER/O safety/O database/O reflects/O exposure/O of/O 2516/O patients/O to/O ARCAPTA/O NEOHALER/O at/O doses/O of/O 75/O mcg/O or/O greater/O for/O at/O least/O 12/O weeks/O in/O six/O confirmatory/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O and/O active/O -/O controlled/O clinical/O trials/O (/O see/O Section/O 14/O )/O ./O
In/O these/O trials/O ,/O 449/O patients/O were/O exposed/O to/O the/O recommended/O dose/O of/O 75/O mcg/O for/O up/O to/O 3/O months/O ,/O and/O 144/O ,/O 583/O and/O 425/O COPD/O patients/O were/O exposed/O to/O a/O dose/O of/O 150/O ,/O 300/O or/O 600/O mcg/O for/O one/O year/O ,/O respectively/O ./O
Overall/O ,/O patients/O had/O a/O mean/O pre/O -/O bronchodilator/O forced/O expiratory/O volume/O in/O one/O second/O (/O FEV1/O )/O percent/O predicted/O of/O 54/O %/O ./O
The/O mean/O age/O of/O patients/O was/O 64/O years/O ,/O with/O 47/O %/O of/O patients/O aged/O 65/O years/O or/O older/O ,/O and/O the/O majority/O (/O 88/O %/O )/O was/O Caucasian/O ./O
In/O these/O six/O clinical/O trials/O ,/O 48/O %/O of/O patients/O treated/O with/O any/O dose/O of/O ARCAPTA/O NEOHALER/O reported/O an/O adverse/O reaction/O compared/O with/O 43/O %/O of/O patients/O treated/O with/O placebo/O ./O
The/O proportion/O of/O patients/O who/O discontinued/O treatment/O due/O to/O adverse/O reaction/O was/O 5/O %/O for/O ARCAPTA/O NEOHALER/O -/O treated/O patients/O and/O 5/O %/O for/O placebo/O -/O treated/O patients/O ./O
The/O most/O common/O adverse/O reactions/O that/O lead/O to/O discontinuation/O of/O ARCAPTA/O NEOHALER/O were/O COPD/B-AdverseReaction and/O dyspnea/B-AdverseReaction ./O
The/O most/O common/O serious/O adverse/O reactions/O were/O COPD/B-AdverseReaction exacerbation/I-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O angina/B-AdverseReaction pectoris/I-AdverseReaction ,/O and/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction ,/O which/O occurred/O at/O similar/O rates/O across/O treatment/O groups/O ./O
Table/O 1/O displays/O adverse/O drug/O reactions/O reported/O by/O at/O least/O 2/O %/O of/O patients/O (/O and/O higher/O than/O placebo/O )/O during/O a/O 3/O month/O exposure/O at/O the/O recommended/O 75/O mcg/O once/O daily/O dose/O ./O
Adverse/O drug/O reactions/O are/O listed/O according/O to/O MedDRA/O (/O version/O 13.0/O )/O system/O organ/O class/O and/O sorted/O in/O descending/O order/O of/O frequency/O ./O
Table/O 1/O :/O Number/O and/O frequency/O of/O adverse/O drug/O reactions/O greater/O than/O 2/O %/O (/O and/O higher/O than/O placebo/O )/O in/O COPD/O patients/O exposed/O to/O ARCAPTA/O NEOHALER/O 75/O mcg/O for/O up/O to/O 3/O months/O in/O multiple/O dose/O ,/O controlled/O trials/O Indacaterol/O 75/O mcg/O once/O daily/O Placebo/O n=449/O n=/O 445/O n/O (/O %/O )/O n/O (/O %/O )/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O -/O Cough/B-AdverseReaction 29/O (/O 6.5/O )/O 20/O (/O 4.5/O )/O -/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 10/O (/O 2.2/O )/O 3/O (/O 0.7/O )/O Infections/O and/O infestations/O -/O Nasopharyngitis/B-AdverseReaction 24/O (/O 5.3/O )/O 12/O (/O 2.7/O )/O Nervous/O system/O disorders/O -/O Headache/B-AdverseReaction 23/O (/O 5.1/O )/O 11/O (/O 2.5/O )/O Gastrointestinal/O disorders/O -/O Nausea/B-AdverseReaction 11/O (/O 2.4/O )/O 4/O (/O 0.9/O )/O In/O these/O trials/O the/O overall/O frequency/O of/O all/O cardiovascular/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction was/O 2.5/O %/O for/O ARCAPTA/O NEOHALER/O 75/O mcg/O and/O 1.6/O %/O for/O placebo/O during/O a/O 3/O month/O exposure/O ./O
There/O were/O no/O frequently/O occurring/O specific/O cardiovascular/O adverse/O reactions/O for/O ARCAPTA/O NEOHALER/O 75/O mcg/O (/O frequency/O at/O least/O 1/O %/O and/O greater/O than/O placebo/O )/O ./O
Additional/O adverse/O drug/O reactions/O reported/O in/O greater/O than/O 2/O %/O (/O and/O higher/O than/O on/O placebo/O )/O in/O patients/O dosed/O with/O 150/O ,/O 300/O or/O 600/O mcg/O for/O up/O to/O 12/O months/O were/O as/O follows/O :/O Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O muscle/B-AdverseReaction spasm/I-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction General/O disorders/O and/O administration/O site/O conditions/O :/O edema/B-AdverseReaction peripheral/I-AdverseReaction Metabolism/O and/O nutrition/O disorder/O :/O diabetes/B-AdverseReaction mellitus/I-AdverseReaction ,/O hyperglycemia/B-AdverseReaction Infections/O and/O infestations/O :/O sinusitis/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction C/O ough/O experienced/O p/O ost/O -/O inhalation/O In/O the/O clinical/O trials/O ,/O health/O care/O providers/O observed/O during/O clinic/O visits/O that/O an/O average/O of/O 24/O %/O of/O patients/O experienced/O a/O cough/B-AdverseReaction on/O at/O least/O 20/O %/O of/O visits/O following/O inhalation/O of/O the/O recommended/O 75/O mcg/O dose/O of/O ARCAPTA/O NEOHALER/O compared/O to/O 7/O %/O of/O patients/O receiving/O placebo/O ./O
The/O cough/B-AdverseReaction usually/O occurred/O within/O 15/O seconds/O following/O inhalation/O and/O lasted/O for/O no/O more/O than/O 15/O seconds/O ./O
Cough/B-AdverseReaction following/O inhalation/O in/O clinical/O trials/O was/O not/B-Negation associated/O with/O bronchospasm/B-AdverseReaction ,/O exacerbations/O ,/O deteriorations/O of/O disease/O or/O loss/B-AdverseReaction of/I-AdverseReaction efficacy/I-AdverseReaction ./O
6.2/O Clinical/O Trials/O Experience/O in/O Asthma/O In/O a/O 6-month/O randomized/O ,/O active/O controlled/O asthma/O safety/O trial/O ,/O 805/O adult/O patients/O with/O moderate/O to/O severe/O persistent/O asthma/O were/O treated/O with/O ARCAPTA/O NEOHALER/O 300/O mcg/O (/O n=268/O )/O ,/O ARCAPTA/O NEOHALER/O 600/O mcg/O (/O n=268/O )/O ,/O and/O salmeterol/O (/O n=269/O )/O ,/O all/O concomitant/O with/O inhaled/O corticosteroids/O ,/O which/O were/O not/O co/O -/O randomized/O ./O
Of/O these/O patients/O ,/O there/O were/O 2/O respiratory/O -/O related/O deaths/B-AdverseReaction in/O the/O ARCAPTA/O NEOHALER/O 300/O mcg/O dose/O group/O ./O
There/O were/O no/B-Negation deaths/B-AdverseReaction in/O the/O ARCAPTA/O NEOHALER/O 600/O mcg/O dose/O group/O or/O in/O the/O salmeterol/O active/O control/O group/O ./O
Serious/O adverse/O reactions/O related/O to/O asthma/B-AdverseReaction exacerbation/I-AdverseReaction were/O reported/O for/O 2/O patients/O in/O the/O indacaterol/O 300/O mcg/O group/O ,/O 3/O patients/O in/O the/O indacaterol/O 600/O mcg/O group/O ,/O and/O no/O patients/O in/O the/O salmeterol/O active/O control/O group/O ./O
In/O addition/O ,/O a/O two/O -/O week/O dose/O -/O ranging/O trial/O was/O conducted/O in/O 511/O adult/O patients/O with/O mild/O persistent/O asthma/O taking/O inhaled/O corticosteroids/O ./O
No/B-Negation deaths/B-AdverseReaction ,/O intubations/O ,/O or/O serious/O adverse/O reactions/O related/O to/O asthma/B-AdverseReaction exacerbation/I-AdverseReaction were/O reported/O in/O this/O trial/O ./O
6.3/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O worldwide/O post/O -/O approval/O use/O of/O indacaterol/O ,/O the/O active/O ingredient/O in/O ARCAPTA/O NEOHALER/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
These/O adverse/O reactions/O are/O :/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O paradoxical/B-AdverseReaction bronchospasm/I-AdverseReaction ,/O tachycardia/B-AdverseReaction heart/B-AdverseReaction rate/I-AdverseReaction increase/I-AdverseReaction palpitations/B-AdverseReaction ,/O pruritus/B-AdverseReaction rash/B-AdverseReaction and/O dizziness/B-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O ASTHMA/O -/O RELATED/O DEATH/B-AdverseReaction WARNING/O :/O ASTHMA/O -/O RELATED/O DEATH/B-AdverseReaction L/B-DrugClass ong/I-DrugClass -/I-DrugClass acting/I-DrugClass beta/I-DrugClass 2/O -adrenergic/O agonist/O s/O (/O LABA/B-DrugClass )/O increase/O the/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction ./O
Data/O from/O a/O large/O placebo/O -/O controlled/O US/O study/O that/O compared/O the/O safety/O of/O another/O long/B-DrugClass -/I-DrugClass acting/I-DrugClass beta/I-DrugClass 2/O -adrenergic/O agonist/O (/O salmeterol/O )/O or/O placebo/O added/O to/O usual/O asthma/O therapy/O showed/O an/O increase/O in/O asthma/O -/O related/O deaths/B-AdverseReaction in/O patients/O receiving/O salmeterol/O ./O
This/O finding/O with/O salmeterol/O is/O considered/O a/O class/O effect/O of/O LABA/O ,/O including/O indacaterol/O ,/O the/O active/O ingredient/O in/O ARCAPTA/O NEOHALER/O ./O
The/O safety/O and/O efficacy/O of/O ARCAPTA/O NEOHALER/O in/O patients/O with/O asthma/O have/O not/O been/O established/O ./O
A/O RCAPTA/O NEOHALER/O is/O not/O indicated/O for/O the/O treatment/O of/O asthma/O ./O
[/O See/O C/O ontraindications/O (/O 4/O )/O ,/O W/O arnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O ASTHMA/O -/O RELATED/O DEATH/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O Long/B-DrugClass -/I-DrugClass acting/I-DrugClass beta2-adrenergic/O agonists/O (/O LABA/B-DrugClass )/O increase/O the/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction (/O 5.1/O )/O ./O
A/O placebo/O -/O controlled/O study/O with/O another/O long/B-DrugClass -/I-DrugClass acting/I-DrugClass beta2-adrenergic/O agonist/O (/O salmeterol/O )/O showed/O an/O increase/O in/O asthma/O -/O related/O deaths/B-AdverseReaction in/O patients/O receiving/O salmeterol/O ./O
(/O 5.1/O )/O This/O finding/O of/O an/O increased/O risk/B-Factor of/O asthma/O -/O related/O death/B-AdverseReaction with/O salmeterol/O is/O considered/O a/O class/O effect/O of/O LABA/O ,/O including/O indacaterol/O ,/O the/O active/O ingredient/O in/O ARCAPTA/O NEOHALER/O ./O
The/O safety/O and/O efficacy/O of/O ARCAPTA/O NEOHALER/O in/O patients/O with/O asthma/O have/O not/O been/O established/O ./O
ARCAPTA/O NEOHALER/O is/O not/O indicated/O for/O the/O treatment/O of/O asthma/O ./O
(/O 4/O ,/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Do/O not/O initiate/O in/O acutely/O deteriorating/O COPD/O patients/O (/O 5.2/O )/O Do/O not/O use/O for/O relief/O of/O acute/O symptoms/O ./O
Concomitant/O short/O -/O acting/O beta2-agonists/O can/O be/O used/O as/O needed/O for/O acute/O relief/O (/O 5.2/O )/O Do/O not/O exceed/O the/O recommended/O dose/O ./O
Excessive/O use/O or/O use/O in/O conjunction/O with/O other/O medications/O containing/O LABA/B-DrugClass can/O result/O in/O clinically/O significant/B-Severity cardiovascular/B-AdverseReaction effects/I-AdverseReaction and/O may/O be/O fatal/B-AdverseReaction (/O 5.3/O )/O Immediate/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction may/B-Factor occur/O ./O
Discontinue/O immediately/O ./O
(/O 5.4/O )/O Life/B-Severity -/O threatening/O paradoxical/B-AdverseReaction bronchospasm/I-AdverseReaction can/B-Factor occur/O ./O
Discontinue/O immediately/O ./O
(/O 5.5/O )/O Use/O with/O caution/O in/O patients/O with/O cardiovascular/O or/O convulsive/O disorders/O ,/O thyrotoxicosis/O or/O sensitivity/O to/O sympathomimetic/O drugs/O ./O
(/O 5.6/O ,/O 5.7/O )/O 5.1/O Asthma/O -/O Related/O Death/O [/O See/O Boxed/O Warning/O ]/O Data/O from/O a/O large/O placebo/O -/O controlled/O study/O in/O asthma/O patients/O showed/O that/O long/B-DrugClass -/I-DrugClass acting/I-DrugClass beta/I-DrugClass 2/O -adrenergic/O agonists/O may/O increase/O the/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction ./O
Data/O are/O not/O available/O to/O determine/O whether/O the/O rate/O of/O death/O in/O patients/O with/O COPD/O is/O increased/O by/O long/O -/O acting/O beta/O 2/O -adrenergic/O agonists/O ./O
A/O 28-week/O ,/O placebo/O -/O controlled/O US/O study/O comparing/O the/O safety/O of/O another/O long/B-DrugClass -/I-DrugClass acting/I-DrugClass beta/I-DrugClass 2/O -adrenergic/O agonist/O (/O salmeterol/O )/O with/O placebo/O ,/O each/O added/O to/O usual/O asthma/O therapy/O ,/O showed/O an/O increase/O in/O asthma/O -/O related/O deaths/B-AdverseReaction in/O patients/O receiving/O salmeterol/O (/O 13/13,176/O in/O patients/O treated/O with/O salmeterol/O vs./O 3/13,179/O in/O patients/O treated/O with/O placebo/O ;/O RR/O 4.37/O ,/O 95/O %/O CI/O 1.25/O ,/O 15.34/O )/O ./O
The/O increased/O risk/B-Factor of/O asthma/O -/O related/O death/B-AdverseReaction is/O considered/O a/O class/O effect/O of/O the/O long/O -/O acting/O beta/O 2/O -adrenergic/O agonists/O ,/O including/O ARCAPTA/O NEOHALER/O ./O
No/O study/O adequate/O to/O determine/O whether/O the/O rate/O of/O asthma/O -/O related/O death/O is/O increased/O in/O patients/O treated/O with/O ARCAPTA/O NEOHALER/O has/O been/O conducted/O ./O
The/O safety/O and/O efficacy/O of/O ARCAPTA/O NEOHALER/O in/O patients/O with/O asthma/O have/O not/O been/O established/O ./O
ARCAPTA/O NEOHALER/O is/O not/O indicated/O for/O the/O treatment/O of/O asthma/O ./O
[/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
Serious/O asthma/O -/O related/O events/O ,/O including/O death/B-AdverseReaction ,/O were/O reported/O in/O clinical/O studies/O with/O ARCAPTA/O NEOHALER/O ./O
The/O sizes/O of/O these/O studies/O were/O not/O adequate/O to/O precisely/O quantify/O the/O differences/O in/O serious/O asthma/O exacerbation/O rates/O between/O treatment/O groups/O ./O
[/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
5.2/O Deterioration/O of/O Disease/O and/O Acute/O Episodes/O ARCAPTA/O NEOHALER/O should/O not/O be/O initiated/O in/O patients/O with/O acutely/O deteriorating/O COPD/O ,/O which/O may/O be/O a/O life/O -/O threatening/O condition/O ./O
ARCAPTA/O NEOHALER/O has/O not/O been/O studied/O in/O patients/O with/O acutely/O deteriorating/O COPD/O ./O
The/O use/O of/O ARCAPTA/O NEOHALER/O in/O this/O setting/O is/O inappropriate/O ./O
ARCAPTA/O NEOHALER/O should/O not/O be/O used/O for/O the/O relief/O of/O acute/O symptoms/O ,/O i.e./O as/O rescue/O therapy/O for/O the/O treatment/O of/O acute/O episodes/O of/O bronchospasm/O ./O
ARCAPTA/O NEOHALER/O has/O not/O been/O studied/O in/O the/O relief/O of/O acute/O symptoms/O and/O extra/O doses/O should/O not/O be/O used/O for/O that/O purpose/O ./O
Acute/O symptoms/O should/O be/O treated/O with/O an/O inhaled/O short/O -/O acting/O beta2-agonist/O ./O
When/O beginning/O ARCAPTA/O NEOHALER/O ,/O patients/O who/O have/O been/O taking/O inhaled/O ,/O short/O -/O acting/O beta2-agonists/O on/O a/O regular/O basis/O (/O e.g./O ,/O four/O times/O a/O day/O )/O should/O be/O instructed/O to/O discontinue/O the/O regular/O use/O of/O these/O drugs/O and/O use/O them/O only/O for/O symptomatic/O relief/O of/O acute/O respiratory/O symptoms/O ./O
When/O prescribing/O ARCAPTA/O NEOHALER/O ,/O the/O healthcare/O provider/O should/O also/O prescribe/O an/O inhaled/O ,/O short/O -/O acting/O beta2-/O agonist/O and/O instruct/O the/O patient/O on/O how/O it/O should/O be/O used/O ./O
Increasing/O inhaled/O beta2-agonist/O use/O is/O a/O signal/O of/O deteriorating/O disease/O for/O which/O prompt/O medical/O attention/O is/O indicated/O ./O
COPD/O may/O deteriorate/O acutely/O over/O a/O period/O of/O hours/O or/O chronically/O over/O several/O days/O or/O longer/O ./O
If/O ARCAPTA/O NEOHALER/O no/O longer/O controls/O the/O symptoms/O of/O bronchoconstriction/O ,/O or/O the/O patient/O 's/O inhaled/O ,/O short/O -/O acting/O beta2-agonist/O becomes/O less/O effective/O or/O the/O patient/O needs/O more/O inhalation/O of/O short/O -/O acting/O beta2-agonist/O than/O usual/O ,/O these/O may/O be/O markers/O of/O deterioration/O of/O disease/O ./O
In/O this/O setting/O ,/O a/O re/O -/O evaluation/O of/O the/O patient/O and/O the/O COPD/O treatment/O regimen/O should/O be/O undertaken/O at/O once/O ./O
Increasing/O the/O daily/O dosage/O of/O ARCAPTA/O NEOHALER/O beyond/O the/O recommended/O dose/O is/O not/O appropriate/O in/O this/O situation/O ./O
5.3/O Excessive/O Use/O of/O ARCAPTA/O NEOHALER/O and/O Use/O with/O Other/O Long/O -/O Acting/O Beta2-Agonists/O As/O with/O other/O inhaled/O beta2-adrenergic/O drugs/O ,/O ARCAPTA/O NEOHALER/O should/O not/O be/O used/O more/O often/O ,/O at/O higher/O doses/O than/O recommended/O ,/O or/O in/O conjunction/O with/O other/O medications/O containing/O long/O -/O acting/O beta2-agonists/O ,/O as/O an/O overdose/O may/O result/O ./O
Clinically/O significant/O cardiovascular/O effects/O and/O fatalities/O have/O been/O reported/O in/O association/O with/O excessive/O use/O of/O inhaled/O sympathomimetic/O drugs/O ./O
5.4/O Immediate/O Hypersensitivity/O Reactions/O Immediate/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction may/B-Factor occur/O after/O administration/O of/O ARCAPTA/O NEOHALER/O ./O
If/O signs/O suggesting/O allergic/O reactions/O (/O in/O particular/O ,/O difficulties/O in/O breathing/O or/O swallowing/O ,/O swelling/O of/O tongue/O ,/O lips/O and/O face/O ,/O urticaria/O ,/O skin/O rash/O )/O occur/O ,/O ARCAPTA/O NEOHALER/O should/O be/O discontinued/O immediately/O and/O alternative/O therapy/O instituted/O ./O
5.5/O Paradoxical/O Bronchospasm/O As/O with/O other/O inhaled/O beta2-agonists/O ,/O ARCAPTA/O NEOHALER/O may/B-Factor produce/O paradoxical/B-AdverseReaction bronchospasm/I-AdverseReaction that/O may/O be/O life/B-Severity -/O threatening/O ./O
If/O paradoxical/O bronchospasm/O occurs/O ,/O ARCAPTA/O NEOHALER/O should/O be/O discontinued/O immediately/O and/O alternative/O therapy/O instituted/O ./O
5.6/O Cardiovascular/O Effects/O ARCAPTA/O NEOHALER/O ,/O like/O other/O beta2-agonists/O ,/O can/B-Factor produce/O a/O clinically/O significant/B-Severity cardiovascular/B-AdverseReaction effect/I-AdverseReaction in/O some/O patients/O as/O measured/O by/O increases/B-AdverseReaction in/I-AdverseReaction pulse/I-AdverseReaction rate/I-AdverseReaction ,/O systolic/O or/O diastolic/O blood/O pressure/O ,/O or/O symptoms/O ./O
If/O such/O effects/O occur/O ,/O ARCAPTA/O NEOHALER/O may/O need/O to/O be/O discontinued/O ./O
In/O addition/O ,/O beta/B-DrugClass -/O agonists/O have/O been/O reported/O to/O produce/O ECG/B-AdverseReaction changes/I-AdverseReaction ,/O such/O as/O flattening/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction T/I-AdverseReaction wave/I-AdverseReaction ,/O prolongation/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction QTc/I-AdverseReaction interval/I-AdverseReaction ,/O and/O ST/B-AdverseReaction segment/I-AdverseReaction depression/I-AdverseReaction ,/O although/O the/O clinical/O significance/O of/O these/O findings/O is/O unknown/O ./O
Therefore/O ,/O ARCAPTA/O NEOHALER/O ,/O like/O other/O sympathomimetic/O amines/O ,/O should/O be/O used/O with/O caution/O in/O patients/O with/O cardiovascular/O disorders/O ,/O especially/O coronary/O insufficiency/O ,/O cardiac/O arrhythmias/O ,/O and/O hypertension/O ./O
5.7/O Coexisting/O Conditions/O ARCAPTA/O NEOHALER/O ,/O like/O other/O sympathomimetic/O amines/O ,/O should/O be/O used/O with/O caution/O in/O patients/O with/O convulsive/O disorders/O or/O thyrotoxicosis/O ,/O and/O in/O patients/O who/O are/O unusually/O responsive/O to/O sympathomimetic/O amines/O ./O
Doses/O of/O the/O related/O beta2-agonist/B-DrugClass albuterol/O ,/O when/O administered/O intravenously/O ,/O have/O been/O reported/O to/O aggravate/B-AdverseReaction pre/I-AdverseReaction -/I-AdverseReaction existing/I-AdverseReaction diabetes/O mellitus/O and/O ketoacidosis/O ./O
5.8/O Hypokalemia/O and/O Hyperglycemia/O Beta2-agonist/B-DrugClass medications/O may/O produce/O significant/B-Severity hypokalemia/B-AdverseReaction in/O some/O patients/O ,/O possibly/O through/O intracellular/O shunting/O ,/O which/O has/O the/O potential/O to/O produce/O adverse/B-AdverseReaction cardiovascular/I-AdverseReaction effects/I-AdverseReaction [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
The/O decrease/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction potassium/I-AdverseReaction is/O usually/O transient/O ,/O not/O requiring/O supplementation/O ./O
Inhalation/O of/O high/O doses/O of/O beta2-adrenergic/B-DrugClass agonists/I-DrugClass may/O produce/O increases/B-AdverseReaction in/I-AdverseReaction plasma/I-AdverseReaction glucose/I-AdverseReaction ./O
Clinically/O notable/O decreases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction potassium/I-AdverseReaction or/O changes/B-AdverseReaction in/I-AdverseReaction blood/I-AdverseReaction glucose/I-AdverseReaction were/O infrequent/O during/O clinical/O studies/O with/O long/O -/O term/O administration/O of/O ARCAPTA/O NEOHALER/O with/O the/O rates/O similar/O to/O those/O for/O placebo/O controls/O ./O
ARCAPTA/O NEOHALER/O has/O not/O been/O investigated/O in/O patients/O whose/O diabetes/O mellitus/O is/O not/O well/O controlled/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reaction/O occurring/O in/O approximately/O 25/O %/O of/O patients/O was/O a/O mild/B-Severity taste/B-AdverseReaction following/I-AdverseReaction instillation/I-AdverseReaction ./O
Other/O adverse/O reactions/O which/O occurred/O in/O 2/O -/O 5/O %/O of/O subjects/O were/O eye/B-AdverseReaction irritation/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O nasopharyngitis/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bausch/O &/O Lomb/O Incorporated/O ./O
at/O 1/O -/O 800/O -/O 323/O -/O 0000/O ,/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O most/O common/O reported/O adverse/O reaction/O occurring/O in/O approximately/O 25/O %/O of/O subjects/O was/O a/O mild/B-Severity taste/B-AdverseReaction following/I-AdverseReaction instillation/I-AdverseReaction ./O
Other/O adverse/O reactions/O occurring/O in/O 2/O -/O 5/O %/O of/O subjects/O were/O eye/B-AdverseReaction irritation/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O nasopharyngitis/B-AdverseReaction ./O
6.2/O Post/O Marketing/O Experience/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O rarely/O during/O the/O post/O -/O marketing/O use/O of/O BEPREVE/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O unknown/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O casual/O relationship/O to/O drug/O exposure/O ./O
The/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction include/O itching/B-AdverseReaction ,/O body/B-AdverseReaction rash/I-AdverseReaction ,/O and/O swelling/B-AdverseReaction of/I-AdverseReaction lips/I-AdverseReaction ,/O tongue/O and/or/O throat/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O To/O minimize/O the/O risk/O of/O contamination/O ,/O do/O not/O touch/O dropper/O tip/O to/O any/O surface/O ./O
Keep/O bottle/O tightly/O closed/O when/O not/O in/O use/O ./O
(/O 5.1/O )/O BEPREVE/O should/O not/O be/O used/O to/O treat/O contact/O lens/O -/O related/O irritation/O ./O
(/O 5.2/O )/O Remove/O contact/O lenses/O prior/O to/O instillation/O of/O BEPREVE/O ./O
(/O 5.2/O )/O 5.1/O Contamination/O of/O Tip/O and/O Solution/O To/O minimize/O contaminating/O the/O dropper/O tip/O and/O solution/O ,/O care/O should/O be/O taken/O not/O to/O touch/O the/O eyelids/O or/O surrounding/O areas/O with/O the/O dropper/O tip/O of/O the/O bottle/O ./O
Keep/O bottle/O tightly/O closed/O when/O not/O in/O use/O ./O
5.2/O Contact/O Lens/O Use/O Patients/O should/O be/O advised/O not/O to/O wear/O a/O contact/O lens/O if/O their/O eye/O is/O red/O ./O
BEPREVE/O should/O not/O be/O used/O to/O treat/O contact/O lens/O -/O related/O irritation/O ./O
BEPREVE/O should/O not/O be/O instilled/O while/O wearing/O contact/O lenses/O ./O
Remove/O contact/O lenses/O prior/O to/O instillation/O of/O BEPREVE/O ./O
The/O preservative/O in/O BEPREVE/O ,/O benzalkonium/O chloride/O ,/O may/O be/O absorbed/O by/O soft/O contact/O lenses/O ./O
Lenses/O may/O be/O reinserted/O after/O 10/O minutes/O following/O administration/O of/O BEPREVE/O ./O
5.3/O Topical/O Ophthalmic/O Use/O Only/O BEPREVE/O is/O for/O topical/O ophthalmic/O use/O only/O ./O
6/O ADVERSE/O REACTIONS/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O one/O clinical/O trial/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O the/O rates/O in/O the/O clinical/O trials/O of/O the/O same/O or/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O data/O described/O below/O reflect/O exposure/O to/O Besivance/O in/O approximately/O 1,000/O patients/O between/O 1/O and/O 98/O years/O old/O with/O clinical/O signs/O and/O symptoms/O of/O bacterial/O conjunctivitis/O ./O
The/O most/O frequently/O reported/O ocular/B-AdverseReaction adverse/I-AdverseReaction reaction/I-AdverseReaction was/O conjunctival/B-AdverseReaction redness/I-AdverseReaction ,/O reported/O in/O approximately/O 2/O %/O of/O patients/O ./O
Other/O adverse/O reactions/O reported/O in/O patients/O receiving/O Besivance/O occurring/O in/O approximately/O 1/O -/O 2/O %/O of/O patients/O included/O :/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O eye/B-AdverseReaction pain/I-AdverseReaction ,/O eye/B-AdverseReaction irritation/I-AdverseReaction ,/O eye/B-AdverseReaction pruritus/I-AdverseReaction and/O headache/B-AdverseReaction ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reaction/O reported/O in/O 2/O %/O of/O patients/O treated/O with/O Besivance/O was/O conjunctival/B-AdverseReaction redness/I-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bausch/O &/O Lomb/O Incorporated/O at/O 1/O -/O 800/O -/O 323/O -/O 0000/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Topical/O Ophthalmic/O Use/O Only/O ./O
(/O 5.1/O )/O Growth/O of/O Resistant/O Organisms/O with/O Prolonged/O Use/O ./O
(/O 5.2/O )/O Avoidance/O of/O Contact/O Lenses/O ./O
Patients/O should/O not/O wear/O contact/O lenses/O if/O they/O have/O signs/O or/O symptoms/O of/O bacterial/O conjunctivitis/O or/O during/O the/O course/O of/O therapy/O with/O Besivance/O (/O 5.3/O )/O 5.1/O Topical/O Ophthalmic/O Use/O Only/O NOT/O FOR/O INJECTION/O INTO/O THE/O EYE/O ./O
Besivance/O is/O for/O topical/O ophthalmic/O use/O only/O ,/O and/O should/O not/O be/O injected/O subconjunctivally/O ,/O nor/O should/O it/O be/O introduced/O directly/O into/O the/O anterior/O chamber/O of/O the/O eye/O ./O
5.2/O Growth/O of/O Resistant/O Organisms/O with/O Prolonged/O Use/O As/O with/O other/O anti/O -/O infectives/O ,/O prolonged/O use/O of/O Besivance/O (/O besifloxacin/O ophthalmic/O suspension/O )/O 0.6/O %/O may/B-Factor result/O in/O overgrowth/B-AdverseReaction of/I-AdverseReaction non/I-AdverseReaction -/I-AdverseReaction susceptible/O organisms/O ,/O including/O fungi/O ./O
If/O super/O -/O infection/O occurs/O ,/O discontinue/O use/O and/O institute/O alternative/O therapy/O ./O
Whenever/O clinical/O judgment/O dictates/O ,/O the/O patient/O should/O be/O examined/O with/O the/O aid/O of/O magnification/O ,/O such/O as/O slit/O -/O lamp/O biomicroscopy/O ,/O and/O ,/O where/O appropriate/O ,/O fluorescein/O staining/O ./O
5.3/O Avoidance/O of/O Contact/O Lenses/O Patients/O should/O not/O wear/O contact/O lenses/O if/O they/O have/O signs/O or/O symptoms/O of/O bacterial/O conjunctivitis/O or/O during/O the/O course/O of/O therapy/O with/O Besivance/O ./O
6/O ./O
ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O label/O :/O Cytokine/B-AdverseReaction Release/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Neurological/B-AdverseReaction Toxicities/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Neutropenia/B-AdverseReaction and/O Febrile/B-AdverseReaction Neutropenia/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Effects/B-AdverseReaction on/I-AdverseReaction Ability/I-AdverseReaction to/I-AdverseReaction Drive/I-AdverseReaction and/O Use/O Machines/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Elevated/B-AdverseReaction Liver/I-AdverseReaction Enzymes/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Leukoencephalopathy/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Preparation/O and/O Administration/O Errors/O [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O The/O most/O common/O adverse/O reactions/O (/O 20/O %/O )/O were/O pyrexia/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O tremor/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O constipation/B-AdverseReaction ./O
(/O 6.1/O )/O EXCERPT/O :/O }/O }/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Amgen/O Inc./O at/O 1/O -/O 800/O -/O 77-AMGEN/O (/O 1/O -/O 800/O -/O 772/O -/O 6436/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O safety/O data/O described/O in/O this/O section/O reflect/O exposure/O to/O BLINCYTO/O in/O clinical/O trials/O in/O which/O 212/O patients/O with/O relapsed/O or/O refractory/O ALL/O received/O up/O to/O 28/O mcg/O day/O ./O
All/O patients/O received/O at/O least/O one/O dose/O of/O BLINCYTO/O ./O
The/O median/O age/O of/O the/O study/O population/O was/O 37/O years/O (/O range/O :/O 18/O to/O 79/O years/O )/O ,/O 63/O %/O were/O male/O ,/O 79/O %/O were/O White/O ,/O 3/O %/O were/O Asian/O ,/O and/O 3/O %/O were/O Black/O or/O African/O American/O ./O
The/O most/O common/O adverse/O reactions/O (/O 20/O %/O )/O were/O pyrexia/B-AdverseReaction (/O 62/O %/O )/O ,/O headache/B-AdverseReaction (/O 36/O %/O )/O ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction (/O 25/O %/O )/O ,/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction (/O 25/O %/O )/O ,/O nausea/B-AdverseReaction (/O 25/O %/O )/O ,/O hypokalemia/B-AdverseReaction (/O 23/O %/O )/O ,/O and/O constipation/B-AdverseReaction (/O 20/O %/O )/O ./O
Serious/O adverse/O reactions/O were/O reported/O in/O 65/O %/O of/O patients/O ./O
The/O most/O common/O serious/O adverse/O reactions/O (/O 2/O %/O )/O included/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O device/B-AdverseReaction -/I-AdverseReaction related/O infection/O ,/O tremor/B-AdverseReaction ,/O encephalopathy/B-AdverseReaction ,/O infection/B-AdverseReaction ,/O overdose/B-AdverseReaction ,/O confusion/B-AdverseReaction ,/O Staphylococcal/B-AdverseReaction bacteremia/O ,/O and/O headache/B-AdverseReaction ./O
Adverse/O reactions/O of/O Grade/O 3/O or/O higher/O were/O reported/O in/O 80/O %/O of/O patients/O ./O
Discontinuation/O of/O therapy/O due/O to/O adverse/O reactions/O occurred/O in/O 18/O %/O of/O patients/O treated/O with/O BLINCYTO/O ./O
The/O adverse/O reactions/O reported/O most/O frequently/O as/O the/O reason/O for/O discontinuation/O of/O treatment/O included/O encephalopathy/B-AdverseReaction and/O sepsis/B-AdverseReaction ./O
Fatal/B-AdverseReaction adverse/O events/O occurred/O in/O 15/O %/O of/O patients/O ./O
The/O majority/O of/O these/O events/O were/O infections/B-AdverseReaction ./O
No/B-Negation fatal/B-AdverseReaction adverse/O events/O occurred/O on/O treatment/O among/O patients/O in/O remission/O ./O
The/O adverse/O reactions/O with/O 10/O %/O incidence/O for/O any/O grade/O or/O 5/O %/O incidence/O for/O Grade/O 3/O or/O higher/O are/O summarized/O in/O Table/O 2/O ./O
Table/O 2/O ./O
Adverse/O Reactions/O With/O 10/O %/O Incidence/O for/O Any/O Grade/O or/O 5/O %/O Incidence/O for/O Grade/O 3/O or/O Higher/O (/O N/O 212/O )/O Adverse/O Reaction/O Any/O GradeGrading/O based/O on/O NCI/O Common/O Terminology/O Criteria/O for/O Adverse/O Events/O (/O CTCAE/O )/O version/O 4.0(%/O )/O Grade/O 3/O or/O Higher(%/O )/O Blood/O and/O lymphatic/O system/O disorders/O Febrile/B-AdverseReaction neutropenia/I-AdverseReaction Anemia/B-AdverseReaction Neutropenia/B-AdverseReaction Thrombocytopenia/B-AdverseReaction Leukopenia/B-AdverseReaction 251816119/O 23131588/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction Constipation/B-AdverseReaction DiarrheaDiarrhea/B-AdverseReaction includes/O the/O following/O terms/O :/O colitis/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O enteritis/B-AdverseReaction ,/O and/O neutropenic/B-AdverseReaction colitis/I-AdverseReaction ./O
Abdominal/B-AdverseReaction pain/I-AdverseReaction Vomiting/B-AdverseReaction 2520201513/O 0/O 1120/O General/O disorders/O and/O administration/O site/O conditions/O Pyrexia/B-AdverseReaction Peripheral/B-AdverseReaction edema/I-AdverseReaction Fatigue/B-AdverseReaction Chills/B-AdverseReaction Chest/B-AdverseReaction pain/I-AdverseReaction 6225171511/O 7/O 1101/O Immune/O system/O disorders/O Cytokine/B-AdverseReaction release/I-AdverseReaction syndrome/I-AdverseReaction 11/O 1/O Infections/O and/O infestations/O Other/O pathogen/O infections/B-AdverseReaction Bacterial/B-AdverseReaction infections/I-AdverseReaction Fungal/B-AdverseReaction infections/I-AdverseReaction Viral/B-AdverseReaction infections/I-AdverseReaction Pneumonia/B-AdverseReaction Sepsis/B-AdverseReaction 4419151397/O 25127486/O Investigations/O Increased/B-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction Increased/B-AdverseReaction aspartate/I-AdverseReaction aminotransferase/I-AdverseReaction Increased/B-AdverseReaction weight/I-AdverseReaction 121111/O 640/O Metabolism/O and/O nutrition/O disorders/O Hypokalemia/B-AdverseReaction Hypomagnesemia/B-AdverseReaction Hyperglycemia/B-AdverseReaction Decreased/B-AdverseReaction appetite/I-AdverseReaction Hypophosphatemia/B-AdverseReaction 231211106/O 60735/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Back/B-AdverseReaction pain/I-AdverseReaction Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction Bone/B-AdverseReaction pain/I-AdverseReaction Arthralgia/B-AdverseReaction 14121110/O 2132/O Nervous/O system/O disorders/O Headache/B-AdverseReaction TremorTremor/B-AdverseReaction includes/O the/O following/O terms/O :/O resting/B-AdverseReaction tremor/I-AdverseReaction and/O tremor/B-AdverseReaction ./O
Dizziness/B-AdverseReaction 362014/O 31/O 1/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 15/O 0/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction DyspneaDyspnea/B-AdverseReaction includes/O the/O following/O terms/O :/O acute/B-AdverseReaction respiratory/I-AdverseReaction failure/I-AdverseReaction ,/O bronchial/B-AdverseReaction hyperactivity/I-AdverseReaction ,/O bronchospasm/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O dyspnea/B-AdverseReaction exertional/I-AdverseReaction ,/O respiratory/B-AdverseReaction distress/I-AdverseReaction ,/O respiratory/B-AdverseReaction failure/I-AdverseReaction ,/O and/O wheezing/B-AdverseReaction ./O
1915/O 05/O Skin/O and/O subcutaneous/O tissue/O disorders/O RashRash/B-AdverseReaction includes/O the/O following/O terms/O :/O erythema/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O erythematous/B-AdverseReaction rash/I-AdverseReaction ,/O generalized/B-AdverseReaction rash/I-AdverseReaction ,/O macular/B-AdverseReaction rash/I-AdverseReaction ,/O maculo/B-AdverseReaction -/I-AdverseReaction papular/O rash/O ,/O papular/B-AdverseReaction rash/I-AdverseReaction ,/O and/O vesicular/B-AdverseReaction rash/I-AdverseReaction ./O
21/O 2/O Vascular/O disorders/O Hypotension/B-AdverseReaction Hypertension/B-AdverseReaction 118/O 25/O Additional/O important/O adverse/O reactions/O that/O did/O not/O meet/O the/O threshold/O criteria/O for/O inclusion/O in/O Table/O 2/O were/O :/O Blood/O and/O lymphatic/O system/O disorders/O :/O leukocytosis/B-AdverseReaction (/O 2/O %/O )/O ,/O lymphopenia/B-AdverseReaction (/O 1/O %/O )/O Cardiac/O disorders/O :/O tachycardia/B-AdverseReaction (/O 8/O %/O )/O General/O disorders/O and/O administration/O site/O conditions/O :/O edema/B-AdverseReaction (/O 5/O %/O )/O Immune/O system/O disorders/O :/O cytokine/B-AdverseReaction storm/I-AdverseReaction (/O 1/O %/O )/O Investigations/O :/O decreased/B-AdverseReaction immunoglobulins/I-AdverseReaction (/O 9/O %/O )/O ,/O increased/B-AdverseReaction blood/I-AdverseReaction bilirubin/I-AdverseReaction (/O 8/O %/O )/O ,/O increased/B-AdverseReaction gamma/I-AdverseReaction -/O glutamyl/O -/O transferase/O (/O 6/O %/O )/O ,/O increased/B-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction (/O 1/O %/O )/O Metabolism/O and/O nutrition/O disorders/O :/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction (/O 4/O %/O )/O ,/O hypoalbuminemia/B-AdverseReaction (/O 4/O %/O )/O Nervous/O system/O disorders/O :/O encephalopathy/B-AdverseReaction (/O 5/O %/O )/O ,/O paresthesia/B-AdverseReaction (/O 5/O %/O )/O ,/O aphasia/B-AdverseReaction (/O 4/O %/O )/O ,/O convulsion/B-AdverseReaction (/O 2/O %/O )/O ,/O memory/B-AdverseReaction impairment/I-AdverseReaction (/O 2/O %/O )/O ,/O cognitive/B-AdverseReaction disorder/I-AdverseReaction (/O 1/O %/O )/O ,/O speech/B-AdverseReaction disorder/I-AdverseReaction (/O 1/O %/O )/O Psychiatric/O disorders/O :/O confusion/B-AdverseReaction (/O 7/O %/O )/O ,/O disorientation/B-AdverseReaction (/O 3/O %/O )/O Vascular/O disorders/O :/O capillary/B-AdverseReaction leak/I-AdverseReaction syndrome/I-AdverseReaction (/O 1/O %/O )/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction related/O to/O BLINCYTO/O treatment/O were/O hypersensitivity/B-AdverseReaction (/O 1/O %/O )/O and/O bronchospasm/B-AdverseReaction (/O 1/O %/O )/O ./O
6.2/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O potential/O for/O immunogenicity/O ./O
The/O immunogenicity/O of/O BLINCYTO/O has/O been/O evaluated/O using/O either/O an/O electrochemiluminescence/O detection/O technology/O (/O ECL/O )/O or/O an/O enzyme/O -/O linked/O immunosorbent/O assay/O (/O ELISA/O )/O screening/O immunoassay/O for/O the/O detection/O of/O binding/O anti/O -/O blinatumomab/O antibodies/O ./O
For/O patients/O whose/O sera/O tested/O positive/O in/O the/O screening/O immunoassay/O ,/O an/O in/O vitro/O biological/O assay/O was/O performed/O to/O detect/O neutralizing/O antibodies/O ./O
In/O clinical/O studies/O ,/O less/O than/O 1/O %/O of/O patients/O treated/O with/O BLINCYTO/O tested/O positive/O for/O binding/O anti/O -/O blinatumomab/O antibodies/O ./O
All/O patients/O who/O tested/O positive/O for/O binding/O antibodies/O also/O tested/O positive/O for/O neutralizing/O anti/O -/O blinatumomab/O antibodies/O ./O
Anti/O -/O blinatumomab/O antibody/O formation/O may/O affect/O pharmacokinetics/O of/O BLINCYTO/O ./O
No/O association/O was/O seen/O between/O antibody/O development/O and/O development/O of/O adverse/O events/O ./O
If/O formation/O of/O anti/O -/O blinatumomab/O antibodies/O with/O a/O clinically/O significant/O effect/O is/O suspected/O ,/O contact/O Amgen/O at/O 1/O -/O 800/O -/O 77-AMGEN/O (/O 1/O -/O 800/O -/O 772/O -/O 6436/O )/O to/O discuss/O antibody/O testing/O ./O
The/O detection/O of/O anti/O -/O blinatumomab/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O ,/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O blinatumomab/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O CYTOKINE/B-AdverseReaction RELEASE/I-AdverseReaction SYNDROME/I-AdverseReaction and/O NEUROLOGICAL/B-AdverseReaction TOXICITIES/I-AdverseReaction WARNING/O :/O CYTOKINE/B-AdverseReaction RELEASE/I-AdverseReaction SYNDROME/I-AdverseReaction and/O NEUROLOGICAL/B-AdverseReaction TOXICITIES/I-AdverseReaction Cytokine/B-AdverseReaction Release/I-AdverseReaction Syndrome/I-AdverseReaction (/O CRS/B-AdverseReaction )/O ,/O which/O may/B-Factor be/O life/B-Severity -/O threatening/O or/O fatal/B-AdverseReaction ,/O occurred/O in/O patients/O receiving/O BLINCYTO/O ./O
Interrupt/O or/O discontinue/O BLINCYTO/O as/O recommended/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.3/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Neurological/B-AdverseReaction toxicities/I-AdverseReaction ,/O which/O may/B-Factor be/O severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction ,/O occurred/O in/O patients/O receiving/O BLINCYTO/O ./O
Interrupt/O or/O discontinue/O BLINCYTO/O as/O recommended/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.3/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O CYTOKINE/B-AdverseReaction RELEASE/I-AdverseReaction SYNDROME/I-AdverseReaction and/O NEUROLOGICAL/B-AdverseReaction TOXICITIES/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Cytokine/B-AdverseReaction Release/I-AdverseReaction Syndrome/I-AdverseReaction (/O CRS/B-AdverseReaction )/O ,/O which/O may/B-Factor be/O life/B-Severity -/O threatening/O or/O fatal/B-AdverseReaction ,/O occurred/O in/O patients/O receiving/O BLINCYTO/O ./O
Interrupt/O or/O discontinue/O BLINCYTO/O as/O recommended/O ./O
(/O 2.3/O )/O ,/O (/O 5.1/O )/O Neurological/B-AdverseReaction toxicities/I-AdverseReaction ,/O which/O may/B-Factor be/O severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction ,/O occurred/O in/O patients/O receiving/O BLINCYTO/O ./O
Interrupt/O or/O discontinue/O BLINCYTO/O as/O recommended/O ./O
(/O 2.3/O )/O ,/O (/O 5.2/O )/O 5/O ./O
WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Infections/B-AdverseReaction :/O Monitor/O patients/O for/O signs/O or/O symptoms/O and/O treat/O appropriately/O ./O
(/O 5.3/O )/O Effects/B-AdverseReaction on/I-AdverseReaction Ability/I-AdverseReaction to/I-AdverseReaction Drive/I-AdverseReaction and/O Use/O Machines/O :/O Advise/O patients/O to/O refrain/O from/O driving/O and/O engaging/O in/O hazardous/O occupations/O or/O activities/O such/O as/O operating/O heavy/O or/O potentially/O dangerous/O machinery/O while/O BLINCYTO/O is/O being/O administered/O ./O
(/O 5.6/O )/O Preparation/O and/O Administration/O Errors/O :/O Strictly/O follow/O instructions/O for/O preparation/O (/O including/O admixing/O )/O and/O administration/O ./O
(/O 5.9/O )/O 5.1/O Cytokine/O Release/O Syndrome/O Cytokine/B-AdverseReaction Release/I-AdverseReaction Syndrome/I-AdverseReaction (/O CRS/B-AdverseReaction )/O ,/O which/O may/B-Factor be/O life/B-Severity -/O threatening/O or/O fatal/B-AdverseReaction ,/O occurred/O in/O patients/O receiving/O BLINCYTO/O ./O
Infusion/B-AdverseReaction reactions/I-AdverseReaction have/O occurred/O with/O the/O BLINCYTO/O infusion/O and/O may/O be/O clinically/O indistinguishable/O from/O manifestations/O of/O CRS/O ./O
Serious/O adverse/O events/O that/O may/O be/O associated/O with/O CRS/B-AdverseReaction included/O pyrexia/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O increased/B-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction ,/O increased/B-AdverseReaction aspartate/I-AdverseReaction aminotransferase/I-AdverseReaction ,/O and/O increased/B-AdverseReaction total/I-AdverseReaction bilirubin/I-AdverseReaction ;/O these/O events/O infrequently/O led/O to/O BLINCYTO/O discontinuation/O ./O
Life/B-Severity -/O threatening/O or/O fatal/B-AdverseReaction CRS/B-AdverseReaction was/O infrequently/O reported/O in/O patients/O receiving/O BLINCYTO/O ./O
In/O some/O cases/O ,/O disseminated/B-AdverseReaction intravascular/I-AdverseReaction coagulation/I-AdverseReaction (/O DIC/B-AdverseReaction )/O ,/O capillary/B-AdverseReaction leak/I-AdverseReaction syndrome/I-AdverseReaction (/O CLS/B-AdverseReaction )/O ,/O and/O hemophagocytic/B-AdverseReaction lymphohistiocytosis/I-AdverseReaction macrophage/B-AdverseReaction activation/I-AdverseReaction syndrome/I-AdverseReaction (/O HLH/B-AdverseReaction MAS/B-AdverseReaction )/O have/O been/O reported/O in/O the/O setting/O of/O CRS/B-AdverseReaction ./O
Patients/O should/O be/O closely/O monitored/O for/O signs/O or/O symptoms/O of/O these/O events/O ./O
Management/O of/O these/O events/O may/O require/O either/O temporary/O interruption/O or/O discontinuation/O of/O BLINCYTO/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.2/O Neurological/O Toxicities/O In/O patients/O receiving/O BLINCYTO/O in/O clinical/O trials/O ,/O neurological/B-AdverseReaction toxicities/I-AdverseReaction have/O occurred/O in/O approximately/O 50/O %/O of/O patients/O ./O
The/O median/O time/O to/O onset/O of/O any/O neurological/O toxicity/O was/O 7/O days/O ./O
Grade/B-Severity 3/I-Severity or/O higher/O (/O severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction )/O neurological/B-AdverseReaction toxicities/I-AdverseReaction following/O initiation/O of/O BLINCYTO/O administration/O occurred/O in/O approximately/O 15/O %/O of/O patients/O and/O included/O encephalopathy/B-AdverseReaction ,/O convulsions/B-AdverseReaction ,/O speech/B-AdverseReaction disorders/I-AdverseReaction ,/O disturbances/B-AdverseReaction in/I-AdverseReaction consciousness/I-AdverseReaction ,/O confusion/B-AdverseReaction and/O disorientation/B-AdverseReaction ,/O and/O coordination/O and/O balance/B-AdverseReaction disorders/I-AdverseReaction ./O
The/O majority/O of/O events/O resolved/O following/O interruption/O of/O BLINCYTO/O ,/O but/O some/O resulted/O in/O treatment/O discontinuation/O ./O
Monitor/O patients/O receiving/O BLINCYTO/O for/O signs/O and/O symptoms/O of/O neurological/O toxicities/O ,/O and/O interrupt/O or/O discontinue/O BLINCYTO/O as/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.3/O Infections/O In/O patients/O receiving/O BLINCYTO/O in/O clinical/O trials/O ,/O serious/B-Severity infections/B-AdverseReaction such/O as/O sepsis/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O bacteremia/B-AdverseReaction ,/O opportunistic/B-AdverseReaction infections/I-AdverseReaction ,/O and/O catheter/B-AdverseReaction -/I-AdverseReaction site/O infections/O were/O observed/O in/O approximately/O 25/O %/O of/O patients/O ,/O some/O of/O which/O were/O life/B-Severity -/O threatening/O or/O fatal/B-AdverseReaction ./O
As/O appropriate/O ,/O administer/O prophylactic/O antibiotics/O and/O employ/O surveillance/O testing/O during/O treatment/O with/O BLINCYTO/O ./O
Monitor/O patients/O for/O signs/O and/O symptoms/O of/O infection/O and/O treat/O appropriately/O ./O
5.4/O Tumor/O Lysis/O Syndrome/O Tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction (/O TLS/B-AdverseReaction )/O ,/O which/O may/B-Factor be/O life/B-Severity -/O threatening/O or/O fatal/B-AdverseReaction ,/O has/O been/O observed/O in/O patients/O receiving/O BLINCYTO/O ./O
Appropriate/O prophylactic/O measures/O ,/O including/O pretreatment/O nontoxic/O cytoreduction/O and/O on/O -/O treatment/O hydration/O ,/O should/O be/O used/O for/O the/O prevention/O of/O TLS/O during/O BLINCYTO/O treatment/O ./O
Monitor/O for/O signs/O or/O symptoms/O of/O TLS/O ./O
Management/O of/O these/O events/O may/O require/O either/O temporary/O interruption/O or/O discontinuation/O of/O BLINCYTO/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.5/O Neutropenia/O and/O Febrile/O Neutropenia/O Neutropenia/B-AdverseReaction and/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O including/O life/B-Severity -/O threatening/O cases/O ,/O have/O been/O observed/O in/O patients/O receiving/O BLINCYTO/O ./O
Monitor/O laboratory/O parameters/O (/O including/O ,/O but/O not/O limited/O to/O ,/O white/O blood/O cell/O count/O and/O absolute/O neutrophil/O count/O )/O during/O BLINCYTO/O infusion/O ./O
Interrupt/O BLINCYTO/O if/O prolonged/O neutropenia/O occurs/O ./O
5.6/O Effects/O on/O Ability/O to/O Drive/O and/O Use/O Machines/O Due/O to/O the/O potential/B-Factor for/O neurologic/B-AdverseReaction events/I-AdverseReaction ,/O including/O seizures/B-AdverseReaction ,/O patients/O receiving/O BLINCYTO/O are/O at/O risk/B-Factor for/O loss/B-AdverseReaction of/I-AdverseReaction consciousness/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Advise/O patients/O to/O refrain/O from/O driving/O and/O engaging/O in/O hazardous/O occupations/O or/O activities/O such/O as/O operating/O heavy/O or/O potentially/O dangerous/O machinery/O while/O BLINCYTO/O is/O being/O administered/O ./O
5.7/O Elevated/O Liver/O Enzymes/O Treatment/O with/O BLINCYTO/O was/O associated/O with/O transient/B-Severity elevations/B-AdverseReaction in/I-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction ./O
Although/O the/O majority/O of/O these/O events/O were/O observed/O in/O the/O setting/O of/O CRS/B-AdverseReaction ,/O some/O were/O observed/O outside/O of/O this/O setting/O ./O
For/O these/O events/O ,/O the/O median/O time/O to/O onset/O was/O 15/O days/O ./O
In/O patients/O receiving/O BLINCYTO/O in/O clinical/O trials/O ,/O Grade/B-Severity 3/I-Severity or/O greater/O elevations/B-AdverseReaction in/I-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction occurred/O in/O approximately/O 6/O %/O of/O patients/O outside/B-Negation the/O setting/O of/O CRS/B-AdverseReaction and/O resulted/O in/O treatment/O discontinuation/O in/O less/O than/O 1/O %/O of/O patients/O ./O
Monitor/O alanine/O aminotransferase/O (/O ALT/O )/O ,/O aspartate/O aminotransferase/O (/O AST/O )/O ,/O gamma/O -/O glutamyl/O transferase/O (/O GGT/O )/O ,/O and/O total/O blood/O bilirubin/O prior/O to/O the/O start/O of/O and/O during/O BLINCYTO/O treatment/O ./O
Interrupt/O BLINCYTO/O if/O the/O transaminases/O rise/O to/O greater/O than/O 5/O times/O the/O upper/O limit/O of/O normal/O or/O if/O bilirubin/O rises/O to/O more/O than/O 3/O times/O the/O upper/O limit/O of/O normal/O ./O
5.8/O Leukoencephalopathy/O Cranial/O magnetic/O resonance/O imaging/O (/O MRI/O )/O changes/O showing/O leukoencephalopathy/B-AdverseReaction have/O been/O observed/O in/O patients/O receiving/O BLINCYTO/O ,/O especially/O in/O patients/O with/O prior/O treatment/O with/O cranial/O irradiation/O and/O antileukemic/O chemotherapy/O (/O including/O systemic/O high/O -/O dose/O methotrexate/O or/O intrathecal/O cytarabine/O )/O ./O
The/O clinical/O significance/O of/O these/O imaging/O changes/O is/O unknown/O ./O
5.9/O Preparation/O and/O Administration/O Errors/O Preparation/O and/O administration/O errors/O have/O occurred/O with/O BLINCYTO/O treatment/O ./O
Follow/O instructions/O for/O preparation/O (/O including/O admixing/O )/O and/O administration/O strictly/O to/O minimize/O medication/O errors/O (/O including/O underdose/O and/O overdose/O )/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O (/O 2.4/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Gastrointestinal/B-AdverseReaction toxicity/I-AdverseReaction [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Myelosuppression/B-AdverseReaction [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Hepatic/B-AdverseReaction toxicity/I-AdverseReaction [/O see/O Dosage/O and/O Administration/O (/O 2.5/O )/O and/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Fluid/B-AdverseReaction retention/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Renal/B-AdverseReaction toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O greater/O than/O 20/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O rash/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O and/O fatigue/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Pfizer/O Inc./O at/O 1/O -/O 800/O -/O 438/O -/O 1985/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Serious/O adverse/O reactions/O reported/O include/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O ]/O ,/O myelosuppression/B-AdverseReaction ,/O gastrointestinal/B-AdverseReaction toxicity/I-AdverseReaction (/O diarrhea/B-AdverseReaction )/O ,/O fluid/B-AdverseReaction retention/I-AdverseReaction ,/O hepatotoxicity/B-AdverseReaction and/O rash/B-AdverseReaction ./O
Adverse/O reactions/O of/O any/O toxicity/O grade/O reported/O for/O greater/O than/O 20/O %/O of/O patients/O in/O the/O Phase/O 1/2/O safety/O population/O (/O n=546/O )/O were/O diarrhea/B-AdverseReaction (/O 82/O %/O )/O ,/O nausea/B-AdverseReaction (/O 46/O %/O )/O ,/O thrombocytopenia/B-AdverseReaction (/O 41/O %/O )/O ,/O vomiting/B-AdverseReaction (/O 39/O %/O )/O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction (/O 37/O %/O )/O ,/O rash/B-AdverseReaction (/O 35/O %/O )/O ,/O anemia/B-AdverseReaction (/O 27/O %/O )/O ,/O pyrexia/B-AdverseReaction (/O 26/O %/O )/O ,/O and/O fatigue/B-AdverseReaction (/O 24/O %/O )/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Adverse/O Reactions/O in/O Patients/O with/O Imatinib/O -/O Resistant/O or/O -Intolerant/O Ph+/O Chronic/O Phase/O (/O CP/O )/O ,/O Accelerated/O Phase/O (/O AP/O )/O ,/O and/O Blast/O Phase/O (/O BP/O )/O CML/O The/O single/O -/O arm/O Phase/O 1/2/O clinical/O trial/O (/O Study/O 1/O )/O enrolled/O patients/O with/O Ph+/O chronic/O ,/O accelerated/O ,/O or/O blast/O phase/O chronic/O myelogenous/O leukemia/O (/O CML/O )/O and/O with/O resistance/O or/O intolerance/O to/O prior/O therapy/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
The/O safety/O population/O (/O received/O at/O least/O 1/O dose/O of/O BOSULIF/O )/O included/O 546/O CML/O patients/O :/O 287/O patients/O with/O CP/O CML/O previously/O treated/O with/O imatinib/O only/O who/O had/O a/O median/O duration/O of/O BOSULIF/O treatment/O of/O 24/O months/O ,/O and/O a/O median/O dose/O intensity/O of/O 484/O mg/O day/O ./O
119/O patients/O with/O CP/O CML/O previously/O treated/O with/O both/O imatinib/O and/O at/O least/O 1/O additional/O TKI/O who/O had/O a/O median/O duration/O of/O BOSULIF/O treatment/O of/O 9/O months/O and/O a/O median/O dose/O intensity/O of/O 475/O mg/O day/O ./O
140/O patients/O with/O advanced/O phase/O CML/O including/O 76/O patients/O with/O AP/O CML/O and/O 64/O patients/O with/O BP/O CML/O ./O
In/O the/O patients/O with/O AP/O CML/O and/O BP/O CML/O ,/O the/O median/O duration/O of/O BOSULIF/O treatment/O was/O 10/O months/O and/O 3/O months/O ,/O respectively/O ./O
The/O median/O dose/O intensity/O was/O 483/O mg/O day/O ,/O and/O 500/O mg/O day/O ,/O in/O the/O AP/O CML/O and/O BP/O CML/O cohorts/O ,/O respectively/O ./O
Table/O 3/O identifies/O adverse/O reactions/O greater/O than/O or/O equal/O to/O 10/O %/O for/O all/O grades/O and/O grades/O 3/O or/O 4/O for/O the/O Phase/O 1/2/O CML/O safety/O population/O ./O
Table/O 3/O :/O Adverse/O Reactions/O (/O 10/O %/O or/O Greater/O )/O in/O Patients/O with/O CML/O in/O Study/O 1/O Chronic/O Phase/O CMLN=406/O Advanced/O Phase/O CMLN=140/O All/O Grades(%/O )/O Grade/O 3/4(%/O )/O All/O Grades(%/O )/O Grade/O 3/4(%/O )/O Advanced/O Phase/O CML/O includes/O patients/O with/O Accelerated/O Phase/O and/O Blast/O Phase/O CML/O Diarrhea/B-AdverseReaction 84/O 9/O 76/O 5/O Nausea/B-AdverseReaction 46/O 1/O 47/O 2/O Abdominal/B-AdverseReaction Pain/I-AdverseReaction 40/O 1/O 29/O 5/O Thrombocytopenia/B-AdverseReaction 40/O 26/O 42/O 37/O Vomiting/B-AdverseReaction 37/O 3/O 42/O 4/O Rash/B-AdverseReaction 34/O 8/O 35/O 4/O Fatigue/B-AdverseReaction 26/O 1/O 20/O 4/O Anemia/B-AdverseReaction 23/O 9/O 37/O 26/O Pyrexia/B-AdverseReaction 22/O 1/O 36/O 3/O Increased/B-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction 20/O 7/O 10/O 5/O Headache/B-AdverseReaction 20/O 1/O 18/O 4/O Cough/B-AdverseReaction 20/O 0/O 21/O 0/O Increased/B-AdverseReaction aspartate/I-AdverseReaction aminotransferase/I-AdverseReaction 16/O 4/O 11/O 3/O Neutropenia/B-AdverseReaction 16/O 11/O 19/O 18/O Edema/B-AdverseReaction 14/O 1/O 14/O 1/O Arthralgia/B-AdverseReaction 14/O 1/O 13/O 0/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 13/O 1/O 14/O 0/O Respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 12/O 1/O 10/O 0/O Nasopharyngitis/B-AdverseReaction 12/O 0/O 5/O 0/O Back/B-AdverseReaction pain/I-AdverseReaction 12/O 1/O 7/O 1/O Asthenia/B-AdverseReaction 11/O 1/O 10/O 1/O Pruritus/B-AdverseReaction 11/O 1/O 8/O 0/O Dizziness/B-AdverseReaction 10/O 0/O 13/O 1/O Dyspnea/B-AdverseReaction 10/O 1/O 19/O 6/O In/O the/O single/O -/O arm/O Phase/O 1/2/O clinical/O trial/O ,/O one/O patient/O (/O 0.2/O %/O )/O experienced/O QTcF/B-AdverseReaction interval/I-AdverseReaction of/I-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 500/I-AdverseReaction milliseconds/I-AdverseReaction ./O
Patients/O with/O uncontrolled/O or/O significant/O cardiovascular/O disease/O including/O QT/O interval/O prolongation/O were/O excluded/O by/O protocol/O ./O
Table/O 4/O identifies/O the/O clinically/O relevant/O or/O severe/O Grade/O 3/4/O laboratory/O test/O abnormalities/O for/O the/O Phase/O 1/2/O CML/O safety/O population/O ./O
Table/O 4/O :/O Number/O (/O %/O )/O of/O Patients/O with/O Clinically/O Relevant/O or/O Severe/O Grade/O 3/4/O Laboratory/O Test/O Abnormalities/O in/O Patients/O with/O CML/O in/O Study/O 1/O ,/O Safety/O Population/O Chronic/O Phase/O CML/O Advanced/O Phase/O CML/O All/O CP/O and/O AdvP/O CML/O N=406/O N=140/O N=546/O n/O (/O %/O )/O n/O (/O %/O )/O n/O (/O %/O )/O Hematology/O Parameters/O Platelet/O Count/O (/O Low/O )/O less/O than/O 50/B-Severity 10/I-Severity 9/O /L/O 102/O (/O 25/O )/O 80/O (/O 57/O )/O 182/O (/O 33/O )/O Absolute/B-AdverseReaction Neutrophil/I-AdverseReaction Count/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 1/I-AdverseReaction 10/I-AdverseReaction 9/O /L/O 74/O (/O 18/O )/O 52/O (/O 37/O )/O 126/O (/O 23/O )/O Hemoglobin/O (/O Low/O )/O less/O than/O 80/B-Severity g/I-Severity L/O 53/O (/O 13/O )/O 49/O (/O 35/O )/O 102/O (/O 19/O )/O Biochemistry/O Parameters/O SGPT/O ALT/B-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 5.0*ULN/I-AdverseReaction 39/O (/O 10/O )/O 8/O (/O 6/O )/O 47/O (/O 9/O )/O SGOT/O AST/B-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 5.0*ULN/I-AdverseReaction 17/O (/O 4/O )/O 4/O (/O 3/O )/O 21/O (/O 4/O )/O Lipase/B-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 2*ULN/I-AdverseReaction 33/O (/O 8)/O 4/O (/O 3/O )/O 37/O (/O 7/O )/O Phosphorus/O (/O Low/O )/O less/O than/O 0.6/B-Severity mmol/I-Severity L/O 30/O (/O 7/O )/O 10/O (/O 7/O )/O 40/O (/O 7/O )/O Total/B-AdverseReaction Bilirubin/I-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 3.0*ULN/I-AdverseReaction 3/O (/O 1/O )/O 2/O (/O 1/O )/O 5/O (/O 1/O )/O Additional/O Adverse/O Reactions/O from/O Multiple/O Clinical/O Trials/O The/O following/O adverse/O reactions/O were/O reported/O in/O patients/O in/O clinical/O trials/O with/O BOSULIF/O (/O less/O than/O 10/O %/O of/O BOSULIF/O -/O treated/O patients/O )/O ./O
They/O represent/O an/O evaluation/O of/O the/O adverse/O reaction/O data/O from/O 870/O patients/O with/O Ph+/O leukemia/O who/O received/O at/O least/O 1/O dose/O of/O single/O -/O agent/O BOSULIF/O ./O
These/O adverse/O reactions/O are/O presented/O by/O system/O organ/O class/O and/O are/O ranked/O by/O frequency/O ./O
These/O adverse/O reactions/O are/O included/O based/O on/O clinical/O relevance/O and/O ranked/O in/O order/O of/O decreasing/O seriousness/O within/O each/O category/O ./O
Blood/O and/O Lymphatic/O System/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction Cardiac/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O pericardial/B-AdverseReaction effusion/I-AdverseReaction ;/O 0.1/O %/O and/O less/O than/O 1/O %/O -/O pericarditis/B-AdverseReaction Ear/O and/O Labyrinth/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O tinnitus/B-AdverseReaction Gastrointestinal/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O gastritis/B-AdverseReaction ;/O 0.1/O %/O and/O less/O than/O 1/O %/O -/O acute/B-AdverseReaction pancreatitis/I-AdverseReaction ,/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction (/O includes/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O gastric/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O upper/B-AdverseReaction gastrointestinal/I-AdverseReaction hemorrhage/I-AdverseReaction )/O General/O Disorders/O and/O Administrative/O Site/O Conditions/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O chest/B-AdverseReaction pain/I-AdverseReaction (/O includes/O chest/B-AdverseReaction pain/I-AdverseReaction and/O chest/B-AdverseReaction discomfort/I-AdverseReaction )/O ,/O pain/B-AdverseReaction Hepatobiliary/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O hepatotoxicity/B-AdverseReaction (/O includes/O hepatotoxicity/B-AdverseReaction ,/O toxic/B-AdverseReaction hepatitis/I-AdverseReaction ,/O and/O cytolytic/B-AdverseReaction hepatitis/I-AdverseReaction )/O ,/O abnormal/B-AdverseReaction hepatic/I-AdverseReaction function/I-AdverseReaction (/O includes/O abnormal/B-AdverseReaction hepatic/I-AdverseReaction function/I-AdverseReaction ,/O liver/B-AdverseReaction disorder/I-AdverseReaction )/O ;/O 0.1/O %/O and/O less/O than/O 1/O %/O -/O liver/B-AdverseReaction injury/I-AdverseReaction Immune/O System/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O drug/B-AdverseReaction hypersensitivity/I-AdverseReaction ;/O 0.1/O %/O and/O less/O than/O 1/O %/O -/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction Infections/O and/O Infestations/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O pneumonia/B-AdverseReaction (/O includes/O pneumonia/B-AdverseReaction ,/O bronchopneumonia/B-AdverseReaction ,/O lobar/B-AdverseReaction pneumonia/I-AdverseReaction ,/O primary/B-AdverseReaction atypical/I-AdverseReaction pneumonia/I-AdverseReaction )/O ,/O influenza/B-AdverseReaction ,/O bronchitis/B-AdverseReaction Investigations/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O electrocardiogram/B-AdverseReaction QT/I-AdverseReaction prolonged/I-AdverseReaction ,/O increased/B-AdverseReaction blood/I-AdverseReaction creatine/I-AdverseReaction phosphokinase/I-AdverseReaction ,/O increased/B-AdverseReaction blood/I-AdverseReaction creatinine/I-AdverseReaction Metabolism/O and/O Nutrition/O Disorder/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O hyperkalemia/B-AdverseReaction ,/O dehydration/B-AdverseReaction Musculoskeletal/O and/O Connective/O Tissue/O Disorder/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O myalgia/B-AdverseReaction Nervous/O System/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O dysgeusia/B-AdverseReaction Renal/O and/O Urinary/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O pleural/B-AdverseReaction effusion/I-AdverseReaction ;/O 0.1/O %/O and/O less/O than/O 1/O %/O -/O acute/B-AdverseReaction pulmonary/I-AdverseReaction edema/I-AdverseReaction ,/O respiratory/B-AdverseReaction failure/I-AdverseReaction ,/O pulmonary/B-AdverseReaction hypertension/I-AdverseReaction Skin/O and/O Subcutaneous/O Disorders/O :/O 1/O %/O and/O less/O than/O 10/O %/O -/O urticaria/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O acne/B-AdverseReaction ;/O 0.1/O %/O and/O less/O than/O 1/O %/O -/O erythema/B-AdverseReaction multiforme/I-AdverseReaction ,/O exfoliative/B-AdverseReaction rash/I-AdverseReaction ,/O drug/B-AdverseReaction eruption/I-AdverseReaction 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Gastrointestinal/B-AdverseReaction Toxicity/I-AdverseReaction :/O Monitor/O and/O manage/O as/O necessary/O ./O
Withhold/O ,/O dose/O reduce/O ,/O or/O discontinue/O BOSULIF/O ./O
(/O 2.3/O ,/O 5.1/O )/O Myelosuppression/B-AdverseReaction :/O Monitor/O blood/O counts/O and/O manage/O as/O necessary/O ./O
(/O 2.4/O ,/O 5.2/O )/O Hepatic/B-AdverseReaction Toxicity/I-AdverseReaction :/O Monitor/O liver/O enzymes/O at/O least/O monthly/O for/O the/O first/O three/O months/O and/O as/O needed/O ./O
Withhold/O ,/O dose/O reduce/O ,/O or/O discontinue/O BOSULIF/O ./O
(/O 2.3/O ,/O 5.3/O )/O Fluid/B-AdverseReaction Retention/I-AdverseReaction :/O Monitor/O patients/O and/O manage/O using/O standard/O of/O care/O treatment/O ./O
Withhold/O ,/O dose/O reduce/O ,/O or/O discontinue/O BOSULIF/O ./O
(/O 2.3/O ,/O 5.4/O )/O Renal/B-AdverseReaction Toxicity/I-AdverseReaction Monitor/O patients/O for/O renal/O function/O at/O baseline/O and/O during/O therapy/O with/O BOSULIF/O (/O 5.5/O )/O Embryofetal/B-AdverseReaction Toxicity/I-AdverseReaction :/O May/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Females/O of/O reproductive/O potential/O should/O avoid/O becoming/O pregnant/O while/O being/O treated/O with/O BOSULIF/O ./O
(/O 5.6/O )/O 5.1/O Gastrointestinal/O Toxicity/O Diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O and/O abdominal/B-AdverseReaction pain/I-AdverseReaction occur/O with/O BOSULIF/O treatment/O ./O
Monitor/O and/O manage/O patients/O using/O standards/O of/O care/O ,/O including/O antidiarrheals/O ,/O antiemetics/O ,/O and/O fluid/O replacement/O ./O
In/O the/O single/O -/O arm/O Phase/O 1/2/O clinical/O trial/O ,/O the/O median/O time/O to/O onset/O for/O diarrhea/O (/O all/O grades/O )/O was/O 2/O days/O and/O the/O median/O duration/O per/O event/O was/O 1/O day/O ./O
Among/O the/O patients/O who/O experienced/O diarrhea/O ,/O the/O median/O number/O of/O episodes/O of/O diarrhea/O per/O patient/O during/O treatment/O with/O BOSULIF/O was/O 3/O (/O range/O 1/O -/O 221/O )/O ./O
To/O manage/O gastrointestinal/O toxicity/O ,/O withhold/O ,/O dose/O reduce/O ,/O or/O discontinue/O BOSULIF/O as/O necessary/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.2/O Myelosuppression/O Thrombocytopenia/B-AdverseReaction ,/O anemia/B-AdverseReaction and/O neutropenia/B-AdverseReaction occur/O with/O BOSULIF/O treatment/O ./O
Perform/O complete/O blood/O counts/O weekly/O for/O the/O first/O month/O of/O therapy/O and/O then/O monthly/O thereafter/O ,/O or/O as/O clinically/O indicated/O ./O
To/O manage/O myelosuppression/O ,/O withhold/O ,/O dose/O reduce/O ,/O or/O discontinue/O BOSULIF/O as/O necessary/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.3/O Hepatic/O Toxicity/O One/O case/O consistent/O with/O drug/B-AdverseReaction induced/I-AdverseReaction liver/I-AdverseReaction injury/I-AdverseReaction (/O defined/O as/O concurrent/O elevations/B-AdverseReaction in/I-AdverseReaction ALT/I-AdverseReaction or/O AST/O greater/O than/O or/O equal/O to/O 3*ULN/B-Severity with/O total/B-AdverseReaction bilirubin/I-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 2*ULN/I-AdverseReaction and/O alkaline/B-AdverseReaction phosphatase/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 2*ULN/I-AdverseReaction )/O occurred/O in/O a/O trial/O of/O BOSULIF/O in/O combination/O with/O letrozole/O ./O
The/O patient/O recovered/O fully/O following/O discontinuation/O of/O BOSULIF/O ./O
This/O case/O represented/O 1/O out/O of/O 1209/O patients/O in/O BOSULIF/O clinical/O trials/O ./O
In/O the/O 546/O patients/O from/O the/O safety/O population/O ,/O the/O incidence/O of/O ALT/B-AdverseReaction elevation/I-AdverseReaction was/O 17/O %/O and/O AST/B-AdverseReaction elevation/I-AdverseReaction was/O 14/O %/O ./O
Twenty/O percent/O of/O the/O patients/O experienced/O an/O increase/O in/O either/O ALT/O or/O AST/O ./O
Most/O cases/O of/O transaminase/B-AdverseReaction elevations/I-AdverseReaction occurred/O early/O in/O treatment/O ;/O of/O patients/O who/O experienced/O transaminase/B-AdverseReaction elevations/I-AdverseReaction of/O any/O grade/O ,/O more/O than/O 80/O %/O experienced/O their/O first/O event/O within/O the/O first/O 3/O months/O ./O
The/O median/O time/O to/O onset/O of/O increased/B-AdverseReaction ALT/I-AdverseReaction and/O AST/O was/O 30/O and/O 33/O days/O ,/O respectively/O ,/O and/O the/O median/O duration/O for/O each/O was/O 21/O days/O ./O
Perform/O hepatic/O enzyme/O tests/O monthly/O for/O the/O first/O three/O months/O of/O BOSULIF/O treatment/O and/O as/O clinically/O indicated/O ./O
In/O patients/O with/O transaminase/O elevations/O ,/O monitor/O liver/O enzymes/O more/O frequently/O ./O
Withhold/O ,/O dose/O reduce/O ,/O or/O discontinue/O BOSULIF/O as/O necessary/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.4/O Fluid/O Retention/O Fluid/B-AdverseReaction retention/I-AdverseReaction occurs/O with/O BOSULIF/O and/O may/B-Factor manifest/O as/O pericardial/B-AdverseReaction effusion/I-AdverseReaction ,/O pleural/B-AdverseReaction effusion/I-AdverseReaction ,/O pulmonary/B-AdverseReaction edema/I-AdverseReaction ,/O and/or/O peripheral/B-AdverseReaction edema/I-AdverseReaction ./O
In/O the/O single/O -/O arm/O Phase/O 1/2/O clinical/O trial/O in/O 546/O patients/O with/O CML/O treated/O with/O prior/O therapy/O ,/O severe/B-Severity fluid/B-AdverseReaction retention/I-AdverseReaction was/O reported/O in/O 14/O patients/O (/O 3/O %/O )/O ./O
Specifically/O ,/O 9/O patients/O had/O a/O Grade/B-Severity 3/I-Severity or/O 4/O pleural/B-AdverseReaction effusion/I-AdverseReaction ,/O 3/O patients/O experienced/O both/O Grade/B-Severity 3/I-Severity or/O Grade/B-Severity 4/I-Severity pleural/O and/O pericardial/B-AdverseReaction effusions/I-AdverseReaction ,/O 1/O patient/O experienced/O Grade/B-Severity 3/I-Severity peripheral/O and/O pulmonary/B-AdverseReaction edema/I-AdverseReaction ,/O and/O 1/O patient/O had/O a/O Grade/B-Severity 3/I-Severity edema/B-AdverseReaction ./O
Monitor/O and/O manage/O patients/O using/O standards/O of/O care/O ./O
Interrupt/O ,/O dose/O reduce/O or/O discontinue/O BOSULIF/O as/O necessary/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.5/O Renal/O Toxicity/O An/O on/O -/O treatment/O decline/B-AdverseReaction in/I-AdverseReaction estimated/I-AdverseReaction glomerular/I-AdverseReaction filtration/I-AdverseReaction rate/I-AdverseReaction (/O eGFR/O )/O has/O occurred/O in/O patients/O treated/O with/O BOSULIF/O ./O
Table/O 2/O identifies/O the/O shift/O from/O baseline/O to/O lowest/O observed/O estimated/O glomerular/O filtration/O rate/O (/O eGFR/O )/O during/O BOSULIF/O therapy/O for/O patients/O in/O the/O global/O Ph+/O Leukemia/O studies/O ./O
The/O median/O duration/O of/O therapy/O with/O BOSULIF/O was/O approximately/O 17/O months/O (/O range/O ,/O 0.03/O to/O 95/O )/O for/O patients/O in/O these/O studies/O ./O
Table/O 2/O :/O Shift/O from/O Baseline/O to/O Lowest/O Observed/O eGFR/O Group/O During/O Treatment/O Safety/O Population/O in/O Clinical/O Studies/O (/O n=818)Among/O the/O 818/O patients/O ,/O eGFR/O was/O missing/O in/O 5/O patients/O at/O baseline/O or/O on/O -/O therapy/O ./O
There/O were/O no/O patients/O with/O kidney/O failure/O at/O baseline/O ./O
Baseline/O Follow/O Up/O Renal/O Function/O Status/O n/O Normaln/O (/O %/O )/O Mildn/O (/O %/O )/O Mild/O to/O Moderaten/O (/O %/O )/O Moderate/O to/O Severen/O (/O %/O )/O Severen/O (/O %/O )/O Kidney/B-AdverseReaction Failuren/I-AdverseReaction (/O %/O )/O Notes/O :/O Grading/O is/O based/O on/O Modification/O in/O Diet/O in/O Renal/O Disease/O method/O (/O MDRD).KDIGO/O Classification/O by/O eGFR/O :/O Normal/O :/O greater/O than/O or/O equal/O to/O 90/O ,/O Mild/O :/O 60/O to/O less/O than/O 90/O ,/O Mild/O to/O Moderate/O :/O 45/O to/O less/O than/O 60/O ,/O Moderate/O to/O Severe/O :/O 30/O to/O less/O than/O 45/O ,/O Severe/O :/O 15/O to/O less/O than/O 30/O ,/O Kidney/O Failure/O :/O less/O than/O 15/O ml/O min/1.73/O m/O 2/O ./O
Normal/O 274/O 53/O (/O 19/O )/O 174/O (/O 64/O )/O 30/O (/O 11/O )/O 14/O (/O 5/O )/O 1/O (/O 1/O )/O 1/O (/O 1/O )/O Mild/O 438/O 10/O (/O 2/O )/O 170/O (/O 39/O )/O 177/O (/O 40/O )/O 63/O (/O 14/O )/O 14/O (/O 3/O )/O 2/O (/O 1/O )/O Mild/O to/O Moderate/O 79/O 0/O 4/O (/O 5/O )/O 28/O (/O 35/O )/O 37/O (/O 47/O )/O 10/O (/O 13/O )/O 0/O Moderate/O to/O Severe/O 24/O 0/O 1/O (/O 4/O )/O 1/O (/O 4/O )/O 6/O (/O 25/O )/O 15/O (/O 63/O )/O 1/O (/O 4/O )/O Severe/O 1/O 0/O 0/O 0/O 0/O 0/O 1/O (/O 100/O )/O Total/O 816/O 63/O (/O 8)/O 349/O (/O 43/O )/O 236/O (/O 29/O )/O 120/O (/O 15/O )/O 40/O (/O 5/O )/O 5/O (/O 1/O )/O Monitor/O renal/O function/O at/O baseline/O and/O during/O therapy/O with/O BOSULIF/O ,/O with/O particular/O attention/O to/O those/O patients/O who/O have/O preexisting/O renal/O impairment/O or/O risk/O factors/O for/O renal/O dysfunction/O ./O
Consider/O dose/O adjustment/O in/O patients/O with/O baseline/O and/O treatment/O emergent/O renal/O impairment/O [/O see/O Dosage/O and/O Administration/O (/O 2.7/O )/O ]/O ./O
5.6/O Embryofetal/O Toxicity/O There/O are/O no/O adequate/O and/O well/O controlled/O studies/O of/O BOSULIF/O in/O pregnant/O women/O ./O
BOSULIF/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Bosutinib/O caused/O embryofetal/B-AdverseReaction toxicities/I-AdverseReaction in/O rabbits/B-Animal at/O maternal/O exposures/O that/O were/O greater/O than/O the/O clinical/O exposure/O at/O the/O recommended/O bosutinib/O dose/O of/O 500/O mg/O day/O ./O
Females/O of/O reproductive/O potential/O should/O be/O advised/O to/O avoid/O pregnancy/O while/O being/O treated/O with/O BOSULIF/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O LABA/O ,/O such/O as/O vilanterol/O ,/O one/O of/O the/O active/O ingredients/O in/O BREO/O ELLIPTA/O ,/O increase/O the/O risk/B-Factor of/O asthma/O -/O related/O death/B-AdverseReaction ./O
Currently/O available/O data/O are/O inadequate/O to/O determine/O whether/O concurrent/O use/O of/O inhaled/O corticosteroids/O or/O other/O long/O -/O term/O asthma/O control/O drugs/O mitigates/O the/O increased/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction from/O LABA/B-DrugClass ./O
Available/O data/O from/O controlled/O clinical/O trials/O suggest/O that/O LABA/O increase/O the/O risk/O of/O asthma/O -/O related/O hospitalization/O in/O pediatric/O and/O adolescent/O patients/O ./O
Data/O from/O a/O large/O placebo/O -/O controlled/O US/O trial/O that/O compared/O the/O safety/O of/O another/O LABA/B-DrugClass (/O salmeterol/O )/O or/O placebo/O added/O to/O usual/O asthma/O therapy/O showed/O an/O increase/O in/O asthma/O -/O related/O deaths/B-AdverseReaction in/O subjects/O receiving/O salmeterol/O ./O
[/O See/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ./O
]/O Systemic/O and/O local/O corticosteroid/O use/O may/O result/O in/O the/O following/O :/O Candida/B-AdverseReaction albicans/I-AdverseReaction infection/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Increased/O risk/B-Factor of/O pneumonia/B-AdverseReaction in/O COPD/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Immunosuppression/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Hypercorticism/B-AdverseReaction and/O adrenal/B-AdverseReaction suppression/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Reduction/B-AdverseReaction in/I-AdverseReaction bone/I-AdverseReaction mineral/I-AdverseReaction density/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.13/O )/O ]/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
EXCERPT/O :/O COPD/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O greater/O than/O or/O equal/O to/O 3/O %/O )/O are/O nasopharyngitis/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O oral/B-AdverseReaction candidiasis/I-AdverseReaction ./O
(/O 6.1/O )/O Asthma/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O greater/O than/O or/O equal/O to/O 2/O %/O )/O are/O nasopharyngitis/B-AdverseReaction ,/O oral/B-AdverseReaction candidiasis/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O and/O cough/B-AdverseReaction ./O
(/O 6.2/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GlaxoSmithKline/O at/O 1/O -/O 888/O -/O 825/O -/O 5249/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O in/O Chronic/O Obstructive/O Pulmonary/O Disease/O The/O clinical/O program/O for/O BREO/O ELLIPTA/O included/O 7,700/O subjects/O with/O COPD/O in/O two/O 6-month/O lung/O function/O trials/O ,/O two/O 12-month/O exacerbation/O trials/O ,/O and/O 6/O other/O trials/O of/O shorter/O duration/O ./O
A/O total/O of/O 2,034/O subjects/O with/O COPD/O received/O at/O least/O 1/O dose/O of/O BREO/O ELLIPTA/O 100/25/O ,/O and/O 1,087/O subjects/O received/O a/O higher/O strength/O of/O fluticasone/O furoate/O vilanterol/O ./O
The/O safety/O data/O described/O below/O are/O based/O on/O the/O confirmatory/O 6-/O and/O 12-month/O trials/O ./O
Adverse/O reactions/O observed/O in/O the/O other/O trials/O were/O similar/O to/O those/O observed/O in/O the/O confirmatory/O trials/O ./O
6-Month/O Trials/O The/O incidence/O of/O adverse/O reactions/O associated/O with/O BREO/O ELLIPTA/O 100/25/O in/O Table/O 1/O is/O based/O on/O 2/O placebo/O -/O controlled/O ,/O 6-month/O clinical/O trials/O (/O Trials/O 1/O and/O 2/O ;/O n/O 1,224/O and/O n/O 1,030/O ,/O respectively/O )/O ./O
Of/O the/O 2,254/O subjects/O ,/O 70/O %/O were/O male/O and/O 84/O %/O were/O white/O ./O
They/O had/O a/O mean/O age/O of/O 62/O years/O and/O an/O average/O smoking/O history/O of/O 44/O pack/O -/O years/O ,/O with/O 54/O %/O identified/O as/O current/O smokers/O ./O
At/O screening/O ,/O the/O mean/O postbronchodilator/O percent/O predicted/O FEV1was/O 48/O %/O (/O range/O :/O 14/O %/O to/O 87/O %/O )/O ,/O the/O mean/O postbronchodilator/O FEV1/O forced/O vital/O capacity/O (/O FVC/O )/O ratio/O was/O 47/O %/O (/O range/O :/O 17/O %/O to/O 88/O %/O )/O ,/O and/O the/O mean/O percent/O reversibility/O was/O 14/O %/O (/O range/O :/O -41/O %/O to/O 152/O %/O )/O ./O
Subjects/O received/O 1/O inhalation/O once/O daily/O of/O the/O following/O :/O BREO/O ELLIPTA/O 100/25/O ,/O BREO/O ELLIPTA/O 200/25/O ,/O fluticasone/O furoate/O vilanterol/O 50/O mcg/25/O mcg/O ,/O fluticasone/O furoate/O 100/O mcg/O ,/O fluticasone/O furoate/O 200/O mcg/O ,/O vilanterol/O 25/O mcg/O ,/O or/O placebo/O ./O
Table/O 1/O ./O
Adverse/O Reactions/O with/O BREO/O ELLIPTA/O 100/25/O with/O =3/O %/O Incidence/O and/O More/O Common/O than/O Placebo/O in/O Subjects/O with/O Chronic/O Obstructive/O Pulmonary/O Disease/O Adverse/O Reaction/O BREO/O ELLIPTA/O 100/25/O (/O n/O 410/O )/O %/O Vilanterol/O 25/O mcg/O (/O n/O 408/O )/O %/O Fluticasone/O Furoate/O 100/O mcg/O (/O n/O 410/O )/O %/O Placebo/O (/O n/O 412/O )/O %/O Infections/O and/O infestations/O Nasopharyngitis/B-AdverseReaction 9/O 10/O 8/O 8/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 7/O 5/O 4/O 3/O Oropharyngeal/B-AdverseReaction candidiasis/I-AdverseReaction a/O 5/O 2/O 3/O 2/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 7/O 9/O 7/O 5/O a/O Includes/O oral/B-AdverseReaction candidiasis/I-AdverseReaction ,/O oropharyngeal/B-AdverseReaction candidiasis/I-AdverseReaction ,/O candidiasis/B-AdverseReaction ,/O and/O fungal/B-AdverseReaction oropharyngitis/I-AdverseReaction ./O
12-Month/O Trials/O Long/O -/O term/O safety/O data/O is/O based/O on/O two/O 12-month/O trials/O (/O Trials/O 3/O and/O 4/O ;/O n/O 1,633/O and/O n/O 1,622/O ,/O respectively/O )/O ./O
Trials/O 3/O and/O 4/O included/O 3,255/O subjects/O ,/O of/O which/O 57/O %/O were/O male/O and/O 85/O %/O were/O white/O ./O
They/O had/O a/O mean/O age/O of/O 64/O years/O and/O an/O average/O smoking/O history/O of/O 46/O pack/O -/O years/O ,/O with/O 44/O %/O identified/O as/O current/O smokers/O ./O
At/O screening/O ,/O the/O mean/O postbronchodilator/O percent/O predicted/O FEV1was/O 45/O %/O (/O range/O :/O 12/O %/O to/O 91/O %/O )/O ,/O and/O the/O mean/O postbronchodilator/O FEV1/O FVC/O ratio/O was/O 46/O %/O (/O range/O :/O 17/O %/O to/O 81/O %/O )/O ,/O indicating/O that/O the/O subject/O population/O had/O moderate/O to/O very/O severely/O impaired/O airflow/O obstruction/O ./O
Subjects/O received/O 1/O inhalation/O once/O daily/O of/O the/O following/O :/O BREO/O ELLIPTA/O 100/25/O ,/O BREO/O ELLIPTA/O 200/25/O ,/O fluticasone/O furoate/O vilanterol/O 50/O mcg/25/O mcg/O ,/O or/O vilanterol/O 25/O mcg/O ./O
In/O addition/O to/O the/O reactions/O shown/O in/O Table/O 1/O ,/O adverse/O reactions/O occurring/O in/O greater/O than/O or/O equal/O to/O 3/O %/O of/O the/O subjects/O treated/O with/O BREO/O ELLIPTA/O 100/25/O (/O n/O 806/O )/O for/O 12/O months/O included/O back/B-AdverseReaction pain/I-AdverseReaction ,/O pneumonia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ,/O bronchitis/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O and/O pyrexia/B-AdverseReaction ./O
6.2/O Clinical/O Trials/O Experience/O in/O Asthma/O BREO/O ELLIPTA/O for/O the/O treatment/O of/O asthma/O was/O studied/O in/O 18/O double/O -/O blind/O ,/O parallel/O -/O group/O ,/O controlled/O trials/O (/O 11/O with/O placebo/O )/O of/O 4/O to/O 76/O weeks/O '/O duration/O ,/O which/O enrolled/O 9,969/O subjects/O with/O asthma/O ./O
BREO/O ELLIPTA/O 100/25/O was/O studied/O in/O 2,369/O subjects/O and/O BREO/O ELLIPTA/O 200/25/O was/O studied/O in/O 956/O subjects/O ./O
While/O subjects/O aged/O 12/O to/O 17/O years/O were/O included/O in/O these/O trials/O ,/O BREO/O ELLIPTA/O is/O not/O approved/O for/O use/O in/O this/O age/O -/O group/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.4/O )/O ]/O ./O
The/O safety/O data/O described/O below/O are/O based/O on/O two/O 12-week/O efficacy/O trials/O ,/O one/O 24-week/O efficacy/O trial/O ,/O and/O two/O long/O -/O term/O trials/O ./O
12-Week/O Trials/O Trial/O 1/O was/O a/O 12-week/O trial/O that/O evaluated/O the/O efficacy/O of/O BREO/O ELLIPTA/O 100/25/O in/O adolescent/O and/O adult/O subjects/O with/O asthma/O compared/O with/O fluticasone/O furoate/O 100/O mcg/O and/O placebo/O ./O
Of/O the/O 609/O subjects/O ,/O 58/O %/O were/O female/O and/O 84/O %/O were/O white/O ;/O the/O mean/O age/O was/O 40/O years/O ./O
The/O incidence/O of/O adverse/O reactions/O associated/O with/O BREO/O ELLIPTA/O 100/25/O is/O shown/O in/O Table/O 2/O ./O
Table/O 2/O ./O
Adverse/O Reactions/O with/O BREO/O ELLIPTA/O 100/25/O with/O 2/O %/O Incidence/O and/O More/O Common/O than/O Placebo/O in/O Subjects/O with/O Asthma/O (/O Trial/O 1/O )/O Adverse/O Reaction/O BREO/O ELLIPTA/O 100/25/O (/O n/O 201/O )/O %/O Fluticasone/O Furoate/O 100/O mcg/O (/O n/O 205/O )/O %/O Placebo/O (/O n/O 203/O )/O %/O Infections/O and/O infestations/O Nasopharyngitis/B-AdverseReaction 10/O 7/O 7/O Oral/B-AdverseReaction candidiasis/I-AdverseReaction a/O 2/O 2/O 0/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 5/O 4/O 4/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 2/O 2/O 1/O Dysphonia/B-AdverseReaction 2/O 1/O 0/O a/O Includes/O oral/B-AdverseReaction candidiasis/I-AdverseReaction and/O oropharyngeal/B-AdverseReaction candidiasis/I-AdverseReaction ./O
Trial/O 2/O was/O a/O 12-week/O trial/O that/O evaluated/O the/O efficacy/O of/O BREO/O ELLIPTA/O 100/25/O ,/O BREO/O ELLIPTA/O 200/25/O ,/O and/O fluticasone/O furoate/O 100/O mcg/O in/O adolescent/O and/O adult/O subjects/O with/O asthma/O ./O
This/O trial/O did/O not/O have/O a/O placebo/O arm/O ./O
Of/O the/O 1,039/O subjects/O ,/O 60/O %/O were/O female/O and/O 88/O %/O were/O white/O ;/O the/O mean/O age/O was/O 46/O years/O ./O
The/O incidence/O of/O adverse/O reactions/O associated/O with/O BREO/O ELLIPTA/O 100/25/O and/O BREO/O ELLIPTA/O 200/25/O is/O shown/O in/O Table/O 3/O ./O
Table/O 3/O ./O
Adverse/O Reactions/O with/O BREO/O ELLIPTA/O 100/25/O and/O BREO/O ELLIPTA/O 200/25/O with/O 2/O %/O Incidence/O in/O Subjects/O with/O Asthma/O (/O Trial/O 2/O )/O Adverse/O Reaction/O BREO/O ELLIPTA/O 200/25/O (/O n/O 346/O )/O %/O BREO/O ELLIPTA/O 100/25/O (/O n/O 346/O )/O %/O Fluticasone/O Furoate/O 100/O mcg/O (/O n/O 347/O )/O %/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 8/O 8/O 9/O Infections/O and/O infestations/O Nasopharyngitis/B-AdverseReaction 7/O 6/O 7/O Influenza/B-AdverseReaction 3/O 3/O 1/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 2/O 2/O 3/O Sinusitis/B-AdverseReaction 2/O 1/O 1/O Bronchitis/B-AdverseReaction 2/O 1/O 2/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 2/O 2/O 1/O Cough/B-AdverseReaction 1/O 2/O 1/O 24-Week/O Trial/O Trial/O 3/O was/O a/O 24-week/O trial/O that/O evaluated/O the/O efficacy/O of/O BREO/O ELLIPTA/O 200/25/O once/O daily/O ,/O fluticasone/O furoate/O 200/O mcg/O once/O daily/O ,/O and/O fluticasone/O propionate/O 500/O mcg/O twice/O daily/O in/O adolescent/O and/O adult/O subjects/O with/O asthma/O ./O
Of/O the/O 586/O subjects/O ,/O 59/O %/O were/O female/O and/O 84/O %/O were/O white/O ;/O the/O mean/O age/O was/O 46/O years/O ./O
This/O trial/O did/O not/O have/O a/O placebo/O arm/O ./O
In/O addition/O to/O the/O reactions/O shown/O in/O Tables/O 2/O and/O 3/O ,/O adverse/O reactions/O occurring/O in/O greater/O than/O or/O equal/O to/O 2/O %/O of/O subjects/O treated/O with/O BREO/O ELLIPTA/O 200/25/O included/O viral/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O and/O arthralgia/B-AdverseReaction ./O
12-Month/O Trial/O Long/O -/O term/O safety/O data/O is/O based/O on/O a/O 12-month/O trial/O that/O evaluated/O the/O safety/O of/O BREO/O ELLIPTA/O 100/25/O once/O daily/O (/O n/O 201/O )/O ,/O BREO/O ELLIPTA/O 200/25/O once/O daily/O (/O n/O 202/O )/O ,/O and/O fluticasone/O propionate/O 500/O mcg/O twice/O daily/O (/O n/O 100/O )/O in/O adolescent/O and/O adult/O subjects/O with/O asthma/O (/O Trial/O 4/O )/O ./O
Overall/O ,/O 63/O %/O were/O female/O and/O 67/O %/O were/O white/O ./O
The/O mean/O age/O was/O 39/O years/O ;/O adolescents/O (/O aged/O 12/O to/O 17/O years/O )/O made/O up/O 16/O %/O of/O the/O population/O ./O
In/O addition/O to/O the/O reactions/O shown/O in/O Tables/O 2/O and/O 3/O ,/O adverse/O reactions/O occurring/O in/O greater/O than/O or/O equal/O to/O 2/O %/O of/O the/O subjects/O treated/O with/O BREO/O ELLIPTA/O 100/25/O or/O BREO/O ELLIPTA/O 200/25/O for/O 12/O months/O included/O pyrexia/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O extrasystoles/B-AdverseReaction ,/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction ,/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O allergic/B-AdverseReaction rhinitis/I-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O rhinitis/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O supraventricular/B-AdverseReaction extrasystoles/I-AdverseReaction ,/O ventricular/B-AdverseReaction extrasystoles/I-AdverseReaction ,/O acute/B-AdverseReaction sinusitis/I-AdverseReaction ,/O and/O pneumonia/B-AdverseReaction ./O
Exacerbation/O Trial/O In/O a/O 24-/O to/O 76-week/O trial/O ,/O subjects/O received/O BREO/O ELLIPTA/O 100/25/O (/O n/O 1,009/O )/O or/O fluticasone/O furoate/O 100/O mcg/O (/O n/O 1,010/O )/O (/O Trial/O 5/O )/O ./O
Subjects/O participating/O in/O this/O trial/O had/O a/O history/O of/O one/O or/O more/O asthma/O exacerbations/O that/O required/O treatment/O with/O oral/O systemic/O corticosteroids/O or/O emergency/O department/O visit/O or/O in/O -/O patient/O hospitalization/O for/O the/O treatment/O of/O asthma/O in/O the/O year/O prior/O to/O trial/O entry/O ./O
Overall/O ,/O 67/O %/O were/O female/O and/O 73/O %/O were/O white/O ;/O the/O mean/O age/O was/O 42/O years/O (/O adolescents/O aged/O 12/O to/O 17/O years/O made/O up/O 14/O %/O of/O the/O population/O )/O ./O
While/O subjects/O aged/O 12/O to/O 17/O years/O were/O included/O in/O this/O trial/O ,/O BREO/O ELLIPTA/O is/O not/O approved/O for/O use/O in/O this/O age/O -/O group/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.4/O )/O ]/O ./O
Asthma/O -/O related/O hospitalizations/O occurred/O in/O 10/O subjects/O (/O 1/O %/O )/O treated/O with/O BREO/O ELLIPTA/O 100/25/O compared/O with/O 7/O subjects/O (/O 0.7/O %/O )/O treated/O with/O fluticasone/O furoate/O 100/O mcg/O ./O
Among/O subjects/O aged/O 12/O to/O 17/O years/O ,/O asthma/O -/O related/O hospitalizations/O occurred/O in/O 4/O subjects/O (/O 2.6/O %/O )/O treated/O with/O BREO/O ELLIPTA/O 100/25/O (/O n/O 151/O )/O compared/O with/O 0/O subjects/O treated/O with/O fluticasone/O furoate/O 100/O mcg/O (/O n/O 130/O )/O ./O
There/O were/O no/B-Negation asthma/O -/O related/O deaths/B-AdverseReaction or/O asthma/O -/O related/O intubations/O observed/O in/O this/O trial/O ./O
6.3/O Postmarketing/O Experience/O In/O addition/O to/O adverse/O reactions/O reported/O from/O clinical/O trials/O ,/O the/O following/O adverse/O reactions/O have/O been/O identified/O during/O postapproval/O use/O of/O BREO/O ELLIPTA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
These/O events/O have/O been/O chosen/O for/O inclusion/O due/O to/O either/O their/O seriousness/O ,/O frequency/O of/O reporting/O ,/O or/O causal/O connection/O to/O BREO/O ELLIPTA/O or/O a/O combination/O of/O these/O factors/O ./O
Cardiac/O Disorders/O Palpitations/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ./O
Immune/O System/O Disorders/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O urticaria/B-AdverseReaction ./O
Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Muscle/B-AdverseReaction spasms/I-AdverseReaction ./O
Nervous/O System/O Disorders/O Tremor/B-AdverseReaction ./O
Psychiatric/O Disorders/O Nervousness/B-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O ASTHMA/O -/O RELATED/O DEATH/B-AdverseReaction WARNING/O :/O ASTHMA/O -/O RELATED/O DEATH/B-AdverseReaction Long/O -/O acting/O beta2-adrenergic/O agonists/O (/O LABA/B-DrugClass )/O ,/O such/O as/O vilanterol/O ,/O one/O of/O the/O active/O ingredients/O in/O BREO/O ELLIPTA/O ,/O increase/O the/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction ./O
Data/O from/O a/O large/O placebo/O -/O controlled/O US/O trial/O that/O compared/O the/O safety/O of/O another/O LABA/B-DrugClass (/O salmeterol/O )/O with/O placebo/O added/O to/O usual/O asthma/O therapy/O showed/O an/O increase/O in/O asthma/O -/O related/O deaths/B-AdverseReaction in/O subjects/O receiving/O salmeterol/O ./O
This/O finding/O with/O salmeterol/O is/O considered/O a/O class/O effect/O of/O LABA/O ./O
Currently/O available/O data/O are/O inadequate/O to/O determine/O whether/O concurrent/O use/O of/O inhaled/O corticosteroids/O (/O ICS/O )/O or/O other/O long/O -/O term/O asthma/O control/O drugs/O mitigates/O the/O increased/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction from/O LABA/B-DrugClass ./O
Available/O data/O from/O controlled/O clinical/O trials/O suggest/O that/O LABA/O increase/O the/O risk/O of/O asthma/O -/O related/O hospitalization/O in/O pediatric/O and/O adolescent/O patients/O ./O
Therefore/O ,/O when/O treating/O patients/O with/O asthma/O ,/O physicians/O should/O only/O prescribe/O BREO/O ELLIPTA/O for/O patients/O not/O adequately/O controlled/O on/O a/O long/O -/O term/O asthma/O control/O medication/O ,/O such/O as/O an/O inhaled/O corticosteroid/O ,/O or/O whose/O disease/O severity/O clearly/O warrants/O initiation/O of/O treatment/O with/O both/O an/O inhaled/O corticosteroid/O and/O a/O LABA/O ./O
Once/O asthma/O control/O is/O achieved/O and/O maintained/O ,/O assess/O the/O patient/O at/O regular/O intervals/O and/O step/O down/O therapy/O (/O e.g./O ,/O discontinue/O BREO/O ELLIPTA/O )/O if/O possible/O without/O loss/O of/O asthma/O control/O and/O maintain/O the/O patient/O on/O a/O long/O -/O term/O asthma/O control/O medication/O ,/O such/O as/O an/O inhaled/O corticosteroid/O ./O
Do/O not/O use/O BREO/O ELLIPTA/O for/O patients/O whose/O asthma/O is/O adequately/O controlled/O on/O low-/O or/O medium/O -/O dose/O inhaled/O corticosteroids/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O ASTHMA/O -/O RELATED/O DEATH/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Long/O -/O acting/O beta2-adrenergic/O agonists/O (/O LABA/B-DrugClass )/O ,/O such/O as/O vilanterol/O ,/O increase/O the/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction ./O
A/O placebo/O -/O controlled/O trial/O with/O another/O LABA/B-DrugClass (/O salmeterol/O )/O showed/O an/O increase/O in/O asthma/O -/O related/O deaths/B-AdverseReaction ./O
This/O finding/O with/O salmeterol/O is/O considered/O a/O class/O effect/O of/O all/O LABA/O ./O
Currently/O available/O data/O are/O inadequate/O to/O determine/O whether/O concurrent/O use/O of/O inhaled/O corticosteroids/O (/O ICS/O )/O or/O other/O long/O -/O term/O asthma/O control/O drugs/O mitigates/O the/O increased/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction from/O LABA/B-DrugClass ./O
Available/O data/O from/O controlled/O clinical/O trials/O suggest/O that/O LABA/O increase/O the/O risk/O of/O asthma/O -/O related/O hospitalization/O in/O pediatric/O and/O adolescent/O patients/O ./O
(/O 5.1/O )/O When/O treating/O patients/O with/O asthma/O ,/O only/O prescribe/O BREO/O ELLIPTA/O for/O patients/O not/O adequately/O controlled/O on/O a/O long/O -/O term/O asthma/O control/O medication/O ,/O such/O as/O an/O ICS/O ,/O or/O whose/O disease/O severity/O clearly/O warrants/O initiation/O of/O treatment/O with/O both/O an/O ICS/O and/O a/O LABA/O ./O
Once/O asthma/O control/O is/O achieved/O and/O maintained/O ,/O assess/O the/O patient/O at/O regular/O intervals/O and/O step/O down/O therapy/O (/O e.g./O ,/O discontinue/O BREO/O ELLIPTA/O )/O if/O possible/O without/O loss/O of/O asthma/O control/O and/O maintain/O the/O patient/O on/O a/O long/O -/O term/O asthma/O control/O medication/O ,/O such/O as/O an/O ICS/O ./O
Do/O not/O use/O BREO/O ELLIPTA/O for/O patients/O whose/O asthma/O is/O adequately/O controlled/O on/O low-/O or/O medium/O -/O dose/O ICS.(1.2/O ,/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O LABA/B-DrugClass increase/O the/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction and/O asthma/O -/O related/O hospitalizations/O ./O
Prescribe/O only/O for/O recommended/O patient/O populations/O ./O
(/O 5.1/O )/O Do/O not/O initiate/O in/O acutely/O deteriorating/O COPD/O or/O asthma/O ./O
Do/O not/O use/O to/O treat/O acute/O symptoms/O ./O
(/O 5.2/O )/O Do/O not/O use/O in/O combination/O with/O an/O additional/O medicine/O containing/O a/O LABA/O because/O of/O risk/O of/O overdose/O ./O
(/O 5.3/O )/O Candida/B-AdverseReaction albicans/I-AdverseReaction infection/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction mouth/I-AdverseReaction and/O pharynx/O may/B-Factor occur/O ./O
Monitor/O patients/O periodically/O ./O
Advise/O the/O patient/O to/O rinse/O his/O her/O mouth/O with/O water/O without/O swallowing/O after/O inhalation/O to/O help/O reduce/O the/O risk/O ./O
(/O 5.4/O )/O Increased/O risk/B-Factor of/O pneumonia/B-AdverseReaction in/O patients/O with/O COPD/O ./O
Monitor/O patients/O for/O signs/O and/O symptoms/O of/O pneumonia/O ./O
(/O 5.5/O )/O Potential/B-Factor worsening/B-AdverseReaction of/I-AdverseReaction infections/I-AdverseReaction (/O e.g./O ,/O existing/O tuberculosis/O ;/O fungal/O ,/O bacterial/O ,/O viral/O ,/O or/O parasitic/O infections/O ;/O ocular/O herpes/O simplex/O )/O ./O
Use/O with/O caution/O in/O patients/O with/O these/O infections/O ./O
More/O serious/B-Severity or/O even/O fatal/B-AdverseReaction course/O of/O chickenpox/B-AdverseReaction or/O measles/B-AdverseReaction can/B-Factor occur/O in/O susceptible/O patients/O ./O
(/O 5.6/O )/O Risk/B-Factor of/O impaired/B-AdverseReaction adrenal/I-AdverseReaction function/I-AdverseReaction when/O transferring/O from/O systemic/O corticosteroids/O ./O
Taper/O patients/O slowly/O from/O systemic/O corticosteroids/O if/O transferring/O to/O BREO/O ELLIPTA/O ./O
(/O 5.7/O )/O Hypercorticism/B-AdverseReaction and/O adrenal/B-AdverseReaction suppression/I-AdverseReaction may/B-Factor occur/O with/O very/O high/O dosages/O or/O at/O the/O regular/O dosage/O in/O susceptible/O individuals/O ./O
If/O such/O changes/O occur/O ,/O discontinue/O BREO/O ELLIPTA/O slowly/O ./O
(/O 5.8/O )/O If/O paradoxical/O bronchospasm/O occurs/O ,/O discontinue/O BREO/O ELLIPTA/O and/O institute/O alternative/O therapy/O ./O
(/O 5.10/O )/O Use/O with/O caution/O in/O patients/O with/O cardiovascular/O disorders/O because/O of/O beta/O -/O adrenergic/O stimulation/O ./O
(/O 5.12/O )/O Assess/O for/O decrease/O in/O bone/O mineral/O density/O initially/O and/O periodically/O thereafter/O ./O
(/O 5.13/O )/O Close/O monitoring/O for/O glaucoma/O and/O cataracts/O is/O warranted/O ./O
(/O 5.14/O )/O Use/O with/O caution/O in/O patients/O with/O convulsive/O disorders/O ,/O thyrotoxicosis/O ,/O diabetes/O mellitus/O ,/O and/O ketoacidosis/O ./O
(/O 5.15/O )/O Be/O alert/O to/O hypokalemia/O and/O hyperglycemia/O ./O
(/O 5.16/O )/O 5.1/O Asthma/O -/O Related/O Death/O LABA/B-DrugClass ,/O such/O as/O vilanterol/O ,/O one/O of/O the/O active/O ingredients/O in/O BREO/O ELLIPTA/O ,/O increase/O the/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction ./O
Currently/O available/O data/O are/O inadequate/O to/O determine/O whether/O concurrent/O use/O of/O inhaled/O corticosteroids/O or/O other/O long/O -/O term/O asthma/O control/O drugs/O mitigates/O the/O increased/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction from/O LABA/B-DrugClass ./O
Available/O data/O from/O controlled/O clinical/O trials/O suggest/O that/O LABA/O increase/O the/O risk/O of/O asthma/O -/O related/O hospitalization/O in/O pediatric/O and/O adolescent/O patients/O ./O
Therefore/O ,/O when/O treating/O patients/O with/O asthma/O ,/O physicians/O should/O only/O prescribe/O BREO/O ELLIPTA/O for/O patients/O not/O adequately/O controlled/O on/O a/O long/O -/O term/O asthma/O control/O medication/O ,/O such/O as/O an/O inhaled/O corticosteroid/O ,/O or/O whose/O disease/O severity/O clearly/O warrants/O initiation/O of/O treatment/O with/O both/O an/O inhaled/O corticosteroid/O and/O a/O LABA/O ./O
Once/O asthma/O control/O is/O achieved/O and/O maintained/O ,/O assess/O the/O patient/O at/O regular/O intervals/O and/O step/O down/O therapy/O (/O e.g./O ,/O discontinue/O BREO/O ELLIPTA/O )/O if/O possible/O without/O loss/O of/O asthma/O control/O and/O maintain/O the/O patient/O on/O a/O long/O -/O term/O asthma/O control/O medication/O ,/O such/O as/O an/O inhaled/O corticosteroid/O ./O
Do/O not/O use/O BREO/O ELLIPTA/O for/O patients/O whose/O asthma/O is/O adequately/O controlled/O on/O low-/O or/O medium/O -/O dose/O inhaled/O corticosteroids/O ./O
A/O 28-week/O ,/O placebo/O -/O controlled/O ,/O US/O trial/O that/O compared/O the/O safety/O of/O another/O LABA/B-DrugClass (/O salmeterol/O )/O with/O placebo/O ,/O each/O added/O to/O usual/O asthma/O therapy/O ,/O showed/O an/O increase/O in/O asthma/O -/O related/O deaths/B-AdverseReaction in/O subjects/O receiving/O salmeterol/O (/O 13/13,176/O in/O subjects/O treated/O with/O salmeterol/O vs./O 3/13,179/O in/O subjects/O treated/O with/O placebo/O ;/O relative/O risk/O :/O 4.37/O [/O 95/O %/O CI/O :/O 1.25/O ,/O 15.34/O ]/O )/O ./O
The/O increased/O risk/O of/O asthma/O -/O related/O death/B-AdverseReaction is/O considered/O a/O class/O effect/O of/O LABA/B-DrugClass ,/O including/O vilanterol/O ,/O one/O of/O the/O active/O ingredients/O in/O BREO/O ELLIPTA/O ./O
No/B-Factor trial/I-Factor adequate/I-Factor to/O determine/O whether/O the/O rate/O of/O asthma/O -/O related/O death/B-AdverseReaction is/O increased/O in/O subjects/O treated/O with/O BREO/O ELLIPTA/O has/O been/O conducted/O ./O
Data/O are/O not/B-Factor available/I-Factor to/O determine/O whether/O the/O rate/O of/O death/B-AdverseReaction in/O patients/O with/O COPD/O is/O increased/O by/O LABA/O ./O
5.2/O Deterioration/O of/O Disease/O and/O Acute/O Episodes/O BREO/O ELLIPTA/O should/O not/O be/O initiated/O in/O patients/O during/O rapidly/O deteriorating/O or/O potentially/O life/O -/O threatening/O episodes/O of/O COPD/O or/O asthma/O ./O
BREO/O ELLIPTA/O has/O not/O been/O studied/O in/O subjects/O with/O acutely/O deteriorating/O COPD/O or/O asthma/O ./O
The/O initiation/O of/O BREO/O ELLIPTA/O in/O this/O setting/O is/O not/O appropriate/O ./O
COPD/O may/O deteriorate/O acutely/O over/O a/O period/O of/O hours/O or/O chronically/O over/O several/O days/O or/O longer/O ./O
If/O BREO/O ELLIPTA/O 100/25/O no/O longer/O controls/O symptoms/O of/O bronchoconstriction/O ;/O the/O patient/O 's/O inhaled/O ,/O short/O -/O acting/O ,/O beta2-agonist/O becomes/O less/O effective/O ;/O or/O the/O patient/O needs/O more/O short/O -/O acting/O beta2-agonist/O than/O usual/O ,/O these/O may/O be/O markers/O of/O deterioration/O of/O disease/O ./O
In/O this/O setting/O a/O reevaluation/O of/O the/O patient/O and/O the/O COPD/O treatment/O regimen/O should/O be/O undertaken/O at/O once/O ./O
For/O COPD/O ,/O increasing/O the/O daily/O dose/O of/O BREO/O ELLIPTA/O 100/25/O is/O not/O appropriate/O in/O this/O situation/O ./O
Increasing/O use/O of/O inhaled/O ,/O short/O -/O acting/O beta2-agonists/O is/O a/O marker/O of/O deteriorating/O asthma/O ./O
In/O this/O situation/O ,/O the/O patient/O requires/O immediate/O reevaluation/O with/O reassessment/O of/O the/O treatment/O regimen/O ,/O giving/O special/O consideration/O to/O the/O possible/O need/O for/O replacing/O the/O current/O strength/O of/O BREO/O ELLIPTA/O with/O a/O higher/O strength/O ,/O adding/O additional/O inhaled/O corticosteroid/O ,/O or/O initiating/O systemic/O corticosteroids/O ./O
Patients/O should/O not/O use/O more/O than/O 1/O inhalation/O once/O daily/O of/O BREO/O ELLIPTA/O ./O
BREO/O ELLIPTA/O should/O not/O be/O used/O for/O the/O relief/O of/O acute/O symptoms/O ,/O i.e./O ,/O as/O rescue/O therapy/O for/O the/O treatment/O of/O acute/O episodes/O of/O bronchospasm/O ./O
BREO/O ELLIPTA/O has/O not/O been/O studied/O in/O the/O relief/O of/O acute/O symptoms/O and/O extra/O doses/O should/O not/O be/O used/O for/O that/O purpose/O ./O
Acute/O symptoms/O should/O be/O treated/O with/O an/O inhaled/O ,/O short/O -/O acting/O beta2-agonist/O ./O
When/O beginning/O treatment/O with/O BREO/O ELLIPTA/O ,/O patients/O who/O have/O been/O taking/O oral/O or/O inhaled/O ,/O short/O -/O acting/O beta2-agonists/O on/O a/O regular/O basis/O (/O e.g./O ,/O 4/O times/O a/O day/O )/O should/O be/O instructed/O to/O discontinue/O the/O regular/O use/O of/O these/O drugs/O and/O to/O use/O them/O only/O for/O symptomatic/O relief/O of/O acute/O respiratory/O symptoms/O ./O
When/O prescribing/O BREO/O ELLIPTA/O ,/O the/O healthcare/O provider/O should/O also/O prescribe/O an/O inhaled/O ,/O short/O -/O acting/O beta2-agonist/O and/O instruct/O the/O patient/O on/O how/O it/O should/O be/O used/O ./O
5.3/O Excessive/O Use/O of/O BREO/O ELLIPTA/O and/O Use/O with/O Other/O Long/O -/O Acting/O Beta2-Agonists/O BREO/O ELLIPTA/O should/O not/O be/O used/O more/O often/O than/O recommended/O ,/O at/O higher/O doses/O than/O recommended/O ,/O or/O in/O conjunction/O with/O other/O medicines/O containing/O LABA/O ,/O as/O an/O overdose/O may/O result/O ./O
Clinically/O significant/O cardiovascular/O effects/O and/O fatalities/B-AdverseReaction have/O been/O reported/O in/O association/O with/O excessive/O use/O of/O inhaled/B-DrugClass sympathomimetic/I-DrugClass drugs/I-DrugClass ./O
Patients/O using/O BREO/O ELLIPTA/O should/O not/O use/O another/O medicine/O containing/O a/O LABA/O (/O e.g./O ,/O salmeterol/O ,/O formoterol/O fumarate/O ,/O arformoterol/O tartrate/O ,/O indacaterol/O )/O for/O any/O reason/O ./O
5.4/O Local/O Effects/O of/O Inhaled/O Corticosteroids/O In/O clinical/O trials/O ,/O the/O development/O of/O localized/O infections/O of/O the/O mouth/O and/O pharynx/O with/O Candida/O albicans/O has/O occurred/O in/O subjects/O treated/O with/O BREO/O ELLIPTA/O ./O
When/O such/O an/O infection/O develops/O ,/O it/O should/O be/O treated/O with/O appropriate/O local/O or/O systemic/O (/O i.e./O ,/O oral/O )/O antifungal/O therapy/O while/O treatment/O with/O BREO/O ELLIPTA/O continues/O ,/O but/O at/O times/O therapy/O with/O BREO/O ELLIPTA/O may/O need/O to/O be/O interrupted/O ./O
Advise/O the/O patient/O to/O rinse/O his/O her/O mouth/O with/O water/O without/O swallowing/O following/O inhalation/O to/O help/O reduce/O the/O risk/O of/O oropharyngeal/O candidiasis/O ./O
5.5/O Pneumonia/O An/O increase/O in/O the/O incidence/O of/O pneumonia/B-AdverseReaction has/O been/O observed/O in/O subjects/O with/O COPD/O receiving/O BREO/O ELLIPTA/O 100/25/O in/O clinical/O trials/O ./O
There/O was/O also/O an/O increased/O incidence/O of/O pneumonias/B-AdverseReaction resulting/O in/O hospitalization/O ./O
In/O some/O incidences/O these/O pneumonia/B-AdverseReaction events/O were/O fatal/B-AdverseReaction ./O
Physicians/O should/O remain/O vigilant/O for/O the/O possible/O development/O of/O pneumonia/O in/O patients/O with/O COPD/O as/O the/O clinical/O features/O of/O such/O infections/O overlap/O with/O the/O symptoms/O of/O COPD/O exacerbations/O ./O
In/O replicate/O 12-month/O trials/O in/O 3,255/O subjects/O with/O COPD/O who/O had/O experienced/O a/O COPD/O exacerbation/O in/O the/O previous/O year/O ,/O there/O was/O a/O higher/O incidence/O of/O pneumonia/B-AdverseReaction reported/O in/O subjects/O receiving/O fluticasone/O furoate/O vilanterol/O 50/O mcg/25/O mcg/O :/O 6/O %/O (/O 48/O of/O 820/O subjects/O )/O ;/O BREO/O ELLIPTA/O 100/25/O :/O 6/O %/O (/O 51/O of/O 806/O subjects/O )/O ;/O or/O BREO/O ELLIPTA/O 200/25/O :/O 7/O %/O (/O 55/O of/O 811/O subjects/O )/O than/O in/O subjects/O receiving/O vilanterol/O 25/O mcg/O :/O 3/O %/O (/O 27/O of/O 818/O subjects/O )/O ./O
There/O was/O no/B-Negation fatal/B-AdverseReaction pneumonia/B-AdverseReaction in/O subjects/O receiving/O vilanterol/O or/O fluticasone/O furoate/O vilanterol/O 50/O mcg/25/O mcg/O ./O
There/O was/O fatal/B-AdverseReaction pneumonia/B-AdverseReaction in/O 1/O subject/O receiving/O BREO/O ELLIPTA/O 100/25/O and/O in/O 7/O subjects/O receiving/O BREO/O ELLIPTA/O 200/25/O (/O less/O than/O 1/O %/O for/O each/O treatment/O group/O )/O ./O
5.6/O Immunosuppression/O Persons/O who/O are/O using/O drugs/B-DrugClass that/I-DrugClass suppress/I-DrugClass the/I-DrugClass immune/I-DrugClass system/I-DrugClass are/O more/O susceptible/O to/O infections/B-AdverseReaction than/O healthy/O individuals/O ./O
Chickenpox/B-AdverseReaction and/O measles/B-AdverseReaction ,/O for/O example/O ,/O can/O have/O a/O more/O serious/B-Severity or/O even/O fatal/B-AdverseReaction course/O in/O susceptible/O children/O or/O adults/O using/O corticosteroids/B-DrugClass ./O
In/O such/O children/O or/O adults/O who/O have/O not/O had/O these/O diseases/O or/O been/O properly/O immunized/O ,/O particular/O care/O should/O be/O taken/O to/O avoid/O exposure/O ./O
How/O the/O dose/O ,/O route/O ,/O and/O duration/O of/O corticosteroid/O administration/O affect/O the/O risk/O of/O developing/O a/O disseminated/O infection/O is/O not/O known/O ./O
The/O contribution/O of/O the/O underlying/O disease/O and/or/O prior/O corticosteroid/O treatment/O to/O the/O risk/O is/O also/O not/O known/O ./O
If/O a/O patient/O is/O exposed/O to/O chickenpox/O ,/O prophylaxis/O with/O varicella/O zoster/O immune/O globulin/O (/O VZIG/O )/O may/O be/O indicated/O ./O
If/O a/O patient/O is/O exposed/O to/O measles/O ,/O prophylaxis/O with/O pooled/O intramuscular/O immunoglobulin/O (/O IG/O )/O may/O be/O indicated/O ./O
(/O See/O the/O respective/O package/O inserts/O for/O complete/O VZIG/O and/O IG/O prescribing/O information/O ./O
)/O If/O chickenpox/O develops/O ,/O treatment/O with/O antiviral/O agents/O may/O be/O considered/O ./O
Inhaled/O corticosteroids/O should/O be/O used/O with/O caution/O ,/O if/O at/O all/O ,/O in/O patients/O with/O active/O or/O quiescent/O tuberculosis/O infections/O of/O the/O respiratory/O tract/O ;/O systemic/O fungal/O ,/O bacterial/O ,/O viral/O ,/O or/O parasitic/O infections/O ;/O or/O ocular/O herpes/O simplex/O ./O
5.7/O Transferring/O Patients/O from/O Systemic/O Corticosteroid/O Therapy/O Particular/O care/O is/O needed/O for/O patients/O who/O have/O been/O transferred/O from/O systemically/O active/O corticosteroids/O to/O inhaled/O corticosteroids/O because/O deaths/O due/O to/O adrenal/O insufficiency/O have/O occurred/O in/O patients/O with/O asthma/O during/O and/O after/O transfer/O from/O systemic/O corticosteroids/O to/O less/O systemically/O available/O inhaled/O corticosteroids/O ./O
After/O withdrawal/O from/O systemic/O corticosteroids/O ,/O a/O number/O of/O months/O are/O required/O for/O recovery/O of/O hypothalamic/O -/O pituitary/O -/O adrenal/O (/O HPA/O )/O function/O ./O
Patients/O who/O have/O been/O previously/O maintained/O on/O 20/O mg/O or/O more/O of/O prednisone/O (/O or/O its/O equivalent/O )/O may/O be/O most/O susceptible/O ,/O particularly/O when/O their/O systemic/O corticosteroids/O have/O been/O almost/O completely/O withdrawn/O ./O
During/O this/O period/O of/O HPA/O suppression/O ,/O patients/O may/O exhibit/O signs/O and/O symptoms/O of/O adrenal/O insufficiency/O when/O exposed/O to/O trauma/O ,/O surgery/O ,/O or/O infection/O (/O particularly/O gastroenteritis/O )/O or/O other/O conditions/O associated/O with/O severe/O electrolyte/O loss/O ./O
Although/O BREO/O ELLIPTA/O may/O control/O COPD/O or/O asthma/O symptoms/O during/O these/O episodes/O ,/O in/O recommended/O doses/O it/O supplies/O less/O than/O normal/O physiological/O amounts/O of/O glucocorticoid/O systemically/O and/O does/O NOT/O provide/O the/O mineralocorticoid/O activity/O that/O is/O necessary/O for/O coping/O with/O these/O emergencies/O ./O
During/O periods/O of/O stress/O ,/O a/O severe/O COPD/O exacerbation/O ,/O or/O a/O severe/O asthma/O attack/O ,/O patients/O who/O have/O been/O withdrawn/O from/O systemic/O corticosteroids/O should/O be/O instructed/O to/O resume/O oral/O corticosteroids/O (/O in/O large/O doses/O )/O immediately/O and/O to/O contact/O their/O physicians/O for/O further/O instruction/O ./O
These/O patients/O should/O also/O be/O instructed/O to/O carry/O a/O warning/O card/O indicating/O that/O they/O may/O need/O supplementary/O systemic/O corticosteroids/O during/O periods/O of/O stress/O ,/O a/O severe/O COPD/O exacerbation/O ,/O or/O a/O severe/O asthma/O attack/O ./O
Patients/O requiring/O oral/O corticosteroids/O should/O be/O weaned/O slowly/O from/O systemic/O corticosteroid/O use/O after/O transferring/O to/O BREO/O ELLIPTA/O ./O
Prednisone/O reduction/O can/O be/O accomplished/O by/O reducing/O the/O daily/O prednisone/O dose/O by/O 2.5/O mg/O on/O a/O weekly/O basis/O during/O therapy/O with/O BREO/O ELLIPTA/O ./O
Lung/O function/O (/O FEV1or/O peak/O expiratory/O flow/O )/O ,/O beta/O -/O agonist/O use/O ,/O and/O COPD/O or/O asthma/O symptoms/O should/O be/O carefully/O monitored/O during/O withdrawal/O of/O oral/O corticosteroids/O ./O
In/O addition/O ,/O patients/O should/O be/O observed/O for/O signs/O and/O symptoms/O of/O adrenal/O insufficiency/O ,/O such/O as/O fatigue/O ,/O lassitude/O ,/O weakness/O ,/O nausea/O and/O vomiting/O ,/O and/O hypotension/O ./O
Transfer/O of/O patients/O from/O systemic/O corticosteroid/O therapy/O to/O BREO/O ELLIPTA/O may/O unmask/O allergic/O conditions/O previously/O suppressed/O by/O the/O systemic/O corticosteroid/O therapy/O (/O e.g./O ,/O rhinitis/O ,/O conjunctivitis/O ,/O eczema/O ,/O arthritis/O ,/O eosinophilic/O conditions/O )/O ./O
During/O withdrawal/O from/O oral/O corticosteroids/O ,/O some/O patients/O may/O experience/O symptoms/O of/O systemically/O active/O corticosteroid/O withdrawal/O (/O e.g./O ,/O joint/O and/or/O muscular/O pain/O ,/O lassitude/O ,/O depression/O )/O despite/O maintenance/O or/O even/O improvement/O of/O respiratory/O function/O ./O
5.8/O Hypercorticism/O and/O Adrenal/O Suppression/O Inhaled/O fluticasone/O furoate/O is/O absorbed/O into/O the/O circulation/O and/O can/O be/O systemically/O active/O ./O
Effects/O of/O fluticasone/O furoate/O on/O the/O HPA/O axis/O are/O not/O observed/O with/O the/O therapeutic/O doses/O of/O BREO/O ELLIPTA/O ./O
However/O ,/O exceeding/O the/O recommended/O dosage/O or/O coadministration/O with/O a/O strong/O cytochrome/O P450/O 3A4/O (/O CYP3A4/O )/O inhibitor/O may/B-Factor result/O in/O HPA/B-AdverseReaction dysfunction/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ,/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
Because/O of/O the/O possibility/O of/O significant/O systemic/O absorption/O of/O inhaled/O corticosteroids/O in/O sensitive/O patients/O ,/O patients/O treated/O with/O BREO/O ELLIPTA/O should/O be/O observed/O carefully/O for/O any/O evidence/O of/O systemic/O corticosteroid/O effects/O ./O
Particular/O care/O should/O be/O taken/O in/O observing/O patients/O postoperatively/O or/O during/O periods/O of/O stress/O for/O evidence/O of/O inadequate/O adrenal/O response/O ./O
It/O is/O possible/O that/O systemic/O corticosteroid/O effects/O such/O as/O hypercorticism/B-AdverseReaction and/O adrenal/B-AdverseReaction suppression/I-AdverseReaction (/O including/O adrenal/B-AdverseReaction crisis/I-AdverseReaction )/O may/B-Factor appear/O in/O a/O small/O number/O of/O patients/O who/O are/O sensitive/O to/O these/O effects/O ./O
If/O such/O effects/O occur/O ,/O BREO/O ELLIPTA/O should/O be/O reduced/O slowly/O ,/O consistent/O with/O accepted/O procedures/O for/O reducing/O systemic/O corticosteroids/O ,/O and/O other/O treatments/O for/O management/O of/O COPD/O or/O asthma/O symptoms/O should/O be/O considered/O ./O
5.9/O Drug/O Interactions/O with/O Strong/O Cytochrome/O P450/O 3A4/O Inhibitors/O Caution/O should/O be/O exercised/O when/O considering/O the/O coadministration/O of/O BREO/O ELLIPTA/O with/O long/O -/O term/O ketoconazole/O and/O other/O known/O strong/O CYP3A4/O inhibitors/O (/O e.g./O ,/O ritonavir/O ,/O clarithromycin/O ,/O conivaptan/O ,/O indinavir/O ,/O itraconazole/O ,/O lopinavir/O ,/O nefazodone/O ,/O nelfinavir/O ,/O saquinavir/O ,/O telithromycin/O ,/O troleandomycin/O ,/O voriconazole/O )/O because/O increased/O systemic/O corticosteroid/O and/O increased/O cardiovascular/O adverse/O effects/O may/O occur/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ,/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.10/O Paradoxical/O Bronchospasm/O As/O with/O other/O inhaled/O medicines/O ,/O BREO/O ELLIPTA/O can/B-Factor produce/O paradoxical/B-AdverseReaction bronchospasm/I-AdverseReaction ,/O which/O may/B-Factor be/O life/B-Severity threatening/I-Severity ./O
If/O paradoxical/O bronchospasm/O occurs/O following/O dosing/O with/O BREO/O ELLIPTA/O ,/O it/O should/O be/O treated/O immediately/O with/O an/O inhaled/O ,/O short/O -/O acting/O bronchodilator/O ;/O BREO/O ELLIPTA/O should/O be/O discontinued/O immediately/O ;/O and/O alternative/O therapy/O should/O be/O instituted/O ./O
5.11/O Hypersensitivity/O Reactions/O ,/O Including/O Anaphylaxis/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction such/O as/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O urticaria/B-AdverseReaction may/B-Factor occur/O after/O administration/O of/O BREO/O ELLIPTA/O ./O
Discontinue/O BREO/O ELLIPTA/O if/O such/O reactions/O occur/O ./O
There/O have/O been/O reports/O of/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction in/O patients/O with/O severe/O milk/O protein/O allergy/O after/O inhalation/O of/O other/O powder/B-DrugClass medications/I-DrugClass containing/I-DrugClass lactose/I-DrugClass ;/O therefore/O ,/O patients/O with/O severe/O milk/O protein/O allergy/O should/O not/O use/O BREO/O ELLIPTA/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.12/O Cardiovascular/O Effects/O Vilanterol/O ,/O like/O other/O beta2-agonists/O ,/O can/B-Factor produce/O a/O clinically/O significant/O cardiovascular/O effect/O in/O some/O patients/O as/O measured/O by/O increases/B-AdverseReaction in/I-AdverseReaction pulse/I-AdverseReaction rate/I-AdverseReaction ,/O systolic/O or/O diastolic/O blood/O pressure/O ,/O and/O also/O cardiac/B-AdverseReaction arrhythmias/I-AdverseReaction ,/O such/O as/O supraventricular/B-AdverseReaction tachycardia/I-AdverseReaction and/O extrasystoles/B-AdverseReaction ./O
If/O such/O effects/O occur/O ,/O BREO/O ELLIPTA/O may/O need/O to/O be/O discontinued/O ./O
In/O addition/O ,/O beta/B-DrugClass -/O agonists/O have/O been/O reported/O to/O produce/O electrocardiographic/B-AdverseReaction changes/I-AdverseReaction ,/O such/O as/O flattening/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction T/I-AdverseReaction wave/I-AdverseReaction ,/O prolongation/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction QTc/I-AdverseReaction interval/I-AdverseReaction ,/O and/O ST/B-AdverseReaction segment/I-AdverseReaction depression/I-AdverseReaction ,/O although/O the/O clinical/O significance/O of/O these/O findings/O is/O unknown/O ./O
Fatalities/B-AdverseReaction have/O been/O reported/O in/O association/O with/O excessive/O use/O of/O inhaled/O sympathomimetic/O drugs/O ./O
In/O healthy/O subjects/O ,/O large/O doses/O of/O inhaled/O fluticasone/O furoate/O vilanterol/O (/O 4/O times/O the/O recommended/O dose/O of/O vilanterol/O ,/O representing/O a/O 12-/O or/O 10-fold/O higher/O systemic/O exposure/O than/O seen/O in/O subjects/O with/O COPD/O or/O asthma/O ,/O respectively/O )/O have/O been/O associated/O with/O clinically/B-Severity significant/I-Severity prolongation/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction QTc/I-AdverseReaction interval/I-AdverseReaction ,/O which/O has/O the/O potential/B-Factor for/O producing/O ventricular/B-AdverseReaction arrhythmias/I-AdverseReaction ./O
Therefore/O ,/O BREO/O ELLIPTA/O ,/O like/O other/O sympathomimetic/O amines/O ,/O should/O be/O used/O with/O caution/O in/O patients/O with/O cardiovascular/O disorders/O ,/O especially/O coronary/O insufficiency/O ,/O cardiac/O arrhythmias/O ,/O and/O hypertension/O ./O
5.13/O Reduction/O in/O Bone/O Mineral/O Density/O Decreases/B-AdverseReaction in/I-AdverseReaction bone/I-AdverseReaction mineral/I-AdverseReaction density/I-AdverseReaction (/O BMD/O )/O have/O been/O observed/O with/O long/O -/O term/O administration/O of/O products/O containing/O inhaled/O corticosteroids/B-DrugClass ./O
The/O clinical/O significance/O of/O small/O changes/O in/O BMD/O with/O regard/O to/O long/O -/O term/O consequences/O such/O as/O fracture/O is/O unknown/O ./O
Patients/O with/O major/O risk/O factors/O for/O decreased/O bone/O mineral/O content/O ,/O such/O as/O prolonged/O immobilization/O ,/O family/O history/O of/O osteoporosis/O ,/O postmenopausal/O status/O ,/O tobacco/O use/O ,/O advanced/O age/O ,/O poor/O nutrition/O ,/O or/O chronic/O use/O of/O drugs/O that/O can/O reduce/O bone/O mass/O (/O e.g./O ,/O anticonvulsants/O ,/O oral/O corticosteroids/O )/O should/O be/O monitored/O and/O treated/O with/O established/O standards/O of/O care/O ./O
Since/O patients/O with/O COPD/O often/O have/O multiple/O risk/O factors/O for/O reduced/O BMD/O ,/O assessment/O of/O BMD/O is/O recommended/O prior/O to/O initiating/O BREO/O ELLIPTA/O and/O periodically/O thereafter/O ./O
If/O significant/O reductions/O in/O BMD/O are/O seen/O and/O BREO/O ELLIPTA/O is/O still/O considered/O medically/O important/O for/O that/O patient/O 's/O COPD/O therapy/O ,/O use/O of/O medicine/O to/O treat/O or/O prevent/O osteoporosis/O should/O be/O strongly/O considered/O ./O
5.14/O Glaucoma/O and/O Cataracts/O Glaucoma/B-AdverseReaction ,/O increased/B-AdverseReaction intraocular/I-AdverseReaction pressure/I-AdverseReaction ,/O and/O cataracts/B-AdverseReaction have/O been/O reported/O in/O patients/O with/O COPD/O or/O asthma/O following/O the/O long/O -/O term/O administration/O of/O inhaled/O corticosteroids/B-DrugClass ./O
Therefore/O ,/O close/O monitoring/O is/O warranted/O in/O patients/O with/O a/O change/O in/O vision/O or/O with/O a/O history/O of/O increased/O intraocular/O pressure/O ,/O glaucoma/O ,/O and/or/O cataracts/O ./O
5.15/O Coexisting/O Conditions/O BREO/O ELLIPTA/O ,/O like/O all/O medicines/O containing/O sympathomimetic/O amines/O ,/O should/O be/O used/O with/O caution/O in/O patients/O with/O convulsive/O disorders/O or/O thyrotoxicosis/O and/O in/O those/O who/O are/O unusually/O responsive/O to/O sympathomimetic/O amines/O ./O
Doses/O of/O the/O related/O beta2-adrenoceptor/B-DrugClass agonist/I-DrugClass albuterol/O ,/O when/O administered/O intravenously/O ,/O have/O been/O reported/O to/O aggravate/B-AdverseReaction preexisting/I-AdverseReaction diabetes/I-AdverseReaction mellitus/I-AdverseReaction and/O ketoacidosis/O ./O
5.16/O Hypokalemia/O and/O Hyperglycemia/O Beta/O -/O adrenergic/O agonist/O medicines/O may/B-Factor produce/O significant/B-Severity hypokalemia/B-AdverseReaction in/O some/O patients/O ,/O possibly/O through/O intracellular/O shunting/O ,/O which/O has/O the/O potential/O to/O produce/O adverse/O cardiovascular/O effects/O ./O
The/O decrease/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction potassium/I-AdverseReaction is/O usually/O transient/O ,/O not/O requiring/O supplementation/O ./O
Beta/B-DrugClass -/I-DrugClass agonist/O medications/O may/O produce/O transient/B-Severity hyperglycemia/B-AdverseReaction in/O some/O patients/O ./O
In/O clinical/O trials/O evaluating/O BREO/O ELLIPTA/O in/O subjects/O with/O COPD/O or/O asthma/O ,/O there/O was/O no/O evidence/O of/O a/O treatment/O effect/O on/O serum/O glucose/O or/O potassium/O ./O
5.17/O Effect/O on/O Growth/O Orally/B-DrugClass inhaled/I-DrugClass corticosteroids/I-DrugClass may/O cause/O a/O reduction/B-AdverseReaction in/I-AdverseReaction growth/I-AdverseReaction velocity/I-AdverseReaction when/O administered/O to/O children/O and/O adolescents/O ./O
[/O See/O Use/O in/O Specific/O Populations/O (/O 8.4/O )/O ./O
]/O 6/O ADVERSE/O REACTIONS/O Exclusive/O of/O an/O uncommon/O ,/O mild/B-Severity injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O no/O adverse/O reactions/O to/O 11/O C/O -/O choline/O have/O been/O reported/O ./O
EXCERPT/O :/O Exclusive/O of/O an/O uncommon/O ,/O mild/B-Severity injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O no/O other/O adverse/O reactions/O have/O been/O reported/O (/O 6/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Division/O of/O Nuclear/O Medicine/O ,/O Department/O of/O Radiology/O ,/O Mayo/O Clinic/O at/O 507/O -/O 284/O -/O 2511/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Imaging/O errors/O have/O been/O reported/O ;/O blood/O PSA/O levels/O 2/O ng/O mL/O have/O been/O associated/O with/O poor/O imaging/O performance/O (/O 5.1/O )/O ./O
Allergic/B-AdverseReaction reactions/I-AdverseReaction :/O have/O emergency/O resuscitation/O equipment/O and/O personnel/O readily/O available/O (/O 5.2/O )/O ./O
Radiation/B-AdverseReaction risk/I-AdverseReaction :/O Choline/O C/O 11/O Injection/O contributes/O to/O a/O patient/O 's/O long/O -/O term/O cumulative/O radiation/O exposure/O ./O
Ensure/O safe/O handling/O to/O protect/O the/O patient/O and/O health/O care/O worker/O (/O 5.3/O )/O ./O
5.1/O Imaging/O Errors/O Imaging/O errors/O have/O been/O reported/O with/O 11/O C/O -/O choline/O PET/O and/O PET/O CT/O imaging/O ./O
A/O negative/O image/O does/O not/O rule/O out/O the/O presence/O of/O recurrent/O prostate/O cancer/O and/O a/O positive/O image/O does/O not/O confirm/O the/O presence/O of/O recurrent/O cancer/O ./O
11/O C/O -/O choline/O uptake/O is/O not/O specific/O for/O prostate/O cancer/O and/O may/O occur/O with/O other/O types/O of/O cancer/O (/O such/O as/O lung/O carcinoma/O and/O brain/O tumors/O )/O ./O
Clinical/O correlation/O ,/O including/O histopathological/O evaluation/O of/O the/O suspected/O recurrence/O site/O ,/O is/O essential/O to/O proper/O use/O of/O the/O PET/O imaging/O information/O ./O
Blood/O PSA/O levels/O 2/O ng/O mL/O have/O been/O associated/O with/O poor/O performance/O of/O 11/O C/O -/O choline/O PET/O imaging/O (/O higher/O numbers/O of/O false/O positive/O and/O false/O negative/O results/O )/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Tissue/O inflammation/O as/O well/O as/O prostatic/O hyperplasia/O have/O been/O associated/O with/O false/O positive/O 11/O C/O -/O choline/O PET/O images/O ./O
Concomitant/O colchicine/O or/O androgen/O -/O deprivation/O therapeutic/O drugs/O (/O such/O as/O luteinizing/O hormone/O -/O releasing/O analogs/O and/O anti/O -/O androgen/O drugs/O )/O may/O interfere/O with/O 11/O C/O -/O choline/O PET/O imaging/O ./O
One/O published/O report/O of/O 18/O F/O -/O methylcholine/O PET/O imaging/O indicated/O that/O discontinuation/O of/O colchicine/O for/O two/O weeks/O resolved/O the/O colchicine/O effect/O ./O
The/O impact/O of/O discontinuation/O of/O androgen/O -/O deprivation/O therapy/O upon/O 11/O C/O -/O choline/O PET/O imaging/O has/O not/O been/O established/O [/O see/O Drug/O Interactions/O (/O 7/O )/O ]/O ./O
5.2/O Allergic/O Reactions/O As/O with/O any/O injectable/O drug/O product/O ,/O allergic/B-AdverseReaction reactions/I-AdverseReaction and/O anaphylaxis/B-AdverseReaction may/B-Factor occur/O ./O
Emergency/O resuscitation/O equipment/O and/O personnel/O should/O be/O immediately/O available/O ./O
5.3/O Radiation/O Risks/O Choline/O C/O 11/O Injection/O contributes/O to/O a/O patient/O 's/O overall/O long/O -/O term/O cumulative/O radiation/O exposure/O ./O
Long/O -/O term/O cumulative/O radiation/O exposure/O is/O associated/O with/O an/O increased/O risk/B-Factor for/O cancer/B-AdverseReaction ./O
Safe/O handling/O should/O be/O ensured/O to/O minimize/O radiation/O exposure/O to/O the/O patient/O and/O health/O care/O workers/O [/O see/O Dosage/O and/O Administration/O (/O 2/O ./O
1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O incidence/O 7/O %/O and/O higher/O than/O placebo/O )/O :/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O UCB/O ,/O Inc./O at/O 1/O -/O 866/O -/O 822/O -/O 0068/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O The/O most/O serious/O adverse/O reactions/O were/O :/O Serious/B-Severity Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Malignancies/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Heart/B-AdverseReaction Failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Because/O clinical/O studies/O are/O conducted/O under/O widely/O varying/O and/O controlled/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O studies/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O ,/O and/O may/O not/O predict/O the/O rates/O observed/O in/O a/O broader/O patient/O population/O in/O clinical/O practice/O ./O
In/O premarketing/O controlled/O trials/O of/O all/O patient/O populations/O combined/O the/O most/O common/O adverse/O reactions/O (/O 8/O %/O )/O were/O upper/B-AdverseReaction respiratory/I-AdverseReaction infections/I-AdverseReaction (/O 18/O %/O )/O ,/O rash/B-AdverseReaction (/O 9/O %/O )/O and/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction (/O 8/O %/O )/O ./O
Adverse/O Reactions/O Most/O Commonly/O Leading/O to/O Discontinuation/O of/O Treatment/O in/O Premarketing/O Controlled/O Trials/O The/O proportion/O of/O patients/O with/O Crohn/O 's/O disease/O who/O discontinued/O treatment/O due/O to/O adverse/O reactions/O in/O the/O controlled/O clinical/O studies/O was/O 8/O %/O for/O CIMZIA/O and/O 7/O %/O for/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O the/O discontinuation/O of/O CIMZIA/O (/O for/O at/O least/O 2/O patients/O and/O with/O a/O higher/O incidence/O than/O placebo/O )/O were/O abdominal/B-AdverseReaction pain/I-AdverseReaction (/O 0.4/O %/O CIMZIA/O ,/O 0.2/O %/O placebo/O )/O ,/O diarrhea/B-AdverseReaction (/O 0.4/O %/O CIMZIA/O ,/O 0/O %/O placebo/O )/O ,/O and/O intestinal/B-AdverseReaction obstruction/I-AdverseReaction (/O 0.4/O %/O CIMZIA/O ,/O 0/O %/O placebo/O )/O ./O
The/O proportion/O of/O patients/O with/O rheumatoid/O arthritis/O who/O discontinued/O treatment/O due/O to/O adverse/O reactions/O in/O the/O controlled/O clinical/O studies/O was/O 5/O %/O for/O CIMZIA/O and/O 2.5/O %/O for/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O of/O CIMZIA/O were/O tuberculosis/B-AdverseReaction infections/I-AdverseReaction (/O 0.5/O %/O )/O ;/O and/O pyrexia/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O and/O rash/B-AdverseReaction (/O 0.3/O %/O )/O ./O
Controlled/O Studies/O with/O Crohn/O 's/O Disease/O The/O data/O described/O below/O reflect/O exposure/O to/O CIMZIA/O at/O 400/O mg/O subcutaneous/O dosing/O in/O studies/O of/O patients/O with/O Crohn/O 's/O disease/O ./O
In/O the/O safety/O population/O in/O controlled/O studies/O ,/O a/O total/O of/O 620/O patients/O with/O Crohn/O 's/O disease/O received/O CIMZIA/O at/O a/O dose/O of/O 400/O mg/O ,/O and/O 614/O subjects/O received/O placebo/O (/O including/O subjects/O randomized/O to/O placebo/O in/O Study/O CD2/O following/O open/O label/O dosing/O of/O CIMZIA/O at/O Weeks/O 0/O ,/O 2/O ,/O 4/O )/O ./O
In/O controlled/O and/O uncontrolled/O studies/O ,/O 1,564/O patients/O received/O CIMZIA/O at/O some/O dose/O level/O ,/O of/O whom/O 1,350/O patients/O received/O 400/O mg/O CIMZIA/O ./O
Approximately/O 55/O %/O of/O subjects/O were/O female/O ,/O 45/O %/O were/O male/O ,/O and/O 94/O %/O were/O Caucasian/O ./O
The/O majority/O of/O patients/O in/O the/O active/O group/O were/O between/O the/O ages/O of/O 18/O and/O 64/O ./O
During/O controlled/O clinical/O studies/O ,/O the/O proportion/O of/O patients/O with/O serious/O adverse/O reactions/O was/O 10/O %/O for/O CIMZIA/O and/O 9/O %/O for/O placebo/O ./O
The/O most/O common/O adverse/O reactions/O (/O occurring/O in/O 5/O %/O of/O CIMZIA/O -/O treated/O patients/O ,/O and/O with/O a/O higher/O incidence/O compared/O to/O placebo/O )/O in/O controlled/O clinical/O studies/O with/O CIMZIA/O were/O upper/B-AdverseReaction respiratory/I-AdverseReaction infections/I-AdverseReaction (/O e.g./O nasopharyngitis/B-AdverseReaction ,/O laryngitis/B-AdverseReaction ,/O viral/B-AdverseReaction infection/I-AdverseReaction )/O in/O 20/O %/O of/O CIMZIA/O -/O treated/O patients/O and/O 13/O %/O of/O placebo/O -/O treated/O patients/O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction (/O e.g./O bladder/B-AdverseReaction infection/I-AdverseReaction ,/O bacteriuria/B-AdverseReaction ,/O cystitis/B-AdverseReaction )/O in/O 7/O %/O of/O CIMZIA/O -/O treated/O patients/O and/O in/O 6/O %/O of/O placebo/O -/O treated/O patients/O ,/O and/O arthralgia/B-AdverseReaction (/O 6/O %/O CIMZIA/O ,/O 4/O %/O placebo/O )/O ./O
Other/O Adverse/O Reactions/O The/O most/O commonly/O occurring/O adverse/O reactions/O in/O controlled/O trials/O of/O Crohn/O 's/O disease/O were/O described/O above/O ./O
Other/O serious/O or/O significant/O adverse/O reactions/O reported/O in/O controlled/O and/O uncontrolled/O studies/O in/O Crohn/O 's/O disease/O and/O other/O diseases/O ,/O occurring/O in/O patients/O receiving/O CIMZIA/O at/O doses/O of/O 400/O mg/O or/O other/O doses/O include/O :/O Blood/O and/O lymphatic/O system/O disorders/O :/O Anemia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O lymphadenopathy/B-AdverseReaction ,/O pancytopenia/B-AdverseReaction ,/O and/O thrombophilia/B-AdverseReaction ./O
Cardiac/O disorders/O :/O Angina/B-AdverseReaction pectoris/I-AdverseReaction ,/O arrhythmias/B-AdverseReaction ,/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction ,/O hypertensive/B-AdverseReaction heart/I-AdverseReaction disease/I-AdverseReaction ,/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O myocardial/B-AdverseReaction ischemia/I-AdverseReaction ,/O pericardial/B-AdverseReaction effusion/I-AdverseReaction ,/O pericarditis/B-AdverseReaction ,/O stroke/B-AdverseReaction and/O transient/B-AdverseReaction ischemic/I-AdverseReaction attack/I-AdverseReaction ./O
Eye/O disorders/O :/O Optic/B-AdverseReaction neuritis/I-AdverseReaction ,/O retinal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O and/O uveitis/B-AdverseReaction ./O
General/O disorders/O and/O administration/O site/O conditions/O :/O Bleeding/B-AdverseReaction and/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ./O
Hepatobiliary/O disorders/O :/O Elevated/B-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction and/O hepatitis/B-AdverseReaction ./O
Immune/O system/O disorders/O :/O Alopecia/B-AdverseReaction totalis/I-AdverseReaction ./O
Psychiatric/O disorders/O :/O Anxiety/B-AdverseReaction ,/O bipolar/B-AdverseReaction disorder/I-AdverseReaction ,/O and/O suicide/B-AdverseReaction attempt/I-AdverseReaction ./O
Renal/O and/O urinary/O disorders/O :/O Nephrotic/B-AdverseReaction syndrome/I-AdverseReaction and/O renal/B-AdverseReaction failure/I-AdverseReaction ./O
Reproductive/O system/O and/O breast/O disorders/O :/O Menstrual/B-AdverseReaction disorder/I-AdverseReaction ./O
Skin/O and/O subcutaneous/O tissue/O disorders/O :/O Dermatitis/B-AdverseReaction ,/O erythema/B-AdverseReaction nodosum/I-AdverseReaction ,/O and/O urticaria/B-AdverseReaction ./O
Vascular/O disorders/O :/O Thrombophlebitis/B-AdverseReaction ,/O vasculitis/B-AdverseReaction ./O
Controlled/O Studies/O with/O Rheumatoid/O Arthritis/O CIMZIA/O was/O studied/O primarily/O in/O placebo/O -/O controlled/O trials/O and/O in/O long/O -/O term/O follow/O -/O up/O studies/O ./O
The/O data/O described/O below/O reflect/O the/O exposure/O to/O CIMZIA/O in/O 2,367/O RA/O patients/O ,/O including/O 2,030/O exposed/O for/O at/O least/O 6/O months/O ,/O 1,663/O exposed/O for/O at/O least/O one/O year/O and/O 282/O for/O at/O least/O 2/O years/O ;/O and/O 1,774/O in/O adequate/O and/O well/O -/O controlled/O studies/O ./O
In/O placebo/O -/O controlled/O studies/O ,/O the/O population/O had/O a/O median/O age/O of/O 53/O years/O at/O entry/O ;/O approximately/O 80/O %/O were/O females/O ,/O 93/O %/O were/O Caucasian/O and/O all/O patients/O were/O suffering/O from/O active/O rheumatoid/O arthritis/O ,/O with/O a/O median/O disease/O duration/O of/O 6.2/O years/O ./O
Most/O patients/O received/O the/O recommended/O dose/O of/O CIMZIA/O or/O higher/O ./O
Table/O 1/O summarizes/O the/O reactions/O reported/O at/O a/O rate/O of/O at/O least/O 3/O %/O in/O patients/O treated/O with/O CIMZIA/O 200/O mg/O every/O other/O week/O compared/O to/O placebo/O (/O saline/O formulation/O )/O ,/O given/O concomitantly/O with/O methotrexate/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Reported/O by/O =3/O %/O of/O Patients/O Treated/O with/O CIMZIA/O Dosed/O Every/O Other/O Week/O during/O Placebo/O -/O Controlled/O Period/O of/O Rheumatoid/O Arthritis/O Studies/O ,/O with/O Concomitant/O Methotrexate/O ./O
Adverse/O Reaction(Preferred/O Term/O )/O Placebo+/O MTX(%)N/O 324/O CIMZIA/O 200/O mg/O EOW/O +/O MTX(%)N/O 640/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 2/O 6/O Headache/B-AdverseReaction 4/O 5/O Hypertension/B-AdverseReaction 2/O 5/O Nasopharyngitis/B-AdverseReaction 1/O 5/O Back/B-AdverseReaction pain/I-AdverseReaction 1/O 4/O Pyrexia/B-AdverseReaction 2/O 3/O Pharyngitis/B-AdverseReaction 1/O 3/O Rash/B-AdverseReaction 1/O 3/O Acute/B-AdverseReaction bronchitis/I-AdverseReaction 1/O 3/O Fatigue/B-AdverseReaction 2/O 3/O Hypertensive/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction were/O observed/O more/O frequently/O in/O patients/O receiving/O CIMZIA/O than/O in/O controls/O ./O
These/O adverse/O reactions/O occurred/O more/O frequently/O among/O patients/O with/O a/O baseline/O history/O of/O hypertension/O and/O among/O patients/O receiving/O concomitant/O corticosteroids/O and/O non/O -/O steroidal/O anti/O -/O inflammatory/O drugs/O ./O
Patients/O receiving/O CIMZIA/O 400/O mg/O as/O monotherapy/O every/O 4/O weeks/O in/O rheumatoid/O arthritis/O controlled/O clinical/O trials/O had/O similar/O adverse/O reactions/O to/O those/O patients/O receiving/O CIMZIA/O 200/O mg/O every/O other/O week/O ./O
Other/O Adverse/O Reactions/O Other/O infrequent/O adverse/O reactions/O (/O occurring/O in/O less/O than/O 3/O %/O of/O RA/O patients/O )/O were/O similar/O to/O those/O seen/O in/O Crohn/O 's/O disease/O patients/O ./O
Psoriatic/O Arthritis/O Clinical/O Study/O CIMZIA/O has/O been/O studied/O in/O 409/O patients/O with/O psoriatic/O arthritis/O (/O PsA/O )/O in/O a/O placebo/O -/O controlled/O trial/O ./O
The/O safety/O profile/O for/O patients/O with/O PsA/O treated/O with/O CIMZIA/O was/O similar/O to/O the/O safety/O profile/O seen/O in/O patients/O with/O RA/O and/O previous/O experience/O with/O CIMZIA/O ./O
Ankylosing/O Spondylitis/O Clinical/O Study/O CIMZIA/O has/O been/O studied/O in/O 325/O patients/O with/O axial/O spondyloarthritis/O of/O whom/O the/O majority/O had/O ankylosing/O spondylitis/O (/O AS/O )/O in/O a/O placebo/O -/O controlled/O study/O (/O AS-1/O )/O ./O
The/O safety/O profile/O for/O patients/O in/O study/O AS-1/O treated/O with/O CIMZIA/O was/O similar/O to/O the/O safety/O profile/O seen/O in/O patients/O with/O RA/O ./O
Infections/O The/O incidence/O of/O infections/B-AdverseReaction in/O controlled/O studies/O in/O Crohn/O 's/O disease/O was/O 38/O %/O for/O CIMZIA/O -/O treated/O patients/O and/O 30/O %/O for/O placebo/O -/O treated/O patients/O ./O
The/O infections/B-AdverseReaction consisted/O primarily/O of/O upper/B-AdverseReaction respiratory/I-AdverseReaction infections/I-AdverseReaction (/O 20/O %/O for/O CIMZIA/O ,/O 13/O %/O for/O placebo/O )/O ./O
The/O incidence/O of/O serious/B-Severity infections/B-AdverseReaction during/O the/O controlled/O clinical/O studies/O was/O 3/O %/O per/O patient/O -/O year/O for/O CIMZIA/O -/O treated/O patients/O and/O 1/O %/O for/O placebo/O -/O treated/O patients/O ./O
Serious/B-Severity infections/B-AdverseReaction observed/O included/O bacterial/O and/O viral/B-AdverseReaction infections/I-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O and/O pyelonephritis/B-AdverseReaction ./O
The/O incidence/O of/O new/O cases/O of/O infections/B-AdverseReaction in/O controlled/O clinical/O studies/O in/O rheumatoid/O arthritis/O was/O 0.91/O per/O patient/O -/O year/O for/O all/O CIMZIA/O -/O treated/O patients/O and/O 0.72/O per/O patient/O -/O year/O for/O placebo/O -/O treated/O patients/O ./O
The/O infections/B-AdverseReaction consisted/O primarily/O of/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction ,/O herpes/B-AdverseReaction infections/I-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction ,/O and/O lower/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction ./O
In/O the/O controlled/O rheumatoid/O arthritis/O studies/O ,/O there/O were/O more/O new/O cases/O of/O serious/B-Severity infection/B-AdverseReaction adverse/O reactions/O in/O the/O CIMZIA/O treatment/O groups/O ,/O compared/O to/O the/O placebo/O groups/O (/O 0.06/O per/O patient/O -/O year/O for/O all/O CIMZIA/O doses/O vs./O 0.02/O per/O patient/O -/O year/O for/O placebo/O )/O ./O
Rates/O of/O serious/B-Severity infections/B-AdverseReaction in/O the/O 200/O mg/O every/O other/O week/O dose/O group/O were/O 0.06/O per/O patient/O -/O year/O and/O in/O the/O 400/O mg/O every/O 4/O weeks/O dose/O group/O were/O 0.04/O per/O patient/O -/O year/O ./O
Serious/B-Severity infections/B-AdverseReaction included/O tuberculosis/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O cellulitis/B-AdverseReaction ,/O and/O pyelonephritis/B-AdverseReaction ./O
In/O the/O placebo/B-Factor group/O ,/O no/O serious/B-Severity infection/B-AdverseReaction occurred/O in/O more/O than/O one/O subject/O ./O
There/O is/O no/O evidence/O of/O increased/O risk/O of/O infections/O with/O continued/O exposure/O over/O time/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Tuberculosis/O and/O Opportunistic/O Infections/O In/O completed/O and/O ongoing/O global/O clinical/O studies/O in/O all/O indications/O including/O 5,118/O CIMZIA/O -/O treated/O patients/O ,/O the/O overall/O rate/O of/O tuberculosis/B-AdverseReaction is/O approximately/O 0.61/O per/O 100/O patient/O -/O years/O across/O all/O indications/O ./O
The/O majority/O of/O cases/O occurred/O in/O countries/O with/O high/O endemic/O rates/O of/O TB/B-AdverseReaction ./O
Reports/O include/O cases/O of/O miliary/O ,/O lymphatic/O ,/O peritoneal/O ,/O as/O well/O as/O pulmonary/B-AdverseReaction TB/I-AdverseReaction ./O
The/O median/O time/O to/O onset/O of/O TB/B-AdverseReaction for/O all/O patients/O exposed/O to/O CIMZIA/O across/O all/O indications/O was/O 345/O days/O ./O
In/O the/O studies/O with/O CIMZIA/O in/O RA/O ,/O there/O were/O 36/O cases/O of/O TB/B-AdverseReaction among/O 2,367/O exposed/O patients/O ,/O including/O some/O fatal/B-AdverseReaction cases/O ./O
Rare/O cases/O of/O opportunistic/B-AdverseReaction infections/I-AdverseReaction have/O also/O been/O reported/O in/O these/O clinical/O trials/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Malignancies/O In/O clinical/O studies/O of/O CIMZIA/O ,/O the/O overall/O incidence/O rate/O of/O malignancies/B-AdverseReaction was/O similar/O for/O CIMZIA/O -/O treated/O and/O control/O patients/O ./O
For/O some/O TNF/O blockers/O ,/O more/O cases/O of/O malignancies/B-AdverseReaction have/O been/O observed/O among/O patients/O receiving/O those/O TNF/B-DrugClass blockers/I-DrugClass compared/O to/O control/O patients/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Heart/O Failure/O In/O placebo/O -/O controlled/O and/O open/O -/O label/O rheumatoid/O arthritis/O studies/O ,/O cases/O of/O new/O or/O worsening/B-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction have/O been/O reported/O for/O CIMZIA/O -/O treated/O patients/O ./O
The/O majority/O of/O these/O cases/O were/O mild/O to/O moderate/O and/O occurred/O during/O the/O first/O year/O of/O exposure/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Autoantibodies/O In/O clinical/O studies/O in/O Crohn/O 's/O disease/O ,/O 4/O %/O of/O patients/O treated/O with/O CIMZIA/O and/O 2/O %/O of/O patients/O treated/O with/O placebo/O that/O had/O negative/O baseline/O ANA/O titers/O developed/O positive/O titers/O during/O the/O studies/O ./O
One/O of/O the/O 1,564/O Crohn/O 's/O disease/O patients/O treated/O with/O CIMZIA/O developed/O symptoms/O of/O a/O lupus/B-AdverseReaction -/I-AdverseReaction like/O syndrome/O ./O
In/O clinical/O trials/O of/O TNF/O blockers/O ,/O including/O CIMZIA/O ,/O in/O patients/O with/O RA/O ,/O some/O patients/O have/O developed/O ANA/B-AdverseReaction ./O
Four/O patients/O out/O of/O 2,367/O patients/O treated/O with/O CIMZIA/O in/O RA/O clinical/O studies/O developed/O clinical/O signs/O suggestive/O of/O a/O lupus/B-AdverseReaction -/I-AdverseReaction like/O syndrome/O ./O
The/O impact/O of/O long/O -/O term/O treatment/O with/O CIMZIA/O on/O the/O development/O of/O autoimmune/O diseases/O is/O unknown/O [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O ./O
Immunogenicity/O Patients/O were/O tested/O at/O multiple/O time/O points/O for/O antibodies/O to/O certolizumab/O pegol/O during/O Studies/O CD1/O and/O CD2/O ./O
The/O overall/O percentage/O of/O antibody/O positive/O patients/O was/O 8/O %/O in/O patients/O continuously/O exposed/O to/O CIMZIA/O ,/O approximately/O 6/O %/O were/O neutralizing/O in/O vitro/O ./O
No/O apparent/O correlation/O of/O antibody/O development/O to/O adverse/O events/O or/O efficacy/O was/O observed/O ./O
Patients/O treated/O with/O concomitant/O immunosuppressants/O had/O a/O lower/O rate/O of/O antibody/O development/O than/O patients/O not/O taking/O immunosuppressants/O at/O baseline/O (/O 3/O %/O and/O 11/O %/O ,/O respectively/O )/O ./O
The/O following/O adverse/O events/O were/O reported/O in/O Crohn/O 's/O disease/O patients/O who/O were/O antibody/O -/O positive/O (/O N/O 100/O )/O at/O an/O incidence/O at/O least/O 3/O %/O higher/O compared/O to/O antibody/O -/O negative/O patients/O (/O N/O 1,242/O )/O :/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O edema/B-AdverseReaction peripheral/I-AdverseReaction ,/O erythema/B-AdverseReaction nodosum/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction erythema/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ,/O and/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
The/O overall/O percentage/O of/O patients/O with/O antibodies/O to/O certolizumab/O pegol/O detectable/O on/O at/O least/O one/O occasion/O was/O 7/O %/O (/O 105/O of/O 1,509/O )/O in/O the/O rheumatoid/O arthritis/O placebo/O -/O controlled/O trials/O ./O
Approximately/O one/O third/O (/O 3/O %/O ,/O 39/O of/O 1,509/O )/O of/O these/O patients/O had/O antibodies/O with/O neutralizing/O activity/O in/O vitro/O ./O
Patients/O treated/O with/O concomitant/O immunosuppressants/O (/O MTX/O )/O had/O a/O lower/O rate/O of/O antibody/O development/O than/O patients/O not/O taking/O immunosuppressants/O at/O baseline/O ./O
Patients/O treated/O with/O concomitant/O immunosuppressant/O therapy/O (/O MTX/O )/O in/O RA/O -/O I/O ,/O RA/O -/O II/O ,/O RA/O -/O III/O had/O a/O lower/O rate/O of/O neutralizing/O antibody/O formation/O overall/O than/O patients/O treated/O with/O CIMZIA/O monotherapy/O in/O RA/O -/O IV/O (/O 2/O %/O vs./O 8/O %/O )/O ./O
Both/O the/O loading/O dose/O of/O 400/O mg/O every/O other/O week/O at/O Weeks/O 0/O ,/O 2/O and/O 4/O and/O concomitant/O use/O of/O MTX/O were/O associated/O with/O reduced/O immunogenicity/O ./O
Antibody/O formation/O was/O associated/O with/O lowered/O drug/O plasma/O concentration/O and/O reduced/O efficacy/O ./O
In/O patients/O receiving/O the/O recommended/O CIMZIA/O dosage/O of/O 200/O mg/O every/O other/O week/O with/O concomitant/O MTX/O ,/O the/O ACR20/O response/O was/O lower/O among/O antibody/O positive/O patients/O than/O among/O antibody/O -/O negative/O patients/O (/O Study/O RA/O -/O I/O ,/O 48/O %/O versus/O 60/O %/O ;/O Study/O RA/O -/O II/O 35/O %/O versus/O 59/O %/O ,/O respectively/O )/O ./O
In/O Study/O RA/O -/O III/O ,/O too/O few/O patients/O developed/O antibodies/O to/O allow/O for/O meaningful/O analysis/O of/O ACR20/O response/O by/O antibody/O status/O ./O
In/O Study/O RA/O -/O IV/O (/O monotherapy/O )/O ,/O the/O ACR20/O response/O was/O 33/O %/O versus/O 56/O %/O ,/O antibody/O -/O positive/O versus/O antibody/O -/O negative/O status/O ,/O respectively/O ./O
[/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
No/O association/O was/O seen/O between/O antibody/O development/O and/O the/O development/O of/O adverse/O events/O ./O
The/O data/O reflect/O the/O percentage/O of/O patients/O whose/O test/O results/O were/O considered/O positive/O for/O antibodies/O to/O certolizumab/O pegol/O in/O an/O ELISA/O ,/O and/O are/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
The/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O is/O highly/O dependent/O on/O several/O factors/O ,/O including/O assay/O sensitivity/O and/O specificity/O ,/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O certolizumab/O pegol/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
Hypersensitivity/O Reactions/O The/O following/O symptoms/O that/O could/O be/O compatible/O with/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O rarely/O following/O CIMZIA/O administration/O to/O patients/O :/O angioedema/B-AdverseReaction ,/O dermatitis/B-AdverseReaction allergic/I-AdverseReaction ,/O dizziness/O (/O postural/O )/O ,/O dyspnea/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ,/O malaise/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O serum/B-AdverseReaction sickness/I-AdverseReaction ,/O and/O (/O vasovagal/O )/O syncope/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O CIMZIA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O estimate/O reliably/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Vascular/O disorder/O :/O systemic/B-AdverseReaction vasculitis/I-AdverseReaction has/O been/O identified/O during/O post/O -/O approval/O use/O of/O TNF/B-DrugClass blockers/I-DrugClass ./O
Skin/O :/O case/O of/O severe/B-Severity skin/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction ,/O erythema/B-AdverseReaction multiforme/I-AdverseReaction ,/O and/O new/O or/O worsening/O psoriasis/B-AdverseReaction (/O all/O sub/O -/O types/O including/O pustular/O and/O palmoplantar/O )/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O TNF/B-DrugClass blockers/I-DrugClass ./O
Immune/O System/O Disorders/O :/O sarcoidosis/B-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction AND/O MALIGNANCY/B-AdverseReaction WARNING/O :/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction AND/O MALIGNANCY/B-AdverseReaction SERIOUS/O INFECTIONS/O Patients/O treated/O with/O CIMZIA/O are/O at/O increased/O risk/B-Factor for/O developing/O serious/B-Severity infections/B-AdverseReaction that/O may/B-Factor lead/O to/O hospitalization/O or/O death/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Most/O patients/O who/O developed/O these/O infections/B-AdverseReaction were/O taking/O concomitant/O immunosuppressants/O such/O as/O methotrexate/O or/O corticosteroids/O ./O
CIMZIA/O should/O be/O discontinued/O if/O a/O patient/O develops/O a/O serious/O infection/O or/O sepsis/O ./O
Reported/O infections/O include/O :/O Active/B-AdverseReaction tuberculosis/I-AdverseReaction ,/O including/O reactivation/B-AdverseReaction of/I-AdverseReaction latent/I-AdverseReaction tuberculosis/I-AdverseReaction ./O
Patients/O with/O tuberculosis/O have/O frequently/O presented/O with/O disseminated/O or/O extrapulmonary/O disease/O ./O
Patients/O should/O be/O tested/O for/O latent/O tuberculosis/O before/O CIMZIA/O use/O and/O during/O therapy/O ./O
Treatment/O for/O latent/O infection/O should/O be/O initiated/O prior/O to/O CIMZIA/O use/O ./O
Invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction ,/O including/O histoplasmosis/B-AdverseReaction ,/O coccidioidomycosis/B-AdverseReaction ,/O candidiasis/B-AdverseReaction ,/O aspergillosis/B-AdverseReaction ,/O blastomycosis/B-AdverseReaction ,/O and/O pneumocystosis/B-AdverseReaction ./O
Patients/O with/O histoplasmosis/B-AdverseReaction or/O other/O invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction may/B-Factor present/O with/O disseminated/O ,/O rather/O than/O localized/O disease/O ./O
Antigen/O and/O antibody/O testing/O for/O histoplasmosis/O may/O be/O negative/O in/O some/O patients/O with/O active/O infection/O ./O
Empiric/O anti/O -/O fungal/O therapy/O should/O be/O considered/O in/O patients/O at/O risk/O for/O invasive/O fungal/O infections/O who/O develop/O severe/O systemic/O illness/O ./O
Bacterial/O ,/O viral/O and/O other/O infections/O due/O to/O opportunistic/O pathogens/O ,/O including/O Legionella/O and/O Listeria/O ./O
The/O risks/O and/O benefits/O of/O treatment/O with/O CIMZIA/O should/O be/O carefully/O considered/O prior/O to/O initiating/O therapy/O in/O patients/O with/O chronic/O or/O recurrent/O infection/O ./O
Patients/O should/O be/O closely/O monitored/O for/O the/O development/O of/O signs/O and/O symptoms/O of/O infection/O during/O and/O after/O treatment/O with/O CIMZIA/O ,/O including/O the/O possible/O development/O of/O tuberculosis/O in/O patients/O who/O tested/O negative/O for/O latent/O tuberculosis/O infection/O prior/O to/O initiating/O therapy/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
MALIGNANCY/O Lymphoma/B-AdverseReaction and/O other/O malignancies/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O in/O children/O and/O adolescent/O patients/O treated/O with/O TNF/B-DrugClass blockers/I-DrugClass ,/O of/O which/O CIMZIA/O is/O a/O member/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
CIMZIA/O is/O not/O indicated/O for/O use/O in/O pediatric/O patients/O ./O
EXCERPT/O :/O WARNING/O :/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction AND/O MALIGNANCY/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Increased/O risk/B-Factor of/O serious/B-Severity infections/B-AdverseReaction leading/O to/O hospitalization/O or/O death/B-AdverseReaction including/O tuberculosis/B-AdverseReaction (/O TB/B-AdverseReaction )/O ,/O bacterial/B-AdverseReaction sepsis/I-AdverseReaction ,/O invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction (/O such/O as/O histoplasmosis/B-AdverseReaction )/O ,/O and/O infections/B-AdverseReaction due/I-AdverseReaction to/I-AdverseReaction other/I-AdverseReaction opportunistic/I-AdverseReaction pathogens/I-AdverseReaction (/O 5.1/O )/O ./O
CIMZIA/O should/O be/O discontinued/O if/O a/O patient/O develops/O a/O serious/O infection/O or/O sepsis/O (/O 5.1/O )/O ./O
Perform/O test/O for/O latent/O TB/O ;/O if/O positive/O ,/O start/O treatment/O for/O TB/O prior/O to/O starting/O CIMZIA/O (/O 5.1/O )/O ./O
Monitor/O all/O patients/O for/O active/O TB/O during/O treatment/O ,/O even/O if/O initial/O latent/O TB/O test/O is/O negative/O (/O 5.1/O )/O Lymphoma/B-AdverseReaction and/O other/O malignancies/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O in/O children/O and/O adolescent/O patients/O treated/O with/O TNF/B-DrugClass blockers/I-DrugClass ,/O of/O which/O CIMZIA/O is/O a/O member/O (/O 5.2/O )/O ./O
CIMZIA/O is/O not/O indicated/O for/O use/O in/O pediatric/O patients/O ./O
(/O 8.4/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Serious/B-Severity infections/B-AdverseReaction -/O do/O not/O start/O CIMZIA/O during/O an/O active/O infection/O ./O
If/O an/O infection/O develops/O ,/O monitor/O carefully/O ,/O and/O stop/O CIMZIA/O if/O infection/O becomes/O serious/O (/O 5.1/O )/O Invasive/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction -/O for/O patients/O who/O develop/O a/O systemic/O illness/O on/O CIMZIA/O ,/O consider/O empiric/O antifungal/O therapy/O for/O those/O who/O reside/O or/O travel/O to/O regions/O where/O mycoses/O are/O endemic/O (/O 5.1/O )/O Cases/O of/O lymphoma/B-AdverseReaction and/O other/O malignancies/B-AdverseReaction have/O been/O observed/O among/O patients/O receiving/O TNF/B-DrugClass blockers/I-DrugClass (/O 5.2/O )/O Heart/B-AdverseReaction failure/I-AdverseReaction ,/I-AdverseReaction worsening/O or/O new/O onset/O may/B-Factor occur/O (/O 5.3/O )/O Anaphylaxis/B-AdverseReaction or/O serious/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction may/B-Factor occur/O (/O 5.4/O )/O Hepatitis/B-AdverseReaction B/I-AdverseReaction virus/I-AdverseReaction reactivation/I-AdverseReaction -/O test/O for/O HBV/O infection/O before/O starting/O CIMZIA/O ./O
Monitor/O HBV/O carriers/O during/O and/O several/O months/O after/O therapy/O ./O
If/O reactivation/O occurs/O ,/O stop/O CIMZIA/O and/O begin/O anti/O -/O viral/O therapy/O (/O 5.5/O )/O Demyelinating/B-AdverseReaction disease/I-AdverseReaction ,/O exacerbation/O or/O new/O onset/O ,/O may/B-Factor occur/O (/O 5.6/O )/O Cytopenias/B-AdverseReaction ,/O pancytopenia/B-AdverseReaction -/O advise/O patients/O to/O seek/O immediate/O medical/O attention/O if/O symptoms/O develop/O ,/O and/O consider/O stopping/O CIMZIA/O (/O 5.7/O )/O Lupus/B-AdverseReaction -/I-AdverseReaction like/O syndrome/O -/O stop/O CIMZIA/O if/O syndrome/O develops/O (/O 5.9/O )/O 5.1/O Risk/O of/O Serious/O Infections/O [/O see/O Boxed/O Warning/O ]/O Patients/O treated/O with/O CIMZIA/O are/O at/O an/O increased/O risk/B-Factor for/O developing/O serious/B-Severity infections/B-AdverseReaction involving/O various/O organ/O systems/O and/O sites/O that/O may/B-Factor lead/O to/O hospitalization/O or/O death/B-AdverseReaction ./O
Opportunistic/B-AdverseReaction infections/I-AdverseReaction due/O to/O bacterial/O ,/O mycobacterial/O ,/O invasive/O fungal/O ,/O viral/O ,/O parasitic/O ,/O or/O other/O opportunistic/O pathogens/O including/O aspergillosis/B-AdverseReaction ,/O blastomycosis/B-AdverseReaction ,/O candidiasis/B-AdverseReaction ,/O coccidioidomycosis/B-AdverseReaction ,/O histoplasmosis/B-AdverseReaction ,/O legionellosis/B-AdverseReaction ,/O listeriosis/B-AdverseReaction ,/O pneumocystosis/B-AdverseReaction and/O tuberculosis/B-AdverseReaction have/O been/O reported/O with/O TNF/B-DrugClass blockers/I-DrugClass ./O
Patients/O have/O frequently/O presented/O with/O disseminated/O rather/O than/O localized/O disease/O ./O
Treatment/O with/O CIMZIA/O should/O not/O be/O initiated/O in/O patients/O with/O an/O active/O infection/O ,/O including/O clinically/O important/O localized/O infections/O ./O
Patients/O greater/O than/O 65/O years/O of/O age/O ,/O patients/O with/O co/O -/O morbid/O conditions/O ,/O and/or/O patients/O taking/O concomitant/O immunosuppressants/O (/O e.g./O corticosteroids/O or/O methotrexate/O )/O may/O be/O at/O a/O greater/O risk/B-Factor of/O infection/B-AdverseReaction ./O
The/O risks/O and/O benefits/O of/O treatment/O should/O be/O considered/O prior/O to/O initiating/O therapy/O in/O patients/O :/O with/O chronic/O or/O recurrent/O infection/O who/O have/O been/O exposed/O to/O tuberculosis/O with/O a/O history/O of/O an/O opportunistic/O infection/O who/O have/O resided/O or/O traveled/O in/O areas/O of/O endemic/O tuberculosis/O or/O endemic/O mycoses/O ,/O such/O as/O histoplasmosis/O ,/O coccidioidomycosis/O ,/O or/O blastomycosis/O with/O underlying/O conditions/O that/O may/O predispose/O them/O to/O infection/O Tuberculosis/O Cases/O of/O reactivation/B-AdverseReaction of/I-AdverseReaction tuberculosis/I-AdverseReaction or/O new/O tuberculosis/B-AdverseReaction infections/I-AdverseReaction have/O been/O observed/O in/O patients/O receiving/O CIMZIA/O ,/O including/O patients/O who/O have/O previously/O received/O treatment/O for/O latent/O or/O active/O tuberculosis/O ./O
Patients/O should/O be/O evaluated/O for/O tuberculosis/O risk/O factors/O and/O tested/O for/O latent/O infection/O prior/O to/O initiating/O CIMZIA/O and/O periodically/O during/O therapy/O ./O
Treatment/O of/O latent/O tuberculosis/O infection/O prior/O to/O therapy/O with/O TNF/O -/O blocking/O agents/O has/O been/O shown/O to/O reduce/O the/O risk/O of/O tuberculosis/O reactivation/O during/O therapy/O ./O
Induration/O of/O 5/O mm/O or/O greater/O with/O tuberculin/O skin/O testing/O should/O be/O considered/O a/O positive/O test/O result/O when/O assessing/O if/O treatment/O for/O latent/O tuberculosis/O is/O needed/O prior/O to/O initiating/O CIMZIA/O ,/O even/O for/O patients/O previously/O vaccinated/O with/O Bacille/O Calmette/O -/O Guerin/O (/O BCG/O )/O ./O
Anti/O -/O tuberculosis/O therapy/O should/O also/O be/O considered/O prior/O to/O initiation/O of/O CIMZIA/O in/O patients/O with/O a/O past/O history/O of/O latent/O or/O active/O tuberculosis/O in/O whom/O an/O adequate/O course/O of/O treatment/O can/O not/O be/O confirmed/O ,/O and/O for/O patients/O with/O a/O negative/O test/O for/O latent/O tuberculosis/O but/O having/O risk/O factors/O for/O tuberculosis/O infection/O ./O
Consultation/O with/O a/O physician/O with/O expertise/O in/O the/O treatment/O of/O tuberculosis/O is/O recommended/O to/O aid/O in/O the/O decision/O of/O whether/O initiating/O anti/O -/O tuberculosis/O therapy/O is/O appropriate/O for/O an/O individual/O patient/O ./O
Tuberculosis/O should/O be/O strongly/O considered/O in/O patients/O who/O develop/O a/O new/O infection/O during/O CIMZIA/O treatment/O ,/O especially/O in/O patients/O who/O have/O previously/O or/O recently/O traveled/O to/O countries/O with/O a/O high/O prevalence/O of/O tuberculosis/O ,/O or/O who/O have/O had/O close/O contact/O with/O a/O person/O with/O active/O tuberculosis/O ./O
Monitoring/O Patients/O should/O be/O closely/O monitored/O for/O the/O development/O of/O signs/O and/O symptoms/O of/O infection/O during/O and/O after/O treatment/O with/O CIMZIA/O ,/O including/O the/O development/O of/O tuberculosis/O in/O patients/O who/O tested/O negative/O for/O latent/O tuberculosis/O infection/O prior/O to/O initiating/O therapy/O ./O
Tests/O for/O latent/O tuberculosis/O infection/O may/O also/O be/O falsely/O negative/O while/O on/O therapy/O with/O CIMZIA/O ./O
CIMZIA/O should/O be/O discontinued/O if/O a/O patient/O develops/O a/O serious/O infection/O or/O sepsis/O ./O
A/O patient/O who/O develops/O a/O new/O infection/O during/O treatment/O with/O CIMZIA/O should/O be/O closely/O monitored/O ,/O undergo/O a/O prompt/O and/O complete/O diagnostic/O workup/O appropriate/O for/O an/O immunocompromised/O patient/O ,/O and/O appropriate/O antimicrobial/O therapy/O should/O be/O initiated/O ./O
Invasive/O Fungal/O Infections/O For/O patients/O who/O reside/O or/O travel/O in/O regions/O where/O mycoses/O are/O endemic/O ,/O invasive/O fungal/O infection/O should/O be/O suspected/O if/O they/O develop/O a/O serious/O systemic/O illness/O ./O
Appropriate/O empiric/O antifungal/O therapy/O should/O be/O considered/O while/O a/O diagnostic/O workup/O is/O being/O performed/O ./O
Antigen/O and/O antibody/O testing/O for/O histoplasmosis/O may/O be/O negative/O in/O some/O patients/O with/O active/O infection/O ./O
When/O feasible/O ,/O the/O decision/O to/O administer/O empiric/O antifungal/O therapy/O in/O these/O patients/O should/O be/O made/O in/O consultation/O with/O a/O physician/O with/O expertise/O in/O the/O diagnosis/O and/O treatment/O of/O invasive/O fungal/O infections/O and/O should/O take/O into/O account/O both/O the/O risk/O for/O severe/O fungal/O infection/O and/O risks/O of/O antifungal/O therapy/O ./O
5.2/O Malignancies/O In/O the/O controlled/O portions/O of/O clinical/O studies/O of/O some/O TNF/O blockers/O ,/O more/O cases/O of/O malignancies/B-AdverseReaction have/O been/O observed/O among/O patients/O receiving/O TNF/B-DrugClass blockers/I-DrugClass compared/O to/O control/O patients/O ./O
During/O controlled/O and/O open/O -/O labeled/O portions/O of/O CIMZIA/O studies/O of/O Crohn/O 's/O disease/O and/O other/O diseases/O ,/O malignancies/B-AdverseReaction (/O excluding/B-Negation non/B-AdverseReaction -/I-AdverseReaction melanoma/I-AdverseReaction skin/O cancer/O )/O were/O observed/O at/O a/O rate/O (/O 95/O %/O confidence/O interval/O )/O of/O 0.5/O (/O 0.4/O ,/O 0.7/O )/O per/O 100/O patient/O -/O years/O among/O 4,650/O CIMZIA/O -/O treated/O patients/O versus/O a/O rate/O of/O 0.6/O (/O 0.1/O ,/O 1.7/O )/O per/O 100/O patient/O -/O years/O among/O 1,319/O placebo/O -/O treated/O patients/O ./O
The/O size/O of/O the/O control/O group/O and/O limited/O duration/O of/O the/O controlled/O portions/O of/O the/O studies/O precludes/O the/O ability/O to/O draw/O firm/O conclusions/O ./O
Malignancies/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O among/O children/O ,/O adolescents/O ,/O and/O young/O adults/O who/O received/O treatment/O with/O TNF/B-DrugClass -/I-DrugClass blocking/O agents/O (/O initiation/O of/O therapy/O 18/O years/O of/O age/O )/O ,/O of/O which/O CIMZIA/O is/O a/O member/O ./O
Approximately/O half/O the/O cases/O were/O lymphomas/B-AdverseReaction ,/O including/O Hodgkin/O 's/O and/O non/B-AdverseReaction -/I-AdverseReaction Hodgkin/O 's/O lymphoma/O ./O
The/O other/O cases/O represented/O a/O variety/O of/O different/O malignancies/B-AdverseReaction and/O included/O rare/B-AdverseReaction malignancies/I-AdverseReaction usually/O associated/O with/O immunosuppression/O and/O malignancies/B-AdverseReaction that/O are/O not/O usually/O observed/O in/O children/O and/O adolescents/O ./O
The/O malignancies/B-AdverseReaction occurred/O after/O a/O median/O of/O 30/O months/O of/O therapy/O (/O range/O 1/O to/O 84/O months/O )/O ./O
Most/O of/O the/O patients/O were/O receiving/O concomitant/O immunosuppressants/O ./O
These/O cases/O were/O reported/O post/O -/O marketing/O and/O are/O derived/O from/O a/O variety/O of/O sources/O including/O registries/O and/O spontaneous/O post/O -/O marketing/O reports/O ./O
CIMZIA/O is/O not/O indicated/O for/O use/O in/O pediatric/O patients/O ./O
In/O the/O controlled/O portions/O of/O clinical/O trials/O of/O all/O the/O TNF/O blockers/O ,/O more/O cases/O of/O lymphoma/B-AdverseReaction have/O been/O observed/O among/O patients/O receiving/O TNF/B-DrugClass blockers/I-DrugClass compared/O to/O control/O patients/O ./O
In/O controlled/O studies/O of/O CIMZIA/O for/O Crohn/O 's/O disease/O and/O other/O investigational/O uses/O ,/O there/O was/O one/O case/O of/O lymphoma/B-AdverseReaction among/O 2,657/O Cimzia/O -/O treated/O patients/O and/O one/O case/O of/O Hodgkin/B-AdverseReaction 's/I-AdverseReaction lymphoma/O among/O 1,319/O placebo/B-Factor -/O treated/O patients/O ./O
In/O the/O CIMZIA/O RA/O clinical/O trials/O (/O placebo/O -/O controlled/O and/O open/O label/O )/O a/O total/O of/O three/O cases/O of/O lymphoma/B-AdverseReaction were/O observed/O among/O 2,367/O patients/O ./O
This/O is/O approximately/O 2-fold/O higher/O than/O expected/O in/O the/O general/O population/O ./O
Patients/O with/O RA/O ,/O particularly/O those/O with/O highly/O active/O disease/O ,/O are/O at/O a/O higher/O risk/O for/O the/O development/O of/O lymphoma/O ./O
Rates/O in/O clinical/O studies/O for/O CIMZIA/O can/O not/O be/O compared/O to/O the/O rates/O of/O clinical/O trials/O of/O other/O TNF/O blockers/O and/O may/O not/O predict/O the/O rates/O observed/O when/O CIMZIA/O is/O used/O in/O a/O broader/O patient/O population/O ./O
Patients/O with/O Crohn/O 's/O disease/O that/O require/O chronic/O exposure/O to/O immunosuppressant/B-DrugClass therapies/I-DrugClass may/O be/O at/O higher/O risk/O than/O the/O general/O population/O for/O the/O development/O of/O lymphoma/B-AdverseReaction ,/O even/O in/O the/O absence/O of/O TNF/O blocker/O therapy/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
The/O potential/O role/O of/O TNF/O blocker/O therapy/O in/O the/O development/O of/O malignancies/O in/O adults/O is/O not/O known/O ./O
Postmarketing/O cases/O of/O hepatosplenic/B-AdverseReaction T/I-AdverseReaction -/I-AdverseReaction cell/O lymphoma/O (/O HSTCL/B-AdverseReaction )/O ,/O a/O rare/O type/O of/O T/O -/O cell/O lymphoma/O that/O has/O a/O very/O aggressive/O disease/O course/O and/O is/O usually/O fatal/B-AdverseReaction ,/O have/O been/O reported/O in/O patients/O treated/O with/O TNF/O blockers/O ,/O including/O CIMZIA/O ./O
The/O majority/O of/O reported/O TNF/O blocker/O cases/O occurred/O in/O adolescent/O and/O young/O adult/O males/O with/O Crohn/O 's/O disease/O or/O ulcerative/O colitis/O ./O
Almost/O all/O of/O these/O patients/O had/O received/O treatment/O with/O the/O immunosuppressants/O azathioprine/O and/or/O 6-mercaptopurine/O (/O 6-MP/O )/O concomitantly/O with/O a/O TNF/O blocker/O at/O or/O prior/O to/O diagnosis/O ./O
It/O is/O uncertain/O whether/O the/O occurrence/O of/O HSTCL/O is/O related/O to/O use/O of/O a/O TNF/O blocker/O or/O a/O TNF/O blocker/O in/O combination/O with/O these/O other/O immunosuppressants/O ./O
The/O potential/O risk/O of/O using/O a/O TNF/O blocker/O in/O combination/O with/O azathioprine/O or/O 6-MP/O should/O be/O carefully/O considered/O ./O
Cases/O of/O acute/O and/O chronic/B-AdverseReaction leukemia/I-AdverseReaction have/O been/O reported/O in/O association/O with/O post/O -/O marketing/O TNF/B-DrugClass -/O blocker/O use/O in/O RA/O and/O other/O indications/O ./O
Even/O in/O the/O absence/O of/O TNF/O -/O blocker/O therapy/O ,/O patients/O with/O RA/O may/O be/O at/O a/O higher/O risk/O (/O approximately/O 2-fold/O )/O than/O the/O general/O population/O for/O the/O development/O of/O leukemia/O ./O
Periodic/O skin/O examinations/O are/O recommended/O for/O all/O patients/O ,/O particularly/O those/O with/O risk/O factors/O for/O skin/O cancer/O ./O
5.3/O Heart/O Failure/O Cases/O of/O worsening/B-AdverseReaction congestive/I-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction (/O CHF/O )/O and/O new/B-AdverseReaction onset/I-AdverseReaction CHF/I-AdverseReaction have/O been/O reported/O with/O TNF/O blockers/O ,/O including/O CIMZIA/O ./O
CIMZIA/O has/O not/O been/O formally/O studied/O in/O patients/O with/O CHF/O ;/O however/O ,/O in/O clinical/O studies/O in/O patients/O with/O CHF/O with/O another/O TNF/B-DrugClass blocker/I-DrugClass ,/O worsening/B-AdverseReaction congestive/I-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction (/O CHF/O )/O and/O increased/B-AdverseReaction mortality/I-AdverseReaction due/O to/O CHF/B-AdverseReaction were/O observed/O ./O
Exercise/O caution/O in/O patients/O with/O heart/O failure/O and/O monitor/O them/O carefully/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.4/O Hypersensitivity/O Reactions/O The/O following/O symptoms/O that/O could/B-Factor be/O compatible/O with/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O rarely/O following/O CIMZIA/O administration/O to/O patients/O :/O angioedema/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O serum/B-AdverseReaction sickness/I-AdverseReaction ,/O and/O urticaria/B-AdverseReaction ./O
Some/O of/O these/O reactions/O occurred/O after/O the/O first/O administration/O of/O CIMZIA/O ./O
If/O such/O reactions/O occur/O ,/O discontinue/O further/O administration/O of/O CIMZIA/O and/O institute/O appropriate/O therapy/O ./O
There/O are/O no/O data/O on/O the/O risks/O of/O using/O CIMZIA/O in/O patients/O who/O have/O experienced/O a/O severe/O hypersensitivity/O reaction/O towards/O another/O TNF/O blocker/O ;/O in/O these/O patients/O caution/O is/O needed/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.5/O Hepatitis/O B/O Virus/O Reactivation/O Use/O of/O TNF/O blockers/O ,/O including/O CIMZIA/O ,/O has/O been/O associated/O with/O reactivation/B-AdverseReaction of/I-AdverseReaction hepatitis/I-AdverseReaction B/I-AdverseReaction virus/I-AdverseReaction (/O HBV/O )/O in/O patients/O who/O are/O chronic/O carriers/O of/O this/O virus/O ./O
In/O some/O instances/O ,/O HBV/B-AdverseReaction reactivation/I-AdverseReaction occurring/O in/O conjunction/O with/O TNF/B-DrugClass blocker/I-DrugClass therapy/O has/O been/O fatal/B-AdverseReaction ./O
The/O majority/O of/O reports/O have/O occurred/O in/O patients/O concomitantly/O receiving/O other/O medications/O that/O suppress/O the/O immune/O system/O ,/O which/O may/O also/O contribute/O to/O HBV/B-AdverseReaction reactivation/I-AdverseReaction ./O
Test/O patients/O for/O HBV/O infection/O before/O initiating/O treatment/O with/O CIMZIA/O ./O
For/O patients/O who/O test/O positive/O for/O HBV/O infection/O ,/O consultation/O with/O a/O physician/O with/O expertise/O in/O the/O treatment/O of/O hepatitis/O B/O is/O recommended/O ./O
Adequate/O data/O are/O not/O available/O on/O the/O safety/O or/O efficacy/O of/O treating/O patients/O who/O are/O carriers/O of/O HBV/O with/O anti/O -/O viral/O therapy/O in/O conjunction/O with/O TNF/O blocker/O therapy/O to/O prevent/O HBV/O reactivation/O ./O
Patients/O who/O are/O carriers/O of/O HBV/O and/O require/O treatment/O with/O CIMZIA/O should/O be/O closely/O monitored/O for/O clinical/O and/O laboratory/O signs/O of/O active/O HBV/O infection/O throughout/O therapy/O and/O for/O several/O months/O following/O termination/O of/O therapy/O ./O
In/O patients/O who/O develop/O HBV/O reactivation/O ,/O discontinue/O CIMZIA/O and/O initiate/O effective/O anti/O -/O viral/O therapy/O with/O appropriate/O supportive/O treatment/O ./O
The/O safety/O of/O resuming/O TNF/O blocker/O therapy/O after/O HBV/O reactivation/O is/O controlled/O is/O not/O known/O ./O
Therefore/O ,/O exercise/O caution/O when/O considering/O resumption/O of/O CIMZIA/O therapy/O in/O this/O situation/O and/O monitor/O patients/O closely/O ./O
5.6/O Neurologic/O Reactions/O Use/O of/O TNF/B-DrugClass blockers/I-DrugClass ,/O of/O which/O CIMZIA/O is/O a/O member/O ,/O has/O been/O associated/O with/O rare/O cases/O of/O new/O onset/O or/O exacerbation/O of/O clinical/O symptoms/O and/or/O radiographic/O evidence/O of/O central/B-AdverseReaction nervous/I-AdverseReaction system/I-AdverseReaction demyelinating/I-AdverseReaction disease/I-AdverseReaction ,/O including/O multiple/B-AdverseReaction sclerosis/I-AdverseReaction ,/O and/O with/O peripheral/B-AdverseReaction demyelinating/I-AdverseReaction disease/I-AdverseReaction ,/O including/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O ./O
Exercise/O caution/O in/O considering/O the/O use/O of/O CIMZIA/O in/O patients/O with/O pre/O -/O existing/O or/O recent/O -/O onset/O central/O or/O peripheral/O nervous/O system/O demyelinating/O disorders/O ./O
Rare/O cases/O of/O neurological/B-AdverseReaction disorders/I-AdverseReaction ,/O including/O seizure/B-AdverseReaction disorder/I-AdverseReaction ,/O optic/B-AdverseReaction neuritis/I-AdverseReaction ,/O and/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction have/O been/O reported/O in/O patients/O treated/O with/O CIMZIA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.7/O Hematological/O Reactions/O Rare/O reports/O of/O pancytopenia/B-AdverseReaction ,/O including/O aplastic/B-AdverseReaction anemia/I-AdverseReaction ,/O have/O been/O reported/O with/O TNF/B-DrugClass blockers/I-DrugClass ./O
Adverse/B-AdverseReaction reactions/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction hematologic/I-AdverseReaction system/I-AdverseReaction ,/O including/O medically/B-Severity significant/I-Severity cytopenia/B-AdverseReaction (/O e.g./O ,/O leukopenia/B-AdverseReaction ,/O pancytopenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction )/O have/O been/O infrequently/O reported/O with/O CIMZIA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
The/O causal/O relationship/O of/O these/O events/O to/O CIMZIA/O remains/O unclear/O ./O
Although/O no/O high/O risk/O group/O has/O been/O identified/O ,/O exercise/O caution/O in/O patients/O being/O treated/O with/O CIMZIA/O who/O have/O ongoing/O ,/O or/O a/O history/O of/O ,/O significant/O hematologic/O abnormalities/O ./O
Advise/O all/O patients/O to/O seek/O immediate/O medical/O attention/O if/O they/O develop/O signs/O and/O symptoms/O suggestive/O of/O blood/O dyscrasias/O or/O infection/O (/O e.g./O ,/O persistent/O fever/O ,/O bruising/O ,/O bleeding/O ,/O pallor/O )/O while/O on/O CIMZIA/O ./O
Consider/O discontinuation/O of/O CIMZIA/O therapy/O in/O patients/O with/O confirmed/O significant/O hematologic/O abnormalities/O ./O
5.8/O Use/O with/O Biological/O Disease/O -/O Modifying/O Antirheumatic/O Drugs/O (/O Biological/O DMARDs/O )/O Serious/B-Severity infections/B-AdverseReaction were/O seen/O in/O clinical/O studies/O with/O concurrent/O use/O of/O anakinra/O (/O an/O interleukin-1/O antagonist/O )/O and/O another/O TNF/O blocker/O ,/O etanercept/B-DrugClass ,/O with/O no/O added/O benefit/O compared/O to/O etanercept/O alone/O ./O
A/O higher/O risk/B-Factor of/O serious/B-Severity infections/B-AdverseReaction was/O also/O observed/O in/O combination/O use/O of/O TNF/B-DrugClass blockers/I-DrugClass with/O abatacept/O and/O rituximab/O ./O
Because/O of/O the/O nature/O of/O the/O adverse/O events/O seen/O with/O this/O combination/O therapy/O ,/O similar/O toxicities/O may/O also/O result/O from/O the/O use/O of/O CIMZIA/O in/O this/O combination/O ./O
Therefore/O ,/O the/O use/O of/O CIMZIA/O in/O combination/O with/O other/O biological/O DMARDs/O is/O not/O recommended/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
5.9/O Autoimmunity/O Treatment/O with/O CIMZIA/O may/B-Factor result/O in/O the/O formation/B-AdverseReaction of/I-AdverseReaction autoantibodies/I-AdverseReaction and/O rarely/O ,/O in/O the/O development/O of/O a/O lupus/B-AdverseReaction -/I-AdverseReaction like/O syndrome/O ./O
If/O a/O patient/O develops/O symptoms/O suggestive/O of/O a/O lupus/O -/O like/O syndrome/O following/O treatment/O with/O CIMZIA/O ,/O discontinue/O treatment/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.10/O Immunizations/O Patients/O treated/O with/O CIMZIA/O may/O receive/O vaccinations/O ,/O except/O for/O live/O or/O live/O attenuated/O vaccines/O ./O
No/O data/O are/O available/O on/O the/O response/O to/O live/O vaccinations/O or/O the/O secondary/O transmission/O of/O infection/O by/O live/O vaccines/O in/O patients/O receiving/O CIMZIA/O ./O
In/O a/O placebo/O -/O controlled/O clinical/O trial/O of/O patients/O with/O rheumatoid/O arthritis/O ,/O no/O difference/O was/O detected/O in/O antibody/O response/O to/O vaccine/O between/O CIMZIA/O and/O placebo/O treatment/O groups/O when/O the/O pneumococcal/O polysaccharide/O vaccine/O and/O influenza/O vaccine/O were/O administered/O concurrently/O with/O CIMZIA/O ./O
Similar/O proportions/O of/O patients/O developed/O protective/O levels/O of/O anti/O -/O vaccine/O antibodies/O between/O CIMZIA/O and/O placebo/O treatment/O groups/O ;/O however/O patients/O receiving/O CIMZIA/O and/O concomitant/O methotrexate/O had/O a/O lower/O humoral/O response/O compared/O with/O patients/O receiving/O CIMZIA/O alone/O ./O
The/O clinical/O significance/O of/O this/O is/O unknown/O ./O
5.11/O Immunosuppression/O Since/O TNF/O mediates/O inflammation/O and/O modulates/O cellular/O immune/O responses/O ,/O the/O possibility/O exists/O for/O TNF/O blockers/O ,/O including/O CIMZIA/O ,/O to/O affect/O host/O defenses/O against/O infections/O and/O malignancies/O ./O
The/O impact/O of/O treatment/O with/O CIMZIA/O on/O the/O development/O and/O course/O of/O malignancies/O ,/O as/O well/O as/O active/O and/or/O chronic/O infections/O ,/O is/O not/O fully/O understood/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O ,/O 5.2/O ,/O 5.5/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
The/O safety/O and/O efficacy/O of/O CIMZIA/O in/O patients/O with/O immunosuppression/O has/O not/O been/O formally/O evaluated/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O risk/O is/O discussed/O elsewhere/O in/O the/O labeling/O :/O Hypotension/B-AdverseReaction and/O Reflex/B-AdverseReaction Tachycardia/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 2/O %/O )/O are/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O The/O Medicines/O Company/O at/O 1/O -/O 888/O -/O 977-MDCO/O (/O 6326/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Cleviprex/O clinical/O development/O included/O 19/O studies/O ,/O with/O 99/O healthy/O subjects/O and/O 1307/O hypertensive/O patients/O who/O received/O at/O least/O one/O dose/O of/O clevidipine/O (/O 1406/O total/O exposures/O )/O ./O
Clevidipine/O was/O evaluated/O in/O 15/O studies/O in/O hypertensive/O patients/O :/O 1099/O patients/O with/O perioperative/O hypertension/O ,/O 126/O with/O severe/O hypertension/O and/O 82/O patients/O with/O essential/O hypertension/O ./O
The/O desired/O therapeutic/O response/O was/O achieved/O at/O doses/O of/O 4/O -/O 6/O mg/O hour/O ./O
Cleviprex/O was/O infused/O for/O 24/O hours/O in/O the/O majority/O of/O patients/O (/O n=1199/O )/O ;/O it/O was/O infused/O as/O a/O continuous/O infusion/O in/O an/O additional/O 93/O patients/O for/O durations/O between/O 24/O and/O 72/O hours/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Perioperative/O Hypertension/O The/O placebo/O -/O controlled/O experience/O with/O Cleviprex/O in/O the/O perioperative/O setting/O was/O both/O small/O and/O brief/O (/O about/O 30/O minutes/O )/O ./O
Table/O 2/O shows/O treatment/O -/O emergent/O adverse/O reactions/O and/O the/O category/O of/O "/O any/O common/O adverse/O event/O "/O in/O ESCAPE-1/O and/O ESCAPE-2/O where/O the/O rate/O on/O Cleviprex/O exceeded/O the/O rate/O on/O placebo/O by/O at/O least/O 5/O %/O (/O common/O adverse/O reactions/O )/O ./O
Table/O 2/O ./O
Common/O adverse/O reactions/O in/O placebo/O -/O controlled/O perioperative/O studies/O ./O
ESCAPE-1/O ESCAPE-2/O CLVN=53(%/O )/O PBON=51(%/O )/O CLVN=61(%/O )/O PBON=49(%/O )/O Any/O common/O adverse/O event/O 27/O (/O 51/O %/O )/O 21/O (/O 41/O %/O )/O 32/O (/O 53/O %/O )/O 24/O (/O 49/O %/O )/O Acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction 5/O (/O 9/O %/O )/O 1/O (/O 2/O %/O )/O --/O --/O Atrial/B-AdverseReaction fibrillation/I-AdverseReaction --/O --/O 13/O (/O 21/O %/O )/O 6/O (/O 12/O %/O )/O Nausea/B-AdverseReaction --/O --/O 13/O (/O 21/O %/O )/O 6/O (/O 12/O %/O )/O Three/O randomized/O ,/O parallel/O ,/O open/O -/O label/O studies/O called/O ECLIPSE/O ,/O with/O longer/O exposure/O in/O cardiac/O surgery/O patients/O define/O the/O adverse/O reactions/O for/O patients/O with/O perioperative/O hypertension/O ./O
Each/O ECLIPSE/O study/O compared/O Cleviprex/O (/O n=752/O )/O to/O an/O active/O comparator/O :/O nitroglycerin/O (/O NTG/O ,/O n=278/O )/O ,/O sodium/O nitroprusside/O (/O SNP/O ,/O n=283/O )/O ,/O or/O nicardipine/O (/O NIC/O ,/O n=193/O )/O ./O
The/O pooled/O mean/O maximum/O dose/O in/O these/O studies/O was/O 10/O mg/O hour/O and/O the/O mean/O duration/O of/O treatment/O was/O 8/O hours/O ./O
There/O were/O many/O adverse/O events/O associated/O with/O the/O operative/O procedure/O in/O the/O clinical/O studies/O of/O Cleviprex/O and/O relatively/O few/O plausibly/O related/O to/O the/O drugs/O used/O to/O lower/O blood/O pressure/O ./O
Thus/O ,/O the/O ability/O to/O differentiate/O the/O adverse/O event/O profile/O between/O treatments/O is/O limited/O ./O
The/O adverse/O events/O observed/O within/O one/O hour/O of/O the/O end/O of/O the/O infusion/O were/O similar/O in/O patients/O who/O received/O Cleviprex/O and/O in/O those/O who/O received/O comparator/O agents/O ./O
There/O was/O no/O adverse/O reaction/O that/O was/O more/O than/O 2/O %/O more/O common/O on/O Cleviprex/O than/O on/O the/O average/O of/O all/O comparators/O ./O
Serious/O Adverse/O Events/O and/O Discontinuation/O -/O Perioperative/O Hypertension/O Studies/O The/O incidence/O of/O adverse/O events/O leading/O to/O study/O drug/O discontinuation/O in/O patients/O with/O perioperative/O hypertension/O receiving/O Cleviprex/O was/O 5.9/O %/O versus/O 3.2/O %/O for/O all/O active/O comparators/O ./O
For/O patients/O receiving/O Cleviprex/O and/O all/O active/O comparators/O the/O incidence/O of/O serious/O adverse/O events/O within/O one/O hour/O of/O drug/O infusion/O discontinuation/O was/O similar/O ./O
Severe/O Hypertension/O The/O adverse/O events/O for/O patients/O with/O severe/O hypertension/O are/O based/O on/O an/O uncontrolled/O study/O in/O patients/O with/O severe/O hypertension/O (/O VELOCITY/O ,/O n=126/O )/O ./O
The/O common/O adverse/O reactions/O for/O Cleviprex/O in/O severe/O hypertension/O included/O headache/B-AdverseReaction (/O 6.3/O %/O )/O ,/O nausea/B-AdverseReaction (/O 4.8/O %/O )/O ,/O and/O vomiting/B-AdverseReaction (/O 3.2/O %/O )/O ./O
The/O incidence/O of/O adverse/O events/O leading/O to/O study/O drug/O discontinuation/O for/O Cleviprex/O in/O severe/O hypertension/O was/O 4.8/O %/O ./O
Less/O Common/O Adverse/O Reactions/O in/O Patients/O with/O Severe/O or/O Essential/O Hypertension/O Adverse/O reactions/O that/O were/O reported/O in/O 1/O %/O of/O patients/O with/O severe/O or/O essential/O hypertension/O included/O :/O Cardiac/O :/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O cardiac/B-AdverseReaction arrestNervous/I-AdverseReaction system/O :/O syncopeRespiratory/B-AdverseReaction :/O dyspnea/B-AdverseReaction 6.2/O Post/O -/O Marketing/O and/O Other/O Clinical/O Experience/O Because/O adverse/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O estimate/O reliably/O their/O frequency/O or/O to/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O Cleviprex/O :/O increased/B-AdverseReaction blood/I-AdverseReaction triglycerides/I-AdverseReaction ,/O ileus/B-AdverseReaction ,/O hypersensitivity/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O decreased/B-AdverseReaction oxygen/I-AdverseReaction saturation/I-AdverseReaction (/O possible/B-Factor pulmonary/B-AdverseReaction shunting/I-AdverseReaction )/O and/O reflex/B-AdverseReaction tachycardia/I-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Maintain/O aseptic/O technique/O ./O
Discard/O unused/O portion/O 12/O hours/O after/O stopper/O puncture/O ./O
(/O 5.1/O )/O Hypotension/B-AdverseReaction and/O reflex/B-AdverseReaction tachycardia/I-AdverseReaction are/O potential/B-Factor consequences/O of/O rapid/O upward/O titration/O of/O Cleviprex/O ./O
(/O 5.2/O )/O Dihydropyridine/B-DrugClass calcium/I-DrugClass channel/I-DrugClass blockers/I-DrugClass can/O produce/O negative/B-AdverseReaction inotropic/I-AdverseReaction effects/I-AdverseReaction and/O exacerbate/B-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction ./O
Monitor/O heart/O failure/O patients/O carefully/O ./O
(/O 5.4/O )/O Cleviprex/O gives/O no/O protection/O against/O the/O effects/O of/O abrupt/O beta/O -/O blocker/O withdrawal/O ./O
(/O 5.5/O )/O Patients/O who/O receive/O prolonged/O Cleviprex/O infusions/O and/O are/O not/O transitioned/O to/O other/O antihypertensive/O therapies/O should/O be/O monitored/O for/O the/O possibility/O of/O rebound/O hypertension/O for/O at/O least/O 8/O hours/O after/O the/O infusion/O is/O stopped/O ./O
(/O 5.6/O )/O 5.1/O Need/O for/O Aseptic/O Technique/O Use/O aseptic/O technique/O and/O discard/O any/O unused/O product/O within/O 12/O hours/O of/O stopper/O puncture/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.2/O Hypotension/O and/O Reflex/O Tachycardia/O Cleviprex/O may/B-Factor produce/O systemic/B-AdverseReaction hypotension/I-AdverseReaction and/O reflex/B-AdverseReaction tachycardia/I-AdverseReaction ./O
If/O either/O occurs/O ,/O decrease/O the/O dose/O of/O Cleviprex/O ./O
There/O is/O limited/O experience/O with/O short/O -/O duration/O therapy/O with/O beta/O -/O blockers/O as/O a/O treatment/O for/O Cleviprex/O -/O induced/O tachycardia/O ./O
Beta/O -/O blocker/O use/O for/O this/O purpose/O is/O not/O recommended/O ./O
5.3/O Lipid/O Intake/O Cleviprex/O contains/O approximately/O 0.2/O g/O of/O lipid/O per/O mL/O (/O 2.0/O kcal/O )/O ./O
Lipid/O intake/O restrictions/O may/O be/O necessary/O for/O patients/O with/O significant/O disorders/O of/O lipid/O metabolism/O ./O
For/O these/O patients/O ,/O a/O reduction/O in/O the/O quantity/O of/O concurrently/O administered/O lipids/O may/O be/O necessary/O to/O compensate/O for/O the/O amount/O of/O lipid/O infused/O as/O part/O of/O the/O Cleviprex/O formulation/O ./O
5.4/O Negative/O Inotropy/O Dihydropyridine/B-DrugClass calcium/I-DrugClass channel/I-DrugClass blockers/I-DrugClass can/O produce/O negative/B-AdverseReaction inotropic/I-AdverseReaction effects/I-AdverseReaction and/O exacerbate/B-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction ./O
Monitor/O heart/O failure/O patients/O carefully/O ./O
5.5/O Beta/O -/O Blocker/O Withdrawal/O Cleviprex/O is/O not/O a/O beta/O -/O blocker/O ,/O does/O not/O reduce/O heart/O rate/O ,/O and/O gives/O no/O protection/O against/O the/O effects/O of/O abrupt/O beta/O -/O blocker/O withdrawal/O ./O
Beta/O -/O blockers/O should/O be/O withdrawn/O only/O after/O a/O gradual/O reduction/O in/O dose/O ./O
5.6/O Rebound/O Hypertension/O Patients/O who/O receive/O prolonged/O Cleviprex/O infusions/O and/O are/O not/O transitioned/O to/O other/O antihypertensive/O therapies/O should/O be/O monitored/O for/O the/O possibility/O of/O rebound/O hypertension/O for/O at/O least/O 8/O hours/O after/O the/O infusion/O is/O stopped/O ./O
5.7/O Pheochromocytoma/O There/O is/O no/O information/O to/O guide/O use/O of/O Cleviprex/O in/O treating/O hypertension/O associated/O with/O pheochromocytoma/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O in/O adults/O (/O 30/O %/O )/O are/O headache/B-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O arthralgia/B-AdverseReaction and/O myalgia/B-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O in/O children/O (/O 12/O %/O )/O are/O pyrexia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
(/O 6.2/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Novartis/O Pharmaceuticals/O Corporation/O at/O 1/O -/O 888/O -/O 669/O -/O 6682/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Serious/O Adverse/O Reactions/O The/O following/O serious/O and/O otherwise/O important/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O labeling/O :/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O and/O Adverse/O Reactions/O (/O 6.3/O )/O ]/O ./O
6.2/O Clinical/O Studies/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rate/O observed/O in/O practice/O ./O
The/O data/O described/O below/O reflect/O exposure/O to/O a/O 6-dose/O regimen/O of/O Coartem/O Tablets/O in/O 1,979/O patients/O including/O 647/O adults/O (/O older/O than/O 16/O years/O )/O and/O 1,332/O children/O (/O 16/O years/O and/O younger/O )/O ./O
For/O the/O 6-dose/O regimen/O ,/O Coartem/O Tablets/O was/O studied/O in/O active/O -/O controlled/O (/O 366/O patients/O )/O and/O non/O -/O controlled/O ,/O open/O -/O label/O trials/O (/O 1,613/O patients/O )/O ./O
The/O 6-dose/O Coartem/O Tablets/O population/O was/O patients/O with/O malaria/O between/O ages/O 2/O months/O and/O 71/O years/O :/O 67/O %/O (/O 1,332/O )/O were/O 16/O years/O and/O younger/O and/O 33/O %/O (/O 647/O )/O were/O older/O than/O 16/O years/O ./O
Males/O represented/O 73/O %/O and/O 53/O %/O of/O the/O adult/O and/O pediatric/O populations/O ,/O respectively/O ./O
The/O majority/O of/O adult/O patients/O were/O enrolled/O in/O studies/O in/O Thailand/O ,/O while/O the/O majority/O of/O pediatric/O patients/O were/O enrolled/O in/O Africa/O ./O
Tables/O 1/O and/O 2/O show/O the/O most/O frequently/O reported/O adverse/O reactions/O (/O =3/O %/O )/O in/O adults/O and/O children/O respectively/O who/O received/O the/O 6-dose/O regimen/O of/O Coartem/O Tablets/O ./O
Adverse/O reactions/O collected/O in/O clinical/O trials/O included/O signs/O and/O symptoms/O at/O baseline/O but/O only/O treatment/O emergent/O adverse/O events/O ,/O defined/O as/O events/O that/O appeared/O or/O worsened/O after/O the/O start/O of/O treatment/O ,/O are/O presented/O below/O ./O
In/O adults/O ,/O the/O most/O frequently/O reported/O adverse/O reactions/O were/O headache/B-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O and/O asthenia/B-AdverseReaction ./O
In/O children/O ,/O the/O adverse/O reactions/O were/O pyrexia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
Most/O adverse/O reactions/O were/O mild/O ,/O did/O not/O lead/O to/O discontinuation/O of/O study/O medication/O ,/O and/O resolved/O ./O
In/O limited/O comparative/O studies/O ,/O the/O adverse/O reaction/O profile/O of/O Coartem/O Tablets/O appeared/O similar/O to/O that/O of/O another/O antimalarial/O regimen/O ./O
Discontinuation/O of/O Coartem/O Tablets/O due/O to/O adverse/O drug/O reactions/O occurred/O in/O 1.1/O %/O of/O patients/O treated/O with/O the/O 6-dose/O regimen/O overall/O :/O 0.2/O %/O (/O 1/647/O )/O in/O adults/O and/O 1.6/O %/O (/O 21/1,332/O )/O in/O children/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Occurring/O in/O 3/O %/O or/O More/O of/O Adult/O Patients/O Treated/O in/O Clinical/O Trials/O with/O the/O 6-dose/O Regimen/O of/O Coartem/O Tablets/O System/O Organ/O Class/O Preferred/O Term/O Adults/O N=647/O (/O %/O )/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 360/O (/O 56/O )/O Dizziness/B-AdverseReaction 253/O (/O 39/O )/O Metabolism/O and/O nutrition/O disorders/O Anorexia/B-AdverseReaction 260/O (/O 40/O )/O General/O disorders/O and/O administration/O site/O conditions/O Asthenia/B-AdverseReaction 243/O (/O 38/O )/O Pyrexia/B-AdverseReaction 159/O (/O 25/O )/O Chills/B-AdverseReaction 147/O (/O 23/O )/O Fatigue/B-AdverseReaction 111/O (/O 17/O )/O Malaise/B-AdverseReaction 20/O (/O 3/O )/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 219/O (/O 34/O )/O Myalgia/B-AdverseReaction 206/O (/O 32/O )/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 169/O (/O 26/O )/O Vomiting/B-AdverseReaction 113/O (/O 17/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 112/O (/O 17/O )/O Diarrhea/B-AdverseReaction 46/O (/O 7/O )/O Psychiatric/O disorders/O Sleep/B-AdverseReaction disorder/I-AdverseReaction 144/O (/O 22/O )/O Insomnia/B-AdverseReaction 32/O (/O 5/O )/O Cardiac/O disorders/O Palpitations/B-AdverseReaction 115/O (/O 18/O )/O Hepatobiliary/O disorders/O Hepatomegaly/B-AdverseReaction 59/O (/O 9/O )/O Blood/O and/O lymphatic/O system/O disorders/O Splenomegaly/B-AdverseReaction 57/O (/O 9/O )/O Anemia/B-AdverseReaction 23/O (/O 4/O )/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 37/O (/O 6/O )/O Skin/O and/O subcutaneous/O tissue/O disorders/O Pruritus/B-AdverseReaction 24/O (/O 4/O )/O Rash/B-AdverseReaction 21/O (/O 3/O )/O Ear/O and/O labyrinth/O disorders/O Vertigo/B-AdverseReaction 21/O (/O 3/O )/O Infections/O and/O infestations/O Malaria/B-AdverseReaction 18/O (/O 3/O )/O Nasopharyngitis/B-AdverseReaction 17/O (/O 3/O )/O Adult/O patients/O defined/O as/O 16/O years/O of/O age/O Table/O 2/O :/O Adverse/O Reactions/O Occurring/O in/O 3/O %/O or/O More/O of/O Pediatric/O Patients/O Treated/O in/O Clinical/O Trials/O with/O the/O 6-dose/O Regimen/O of/O Coartem/O Tablets/O System/O Organ/O Class/O Preferred/O Term/O Children/O N=1,332/O (/O %/O )/O General/O disorders/O and/O administration/O site/O conditions/O Pyrexia/B-AdverseReaction 381/O (/O 29/O )/O Chills/B-AdverseReaction 72/O (/O 5/O )/O Asthenia/B-AdverseReaction 63/O (/O 5/O )/O Fatigue/B-AdverseReaction 46/O (/O 3/O )/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 302/O (/O 23/O )/O Gastrointestinal/O disorders/O Vomiting/B-AdverseReaction 242/O (/O 18/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 112/O (/O 8)/O Diarrhea/B-AdverseReaction 100/O (/O 8)/O Nausea/B-AdverseReaction 61/O (/O 5/O )/O Infections/O and/O infestations/O Plasmodium/B-AdverseReaction falciparum/I-AdverseReaction infection/O 224/O (/O 17/O )/O Rhinitis/B-AdverseReaction 51/O (/O 4/O )/O Metabolism/O and/O nutrition/O disorders/O Anorexia/B-AdverseReaction 175/O (/O 13/O )/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 168/O (/O 13/O )/O Dizziness/B-AdverseReaction 56/O (/O 4/O )/O Blood/O and/O lymphatic/O system/O disorders/O Splenomegaly/B-AdverseReaction 124/O (/O 9/O )/O Anemia/B-AdverseReaction 115/O (/O 9/O )/O Hepatobiliary/O disorders/O Hepatomegaly/B-AdverseReaction 75/O (/O 6/O )/O Investigations/O Aspartate/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction 51/O (/O 4/O )/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 39/O (/O 3/O )/O Myalgia/B-AdverseReaction 39/O (/O 3/O )/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 38/O (/O 3/O )/O Children/O defined/O as/O patients/O 16/O years/O of/O age/O Clinically/O significant/O adverse/O reactions/O reported/O in/O adults/O and/or/O children/O treated/O with/O the/O 6-dose/O regimen/O of/O Coartem/O Tablets/O which/O occurred/O in/O clinical/O studies/O at/O <3/O %/O regardless/O of/O causality/O are/O listed/O below/O :/O Blood/O and/O lymphatic/O system/O disorders/O :/O eosinophilia/B-AdverseReaction Ear/O and/O labyrinth/O disorders/O :/O tinnitus/B-AdverseReaction Eye/O disorders/O :/O conjunctivitis/B-AdverseReaction Gastrointestinal/O disorders/O :/O constipation/B-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O peptic/B-AdverseReaction ulcer/I-AdverseReaction General/O disorders/O :/O gait/B-AdverseReaction disturbance/I-AdverseReaction Infections/O and/O infestations/O :/O abscess/B-AdverseReaction ,/O acrodermatitis/B-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O ear/B-AdverseReaction infection/I-AdverseReaction ,/O gastroenteritis/B-AdverseReaction ,/O helminthic/B-AdverseReaction infection/O ,/O hookworm/B-AdverseReaction infection/I-AdverseReaction ,/O impetigo/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O lower/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O malaria/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O oral/B-AdverseReaction herpes/I-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O subcutaneous/B-AdverseReaction abscess/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction Investigations/O :/O alanine/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O aspartate/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O hematocrit/B-AdverseReaction decreased/O ,/O lymphocyte/B-AdverseReaction morphology/I-AdverseReaction abnormal/I-AdverseReaction ,/O platelet/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction ,/O platelet/B-AdverseReaction count/I-AdverseReaction increased/I-AdverseReaction ,/O white/B-AdverseReaction blood/I-AdverseReaction cell/I-AdverseReaction count/I-AdverseReaction decreased/O ,/O white/B-AdverseReaction blood/I-AdverseReaction cell/I-AdverseReaction count/I-AdverseReaction increased/I-AdverseReaction Metabolism/O and/O nutrition/O disorders/O :/O hypokalemia/B-AdverseReaction Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O back/B-AdverseReaction pain/I-AdverseReaction Nervous/O system/O disorders/O :/O ataxia/B-AdverseReaction ,/O clonus/B-AdverseReaction ,/O fine/B-AdverseReaction motor/I-AdverseReaction delay/I-AdverseReaction ,/O hyperreflexia/B-AdverseReaction ,/O hypoesthesia/B-AdverseReaction ,/O nystagmus/B-AdverseReaction ,/O tremor/B-AdverseReaction Psychiatric/O disorders/O :/O agitation/B-AdverseReaction ,/O mood/B-AdverseReaction swings/I-AdverseReaction Renal/O and/O urinary/O disorders/O :/O hematuria/B-AdverseReaction ,/O proteinuria/B-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O asthma/B-AdverseReaction ,/O pharyngo/B-AdverseReaction -/I-AdverseReaction laryngeal/O pain/O Skin/O and/O subcutaneous/O tissue/O disorders/O :/O urticaria/B-AdverseReaction 6.3/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O Coartem/O Tablets/O ./O
Because/O these/O events/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Hypersensitivity/O reactions/O :/O anaphylaxis/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O and/O serious/B-Severity skin/B-AdverseReaction reactions/I-AdverseReaction (/O bullous/B-AdverseReaction eruption/I-AdverseReaction )/O have/O been/O reported/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Avoid/O use/O in/O patients/O with/O known/O QT/O prolongation/O ,/O those/O with/O hypokalemia/O or/O hypomagnesemia/O ,/O and/O those/O taking/O other/O drugs/O that/O prolong/O the/O QT/O interval/O ./O
(/O 5.1,12.6/O )/O Halofantrine/O and/O Coartem/O Tablets/O should/O not/O be/O administered/O within/O one/O month/O of/O each/O other/O due/O to/O potential/O additive/O effects/O on/O the/O QT/O interval/O ./O
(/O 5.1,5.2,12.3/O )/O Antimalarials/O should/O not/O be/O given/O concomitantly/O ,/O unless/O there/O is/O no/O other/O treatment/O option/O ,/O due/O to/O limited/O safety/O data/O ./O
(/O 5.2/O )/O QT/O prolonging/O drugs/O ,/O including/O quinine/O and/O quinidine/O ,/O should/O be/O used/O cautiously/O following/O Coartem/O Tablets/O ./O
(/O 5.1,5.2,7.7,12.3/O )/O Substrates/O ,/O inhibitors/O ,/O or/O inducers/O of/O CYP3A4/O ,/O including/O antiretroviral/O medications/O ,/O should/O be/O used/O cautiously/O with/O Coartem/O Tablets/O ,/O due/O to/O a/O potential/O loss/O of/O efficacy/O of/O the/O concomitant/O drug/O or/O additive/O QT/O prolongation/O ./O
(/O 5.3,7.2,7.3/O )/O 5.1/O Prolongation/O of/O the/O QT/O Interval/O Some/O antimalarials/O (/O e.g./O ,/O halofantrine/O ,/O quinine/O ,/O quinidine/O )/O including/O Coartem/O Tablets/O have/O been/O associated/O with/O prolongation/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction QT/I-AdverseReaction interval/I-AdverseReaction on/O the/O electrocardiogram/O ./O
Coartem/O Tablets/O should/O be/O avoided/O in/O patients/O :/O with/O congenital/O prolongation/O of/O the/O QT/O interval/O (/O e.g./O ,/O long/O QT/O syndrome/O )/O or/O any/O other/O clinical/O condition/O known/O to/O prolong/O the/O QTc/O interval/O such/O as/O patients/O with/O a/O history/O of/O symptomatic/O cardiac/O arrhythmias/O ,/O with/O clinically/O relevant/O bradycardia/O or/O with/O severe/O cardiac/O disease/O ./O
with/O a/O family/O history/O of/O congenital/O prolongation/O of/O the/O QT/O interval/O or/O sudden/O death/O ./O
with/O known/O disturbances/O of/O electrolyte/O balance/O ,/O e.g./O ,/O hypokalemia/O or/O hypomagnesemia/O ./O
receiving/O other/O medications/O that/O prolong/O the/O QT/O interval/O ,/O such/O as/O class/O IA/O (/O quinidine/O ,/O procainamide/O ,/O disopyramide/O )/O ,/O or/O class/O III/O (/O amiodarone/O ,/O sotalol/O )/O antiarrhythmic/O agents/O ;/O antipsychotics/O (/O pimozide/O ,/O ziprasidone/O )/O ;/O antidepressants/O ;/O certain/O antibiotics/O (/O macrolide/O antibiotics/O ,/O fluoroquinolone/O antibiotics/O ,/O imidazole/O ,/O and/O triazole/O antifungal/O agents/O )/O [/O see/O Clinical/O Pharmacology/O (/O 12.6/O )/O ]/O ./O
receiving/O medications/O that/O are/O metabolized/O by/O the/O cytochrome/O enzyme/O CYP2D6/O which/O also/O have/O cardiac/O effects/O (/O e.g./O ,/O flecainide/O ,/O imipramine/O ,/O amitriptyline/O ,/O clomipramine/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ,/O Drug/O Interactions/O (/O 7.6/O )/O ,/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.2/O Use/O of/O QT/O Prolonging/O Drugs/O and/O Other/O Antimalarials/O Halofantrine/O and/O Coartem/O Tablets/O should/O not/O be/O administered/O within/O 1/O month/O of/O each/O other/O due/O to/O the/O long/O elimination/O half/O -/O life/O of/O lumefantrine/O (/O 3/O to/O 6/O days/O )/O and/O potential/O additive/O effects/O on/O the/O QT/O interval/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
Antimalarials/O should/O not/O be/O given/O concomitantly/O with/O Coartem/O Tablets/O ,/O unless/O there/O is/O no/O other/O treatment/O option/O ,/O due/O to/O limited/O safety/O data/O ./O
Drugs/O that/O prolong/O the/O QT/O interval/O ,/O including/O antimalarials/O such/O as/O quinine/O and/O quinidine/O ,/O should/O be/O used/O cautiously/O following/O Coartem/O Tablets/O ,/O due/O to/O the/O long/O elimination/O half/O -/O life/O of/O lumefantrine/O (/O 3/O to/O 6/O days/O )/O and/O the/O potential/O for/O additive/O effects/O on/O the/O QT/O interval/O ;/O ECG/O monitoring/O is/O advised/O if/O use/O of/O drugs/O that/O prolong/O the/O QT/O interval/O is/O medically/O required/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O Drug/O Interactions/O (/O 7.7/O )/O ,/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
If/O mefloquine/O is/O administered/O immediately/O prior/O to/O Coartem/O Tablets/O there/O may/O be/O a/O decreased/O exposure/O to/O lumefantrine/O ,/O possibly/O due/O to/O a/O mefloquine/O -/O induced/O decrease/O in/O bile/O production/O ./O
Therefore/O ,/O patients/O should/O be/O monitored/O for/O decreased/O efficacy/O and/O food/O consumption/O should/O be/O encouraged/O while/O taking/O Coartem/O Tablets/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ,/O Drug/O Interactions/O (/O 7.4/O )/O ,/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.3/O Drug/O Interactions/O with/O CYP3A4/O When/O Coartem/O Tablets/O are/O coadministered/O with/O substrates/O of/O CYP3A4/O it/O may/O result/O in/O decreased/O concentrations/O of/O the/O substrate/O and/O potential/O loss/O of/O substrate/O efficacy/O ./O
When/O Coartem/O Tablets/O are/O coadministered/O with/O an/O inhibitor/O of/O CYP3A4/O ,/O including/O grapefruit/O juice/O it/O may/B-Factor result/O in/O increased/O concentrations/O of/O artemether/O and/or/O lumefantrine/O and/O potentiate/O QT/B-AdverseReaction prolongation/I-AdverseReaction ./O
When/O Coartem/O Tablets/O are/O coadministered/O with/O inducers/O of/O CYP3A4/O it/O may/O result/O in/O decreased/O concentrations/O of/O artemether/O and/or/O lumefantrine/O and/O loss/O of/O antimalarial/O efficacy/O [/O see/O Contraindications/O (/O 4/O )/O and/O Drug/O Interactions/O (/O 7/O )/O ]/O ./O
Drugs/O that/O have/O a/O mixed/O effect/O on/O CYP3A4/O ,/O especially/O antiretroviral/O drugs/O such/O as/O HIV/O protease/O inhibitors/O and/O non/O -/O nucleoside/O reverse/O transcriptase/O inhibitors/O ,/O and/O those/O that/O have/O an/O effect/O on/O the/O QT/O interval/O should/O be/O used/O with/O caution/O in/O patients/O taking/O Coartem/O Tablets/O [/O see/O Drug/O Interactions/O (/O 7.3/O ,/O 7.7/O )/O ]/O ./O
Coartem/O Tablets/O may/O reduce/O the/O effectiveness/O of/O hormonal/O contraceptives/O ./O
Therefore/O ,/O patients/O using/O oral/O ,/O transdermal/O patch/O ,/O or/O other/O systemic/O hormonal/O contraceptives/O should/O be/O advised/O to/O use/O an/O additional/O non/O -/O hormonal/O method/O of/O birth/O control/O [/O see/O Drug/O Interactions/O (/O 7.5/O )/O ]/O ./O
5.4/O Drug/O Interactions/O with/O CYP2D6/O Administration/O of/O Coartem/O Tablets/O with/O drugs/O that/O are/O metabolized/O by/O CYP2D6/O may/O significantly/O increase/O plasma/O concentrations/O of/O the/O coadministered/O drug/O and/O increase/O the/O risk/O of/O adverse/O effects/O ./O
Many/O of/O the/O drugs/O metabolized/O by/O CYP2D6/O can/O prolong/O the/O QT/O interval/O and/O should/O not/O be/O administered/O with/O Coartem/O Tablets/O due/O to/O the/O potential/O additive/O effect/O on/O the/O QT/O interval/O (/O e.g./O ,/O flecainide/O ,/O imipramine/O ,/O amitriptyline/O ,/O clomipramine/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O Drug/O Interactions/O (/O 7.6/O )/O ,/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.5/O Recrudescence/O Food/O enhances/O absorption/O of/O artemether/O and/O lumefantrine/O following/O administration/O of/O Coartem/O Tablets/O ./O
Patients/O who/O remain/O averse/O to/O food/O during/O treatment/O should/O be/O closely/O monitored/O as/O the/O risk/O of/O recrudescence/O may/O be/O greater/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
In/O the/O event/O of/O recrudescent/O P./O falciparum/O infection/O after/O treatment/O with/O Coartem/O Tablets/O ,/O patients/O should/O be/O treated/O with/O a/O different/O antimalarial/O drug/O ./O
5.6/O Hepatic/O and/O Renal/O Impairment/O Coartem/O Tablets/O have/O not/O been/O studied/O for/O efficacy/O and/O safety/O in/O patients/O with/O severe/O hepatic/O and/or/O renal/O impairment/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O ]/O ./O
5.7/O Plasmodium/O vivax/O Infection/O Coartem/O Tablets/O have/O been/O shown/O in/O limited/O data/O (/O 43/O patients/O )/O to/O be/O effective/O in/O treating/O the/O erythrocytic/O stage/O of/O P./O vivax/O infection/O ./O
However/O ,/O relapsing/O malaria/O caused/O by/O P./O vivax/O requires/O additional/O treatment/O with/O other/O antimalarial/O agents/O to/O achieve/O radical/O cure/O i.e./O ,/O eradicate/O any/O hypnozoites/O forms/O that/O may/O remain/O dormant/O in/O the/O liver/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O elsewhere/O in/O the/O label/O :/O Perforations/B-AdverseReaction and/O Fistula/B-AdverseReaction [/O see/O Boxed/O Warning/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Hemorrhage/B-AdverseReaction [/O see/O Boxed/O Warning/O ,/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Thromboembolic/B-AdverseReaction Events/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Wound/B-AdverseReaction Complications/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Hypertension/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Osteonecrosis/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction Jaw/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Proteinuria/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Reversible/B-AdverseReaction Posterior/I-AdverseReaction Leukoencephalopathy/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O EXCERPT/O :/O The/O most/O commonly/O reported/O adverse/O drug/O reactions/O (/O 25/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O (/O PPES/B-AdverseReaction )/O ,/O decreased/B-AdverseReaction weight/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O oral/B-AdverseReaction pain/I-AdverseReaction ,/O hair/B-AdverseReaction color/I-AdverseReaction changes/I-AdverseReaction ,/O dysgeusia/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O constipation/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O 25/O %/O )/O are/O increased/B-AdverseReaction AST/I-AdverseReaction ,/O increased/B-AdverseReaction ALT/I-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O increased/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O hypocalcemia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O and/O hyperbilirubinemia/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Exelixis/O ,/O Inc./O at/O 1/O -/O 855/O -/O 500/O -/O 3935/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O safety/O of/O COMETRIQ/O was/O evaluated/O in/O 330/O patients/O with/O progressive/O metastatic/O medullary/O thyroid/O cancer/O randomized/O to/O receive/O 140/O mg/O COMETRIQ/O (/O n/O 214/O )/O or/O placebo/O (/O n/O 109/O )/O administered/O daily/O until/O disease/O progression/O or/O intolerable/O toxicity/O in/O a/O randomized/O ,/O doubleblind/O ,/O controlled/O trial/O ./O
[/O See/O Clinical/O Studies/O (/O 14/O )/O ./O
]/O The/O data/O described/O below/O reflect/O a/O median/O exposure/O to/O COMETRIQ/O for/O 204/O days/O ./O
The/O population/O exposed/O to/O COMETRIQ/O was/O 70/O %/O male/O ,/O 90/O %/O white/O ,/O and/O had/O a/O median/O age/O of/O 55/O years/O ./O
Adverse/O reactions/O which/O occurred/O in/O 25/O %/O of/O COMETRIQ/O -/O treated/O patients/O occurring/O more/O frequently/O in/O the/O COMETRIQ/O arm/O with/O a/O between/O -/O arm/O difference/O of/O 5/O %/O included/O ,/O in/O order/O of/O decreasing/O frequency/O :/O diarrhea/B-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O (/O PPES/B-AdverseReaction )/O ,/O decreased/B-AdverseReaction weight/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O oral/B-AdverseReaction pain/I-AdverseReaction ,/O hair/B-AdverseReaction color/I-AdverseReaction changes/I-AdverseReaction ,/O dysgeusia/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O constipation/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O 25/O %/O )/O were/O increased/B-AdverseReaction AST/I-AdverseReaction ,/O increased/B-AdverseReaction ALT/I-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O increased/B-AdverseReaction ALP/I-AdverseReaction ,/O hypocalcemia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O and/O hyperbilirubinemia/B-AdverseReaction ./O
Grade/B-Severity 3/I-Severity -/O 4/O adverse/O reactions/O and/O laboratory/O abnormalities/O which/O occurred/O in/O 5/O %/O of/O COMETRIQ/O -/O treated/O patients/O occurring/O more/O frequently/O in/O the/O COMETRIQ/O arm/O with/O a/O between/O -/O arm/O difference/O of/O 2/O %/O included/O ,/O in/O order/O of/O decreasing/O frequency/O ;/O diarrhea/B-AdverseReaction ,/O PPES/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O hypocalcemia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O increased/B-AdverseReaction ALT/I-AdverseReaction ,/O decreased/B-AdverseReaction weight/I-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O and/O decreased/B-AdverseReaction appetite/I-AdverseReaction (/O see/O Table/O 1/O ,/O Table/O 2/O )/O ./O
Fatal/B-AdverseReaction adverse/O reactions/O occurred/O in/O 6/O %/O of/O patients/O receiving/O COMETRIQ/O and/O resulted/O from/O hemorrhage/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O septicemia/B-AdverseReaction ,/O fistulas/B-AdverseReaction ,/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O respiratory/B-AdverseReaction failure/I-AdverseReaction ,/O and/O unspecified/O death/B-AdverseReaction ./O
Fatal/B-AdverseReaction adverse/O reactions/O occurred/O in/O 5/O %/O of/O patients/O receiving/O placebo/B-Factor and/O resulted/O from/O septicemia/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O and/O general/B-AdverseReaction deterioration/I-AdverseReaction ./O
The/O dose/O was/O reduced/O in/O 79/O %/O of/O patients/O receiving/O COMETRIQ/O compared/O to/O 9/O %/O of/O patients/O receiving/O placebo/O ./O
The/O median/O number/O of/O dosing/O delays/O was/O one/O in/O patients/O receiving/O COMETRIQ/O compared/O to/O none/O in/O patients/O receiving/O placebo/O ./O
Adverse/O reactions/O led/O to/O study/O treatment/O discontinuation/O in/O 16/O %/O of/O patients/O receiving/O COMETRIQ/O and/O in/O 8/O %/O of/O patients/O receiving/O placebo/O ./O
The/O most/O frequent/O adverse/O reactions/O leading/O to/O permanent/O discontinuation/O in/O patients/O treated/O with/O COMETRIQ/O were/O :/O hypocalcemia/B-AdverseReaction ,/O increased/B-AdverseReaction lipase/I-AdverseReaction ,/O PPES/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O tracheal/B-AdverseReaction fistula/I-AdverseReaction formation/I-AdverseReaction and/O vomiting/B-AdverseReaction ./O
Increased/B-AdverseReaction levels/I-AdverseReaction of/I-AdverseReaction thyroid/I-AdverseReaction stimulating/I-AdverseReaction hormone/I-AdverseReaction (/O TSH/O )/O were/O observed/O in/O 57/O %/O of/O patients/O receiving/O COMETRIQ/O after/O the/O first/O dose/O compared/O to/O 19/O %/O of/O patients/O receiving/O placebo/O (/O regardless/O of/O baseline/O value/O )/O ./O
Ninety/O -/O two/O percent/O (/O 92/O %/O )/O of/O patients/O on/O the/O COMETRIQ/O arm/O had/O a/O prior/O thyroidectomy/O ,/O and/O 89/O %/O were/O taking/O thyroid/O hormone/O replacement/O prior/O to/O the/O first/O dose/O ./O
Table/O 1/O Per/O -/O Patient/O Incidence/O of/O Selected/O Adverse/O Reactions/O in/O Protocol/O XL184/O -/O 301/O Occurring/O at/O a/O Higher/O Incidence/O in/O COMETRIQ/O -/O Treated/O Patients/O [/O Between/O Arm/O Difference/O of/O 5/O %/O (/O All/O Grades)National/O Cancer/O Institute/O Common/O Terminology/O Criteria/O for/O Adverse/O Events/O Version/O 3.0/O or/O 2/O %/O (/O Grades/O 3/O -/O 4/O )/O ]/O MedDRA/O System/O Organ/O Class/O Preferred/O Terms/O COMETRIQ(n=214/O )/O Placebo(n=109/O )/O AllGrades/O Grades3/O -/O 4/O AllGrades/O Grades3/O -/O 4/O GASTROINTESTINAL/O DISORDERS/O Diarrhea/B-AdverseReaction 63/O 16/O 33/O 2/O Stomatitis/B-AdverseReaction 51/O 5/O 6/O 0/O Nausea/B-AdverseReaction 43/O 1/O 21/O 0/O Oral/B-AdverseReaction pain/I-AdverseReaction 36/O 2/O 6/O 0/O Constipation/B-AdverseReaction 27/O 0/O 6/O 0/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 27/O 3/O 13/O 1/O Vomiting/B-AdverseReaction 24/O 2/O 2/O 1/O Dysphagia/B-AdverseReaction 13/O 4/O 6/O 1/O Dyspepsia/B-AdverseReaction 11/O 0/O 0/O 0/O Hemorrhoids/B-AdverseReaction 9/O 0/O 3/O 0/O GENERAL/O DISORDERS/O AND/O ADMINISTRATION/O SITE/O CONDITIONS/O Fatigue/B-AdverseReaction 41/O 9/O 28/O 3/O Asthenia/B-AdverseReaction 21/O 6/O 15/O 1/O INVESTIGATIONS/O Decreased/B-AdverseReaction weight/I-AdverseReaction 48/O 5/O 10/O 0/O METABOLISM/O AND/O NUTRITION/O DISORDERS/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 46/O 5/O 16/O 1/O Dehydration/B-AdverseReaction 7/O 2/O 2/O 1/O MUSCULOSKELETAL/O AND/O CONNECTIVE/O TISSUE/O DISORDERS/O Arthralgia/B-AdverseReaction 14/O 1/O 7/O 0/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 12/O 0/O 5/O 0/O Musculoskeletal/B-AdverseReaction chest/I-AdverseReaction pain/I-AdverseReaction 9/O 1/O 4/O 0/O NERVOUS/O SYSTEM/O DISORDERS/O Dysgeusia/B-AdverseReaction 34/O 0/O 6/O 0/O Headache/B-AdverseReaction 18/O 0/O 8/O 0/O Dizziness/B-AdverseReaction 14/O 0/O 7/O 0/O Paresthesia/B-AdverseReaction 7/O 0/O 2/O 0/O Peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction 7/O 0/O 0/O 0/O Peripheral/B-AdverseReaction neuropathy/I-AdverseReaction 5/O 0/O 0/O 0/O PSYCHIATRIC/O DISORDERS/O Anxiety/B-AdverseReaction 9/O 0/O 2/O 0/O RESPIRATORY/O ,/O THORACIC/O AND/O MEDIASTINAL/O DISORDERS/O Dysphonia/B-AdverseReaction 20/O 0/O 9/O 0/O SKIN/O AND/O SUBCUTANEOUS/O TISSUE/O DISORDERS/O PPES/B-AdverseReaction 50/O 13/O 2/O 0/O Hair/B-AdverseReaction color/I-AdverseReaction changes//I-AdverseReaction depigmentation/O ,/O graying/O 34/O 0/O 1/O 0/O Rash/B-AdverseReaction 19/O 1/O 10/O 0/O Dry/B-AdverseReaction skin/I-AdverseReaction 19/O 0/O 3/O 0/O Alopecia/B-AdverseReaction 16/O 0/O 2/O 0/O Erythema/B-AdverseReaction 11/O 1/O 2/O 0/O Hyperkeratosis/B-AdverseReaction 7/O 0/O 0/O 0/O VASCULAR/O DISORDERS/O Hypertension/B-AdverseReaction 33/O 8/O 4/O 0/O Hypotension/B-AdverseReaction 7/O 1/O 0/O 0/O Table/O 2/O Percent/O -/O Patient/O Incidence/O of/O Laboratory/O Abnormalities/O Occurring/O at/O a/O Higher/O Incidence/O in/O COMETRIQ/O -/O Treated/O Patients/O in/O Protocol/O XL184/O -/O 301/O [/O Between/O Arm/O Difference/O of/O 5/O %/O (/O All/O Grades/O )/O or/O 2/O %/O (/O Grades/O 3/O -/O 4/O )/O ]/O Adverse/O Event/O COMETRIQ(n=214/O )/O Placebo(N=109/O )/O AllGrades/O Grade3/O -/O 4/O AllGrades/O Grade3/O -/O 4/O Chemistries/O Increased/B-AdverseReaction AST/I-AdverseReaction 86/O 3/O 35/O 2/O Increased/B-AdverseReaction ALT/I-AdverseReaction 86/O 6/O 41/O 2/O Increased/B-AdverseReaction ALP/I-AdverseReaction 52/O 3/O 35/O 3/O Hypocalcemia/B-AdverseReaction 52/O 12/O 27/O 3/O Hypophosphatemia/B-AdverseReaction 28/O 3/O 10/O 1/O Hyperbilirubinemia/B-AdverseReaction 25/O 2/O 14/O 5/O Hypomagnesemia/B-AdverseReaction 19/O 1/O 4/O 0/O Hypokalemia/B-AdverseReaction 18/O 4/O 9/O 3/O Hyponatremia/B-AdverseReaction 10/O 2/O 5/O 0/O Hematologic/O Lymphopenia/B-AdverseReaction 53/O 16/O 51/O 11/O Neutropenia/B-AdverseReaction 35/O 3/O 15/O 2/O Thrombocytopenia/B-AdverseReaction 35/O 0/O 4/O 3/O ALT/O ,/O alanine/O aminotransferase/O ;/O ALP/O ,/O alkaline/O phosphatase/O ;/O AST/O ,/O aspartate/O aminotransferase/O Nearly/O all/O COMETRIQ/O -/O treated/O patients/O (/O 96/O %/O vs./O 84/O %/O placebo/O )/O experienced/O elevated/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction and/O there/O was/O a/O doubling/O in/O the/O incidence/O of/O overt/O hypertension/B-AdverseReaction in/O COMETRIQ/O -/O treated/O patients/O over/O placebo/O -/O treated/O patients/O (/O 61/O %/O vs./O 30/O %/O )/O according/O to/O modified/O Joint/O National/O Committee/O on/O Prevention/O ,/O Detection/O ,/O Evaluation/O ,/O and/O Treatment/O of/O High/O Blood/O Pressure/O (/O JNC/O )/O staging/O criteria/O ./O
No/B-Negation patients/O developed/O malignant/B-AdverseReaction hypertension/I-AdverseReaction ./O
Table/O 3/O Per/O -/O Patient/O Incidence/O of/O Hypertension/B-AdverseReaction in/O Protocol/O XL184/O -/O 301/O Hypertension/B-AdverseReaction ,/O JNCStage/O COMETRIQN=211(%/O )/O PlaceboN=107(%/O )/O Normal/O :/O Grade/O 0/O :/O Systolic/O 120/O mmHg/O and/O Diastolic/O 80/O mmHg/O 4/O 15/O Pre/B-AdverseReaction -/O hypertension/O :/O Systolic/O 120/O mmHg/O or/O Diastolic/O 80/O mmHg/O 34/O 54/O Stage/O 1/O :/O Systolic/O 140/O mmHg/O or/O Diastolic/O 90/O mmHg/O 46/O 25/O Stage/O 2/O :/O Systolic/O 160/O mmHg/O or/O Diastolic/O 100/O mmHg/O 15/O 5/O Malignant/O :/O Diastolic/O 120/O mmHg/O 0/O 0/O BOXED/O WARNING/O :/O WARNING/O :/O PERFORATIONS/B-AdverseReaction AND/O FISTULAS/B-AdverseReaction ,/O and/O HEMORRHAGE/B-AdverseReaction WARNING/O :/O PERFORATIONS/B-AdverseReaction AND/O FISTULAS/B-AdverseReaction ,/O and/O HEMORRHAGE/B-AdverseReaction Perforations/B-AdverseReaction and/O fistulas/B-AdverseReaction :/O Gastrointestinal/B-AdverseReaction perforations/I-AdverseReaction occurred/O in/O 3/O %/O and/O fistula/B-AdverseReaction formation/I-AdverseReaction in/O 1/O %/O of/O COMETRIQTM/O -/O treated/O patients/O ./O
Discontinue/O COMETRIQ/O for/O perforation/O or/O for/O fistula/O formation/O [/O See/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Hemorrhage/B-AdverseReaction :/O Severe/B-Severity ,/O sometimes/O fatal/B-AdverseReaction ,/O hemorrhage/B-AdverseReaction including/O hemoptysis/B-AdverseReaction and/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction occurred/O in/O 3/O %/O of/O COMETRIQ/O -/O treated/O patients/O ./O
Monitor/O patients/O for/O signs/O and/O symptoms/O of/O bleeding/O ./O
Do/O not/O administer/O COMETRIQ/O to/O patients/O with/O severe/O hemorrhage/O [/O See/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O PERFORATIONS/B-AdverseReaction AND/O FISTULAS/B-AdverseReaction ,/O andHEMORRHAGE/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Perforations/B-AdverseReaction and/O Fistulas/B-AdverseReaction :/O Gastrointestinal/B-AdverseReaction perforations/I-AdverseReaction occurred/O in/O 3/O %/O and/O fistula/B-AdverseReaction formation/I-AdverseReaction in/O 1/O %/O of/O COMETRIQ/O -/O treated/O patients/O ./O
Discontinue/O COMETRIQ/O in/O patients/O with/O perforation/O or/O fistula/O ./O
(/O 5.1/O )/O Hemorrhage/B-AdverseReaction :/O Severe/B-Severity ,/O sometimes/O fatal/B-AdverseReaction ,/O hemorrhage/B-AdverseReaction including/O hemoptysis/B-AdverseReaction and/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction occurred/O in/O 3/O %/O of/O COMETRIQ/O -/O treated/O patients/O ./O
Monitor/O patients/O for/O signs/O and/O symptoms/O of/O bleeding/O ./O
Do/O not/O administer/O COMETRIQ/O to/O patients/O with/O severe/O hemorrhage/O ./O
(/O 5.2/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Thrombotic/B-AdverseReaction Events/I-AdverseReaction :/O Discontinue/O COMETRIQ/O for/O myocardial/O infarction/O ,/O cerebral/O infarction/O ,/O or/O other/O serious/O arterial/O thromboembolic/O events/O ./O
(/O 5.3/O )/O Wound/B-AdverseReaction Complications/I-AdverseReaction :/O Withhold/O COMETRIQ/O for/O dehiscence/O or/O complications/O requiring/O medical/O intervention/O ./O
(/O 5.4/O )/O Hypertension/B-AdverseReaction :/O Monitor/O blood/O pressure/O regularly/O ./O
Discontinue/O COMETRIQ/O for/O hypertensive/O crisis/O ./O
(/O 5.5/O )/O Osteonecrosis/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction jaw/I-AdverseReaction :/O Discontinue/O COMETRIQ/O ./O
(/O 5.6/O )/O ./O
Palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction Erythrodysesthesia/O syndrome/O (/O PPES/B-AdverseReaction )/O :/O Interrupt/O COMETRIQ/O ,/O decrease/O dose/O ./O
(/O 5.7/O )/O Proteinuria/B-AdverseReaction :/O Monitor/O urine/O protein/O ./O
Discontinue/O for/O nephrotic/O syndrome/O ./O
(/O 5.8/O )/O Reversible/B-AdverseReaction posterior/I-AdverseReaction leukoencephalopathy/I-AdverseReaction syndrome/I-AdverseReaction (/O RPLS/B-AdverseReaction )/O :/O Discontinue/O COMETRIQ/O ./O
(/O 5.9/O )/O Embryofetal/B-AdverseReaction toxicity/I-AdverseReaction :/O Can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Advise/O women/O of/O potential/O risk/O to/O a/O fetus/O ./O
(/O 5.11/O ,/O 8.1/O )/O 5.1/O Perforations/O and/O Fistulas/O Gastrointestinal/O (/O GI/O )/O perforations/O and/O fistulas/O were/O reported/O in/O 3/O %/O and/O 1/O %/O of/O COMETRIQ/O -/O treated/O patients/O ,/O respectively/O ./O
All/O were/O serious/B-Severity and/O one/O GI/B-AdverseReaction fistula/I-AdverseReaction was/O fatal/B-AdverseReaction (/O 1/O %/O )/O ./O
Non/B-AdverseReaction -/I-AdverseReaction GI/O fistulas/O including/O tracheal/O esophageal/O were/O reported/O in/O 4/O %/O of/O COMETRIQ/O -/O treated/O patients/O ./O
Two/O (/O 1/O %/O )/O of/O these/O were/O fatal/B-AdverseReaction ./O
Monitor/O patients/O for/O symptoms/O of/O perforations/O and/O fistulas/O ./O
Discontinue/O COMETRIQ/O in/O patients/O who/O experience/O a/O perforation/O or/O a/O fistula/O ./O
5.2/O Hemorrhage/O Serious/B-Severity and/O sometimes/O fatal/B-AdverseReaction hemorrhage/B-AdverseReaction occurred/O with/O COMETRIQ/O ./O
The/O incidence/O of/O Grade/O =3/O hemorrhagic/B-AdverseReaction events/I-AdverseReaction was/O higher/O in/O COMETRIQ/O -/O treated/O patients/O compared/O with/O placebo/O (/O 3/O %/O vs./O 1/O %/O )/O ./O
Do/O not/O administer/O COMETRIQ/O to/O patients/O with/O a/O recent/O history/O of/O hemorrhage/O or/O hemoptysis/O ./O
5.3/O Thrombotic/O Events/O COMETRIQ/O treatment/O results/O in/O an/O increased/O incidence/O of/O thrombotic/B-AdverseReaction events/I-AdverseReaction (/O venous/B-AdverseReaction thromboembolism/I-AdverseReaction :/O 6/O %/O vs./O 3/O %/O and/O arterial/B-AdverseReaction thromboembolism/I-AdverseReaction :/O 2/O %/O vs./O 0/O %/O in/O COMETRIQ/O -/O treated/O and/O placebo/O -/O treated/O patients/O ,/O respectively/O )/O ./O
Discontinue/O COMETRIQ/O in/O patients/O who/O develop/O an/O acute/O myocardial/O infarction/O or/O any/O other/O clinically/O significant/O arterial/O thromboembolic/O complication/O ./O
5.4/O Wound/O Complications/O Wound/B-AdverseReaction complications/I-AdverseReaction have/O been/O reported/O with/O COMETRIQ/O ./O
Stop/O treatment/O with/O COMETRIQ/O at/O least/O 28/O days/O prior/O to/O scheduled/O surgery/O ./O
Resume/O COMETRIQ/O therapy/O after/O surgery/O based/O on/O clinical/O judgment/O of/O adequate/O wound/O healing/O ./O
Withhold/O COMETRIQ/O in/O patients/O with/O dehiscence/O or/O wound/O healing/O complications/O requiring/O medical/O intervention/O ./O
5.5/O Hypertension/O COMETRIQ/O treatment/O results/O in/O an/O increased/O incidence/O of/O treatment/O -/O emergent/O hypertension/B-AdverseReaction with/O Joint/O National/O Committee/O on/O Prevention/O ,/O Detection/O ,/O Evaluation/O ,/O and/O Treatment/O of/O High/O Blood/O Pressure/O (/O modified/O JNC/O criteria/O )/O stage/B-Severity 1/I-Severity or/O 2/O hypertension/B-AdverseReaction identified/O in/O 61/O %/O in/O COMETRIQ/O -/O treated/O patients/O compared/O with/O 30/O %/O of/O placebo/O -/O treated/O patients/O in/O the/O randomized/O trial/O ./O
Monitor/O blood/O pressure/O prior/O to/O initiation/O and/O regularly/O during/O COMETRIQ/O treatment/O ./O
Withhold/O COMETRIQ/O for/O hypertension/O that/O is/O not/O adequately/O controlled/O with/O medical/O management/O ;/O when/O controlled/O ,/O resume/O COMETRIQ/O at/O a/O reduced/O dose/O ./O
Discontinue/O COMETRIQ/O for/O severe/O hypertension/O that/O can/O not/O be/O controlled/O with/O anti/O -/O hypertensive/O therapy/O ./O
5.6/O Osteonecrosis/O of/O the/O Jaw/O Osteonecrosis/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction jaw/I-AdverseReaction (/O ONJ/B-AdverseReaction )/O occurred/O in/O 1/O %/O of/O COMETRIQ/O -/O treated/O patients/O ./O
ONJ/B-AdverseReaction can/B-Factor manifest/O as/O jaw/B-AdverseReaction pain/I-AdverseReaction ,/O osteomyelitis/B-AdverseReaction ,/O osteitis/B-AdverseReaction ,/O bone/B-AdverseReaction erosion/I-AdverseReaction ,/O tooth/O or/O periodontal/B-AdverseReaction infection/I-AdverseReaction ,/O toothache/B-AdverseReaction ,/O gingival/B-AdverseReaction ulceration/I-AdverseReaction or/O erosion/O ,/O persistent/B-AdverseReaction jaw/I-AdverseReaction pain/I-AdverseReaction or/O slow/O healing/O of/O the/O mouth/O or/O jaw/O after/O dental/O surgery/O ./O
Perform/O an/O oral/O examination/O prior/O to/O initiation/O of/O COMETRIQ/O and/O periodically/O during/O COMETRIQ/O therapy/O ./O
Advise/O patients/O regarding/O good/O oral/O hygiene/O practices/O ./O
For/O invasive/O dental/O procedures/O ,/O withhold/O COMETRIQ/O treatment/O for/O at/O least/O 28/O days/O prior/O to/O scheduled/O surgery/O ,/O if/O possible/O ./O
5.7/O Palmar/O -/O Plantar/O Erythrodysesthesia/O Syndrome/O Palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O (/O PPES/B-AdverseReaction )/O occurred/O in/O 50/O %/O of/O patients/O treated/O with/O COMETRIQ/O and/O was/O severe/B-Severity (/O Grade/B-Severity 3/I-Severity )/O in/O 13/O %/O of/O patients/O ./O
Withhold/O COMETRIQ/O in/O patients/O who/O develop/O intolerable/O Grade/O 2/O PPES/O or/O Grade/O 3/O -/O 4/O PPES/O until/O improvement/O to/O Grade/O 1/O ;/O resume/O COMETRIQ/O at/O a/O reduced/O dose/O ./O
5.8/O Proteinuria/O Proteinuria/B-AdverseReaction was/O observed/O in/O 4/O (/O 2/O %/O )/O of/O patients/O receiving/O COMETRIQ/O ,/O including/O one/O with/O nephrotic/B-AdverseReaction syndrome/I-AdverseReaction ,/O as/O compared/O to/O none/O of/O the/O patients/O receiving/O placebo/O ./O
Monitor/O urine/O protein/O regularly/O during/O COMETRIQ/O treatment/O ./O
Discontinue/O COMETRIQ/O in/O patients/O who/O develop/O nephrotic/O syndrome/O ./O
5.9/O Reversible/O Posterior/O Leukoencephalopathy/O Syndrome/O Reversible/B-AdverseReaction Posterior/I-AdverseReaction Leukoencephalopathy/I-AdverseReaction Syndrome/I-AdverseReaction (/O RPLS/B-AdverseReaction )/O ,/O a/O syndrome/O of/O subcortical/B-AdverseReaction vasogenic/I-AdverseReaction edema/I-AdverseReaction diagnosed/O by/O characteristic/O finding/O on/O MRI/O ,/O occurred/O in/O one/O (/O 1/O %/O )/O patient/O ./O
Perform/O an/O evaluation/O for/O RPLS/O in/O any/O patient/O presenting/O with/O seizures/O ,/O headache/O ,/O visual/O disturbances/O ,/O confusion/O or/O altered/O mental/O function/O ./O
Discontinue/O COMETRIQ/O in/O patients/O who/O develop/O RPLS/O ./O
5.10/O Drug/O Interactions/O Avoid/O administration/O of/O COMETRIQ/O with/O agents/O that/O are/O strong/O CYP3A4/O inducers/O or/O inhibitors/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O and/O Drug/O Interactions/O (/O 7.1/O ,/O 7.2/O )/O ]/O ./O
5.11/O Hepatic/O Impairment/O COMETRIQ/O is/O not/O recommended/O for/O use/O in/O patients/O with/O moderate/O or/O severe/O hepatic/O impairment/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
5.12/O Embryo/O -/O fetal/O Toxicity/O COMETRIQ/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Cabozantinib/O was/O embryolethal/B-AdverseReaction in/O rats/B-Animal at/O exposures/O below/O the/O recommended/O human/O dose/O ,/O with/O increased/O incidences/O of/O skeletal/B-AdverseReaction variations/I-AdverseReaction in/O rats/B-Animal and/O visceral/B-AdverseReaction variations/I-AdverseReaction and/O malformations/O in/O rabbits/B-Animal ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O [/O See/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O are/O nausea/B-AdverseReaction (/O 11/O %/O )/O ,/O vomiting/B-AdverseReaction (/O 7/O %/O )/O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction (/O 6/O %/O )/O ,/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction (/O 4/O %/O )/O ,/O anemia/B-AdverseReaction (/O 2/O %/O )/O ,/O and/O neutropenia/B-AdverseReaction (/O 2/O %/O )/O (/O 6/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Cubist/O Pharmaceuticals/O at/O 1/O -/O 877-CUBIST-6/O (/O 1/O -/O 877/O -/O 282/O -/O 4786/O )/O or/O FDA/O at/O (/O 1/O -/O 800-FDA-1088/O )/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O event/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O any/O other/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O safety/O of/O DIFICID/O 200/O mg/O tablets/O taken/O twice/O a/O day/O for/O 10/O days/O was/O evaluated/O in/O 564/O patients/O with/O CDAD/O in/O two/O active/O -/O comparator/O controlled/O trials/O with/O 86.7/O %/O of/O patients/O receiving/O a/O full/O course/O of/O treatment/O ./O
Thirty/O -/O three/O patients/O receiving/O DIFICID/O (/O 5.9/O %/O )/O withdrew/O from/O trials/O as/O a/O result/O of/O adverse/O reactions/O (/O AR/O )/O ./O
The/O types/O of/O AR/O resulting/O in/O withdrawal/O from/O the/O study/O varied/O considerably/O ./O
Vomiting/B-AdverseReaction was/O the/O primary/O adverse/O reaction/O leading/O to/O discontinuation/O of/O dosing/O ;/O this/O occurred/O at/O an/O incidence/O of/O 0.5/O %/O in/O both/O the/O fidaxomicin/O and/O vancomycin/O patients/O in/O Phase/O 3/O studies/O ./O
Table/O 1/O ./O
Selected/O Adverse/O Reactions/O with/O an/O Incidence/O of/O 2/O %/O Reported/O in/O DIFICID/O Patients/O in/O Controlled/O Trials/O DIFICID/O (/O N=564/O )/O Vancomycin/O (/O N=583/O )/O System/O Organ/O Class/O Preferred/O Term/O n/O (/O %/O )/O n/O (/O %/O )/O Blood/O and/O Lymphatic/O System/O Disorders/O Anemia/B-AdverseReaction 14/O (/O 2/O %/O )/O 12/O (/O 2/O %/O )/O Neutropenia/B-AdverseReaction 14/O (/O 2/O %/O )/O 6/O (/O 1/O %/O )/O Gastrointestinal/O Disorders/O Nausea/B-AdverseReaction 62/O (/O 11/O %/O )/O 66/O (/O 11/O %/O )/O Vomiting/B-AdverseReaction 41/O (/O 7/O %/O )/O 37/O (/O 6/O %/O )/O Abdominal/B-AdverseReaction Pain/I-AdverseReaction 33/O (/O 6/O %/O )/O 23/O (/O 4/O %/O )/O Gastrointestinal/B-AdverseReaction Hemorrhage/I-AdverseReaction 20/O (/O 4/O %/O )/O 12/O (/O 2/O %/O )/O The/O following/O adverse/O reactions/O were/O reported/O in/O 2/O %/O of/O patients/O taking/O DIFICID/O tablets/O in/O controlled/O trials/O :/O Gastrointestinal/O Disorders/O :/O abdominal/B-AdverseReaction distension/I-AdverseReaction ,/O abdominal/B-AdverseReaction tenderness/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O flatulence/B-AdverseReaction ,/O intestinal/B-AdverseReaction obstruction/I-AdverseReaction ,/O megacolon/B-AdverseReaction Investigations/O :/O increased/B-AdverseReaction blood/I-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O decreased/B-AdverseReaction blood/I-AdverseReaction bicarbonate/I-AdverseReaction ,/O increased/B-AdverseReaction hepatic/I-AdverseReaction enzymes/I-AdverseReaction ,/O decreased/B-AdverseReaction platelet/I-AdverseReaction count/I-AdverseReaction Metabolism/O and/O Nutrition/O Disorders/O :/O hyperglycemia/B-AdverseReaction ,/O metabolic/B-AdverseReaction acidosis/I-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O drug/B-AdverseReaction eruption/I-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O rash/B-AdverseReaction 6.2/O Post/O Marketing/O Experience/O Adverse/O reactions/O reported/O in/O the/O post/O marketing/O setting/O arise/O from/O a/O population/O of/O unknown/O size/O and/O are/O voluntary/O in/O nature/O ./O
As/O such/O ,/O reliability/O in/O estimating/O their/O frequency/O or/O in/O establishing/O a/O causal/O relationship/O to/O drug/O exposure/O is/O not/O always/O possible/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O dyspnea/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O pruritus/B-AdverseReaction )/O have/O been/O reported/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O DIFICID/O should/O not/O be/O used/O for/O systemic/O infections/O ./O
(/O 5.1/O )/O Acute/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction (/O angioedema/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O and/O rash/B-AdverseReaction )/O have/O been/O reported/O ./O
In/O the/O event/O of/O a/O severe/O reaction/O ,/O discontinue/O DIFICID/O ./O
(/O 5.2/O )/O Development/O of/O drug/O -/O resistant/O bacteria/O :/O Only/O use/O DIFICID/O for/O infection/O proven/O or/O strongly/O suspected/O to/O be/O caused/O by/O C./O difficile/O ./O
(/O 5.3/O )/O 5.1/O Not/O for/O Systemic/O Infections/O Since/O there/O is/O minimal/O systemic/O absorption/O of/O fidaxomicin/O ,/O DIFICID/O is/O not/O effective/O for/O treatment/O of/O systemic/O infections/O ./O
5.2/O Hypersensitivity/O Reactions/O Acute/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O dyspnea/B-AdverseReaction ,/O rash/B-AdverseReaction pruritus/B-AdverseReaction ,/O and/O angioedema/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction mouth/I-AdverseReaction ,/O throat/O ,/O and/O face/O have/O been/O reported/O with/O fidaxomicin/O ./O
If/O a/O severe/O hypersensitivity/O reaction/O occurs/O ,/O DIFICID/O (/O r/O )/O should/O be/O discontinued/O and/O appropriate/O therapy/O should/O be/O instituted/O ./O
Some/O patients/O with/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction also/O reported/O a/O history/O of/O allergy/O to/O other/O macrolides/O ./O
Physicians/O prescribing/O DIFICID/O to/O patients/O with/O a/O known/O macrolide/O allergy/O should/O be/O aware/O of/O the/O possibility/O of/O hypersensitivity/O reactions/O ./O
5.3/O Development/O of/O Drug/O -/O Resistant/O Bacteria/O Prescribing/O DIFICID/O in/O the/O absence/O of/O a/O proven/O or/O strongly/O suspected/O C./O difficile/O infection/O is/O unlikely/O to/O provide/O benefit/O to/O the/O patient/O and/O increases/O the/O risk/O of/O the/O development/O of/O drug/O -/O resistant/O bacteria/O ./O
6/O ADVERSE/O REACTIONS/O GBCAs/B-DrugClass have/O been/O associated/O with/O a/O risk/O for/O NSF/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
NSF/B-AdverseReaction has/O not/B-Negation been/O reported/O in/O patients/O with/O a/O clear/O history/O of/O exposure/O to/O DOTAREM/O alone/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction and/O acute/B-AdverseReaction kidney/I-AdverseReaction injury/I-AdverseReaction are/O described/O in/O other/O sections/O of/O the/O labeling/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O and/O (/O 5.3/O )/O ]/O ./O
EXCERPT/O :/O The/O most/O frequent/O (/O 0.2/O %/O )/O adverse/O reactions/O in/O clinical/O studies/O were/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction coldness/I-AdverseReaction ,/O and/O burning/B-AdverseReaction sensation/I-AdverseReaction ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GUERBET/O LLC/O at/O 1/O -/O 877/O -/O 729/O -/O 6679/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Studies/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O data/O described/O below/O reflect/O DOTAREM/O exposure/O in/O 2813/O patients/O ,/O representing/O 2672/O adults/O and/O 141/O pediatric/O patients/O ./O
Overall/O ,/O 55/O %/O of/O the/O patients/O were/O men/O ./O
In/O clinical/O trials/O where/O ethnicity/O was/O recorded/O the/O ethnic/O distribution/O was/O 74/O %/O Caucasian/O ,/O 12/O %/O Asian/O ,/O 4/O %/O Black/O ,/O and/O 10/O %/O others/O ./O
The/O average/O age/O was/O 53/O years/O (/O range/O from/O 0.1/O to/O 97/O years/O )/O ./O
Overall/O ,/O 3.9/O %/O of/O patients/O reported/O at/O least/O one/O adverse/O reaction/O ,/O primarily/O occurring/O immediately/O or/O several/O days/O following/O DOTAREM/O administration/O ./O
Most/O adverse/O reactions/O were/O mild/O or/O moderate/O in/O severity/O and/O transient/O in/O nature/O ./O
Table/O 2/O lists/O adverse/O reactions/O that/O occurred/O in/O 0.2/O %/O patients/O who/O received/O DOTAREM/O ./O
Table/O 2/O :/O Adverse/O Reactions/O in/O Clinical/O Trials/O Reaction/O Rate/O (/O %/O )/O n=2813/O Nausea/B-AdverseReaction 0.6/O %/O Headache/B-AdverseReaction 0.5/O %/O Injection/B-AdverseReaction Site/I-AdverseReaction Pain/I-AdverseReaction 0.4/O %/O Injection/B-AdverseReaction Site/I-AdverseReaction Coldness/I-AdverseReaction 0.2/O %/O Burning/B-AdverseReaction Sensation/I-AdverseReaction 0.2/O %/O Adverse/O reactions/O that/O occurred/O with/O a/O frequency/O 0.2/O %/O in/O patients/O who/O received/O DOTAREM/O include/O :/O feeling/B-AdverseReaction cold/I-AdverseReaction ,/O rash/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O paresthesia/B-AdverseReaction ,/O dysgeusia/B-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ,/O anxiety/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O palpitations/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction discomfort/I-AdverseReaction ,/O serum/B-AdverseReaction creatinine/I-AdverseReaction increased/I-AdverseReaction and/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O site/O inflammation/O ,/O extravasation/O ,/O pruritus/O ,/O and/O warmth/O ./O
Adverse/O Reactions/O in/O Pediatric/O Patients/O During/O clinical/O trials/O ,/O 141/O pediatric/O patients/O (/O 7/O aged/O 24/O months/O ,/O 33/O aged/O 2/O -/O 5/O years/O ,/O 58/O aged/O 6/O -/O 11/O years/O and/O 43/O aged/O 12/O -/O 17/O )/O received/O DOTAREM/O ./O
Overall/O ,/O 6/O pediatric/O patients/O (/O 4.3/O %/O )/O reported/O at/O least/O one/O adverse/O reaction/O following/O DOTAREM/O administration/O ./O
The/O most/O frequently/O reported/O adverse/O reaction/O was/O headache/B-AdverseReaction (/O 1.5/O %/O )/O ./O
Most/O adverse/O events/O were/O mild/O in/O severity/O and/O transient/O in/O nature/O ,/O and/O all/O patients/O recovered/O without/O treatment/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O additional/O adverse/O reactions/O have/O been/O identified/O during/O postmarketing/O use/O of/O DOTAREM/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Table/O 3/O :/O Adverse/O Reactions/O in/O the/O Postmarketing/O Experience/O System/O Organ/O Class/O Adverse/O Reaction/O Cardiac/O Disorders/O bradycardia/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O arrhythmia/B-AdverseReaction Immune/O System/O Disorders/O hypersensitivity/B-AdverseReaction /anaphylactoid/O reactions/O including/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O respiratory/B-AdverseReaction arrest/I-AdverseReaction ,/O cyanosis/B-AdverseReaction pharyngeal/B-AdverseReaction edema/I-AdverseReaction ,/O laryngospasm/B-AdverseReaction ,/O bronchospasm/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O conjunctivitis/B-AdverseReaction ,/O ocular/B-AdverseReaction hyperemia/I-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O lacrimation/B-AdverseReaction increased/I-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O urticaria/B-AdverseReaction Nervous/O System/O Disorders/O coma/B-AdverseReaction ,/O convulsion/B-AdverseReaction ,/O syncope/B-AdverseReaction ,/O presyncope/B-AdverseReaction ,/O parosmia/B-AdverseReaction ,/O tremor/B-AdverseReaction Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O muscle/B-AdverseReaction contracture/I-AdverseReaction ,/O muscle/B-AdverseReaction weakness/I-AdverseReaction Gastrointestinal/O Disorders/O diarrhea/B-AdverseReaction ,/O salivary/B-AdverseReaction hypersecretion/I-AdverseReaction General/O Disorders/O and/O Administration/O Site/O Conditions/O malaise/B-AdverseReaction ,/O fever/B-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O NSF/B-AdverseReaction ,/O in/O patients/O whose/O reports/O were/O confounded/O by/O the/O receipt/O of/O other/O GBCAs/B-DrugClass or/O in/O situations/O where/O receipt/O of/O other/O GBCAs/O could/O not/O be/O ruled/O out/O ./O
No/B-Negation unconfounded/O cases/O of/O NSF/B-AdverseReaction have/O been/O reported/O with/O DOTAREM/O ./O
Vascular/O Disorders/O superficial/B-AdverseReaction phlebitis/I-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction (/O NSF/B-AdverseReaction )/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction (/O NSF/B-AdverseReaction )/O Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/O for/O NSF/B-AdverseReaction among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O in/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrasted/O MRI/O or/O other/O modalities/O ./O
NSF/B-AdverseReaction may/B-Factor result/O in/O fatal/B-AdverseReaction or/O debilitating/B-Severity fibrosis/B-AdverseReaction affecting/O the/O skin/O ,/O muscle/O and/O internal/O organs/O ./O
The/O risk/B-Factor for/O NSF/B-AdverseReaction appears/O highest/O among/O patients/O with/O :/O Chronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73/O m2/O )/O ,/O orAcute/O kidney/O injury/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O e.g./O age/O 60/O years/O ,/O hypertension/O ,/O diabetes/O )/O ,/O estimate/O the/O glomerular/O filtration/O rate/O (/O GFR/O )/O through/O laboratory/O testing/O (/O 5.1/O )/O ./O
For/O patients/O at/O highest/O risk/O for/O NSF/O ,/O do/O not/O exceed/O the/O recommended/O DOTAREM/O dose/O and/O allow/O a/O sufficient/O period/O of/O time/O for/O elimination/O of/O the/O drug/O from/O the/O body/O prior/O to/O any/O re/O -/O administration/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction (/O NSF/B-AdverseReaction )/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/O for/O NSF/B-AdverseReaction among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O in/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrasted/O MRI/O or/O other/O modalities/O ./O
The/O risk/B-Factor for/O NSF/B-AdverseReaction appears/O highest/O among/O patients/O with/O :/O Chronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73/O m2/O )/O ,/O orAcute/O kidney/O injury/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O for/O example/O age/O 60/O years/O ,/O hypertension/O or/O diabetes/O )/O ,/O estimate/O the/O glomerular/O filtration/O rate/O (/O GFR/O )/O through/O laboratory/O testing/O (/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Nephrogenic/B-AdverseReaction Systemic/I-AdverseReaction Fibrosis/I-AdverseReaction has/O occurred/O in/O patients/O with/O impaired/O elimination/O of/O GBCAs/O ./O
Higher/O than/O recommended/O dosing/O or/O repeat/O dosing/O appear/O to/O increase/O the/O risk/O ./O
(/O 5.1/O )/O Hypersensitivity/B-AdverseReaction :/O Anaphylactoid/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction with/O cardiovascular/O ,/O respiratory/O or/O cutaneous/B-AdverseReaction manifestations/I-AdverseReaction ,/O ranging/O from/O mild/B-Severity to/O severe/B-Severity ,/O including/O death/B-AdverseReaction ,/O have/O uncommonly/O occurred/O ./O
Monitor/O patients/O closely/O for/O need/O of/O emergency/O cardiorespiratory/O support/O ./O
(/O 5.2/O )/O 5.1/O Nephrogenic/O Systemic/O Fibrosis/O Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/O for/O nephrogenic/B-AdverseReaction systemic/I-AdverseReaction fibrosis/I-AdverseReaction (/O NSF/B-AdverseReaction )/O among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O among/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrast/O MRI/O or/O other/O modalities/O ./O
The/O GBCA/B-DrugClass -/O associated/O NSF/B-AdverseReaction risk/O appears/O highest/O for/O patients/O with/O chronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73/O m/O 2/O )/O as/O well/O as/O patients/O with/O acute/O kidney/O injury/O ./O
The/O risk/O appears/O lower/O for/O patients/O with/O chronic/O ,/O moderate/O kidney/O disease/O (/O GFR/O 30/O -/O 59/O mL/O min/1.73/O m/O 2/O )/O and/O little/O ,/O if/O any/O ,/O for/O patients/O with/O chronic/O ,/O mild/O kidney/O disease/O (/O GFR/O 60/O -/O 89/O mL/O min/1.73/O m/O 2/O )/O ./O
NSF/B-AdverseReaction may/B-Factor result/O in/O fatal/B-AdverseReaction or/O debilitating/B-Severity fibrosis/B-AdverseReaction affecting/O the/O skin/O ,/O muscle/O and/O internal/O organs/O ./O
Report/O any/O diagnosis/O of/O NSF/O following/O DOTAREM/O administration/O to/O Guerbet/O LLC/O (/O 1/O -/O 877/O -/O 729/O -/O 6679/O )/O or/O FDA/O (/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O )/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
Features/O of/O acute/O kidney/O injury/O consist/O of/O rapid/O (/O over/O hours/O to/O days/O )/O and/O usually/O reversible/O decrease/O in/O kidney/O function/O ,/O commonly/O in/O the/O setting/O of/O surgery/O ,/O severe/O infection/O ,/O injury/O or/O drug/O -/O induced/O kidney/O toxicity/O ./O
Serum/O creatinine/O levels/O and/O estimated/O GFR/O may/O not/O reliably/O assess/O renal/O function/O in/O the/O setting/O of/O acute/O kidney/O injury/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O e.g./O ,/O age/O 60/O years/O ,/O diabetes/O mellitus/O or/O chronic/O hypertension/O )/O ,/O estimate/O the/O GFR/O through/O laboratory/O testing/O ./O
Among/O the/O factors/O that/O may/O increase/O the/O risk/O for/O NSF/O are/O repeated/O or/O higher/O than/O recommended/O doses/O of/O a/O GBCA/O and/O the/O degree/O of/O renal/O impairment/O at/O the/O time/O of/O exposure/O ./O
Record/O the/O specific/O GBCA/O and/O the/O dose/O administered/O to/O a/O patient/O ./O
For/O patients/O at/O highest/O risk/O for/O NSF/O ,/O do/O not/O exceed/O the/O recommended/O DOTAREM/O dose/O and/O allow/O a/O sufficient/O period/O of/O time/O for/O elimination/O of/O the/O drug/O prior/O to/O re/O -/O administration/O ./O
For/O patients/O receiving/O hemodialysis/O ,/O physicians/O may/O consider/O the/O prompt/O initiation/O of/O hemodialysis/O following/O the/O administration/O of/O a/O GBCA/O in/O order/O to/O enhance/O the/O contrast/O agent/O 's/O elimination/O ./O
The/O usefulness/O of/O hemodialysis/O in/O the/O prevention/O of/O NSF/O is/O unknown/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O and/O Clinical/O Pharmacology/O (/O 12/O )/O ]/O ./O
5.2/O Hypersensitivity/O Reactions/O Anaphylactic/O and/O anaphylactoid/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O with/O DOTAREM/O ,/O involving/O cardiovascular/O ,/O respiratory/O ,/O and/or/O cutaneous/O manifestations/O ./O
Some/O patients/O experienced/O circulatory/B-AdverseReaction collapse/I-AdverseReaction and/O died/B-AdverseReaction ./O
In/O most/O cases/O ,/O initial/O symptoms/O occurred/O within/O minutes/O of/O DOTAREM/O administration/O and/O resolved/O with/O prompt/O emergency/O treatment/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Before/O DOTAREM/O administration/O ,/O assess/O all/O patients/O for/O any/O history/O of/O a/O reaction/O to/O contrast/O media/O ,/O bronchial/O asthma/O and/or/O allergic/O disorders/O ./O
These/O patients/O may/B-Factor have/O an/O increased/O risk/O for/O a/O hypersensitivity/B-AdverseReaction reaction/I-AdverseReaction to/O DOTAREM/O ./O
Administer/O DOTAREM/O only/O in/O situations/O where/O trained/O personnel/O and/O therapies/O are/O promptly/O available/O for/O the/O treatment/O of/O hypersensitivity/O reactions/O ,/O including/O personnel/O trained/O in/O resuscitation/O ./O
During/O and/O following/O DOTAREM/O administration/O ,/O observe/O patients/O for/O signs/O and/O symptoms/O of/O hypersensitivity/O reactions/O ./O
5.3/O Acute/O Kidney/O Injury/O In/O patients/O with/O chronically/O reduced/O renal/O function/O ,/O acute/B-AdverseReaction kidney/I-AdverseReaction injury/I-AdverseReaction requiring/O dialysis/O has/O occurred/O with/O the/O use/O of/O GBCAs/B-DrugClass ./O
The/O risk/O of/O acute/O kidney/O injury/O may/O increase/O with/O increasing/O dose/O of/O the/O contrast/O agent/O ;/O administer/O the/O lowest/O dose/O necessary/O for/O adequate/O imaging/O ./O
Screen/O all/O patients/O for/O renal/O impairment/O by/O obtaining/O a/O history/O and/or/O laboratory/O tests/O ./O
Consider/O follow/O -/O up/O renal/O function/O assessments/O for/O patients/O with/O a/O history/O of/O renal/O dysfunction/O ./O
5.4/O Extravasation/O and/O Injection/O Site/O Reactions/O Ensure/O catheter/O and/O venous/O patency/O before/O the/O injection/O of/O DOTAREM/O ./O
Extravasation/O into/O tissues/O during/O DOTAREM/O administration/O may/B-Factor result/O in/O tissue/O irritation/O [/O see/O Nonclinical/O Toxicology/O (/O 13.2/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O label/O :/O Cardiovascular/B-AdverseReaction Disorders/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Malignant/B-AdverseReaction Neoplasms/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Gallbladder/B-AdverseReaction Disease/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Hypertriglyceridemia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O EXCERPT/O :/O In/O four/O prospective/O ,/O randomized/O ,/O placebo/O -/O controlled/O trials/O the/O common/O adverse/O reactions/O (/O incidence/O 5/O %/O )/O were/O muscle/B-AdverseReaction spasms/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O and/O neck/B-AdverseReaction pain/I-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Pfizer/O Inc./O at/O 1/O -/O 800/O -/O 438/O -/O 1985/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O safety/O of/O conjugated/O estrogens/O bazedoxifene/O was/O evaluated/O in/O four/O Phase/O 3/O clinical/O trials/O ranging/O from/O 12/O weeks/O to/O 24/O months/O in/O duration/O and/O enrolling/O 6,210/O postmenopausal/O women/O age/O 40/O to/O 75/O years/O (/O mean/O age/O 55/O years/O )/O ./O
A/O total/O of/O 1,224/O patients/O were/O treated/O with/O DUAVEE/O and/O 1,069/O patients/O received/O placebo/O ./O
Women/O enrolled/O in/O Studies/O 1/O and/O 2/O received/O calcium/O (/O 600/O -/O 1200/O mg/O )/O and/O vitamin/O D/O (/O 200/O -/O 400/O IU/O )/O daily/O ,/O while/O women/O in/O Studies/O 3/O and/O 4/O received/O no/O calcium/O and/O vitamin/O D/O supplementation/O as/O part/O of/O the/O protocol/O ./O
The/O incidence/O of/O all/O -/O cause/O mortality/B-AdverseReaction was/O 0.0/B-Negation %/O in/O the/O DUAVEE/O group/O and/O 0.2/O %/O in/O the/O placebo/O group/O ./O
The/O incidence/O of/O serious/O adverse/O reactions/O was/O 3.5/O %/O in/O the/O DUAVEE/O group/O and/O 4.8/O %/O in/O the/O placebo/O group/O ./O
The/O percentage/O of/O patients/O who/O withdrew/O from/O treatment/O due/O to/O adverse/O reactions/O was/O 7.5/O %/O in/O the/O DUAVEE/O group/O and/O 10.0/O %/O in/O the/O placebo/O group/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O were/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
The/O most/O commonly/O observed/O adverse/O reactions/O (/O incidence/O 5/O %/O )/O more/O frequently/O reported/O in/O women/O treated/O with/O DUAVEE/O than/O placebo/O are/O presented/O in/O Table/O 1/O ./O
Table/O 1/O :/O Adverse/O Reactions/O (/O Incidence/O 5/O %/O )/O More/O Common/O in/O the/O DUAVEE/O Treatment/O Group/O in/O Placebo/O -/O controlled/O Trials/O DUAVEE/O (/O N=1224)n/O (/O %/O )/O Placebo/O (/O N=1069)n/O (/O %/O )/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 100/O (/O 8)/O 58/O (/O 5/O )/O Diarrhea/B-AdverseReaction 96/O (/O 8)/O 57/O (/O 5/O )/O Dyspepsia/B-AdverseReaction 84/O (/O 7/O )/O 59/O (/O 6/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction 81/O (/O 7/O )/O 58/O (/O 5/O )/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 110/O (/O 9/O )/O 63/O (/O 6/O )/O Neck/B-AdverseReaction pain/I-AdverseReaction 62/O (/O 5/O )/O 46/O (/O 4/O )/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction 65/O (/O 5/O )/O 37/O (/O 3/O )/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 80/O (/O 7/O )/O 61/O (/O 6/O )/O Venous/O thromboembolism/O :/O In/O the/O clinical/O studies/O with/O DUAVEE/O ,/O the/O reporting/O rates/O for/O venous/B-AdverseReaction thromboembolism/I-AdverseReaction (/O deep/B-AdverseReaction venous/I-AdverseReaction thrombosis/I-AdverseReaction ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction ,/O and/O retinal/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction )/O were/O low/O in/O all/O treatment/O groups/O ./O
Adverse/O reactions/O of/O venous/B-AdverseReaction thromboembolism/I-AdverseReaction were/O reported/O in/O 0.0/B-Negation %/O of/O patients/O treated/O with/O DUAVEE/O and/O 0.1/O %/O of/O patients/O treated/O with/O placebo/O ./O
Due/O to/O the/O low/O rate/O of/O events/O in/O both/O groups/O ,/O it/O is/O not/O possible/O to/O conclude/O that/O the/O risk/B-Factor of/O venous/B-AdverseReaction thromboembolism/I-AdverseReaction with/O DUAVEE/O is/O different/O from/O that/O seen/O with/O other/O estrogen/O therapies/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O ENDOMETRIAL/B-AdverseReaction CANCER/I-AdverseReaction ,/O CARDIOVASCULAR/B-AdverseReaction DISORDERS/I-AdverseReaction ,/O AND/O PROBABLE/B-Factor DEMENTIA/B-AdverseReaction WARNING/O :/O ENDOMETRIAL/B-AdverseReaction CANCER/I-AdverseReaction ,/O CARDIOVASCULAR/B-AdverseReaction DISORDERS/I-AdverseReaction ,/O AND/O PROBABLE/B-Factor DEMENTIA/B-AdverseReaction Women/O taking/O DUAVEE/O should/O not/O take/O additional/O estrogens/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O There/O is/O an/O increased/O risk/O of/O endometrial/B-AdverseReaction cancer/I-AdverseReaction in/O a/O woman/O with/O a/O uterus/O who/O uses/O unopposed/O estrogens/B-DrugClass ./O
DUAVEE/O has/O been/O shown/O to/O reduce/B-Factor the/I-Factor risk/I-Factor of/O endometrial/B-AdverseReaction hyperplasia/I-AdverseReaction ,/O which/O may/O be/O a/O precursor/O to/O endometrial/O cancer/O ./O
Adequate/O diagnostic/O measures/O ,/O including/O directed/O or/O random/O endometrial/O sampling/O when/O indicated/O ,/O should/O be/O undertaken/O to/O rule/O out/O malignancy/O in/O postmenopausal/O women/O with/O undiagnosed/O persistent/O or/O recurring/O abnormal/O genital/O bleeding/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Estrogen/O therapy/O should/O not/O be/O used/O for/O the/O prevention/O of/O cardiovascular/O disease/O or/O dementia/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O ,/O 5.4/O )/O ]/O The/O Women/O 's/O Health/O Initiative/O (/O WHI/O )/O estrogen/O -/O alone/O substudy/O reported/O increased/O risks/O of/O stroke/B-AdverseReaction and/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction (/O DVT/B-AdverseReaction )/O in/O postmenopausal/O women/O (/O 50/O to/O 79/O years/O of/O age/O )/O during/O 7.1/O years/O of/O treatment/O with/O daily/O oral/B-DrugClass conjugated/I-DrugClass estrogens/I-DrugClass (/O 0.625/O mg)-alone/O ,/O relative/O to/O placebo/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O The/O WHI/O Memory/O Study/O (/O WHIMS/O )/O estrogen/O -/O alone/O ancillary/O study/O of/O WHI/O reported/O an/O increased/O risk/O of/O probable/O dementia/B-AdverseReaction in/O postmenopausal/O women/O 65/O years/O of/O age/O and/O older/O during/O 5.2/O years/O of/O treatment/O with/O daily/O conjugated/B-DrugClass estrogens/I-DrugClass (/O 0.625/O mg)-alone/O ,/O relative/O to/O placebo/O ./O
It/O is/O unknown/O whether/O this/O finding/O applies/O to/O younger/O postmenopausal/O women/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O In/O the/O absence/O of/O comparable/O data/O ,/O these/O risks/O should/O be/O assumed/O to/O be/O similar/O for/O other/O doses/O of/O conjugated/O estrogens/O and/O other/O dosage/O forms/O of/O estrogens/O ./O
Estrogens/O should/O be/O prescribed/O at/O the/O lowest/O effective/O doses/O and/O for/O the/O shortest/O duration/O consistent/O with/O treatment/O goals/O and/O risks/O for/O the/O individual/O woman/O ./O
EXCERPT/O :/O WARNING/O :/O ENDOMETRIAL/B-AdverseReaction CANCER/I-AdverseReaction ,/O CARDIOVASCULAR/B-AdverseReaction DISORDERS/I-AdverseReaction ,/O AND/O PROBABLE/B-Factor DEMENTIA/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O Boxed/O Warning/O ./O
Women/O taking/O DUAVEE/O should/O not/O take/O additional/O estrogens/O (/O 5.1/O )/O There/O is/O an/O increased/O risk/O of/O endometrial/B-AdverseReaction cancer/I-AdverseReaction in/O a/O woman/O with/O a/O uterus/O who/O uses/O unopposed/O estrogens/B-DrugClass (/O 5.1/O ,/O 5.3/O )/O Estrogen/O therapy/O should/O not/O be/O used/O for/O the/O prevention/O of/O cardiovascular/O disease/O or/O dementia/O (/O 5.2/O ,/O 5.4/O )/O The/O Women/O 's/O Health/O Initiative/O (/O WHI/O )/O estrogen/B-DrugClass -/O alone/O substudy/O reported/O increased/O risks/O of/O stroke/B-AdverseReaction and/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction (/O DVT/B-AdverseReaction )/O (/O 5.2/O )/O The/O WHI/O Memory/O Study/O (/O WHIMS/O )/O estrogen/B-DrugClass -/O alone/O ancillary/O study/O of/O WHI/O reported/O an/O increased/O risk/O of/O probable/O dementia/B-AdverseReaction in/O postmenopausal/O women/O 65/O years/O of/O age/O and/O older/O (/O 5.4/O )/O BOXED/O WARNING/O :/O Patient/O InformationDUAVEE/O (/O r/O )/O (/O DEW/O '/O ah/O -/O vee)(conjugated/O estrogens/O bazedoxifene)Tablets/O Read/O this/O Patient/O Information/O before/O you/O start/O taking/O DUAVEE/O and/O each/O time/O you/O get/O a/O refill/O ./O
There/O may/O be/O new/O information/O ./O
This/O information/O does/O not/O take/O the/O place/O of/O talking/O to/O your/O healthcare/O provider/O about/O your/O medical/O condition/O or/O your/O treatment/O ./O
What/O is/O the/O most/O important/O information/O I/O should/O know/O about/O DUAVEE/O ?/O Do/O not/O take/O additional/O estrogen/O products/O while/O you/O are/O taking/O DUAVEE/O ./O
Using/O estrogens/O may/O increase/O your/O chance/O of/O getting/O cancer/O of/O the/O uterus/O (/O womb/O )/O ./O
Report/O any/O unusual/O vaginal/O bleeding/O right/O away/O while/O you/O are/O taking/O DUAVEE/O ./O
Vaginal/O bleeding/O after/O menopause/O may/O be/O a/O warning/O sign/O of/O cancer/O of/O the/O uterus/O (/O womb/O )/O ./O
Your/O healthcare/O provider/O should/O check/O any/O unusual/O vaginal/O bleeding/O to/O find/O out/O the/O cause/O ./O
Do/O not/O use/O estrogens/O to/O prevent/O heart/O disease/O ,/O heart/O attacks/O ,/O strokes/O or/O dementia/O (/O decline/O in/O brain/O function/O )/O ./O
Using/O estrogens/O may/O increase/O your/O chances/O of/O getting/O strokes/O or/O blood/O clots/O ./O
Using/O estrogens/O may/O increase/O your/O chance/O of/O getting/O dementia/O ,/O based/O on/O a/O study/O of/O women/O 65/O years/O of/O age/O or/O older/O ./O
You/O and/O your/O healthcare/O provider/O should/O talk/O regularly/O about/O whether/O you/O still/O need/O treatment/O with/O DUAVEE/O ./O
What/O is/O DUAVEE/O ?/O DUAVEE/O is/O a/O prescription/O medicine/O that/O contains/O a/O mixture/O of/O estrogens/O and/O bazedoxifene/O ./O
What/O is/O DUAVEE/O used/O for/O ?/O DUAVEE/O is/O used/O after/O menopause/O for/O women/O with/O a/O uterus/O to/O :/O reduce/O moderate/O to/O severe/O hot/O flushesEstrogens/O are/O hormones/O made/O by/O a/O woman/O 's/O ovaries/O ./O
The/O ovaries/O normally/O stop/O making/O estrogens/O when/O a/O woman/O is/O between/O 45/O and/O 55/O years/O old/O ./O
This/O drop/O in/O body/O estrogen/O levels/O causes/O the/O "/O change/O of/O life/O "/O or/O menopause/O (/O the/O end/O of/O monthly/O menstrual/O periods/O )/O ./O
Sometimes/O both/O ovaries/O are/O removed/O during/O an/O operation/O before/O natural/O menopause/O takes/O place/O ./O
The/O sudden/O drop/O in/O estrogen/O levels/O causes/O "/O surgical/O menopause/O ./O
"When/O the/O estrogen/O levels/O begin/O dropping/O ,/O some/O women/O get/O very/O uncomfortable/O symptoms/O ,/O such/O as/O feelings/O of/O warmth/O in/O the/O face/O ,/O neck/O ,/O and/O chest/O ,/O or/O sudden/O intense/O episodes/O of/O heat/O and/O sweating/O (/O "/O hot/O flashes/O "/O or/O "/O hot/O flushes/O "/O )/O ./O
In/O some/O women/O ,/O the/O symptoms/O are/O mild/O ,/O and/O they/O will/O not/O need/O to/O take/O medicines/O ./O
In/O other/O women/O ,/O symptoms/O can/O be/O more/O severe/O ./O
help/O reduce/O your/O chances/O of/O developing/O osteoporosis/O (/O thin/O ,/O weak/O bones)If/O you/O use/O DUAVEE/O only/O to/O prevent/O osteoporosis/O due/O to/O menopause/O ,/O talk/O with/O your/O healthcare/O provider/O about/O whether/O a/O different/O treatment/O or/O medicine/O without/O estrogens/O might/O be/O better/O for/O you/O ./O
DUAVEE/O should/O be/O taken/O for/O the/O shortest/O time/O possible/O and/O only/O for/O as/O long/O as/O treatment/O is/O needed/O ./O
You/O and/O your/O healthcare/O provider/O should/O talk/O regularly/O about/O whether/O you/O still/O need/O treatment/O with/O DUAVEE/O ./O
DUAVEE/O is/O not/O for/O use/O in/O children/O ./O
It/O is/O not/O known/O if/O DUAVEE/O is/O safe/O and/O effective/O in/O people/O with/O kidney/O problems/O ./O
Who/O should/O not/O take/O DUAVEE/O ?/O Do/O not/O take/O DUAVEE/O if/O you/O :/O currently/O have/O or/O have/O had/O blood/O clots/O are/O allergic/O to/O estrogens/O or/O bazedoxifene/O ,/O the/O active/O ingredients/O in/O DUAVEE/O ,/O or/O any/O of/O its/O ingredients/O ./O
See/O the/O list/O of/O ingredients/O in/O DUAVEE/O at/O the/O end/O of/O this/O leaflet/O ./O
have/O unusual/O vaginal/O bleeding/O ./O
Vaginal/O bleeding/O after/O menopause/O may/O be/O a/O warning/O sign/O of/O cancer/O of/O the/O uterus/O (/O womb/O )/O ./O
Your/O healthcare/O provider/O should/O check/O any/O unusual/O vaginal/O bleeding/O to/O find/O out/O the/O cause/O ./O
currently/O have/O or/O have/O had/O certain/O cancers/O ./O
Estrogens/O may/O increase/O the/O chances/O of/O getting/O certain/O types/O of/O cancers/O ,/O including/O cancer/O of/O the/O breast/O or/O uterus/O ./O
If/O you/O have/O or/O have/O had/O cancer/O ,/O talk/O with/O your/O healthcare/O provider/O about/O whether/O you/O should/O use/O DUAVEE/O ./O
currently/O have/O or/O have/O had/O liver/O problems/O have/O been/O diagnosed/O with/O a/O bleeding/O disorder/O think/O you/O may/O be/O pregnant/O ./O
DUAVEE/O is/O not/O for/O pregnant/O women/O ./O
If/O you/O think/O you/O may/O be/O pregnant/O ,/O you/O should/O have/O a/O pregnancy/O test/O and/O know/O the/O results/O ./O
Do/O not/O take/O DUAVEE/O if/O the/O test/O is/O positive/O and/O talk/O to/O your/O healthcare/O provider/O ./O
are/O breastfeeding/O or/O plan/O to/O breastfeed/O ./O
It/O is/O not/O known/O if/O DUAVEE/O passes/O into/O your/O breast/O milk/O ./O
You/O and/O your/O healthcare/O provider/O should/O decide/O if/O you/O will/O take/O DUAVEE/O or/O breastfeed/O ./O
You/O should/O not/O do/O both/O ./O
What/O should/O I/O tell/O my/O healthcare/O provider/O before/O taking/O DUAVEE/O ?/O Before/O you/O take/O DUAVEE/O ,/O tell/O your/O healthcare/O provider/O if/O you/O :/O have/O any/O unusual/O vaginal/O bleeding/O ./O
have/O any/O other/O medical/O conditions/O ./O
Your/O healthcare/O provider/O may/O need/O to/O check/O you/O more/O carefully/O if/O you/O have/O certain/O conditions/O ,/O such/O as/O asthma/O (/O wheezing/O )/O ,/O epilepsy/O (/O seizures/O )/O ,/O diabetes/O ,/O migraine/O ,/O endometriosis/O ,/O lupus/O ,/O or/O problems/O with/O your/O heart/O ,/O liver/O ,/O thyroid/O ,/O kidneys/O ,/O or/O have/O high/O calcium/O levels/O in/O your/O blood/O ./O
are/O going/O to/O have/O surgery/O or/O will/O be/O on/O bed/O rest/O ./O
Your/O healthcare/O provider/O will/O let/O you/O know/O if/O you/O need/O to/O stop/O taking/O DUAVEE/O ./O
Tell/O your/O healthcare/O provider/O about/O all/O the/O medicines/O you/O take/O ,/O including/O prescription/O and/O over/O -/O the/O -/O counter/O medicines/O ,/O vitamins/O ,/O and/O herbal/O supplements/O ./O
Especially/O tell/O your/O healthcare/O provider/O if/O you/O take/O other/O hormonal/O medicines/O ,/O including/O progestins/O or/O other/O medicines/O like/O DUAVEE/O ./O
Ask/O your/O healthcare/O provider/O if/O you/O do/O not/O know/O if/O you/O take/O any/O of/O these/O medicines/O ./O
Some/O medicines/O may/O affect/O how/O DUAVEE/O works/O ./O
DUAVEE/O may/O also/O affect/O how/O your/O other/O medicines/O work/O ./O
Keep/O a/O list/O of/O your/O medicines/O and/O show/O it/O to/O your/O healthcare/O provider/O and/O pharmacist/O when/O you/O get/O a/O new/O medicine/O ./O
How/O should/O I/O take/O DUAVEE/O ?/O DUAVEE/O comes/O in/O a/O blister/O package/O ./O
Record/O the/O date/O you/O open/O the/O foil/O pouch/O in/O the/O space/O provided/O on/O the/O blister/O package/O label/O ./O
Do/O not/O use/O if/O the/O blister/O package/O has/O been/O open/O for/O more/O than/O 60/O days/O ./O
Take/O DUAVEE/O exactly/O as/O your/O healthcare/O provider/O tells/O you/O to/O take/O it/O ./O
Take/O 1/O DUAVEE/O tablet/O at/O the/O same/O time/O each/O day/O ./O
DUAVEE/O should/O be/O swallowed/O whole/O ./O
Take/O DUAVEE/O with/O or/O without/O food/O ./O
You/O should/O not/O remove/O DUAVEE/O from/O the/O blister/O until/O right/O before/O you/O are/O ready/O to/O take/O it/O ./O
Remove/O 1/O tablet/O at/O a/O time/O from/O the/O blister/O package/O ./O
Do/O not/O place/O DUAVEE/O in/O pill/O boxes/O or/O pill/O organizers/O ./O
If/O you/O miss/O a/O dose/O of/O DUAVEE/O ,/O take/O it/O as/O soon/O as/O you/O remember/O ./O
If/O it/O is/O almost/O time/O for/O your/O next/O dose/O ,/O skip/O the/O missed/O dose/O ./O
Take/O the/O next/O dose/O at/O your/O regular/O time/O ./O
Do/O not/O take/O 2/O doses/O at/O the/O same/O time/O unless/O your/O healthcare/O provider/O tells/O you/O to/O ./O
If/O you/O are/O not/O sure/O about/O your/O dosing/O ,/O call/O your/O healthcare/O provider/O ./O
If/O you/O take/O a/O calcium/O or/O vitamin/O D/O supplement/O ,/O you/O may/O take/O it/O at/O the/O same/O time/O you/O take/O DUAVEE/O ./O
If/O you/O take/O too/O much/O DUAVEE/O ,/O call/O your/O healthcare/O provider/O ./O
Symptoms/O of/O taking/O too/O much/O DUAVEE/O include/O :/O nauseavomitingbreast/O tendernessdizzinessabdominal/O painfeeling/O tiredvaginal/O bleeding/O What/O are/O the/O possible/O side/O effects/O of/O DUAVEE/O ?/O Side/O effects/O are/O grouped/O by/O how/O serious/O they/O are/O and/O how/O often/O they/O happen/O when/O you/O are/O treated/O ./O
Serious/O side/O effects/O include/O :/O blood/O clots/O stroke/O heart/O attack/O cancer/O of/O the/O lining/O of/O the/O uterus/O breast/O cancer/O cancer/O of/O the/O ovary/O dementia/O gallbladder/O problems/O loss/O of/O vision/O high/O blood/O pressure/O increased/O fats/O in/O your/O blood/O liver/O problems/O thyroid/O problems/O fluid/O retention/O low/O calcium/O swelling/O of/O your/O mouth/O or/O tongue/O worsening/O of/O other/O medical/O problems/O such/O as/O asthma/O ,/O diabetes/O ,/O epilepsy/O ,/O migraines/O ,/O a/O genetic/O problem/O called/O porphyria/O ,/O lupus/O and/O liver/O problems/O Call/O your/O healthcare/O provider/O right/O away/O if/O you/O get/O any/O of/O the/O following/O warning/O signs/O ,/O or/O any/O other/O unusual/O symptoms/O that/O concern/O you/O :/O new/O breast/O lumps/O unusual/O vaginal/O bleeding/O changes/O in/O vision/O or/O speech/O sudden/O new/O severe/O headaches/O severe/O pains/O in/O your/O chest/O or/O legs/O with/O or/O without/O shortness/O of/O breath/O ,/O weakness/O and/O fatigue/O Less/O serious/O ,/O but/O common/O side/O effects/O include/O :/O muscle/O spasms/O nausea/O diarrhea/O upset/O stomach/O abdominal/O pain/O throat/O pain/O dizziness/O neck/O pain/O These/O are/O not/O all/O the/O possible/O side/O effects/O of/O DUAVEE/O ./O
For/O more/O information/O ,/O ask/O your/O healthcare/O provider/O or/O pharmacist/O ./O
Tell/O your/O healthcare/O provider/O if/O you/O have/O any/O side/O effects/O that/O bother/O you/O or/O do/O not/O go/O away/O ./O
Call/O your/O doctor/O for/O medical/O advice/O about/O side/O effects/O ./O
You/O may/O report/O side/O effects/O to/O FDA/O at/O 1/O -/O 800-FDA-1088/O ./O
What/O can/O I/O do/O to/O lower/O my/O chances/O of/O a/O serious/O side/O effect/O with/O DUAVEE/O ?/O Talk/O with/O your/O healthcare/O provider/O regularly/O about/O whether/O you/O should/O continue/O taking/O DUAVEE/O ./O
See/O you/O healthcare/O provider/O right/O away/O if/O you/O get/O vaginal/O bleeding/O while/O taking/O DUAVEE/O ./O
Have/O a/O pelvic/O exam/O ,/O breast/O exam/O and/O mammogram/O (/O breast/O X/O -/O ray/O )/O every/O year/O unless/O your/O healthcare/O provider/O tells/O you/O something/O else/O ./O
If/O members/O of/O your/O family/O have/O had/O breast/O cancer/O or/O if/O you/O have/O ever/O had/O breast/O lumps/O or/O an/O abnormal/O mammogram/O ,/O you/O may/O need/O to/O have/O breast/O exams/O more/O often/O ./O
If/O you/O have/O high/O blood/O pressure/O ,/O high/O cholesterol/O (/O fat/O in/O the/O blood/O )/O ,/O diabetes/O ,/O are/O overweight/O ,/O or/O if/O you/O use/O tobacco/O ,/O you/O may/O have/O higher/O chances/O of/O getting/O heart/O disease/O ./O
Ask/O your/O healthcare/O provider/O for/O ways/O to/O lower/O your/O chances/O of/O getting/O heart/O disease/O ./O
How/O do/O I/O store/O DUAVEE/O ?/O Store/O DUAVEE/O at/O room/O temperature/O between/O 68/O degrees/O F/O to/O 77/O degrees/O F/O (/O 20/O degrees/O C/O to/O 25/O degrees/O C/O )/O ./O
Keep/O DUAVEE/O in/O the/O blister/O until/O you/O are/O ready/O to/O take/O it/O to/O protect/O the/O tablet/O from/O moisture/O ./O
Do/O not/O place/O DUAVEE/O in/O pill/O boxes/O or/O pill/O organizers/O ./O
After/O opening/O the/O foil/O pouch/O the/O DUAVEE/O blisters/O come/O in/O ,/O DUAVEE/O must/O be/O used/O within/O 60/O days/O ./O
Keep/O DUAVEE/O and/O all/O other/O medicines/O out/O of/O the/O reach/O of/O children/O ./O
General/O information/O about/O the/O safe/O and/O effective/O use/O of/O DUAVEE/O Medicines/O are/O sometimes/O prescribed/O for/O purposes/O other/O than/O those/O listed/O in/O a/O Patient/O Information/O leaflet/O ./O
Do/O not/O use/O DUAVEE/O for/O a/O condition/O for/O which/O it/O was/O not/O prescribed/O ./O
Do/O not/O give/O DUAVEE/O to/O other/O people/O ,/O even/O if/O they/O have/O the/O same/O symptoms/O you/O have/O ./O
It/O may/O harm/O them/O ./O
This/O Patient/O Information/O summarizes/O the/O most/O important/O information/O about/O DUAVEE/O ./O
If/O you/O would/O like/O more/O information/O ,/O talk/O with/O your/O healthcare/O provider/O ./O
You/O can/O ask/O your/O pharmacist/O or/O healthcare/O provider/O for/O information/O about/O DUAVEE/O that/O is/O written/O for/O health/O professionals/O ./O
For/O more/O information/O ,/O go/O to/O www.DUAVEE.com/O ,/O or/O call/O 1/O -/O 800/O -/O 438/O -/O 1985/O ./O
What/O are/O the/O ingredients/O in/O DUAVEE/O ?/O Active/O Ingredients/O :/O conjugated/O estrogens/O and/O bazedoxifene/O ./O
Conjugated/O estrogens/O are/O a/O mixture/O of/O sodium/O estrone/O sulfate/O and/O sodium/O equilin/O sulfate/O and/O other/O components/O ,/O including/O sodium/O sulfate/O conjugates/O ,/O 17alpha/O -/O dihydroequilin/O ,/O 17alpha/O -/O estradiol/O ,/O and/O 17beta/O -/O dihydroequilin/O ./O
Inactive/O Ingredients/O :/O calcium/O phosphate/O tribasic/O ,/O hydroxypropyl/O cellulose/O ,/O microcrystalline/O cellulose/O ,/O powdered/O cellulose/O ,/O hypromellose/O ,/O lactose/O monohydrate/O ,/O magnesium/O stearate/O ,/O polyethylene/O glycol/O ,/O sucrose/O ,/O ascorbic/O acid/O ,/O sucrose/O palmitic/O acid/O ester/O ,/O hydroxyethylcellulose/O ,/O titanium/O dioxide/O ,/O red/O iron/O oxide/O ,/O yellow/O iron/O oxide/O ,/O black/O iron/O oxide/O ,/O povidone/O ,/O polydextrose/O ,/O maltitol/O ,/O poloxamer/O 188/O ,/O propylene/O glycol/O ,/O isopropyl/O alcohol/O ./O
This/O Patient/O Information/O has/O been/O approved/O by/O the/O U.S./O Food/O and/O Drug/O Administration/O ./O
This/O product/O 's/O label/O may/O have/O been/O updated/O ./O
For/O current/O full/O prescribing/O information/O ,/O please/O visit/O www.pfizer.com/O ./O
LAB-0583/O -/O 1.0/O October/O 2013/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Women/O taking/O DUAVEE/O should/O not/O take/O progestins/O ,/O additional/O estrogens/O or/O additional/O estrogen/O agonist/O antagonists/O (/O 5.1/O )/O Cardiovascular/B-AdverseReaction disorders/I-AdverseReaction ,/O including/O venous/B-AdverseReaction thromboembolism/I-AdverseReaction ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction ,/O stroke/B-AdverseReaction ,/O and/O retinal/B-AdverseReaction vascular/I-AdverseReaction thrombosis/I-AdverseReaction (/O 5.2/O ,/O 5.6/O )/O Malignant/B-AdverseReaction neoplasms/I-AdverseReaction ,/O including/O endometrial/B-AdverseReaction cancer/I-AdverseReaction ,/O breast/B-AdverseReaction cancer/I-AdverseReaction ,/O and/O ovarian/B-AdverseReaction cancer/I-AdverseReaction (/O 5.3/O )/O Estrogens/O increase/O the/O risk/B-Factor of/O gallbladder/B-AdverseReaction disease/I-AdverseReaction (/O 5.5/O )/O Discontinue/O estrogen/O if/O loss/O of/O vision/O ,/O severe/O hypertriglyceridemia/O or/O cholestatic/O jaundice/O occurs/O (/O 5.6/O ,/O 5.8/O ,/O 5.9/O )/O Monitor/O thyroid/O function/O in/O women/O on/O thyroid/O replacement/O therapy/O (/O 5.10/O ,/O 5.17/O )/O 5.1/O Drugs/O Containing/O Progestins/O ,/O Estrogens/O or/O Estrogen/O Agonist/O Antagonists/O DUAVEE/O contains/O conjugated/O estrogens/O and/O bazedoxifene/O ,/O an/O estrogen/O agonist/O antagonist/O ./O
Women/O taking/O DUAVEE/O should/O not/O take/O progestins/O ,/O additional/O estrogens/O or/O additional/O estrogen/O agonist/O antagonists/O ./O
5.2/O Cardiovascular/O Disorders/O Estrogen/O agonist/O antagonists/O (/O including/O bazedoxifene/O ,/O a/O component/O of/O DUAVEE/O )/O and/O estrogens/O individually/O are/O known/O to/O increase/O the/O risk/B-Factor of/O VTE/B-AdverseReaction ./O
An/O increased/O risk/O of/O stroke/B-AdverseReaction and/O DVT/B-AdverseReaction has/O been/O reported/O with/O estrogen/B-DrugClass -/O alone/O therapy/O ./O
Should/O any/O of/O these/O occur/O or/O be/O suspected/O ,/O DUAVEE/O should/O be/O discontinued/O immediately/O ./O
Risk/O factors/O for/O arterial/O vascular/O disease/O (/O for/O example/O ,/O hypertension/O ,/O diabetes/O mellitus/O ,/O tobacco/O use/O ,/O hypercholesterolemia/O ,/O and/O obesity/O )/O and/or/O VTE/O (/O for/O example/O ,/O personal/O history/O or/O family/O history/O of/O VTE/O ,/O obesity/O ,/O and/O systemic/O lupus/O erythematosus/O )/O should/O be/O managed/O appropriately/O ./O
Stroke/O In/O the/O WHI/O estrogen/O -/O alone/O substudy/O ,/O a/O statistically/O significant/O increased/O risk/O of/O stroke/B-AdverseReaction was/O reported/O in/O women/O 50/O to/O 79/O years/O of/O age/O receiving/O daily/O conjugated/B-DrugClass estrogens/I-DrugClass (/O CE/O )/O (/O 0.625/O mg)-alone/O compared/O to/O women/O in/O the/O same/O age/O group/O receiving/O placebo/O (/O 45/O versus/O 33/O per/O 10,000/O women/O -/O years/O )/O ./O
The/O increase/O in/O risk/O was/O demonstrated/O in/O year/O 1/O and/O persisted/O [/O see/O Clinical/O Studies/O (/O 14.5/O )/O ]/O ./O
Subgroup/O analyses/O of/O women/O 50/O to/O 59/O years/O of/O age/O suggest/O no/B-Negation increased/O risk/O of/O stroke/B-AdverseReaction for/O those/O women/O receiving/O conjugated/B-DrugClass estrogens/I-DrugClass (/O 0.625/O mg)-alone/O versus/O those/O receiving/O placebo/O (/O 18/O versus/O 21/O per/O 10,000/O women/O -/O years/O )/O ./O
Should/O a/O stroke/O occur/O or/O be/O suspected/O ,/O DUAVEE/O should/O be/O discontinued/O immediately/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
Coronary/O Heart/O Disease/O In/O the/O WHI/O estrogen/O -/O alone/O substudy/O ,/O no/O overall/O effect/O on/O coronary/B-AdverseReaction heart/I-AdverseReaction disease/I-AdverseReaction (/O CHD/B-AdverseReaction )/O events/O (/O defined/O as/O nonfatal/B-Severity myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O silent/B-AdverseReaction myocardial/I-AdverseReaction infarction/I-AdverseReaction ,/O or/O CHD/B-AdverseReaction death/I-AdverseReaction )/O was/O reported/O in/O women/O receiving/O estrogen/B-DrugClass -/O alone/O compared/O to/O placebo/O [/O see/O Clinical/O Studies/O (/O 14.5/O )/O ]/O ./O
Subgroup/O analyses/O of/O women/O 50/O to/O 59/O years/O of/O age/O suggest/O a/O statistically/O non/O -/O significant/O reduction/B-Negation in/O CHD/B-AdverseReaction events/O (/O CE/O [/O 0.625/O mg]-alone/O compared/O to/O placebo/O )/O in/O women/O with/O less/O than/O 10/O years/O since/O menopause/O (/O 8/O versus/O 16/O per/O 10,000/O women/O -/O years/O )/O ./O
Venous/O Thromboembolism/O (/O VTE/O )/O In/O the/O WHI/O estrogen/O -/O alone/O substudy/O ,/O the/O risk/O of/O VTE/B-AdverseReaction [/O DVT/B-AdverseReaction and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O PE/B-AdverseReaction )/O ]/O was/O increased/O for/O women/O receiving/O daily/O conjugated/B-DrugClass estrogens/I-DrugClass (/O 0.625/O mg)-alone/O compared/O to/O placebo/O (/O 30/O versus/O 22/O per/O 10,000/O women/O -/O years/O )/O ,/O although/O only/O the/O increased/O risk/O of/O DVT/B-AdverseReaction reached/O statistical/O significance/O (/O 23/O versus/O 15/O per/O 10,000/O women/O -/O years/O )/O ./O
The/O increase/O in/O VTE/B-AdverseReaction risk/B-Factor was/O demonstrated/O during/O the/O first/O 2/O years/O [/O see/O Clinical/O Studies/O (/O 14.5/O )/O ]/O ./O
If/O feasible/O ,/O DUAVEE/O should/O be/O discontinued/O at/O least/O 4/O to/O 6/O weeks/O before/O surgery/O of/O the/O type/O associated/O with/O an/O increased/O risk/O of/O thromboembolism/O ,/O or/O during/O periods/O of/O prolonged/O immobilization/O ./O
Because/O immobilization/O increases/O the/O risk/O for/O venous/O thromboembolic/O events/O independent/O of/O therapy/O ,/O DUAVEE/O should/O be/O discontinued/O prior/O to/O and/O during/O prolonged/O immobilization/O (/O e.g./O ,/O post/O -/O surgical/O recovery/O ,/O prolonged/O bed/O rest/O )/O and/O DUAVEE/O therapy/O should/O be/O resumed/O only/O after/O the/O patient/O is/O fully/O ambulatory/O ./O
In/O addition/O ,/O women/O taking/O DUAVEE/O should/O be/O advised/O to/O move/O about/O periodically/O during/O travel/O involving/O prolonged/O immobilization/O ./O
5.3/O Malignant/O Neoplasms/O Endometrial/O Cancer/O An/O increased/O risk/O of/O endometrial/B-AdverseReaction cancer/I-AdverseReaction has/O been/O reported/O with/O the/O use/O of/O unopposed/O estrogen/B-DrugClass therapy/O in/O women/O with/O a/O uterus/O ./O
The/O reported/O endometrial/B-AdverseReaction cancer/I-AdverseReaction risk/O among/O unopposed/O estrogen/B-DrugClass users/O is/O about/O 2/O to/O 12/O times/O greater/O than/O in/O non/O -/O users/O ,/O and/O appears/O dependent/O on/O duration/O of/O treatment/O and/O on/O estrogen/O dose/O ./O
Most/O studies/O show/O no/O significant/O increased/O risk/O associated/O with/O use/O of/O estrogens/O for/O less/O than/O 1/O year/O ./O
The/O greatest/O risk/O appears/O associated/O with/O prolonged/O use/O ,/O with/O increased/O risks/O of/O 15-/O to/O 24-fold/O for/O 5/O to/O 10/O years/O or/O more/O of/O treatment/O ./O
This/O risk/O has/O been/O shown/O to/O persist/O for/O at/O least/O 8/O to/O 15/O years/O after/O estrogen/O therapy/O is/O discontinued/O ./O
DUAVEE/O contains/O an/O estrogen/O agonist/O antagonist/O ./O
This/O component/O reduces/O the/O risk/O of/O endometrial/O hyperplasia/O that/O can/O occur/O with/O the/O conjugated/O estrogens/O component/O ./O
Endometrial/O hyperplasia/O may/O be/O a/O precursor/O to/O endometrial/O cancer/O ./O
Women/O taking/O DUAVEE/O should/O not/O take/O additional/O estrogens/O as/O this/O may/O increase/O the/O risk/O of/O endometrial/O hyperplasia/O ./O
Clinical/O surveillance/O of/O all/O women/O taking/O DUAVEE/O is/O important/O ./O
Adequate/O diagnostic/O measures/O ,/O including/O directed/O or/O random/O endometrial/O sampling/O when/O indicated/O ,/O should/O be/O undertaken/O to/O rule/O out/O malignancy/O in/O postmenopausal/O women/O with/O undiagnosed/O persistent/O or/O recurring/O abnormal/O genital/O bleeding/O ./O
Breast/O Cancer/O The/O most/O important/O randomized/O clinical/O study/O providing/O information/O about/O breast/O cancer/O in/O estrogen/O -/O alone/O users/O is/O the/O WHI/O substudy/O of/O daily/O conjugated/O estrogens/O (/O 0.625/O mg)-alone/O ./O
In/O the/O WHI/O estrogen/O -/O alone/O substudy/O ,/O after/O an/O average/O follow/O -/O up/O of/O 7.1/O years/O ,/O daily/O conjugated/B-DrugClass estrogen/I-DrugClass (/O 0.625/O mg)-alone/O was/O not/O associated/O with/O an/O increased/O risk/O of/O invasive/B-AdverseReaction breast/I-AdverseReaction cancer/I-AdverseReaction (/O relative/O risk/O [/O RR/O ]/O 0.80/O )/O ./O
The/O use/O of/O estrogen/O -/O alone/O has/O been/O reported/O to/O result/O in/O an/O increase/O in/O abnormal/O mammograms/O requiring/O further/O evaluation/O ./O
The/O effect/O of/O treatment/O with/O DUAVEE/O on/O the/O risk/O of/O breast/O cancer/O is/O unknown/O ./O
All/O women/O should/O receive/O yearly/O breast/O examinations/O by/O a/O healthcare/O provider/O and/O perform/O monthly/O breast/O self/O -/O examinations/O ./O
In/O addition/O ,/O mammography/O examinations/O should/O be/O scheduled/O based/O on/O patient/O age/O ,/O risk/O factors/O ,/O and/O prior/O mammogram/O results/O ./O
Ovarian/O Cancer/O In/O some/O epidemiological/O studies/O ,/O the/O use/O of/O estrogen/B-DrugClass -/O only/O products/O ,/O in/O particular/O for/O 5/O or/O more/O years/O ,/O has/O been/O associated/O with/O an/O increased/O risk/O of/O ovarian/B-AdverseReaction cancer/I-AdverseReaction ./O
However/O ,/O the/O duration/O of/O exposure/O associated/O with/O increased/O risk/O is/O not/O consistent/O across/O all/O epidemiologic/O studies/O ,/O and/O some/O report/O no/O association/O ./O
The/O effect/O of/O treatment/O with/O DUAVEE/O on/O the/O risk/O of/O ovarian/O cancer/O is/O unknown/O ./O
5.4/O Probable/O Dementia/O In/O the/O WHIMS/O estrogen/O -/O alone/O ancillary/O study/O of/O WHI/O ,/O a/O population/O of/O 2,947/O hysterectomized/O women/O 65/O to/O 79/O years/O of/O age/O was/O randomized/O to/O daily/O CE/O (/O 0.625/O mg)-alone/O or/O placebo/O ./O
After/O an/O average/O follow/O -/O up/O of/O 5.2/O years/O ,/O 28/O women/O in/O the/O estrogen/B-DrugClass -/O alone/O group/O and/O 19/O women/O in/O the/O placebo/O group/O were/O diagnosed/O with/O probable/O dementia/B-AdverseReaction ./O
The/O relative/O risk/O of/O probable/O dementia/B-AdverseReaction for/O CE/B-DrugClass -/O alone/O versus/O placebo/O was/O 1.49/O (/O 95/O percent/O CI/O ,/O 0.83/O -/O 2.66/O )/O ./O
The/O absolute/O risk/O of/O probable/O dementia/B-AdverseReaction for/O CE/B-DrugClass -/O alone/O versus/O placebo/O was/O 37/O versus/O 25/O cases/O per/O 10,000/O women/O -/O years/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.5/O )/O and/O Clinical/O Studies/O (/O 14.6/O )/O ]/O ./O
5.5/O Gallbladder/O Disease/O A/O 2-/O to/O 4-fold/O increase/O in/O the/O risk/B-Factor of/O gallbladder/B-AdverseReaction disease/I-AdverseReaction requiring/O surgery/O in/O postmenopausal/O women/O receiving/O estrogens/O has/O been/O reported/O ./O
5.6/O Visual/O Abnormalities/O Retinal/B-AdverseReaction vascular/I-AdverseReaction thrombosis/I-AdverseReaction has/O been/O reported/O in/O patients/O receiving/O estrogens/O ./O
Discontinue/O medication/O pending/O examination/O if/O there/O is/O sudden/O partial/O or/O complete/O loss/O of/O vision/O ,/O or/O a/O sudden/O onset/O of/O proptosis/O ,/O diplopia/O ,/O or/O migraine/O ./O
If/O examination/O reveals/O papilledema/O or/O retinal/O vascular/O lesions/O ,/O DUAVEE/O should/O be/O permanently/O discontinued/O ./O
5.7/O Elevated/O Blood/O Pressure/O In/O a/O small/O number/O of/O case/O reports/O in/O women/O receiving/O estrogens/O ,/O substantial/B-Severity increases/B-AdverseReaction in/I-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction have/O been/O attributed/O to/O idiosyncratic/O reactions/O to/O estrogens/O ./O
In/O a/O large/O ,/O randomized/O ,/O placebo/O -/O controlled/O clinical/O study/O ,/O a/O generalized/O effect/O of/O estrogens/O on/O blood/O pressure/O was/O not/B-Negation seen/O ./O
5.8/O Hypertriglyceridemia/O In/O women/O with/O pre/O -/O existing/O hypertriglyceridemia/O ,/O treatment/O with/O estrogens/O may/B-Factor be/O associated/O with/O elevations/B-AdverseReaction of/I-AdverseReaction plasma/I-AdverseReaction triglycerides/I-AdverseReaction leading/O to/O pancreatitis/B-AdverseReaction ./O
Consider/O discontinuation/O of/O DUAVEE/O if/O pancreatitis/O occurs/O ./O
5.9/O Hepatic/O Impairment/O and/O Past/O History/O of/O Cholestatic/O Jaundice/O DUAVEE/O has/O not/O been/O studied/O in/O women/O with/O impaired/O liver/O function/O or/O past/O history/O of/O cholestatic/O jaundice/O ./O
Estrogens/O may/O be/O poorly/O metabolized/O in/O women/O with/O impaired/O liver/O function/O ./O
On/O average/O ,/O women/O with/O hepatic/O impairment/O treated/O with/O bazedoxifene/O alone/O showed/O a/O 4.3-fold/O increase/O in/O overall/O exposures/O compared/O with/O controls/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.7/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
For/O women/O with/O a/O history/O of/O cholestatic/O jaundice/O associated/O with/O past/O estrogen/O use/O or/O with/O pregnancy/O ,/O caution/O should/O be/O exercised/O ;/O and/O in/O the/O case/O of/O recurrence/O ,/O DUAVEE/O should/O be/O discontinued/O ./O
Use/O of/O DUAVEE/O in/O patients/O with/O hepatic/O impairment/O is/O contraindicated/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.10/O Hypothyroidism/O Estrogen/O administration/O leads/O to/O increased/O thyroid/O -/O binding/O globulin/O (/O TBG/O )/O levels/O ./O
Women/O with/O normal/O thyroid/O function/O can/O compensate/O for/O the/O increased/B-AdverseReaction TBG/I-AdverseReaction by/O making/O more/O thyroid/O hormone/O ,/O thus/O maintaining/O free/O T4/O and/O T3/O serum/O concentrations/O in/O the/O normal/O range/O ./O
Women/O dependent/O on/O thyroid/O hormone/O replacement/O therapy/O who/O are/O also/O receiving/O estrogens/O may/O require/O increased/O doses/O of/O their/O thyroid/O replacement/O therapy/O ./O
These/O women/O should/O have/O their/O thyroid/O function/O monitored/O in/O order/O to/O maintain/O their/O free/O thyroid/O hormone/O levels/O in/O an/O acceptable/O range/O ./O
5.11/O Fluid/O Retention/O Estrogens/O may/B-Factor cause/O some/O degree/O of/O fluid/B-AdverseReaction retention/I-AdverseReaction ./O
Because/O of/O this/O ,/O patients/O who/O have/O conditions/O that/O might/O be/O influenced/O by/O this/O factor/O ,/O such/O as/O cardiac/O dysfunction/O or/O renal/O impairment/O ,/O warrant/O careful/O observation/O when/O estrogens/O are/O prescribed/O ./O
Use/O of/O DUAVEE/O in/O patients/O with/O renal/O impairment/O is/O not/O recommended/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
5.12/O Hypocalcemia/O Estrogen/O therapy/O should/O be/O used/O with/O caution/O in/O women/O with/O hypoparathyroidism/O as/O estrogen/O -/O induced/O hypocalcemia/O may/O occur/O ./O
5.13/O Hereditary/O Angioedema/O Exogenous/O estrogens/O may/B-Factor exacerbate/O symptoms/O of/O angioedema/O in/O women/O with/O hereditary/O angioedema/O ./O
5.14/O Exacerbation/O of/O Other/O Conditions/O Estrogens/O may/O cause/O an/O exacerbation/O of/O asthma/O ,/O diabetes/O mellitus/O ,/O epilepsy/O ,/O migraine/O or/O porphyria/O ,/O systemic/O lupus/O erythematosus/O ,/O and/O hepatic/O hemangiomas/O and/O should/O be/O used/O with/O caution/O in/O women/O with/O these/O conditions/O ./O
5.15/O Premenopausal/O Women/O There/O is/O no/O indication/O for/O premenopausal/O use/O of/O DUAVEE/O ./O
The/O efficacy/O and/O safety/O of/O DUAVEE/O in/O premenopausal/O women/O have/O not/O been/O established/O ,/O and/O its/O use/O is/O not/O recommended/O ./O
5.16/O Laboratory/O Tests/O Serum/O follicle/O stimulating/O hormone/O (/O FSH/O )/O and/O estradiol/O levels/O have/O not/O been/O shown/O to/O be/O useful/O in/O the/O management/O of/O moderate/O to/O severe/O vasomotor/O symptoms/O ./O
5.17/O Drug/O -/O Laboratory/O Test/O Interactions/O Accelerated/B-AdverseReaction prothrombin/I-AdverseReaction time/I-AdverseReaction ,/O partial/O thromboplastin/O time/O ,/O and/O platelet/O aggregation/O time/O ;/O increased/B-AdverseReaction platelet/I-AdverseReaction count/I-AdverseReaction ;/O increased/B-AdverseReaction factors/I-AdverseReaction II/I-AdverseReaction ,/O VII/O antigen/O ,/O VIII/O antigen/O ,/O VIII/O coagulant/O activity/O ,/O IX/O ,/O X/O ,/O XII/O ,/O VII/O -/O X/O complex/O ,/O II/O -/O VII/O -/O X/O complex/O ,/O and/O beta/O -/O thromboglobulin/O ;/O decreased/B-AdverseReaction levels/I-AdverseReaction of/I-AdverseReaction antifactor/I-AdverseReaction Xa/I-AdverseReaction and/O antithrombin/O III/O ,/O decreased/B-AdverseReaction antithrombin/I-AdverseReaction III/I-AdverseReaction activity/I-AdverseReaction ;/O increased/B-AdverseReaction levels/I-AdverseReaction of/I-AdverseReaction fibrinogen/I-AdverseReaction and/O fibrinogen/O activity/O ;/O increased/B-AdverseReaction plasminogen/I-AdverseReaction antigen/I-AdverseReaction and/O activity/O ./O
Increased/B-AdverseReaction thyroid/I-AdverseReaction -/I-AdverseReaction binding/O globulin/O (/O TBG/O )/O leading/O to/O increased/B-AdverseReaction circulating/I-AdverseReaction total/I-AdverseReaction thyroid/I-AdverseReaction hormone/I-AdverseReaction ,/O as/O measured/O by/O protein/O -/O bound/O iodine/O (/O PBI/O )/O ,/O T4/O levels/O (/O by/O column/O or/O by/O radioimmunoassay/O )/O ,/O or/O T3/O levels/O by/O radioimmunoassay/O ./O
T3/O resin/O uptake/O is/O decreased/O ,/O reflecting/O the/O elevated/B-AdverseReaction TBG/I-AdverseReaction ./O
Free/O T4/O and/O free/O T3/O concentrations/O are/O unaltered/O ./O
Women/O on/O thyroid/O replacement/O therapy/O may/O require/O higher/O doses/O of/O thyroid/O hormone/O ./O
Other/O binding/O proteins/O may/B-Factor be/O elevated/O in/O serum/O ,/O for/O example/O ,/O corticosteroid/O binding/O globulin/O (/O CBG/O )/O ,/O sex/O hormone/O -/O binding/O globulin/O (/O SHBG/O )/O ,/O leading/O to/O increased/B-AdverseReaction total/I-AdverseReaction circulating/I-AdverseReaction corticosteroids/I-AdverseReaction and/O sex/O steroids/O ,/O respectively/O ./O
Free/O hormone/O concentrations/O ,/O such/O as/O testosterone/O and/O estradiol/O ,/O may/B-Factor be/O decreased/O ./O
Other/O plasma/O proteins/O may/B-Factor be/O increased/O (/O angiotensinogen/O renin/O substrate/O ,/O alpha-1-antitrypsin/O ,/O ceruloplasmin/O )/O ./O
Increased/B-AdverseReaction plasma/I-AdverseReaction high/I-AdverseReaction -/I-AdverseReaction density/O lipoprotein/O (/O HDL/O )/O and/O HDL2/O cholesterol/O subfraction/O concentrations/O ,/O reduced/O low/O -/O density/O lipoprotein/O (/O LDL/O )/O cholesterol/O concentrations/O ,/O increased/B-AdverseReaction triglyceride/I-AdverseReaction levels/I-AdverseReaction ./O
Impaired/B-AdverseReaction glucose/I-AdverseReaction tolerance/I-AdverseReaction ./O
6/O ADVERSE/O REACTIONS/O Adverse/O reactions/O associated/O with/O ophthalmic/B-DrugClass steroids/I-DrugClass include/O elevated/B-AdverseReaction intraocular/I-AdverseReaction pressure/I-AdverseReaction ,/O which/O may/O be/O associated/O with/O optic/B-AdverseReaction nerve/I-AdverseReaction damage/I-AdverseReaction ,/O visual/O acuity/O and/O field/O defects/O ,/O posterior/B-AdverseReaction subcapsular/I-AdverseReaction cataract/I-AdverseReaction formation/I-AdverseReaction ;/O secondary/B-AdverseReaction ocular/I-AdverseReaction infection/I-AdverseReaction from/O pathogens/O including/O herpes/O simplex/O ,/O and/O perforation/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction globe/I-AdverseReaction where/O there/O is/O thinning/O of/O the/O cornea/O or/O sclera/O ./O
6.1/O Ocular/O Surgery/O Ocular/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction occurring/O in/O 5/O -/O 15/O %/O of/O subjects/O in/O clinical/O studies/O with/O DUREZOL/O included/O corneal/B-AdverseReaction edema/I-AdverseReaction ,/O ciliary/O and/O conjunctival/B-AdverseReaction hyperemia/I-AdverseReaction ,/O eye/B-AdverseReaction pain/I-AdverseReaction ,/O photophobia/B-AdverseReaction ,/O posterior/B-AdverseReaction capsule/I-AdverseReaction opacification/I-AdverseReaction ,/O anterior/B-AdverseReaction chamber/I-AdverseReaction cells/I-AdverseReaction ,/O anterior/B-AdverseReaction chamber/I-AdverseReaction flare/I-AdverseReaction ,/O conjunctival/B-AdverseReaction edema/I-AdverseReaction ,/O and/O blepharitis/B-AdverseReaction ./O
Other/O ocular/O adverse/O reactions/O occurring/O in/O 1/O -/O 5/O %/O of/O subjects/O included/O reduced/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ,/O punctate/B-AdverseReaction keratitis/I-AdverseReaction ,/O eye/B-AdverseReaction inflammation/I-AdverseReaction ,/O and/O iritis/B-AdverseReaction ./O
Ocular/O adverse/O reactions/O occurring/O in/O 1/O %/O of/O subjects/O included/O application/B-AdverseReaction site/I-AdverseReaction discomfort/I-AdverseReaction or/O irritation/O ,/O corneal/B-AdverseReaction pigmentation/I-AdverseReaction and/O striae/O ,/O episcleritis/B-AdverseReaction ,/O eye/B-AdverseReaction pruritis/I-AdverseReaction ,/O eyelid/B-AdverseReaction irritation/I-AdverseReaction and/O crusting/O ,/O foreign/B-AdverseReaction body/I-AdverseReaction sensation/I-AdverseReaction ,/O increased/B-AdverseReaction lacrimation/I-AdverseReaction ,/O macular/B-AdverseReaction edema/I-AdverseReaction ,/O sclera/B-AdverseReaction hyperemia/I-AdverseReaction ,/O and/O uveitis/B-AdverseReaction ./O
Most/O of/O these/O reactions/O may/O have/O been/O the/O consequence/O of/O the/O surgical/O procedure/O ./O
6.2/O Endogenous/O Anterior/O Uveitis/O A/O total/O of/O 200/O subjects/O participated/O in/O the/O clinical/O trials/O for/O endogenous/O anterior/O uveitis/O ,/O of/O which/O 106/O were/O exposed/O to/O DUREZOL/O ./O
The/O most/O common/O adverse/O reactions/O of/O those/O exposed/O to/O DUREZOL/O occurring/O in/O 5/O -/O 10/O %/O of/O subjects/O included/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O eye/B-AdverseReaction irritation/I-AdverseReaction ,/O eye/B-AdverseReaction pain/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O increased/B-AdverseReaction IOP/I-AdverseReaction ,/O iritis/B-AdverseReaction ,/O limbal/O and/O conjunctival/B-AdverseReaction hyperemia/I-AdverseReaction ,/O punctate/B-AdverseReaction keratitis/I-AdverseReaction ,/O and/O uveitis/B-AdverseReaction ./O
Adverse/O reactions/O occurring/O in/O 2/O -/O 5/O %/O of/O subjects/O included/O anterior/B-AdverseReaction chamber/I-AdverseReaction flare/I-AdverseReaction ,/O corneal/B-AdverseReaction edema/I-AdverseReaction ,/O dry/B-AdverseReaction eye/I-AdverseReaction ,/O iridocyclitis/B-AdverseReaction ,/O photophobia/B-AdverseReaction ,/O and/O reduced/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Intraocular/O pressure/O (/O IOP/O )/O increase-/O Prolonged/O use/O of/O corticosteroids/B-DrugClass may/O result/O in/O glaucoma/B-AdverseReaction with/O damage/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction optic/I-AdverseReaction nerve/I-AdverseReaction ,/O defects/B-AdverseReaction in/I-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction and/O fields/O of/O vision/O ./O
If/O this/O product/O is/O used/O for/O 10/O days/O or/O longer/O ,/O IOP/O should/O be/O monitored/O ./O
(/O 5.1/O )/O item/O {/O Cataracts-/O Use/O of/O corticosteroids/B-DrugClass may/O result/O in/O posterior/B-AdverseReaction subcapsular/I-AdverseReaction cataract/I-AdverseReaction formation/O ./O
(/O 5.2/O )/O item/O {/O Delayed/O healing-/O The/O use/O of/O steroids/B-DrugClass after/O cataract/O surgery/O may/O delay/B-AdverseReaction healing/I-AdverseReaction and/O increase/O the/O incidence/O of/O bleb/O formation/O ./O
In/O those/O diseases/O causing/O thinning/O of/O the/O cornea/O or/O sclera/O ,/O perforations/B-AdverseReaction have/O been/O known/O to/O occur/O with/O the/O use/O of/O topical/O steroids/B-DrugClass ./O
The/O initial/O prescription/O and/O renewal/O of/O the/O medication/O order/O beyond/O 28/O days/O should/O be/O made/O by/O a/O physician/O only/O after/O examination/O of/O the/O patient/O with/O the/O aid/O of/O magnification/O such/O as/O slit/O lamp/O biomicroscopy/O and/O ,/O where/O appropriate/O ,/O fluorescein/O staining/O ./O
(/O 5.3/O )/O item/O {/O Bacterial/O infections-/O Prolonged/O use/O of/O corticosteroids/B-DrugClass may/O suppress/B-AdverseReaction the/I-AdverseReaction host/I-AdverseReaction response/I-AdverseReaction and/O thus/O increase/O the/O hazard/O of/O secondary/B-AdverseReaction ocular/I-AdverseReaction infections/I-AdverseReaction ./O
In/O acute/O purulent/O conditions/O ,/O steroids/O may/O mask/O infection/O or/O enhance/O existing/O infection/O ./O
If/O signs/O and/O symptoms/O fail/O to/O improve/O after/O 2/O days/O ,/O the/O patient/O should/O be/O re/O -/O evaluated/O ./O
(/O 5.4/O )/O item/O {/O Viral/O infections-/O Employment/O of/O a/O corticosteroid/O medication/O in/O the/O treatment/O of/O patients/O with/O a/O history/O of/O herpes/O simplex/O requires/O great/O caution/O ./O
Use/O of/O ocular/O steroids/B-DrugClass may/O prolong/O the/O course/O and/O may/O exacerbate/O the/O severity/O of/O many/O viral/O infections/O of/O the/O eye/O (/O including/O herpes/O simplex/O )/O ./O
(/O 5.5/O )/O item/O {/O Fungal/O infections-/O Fungal/B-AdverseReaction infections/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction cornea/I-AdverseReaction are/O particularly/O prone/O to/O develop/O coincidentally/O with/O long/O -/O term/O local/O steroid/B-DrugClass application/O ./O
Fungus/O invasion/O must/O be/O considered/O in/O any/O persistent/O corneal/O ulceration/O where/O a/O steroid/O has/O been/O used/O or/O is/O in/O use/O ./O
(/O 5.6/O )/O }/O }/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Alcon/O Laboratories/O ,/O Inc./O at/O 1/O -/O 800/O -/O 757/O -/O 9195/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
5.1/O IOP/O Increase/O Prolonged/O use/O of/O corticosteroids/B-DrugClass may/O result/O in/O glaucoma/B-AdverseReaction with/O damage/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction optic/I-AdverseReaction nerve/I-AdverseReaction ,/O defects/B-AdverseReaction in/I-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction and/O fields/O of/O vision/O ./O
Steroids/O should/O be/O used/O with/O caution/O in/O the/O presence/O of/O glaucoma/O ./O
If/O this/O product/O is/O used/O for/O 10/O days/O or/O longer/O ,/O intraocular/O pressure/O should/O be/O monitored/O ./O
5.2/O Cataracts/O Use/O of/O corticosteroids/B-DrugClass may/O result/O in/O posterior/B-AdverseReaction subcapsular/I-AdverseReaction cataract/I-AdverseReaction formation/O ./O
5.3/O Delayed/O Healing/O The/O use/O of/O steroids/B-DrugClass after/O cataract/O surgery/O may/O delay/B-AdverseReaction healing/I-AdverseReaction and/O increase/O the/O incidence/O of/O bleb/O formation/O ./O
In/O those/O diseases/O causing/O thinning/O of/O the/O cornea/O or/O sclera/O ,/O perforations/B-AdverseReaction have/O been/O known/O to/O occur/O with/O the/O use/O of/O topical/O steroids/B-DrugClass ./O
The/O initial/O prescription/O and/O renewal/O of/O the/O medication/O order/O beyond/O 28/O days/O should/O be/O made/O by/O a/O physician/O only/O after/O examination/O of/O the/O patient/O with/O the/O aid/O of/O magnification/O such/O as/O slit/O lamp/O biomicroscopy/O and/O ,/O where/O appropriate/O ,/O fluorescein/O staining/O ./O
5.4/O Bacterial/O Infections/O Prolonged/O use/O of/O corticosteroids/B-DrugClass may/O suppress/B-AdverseReaction the/I-AdverseReaction host/I-AdverseReaction response/I-AdverseReaction and/O thus/O increase/O the/O hazard/O of/O secondary/B-AdverseReaction ocular/I-AdverseReaction infections/I-AdverseReaction ./O
In/O acute/O purulent/O conditions/O ,/O steroids/O may/O mask/O infection/O or/O enhance/O existing/O infection/O ./O
If/O signs/O and/O symptoms/O fail/O to/O improve/O after/O 2/O days/O ,/O the/O patient/O should/O be/O re/O -/O evaluated/O ./O
5.5/O Viral/O Infections/O Employment/O of/O a/O corticosteroid/O medication/O in/O the/O treatment/O of/O patients/O with/O a/O history/O of/O herpes/O simplex/O requires/O great/O caution/O ./O
Use/O of/O ocular/O steroids/B-DrugClass may/O prolong/O the/O course/O and/O may/O exacerbate/O the/O severity/O of/O many/O viral/O infections/O of/O the/O eye/O (/O including/O herpes/O simplex/O )/O ./O
5.6/O Fungal/O Infections/O Fungal/B-AdverseReaction infections/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction cornea/I-AdverseReaction are/O particularly/O prone/O to/O develop/O coincidentally/O with/O long/O -/O term/O local/O steroid/B-DrugClass application/O ./O
Fungus/O invasion/O must/O be/O considered/O in/O any/O persistent/O corneal/O ulceration/O where/O a/O steroid/O has/O been/O used/O or/O is/O in/O use/O ./O
Fungal/O culture/O should/O be/O taken/O when/O appropriate/O ./O
5.7/O Topical/O Ophthalmic/O Use/O Only/O DUREZOL/O is/O not/O indicated/O for/O intraocular/O administration/O ./O
5.8/O Contact/O Lens/O Wear/O DUREZOL/O should/O not/O be/O instilled/O while/O wearing/O contact/O lenses/O ./O
Remove/O contact/O lenses/O prior/O to/O instillation/O of/O DUREZOL/O ./O
The/O preservative/O in/O DUREZOL/O may/O be/O absorbed/O by/O soft/O contact/O lenses/O ./O
Lenses/O may/O be/O reinserted/O after/O 10/O minutes/O following/O administration/O of/O DUREZOL/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O below/O and/O elsewhere/O in/O labeling/O :/O Distant/B-AdverseReaction Spread/I-AdverseReaction of/I-AdverseReaction Toxin/I-AdverseReaction Effect/I-AdverseReaction [/O seeBoxed/O Warning/O ]/O Lack/O of/O Interchangeability/O between/O Botulinum/O Toxin/O Products/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Spread/B-AdverseReaction of/I-AdverseReaction Effects/I-AdverseReaction from/I-AdverseReaction Toxin/I-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Dysphagia/B-AdverseReaction and/O Breathing/B-AdverseReaction Difficulties/I-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Facial/O Anatomy/O in/O the/O Treatment/O of/O Glabellar/O Lines/O [/O seeWarnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Pre/O -/O existing/O Neuromuscular/O Disorders/O [/O seeWarnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Human/O Albumin/O [/O seeWarnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Intradermal/B-AdverseReaction Immune/I-AdverseReaction Reaction/I-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5/O ./O
7/O )/O ]/O EXCERPT/O :/O Cervical/O Dystonia/O Most/O commonly/O observed/O adverse/O reactions/O (/O 5/O %/O of/O patients/O )/O are/O :/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction discomfort/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O neck/B-AdverseReaction pain/I-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O and/O eye/B-AdverseReaction disorders/I-AdverseReaction ./O
(/O 6.1/O )/O Glabellar/O Lines/O The/O most/O frequently/O reported/O adverse/O reactions/O (/O 2/O %/O )/O are/O :/O nasopharyngitis/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
(/O 6.1/O )/O Upper/O Limb/O Spasticity/O The/O most/O frequently/O reported/O adverse/O reactions/O (/O 2/O %/O )/O are/O :/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O fall/B-AdverseReaction and/O depression.(6.1/B-AdverseReaction )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Ipsen/O Biopharmaceuticals/O ,/O Inc./O at/O 877/O -/O 397/O -/O 7671/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Cervical/O Dystonia/O The/O data/O described/O below/O reflect/O exposure/O to/O DYSPORT/O (/O r/O )/O in/O 357/O cervical/O dystonia/O patients/O in/O 6/O studies/O ./O
Of/O these/O ,/O two/O studies/O were/O randomized/O ,/O double/O -/O blind/O ,/O single/O treatment/O ,/O placebo/O controlled/O studies/O with/O subsequent/O optional/O open/O label/O treatment/O in/O which/O dose/O optimization/O (/O 250/O to/O 1000/O Units/O per/O treatment/O )/O over/O the/O course/O of/O 5/O treatment/O cycles/O was/O allowed/O ./O
The/O population/O was/O almost/O entirely/O Caucasian/O (/O 99/O %/O )/O with/O a/O median/O age/O of/O 51/O years/O (/O range/O 18/O -/O 82/O years/O )/O ./O
Most/O patients/O (/O 87/O %/O )/O were/O less/O than/O 65/O years/O of/O age/O ;/O 58.4/O %/O were/O women/O ./O
Common/O Adverse/O Reactions/O The/O most/O commonly/O reported/O adverse/O reactions/O (/O occurring/O in/O more/O than/O 5/O %/O of/O patients/O who/O received/O 500/O Units/O of/O DYSPORT/O (/O r/O )/O in/O the/O placebo/O controlled/O clinical/O trials/O )/O in/O cervical/O dystonia/O patients/O were/O :/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction discomfort/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O neck/B-AdverseReaction pain/I-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O and/O eye/B-AdverseReaction disorders/I-AdverseReaction (/O consisting/O of/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O and/O reduced/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction and/O accommodation/O )/O ./O
Other/O than/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ,/O most/O adverse/O reactions/O became/O noticeable/O about/O one/O week/O after/O treatment/O and/O lasted/O several/O weeks/O ./O
The/O rates/O of/O adverse/O reactions/O were/O higher/O in/O the/O combined/O controlled/O and/O open/O -/O label/O experience/O than/O in/O the/O placebo/O -/O controlled/O trials/O ./O
During/O the/O clinical/O studies/O ,/O two/O patients/O (/O 1/O %/O )/O experienced/O adverse/O reactions/O leading/O to/O withdrawal/O ./O
One/O patient/O experienced/O disturbance/B-AdverseReaction in/I-AdverseReaction attention/I-AdverseReaction ,/O eyelid/B-AdverseReaction disorder/I-AdverseReaction ,/O feeling/B-AdverseReaction abnormal/I-AdverseReaction and/O headache/B-AdverseReaction ,/O and/O one/O patient/O experienced/O dysphagia/B-AdverseReaction ./O
Table/O 3/O compares/O the/O incidence/O of/O the/O most/O frequent/O adverse/O reactions/O from/O a/O single/O treatment/O cycle/O of/O 500/O Units/O of/O DYSPORT/O (/O r/O )/O compared/O to/O placebo/O [/O seeClinical/O Studies/O (/O 14.1/O )/O ]/O ./O
Table/O 3/O :/O Most/O Common/O Adverse/O Reactions/O (/O 5/O %/O )/O and/O Greater/O than/O Placebo/O in/O the/O Pooled/O ,/O Double/O -/O blind/O Phase/O of/O Clinical/O Trials/O in/O Patients/O with/O Cervical/O Dystonia/O Adverse/O Reaction/O Preferred/O Term/O DYSPORT/O (/O r/O )/O 500/O Units(N=173/O )/O Placebo(N=182/O )/O %/O %/O Any/O Adverse/O Reaction/O 61/O 51/O General/O disorders/O and/O administration/O site/O conditions/O 30/O 23/O Injection/B-AdverseReaction site/I-AdverseReaction discomfort/I-AdverseReaction 13/O 8/O Fatigue/B-AdverseReaction 12/O 10/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 5/O 4/O Musculoskeletal/O and/O connective/O tissue/O disorders/O 30/O 18/O Muscular/B-AdverseReaction weakness/I-AdverseReaction 16/O 4/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 7/O 3/O Gastrointestinal/O disorders/O 28/O 15/O Dysphagia/B-AdverseReaction 15/O 4/O Dry/B-AdverseReaction mouth/I-AdverseReaction 13/O 7/O Nervous/O system/O disorders/O 16/O 13/O Headache/B-AdverseReaction 11/O 9/O Infections/O and/O infestations/O 13/O 9/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O 12/O 8/O Dysphonia/B-AdverseReaction 6/O 2/O Eye/O Disorders/O 7/O 2/O Dose/O -/O response/O relationships/O for/O common/O adverse/O reactions/O in/O a/O randomized/O multiple/O fixed/O -/O dose/O study/O in/O which/O the/O total/O dose/O was/O divided/O between/O two/O muscles/O (/O the/O sternocleidomastoid/O and/O splenius/O capitis/O )/O are/O shown/O in/O Table/O 4/O ./O
Table/O 4/O :/O Common/O Adverse/O Reactions/O by/O Dose/O in/O Fixed/O -/O dose/O Study/O in/O Patients/O with/O Cervical/O Dystonia/O Adverse/O Reaction/O Preferred/O Term/O DYSPORT/O (/O r/O )/O Dose/O Placebo/O 250/O Units/O 500/O Units/O 1000/O Units/O Any/O Adverse/O Event/O 30/O %/O 37/O %/O 65/O %/O 83/O %/O Dysphagia/B-AdverseReaction 5/O %/O 21/O %/O 29/O %/O 39/O %/O Dry/B-AdverseReaction Mouth/I-AdverseReaction 10/O %/O 21/O %/O 18/O %/O 39/O %/O Muscular/B-AdverseReaction Weakness/I-AdverseReaction 0/O %/O 11/O %/O 12/O %/O 56/O %/O Injection/B-AdverseReaction Site/I-AdverseReaction Discomfort/I-AdverseReaction 10/O %/O 5/O %/O 18/O %/O 22/O %/O Dysphonia/B-AdverseReaction 0/O %/O 0/O %/O 18/O %/O 28/O %/O Facial/B-AdverseReaction Paresis/I-AdverseReaction 0/O %/O 5/O %/O 0/O %/O 11/O %/O Eye/O Disorders/O 0/O %/O 0/O %/O 6/O %/O 17/O %/O Injection/O Site/O Reactions/O Injection/B-AdverseReaction site/I-AdverseReaction discomfort/I-AdverseReaction and/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction were/O common/O adverse/O reactions/O following/O DYSPORT/O (/O r/O )/O administration/O ./O
Less/O Common/O Adverse/O Reactions/O The/O following/O adverse/O reactions/O were/O reported/O less/O frequently/O (/O 5/O %/O )/O ./O
Breathing/O Difficulty/O Breathing/B-AdverseReaction difficulties/I-AdverseReaction were/O reported/O by/O approximately/O 3/O %/O of/O patients/O following/O DYSPORT/O (/O r/O )/O administration/O and/O in/O 1/O %/O of/O placebo/O patients/O in/O clinical/O trials/O during/O the/O double/O -/O blind/O phase/O ./O
These/O consisted/O mainly/O of/O dyspnea/B-AdverseReaction ./O
The/O median/O time/O to/O onset/O from/O last/O dose/O of/O DYSPORT/O (/O r/O )/O was/O approximately/O one/O week/O ,/O and/O the/O median/O duration/O was/O approximately/O three/O weeks/O ./O
Other/O adverse/O reactions/O with/O incidences/O of/O less/O than/O 5/O %/O in/O the/O DYSPORT/O (/O r/O )/O 500/O Units/O group/O in/O the/O double/O -/O blind/O phase/O of/O clinical/O trials/O included/O dizziness/B-AdverseReaction in/O 3.5/O %/O of/O DYSPORT/O (/O r/O )/O -treated/O patients/O and/O 1/O %/O of/O placebo/O -/O treated/O patients/O ,/O and/O muscle/B-AdverseReaction atrophy/I-AdverseReaction in/O 1/O %/O of/O DYSPORT/O (/O r/O )/O -treated/O patients/O and/O in/O none/O of/O the/O placebo/O -/O treated/O patients/O ./O
Laboratory/O Findings/O Patients/O treated/O with/O DYSPORT/O (/O r/O )/O exhibited/O a/O small/B-Severity increase/O from/O baseline/O (/O 0.23/O mol/O L/O )/O in/O mean/O blood/O glucose/O relative/O to/O placebo-/O treated/O patients/O ./O
This/O was/O not/O clinically/O significant/O among/O patients/O in/O the/O development/O program/O but/O could/O be/O a/O factor/O in/O patients/O whose/O diabetes/O is/O difficult/O to/O control/O ./O
Electrocardiographic/O Findings/O ECG/O measurements/O were/O only/O recorded/O in/O a/O limited/O number/O of/O patients/O in/O an/O open/O -/O label/O study/O without/O a/O placebo/O or/O active/O control/O ./O
This/O study/O showed/O a/O statistically/O significant/O reduction/B-AdverseReaction in/I-AdverseReaction heart/I-AdverseReaction rate/I-AdverseReaction compared/O to/O baseline/O ,/O averaging/O about/O three/O beats/O per/O minute/O ,/O observed/O thirty/O minutes/O after/O injection/O ./O
Glabellar/O Lines/O In/O placebo/O -/O controlled/O clinical/O trials/O of/O DYSPORT/O (/O r/O )/O ,/O the/O most/O common/O adverse/O reactions(>=2/O %/O )/O following/O injection/O of/O DYSPORT/O (/O r/O )/O were/O nasopharyngitis/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
Table/O 5/O reflects/O exposure/O to/O DYSPORT/O (/O r/O )/O in/O 398/O patients/O 19/O to/O 75/O years/O of/O age/O who/O were/O evaluated/O in/O the/O randomized/O ,/O placebo-/O controlled/O clinical/O studies/O that/O assessed/O the/O use/O of/O DYSPORT/O (/O r/O )/O for/O the/O temporary/O improvement/O in/O the/O appearance/O of/O glabellar/O lines/O [/O seeClinical/O Studies/O (/O 14/O )/O ]/O ./O
Adverse/O reactions/O of/O any/O cause/O occurred/O in/O 48/O %/O of/O the/O DYSPORT/O (/O r/O )/O -treated/O patients/O and/O 33/O %/O of/O the/O placebo-/O treated/O patients/O ./O
Table/O 5/O :/O Most/O Common/O Adverse/O Reactions/O with/O 1/O %/O Incidence/O in/O Pooled/O ,/O Placebo/O -/O Controlled/O Trials/O for/O Glabellar/O Lines/O Adverse/O Reactions/O by/O Body/O System/O DYSPORT/O (/O r/O )/O n=398/O (/O %/O )/O Placebon=496/O (/O %/O )/O Any/O Adverse/O Reaction/O 48/O 33/O Eye/O Disorders/O Eyelid/B-AdverseReaction Edema/I-AdverseReaction 2/O 0/O Eyelid/B-AdverseReaction Ptosis/I-AdverseReaction 2/O 1/O Gastrointestinal/O Disorders/O Nausea/B-AdverseReaction 2/O 1/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Injection/B-AdverseReaction Site/I-AdverseReaction Pain/I-AdverseReaction 3/O 2/O Injection/B-AdverseReaction Site/I-AdverseReaction Reaction/I-AdverseReaction 3/O 1/O Infections/O and/O Infestations/O Nasopharyngitis/B-AdverseReaction 10/O 4/O Upper/B-AdverseReaction Respiratory/I-AdverseReaction Tract/I-AdverseReaction Infection/I-AdverseReaction 3/O 2/O Sinusitis/B-AdverseReaction 2/O 1/O Investigations/O Blood/B-AdverseReaction Present/I-AdverseReaction in/I-AdverseReaction Urine/I-AdverseReaction 2/O 1/O Nervous/O System/O Disorders/O Headache/B-AdverseReaction 9/O 5/O In/O the/O overall/O safety/O database/O ,/O where/O some/O patients/O received/O up/O to/O twelve/O treatments/O with/O DYSPORT/O (/O r/O )/O ,/O adverse/O reactions/O were/O reported/O for/O 57/O %/O (/O 1425/2491/O )/O of/O patients/O ./O
The/O most/O frequently/O reported/O of/O these/O adverse/O reactions/O were/O headache/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O URI/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction bruising/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction (/O numbness/O ,/O discomfort/O ,/O erythema/O ,/O tenderness/O ,/O tingling/O ,/O itching/O ,/O stinging/O ,/O warmth/O ,/O irritation/O ,/O tightness/O ,/O swelling/O )/O ./O
Adverse/O reactions/O that/O occurred/O after/O repeated/O injections/O in/O 2/O -/O 3/O %/O of/O the/O population/O included/O bronchitis/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O pharyngolaryngeal/B-AdverseReaction pain/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O contact/B-AdverseReaction dermatitis/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction swelling/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction discomfort/I-AdverseReaction ./O
The/O incidence/O of/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction did/O not/O increase/O in/O the/O long/O -/O term/O safety/O studies/O with/O multiple/O re/O -/O treatments/O at/O intervals/O three/O months/O ./O
The/O majority/O of/O the/O reports/O of/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction were/O mild/B-Severity to/O moderate/B-Severity in/O severity/O and/O resolved/O over/O several/O weeks/O ./O
[/O seeDosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Upper/O Limb/O Spasticity/O Table/O 6/O lists/O the/O most/O frequently/O reported/O adverse/O reactions/O (/O 2/O %/O )/O in/O any/O DYSPORT/O (/O r/O )/O dose/O group/O and/O more/O frequent/O than/O placebo/O in/O double/O blind/O studies/O evaluating/O the/O treatment/O of/O upper/O limb/O spasticity/O in/O adults/O with/O DYSPORT/O (/O r/O )/O ./O
Table/O 6/O :/O Most/O Common/O Adverse/O Reactions/O Observed/O in/O at/O Least/O 2/O %/O of/O Patients/O Treated/O in/O Pooled/O ,/O Double/O -/O Blind/O Trials/O of/O Patients/O with/O Upper/O Limb/O Spasticity/O Reported/O More/O Frequently/O than/O with/O Placebo/O Adverse/O Reaction/O Preferred/O Term/O DYSPORT/O (/O r/O )/O Placebo/O 500/O Units(N=197)%/O 1000/O Units(N=194)%/O (/O N=279)%/O Infections/O and/O infestations/O Nasopharyngitis/B-AdverseReaction 4/O 1/O 1/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 3/O 1/O 2/O Influenza/B-AdverseReaction 1/O 2/O 1/O Infection/B-AdverseReaction 1/O 2/O 1/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Muscular/B-AdverseReaction weakness/I-AdverseReaction 2/O 4/O 1/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 0/O 2/O 1/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 3/O 2/O 2/O Back/B-AdverseReaction pain/I-AdverseReaction 1/O 2/O 1/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 1/O 2/O 1/O Dizziness/B-AdverseReaction 3/O 1/O 1/O Convulsion/B-AdverseReaction 2/O 2/O 1/O Syncope/B-AdverseReaction 1/O 2/O 0/O Hypoaesthesia/B-AdverseReaction 0/O 2/O 1/O Partial/B-AdverseReaction seizures/I-AdverseReaction 0/O 2/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 2/O 2/O 0/O Asthenia/B-AdverseReaction 2/O 1/O 1/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Fall/B-AdverseReaction 2/O 3/O 2/O Injury/B-AdverseReaction 2/O 2/O 1/O Contusion/B-AdverseReaction 1/O 2/O 1/O Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 1/O 2/O 1/O Nausea/B-AdverseReaction 2/O 1/O 1/O Constipation/B-AdverseReaction 0/O 2/O 1/O Investigation/O Blood/B-AdverseReaction triglycerides/I-AdverseReaction increased/I-AdverseReaction 2/O 1/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 1/O 2/O 1/O Vascular/O disorders/O Hypertension/B-AdverseReaction 1/O 2/O 1/O Psychiatric/O disorders/O Depression/B-AdverseReaction 2/O 3/O 1/O Injection/O Site/O Reactions/O Injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction (/O e.g./O pain/O ,/O bruising/O ,/O haemorrhage/O ,/O injection/B-AdverseReaction site/I-AdverseReaction erythema/I-AdverseReaction haematoma/O etc/O ./O
)/O have/O occurred/O following/O administration/O of/O DYSPORT/O (/O r/O )/O ./O
Less/O Common/O Adverse/O Reactions/O In/O a/O pooled/O analysis/O of/O clinical/O studies/O ,/O adverse/O reactions/O with/O an/O incidence/O of/O less/O than/O 2/O %/O reported/O in/O DYSPORT/O (/O r/O )/O treatment/O groups/O included/O dysphagia/B-AdverseReaction 0.5/O %/O ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction 0.5/O %/O ,/O hypertonia/B-AdverseReaction 0.5/O %/O ,/O and/O sensation/B-AdverseReaction of/I-AdverseReaction heaviness/I-AdverseReaction 0.3/O %/O ./O
6.2/O Postmarketing/O Experience/O Because/O adverse/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O DYSPORT/O (/O r/O )/O :/O vertigo/B-AdverseReaction ,/O photophobia/B-AdverseReaction ,/O influenza/B-AdverseReaction -/I-AdverseReaction like/O illness/O ,/O amyotrophy/B-AdverseReaction ,/O burning/B-AdverseReaction sensation/I-AdverseReaction ,/O facial/B-AdverseReaction paresis/I-AdverseReaction ,/O hypoesthesia/B-AdverseReaction ,/O erythema/B-AdverseReaction ,/O and/O excessive/B-AdverseReaction granulation/I-AdverseReaction tissue/I-AdverseReaction ./O
6.3/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O a/O potential/O for/O immunogenicity/O ./O
The/O incidence/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
In/O addition/O ,/O the/O observed/O incidence/O of/O antibody/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O across/O products/O in/O this/O class/O may/O be/O misleading/O ./O
Cervical/O Dystonia/O About/O 3/O %/O of/O subjects/O developed/O antibodies/O (/O binding/O or/O neutralizing/O )/O over/O time/O with/O DYSPORT/O (/O r/O )/O treatment/O ./O
Glabellar/O Lines/O Testing/O for/O antibodies/O to/O DYSPORT/O (/O r/O )/O was/O performed/O for/O 1554/O subjects/O who/O had/O up/O to/O nine/O cycles/O of/O treatment/O ./O
Two/O subjects/O (/O 0.13/O %/O )/O tested/O positive/O for/O binding/O antibodies/O at/O baseline/O ./O
Three/O additional/O subjects/O tested/O positive/O for/O binding/O antibodies/O after/O receiving/O DYSPORT/O (/O r/O )/O treatment/O ./O
None/O of/O the/O subjects/O tested/O positive/O for/O neutralizing/O antibodies/O ./O
Upper/O Limb/O Spasticity/O From/O 230/O subjects/O treated/O with/O DYSPORT/O (/O r/O )/O and/O tested/O for/O the/O presence/O of/O binding/O antibodies/O ,/O 5/O subjects/O were/O positive/O at/O baseline/O and/O 17/O developed/O antibodies/O after/O treatment/O ./O
Among/O those/O 17/O subjects/O ,/O 10/O subjects/O developed/O neutralizing/O antibodies/O ./O
An/O additional/O 51/O subjects/O from/O a/O separate/O repeat/O dose/O study/O were/O tested/O for/O the/O presence/O of/O neutralizing/O antibodies/O only/O ./O
None/O of/O the/O subjects/O tested/O positive/O ./O
In/O total/O ,/O from/O the/O 281/O subjects/O treated/O in/O the/O long/O -/O term/O studies/O and/O tested/O for/O the/O presence/O of/O neutralizing/O antibodies/O ,/O 3.6/O %/O developed/O neutralizing/O antibodies/O after/O treatment/O ./O
In/O the/O presence/O of/O binding/O and/O neutralizing/O antibodies/O to/O DYSPORT/O (/O r/O )/O some/O patients/O continue/O to/O experience/O clinical/O benefit/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O DISTANT/B-AdverseReaction SPREAD/I-AdverseReaction OF/I-AdverseReaction TOXIN/I-AdverseReaction EFFECT/I-AdverseReaction WARNING/O :/O DISTANT/B-AdverseReaction SPREAD/I-AdverseReaction OF/I-AdverseReaction TOXIN/I-AdverseReaction EFFECT/I-AdverseReaction Postmarketing/O reports/O indicate/O that/O the/O effects/O of/O DYSPORT(r/O )/O and/O all/O botulinum/O toxin/O products/O may/B-Factor spread/O from/O the/O area/O of/O injection/O to/O produce/O symptoms/O consistent/O with/O botulinum/O toxin/O effects/O ./O
These/O may/B-Factor include/O asthenia/B-AdverseReaction ,/O generalized/B-AdverseReaction muscle/I-AdverseReaction weakness/I-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O ptosis/B-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O dysarthria/B-AdverseReaction ,/O urinary/B-AdverseReaction incontinence/I-AdverseReaction and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction ./O
These/O symptoms/O have/O been/O reported/O hours/O to/O weeks/O after/O injection/O ./O
Swallowing/O and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction can/O be/O life/O threatening/O and/O there/O have/O been/O reports/O of/O death/B-AdverseReaction ./O
The/O risk/O of/O symptoms/O is/O probably/O greatest/O in/O children/O treated/O for/O spasticity/O but/O symptoms/O can/O also/O occur/O in/O adults/O treated/O for/O spasticity/O and/O other/O conditions/O ,/O particularly/O in/O those/O patients/O who/O have/O underlying/O conditions/O that/O would/O predispose/O them/O to/O these/O symptoms/O ./O
In/O unapproved/O uses/O ,/O including/O spasticity/O in/O children/O ,/O and/O in/O approved/O indications/O ,/O cases/O of/O spread/O of/O effect/O have/O been/O reported/O at/O doses/O comparable/O to/O or/O lower/O than/O the/O maximum/O recommended/O total/O dose/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O WARNING/O :/O DISTANT/B-AdverseReaction SPREAD/I-AdverseReaction OF/I-AdverseReaction TOXIN/I-AdverseReaction EFFECT/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O The/O effects/O of/O DYSPORT(r/O )/O and/O all/O botulinum/O toxin/O products/O may/B-Factor spread/O from/O the/O area/O of/O injection/O to/O produce/O symptoms/O consistent/O with/O botulinum/O toxin/O effects/O ./O
These/O symptoms/O have/O been/O reported/O hours/O to/O weeks/O after/O injection/O ./O
Swallowing/O and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction can/O be/O life/O threatening/O and/O there/O have/O been/O reports/O of/O death/B-AdverseReaction ./O
The/O risk/O of/O symptoms/O is/O probably/O greatest/O in/O children/O treated/O for/O spasticity/O but/O symptoms/O can/O also/O occur/O in/O adults/O ,/O particularly/O in/O those/O patients/O who/O have/O underlying/O conditions/O that/O would/O predispose/O them/O to/O these/O symptoms/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O The/O potency/O Units/O of/O DYSPORT/O (/O r/O )/O are/O not/O interchangeable/O with/O other/O preparations/O of/O botulinum/O toxin/O products/O and/O ,/O therefore/O ,/O units/O of/O biological/O activity/O of/O DYSPORT/O (/O r/O )/O can/O not/O be/O compared/O to/O or/O converted/O into/O units/O of/O any/O other/O botulinum/O toxin/O products/O (/O 5.1/O )/O Recommended/O dose/O and/O frequency/O of/O administration/O should/O not/O be/O exceeded/O (/O 5.4/O )/O Immediate/O medical/O attention/O may/O be/O required/O in/O cases/O of/O respiratory/O ,/O speech/O or/O swallowing/B-AdverseReaction difficulties/I-AdverseReaction (/O 5.3/O )/O Concomitant/O neuromuscular/O disorder/O may/O exacerbate/O clinical/O effects/O of/O treatment/O (/O 5.5/O )/O DYSPORT/O (/O r/O )/O contains/O human/O albumin/O ./O
There/O is/O a/O risk/B-Factor for/O transmission/O of/O Creutzfeldt/B-AdverseReaction -/I-AdverseReaction Jakob/O disease/O (/O CJD/B-AdverseReaction )/O however/O ,/O no/O cases/O of/O transmission/O of/O viral/B-AdverseReaction diseases/I-AdverseReaction or/O CJD/B-AdverseReaction have/O ever/O been/O identified/O for/O albumin/O (/O 5.6/O )/O 5.1/O Lack/O of/O Interchangeability/O between/O Botulinum/O Toxin/O Products/O The/O potency/O Units/O of/O DYSPORT/O (/O r/O )/O are/O specific/O to/O the/O preparation/O and/O assay/O method/O utilized/O ./O
They/O are/O not/O interchangeable/O with/O other/O preparations/O of/O botulinum/O toxin/O products/O and/O ,/O therefore/O ,/O units/O of/O biological/O activity/O of/O DYSPORT/O (/O r/O )/O can/O not/O be/O compared/O to/O or/O converted/O into/O units/O of/O any/O other/O botulinum/O toxin/O products/O assessed/O with/O any/O other/O specific/O assay/O method/O [/O seeDescription/O (/O 11/O )/O ]/O ./O
5.2/O Spread/O of/O Toxin/O Effect/O Post/O -/O marketing/O safety/O data/O from/O DYSPORT/O (/O r/O )/O and/O other/O approved/O botulinum/O toxins/O suggest/O that/O botulinum/O toxin/O effects/O may/B-Factor ,/O in/O some/O cases/O ,/O be/O observed/O beyond/O the/O site/O of/O local/O injection/O ./O
The/O symptoms/O are/O consistent/O with/O the/O mechanism/O of/O action/O of/O botulinum/O toxin/O and/O may/B-Factor include/O asthenia/B-AdverseReaction ,/O generalized/B-AdverseReaction muscle/I-AdverseReaction weakness/I-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O ptosis/B-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O dysarthria/B-AdverseReaction ,/O urinary/B-AdverseReaction incontinence/I-AdverseReaction and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction ./O
These/O symptoms/O have/O been/O reported/O hours/O to/O weeks/O after/O injection/O ./O
Swallowing/O and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction can/O be/O life/O threatening/O and/O there/O have/O been/O reports/O of/O death/B-AdverseReaction related/O to/O spread/B-AdverseReaction of/I-AdverseReaction toxin/I-AdverseReaction effects/I-AdverseReaction ./O
The/O risk/O of/O the/O symptoms/O is/O probably/O greatest/O in/O children/O treated/O for/O spasticity/O but/O symptoms/O can/O also/O occur/O in/O adults/O treated/O for/O spasticity/O and/O other/O conditions/O ,/O and/O particularly/O in/O those/O patients/O who/O have/O underlying/O conditions/O that/O would/O predispose/O them/O to/O these/O symptoms/O ./O
In/O unapproved/O uses/O ,/O including/O spasticity/O in/O children/O and/O in/O approved/O indications/O ,/O symptoms/O consistent/O with/O spread/B-AdverseReaction of/I-AdverseReaction toxin/I-AdverseReaction effect/I-AdverseReaction have/O been/O reported/O at/O doses/O comparable/O to/O or/O lower/O than/O the/O maximum/O recommended/O total/O dose/O ./O
5.3/O Dysphagia/O and/O Breathing/O Difficulties/O Treatment/O with/O DYSPORT/O (/O r/O )/O and/O other/O botulinum/O toxin/O products/O can/B-Factor result/O in/O swallowing/O or/O breathing/B-AdverseReaction difficulties/I-AdverseReaction ./O
Patients/O with/O pre-/O existing/O swallowing/O or/O breathing/O difficulties/O may/O be/O more/O susceptible/O to/O these/O complications/O ./O
In/O most/O cases/O ,/O this/O is/O a/O consequence/O of/O weakening/O of/O muscles/O in/O the/O area/O of/O injection/O that/O are/O involved/O in/O breathing/O or/O swallowing/O ./O
When/O distant/O effects/O occur/O ,/O additional/O respiratory/O muscles/O may/O be/O involved/O [/O seeWarnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Deaths/B-AdverseReaction as/O a/O complication/O of/O severe/B-Severity dysphagia/B-AdverseReaction have/O been/O reported/O after/O treatment/O with/O botulinum/O toxin/O ./O
Dysphagia/B-AdverseReaction may/O persist/O for/O several/O weeks/O ,/O and/O require/O use/O of/O a/O feeding/O tube/O to/O maintain/O adequate/O nutrition/O and/O hydration/O ./O
Aspiration/B-AdverseReaction may/B-Factor result/O from/O severe/B-Severity dysphagia/B-AdverseReaction and/O is/O a/O particular/O risk/O when/O treating/O patients/O in/O whom/O swallowing/O or/O respiratory/O function/O is/O already/O compromised/O ./O
Treatment/O of/O cervical/O dystonia/O with/O botulinum/O toxins/O may/B-Factor weaken/B-AdverseReaction neck/I-AdverseReaction muscles/I-AdverseReaction that/O serve/O as/O accessory/O muscles/O of/O ventilation/O ./O
This/O may/B-Factor result/O in/O a/O critical/B-Severity loss/B-AdverseReaction of/I-AdverseReaction breathing/I-AdverseReaction capacity/I-AdverseReaction in/O patients/O with/O respiratory/O disorders/O who/O may/O have/O become/O dependent/O upon/O these/O accessory/O muscles/O ./O
There/O have/O been/O post/O -/O marketing/O reports/O of/O serious/B-Severity breathing/B-AdverseReaction difficulties/I-AdverseReaction ,/O including/O respiratory/B-AdverseReaction failure/I-AdverseReaction ./O
Patients/B-Factor treated/O with/O botulinum/O toxin/O may/O require/O immediate/O medical/O attention/O should/O they/O develop/O problems/O with/O swallowing/O ,/O speech/O or/O respiratory/O disorders/O ./O
These/O reactions/O can/O occur/O within/O hours/O to/O weeks/O after/O injection/O with/O botulinum/O toxin/O [/O seeWarnings/O and/O Precautions/O (/O 5.2),Adverse/O Reactions/O (/O 6.1),Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
5.4/O Facial/O Anatomy/O in/O the/O Treatment/O of/O Glabellar/O Lines/O Caution/O should/O be/O exercised/O when/O administering/O DYSPORT/O (/O r/O )/O to/O patients/O with/O surgical/O alterations/O to/O the/O facial/O anatomy/O ,/O excessive/O weakness/O or/O atrophy/O in/O the/O target/O muscle(s/O )/O ,/O marked/O facial/O asymmetry/O ,/O inflammation/O at/O the/O injection/O site(s/O )/O ,/O ptosis/O ,/O excessive/O dermatochalasis/O ,/O deep/O dermal/O scarring/O ,/O thick/O sebaceous/O skin/O [/O seeDosage/O and/O Administration/O (/O 2.3/O ]/O or/O the/O inability/O to/O substantially/O lessen/O glabellar/O lines/O by/O physically/O spreading/O them/O apart/O [/O seeClinical/O Studies/O (/O 14.2/O )/O ]/O ./O
Do/O not/O exceed/O the/O recommended/O dosage/O and/O frequency/O of/O administration/O of/O DYSPORT/B-Factor (/O r/O )/O ./O
In/O clinical/O trials/O ,/O subjects/O who/O received/O a/O higher/O dose/O of/O DYSPORT/O (/O r/O )/O had/O an/O increased/O incidence/O of/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction ./O
5.5/O Pre/O -/O existing/O Neuromuscular/O Disorders/O Individuals/O with/O peripheral/O motor/O neuropathic/O diseases/O ,/O amyotrophic/O lateral/O sclerosis/O or/O neuromuscular/O junction/O disorders/O (/O e.g./O ,/O myasthenia/O gravis/O or/O Lambert/O -/O Eaton/O syndrome/O )/O should/O be/O monitored/O particularly/O closely/O when/O given/O botulinum/O toxin/O ./O
Patients/O with/O neuromuscular/O disorders/O may/O be/O at/O increased/O risk/B-Factor of/O clinically/O significant/O effects/O including/O severe/B-Severity dysphagia/B-AdverseReaction and/O respiratory/B-AdverseReaction compromise/I-AdverseReaction from/O typical/O doses/O of/O DYSPORT/O (/O r/O )/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.6/O Human/O Albumin/O This/O product/O contains/O albumin/O ,/O a/O derivative/O of/O human/O blood/O ./O
Based/O on/O effective/O donor/O screening/O and/O product/O manufacturing/O processes/O ,/O it/O carries/O an/O extremely/O remote/O risk/B-Factor for/O transmission/O of/O viral/B-AdverseReaction diseases/I-AdverseReaction ./O
A/O theoretical/O risk/B-Factor for/O transmission/O of/O Creutzfeldt/B-AdverseReaction -/I-AdverseReaction Jakob/O disease/O (/O CJD/B-AdverseReaction )/O is/O also/O considered/O extremely/O remote/O ./O
No/O cases/O of/O transmission/O of/O viral/B-AdverseReaction diseases/I-AdverseReaction or/O CJD/B-AdverseReaction have/O ever/O been/O reported/O for/O albumin/O ./O
5.7/O Intradermal/O Immune/O Reaction/O The/O possibility/O of/O an/O immune/O reaction/O when/O injected/O intradermally/O is/O unknown/O ./O
The/O safety/O of/O DYSPORT/O (/O r/O )/O for/O the/O treatment/O of/O hyperhidrosis/O has/O not/O been/O established/O ./O
DYSPORT/O (/O r/O )/O is/O approved/O only/O for/O intramuscular/O injection/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reaction/O (/O incidence/O 1.5/O %/O )/O occurring/O with/O a/O higher/O frequency/O than/O placebo/O among/O ENTEREG/O -/O treated/O patients/O undergoing/O surgeries/O that/O included/O a/O bowel/O resection/O was/O dyspepsia/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Merck/O Sharp/O &/O Dohme/O Corp./O ,/O a/O subsidiary/O of/O Merck/O &/O Co./O ,/O Inc./O ,/O at/O 1/O -/O 877/O -/O 888/O -/O 4231/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O compared/O directly/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O adverse/O event/O information/O from/O clinical/O trials/O does/O ,/O however/O ,/O provide/O a/O basis/O for/O identifying/O the/O adverse/O events/O that/O appear/O to/O be/O related/O to/O drug/O use/O and/O for/O approximating/O rates/O ./O
The/O data/O described/O below/O reflect/O exposure/O to/O ENTEREG/O 12/O mg/O in/O 1,793/O patients/O in/O 10/O placebo/O -/O controlled/O studies/O ./O
The/O population/O was/O 19/O to/O 97/O years/O old/O ,/O 64/O %/O were/O female/O ,/O and/O 84/O %/O were/O Caucasian/O ;/O 64/O %/O were/O undergoing/O a/O surgery/O that/O included/O bowel/O resection/O ./O
The/O first/O dose/O of/O ENTEREG/O was/O administered/O 30/O minutes/O to/O 5/O hours/O before/O the/O scheduled/O start/O of/O surgery/O and/O then/O twice/O daily/O until/O hospital/O discharge/O (/O or/O for/O a/O maximum/O of/O 7/O days/O of/O postoperative/O treatment/O )/O ./O
Among/O ENTEREG/O -/O treated/O patients/O undergoing/O surgeries/O that/O included/O a/O bowel/O resection/O ,/O the/O most/O common/O adverse/O reaction/O (/O incidence/O 1.5/O %/O )/O occurring/O with/O a/O higher/O frequency/O than/O placebo/O was/O dyspepsia/B-AdverseReaction (/O ENTEREG/O ,/O 1.5/O %/O ;/O placebo/O ,/O 0.8/O %/O )/O ./O
Adverse/O reactions/O are/O events/O that/O occurred/O after/O the/O first/O dose/O of/O study/O medication/O treatment/O and/O within/O 7/O days/O of/O the/O last/O dose/O of/O study/O medication/O or/O events/O present/O at/O baseline/O that/O increased/O in/O severity/O after/O the/O start/O of/O study/O medication/O treatment/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O POTENTIAL/O RISK/B-Factor OF/O MYOCARDIAL/B-AdverseReaction INFARCTION/I-AdverseReaction WITH/O LONG/O -/O TERM/O USE/O :/O FOR/O SHORT/O -/O TERM/O HOSPITAL/O USE/O ONLY/O WARNING/O :/O POTENTIAL/O RISK/B-Factor OF/O MYOCARDIAL/B-AdverseReaction INFARCTION/I-AdverseReaction WITH/O LONG/O -/O TERM/O USE/O :/O FOR/O SHORT/O -/O TERM/O HOSPITAL/O USE/O ONLY/O There/O was/O a/O greater/O incidence/O of/O myocardial/B-AdverseReaction infarction/I-AdverseReaction in/O alvimopan/O -/O treated/O patients/O compared/O to/O placebo/O -/O treated/O patients/O in/O a/O 12-month/O clinical/O trial/O ,/O although/O a/O causal/O relationship/O has/O not/O been/O established/O ./O
In/O short/O -/O term/O trials/O with/O ENTEREG(r/O )/O ,/O no/B-Negation increased/O risk/O of/O myocardial/B-AdverseReaction infarction/I-AdverseReaction was/O observed/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Because/O of/O the/O potential/O risk/O of/O myocardial/O infarction/O with/O long/O -/O term/O use/O ,/O ENTEREG/O is/O available/O only/O through/O a/O restricted/O program/O for/O short/O -/O term/O use/O (/O 15/O doses/O )/O under/O a/O Risk/O Evaluation/O and/O Mitigation/O Strategy/O (/O REMS/O )/O called/O the/O ENTEREG/O Access/O Support/O and/O Education/O (/O E.A.S.E.(r/O )/O )/O Program/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O and/O (/O 5.2/O )/O ]/O ./O
WARNING/O :/O POTENTIAL/O RISK/B-Factor OF/O MYOCARDIAL/B-AdverseReaction INFARCTION/I-AdverseReaction WITH/O LONG/O -/O TERM/O USE/O :/O FOR/O SHORT/O -/O TERM/O HOSPITAL/O USE/O ONLY/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Increased/O incidence/O of/O myocardial/B-AdverseReaction infarction/I-AdverseReaction was/O seen/O in/O a/O clinical/O trial/O of/O patients/O taking/O alvimopan/O for/O long/O -/O term/O use/O ./O
(/O 5.1/O )/O ENTEREG/O is/O available/O only/O through/O a/O restricted/O program/O for/O short/O -/O term/O use/O (/O 15/O doses/O )/O called/O the/O ENTEREG/O Access/O Support/O and/O Education/O (/O E.A.S.E.(r/O )/O )/O Program/O ./O
(/O 5.1/O ,/O 5.2/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O A/O higher/O number/O of/O myocardial/B-AdverseReaction infarctions/I-AdverseReaction was/O reported/O in/O patients/O treated/O with/O alvimopan/O 0.5/O mg/O twice/O daily/O compared/O with/O placebo/O in/O a/O 12-month/O study/O in/O patients/O treated/O with/O opioids/O for/O chronic/O non/O -/O cancer/O pain/O ,/O although/O a/O causal/O relationship/O with/O long/O -/O term/O use/O has/O not/O been/O established/O ./O
(/O 5.1/O )/O Patients/O recently/O exposed/O to/O opioids/O are/O expected/O to/O be/O more/O sensitive/O to/O the/O effects/O of/O ENTEREG/O and/O therefore/O may/B-Factor experience/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O nausea/B-AdverseReaction and/O vomiting/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction ./O
(/O 5.3/O )/O Not/O recommended/O in/O patients/O with/O severe/O hepatic/O impairment/O ./O
(/O 5.4/O )/O Not/O recommended/O in/O patients/O with/O end/O -/O stage/O renal/O disease/O ./O
(/O 5.5/O )/O Not/O recommended/O in/O patients/O with/O complete/O gastrointestinal/O obstruction/O or/O in/O patients/O who/O have/O surgery/O for/O correction/O of/O complete/O bowel/O obstruction/O ./O
(/O 5.6/O )/O Not/O recommended/O in/O pancreatic/O or/O gastric/O anastomosis/O ./O
(/O 5.7/O )/O 5.1/O Potential/O Risk/O of/O Myocardial/O Infarction/O with/O Long/O -/O term/O Use/O There/O were/O more/O reports/O of/O myocardial/B-AdverseReaction infarctions/I-AdverseReaction in/O patients/O treated/O with/O alvimopan/O 0.5/O mg/O twice/O daily/O compared/O with/O placebo/O -/O treated/O patients/O in/O a/O 12-month/O study/O of/O patients/O treated/O with/O opioids/O for/O chronic/O non/O -/O cancer/O pain/O (/O alvimopan/O 0.5/O mg/O ,/O n/O 538/O ;/O placebo/O ,/O n/O 267/O )/O ./O
In/O this/O study/O ,/O the/O majority/O of/O myocardial/B-AdverseReaction infarctions/I-AdverseReaction occurred/O between/O 1/O and/O 4/O months/O after/O initiation/O of/O treatment/O ./O
This/O imbalance/O has/O not/O been/O observed/O in/O other/O studies/O of/O ENTEREG/O in/O patients/O treated/O with/O opioids/O for/O chronic/O pain/O ,/O nor/O in/O patients/O treated/O within/O the/O surgical/O setting/O ,/O including/O patients/O undergoing/O surgeries/O that/O included/O bowel/O resection/O who/O received/O ENTEREG/O 12/O mg/O twice/O daily/O for/O up/O to/O 7/O days/O (/O the/O indicated/O dose/O and/O patient/O population/O ;/O ENTEREG/O 12/O mg/O ,/O n/O 1,142/O ;/O placebo/O ,/O n/O 1,120/O )/O ./O
A/O causal/O relationship/O with/O alvimopan/O with/O long/O -/O term/O use/O has/O not/O been/O established/O ./O
ENTEREG/O is/O available/O only/O through/O a/O program/O under/O a/O REMS/O that/O restricts/O use/O to/O enrolled/O hospitals/O [/O seeWarnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
5.2/O E.A.S.E./O ENTEREG/O REMS/O Program/O ENTEREG/O is/O available/O only/O through/O a/O program/O called/O the/O ENTEREG/O Access/O Support/O and/O Education/O (/O E.A.S.E./O )/O ENTEREG/O REMS/O Program/O that/O restricts/O use/O to/O enrolled/O hospitals/O because/O of/O the/O potential/O risk/O of/O myocardial/O infarction/O with/O long/O -/O term/O use/O of/O ENTEREG/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Notable/O requirements/O of/O the/O E.A.S.E./O Program/O include/O the/O following/O :/O ENTEREG/O is/O available/O only/O for/O short/O -/O term/O (/O 15/O doses/O )/O use/O in/O hospitalized/O patients/O ./O
Only/O hospitals/O that/O have/O enrolled/O in/O and/O met/O all/O of/O the/O requirements/O for/O the/O E.A.S.E./O program/O may/O use/O ENTEREG/O ./O
To/O enroll/O in/O the/O E.A.S.E./O Program/O ,/O an/O authorized/O hospital/O representative/O must/O acknowledge/O that/O :/O hospital/O staff/O who/O prescribe/O ,/O dispense/O ,/O or/O administer/O ENTEREG/O have/O been/O provided/O the/O educational/O materials/O on/O the/O need/O to/O limit/O use/O of/O ENTEREG/O to/O short/O -/O term/O ,/O inpatient/O use/O ;/O patients/O will/O not/O receive/O more/O than/O 15/O doses/O of/O ENTEREG/O ;/O and/O ENTEREG/O will/O not/O be/O dispensed/O to/O patients/O after/O they/O have/O been/O discharged/O from/O the/O hospital/O ./O
Further/O information/O is/O available/O at/O www.ENTEREGREMS.com/O or/O 1/O -/O 800/O -/O 278/O -/O 0340/O ./O
5.3/O Gastrointestinal/O -/O Related/O Adverse/O Reactions/O in/O Opioid/O -/O Tolerant/O Patients/O Patients/O recently/O exposed/O to/O opioids/O are/O expected/O to/O be/O more/O sensitive/O to/O the/O effects/O of/O mu/O -/O opioid/O receptor/O antagonists/O ,/O such/O as/O ENTEREG/O ./O
Since/O ENTEREG/O acts/O peripherally/O ,/O clinical/O signs/O and/O symptoms/O of/O increased/O sensitivity/O would/O be/O related/O to/O the/O gastrointestinal/O tract/O (/O e.g./O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O nausea/B-AdverseReaction and/O vomiting/B-AdverseReaction ,/O diarrhea/B-AdverseReaction )/O ./O
Patients/O receiving/O more/O than/O 3/O doses/O of/O an/O opioid/O within/O the/O week/O prior/O to/O surgery/O were/O not/O studied/O in/O the/O postoperative/O ileus/O clinical/O trials/O ./O
Therefore/O ,/O if/O ENTEREG/O is/O administered/O to/O these/O patients/O ,/O they/O should/O be/O monitored/O for/O gastrointestinal/O adverse/O reactions/O ./O
ENTEREG/O is/O contraindicated/O in/O patients/O who/O have/O taken/O therapeutic/O doses/O of/O opioids/O for/O more/O than/O 7/O consecutive/O days/O immediately/O prior/O to/O taking/O ENTEREG/O ./O
5.4/O Risk/O of/O Serious/O Adverse/O Reactions/O in/O Patients/O with/O Severe/O Hepatic/O Impairment/O Patients/O with/O severe/O hepatic/O impairment/O may/O be/O at/O higher/O risk/O of/O serious/O adverse/O reactions/O (/O including/O dose/O -/O related/O serious/O adverse/O reactions/O )/O because/O up/O to/O 10-fold/O higher/O plasma/O levels/O of/O drug/O have/O been/O observed/O in/O such/O patients/O compared/O with/O patients/O with/O normal/O hepatic/O function/O ./O
Therefore/O ,/O the/O use/O of/O ENTEREG/O is/O not/O recommended/O in/O this/O population/O ./O
5.5/O End/O -/O Stage/O Renal/O Disease/O No/O studies/O have/O been/O conducted/O in/O patients/O with/O end/O -/O stage/O renal/O disease/O ./O
ENTEREG/O is/O not/O recommended/O for/O use/O in/O these/O patients/O ./O
5.6/O Risk/O of/O Serious/O Adverse/O Reactions/O in/O Patients/O with/O Complete/O Gastrointestinal/O Obstruction/O No/O studies/O have/O been/O conducted/O in/O patients/O with/O complete/O gastrointestinal/O obstruction/O or/O in/O patients/O who/O have/O surgery/O for/O correction/O of/O complete/O bowel/O obstruction/O ./O
ENTEREG/O is/O not/O recommended/O for/O use/O in/O these/O patients/O ./O
5.7/O Risk/O of/O Serious/O Adverse/O Reactions/O in/O Pancreatic/O and/O Gastric/O Anastomoses/O ENTEREG/O has/O not/O been/O studied/O in/O patients/O having/O pancreatic/O or/O gastric/O anastomosis/O ./O
Therefore/O ,/O ENTEREG/O is/O not/O recommended/O for/O use/O in/O these/O patients/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactionsare/O discussed/O elsewhere/O in/O the/O labeling/O :/O Nephrogenic/B-AdverseReaction systemic/I-AdverseReaction fibrosis/I-AdverseReaction (/O NSF/B-AdverseReaction )/O [/O see/O Boxed/O Warning/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 0.5/O %/O )/O are/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O feeling/B-AdverseReaction hot/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O and/O back/B-AdverseReaction pain/I-AdverseReaction (/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bayer/O HealthCare/O Pharmaceuticals/O Inc./O at/O 1/O -/O 888/O -/O 84-BAYER/O (/O 1/O -/O 888/O -/O 842/O -/O 2937/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O adverse/O reactions/O described/O in/O this/O section/O reflect/O EOVIST/O exposure/O in/O 1,989/O subjects/O with/O the/O majority/O (/O 1,581/O subjects/O )/O receiving/O the/O recommended/O dose/O ./O
Overall/O ,/O 59/O %/O of/O the/O subjects/O were/O men/O and/O the/O ethnic/O distribution/O was/O 64/O %/O Caucasian/O ,/O 22/O %/O Asian/O ,/O 3/O %/O Hispanic/O ,/O 2/O %/O Black/O ,/O and/O 0.5/O %/O of/O subjects/O consisted/O of/O other/O ethnic/O groups/O ./O
The/O average/O age/O was/O 57/O years/O (/O age/O range/O from/O 19/O to/O 84/O years/O )/O ./O
Overall/O ,/O 4/O %/O of/O subjects/O reported/O one/O or/O more/O adverse/O reactions/O following/O EOVIST/O administration/O ./O
The/O most/O frequent/O (/O 0.5/O %/O )/O adverse/O reactions/O associated/O with/O the/O use/O of/O EOVIST/O were/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O feeling/B-AdverseReaction hot/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O and/O back/B-AdverseReaction pain/I-AdverseReaction ./O
Adverse/O reactions/O were/O predominantly/O of/O mild/O to/O moderate/O severity/O ./O
Table/O 1/O lists/O adverse/O reactions/O that/O occurred/O in/O 0.1/O %/O of/O subjects/O treated/O with/O EOVIST/O ./O
Table/O 1/O Adverse/O Reactions/O Reaction/O Rate/O (/O %/O )/O n/O 1581/O Nausea/B-AdverseReaction 1.1/O Headache/B-AdverseReaction 1.1/O Feeling/B-AdverseReaction hot/I-AdverseReaction 0.8/O Dizziness/B-AdverseReaction 0.6/O Back/B-AdverseReaction pain/I-AdverseReaction 0.6/O Vomiting/B-AdverseReaction 0.4/O Blood/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction 0.4/O Injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction (/O pain/O ,/O burning/O ,/O coldness/O ,/O extravasation/O ,/O irritation/O )/O 0.4/O Dysgeusia/B-AdverseReaction 0.4/O Paresthesia/B-AdverseReaction 0.3/O Flushing/B-AdverseReaction 0.3/O Parosmia/B-AdverseReaction 0.3/O Pruritus/O (/O generalized/O ,/O eye/O )/O 0.3/O Rash/B-AdverseReaction 0.3/O Respiratory/B-AdverseReaction disorders/I-AdverseReaction (/O dyspnea/B-AdverseReaction ,/O respiratory/B-AdverseReaction distress/I-AdverseReaction )/O 0.2/O Fatigue/B-AdverseReaction 0.2/O Chest/B-AdverseReaction pain/I-AdverseReaction 0.1/O Vertigo/B-AdverseReaction 0.1/O Dry/B-AdverseReaction mouth/I-AdverseReaction 0.1/O Chills/B-AdverseReaction 0.1/O Feeling/B-AdverseReaction abnormal/I-AdverseReaction 0.1/O Adverse/O reactions/O that/O occurred/O with/O a/O frequency/O of/O 0.1/O %/O in/O subjects/O who/O received/O EOVIST/O include/O :/O tremor/B-AdverseReaction ,/O akathisia/B-AdverseReaction ,/O bundle/B-AdverseReaction branch/I-AdverseReaction block/I-AdverseReaction ,/O palpitation/B-AdverseReaction ,/O oral/B-AdverseReaction discomfort/I-AdverseReaction ,/O salivary/B-AdverseReaction hypersecretion/I-AdverseReaction ,/O maculopapular/B-AdverseReaction rash/I-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O discomfort/B-AdverseReaction ,/O and/O malaise/B-AdverseReaction ./O
Elevation/B-AdverseReaction of/I-AdverseReaction serum/I-AdverseReaction iron/I-AdverseReaction values/O and/O serum/O bilirubin/O laboratory/O values/O were/O reported/O in/O less/O than/O 1/O %/O of/O patients/O after/O administration/O of/O EOVIST/O ./O
The/O values/O did/O not/O exceed/O more/O than/O 3/O times/O the/O baseline/O values/O and/O returned/O to/O baseline/O within/O 1/O to/O 4/O days/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O additional/O adverse/O reactions/O have/O been/O reported/O during/O the/O postmarketing/O use/O of/O EOVIST/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O anaphylacticshock/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O pharyngolaryngeal/B-AdverseReaction edema/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O face/B-AdverseReaction edema/I-AdverseReaction ,/O rhinitis/B-AdverseReaction ,/O conjunctivitis/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O hypoesthesia/B-AdverseReaction ,/O sneezing/B-AdverseReaction ,/O cough/B-AdverseReaction and/O pallor/B-AdverseReaction )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Tachycardia/B-AdverseReaction Restlessness/B-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction (/O NSF/B-AdverseReaction )/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction (/O NSF/B-AdverseReaction )/O Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/O for/O NSF/B-AdverseReaction among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O in/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrasted/O MRI/O or/O other/O modalities/O ./O
NSF/B-AdverseReaction may/B-Factor result/O in/O fatal/B-AdverseReaction or/O debilitating/B-Severity fibrosis/B-AdverseReaction affecting/O the/O skin/O ,/O muscle/O and/O internal/O organs/O ./O
The/O risk/B-Factor for/O NSF/B-AdverseReaction appears/O highest/O among/O patients/O with/O :/O oChronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73m2/O )/O ,/O oroAcute/O kidney/O injury/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O for/O example/O ,/O age/O 60/O years/O ,/O hypertension/O or/O diabetes/O )/O ,/O estimate/O the/O glomerular/O filtration/O rate/O (/O GFR/O )/O through/O laboratory/O testing/O ./O
For/O patients/O at/O highest/O risk/O for/O NSF/O ,/O do/O not/O exceed/O the/O recommended/O EOVIST/O dose/O and/O allow/O a/O sufficient/O period/O of/O time/O for/O elimination/O of/O the/O drug/O from/O the/O body/O prior/O to/O any/O re/O -/O administration/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O NEPHROGENIC/B-AdverseReaction SYSTEMIC/I-AdverseReaction FIBROSIS/I-AdverseReaction (/O NSF/B-AdverseReaction )/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/O for/O NSF/B-AdverseReaction among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O in/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrasted/O MRI/O or/O other/O modalities/O ./O
The/O risk/B-Factor for/O NSF/B-AdverseReaction appears/O highest/O among/O patients/O with/O :/O oChronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73m2/O )/O ,/O oroAcute/O kidney/O injury/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O for/O example/O ,/O age/O 60/O years/O ,/O hypertension/O or/O diabetes/O )/O ,/O estimate/O the/O glomerular/O filtration/O rate/O (/O GFR/O )/O through/O laboratory/O testing/O (/O 5.1/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Nephrogenic/B-AdverseReaction Systemic/I-AdverseReaction Fibrosis/I-AdverseReaction has/O occurred/O in/O patients/O with/O impaired/O elimination/O of/O GBCAs/O ./O
Higher/O than/O recommended/O dosing/O or/O repeated/O dosing/O appears/O to/O increase/O the/O risk/O (/O 5.1/O )/O Hypersensitivity/O :/O anaphylactoid/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction with/O cardiovascular/O ,/O respiratory/O and/O cutaneous/B-AdverseReaction manifestations/I-AdverseReaction ,/O ranging/O from/O mild/B-Severity to/O severe/B-Severity reactions/O including/O shock/B-AdverseReaction can/B-Factor occur/O ./O
Monitor/O patients/O closely/O for/O need/O of/O emergency/O cardiorespiratory/O support/O (/O 5.2/O )/O 5.1/O Nephrogenic/O Systemic/O Fibrosis/O (/O NSF/O )/O Gadolinium/B-DrugClass -/I-DrugClass based/I-DrugClass contrast/O agents/O (/O GBCAs/O )/O increase/O the/O risk/B-Factor for/O nephrogenic/B-AdverseReaction systemic/I-AdverseReaction fibrosis/I-AdverseReaction (/O NSF/B-AdverseReaction )/O among/O patients/O with/O impaired/O elimination/O of/O the/O drugs/O ./O
Avoid/O use/O of/O GBCAs/O among/O these/O patients/O unless/O the/O diagnostic/O information/O is/O essential/O and/O not/O available/O with/O non/O -/O contrast/O enhanced/O MRI/O or/O other/O modalities/O ./O
The/O GBCA/B-DrugClass -/O associated/O NSF/B-AdverseReaction risk/O appears/O highest/O for/O patients/O with/O chronic/O ,/O severe/O kidney/O disease/O (/O GFR/O 30/O mL/O min/1.73/O m/O 2/O )/O as/O well/O as/O patients/O with/O acute/O kidney/O injury/O ./O
The/O risk/O appears/O lower/O for/O patients/O with/O chronic/O ,/O moderate/O kidney/O disease/O (/O GFR/O 30/O to/O 59/O mL/O min/1.73/O m/O 2/O )/O and/O little/O ,/O if/O any/O ,/O for/O patients/O with/O chronic/O ,/O mild/O kidney/O disease/O (/O GFR/O 60/O to/O 89/O mL/O min/1.73/O m/O 2/O )/O ./O
NSF/B-AdverseReaction may/B-Factor result/O in/O fatal/B-AdverseReaction or/O debilitating/B-Severity fibrosis/B-AdverseReaction affecting/O the/O skin/O ,/O muscle/O and/O internal/O organs/O ./O
Report/O any/O diagnosis/O of/O NSF/O following/O EOVIST/O administration/O to/O Bayer/O HealthCare/O (/O 1/O -/O 888/O -/O 842/O -/O 2937/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O )/O ./O
Screen/O patients/O for/O acute/O kidney/O injury/O and/O other/O conditions/O that/O may/O reduce/O renal/O function/O ./O
Features/O of/O acute/O kidney/O injury/O consist/O of/O rapid/O (/O over/O hours/O to/O days/O )/O and/O usually/O reversible/O decrease/O in/O kidney/O function/O ,/O commonly/O in/O the/O setting/O of/O surgery/O ,/O severe/O infection/O ,/O injury/O or/O drug/O -/O induced/O kidney/O toxicity/O ./O
Serum/O creatinine/O levels/O and/O estimated/O GFR/O may/O not/O reliably/O assess/O renal/O function/O in/O the/O setting/O of/O acute/O kidney/O injury/O ./O
For/O patients/O at/O risk/O for/O chronically/O reduced/O renal/O function/O (/O for/O example/O ,/O age/O 60/O years/O ,/O diabetes/O mellitus/O or/O chronic/O hypertension/O )/O ,/O estimate/O the/O GFR/O through/O laboratory/O testing/O ./O
Among/O the/O factors/O that/O may/O increase/O the/O risk/B-Factor for/O NSF/B-AdverseReaction are/O repeated/O or/O higher/O than/O recommended/O doses/O of/O a/O GBCA/O and/O degree/O of/O renal/O impairment/O at/O the/O time/O of/O exposure/O ./O
Record/O the/O specific/O GBCA/O and/O the/O dose/O administrated/O to/O a/O patient/O ./O
For/O patients/O at/O highest/O risk/O for/O NSF/O ,/O do/O not/O exceed/O the/O recommended/O EOVIST/O dose/O and/O allow/O a/O sufficient/O period/O of/O time/O for/O elimination/O of/O the/O drug/O prior/O to/O any/O re/O -/O administration/O ./O
For/O patients/O receiving/O hemodialysis/O ,/O physicians/O may/O consider/O the/O prompt/O initiation/O of/O hemodialysis/O following/O the/O administration/O of/O a/O GBCA/O in/O order/O to/O enhance/O the/O contrast/O agent/O 's/O elimination/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
The/O usefulness/O of/O hemodialysis/O in/O the/O prevention/O of/O NSF/O is/O unknown/O ./O
5.2/O Hypersensitivity/O Reactions/O Anaphylactic/O and/O other/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction with/O cardiovascular/O ,/O respiratory/O and/O cutaneous/B-AdverseReaction manifestations/I-AdverseReaction ,/O ranging/O from/O mild/B-Severity to/O severe/B-Severity ,/O including/O shock/B-AdverseReaction have/O uncommonly/O occurred/O following/O EOVIST/O administration/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Before/O EOVIST/O administration/O ,/O assess/O all/O patients/O for/O any/O history/O of/O a/O reaction/O to/O contrast/O media/O ,/O bronchial/O asthma/O and/O allergic/O disorders/O ./O
These/O patients/O may/O have/O an/O increased/O risk/B-Factor for/O a/O hypersensitivity/B-AdverseReaction reaction/I-AdverseReaction to/O EOVIST/O ./O
Administer/O EOVIST/O only/O in/O situations/O where/O trained/O personnel/O and/O therapies/O are/O promptly/O available/O for/O the/O treatment/O of/O hypersensitivity/O reactions/O ,/O including/O personnel/O trained/O in/O resuscitation/O ./O
Most/O hypersensitivity/O reactions/O to/O EOVIST/O have/O occurred/O within/O half/O an/O hour/O after/O administration/O ./O
Delayed/O reactions/O can/B-Factor occur/O up/O to/O several/O days/O after/O EOVIST/O administration/O ./O
Observe/O patients/O for/O signs/O and/O symptoms/O of/O hypersensitivity/O reactions/O during/O and/O following/O EOVIST/O administration/O ./O
5.3/O Acute/O Kidney/O Injury/O In/O patients/O with/O chronic/O renal/O impairment/O ,/O acute/B-AdverseReaction kidney/I-AdverseReaction injury/I-AdverseReaction sometimes/O requiring/O dialysis/O has/O been/O observed/O with/O the/O use/O of/O some/O GBCAs/B-DrugClass ./O
The/O risk/B-Factor of/O acute/B-AdverseReaction kidney/I-AdverseReaction injury/I-AdverseReaction might/O be/O lower/O with/O EOVIST/O due/O to/O its/O dual/O excretory/O pathways/O ./O
Do/O not/O exceed/O the/O recommended/O dose/O ;/O the/O risk/O of/O acute/O kidney/O injury/O may/O increase/O with/O higher/O than/O recommended/O doses/O ./O
5.4/O Extravasation/O and/O Injection/O Site/O Reactions/O Ensure/O catheter/O and/O venous/O patency/O before/O the/O injection/O of/O EOVIST/O ./O
Extravasation/O into/O tissues/O during/O EOVIST/O administration/O may/B-Factor result/O in/O local/O tissue/O reactions/O ./O
Strictly/O avoid/O intramuscular/O administration/O of/O EOVIST/O because/O it/O may/O cause/O myocyte/O necrosis/O and/O inflammation/O [/O see/O Nonclinical/O Toxicology/O (/O 13.2/O )/O ]/O ./O
5.5/O Interference/O with/O Laboratory/O Tests/O Serum/O iron/O determination/O using/O complexometric/O methods/O (/O for/O example/O ,/O ferrocene/O complexation/O method/O )/O may/O result/O in/O falsely/O high/O or/O low/O values/O for/O up/O to/O 24/O hours/O after/O the/O examination/O with/O EOVIST/O because/O of/O the/O caloxetate/O trisodium/O excipients/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.6/O Interference/O with/O Visualization/O of/O Liver/O Lesions/O Severe/O renal/O or/O hepatic/O failure/O may/O impair/O EOVIST/O imaging/O performance/O ./O
In/O patients/O with/O end/O -/O stage/O renal/O failure/O ,/O hepatic/O contrast/O was/O markedly/O reduced/O and/O was/O attributed/O to/O elevated/O serum/O ferritin/O levels/O ./O
In/O patients/O with/O abnormally/O high/O (/O 3/O mg/O dL/O )/O serum/O bilirubin/O ,/O reduced/O hepatic/O contrast/O was/O observed/O ./O
If/O EOVIST/O is/O used/O in/O these/O patients/O ,/O complete/O MRI/O no/O later/O than/O 60/O minutes/O after/O EOVIST/O administration/O and/O use/O a/O paired/O non/O -/O contrast/O and/O contrast/O MRI/O set/O for/O diagnosis/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O label/O :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Pancreatitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Glucose/B-AdverseReaction intolerance/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Thrombosis/B-AdverseReaction and/O hemorrhage/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O The/O most/O common/O adverse/O reactions/O (/O incidence/O 1/O %/O or/O greater/O )/O with/O ERWINAZE/O treatment/O are/O systemic/B-AdverseReaction hypersensitivity/I-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O transaminases/B-AdverseReaction abnormal/I-AdverseReaction ,/O fever/B-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O local/B-AdverseReaction reactions/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O thrombosis/B-AdverseReaction ,/O hyperbilirubinemia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction discomfort/O ,/O and/O diarrhea/B-AdverseReaction ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 1/O %/O or/O greater/O )/O are/O :/O systemic/B-AdverseReaction hypersensitivity/I-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O transaminases/B-AdverseReaction abnormal/I-AdverseReaction ,/O fever/B-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O local/B-AdverseReaction reactions/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O thrombosis/B-AdverseReaction ,/O hyperbilirubinemia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction discomfort/O ,/O and/O diarrhea/B-AdverseReaction ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Jazz/O Pharmaceuticals/O ,/O Inc./O at/O 1/O -/O 800/O -/O 520/O -/O 5568/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Studies/O Because/O clinical/O trials/O are/O conducted/O under/O controlled/O ,/O but/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O trials/O of/O ERWINAZE/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O other/O drugs/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O data/O presented/O below/O are/O based/O on/O information/O collected/O from/O Study/O 1/O ,/O a/O single/O -/O arm/O ,/O multi/O -/O center/O ,/O open/O -/O label/O ,/O safety/O and/O clinical/O pharmacology/O trial/O (/O intramuscular/O administration/O )/O ,/O the/O ERWINAZE/O Master/O Treatment/O Protocol/O (/O EMTP/O )/O ,/O an/O expanded/O access/O program/O (/O both/O intramuscular/O ,/O intravenous/O ,/O and/O other/O or/O unknown/O administration/O )/O ,/O and/O Study/O 2/O ,/O a/O single/O -/O arm/O ,/O multi/O -/O center/O ,/O open/O -/O label/O ,/O pharmacokinetic/O (/O PK/O )/O study/O trial/O of/O intravenous/O administration/O of/O ERWINAZE.Study/O 1/O enrolled/O 58/O patients/O treated/O on/O National/O Cancer/O Institute/O (/O NCI)-sponsored/O cooperative/O group/O ALL/O protocols/O who/O were/O unable/O to/O continue/O to/O receive/O pegaspargase/O due/O to/O hypersensitivity/O reactions/O ./O
Patients/O received/O 6/O doses/O of/O ERWINAZE/O 25,000/O International/O Units/O m/O 2/O intramuscularly/O on/O a/O Monday/O ,/O Wednesday/O ,/O and/O Friday/O schedule/O as/O a/O replacement/O for/O each/O scheduled/O dose/O of/O pegaspargase/O remaining/O on/O their/O original/O treatment/O protocol/O ./O
The/O Study/O 1/O population/O included/O patients/O with/O a/O median/O age/O of/O 11/O years/O (/O 2/O to/O 18/O years/O )/O ;/O 59/O %/O were/O male/O ,/O 78/O %/O were/O White/O ,/O 10/O %/O were/O Black/O African/O American/O ,/O 5/O %/O were/O Asian/O ,/O and/O 7/O %/O were/O other/O or/O unknown/O ./O
A/O total/O of/O 35/O %/O were/O Hispanic/O or/O Latino/O ./O
In/O Study/O 1/O ,/O the/O number/O of/O ERWINAZE/O courses/O ranged/O from/O 1/O to/O 9/O ./O
In/O this/O study/O ,/O 76/O %/O (/O 44/O of/O 58/O )/O completed/O all/O planned/O therapy/O ./O
Fourteen/O (/O 24/O %/O )/O patients/O stopped/O therapy/O prior/O to/O completion/O ;/O seven/O due/O to/O allergic/B-AdverseReaction reactions/I-AdverseReaction ,/O five/O due/O to/O physician/O or/O patient/O choice/O ,/O one/O due/O to/O disease/O progression/O ,/O and/O one/O due/O to/O discontinuation/O during/O frontline/O protocol/O ./O
All/O other/O chemotherapy/O was/O continued/O according/O to/O the/O patient/O 's/O prescribed/O treatment/O regimen/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O .Study/O 2/O enrolled/O 30/O patients/O [/O 29/O were/O being/O treated/O for/O ALL/O and/O one/O for/O lymphoblastic/O lymphoma/O (/O LBL/O )/O ]/O following/O allergy/O to/O native/O E./O coli/O asparaginase/O or/O pegaspargase/O ./O
Patients/O received/O ERWINAZE/O 25,000/O International/O Unit/O m/O 2/O /dose/O ,/O administered/O by/O intravenous/O infusion/O on/O a/O Monday/O ,/O Wednesday/O ,/O and/O Friday/O schedule/O (/O 6/O doses/O )/O as/O a/O replacement/O for/O doses/O remaining/O on/O their/O original/O treatment/O plan/O ./O
The/O Study/O 2/O population/O included/O patients/O with/O a/O median/O age/O of/O 7/O years/O (/O 1/O to/O 17/O years/O )/O ;/O 63/O %/O were/O male/O ,/O 27/O %/O were/O Hispanic/O or/O Latino/O ,/O 83/O %/O were/O White/O ,/O 3/O %/O were/O Black/O African/O American/O ,/O 7/O %/O were/O Asian/O ,/O and/O 7/O %/O were/O other/O (/O American/O Indian/O ,/O Alaska/O Native/O or/O Indian/O )/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
The/O EMTP/O trial/O enrolled/O 1368/O patients/O with/O ALL/O or/O lymphoblastic/O lymphoma/O who/O received/O ERWINAZE/O after/O developing/O systemic/O hypersensitivity/O to/O an/O E./O coli/O -derived/O asparaginase/O ./O
Of/O these/O 1368/O patients/O ,/O safety/O data/O were/O received/O for/O 940/O patients/O with/O a/O median/O age/O of/O 9/O years/O (/O 0/O to/O 76/O years/O )/O ,/O 63/O %/O were/O male/O ,/O 91/O %/O with/O leukemia/O ,/O 3/O %/O with/O lymphoma/O ,/O and/O 6/O %/O with/O unknown/O disease/O information/O ./O
Patients/O received/O ERWINAZE/O according/O to/O several/O schedules/O ,/O and/O treatment/O center/O specifications/O with/O doses/O that/O ranged/O from/O 20,000/O to/O 25,000/O International/O Units/O m/O 2/O ./O
The/O route/O of/O administration/O was/O intramuscular/O n=852/O ,/O intravenous/O n=29/O ,/O other/O or/O unknown/O n=59/O ./O
In/O the/O EMTP/O trial/O ,/O the/O planned/O number/O of/O doses/O of/O ERWINAZE/O ranged/O from/O 3/O to/O 48/O doses/O ./O
Seventy/O -/O eight/O percent/O of/O patients/O (/O 693/O of/O 893/O )/O were/O able/O to/O receive/O all/O planned/O doses/O to/O complete/O their/O prescribed/O treatment/O regimen/O ./O
In/O Study/O 1/O and/O Study/O 2/O ,/O safety/O information/O was/O prospectively/O and/O systematically/O collected/O ./O
In/O Study/O 1/O ,/O all/O Grades/O of/O adverse/O events/O were/O reported/O for/O the/O following/O adverse/O events/O of/O special/O interest/O :/O allergy/B-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O coagulopathy/B-AdverseReaction (/O hemorrhage/B-AdverseReaction ,/O thrombosis/B-AdverseReaction or/O infarct/B-AdverseReaction )/O ,/O hyperbilirubinemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O hyperlipidemia/B-AdverseReaction ,/O ketoacidosis/B-AdverseReaction ,/O and/O CNS/B-AdverseReaction events/I-AdverseReaction (/O hemorrhage/O ,/O thrombosis/O or/O infarction/O ,/O and/O cerebral/B-AdverseReaction venous/I-AdverseReaction thrombosis/I-AdverseReaction )/O and/O only/O Grade/O 3/O and/O 4/O events/O were/O reported/O for/O other/O adverse/O events/O ./O
In/O Study/O 2/O all/O adverse/O events/O of/O all/O Grades/O were/O prospectively/O collected/O ./O
In/O the/O EMTP/O trial/O ,/O safety/O data/O were/O derived/O from/O case/O report/O forms/O that/O collected/O adverse/O event/O information/O ./O
The/O forms/B-Factor specifically/I-Factor requested/I-Factor information/I-Factor on/O occurrence/O of/O allergic/B-AdverseReaction reactions/I-AdverseReaction ,/O thrombotic/B-AdverseReaction events/I-AdverseReaction ,/O hemorrhagic/B-AdverseReaction events/I-AdverseReaction ,/O hepatobiliary/B-AdverseReaction disorders/I-AdverseReaction ,/O pancreatic/B-AdverseReaction disorders/I-AdverseReaction ,/O and/O hyperglycemia/B-AdverseReaction ./O
The/O incidence/O of/O non/O -/O hematologic/O ,/O non/O -/O infectious/O ,/O adverse/O events/O (/O all/O Grades/O )/O in/O Study/O 1/O ,/O Study/O 2/O ,/O and/O the/O EMTP/O trial/O is/O provided/O in/O Table/O 1/O ./O
The/O incidence/O of/O Grade/O 3/O or/O greater/O non/O -/O hematologic/O ,/O non/O -/O infectious/O adverse/O reactions/O occurring/O with/O ERWINAZE/O in/O Study/O 1/O ,/O Study/O 2/O and/O EMTP/O trial/O is/O provided/O in/O Table/O 2/O ./O
Table/O 1/O Table/O 2/O 6.2/O Immunogenicity/O As/O with/O most/O therapeutic/O proteins/O ,/O patients/O may/O develop/O anti/O -/O drug/O antibodies/O (/O ADA/O )/O to/O ERWINAZE.In/O a/O study/O with/O ERWINAZE/O treatment/O by/O intramuscular/O administration/O (/O Study/O 1/O )/O ,/O 6/O of/O 56/O (/O 11/O %/O )/O patients/O treated/O with/O ERWINAZE/O developed/O antibodies/O to/O ERWINAZE/O ./O
Of/O these/O 6/O ADA/O positive/O patients/O ,/O one/O experienced/O a/O hypersensitivity/B-AdverseReaction reaction/I-AdverseReaction during/O Study/O 1/O (/O 2/O %/O ,/O 1/O of/O 56/O )/O ./O
None/O of/O these/O 6/O patients/O had/O neutralizing/O antibodies/O ./O
In/O a/O study/O with/O ERWINAZE/O treatment/O by/O intravenous/O administration/O (/O Study/O 2/O )/O ,/O 4/O of/O 30/O (/O 13.3/O %/O )/O patients/O treated/O with/O ERWINAZE/O developed/O anti/O -/O ERWINAZE/O antibodies/O ./O
Of/O these/O 4/O patients/O who/O developed/O anti/O -/O ERWINAZE/O antibodies/O ,/O 3/O experienced/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O 10/O %/O ,/O 3/O of/O 30/O )/O during/O the/O study/O ./O
None/O of/O these/O 4/O patients/O had/O neutralizing/O antibodies/O ./O
The/O presence/O of/O ADA/O to/O ERWINAZE/O is/O associated/O with/O a/O higher/O risk/B-Factor of/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction in/O patients/O who/O received/O ERWINAZE/O through/O intravenous/O infusion/O compared/O to/O intramuscular/O administration/O of/O ERWINAZE.Immunogenicity/O assay/O are/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O and/O may/O be/O influenced/O by/O several/O factors/O such/O as/O :/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O ERWINAZE/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O If/O the/O following/O occur/O ,/O discontinue/O ERWINAZE/O :/O Serious/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction (/O 5.1)Severe/O or/O hemorrhagic/B-AdverseReaction pancreatitis/B-AdverseReaction (/O 5.2/O )/O Glucose/B-AdverseReaction intolerance/I-AdverseReaction can/B-Factor occur/O and/O ,/O in/O some/O cases/O ,/O may/O be/O irreversible/B-Severity ./O
Perform/O appropriate/O monitoring/O and/O treat/O hyperglycemia/O with/O insulin/O ,/O as/O necessary/O (/O 5.3/O )/O Thrombosis/B-AdverseReaction ,/O hemorrhage/B-AdverseReaction :/O discontinue/O ERWINAZE/O until/O resolved/O (/O 5.4/O )/O 5.1/O Hypersensitivity/O Reactions/O Grade/B-Severity 3/I-Severity and/O 4/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction after/O the/O use/O of/O ERWINAZE/O have/O occurred/O in/O 5/O %/O of/O patients/O in/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Administer/O this/O product/O in/O a/O setting/O with/O resuscitation/O equipment/O and/O other/O agents/O necessary/O to/O treat/O anaphylaxis/O ./O
If/O a/O serious/O hypersensitivity/O reaction/O occurs/O ,/O discontinue/O ERWINAZE/O and/O initiate/O appropriate/O therapy/O ./O
5.2/O Pancreatitis/O Pancreatitis/B-AdverseReaction has/O been/O reported/O in/O 4/O %/O of/O patients/O in/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Evaluate/O patients/O with/O symptoms/O compatible/O with/O pancreatitis/O to/O establish/O a/O diagnosis/O ./O
Discontinue/O ERWINAZE/O for/O severe/O or/O hemorrhagic/O pancreatitis/O manifested/O by/O abdominal/O pain/O 72/O hours/O and/O amylase/O elevation/O 2.0/O x/O ULN/O ./O
Severe/O pancreatitis/O is/O a/O contraindication/O to/O additional/O asparaginase/O administration/O ./O
In/O the/O case/O of/O mild/O pancreatitis/O ,/O hold/O ERWINAZE/O until/O the/O signs/O and/O symptoms/O subside/O and/O amylase/O levels/O return/O to/O normal/O ./O
After/O resolution/O ,/O treatment/O with/O ERWINAZE/O may/O be/O resumed/O ./O
5.3/O Glucose/O Intolerance/O Glucose/O intolerance/O has/O been/O reported/O in/O 5/O %/O of/O patients/O receiving/O ERWINAZE/O in/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O some/O cases/O glucose/B-AdverseReaction intolerance/I-AdverseReaction may/O be/O irreversible/B-Severity ./O
Monitor/O glucose/O levels/O in/O patients/O at/O baseline/O and/O periodically/O during/O treatment/O ./O
Administer/O insulin/O therapy/O as/O necessary/O in/O patients/O with/O hyperglycemia/O ./O
5.4/O Thrombosis/O and/O Hemorrhage/O Serious/B-Severity thrombotic/B-AdverseReaction events/I-AdverseReaction ,/O including/O sagittal/B-AdverseReaction sinus/I-AdverseReaction thrombosis/I-AdverseReaction and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction have/O been/O reported/O with/O both/O E./O coli/O and/O Erwinia/O -derived/O L/O -/O asparaginase/O therapy/O ./O
The/O following/O coagulation/O proteins/O were/O decreased/O in/O the/O majority/O of/O patients/O after/O a/O 2-week/O course/O of/O ERWINAZE/O by/O intramuscular/O administration/O :/O fibrinogen/O ,/O protein/O C/O activity/O ,/O protein/O S/O activity/O ,/O and/O anti/O -/O thrombin/O III/O ./O
Discontinue/O ERWINAZE/O for/O a/O thrombotic/O or/O hemorrhagic/O event/O until/O symptoms/O resolve/O ;/O after/O resolution/O ,/O treatment/O with/O ERWINAZE/O may/O be/O resumed/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O the/O Warnings/O and/O Precautions/O (/O 5/O )/O section/O of/O the/O labeling/O :/O Endophthalmitis/B-AdverseReaction and/O retinal/B-AdverseReaction detachments/I-AdverseReaction Increased/B-AdverseReaction intraocular/I-AdverseReaction pressure/I-AdverseReaction Thromboembolic/B-AdverseReaction events/I-AdverseReaction EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 5/O %/O )/O reported/O in/O patients/O receiving/O EYLEA/O were/O conjunctival/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O eye/B-AdverseReaction pain/I-AdverseReaction ,/O cataract/B-AdverseReaction ,/O vitreous/B-AdverseReaction floaters/I-AdverseReaction ,/O intraocular/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction ,/O and/O vitreous/B-AdverseReaction detachment/I-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Regeneron/O at/O 1/O -/O 855/O -/O 395/O -/O 3248/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O other/O clinical/O trials/O of/O the/O same/O or/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
A/O total/O of/O 2711/O patients/O treated/O with/O EYLEA/O constituted/O the/O safety/O population/O in/O seven/O phase/O 3/O studies/O ./O
Among/O those/O ,/O 2110/O patients/O were/O treated/O with/O the/O recommended/O dose/O of/O 2/O mg/O ./O
Serious/O adverse/O reactions/O related/O to/O the/O injection/O procedure/O have/O occurred/O in/O 0.1/O %/O of/O intravitreal/O injections/O with/O EYLEA/O including/O endophthalmitis/B-AdverseReaction and/O retinal/B-AdverseReaction detachment/I-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O (/O 5/O %/O )/O reported/O in/O patients/O receiving/O EYLEA/O were/O conjunctival/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O eye/B-AdverseReaction pain/I-AdverseReaction ,/O cataract/B-AdverseReaction ,/O vitreous/B-AdverseReaction floaters/I-AdverseReaction ,/O intraocular/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction ,/O and/O vitreous/B-AdverseReaction detachment/I-AdverseReaction ./O
Neovascular/O (/O Wet/O )/O Age/O -/O Related/O Macular/O Degeneration/O (/O AMD/O )/O The/O data/O described/O below/O reflect/O exposure/O to/O EYLEA/O in/O 1824/O patients/O with/O wet/O AMD/O ,/O including/O 1223/O patients/O treated/O with/O the/O 2-mg/O dose/O ,/O in/O 2/O double/O -/O masked/O ,/O active/O -/O controlled/O clinical/O studies/O (/O VIEW1/O and/O VIEW2/O )/O for/O 12/O months/O [/O seeClinical/O Studies/O (/O 14.1/O )/O ]/O ./O
Table/O 1/O :/O Most/O Common/O Adverse/O Reactions/O (/O 1/O %/O )/O in/O Wet/O AMD/O Studies/O Adverse/O Reactions/O EYLEA(N=1824/O )/O Active/O Control/O (/O ranibizumab)(N=595/O )/O Conjunctival/B-AdverseReaction hemorrhage/I-AdverseReaction 25/O %/O 28/O %/O Eye/B-AdverseReaction pain/I-AdverseReaction 9/O %/O 9/O %/O Cataract/B-AdverseReaction 7/O %/O 7/O %/O Vitreous/B-AdverseReaction detachment/I-AdverseReaction 6/O %/O 6/O %/O Vitreous/B-AdverseReaction floaters/I-AdverseReaction 6/O %/O 7/O %/O Intraocular/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction 5/O %/O 7/O %/O Ocular/B-AdverseReaction hyperemia/I-AdverseReaction 4/O %/O 8/O %/O Corneal/B-AdverseReaction epithelium/I-AdverseReaction defect/I-AdverseReaction 4/O %/O 5/O %/O Detachment/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction retinal/I-AdverseReaction pigment/I-AdverseReaction epithelium/I-AdverseReaction 3/O %/O 3/O %/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 3/O %/O 3/O %/O Foreign/B-AdverseReaction body/I-AdverseReaction sensation/I-AdverseReaction in/I-AdverseReaction eyes/I-AdverseReaction 3/O %/O 4/O %/O Lacrimation/B-AdverseReaction increased/I-AdverseReaction 3/O %/O 1/O %/O Vision/B-AdverseReaction blurred/I-AdverseReaction 2/O %/O 2/O %/O Intraocular/B-AdverseReaction inflammation/I-AdverseReaction 2/O %/O 3/O %/O Retinal/B-AdverseReaction pigment/I-AdverseReaction epithelium/I-AdverseReaction tear/I-AdverseReaction 2/O %/O 1/O %/O Injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction 1/O %/O 2/O %/O Eyelid/B-AdverseReaction edema/I-AdverseReaction 1/O %/O 2/O %/O Corneal/B-AdverseReaction edema/I-AdverseReaction 1/O %/O 1/O %/O Less/O common/O serious/O adverse/O reactions/O reported/O in/O 1/O %/O of/O the/O patients/O treated/O with/O EYLEA/O were/O hypersensitivity/B-AdverseReaction ,/O retinal/B-AdverseReaction detachment/I-AdverseReaction ,/O retinal/B-AdverseReaction tear/I-AdverseReaction ,/O and/O endophthalmitis/B-AdverseReaction ./O
Macular/O Edema/O Following/O Retinal/O Vein/O Occlusion/O (/O RVO/O )/O The/O data/O described/O below/O reflect/O 6/O months/O exposure/O to/O EYLEA/O with/O a/O monthly/O 2/O mg/O dose/O in/O 218/O patients/O following/O CRVO/O in/O 2/O clinical/O studies/O (/O COPERNICUS/O and/O GALILEO/O )/O and/O 91/O patients/O following/O BRVO/O in/O one/O clinical/O study/O (/O VIBRANT/O )/O [/O seeClinical/O Studies/O (/O 14.2),(14.3/O )/O ]/O ./O
Table/O 2/O :/O Most/O Common/O Adverse/O Reactions/O (/O 1/O %/O )/O in/O RVO/O Studies/O Adverse/O Reactions/O CRVO/O BRVO/O EYLEA(N=218/O )/O Control(N=142/O )/O EYLEA(N=91/O )/O Control(N=92/O )/O Eye/B-AdverseReaction pain/I-AdverseReaction 13/O %/O 5/O %/O 4/O %/O 5/O %/O Conjunctival/B-AdverseReaction hemorrhage/I-AdverseReaction 12/O %/O 11/O %/O 20/O %/O 4/O %/O Intraocular/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction 8/O %/O 6/O %/O 2/O %/O 0/O %/O Corneal/B-AdverseReaction epithelium/I-AdverseReaction defect/I-AdverseReaction 5/O %/O 4/O %/O 2/O %/O 0/O %/O Vitreous/B-AdverseReaction floaters/I-AdverseReaction 5/O %/O 1/O %/O 1/O %/O 0/O %/O Ocular/B-AdverseReaction hyperemia/I-AdverseReaction 5/O %/O 3/O %/O 2/O %/O 2/O %/O Foreign/B-AdverseReaction body/I-AdverseReaction sensation/I-AdverseReaction in/I-AdverseReaction eyes/I-AdverseReaction 3/O %/O 5/O %/O 3/O %/O 0/O %/O Vitreous/B-AdverseReaction detachment/I-AdverseReaction 3/O %/O 4/O %/O 2/O %/O 0/O %/O Lacrimation/B-AdverseReaction increased/I-AdverseReaction 3/O %/O 4/O %/O 3/O %/O 0/O %/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 3/O %/O 1/O %/O 1/O %/O 0/O %/O Vision/B-AdverseReaction blurred/I-AdverseReaction 1/O %/O 1/O %/O 1/O %/O 1/O %/O Intraocular/B-AdverseReaction inflammation/I-AdverseReaction 1/O %/O 1/O %/O 0/O %/O 0/O %/O Cataract/B-AdverseReaction 1/O %/O 1/O %/O 5/O %/O 0/O %/O Eyelid/B-AdverseReaction edema/I-AdverseReaction 1/O %/O 1/O %/O 1/O %/O 0/O %/O Less/O common/O adverse/O reactions/O reported/O in/O 1/O %/O of/O the/O patients/O treated/O with/O EYLEA/O in/O the/O CRVO/O studies/O were/O corneal/B-AdverseReaction edema/I-AdverseReaction ,/O retinal/B-AdverseReaction tear/I-AdverseReaction ,/O hypersensitivity/B-AdverseReaction ,/O and/O endophthalmitis/B-AdverseReaction ./O
Diabetic/O Macular/O Edema/O (/O DME/O )/O The/O data/O described/O below/O reflect/O exposure/O to/O EYLEA/O in/O 578/O patients/O with/O DME/O treated/O with/O the/O 2-mg/O dose/O in/O 2/O double/O -/O masked/O ,/O controlled/O clinical/O studies/O (/O VIVID/O and/O VISTA/O )/O from/O baseline/O to/O week/O 52/O and/O from/O baseline/O to/O week/O 100/O [/O seeClinical/O Studies/O (/O 14.4/O )/O ]/O ./O
Table/O 3/O :/O Most/O Common/O Adverse/O Reactions/O (/O 1/O %/O )/O in/O DME/O Studies/O Adverse/O Reactions/O Baseline/O to/O Week/O 52/O Baseline/O to/O Week/O 100/O EYLEA(N=578/O )/O Control(N=287/O )/O EYLEA(N=578/O )/O Control(N=287/O )/O Conjunctival/B-AdverseReaction hemorrhage/I-AdverseReaction 28/O %/O 17/O %/O 31/O %/O 21/O %/O Eye/B-AdverseReaction pain/I-AdverseReaction 9/O %/O 6/O %/O 11/O %/O 9/O %/O Cataract/B-AdverseReaction 8/O %/O 9/O %/O 19/O %/O 17/O %/O Vitreous/B-AdverseReaction floaters/I-AdverseReaction 6/O %/O 3/O %/O 8/O %/O 6/O %/O Corneal/B-AdverseReaction epithelium/I-AdverseReaction defect/I-AdverseReaction 5/O %/O 3/O %/O 7/O %/O 5/O %/O Intraocular/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction 5/O %/O 3/O %/O 9/O %/O 5/O %/O Ocular/B-AdverseReaction hyperemia/I-AdverseReaction 5/O %/O 6/O %/O 5/O %/O 6/O %/O Vitreous/B-AdverseReaction detachment/I-AdverseReaction 3/O %/O 3/O %/O 8/O %/O 6/O %/O Foreign/B-AdverseReaction body/I-AdverseReaction sensation/I-AdverseReaction in/I-AdverseReaction eyes/I-AdverseReaction 3/O %/O 3/O %/O 3/O %/O 3/O %/O Lacrimation/B-AdverseReaction increased/I-AdverseReaction 3/O %/O 2/O %/O 4/O %/O 2/O %/O Vision/B-AdverseReaction blurred/I-AdverseReaction 2/O %/O 2/O %/O 3/O %/O 4/O %/O Intraocular/B-AdverseReaction inflammation/I-AdverseReaction 2/O %/O 1/O %/O 3/O %/O 1/O %/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 2/O %/O 1/O %/O 2/O %/O 1/O %/O Eyelid/B-AdverseReaction edema/I-AdverseReaction 1/O %/O 1/O %/O 2/O %/O 1/O %/O Less/O common/O adverse/O reactions/O reported/O in/O 1/O %/O of/O the/O patients/O treated/O with/O EYLEA/O were/O hypersensitivity/B-AdverseReaction ,/O retinal/B-AdverseReaction detachment/I-AdverseReaction ,/O retinal/B-AdverseReaction tear/I-AdverseReaction ,/O corneal/B-AdverseReaction edema/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction ./O
6.2/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O a/O potential/O for/O an/O immune/O response/O in/O patients/O treated/O with/O EYLEA/O ./O
The/O immunogenicity/O of/O EYLEA/O was/O evaluated/O in/O serum/O samples/O ./O
The/O immunogenicity/O data/O reflect/O the/O percentage/O of/O patients/O whose/O test/O results/O were/O considered/O positive/O for/O antibodies/O to/O EYLEA/O in/O immunoassays/O ./O
The/O detection/O of/O an/O immune/O response/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assays/O used/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O EYLEA/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
In/O the/O wet/O AMD/O ,/O RVO/O ,/O and/O DME/O studies/O ,/O the/O pre/O -/O treatment/O incidence/O of/O immunoreactivity/O to/O EYLEA/O was/O approximately/O 1/O %/O to/O 3/O %/O across/O treatment/O groups/O ./O
After/O dosing/O with/O EYLEA/O for/O 24/O -/O 100/O weeks/O ,/O antibodies/O to/O EYLEA/O were/O detected/O in/O a/O similar/O percentage/O range/O of/O patients/O ./O
There/O were/O no/O differences/O in/O efficacy/O or/O safety/O between/O patients/O with/O or/O without/O immunoreactivity/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Endophthalmitis/B-AdverseReaction and/O retinal/B-AdverseReaction detachments/I-AdverseReaction may/B-Factor occur/O following/O intravitreal/O injections/O ./O
Patients/O should/O be/O instructed/O to/O report/O any/O symptoms/O suggestive/O of/O endophthalmitis/O or/O retinal/O detachment/O without/O delay/O and/O should/O be/O managed/O appropriately/O ./O
(/O 5.1/O )/O Increases/B-AdverseReaction in/I-AdverseReaction intraocular/I-AdverseReaction pressure/I-AdverseReaction have/O been/O seen/O within/O 60/O minutes/O of/O an/O intravitreal/O injection/O ./O
(/O 5.2/O )/O There/O is/O a/O potential/O risk/O of/O arterial/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction following/O intravitreal/O use/O of/O VEGF/B-DrugClass inhibitors/I-DrugClass ./O
(/O 5.3/O )/O 5.1/O Endophthalmitis/O and/O Retinal/O Detachments/O Intravitreal/O injections/O ,/O including/O those/O with/O EYLEA/O ,/O have/O been/O associated/O with/O endophthalmitis/B-AdverseReaction and/O retinal/B-AdverseReaction detachments/I-AdverseReaction [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Proper/O aseptic/O injection/O technique/O must/O always/O be/O used/O when/O administering/O EYLEA/O ./O
Patients/O should/O be/O instructed/O to/O report/O any/O symptoms/O suggestive/O of/O endophthalmitis/O or/O retinal/O detachment/O without/O delay/O and/O should/O be/O managed/O appropriately/O [/O seeDosage/O and/O Administration/O (/O 2.7)andPatient/O Counseling/O Information/O (/O 17/O )/O ]/O ./O
5.2/O Increase/O in/O Intraocular/O Pressure/O Acute/B-AdverseReaction increases/I-AdverseReaction in/I-AdverseReaction intraocular/I-AdverseReaction pressure/I-AdverseReaction have/O been/O seen/O within/O 60/O minutes/O of/O intravitreal/O injection/O ,/O including/O with/O EYLEA/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Sustained/B-AdverseReaction increases/I-AdverseReaction in/I-AdverseReaction intraocular/I-AdverseReaction pressure/I-AdverseReaction have/O also/O been/O reported/O after/O repeated/O intravitreal/O dosing/O with/O vascular/O endothelial/O growth/O factor/O (/O VEGF/O )/O inhibitors/O ./O
Intraocular/O pressure/O and/O the/O perfusion/O of/O the/O optic/O nerve/O head/O should/O be/O monitored/O and/O managed/O appropriately/O [/O seeDosage/O and/O Administration/O (/O 2.7/O )/O ]/O ./O
5.3/O Thromboembolic/O Events/O There/O is/O a/O potential/O risk/B-Factor of/O arterial/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction (/O ATEs/B-AdverseReaction )/O following/O intravitreal/O use/O of/O VEGF/O inhibitors/O ,/O including/O EYLEA/O ./O
ATEs/O are/O defined/O as/O nonfatal/O stroke/O ,/O nonfatal/O myocardial/O infarction/O ,/O or/O vascular/O death/O (/O including/O deaths/O of/O unknown/O cause/O )/O ./O
The/O incidence/O of/O reported/O thromboembolic/B-AdverseReaction events/I-AdverseReaction in/O wet/O AMD/O studies/O during/O the/O first/O year/O was/O 1.8/O %/O (/O 32/O out/O of/O 1824/O )/O in/O the/O combined/O group/O of/O patients/O treated/O with/O EYLEA/O ./O
The/O incidence/O in/O the/O DME/O studies/O from/O baseline/O to/O week/O 52/O was/O 3.3/O %/O (/O 19/O out/O of/O 578/O )/O in/O the/O combined/O group/O of/O patients/O treated/O with/O EYLEA/O compared/O with/O 2.8/O %/O (/O 8/O out/O of/O 287/O )/O in/O the/O control/O group/O ;/O from/O baseline/O to/O week/O 100/O ,/O the/O incidence/O was/O 6.4/O %/O (/O 37/O out/O of/O 578/O )/O in/O the/O combined/O group/O of/O patients/O treated/O with/O EYLEA/O compared/O with/O 4.2/O %/O (/O 12/O out/O of/O 287/O )/O in/O the/O control/O group/O ./O
There/O were/O no/B-Negation reported/O thromboembolic/B-AdverseReaction events/I-AdverseReaction in/O the/O patients/O treated/O with/O EYLEA/O in/O the/O first/O six/O months/O of/O the/O RVO/O studies/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O are/O (/O incidence/O 5/O %/O )/O chromaturia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction and/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O alanine/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O arthralgia/B-AdverseReaction and/O neutropenia/B-AdverseReaction ./O
(/O 5.1/O ,/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O ApoPharma/O Inc./O at/O :/O Telephone/O :/O 1/O -/O 866/O -/O 949/O -/O 0995/O Email/O :/O medicalsafety@apopharma.com/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O }/O }/O 6.1/O Clinical/O Trial/O Experience/O The/O following/O adverse/O reactions/O are/O also/O discussed/O in/O other/O sections/O of/O the/O labeling/O :/O Agranulocytosis/B-AdverseReaction Neutropenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Elevated/B-AdverseReaction ALT/I-AdverseReaction (/O 5.3/O )/O ,/O Decreased/B-AdverseReaction plasma/I-AdverseReaction zinc/I-AdverseReaction concentrations/I-AdverseReaction (/O 5.3/O )/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Adverse/O reaction/O information/O for/O Ferriprox/O represents/O the/O pooled/O data/O collected/O from/O 642/O patients/O who/O participated/O in/O single/O arm/O or/O active/O -/O controlled/O clinical/O studies/O ./O
The/O most/O serious/O adverse/O reaction/O reported/O in/O clinical/O trials/O with/O Ferriprox/O was/O agranulocytosis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
The/O most/O common/O adverse/O reactions/O reported/O during/O clinical/O trials/O were/O chromaturia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O alanine/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O arthralgia/B-AdverseReaction and/O neutropenia/B-AdverseReaction ./O
The/O table/O below/O lists/O the/O adverse/O drug/O reactions/O that/O occurred/O in/O at/O least/O 1/O %/O of/O patients/O treated/O with/O Ferriprox/O in/O clinical/O trials/O ./O
Table/O 2/O :/O Adverse/O drug/O reactions/O occurring/O in/O 1/O %/O of/O 642/O Ferriprox/O -/O treated/O patients/O Body/O System/O %/O Subjects/O Preferred/O Term/O BLOOD/O AND/O LYMPHATIC/O SYSTEM/O DISORDERS/O Neutropenia/B-AdverseReaction 6.2/O Agranulocytosis/B-AdverseReaction 1.7/O GASTROINTESTINAL/O DISORDERS/O Nausea/B-AdverseReaction 12.6/O Abdominal/B-AdverseReaction pain/I-AdverseReaction discomfort/O 10.4/O Vomiting/B-AdverseReaction 9.8/O Diarrhea/B-AdverseReaction 3.0/O Dyspepsia/B-AdverseReaction 2.0/O INVESTIGATIONS/O Alanine/B-AdverseReaction Aminotransferase/I-AdverseReaction increased/I-AdverseReaction 7.5/O Neutrophil/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction 7.3/O Weight/B-AdverseReaction increased/I-AdverseReaction 1.9/O Aspartate/B-AdverseReaction Aminotransferase/I-AdverseReaction increased/I-AdverseReaction 1.2/O METABOLISM/O AND/O NUTRITION/O DISORDERS/O Increased/B-AdverseReaction appetite/I-AdverseReaction 4.0/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 1.1/O MUSCULOSKELETAL/O AND/O CONNECTIVE/O TISSUE/O DISORDERS/O Arthralgia/B-AdverseReaction 9.8/O Back/B-AdverseReaction pain/I-AdverseReaction 2.0/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 1.9/O Arthropathy/B-AdverseReaction 1.4/O NERVOUS/O SYSTEM/O DISORDERS/O Headache/B-AdverseReaction 2.5/O URINARY/O DISORDERS/O Chromaturia/B-AdverseReaction 14.6/O Gastrointestinal/O symptoms/O such/O as/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O and/O abdominal/B-AdverseReaction pain/I-AdverseReaction were/O the/O most/O frequent/O adverse/O reactions/O reported/O by/O patients/O participating/O in/O clinical/O trials/O and/O led/O to/O the/O discontinuation/O of/O Ferriprox/O therapy/O in/O 1.6/O %/O of/O patients/O ./O
Chromaturia/B-AdverseReaction (/O reddish/O brown/O discoloration/O of/O the/O urine/O )/O is/O a/O result/O of/O the/O excretion/O of/O the/O iron/O in/O the/O urine/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O additional/O adverse/O reactions/O have/O been/O reported/O in/O patients/O receiving/O Ferriprox/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O to/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Blood/O and/O lymphatic/O system/O disorders/O :/O thrombocytosis/B-AdverseReaction ,/O pancytopenia/B-AdverseReaction ./O
Cardiac/O disorders/O :/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction ./O
Congenital/O ,/O familial/O and/O genetic/O disorders/O :/O hypospadias/B-AdverseReaction ./O
Eye/O disorders/O :/O diplopia/B-AdverseReaction ,/O papilledema/B-AdverseReaction ,/O retinal/B-AdverseReaction toxicity/I-AdverseReaction ./O
Gastrointestinal/O disorders/O :/O enterocolitis/B-AdverseReaction ,/O rectal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O gastric/B-AdverseReaction ulcer/I-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O parotid/B-AdverseReaction gland/I-AdverseReaction enlargement/I-AdverseReaction ./O
General/O disorders/O and/O administration/O site/O conditions/O :/O chills/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O edema/B-AdverseReaction peripheral/I-AdverseReaction ,/O multi/B-AdverseReaction -/I-AdverseReaction organ/O failure/O ./O
Hepatobiliary/O disorders/O :/O jaundice/B-AdverseReaction ,/O hepatomegaly/B-AdverseReaction ./O
Immune/O system/O disorders/O :/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction ,/O hypersensitivity/B-AdverseReaction ./O
I/O nfections/O and/O infestations/O :/O cryptococcal/B-AdverseReaction cutaneous/I-AdverseReaction infection/I-AdverseReaction ,/O enteroviral/B-AdverseReaction encephalitis/I-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O furuncle/B-AdverseReaction ,/O infectious/B-AdverseReaction hepatitis/I-AdverseReaction ,/O rash/B-AdverseReaction pustular/I-AdverseReaction ,/O subcutaneous/B-AdverseReaction abscess/I-AdverseReaction ./O
Investigations/O :/O blood/B-AdverseReaction bilirubin/I-AdverseReaction increased/I-AdverseReaction ,/O blood/B-AdverseReaction creatinine/I-AdverseReaction phosphokinase/I-AdverseReaction increased/I-AdverseReaction ./O
Metabolism/O and/O nutrition/O disorders/O :/O metabolic/B-AdverseReaction acidosis/I-AdverseReaction ,/O dehydration/B-AdverseReaction ./O
Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O myositis/B-AdverseReaction ,/O chondropathy/B-AdverseReaction ,/O trismus/B-AdverseReaction ./O
Nervous/O system/O disorders/O :/O cerebellar/B-AdverseReaction syndrome/I-AdverseReaction ,/O cerebral/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O convulsion/B-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O intracranial/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction ,/O psychomotor/B-AdverseReaction skills/I-AdverseReaction impaired/I-AdverseReaction ,/O pyramidal/B-AdverseReaction tract/I-AdverseReaction syndrome/I-AdverseReaction ,/O somnolence/B-AdverseReaction ./O
Psychiatric/O disorders/O :/O bruxism/B-AdverseReaction ,/O depression/B-AdverseReaction ,/O obsessive/B-AdverseReaction -/I-AdverseReaction compulsive/O disorder/O ./O
Renal/O disorders/O :/O glycosuria/B-AdverseReaction ,/O hemoglobinuria/B-AdverseReaction ./O
Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction ,/O epistaxis/B-AdverseReaction ,/O hemoptysis/B-AdverseReaction ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction ./O
Skin/O ,/O subcutaneous/O tissue/O disorders/O :/O hyperhidrosis/B-AdverseReaction ,/O periorbital/B-AdverseReaction edema/I-AdverseReaction ,/O photosensitivity/B-AdverseReaction reaction/I-AdverseReaction ,/O pruritis/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O Henoch/B-AdverseReaction -/I-AdverseReaction Schonlein/O purpura/O ./O
Vascular/O disorders/O :/O hypotension/B-AdverseReaction ,/O hypertension/B-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O AGRANULOCYTOSIS/B-AdverseReaction NEUTROPENIA/B-AdverseReaction WARNING/O :/O AGRANULOCYTOSIS/B-AdverseReaction NEUTROPENIA/B-AdverseReaction Ferriprox/O can/B-Factor cause/O agranulocytosis/B-AdverseReaction that/O can/B-Factor lead/O to/O serious/B-Severity infections/B-AdverseReaction and/O death/B-AdverseReaction ./O
Neutropenia/B-AdverseReaction may/B-Factor precede/O the/O development/O of/O agranulocytosis/B-AdverseReaction ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Measure/O the/O absolute/O neutrophil/O count/O (/O ANC/O )/O before/O starting/O Ferriprox/O therapy/O and/O monitor/O the/O ANC/O weekly/O on/O therapy/O ./O
Interrupt/O Ferriprox/O therapy/O if/O neutropenia/O develops/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Interrupt/O Ferriprox/O if/O infection/O develops/O ,/O and/O monitor/O the/O ANC/O more/O frequently/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Advise/O patients/O taking/O Ferriprox/O to/O report/O immediately/O any/O symptoms/O indicative/O of/O infection/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O EXCERPT/O :/O WARNING/O :/O AGRANULOCYTOSIS/B-AdverseReaction /NEUTROPENIA/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Ferriprox/O can/B-Factor cause/O agranulocytosis/B-AdverseReaction that/O can/B-Factor lead/O to/O serious/B-Severity infections/B-AdverseReaction and/O death/B-AdverseReaction ./O
Neutropenia/B-AdverseReaction may/B-Factor precede/O the/O development/O of/O agranulocytosis/B-AdverseReaction ./O
(/O 5.1/O )/O Measure/O the/O absolute/O neutrophil/O count/O (/O ANC/O )/O before/O starting/O Ferriprox/O and/O monitor/O the/O ANC/O weekly/O on/O therapy/O ./O
(/O 5.1/O )/O Interrupt/O Ferriprox/O if/O infection/O develops/O and/O monitor/O the/O ANC/O more/O frequently/O ./O
(/O 5.1/O )/O Advise/O patients/O taking/O Ferriprox/O to/O report/O immediately/O any/O symptoms/O indicative/O of/O infection/O ./O
(/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O If/O infection/O occurs/O while/O on/O Ferriprox/O ,/O interrupt/O therapy/O and/O monitor/O the/O ANC/O more/O frequently/O ./O
(/O 5.1/O )/O Ferriprox/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Women/O should/O be/O advised/O of/O the/O potential/O hazard/O to/O the/O fetus/O and/O to/O avoid/O pregnancy/O while/O on/O this/O drug/O ./O
(/O 5.2/O )/O 5.1/O Agranulocytosis/O Neutropenia/O Fatal/B-AdverseReaction agranulocytosis/B-AdverseReaction can/B-Factor occur/O with/O Ferriprox/O use/O ./O
Ferriprox/O can/B-Factor also/O cause/O neutropenia/B-AdverseReaction ,/O which/O may/B-Factor foreshadow/O agranulocytosis/B-AdverseReaction ./O
Measure/O the/O absolute/O neutrophil/O count/O (/O ANC/O )/O before/O starting/O Ferriprox/O therapy/O and/O monitor/O the/O ANC/O weekly/O on/O therapy/O ./O
Interrupt/O Ferriprox/O therapy/O if/O neutropenia/O develops/O (/O ANC/O 1.5/O x/O 10/O 9/O /L/O )/O ./O
Interrupt/O Ferriprox/O if/O infection/O develops/O ,/O and/O monitor/O the/O ANC/O more/O frequently/O ./O
Advise/O patients/O taking/O Ferriprox/O to/O immediately/O interrupt/O therapy/O and/O report/O to/O their/O physician/O if/O they/O experience/O any/O symptoms/O indicative/O of/O infection/O ./O
In/O pooled/O clinical/O trials/O ,/O the/O incidence/O of/O agranulocytosis/B-AdverseReaction was/O 1.7/O %/O of/O patients/O ./O
The/O mechanism/O of/O Ferriprox/O -/O associated/O agranulocytosis/B-AdverseReaction is/O unknown/O ./O
Agranulocytosis/B-AdverseReaction and/O neutropenia/B-AdverseReaction usually/O resolve/O upon/O discontinuation/O of/O Ferriprox/O ,/O but/O there/O have/O been/O reports/O of/O agranulocytosis/B-AdverseReaction leading/O to/O death/B-AdverseReaction ./O
Implement/O a/O plan/O to/O monitor/O for/O and/O to/O manage/O agranulocytosis/O neutropenia/O prior/O to/O initiating/O Ferriprox/O treatment/O ./O
For/O neutropenia/O (/O ANC/O 1.5/O x/O 10/O 9/O /L/O and/O 0.5/O x/O 10/O 9/O /L/O )/O :/O Instruct/O the/O patient/O to/O immediately/O discontinue/O Ferriprox/O and/O all/O other/O medications/O with/O a/O potential/O to/O cause/O neutropenia/O ./O
Obtain/O a/O complete/O blood/O cell/O (/O CBC/O )/O count/O ,/O including/O a/O white/O blood/O cell/O (/O WBC/O )/O count/O corrected/O for/O the/O presence/O of/O nucleated/O red/O blood/O cells/O ,/O an/O absolute/O neutrophil/O count/O (/O ANC/O )/O ,/O and/O a/O platelet/O count/O daily/O until/O recovery/O (/O ANC/O 1.5/O x/O 10/O 9/O /L/O )/O ./O
For/O agranulocytosis/O (/O ANC/O 0.5/O x/O 10/O 9/O /L/O )/O :/O Consider/O hospitalization/O and/O other/O management/O as/O clinically/O appropriate/O ./O
Do/O not/O resume/O Ferriprox/O in/O patients/O who/O have/O developed/O agranulocytosis/O unless/O potential/O benefits/O outweigh/O potential/O risks/O ./O
Do/O not/O rechallenge/O patients/O who/O develop/O neutropenia/O with/O Ferriprox/O unless/O potential/O benefits/O outweigh/O potential/O risks/O ./O
5.2/O Embryofetal/O Toxicity/O Based/O on/O evidence/O of/O genotoxicity/B-AdverseReaction and/O developmental/O toxicity/O in/O animal/B-Animal studies/O ,/O Ferriprox/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
In/O animal/B-Animal studies/O ,/O administration/O of/O deferiprone/O during/O the/O period/O of/O organogenesis/O resulted/O in/O embryofetal/B-AdverseReaction death/I-AdverseReaction and/O malformations/O at/O doses/O lower/O than/O equivalent/O human/O clinical/O doses/O ./O
If/O Ferriprox/O is/O used/O during/O pregnancy/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O Ferriprox/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O ./O
Women/O of/O reproductive/O potential/O should/O be/O advised/O to/O avoid/O pregnancy/O when/O taking/O Ferriprox/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O and/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
5.3/O Laboratory/O Tests/O Serum/O Liver/O Enzyme/O Activities/O In/O clinical/O studies/O ,/O 7.5/O %/O of/O 642/O subjects/O treated/O with/O Ferriprox/O developed/O increased/B-AdverseReaction ALT/I-AdverseReaction values/I-AdverseReaction ./O
Four/O (/O 0.62/O %/O )/O Ferriprox/O -/O treated/O subjects/O discontinued/O the/O drug/O due/O to/O increased/B-AdverseReaction serum/I-AdverseReaction ALT/I-AdverseReaction levels/O and/O 1/O (/O 0.16/O %/O )/O due/O to/O an/O increase/O in/O both/O ALT/O and/O AST/O ./O
Monitor/O serum/O ALT/O values/O monthly/O during/O therapy/O with/O Ferriprox/O ,/O and/O consider/O interruption/O of/O therapy/O if/O there/O is/O a/O persistent/O increase/O in/O the/O serum/O transaminase/O levels/O ./O
Plasma/O Zinc/O Concentration/O Decreased/B-AdverseReaction plasma/I-AdverseReaction zinc/I-AdverseReaction concentrations/I-AdverseReaction have/O been/O observed/O on/O Ferriprox/O therapy/O ./O
Monitor/O plasma/O zinc/O ,/O and/O supplement/O in/O the/O event/O of/O a/O deficiency/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O commonly/O reported/O adverse/O reactions/O were/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction ,/O which/O occurred/O in/O almost/O all/O patients/O (/O 97/O %/O )/O in/O clinical/O trials/O ./O
Other/O common/O adverse/O reactions/O occurring/O in/O greater/O than/O 1/O %/O of/O patients/O included/O pyrexia/B-AdverseReaction ,/O transaminase/B-AdverseReaction increase/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O and/O rash/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Shire/O Human/O Genetic/O Therapies/O at/O the/O OnePath/O (/O r/O )/O phone/O #/O 1/O -/O 866/O -/O 888/O -/O 0660/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O The/O safety/O of/O icatibant/O was/O evaluated/O in/O three/O controlled/O trials/O that/O included/O 223/O patients/O who/O received/O FIRAZYR/O 30/O mg/O (/O n=113/O )/O ,/O placebo/O (/O n=75/O )/O ,/O or/O comparator/O (/O n=38/O )/O ./O
The/O mean/O age/O at/O study/O entry/O was/O 38/O years/O (/O range/O 18/O to/O 83/O years/O )/O ,/O 64/O %/O were/O female/O ,/O and/O 95/O %/O were/O white/O ./O
The/O data/O described/O below/O represent/O adverse/O reactions/O observed/O from/O the/O two/O placebo/O -/O controlled/O trials/O ,/O consisting/O of/O 77/O patients/O who/O received/O FIRAZYR/O at/O a/O dose/O of/O 30/O mg/O SC/O ,/O and/O 75/O who/O received/O placebo/O ./O
The/O most/O frequently/O reported/O adverse/O reactions/O (/O occurring/O in/O greater/O than/O 1/O %/O of/O patients/O and/O at/O a/O higher/O rate/O with/O FIRAZYR/O versus/O placebo/O )/O are/O shown/O in/O Table/O 1/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Table/O 1/O Adverse/O reactions/O observed/O in/O 1/O %/O of/O patients/O with/O acute/O attacks/O of/O HAE/O and/O at/O a/O higher/O rate/O with/O FIRAZYR/O versus/O placebo/O in/O the/O placebo/O -/O controlled/O trialsEvents/O occurring/O within/O 14/O days/O of/O study/O drug/O administration/O FIRAZYR(N/O 77/O )/O Placebo(N/O 75/O )/O System/O Organ/O ClassPreferred/O Term/O Subjects/O (/O %/O )/O Subjects/O (/O %/O )/O General/O disorders/O and/O administration/O site/O conditions/O Injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction 75/O (/O 97/O )/O 25/O (/O 33/O )/O Pyrexia/B-AdverseReaction 3/O (/O 4/O )/O 0/O Investigations/O Transaminase/B-AdverseReaction increased/I-AdverseReaction 3/O (/O 4/O )/O 0/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction 2/O (/O 3/O )/O 1/O (/O 1/O )/O The/O third/O trial/O was/O active/O -/O controlled/O and/O was/O comprised/O of/O 35/O patients/O who/O received/O FIRAZYR/O 30/O mg/O and/O 38/O patients/O who/O received/O the/O comparator/O ./O
Adverse/O reactions/O for/O FIRAZYR/O were/O similar/O in/O nature/O and/O frequency/O to/O those/O reported/O in/O Table/O 1/O ./O
In/O all/O three/O controlled/O trials/O ,/O patients/O were/O eligible/O for/O treatment/O of/O subsequent/O attacks/O in/O an/O open/O -/O label/O extension/O ./O
Patients/O were/O treated/O with/O FIRAZYR/O 30/O mg/O and/O could/O receive/O up/O to/O 3/O doses/O of/O FIRAZYR/O 30/O mg/O administered/O at/O least/O 6/O hours/O apart/O for/O each/O attack/O ./O
A/O total/O of/O 225/O patients/O were/O treated/O with/O 1,076/O doses/O of/O 30/O mg/O FIRAZYR/O for/O 987/O attacks/O of/O acute/O HAE/O ./O
Adverse/O reactions/O similar/O in/O nature/O and/O frequency/O were/O observed/O to/O those/O seen/O in/O the/O controlled/O phase/O of/O the/O trials/O ./O
Other/O adverse/O reactions/O reported/O included/O rash/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O headache/B-AdverseReaction in/O patients/O exposed/O to/O FIRAZYR/O ./O
The/O safety/O of/O self/O -/O administration/O was/O evaluated/O in/O a/O separate/O ,/O open/O -/O label/O trial/O in/O 56/O patients/O with/O HAE/O ./O
In/O this/O trial/O ,/O the/O safety/O profile/O of/O FIRAZYR/O in/O patients/O who/O self/O -/O administered/O FIRAZYR/O was/O similar/O in/O nature/O and/O frequency/O to/O that/O of/O patients/O whose/O therapy/O was/O administered/O by/O healthcare/O professionals/O ./O
6.2/O Immunogenicity/O Across/O repeated/O treatment/O in/O the/O controlled/O trials/O ,/O 4/O patients/O tested/O positive/O for/O anti/O -/O icatibant/O antibodies/O ./O
Three/O of/O these/O patients/O had/O subsequent/O tests/O which/O were/O negative/O ./O
No/B-Negation hypersensitivity/B-AdverseReaction or/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction were/O reported/O with/O FIRAZYR/O ./O
No/O association/O between/O anti/O -/O icatibant/O antibodies/O and/O efficacy/O was/O observed/O ./O
6.3/O Postmarketing/O Experience/O Similar/O adverse/O reactions/O have/O been/O observed/O in/O postmarketing/O use/O as/O compared/O to/O the/O clinical/O trials/O ./O
Because/O these/O events/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Laryngeal/O attacks/O :/O Following/O treatment/O of/O laryngeal/O attacks/O with/O FIRAZYR/O ,/O advise/O patients/O to/O seek/O immediate/O medical/O attention/O ./O
(/O 5.1/O )/O 5.1/O Laryngeal/O Attacks/O Given/O the/O potential/O for/O airway/O obstruction/O during/O acute/O laryngeal/O HAE/O attacks/O ,/O patients/O should/O be/O advised/O to/O seek/O medical/O attention/O in/O an/O appropriate/O healthcare/O facility/O immediately/O in/O addition/O to/O treatment/O with/O FIRAZYR/O ./O
6/O ADVERSE/O REACTIONS/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
A/O total/O of/O 696/O HIV/O -/O positive/O patients/O in/O three/O placebo/O -/O controlled/O trials/O received/O FULYZAQ/O for/O a/O mean/O duration/O of/O 78/O days/O ./O
Of/O the/O total/O population/O across/O the/O three/O trials/O ,/O 229/O patients/O received/O a/O dose/O of/O 125/O mg/O twice/O a/O day/O for/O a/O mean/O duration/O of/O 141/O days/O ,/O 69/O patients/O received/O a/O dose/O of/O 250/O mg/O twice/O a/O day/O for/O a/O mean/O duration/O of/O 139/O days/O ,/O 102/O patients/O received/O a/O dose/O of/O 250/O mg/O four/O times/O a/O day/O for/O a/O mean/O duration/O of/O 14/O days/O ,/O 54/O patients/O received/O a/O dose/O of/O 500/O mg/O twice/O a/O day/O for/O a/O mean/O duration/O of/O 146/O days/O ,/O and/O 242/O patients/O received/O a/O dose/O of/O 500/O mg/O four/O times/O a/O day/O for/O a/O mean/O duration/O of/O 14/O days/O ./O
Adverse/O reactions/O for/O FULYZAQ/O that/O occurred/O in/O at/O least/O 2/O %/O of/O patients/O and/O at/O a/O higher/O incidence/O than/O placebo/O are/O provided/O in/O Table/O 1/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Occurring/O in/O at/O Least/O 2/O %/O of/O Patients/O in/O the/O 125/O mg/O Twice/O Daily/O Group/O Adverse/O Reaction/O Crofelemer/O 125/O mg/O BID*N/O 229n/O (/O %/O )/O PlaceboN/O 274n/O (/O %/O )/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 13/O (/O 5.7/O )/O 4/O (/O 1.5/O )/O Bronchitis/B-AdverseReaction 9/O (/O 3.9/O )/O 0/O Cough/B-AdverseReaction 8/O (/O 3.5/O )/O 3/O (/O 1.1/O )/O Flatulence/B-AdverseReaction 7/O (/O 3.1/O )/O 3/O (/O 1.1/O )/O Increased/B-AdverseReaction bilirubin/I-AdverseReaction 7/O (/O 3.1/O )/O 3/O (/O 1.1/O )/O Nausea/B-AdverseReaction 6/O (/O 2.6/O )/O 4/O (/O 1.5/O )/O Back/B-AdverseReaction pain/I-AdverseReaction 6/O (/O 2.6/O )/O 4/O (/O 1.5/O )/O Arthralgia/B-AdverseReaction 6/O (/O 2.6/O )/O 0/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 5/O (/O 2.2/O )/O 2/O (/O 0.7/O )/O Nasopharyngitis/B-AdverseReaction 5/O (/O 2.2/O )/O 2/O (/O 0.7/O )/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 5/O (/O 2.2/O )/O 1/O (/O 0.4/O )/O Hemorrhoids/B-AdverseReaction 5/O (/O 2.2/O )/O 0/O Giardiasis/B-AdverseReaction 5/O (/O 2.2/O )/O 0/O Anxiety/B-AdverseReaction 5/O (/O 2.2/O )/O 1/O (/O 0.4/O )/O Increased/B-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction 5/O (/O 2.2/O )/O 3/O (/O 1.1/O )/O Abdominal/B-AdverseReaction distension/I-AdverseReaction 5/O (/O 2.2/O )/O 1/O (/O 0.4/O )/O Twice/O daily/O Adverse/O reactions/O that/O occurred/O in/O between/O 1/O %/O and/O 2/O %/O of/O patients/O taking/O a/O 250/O mg/O daily/O dose/O of/O FULYZAQ/O were/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O acne/B-AdverseReaction ,/O increased/B-AdverseReaction aspartate/I-AdverseReaction aminotransferase/I-AdverseReaction ,/O increased/B-AdverseReaction conjugated/I-AdverseReaction bilirubin/I-AdverseReaction ,/O increased/B-AdverseReaction unconjugated/I-AdverseReaction blood/I-AdverseReaction bilirubin/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O depression/B-AdverseReaction ,/O dermatitis/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O gastroenteritis/B-AdverseReaction ,/O herpes/B-AdverseReaction zoster/I-AdverseReaction ,/O nephrolithiasis/B-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ,/O pollakiuria/B-AdverseReaction ,/O procedural/B-AdverseReaction pain/I-AdverseReaction ,/O seasonal/B-AdverseReaction allergy/I-AdverseReaction ,/O sinusitis/B-AdverseReaction and/O decreased/B-AdverseReaction white/I-AdverseReaction blood/I-AdverseReaction cell/I-AdverseReaction count/I-AdverseReaction ./O
Adverse/O reactions/O were/O similar/O in/O patients/O who/O received/O doses/O greater/O than/O 250/O mg/O daily/O ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 3/O %/O )/O are/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O flatulence/B-AdverseReaction and/O increased/B-AdverseReaction bilirubin/I-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Salix/O Pharmaceuticals/O at/O 1/O -/O 800/O -/O 508/O -/O 0024/O or/O www.Salix.com/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 5/O WARNINGS/O AND/O PRECAUTIONS/O 5/O ./O
1/O Risks/O of/O Treatment/O in/O Patients/O with/O Infectious/O Diarrhea/O If/O infectious/O etiologies/O are/O not/O considered/O ,/O and/O FULYZAQ/O is/O initiated/O based/O on/O a/O presumptive/O diagnosis/O of/O non/O -/O infectious/O diarrhea/O ,/O then/O there/O is/O a/O risk/O that/O patients/O with/O infectious/O etiologies/O will/O not/O receive/O the/O appropriate/O treatments/O ,/O and/O their/O disease/O may/O worsen/O ./O
Before/O starting/O FULYZAQ/O ,/O rule/O out/O infectious/O etiologies/O of/O diarrhea/O ./O
FULYZAQ/O is/O not/O indicated/O for/O the/O treatment/O of/O infectious/O diarrhea/O ./O
EXCERPT/O :/O Rule/O out/O infectious/O etiologies/O of/O diarrhea/O before/O starting/O crofelemer/O ./O
If/O infectious/O etiologies/O are/O not/O considered/O ,/O there/O is/O a/O risk/O that/O patients/O with/O infectious/O etiologies/O will/O not/O receive/O the/O appropriate/O therapy/O and/O their/O disease/O may/O worsen/O ./O
(/O 5.1/O )/O 6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O described/O elsewhere/O in/O labeling/O :/O Bradyarrhythmia/B-AdverseReaction and/O Atrioventricular/B-AdverseReaction Blocks/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Macular/B-AdverseReaction Edema/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Posterior/B-AdverseReaction Reversible/I-AdverseReaction Encephalopathy/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Respiratory/B-AdverseReaction Effects/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Liver/B-AdverseReaction Injury/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 10/O %/O and/O placebo/O )/O :/O Headache/B-AdverseReaction ,/O liver/B-AdverseReaction transaminase/I-AdverseReaction elevation/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Novartis/O Pharmaceuticals/O Corporation/O at/O 1/O -/O 888/O -/O 669/O -/O 6682/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
In/O clinical/O trials/O (/O Studies/O 1/O ,/O 2/O ,/O and/O 3/O )/O ,/O a/O total/O of/O 1212/O patients/O with/O relapsing/O forms/O of/O multiple/O sclerosis/O received/O GILENYA/O 0.5/O mg/O ./O
This/O included/O 783/O patients/O who/O received/O GILENYA/O 0.5/O mg/O in/O the/O 2-year/O placebo/O -/O controlled/O trials/O (/O Studies/O 1/O and/O 3/O )/O and/O 429/O patients/O who/O received/O GILENYA/O 0.5/O mg/O in/O the/O 1/O year/O active/O -/O controlled/O trial/O (/O Study/O 2/O )/O ./O
The/O overall/O exposure/O in/O the/O controlled/O trials/O was/O equivalent/O to/O 1716/O person/O -/O years/O ./O
Approximately/O 1000/O patients/O received/O at/O least/O 2/O years/O of/O treatment/O with/O GILENYA/O 0.5/O mg/O ./O
In/O all/O clinical/O studies/O ,/O including/O uncontrolled/O extension/O studies/O ,/O the/O exposure/O to/O GILENYA/O 0.5/O mg/O was/O approximately/O 4119/O person/O -/O years/O ./O
In/O placebo/O -/O controlled/O trials/O ,/O the/O most/O frequent/O adverse/O reactions/O (/O incidence/O 10/O %/O and/O placebo/O )/O for/O GILENYA/O 0.5/O mg/O were/O headache/B-AdverseReaction ,/O liver/B-AdverseReaction transaminase/I-AdverseReaction elevation/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ./O
Adverse/O events/O that/O led/O to/O treatment/O discontinuation/O and/O occurred/O in/O more/O than/O 1/O %/O of/O patients/O taking/O GILENYA/O 0.5/O mg/O were/O serum/B-AdverseReaction transaminase/I-AdverseReaction elevations/I-AdverseReaction (/O 4.7/O %/O compared/O to/O 1/O %/O on/O placebo/O )/O and/O basal/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction (/O 1/O %/O compared/O to/O 0.5/O %/O on/O placebo/O )/O ./O
Table/O 1/O lists/O adverse/O reactions/O that/O occurred/O in/O 1/O %/O of/O GILENYA/O -/O treated/O patients/O and/O 1/O %/O higher/O rate/O than/O for/O placebo/O ./O
Table/O 1/O Adverse/O Reactions/O Reported/O in/O Studies/O 1/O and/O 3/O (/O Occurring/O in/O 1/O %/O of/O Patients/O and/O Reported/O for/O GILENYA/O 0.5/O mg/O at/O 1/O %/O Higher/O Rate/O than/O for/O Placebo/O )/O Primary/O System/O Organ/O Class/O Preferred/O Term/O GILENYA/O 0.5/O mg/O N=783/O %/O Placebo/O N=773/O %/O Infections/O Influenza/B-AdverseReaction 11/O 8/O Sinusitis/B-AdverseReaction 11/O 8/O Bronchitis/B-AdverseReaction 8/O 5/O Herpes/B-AdverseReaction zoster/I-AdverseReaction 2/O 1/O Tinea/B-AdverseReaction versicolor/I-AdverseReaction 2/O 1/O Cardiac/O Disorders/O Bradycardia/B-AdverseReaction 3/O 1/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 25/O 24/O Migraine/B-AdverseReaction 6/O 4/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 13/O 12/O Diarrhea/B-AdverseReaction 13/O 10/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 11/O 10/O General/O disorders/O and/O administration/O site/O conditions/O Asthenia/B-AdverseReaction 2/O 1/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Back/B-AdverseReaction pain/I-AdverseReaction 10/O 9/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 10/O 7/O Skin/O and/O subcutaneous/O tissue/O disorders/O Alopecia/B-AdverseReaction 3/O 2/O Actinic/B-AdverseReaction keratosis/I-AdverseReaction 2/O 1/O Investigations/O Liver/B-AdverseReaction transaminase/I-AdverseReaction elevations/I-AdverseReaction (/O ALT/O GGT/O AST/O )/O 15/O 4/O Blood/B-AdverseReaction triglycerides/I-AdverseReaction increased/I-AdverseReaction 3/O 1/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 12/O 11/O Dyspnea/B-AdverseReaction 9/O 7/O Eye/O disorders/O Vision/B-AdverseReaction blurred/I-AdverseReaction 4/O 2/O Vascular/O disorders/O Hypertension/B-AdverseReaction 8/O 4/O Blood/O and/O lymphatic/O system/O disorders/O Lymphopenia/B-AdverseReaction 7/O 1/O Leukopenia/B-AdverseReaction 2/O 1/O Neoplasms/O benign/O ,/O malignant/O and/O unspecified(including/O cysts/O and/O polyps/O )/O Skin/B-AdverseReaction papilloma/I-AdverseReaction 3/O 2/O Basal/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction 2/O 1/O Adverse/O reactions/O of/O dizziness/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O eczema/B-AdverseReaction and/O pruritus/B-AdverseReaction were/O also/O reported/O in/O Studies/O 1/O and/O 3/O but/O did/O not/O meet/O the/O reporting/O rate/O criteria/O for/O inclusion/O in/O Table/O 1/O (/O difference/O was/O less/O than/O 1/O %/O )/O ./O
Adverse/O reactions/O with/O GILENYA/O 0.5/O mg/O in/O Study/O 2/O ,/O the/O 1-year/O active/O -/O controlled/O (/O versus/O interferon/O beta-1a/O )/O study/O were/O generally/O similar/O to/O those/O in/O Studies/O 1/O and/O 3/O ./O
Vascular/O Events/O Vascular/B-AdverseReaction events/I-AdverseReaction ,/O including/O ischemic/O and/O hemorrhagic/B-AdverseReaction strokes/I-AdverseReaction ,/O and/O peripheral/B-AdverseReaction arterial/I-AdverseReaction occlusive/I-AdverseReaction disease/I-AdverseReaction were/O reported/O in/O premarketing/O clinical/O trials/O in/O patients/O who/O received/O GILENYA/O doses/O (/O 1.25/O -/O 5/O mg/O )/O higher/O than/O recommended/O for/O use/O in/O MS/O ./O
Similar/O events/O have/O been/O reported/O with/O GILENYA/O 0.5/O mg/O in/O the/O postmarketing/O setting/O although/O a/O causal/O relationship/O has/O not/O been/O established/O ./O
Lymphomas/O Cases/O of/O lymphoma/B-AdverseReaction have/O occurred/O in/O premarketing/O clinical/O trials/O and/O in/O the/O postmarketing/O setting/O ./O
The/O relationship/O to/O GILENYA/O remains/O uncertain/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Bradycardia/B-AdverseReaction and/or/O atrioventricular/B-AdverseReaction conduction/I-AdverseReaction after/O first/O dose/O :/O Monitor/O patients/O ./O
(/O 2/O ,/O 5.1/O )/O Infections/B-AdverseReaction :/O GILENYA/O may/O increase/O the/O risk/B-Factor of/O infections/B-AdverseReaction ./O
A/O recent/O CBC/O should/O be/O available/O before/O initiating/O treatment/O ./O
Monitor/O for/O infection/O during/O treatment/O and/O for/O 2/O months/O after/O discontinuation/O ./O
Do/O not/O start/O in/O patients/O with/O active/O infections/O ./O
(/O 5.2/O )/O Progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O ;/O Withhold/O GILENYA/O at/O the/O first/O sign/O or/O symptom/O suggestive/O of/O PML/O ./O
(/O 5.3/O )/O Macular/B-AdverseReaction edema/I-AdverseReaction :/O Perform/O an/O examination/O of/O the/O fundus/O including/O the/O macula/O before/O and/O 3/O -/O 4/O months/O after/O treatment/O initiation/O ./O
Patients/O with/O diabetes/O mellitus/O or/O a/O history/O of/O uveitis/O are/O at/O increased/O risk/O ./O
(/O 5.4/O )/O Posterior/B-AdverseReaction reversible/I-AdverseReaction encephalopathy/I-AdverseReaction syndrome/I-AdverseReaction (/O PRES/B-AdverseReaction )/O :/O If/O suspected/O ,/O discontinue/O GILENYA/O ./O
(/O 5.5/O )/O Decrease/B-AdverseReaction in/I-AdverseReaction pulmonary/I-AdverseReaction function/I-AdverseReaction tests/I-AdverseReaction (/O PFT/O )/O :/O Obtain/O PFT/O when/O clinically/O indicated/O ./O
(/O 5.6/O )/O Liver/B-AdverseReaction injury/I-AdverseReaction :/O liver/O enzyme/O results/O should/O be/O available/O before/O initiation/O ./O
Discontinue/O if/O significant/O liver/O injury/O occurs/O ./O
(/O 5.7/O )/O Women/O of/O childbearing/O potential/O should/O use/O effective/O contraception/O during/O and/O for/O 2/O months/O after/O stopping/O GILENYA/O ./O
(/O 5.8/O )/O Blood/O pressure/O (/O BP/O )/O :/O Monitor/O BP/O during/O treatment/O ./O
(/O 5.9/O )/O 5.1/O Bradyarrhythmia/O and/O Atrioventricular/O Blocks/O Because/O of/O a/O risk/O for/O bradyarrhythmia/O and/O atrioventricular/O (/O AV/O )/O blocks/O ,/O patients/O should/O be/O monitored/O during/O GILENYA/O treatment/O initiation/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
Reduction/O in/O Heart/O Rate/O After/O the/O first/O dose/O of/O GILENYA/O ,/O the/O heart/B-AdverseReaction rate/I-AdverseReaction decrease/I-AdverseReaction starts/O within/O an/O hour/O ./O
On/O Day/O 1/O ,/O the/O maximum/O decline/B-AdverseReaction in/I-AdverseReaction heart/I-AdverseReaction rate/I-AdverseReaction generally/O occurs/O within/O 6/O hours/O and/O recovers/O ,/O although/O not/O to/O baseline/O levels/O ,/O by/O 8/O to/O 10/O hours/O postdose/O ./O
Because/O of/O physiological/O diurnal/O variation/O ,/O there/O is/O a/O second/O period/O of/O heart/B-AdverseReaction rate/I-AdverseReaction decrease/I-AdverseReaction within/O 24/O hours/O after/O the/O first/O dose/O ./O
In/O some/O patients/O ,/O heart/B-AdverseReaction rate/I-AdverseReaction decrease/I-AdverseReaction during/O the/O second/O period/O is/O more/O pronounced/O than/O the/O decrease/O observed/O in/O the/O first/O 6/O hours/O ./O
Heart/B-AdverseReaction rates/I-AdverseReaction below/I-AdverseReaction 40/I-AdverseReaction beats/I-AdverseReaction per/I-AdverseReaction minute/I-AdverseReaction were/O rarely/O observed/O ./O
In/O controlled/O clinical/O trials/O ,/O adverse/O reactions/O of/O symptomatic/B-AdverseReaction bradycardia/I-AdverseReaction following/O the/O first/O dose/O were/O reported/O in/O 0.6/O %/O of/O patients/O receiving/O GILENYA/O 0.5/O mg/O and/O in/O 0.1/O %/O of/O patients/O on/O placebo/O ./O
Patients/O who/O experienced/O bradycardia/B-AdverseReaction were/O generally/O asymptomatic/O ,/O but/O some/O patients/O experienced/O hypotension/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O palpitations/B-AdverseReaction ,/O and/or/O chest/B-AdverseReaction pain/I-AdverseReaction that/O usually/O resolved/O within/O the/O first/O 24/O hours/O on/O treatment/O ./O
Following/O the/O second/O dose/O ,/O a/O further/O decrease/B-AdverseReaction in/I-AdverseReaction heart/I-AdverseReaction rate/I-AdverseReaction may/O occur/O when/O compared/O to/O the/O heart/O rate/O prior/O to/O the/O second/O dose/O ,/O but/O this/O change/O is/O of/O a/O smaller/O magnitude/O than/O that/O observed/O following/O the/O first/O dose/O ./O
With/O continued/O dosing/O ,/O the/O heart/O rate/O returns/O to/O baseline/O within/O 1/O month/O of/O chronic/O treatment/O ./O
Atrioventricular/O Blocks/O Initiation/O of/O GILENYA/O treatment/O has/O resulted/O in/O transient/B-Severity AV/B-AdverseReaction conduction/I-AdverseReaction delays/I-AdverseReaction ./O
In/O controlled/O clinical/O trials/O ,/O first/B-AdverseReaction -/I-AdverseReaction degree/I-AdverseReaction AV/O block/O after/O the/O first/O dose/O occurred/O in/O 4.7/O %/O of/O patients/O receiving/O GILENYA/O and/O 1.6/O %/O of/O patients/O on/O placebo/O ./O
In/O a/O study/O of/O 697/O patients/O with/O available/O 24-hour/O Holter/O monitoring/O data/O after/O their/O first/O dose/O (/O N=351/O receiving/O GILENYA/O and/O N=346/O on/O placebo/O )/O ,/O second/B-AdverseReaction -/I-AdverseReaction degree/I-AdverseReaction AV/O blocks/O (/O Mobitz/O Types/O I/O [/O Wenckebach/O ]/O or/O 2:1/B-AdverseReaction AV/I-AdverseReaction blocks/I-AdverseReaction )/O occurred/O in/O 4/O %/O (/O N=14/O )/O of/O patients/O receiving/O GILENYA/O and/O 2/O %/O (/O N=7/O )/O of/O patients/O on/O placebo/O ./O
Of/O the/O 14/O patients/O receiving/O GILENYA/O ,/O 7/O patients/O had/O 2:1/B-AdverseReaction AV/I-AdverseReaction block/I-AdverseReaction (/O 5/O patients/O within/O the/O first/O 6/O hours/O postdose/O and/O 2/O patients/O after/O 6/O hours/O postdose/O )/O ./O
All/O second/O degree/O AV/O blocks/O on/O placebo/B-Factor were/O Mobitz/O Type/O I/O and/O occurred/O after/O the/O first/O 12/O hours/O postdose/O ./O
The/O conduction/B-AdverseReaction abnormalities/I-AdverseReaction were/O usually/O transient/B-Severity and/O asymptomatic/O ,/O and/O resolved/O within/O the/O first/O 24/O hours/O on/O treatment/O ,/O but/O they/O occasionally/O required/O treatment/O with/O atropine/O or/O isoproterenol/O ./O
Postmarketing/O Experience/O In/O the/O postmarketing/O setting/O ,/O third/B-AdverseReaction -/I-AdverseReaction degree/I-AdverseReaction AV/O block/O and/O AV/B-AdverseReaction block/I-AdverseReaction with/O junctional/B-AdverseReaction escape/I-AdverseReaction have/O been/O observed/O during/O the/O first/O -/O dose/O 6-hour/O observation/O period/O with/O GILENYA/O ./O
Isolated/O delayed/O onset/O events/O ,/O including/O transient/B-Severity asystole/B-AdverseReaction and/O unexplained/O death/B-AdverseReaction ,/O have/O occurred/O within/O 24/O hours/O of/O the/O first/O dose/O ./O
These/O events/O were/O confounded/O by/O concomitant/O medications/O and/or/O preexisting/O disease/O ,/O and/O the/O relationship/O to/O GILENYA/O is/O uncertain/O ./O
Cases/O of/O syncope/B-AdverseReaction were/O also/O reported/O after/O the/O first/O dose/O of/O GILENYA/O ./O
5.2/O Infections/O Risk/O of/O Infections/O GILENYA/O causes/O a/O dose/O -/O dependent/O reduction/B-AdverseReaction in/I-AdverseReaction peripheral/I-AdverseReaction lymphocyte/I-AdverseReaction count/I-AdverseReaction to/O 20%-30/B-Severity %/I-Severity of/I-Severity baseline/O values/O because/O of/O reversible/B-Severity sequestration/B-AdverseReaction of/I-AdverseReaction lymphocytes/I-AdverseReaction in/I-AdverseReaction lymphoid/I-AdverseReaction tissues/I-AdverseReaction ./O
GILENYA/O may/O therefore/O increase/O the/O risk/B-Factor of/O infections/B-AdverseReaction ,/O some/O serious/B-Severity in/O nature/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
Before/O initiating/O treatment/O with/O GILENYA/O ,/O a/O recent/O CBC/O (/O i.e./O ,/O within/O 6/O months/O or/O after/O discontinuation/O of/O prior/O therapy/O )/O should/O be/O available/O ./O
Consider/O suspending/O treatment/O with/O GILENYA/O if/O a/O patient/O develops/O a/O serious/O infection/O ,/O and/O reassess/O the/O benefits/O and/O risks/O prior/O to/O reinitiation/O of/O therapy/O ./O
Because/O the/O elimination/O of/O fingolimod/O after/O discontinuation/O may/O take/O up/O to/O 2/O months/O ,/O continue/O monitoring/O for/O infections/O throughout/O this/O period/O ./O
Instruct/O patients/O receiving/O GILENYA/O to/O report/O symptoms/O of/O infections/O to/O a/O physician/O ./O
Patients/O with/O active/O acute/O or/O chronic/O infections/O should/O not/O start/O treatment/O until/O the/O infection(s/O )/O is/O resolved/O ./O
In/O MS/O placebo/O -/O controlled/O trials/O ,/O the/O overall/O rate/O of/O infections/B-AdverseReaction (/O 72/O %/O )/O with/O GILENYA/O was/O similar/O to/O placebo/O ./O
However/O ,/O bronchitis/B-AdverseReaction ,/O herpes/B-AdverseReaction zoster/I-AdverseReaction ,/O influenza/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O and/O pneumonia/B-AdverseReaction were/O more/O common/O in/O GILENYA/O -/O treated/O patients/O ./O
Serious/B-Severity infections/B-AdverseReaction occurred/O at/O a/O rate/O of/O 2.3/O %/O in/O the/O GILENYA/O group/O versus/O 1.6/O %/O in/O the/O placebo/O group/O ./O
Herpes/O Viral/O Infections/O In/O placebo/O -/O controlled/O trials/O ,/O the/O rate/O of/O herpetic/B-AdverseReaction infections/I-AdverseReaction was/O 9/O %/O in/O patients/O receiving/O GILENYA/O 0.5/O mg/O and/O 7/O %/O on/O placebo/O ./O
Two/O patients/O died/B-AdverseReaction of/O herpetic/B-AdverseReaction infections/I-AdverseReaction during/O controlled/O trials/O ./O
One/O death/B-AdverseReaction was/O due/O to/O disseminated/B-AdverseReaction primary/I-AdverseReaction herpes/I-AdverseReaction zoster/I-AdverseReaction and/O the/O other/O to/O herpes/B-AdverseReaction simplex/I-AdverseReaction encephalitis/I-AdverseReaction ./O
In/O both/O cases/O ,/O the/O patients/O were/O taking/O a/O 1.25/O mg/O dose/O of/O fingolimod/O (/O higher/O than/O the/O recommended/O 0.5/O mg/O dose/O )/O and/O had/O received/O high/O -/O dose/O corticosteroid/O therapy/O to/O treat/O suspected/O MS/O relapses/O ./O
Serious/B-Severity ,/O life/B-Severity -/O threatening/O events/O of/O disseminated/O varicella/O zoster/O and/O herpes/B-AdverseReaction simplex/I-AdverseReaction infections/I-AdverseReaction ,/O including/O cases/O of/O encephalitis/B-AdverseReaction and/O multiorgan/B-AdverseReaction failure/I-AdverseReaction ,/O have/O occurred/O with/O GILENYA/O 0.5/O mg/O in/O the/O postmarketing/O setting/O ./O
One/O of/O these/O events/O was/O fatal/B-AdverseReaction ./O
Include/O disseminated/O herpetic/O infections/O in/O the/O differential/O diagnosis/O of/O patients/O who/O are/O receiving/O GILENYA/O and/O present/O with/O an/O atypical/O MS/O relapse/O or/O multiorgan/O failure/O ./O
Cryptococcal/O infections/O Cryptococcal/B-AdverseReaction infections/I-AdverseReaction ,/O including/O cases/O of/O cryptococcal/B-AdverseReaction meningitis/I-AdverseReaction ,/O have/O been/O reported/O with/O GILENYA/O in/O the/O postmarketing/O setting/O ./O
Patients/O with/O symptoms/O and/O signs/O consistent/O with/O cryptococcal/O meningitis/O should/O undergo/O prompt/O diagnostic/O evaluation/O and/O treatment/O ./O
Prior/O and/O Concomitant/O Treatment/O with/O Antineoplastic/O ,/O Immunosuppressive/O ,/O or/O Immune/O -/O Modulating/O Therapies/O In/O clinical/O studies/O ,/O patients/O who/O received/O GILENYA/O did/O not/O receive/O concomitant/O treatment/O with/O antineoplastic/O ,/O non/O -/O corticosteroid/O immunosuppressive/O ,/O or/O immune/O -/O modulating/O therapies/O used/O for/O treatment/O of/O MS/O ./O
Concomitant/O use/O of/O GILENYA/O with/O any/O of/O these/O therapies/O ,/O and/O also/O with/O corticosteroids/O ,/O would/O be/O expected/O to/O increase/O the/O risk/B-Factor of/O immunosuppression/B-AdverseReaction [/O see/O Drug/O Interactions/O (/O 7/O )/O ]/O ./O
When/O switching/O to/O GILENYA/O from/O immune/O -/O modulating/O or/O immunosuppressive/O medications/O ,/O consider/O the/O duration/O of/O their/O effects/O and/O their/O mode/O of/O action/O to/O avoid/O unintended/O additive/O immunosuppressive/O effects/O ./O
Varicella/O Zoster/O Virus/O Antibody/O Testing/O Vaccination/O Patients/O without/O a/O healthcare/O professional/O confirmed/O history/O of/O chickenpox/O or/O without/O documentation/O of/O a/O full/O course/O of/O vaccination/O against/O varicella/O zoster/O virus/O (/O VZV/O )/O should/O be/O tested/O for/O antibodies/O to/O VZV/O before/O initiating/O GILENYA/O ./O
VZV/O vaccination/O of/O antibody/O -/O negative/O patients/O is/O recommended/O prior/O to/O commencing/O treatment/O with/O GILENYA/O ,/O following/O which/O initiation/O of/O treatment/O with/O GILENYA/O should/O be/O postponed/O for/O 1/O month/O to/O allow/O the/O full/O effect/O of/O vaccination/O to/O occur/O ./O
5.3/O Progressive/O Multifocal/O Leukoencephalopathy/O A/O case/O of/O progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O and/O a/O case/O of/O probable/B-Factor PML/B-AdverseReaction occurred/O in/O patients/O with/O MS/O who/O received/O GILENYA/O in/O the/O post/O marketing/O setting/O ./O
PML/B-AdverseReaction is/O an/O opportunistic/B-AdverseReaction viral/I-AdverseReaction infection/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction brain/I-AdverseReaction caused/O by/O the/O JC/B-AdverseReaction virus/I-AdverseReaction (/O JCV/B-AdverseReaction )/O that/O typically/B-Factor only/O occurs/O in/O patients/O who/O are/O immunocompromised/O ,/O and/O that/O usually/B-Factor leads/O to/O death/B-AdverseReaction or/O severe/B-Severity disability/B-AdverseReaction ./O
One/O patient/O developed/O PML/B-AdverseReaction after/O taking/O GILENYA/O for/O approximately/O 2.5/O years/O ./O
The/O other/O patient/O developed/O probable/B-Factor PML/B-AdverseReaction after/O taking/O GILENYA/O for/O approximately/O 4/O years/O ./O
The/O diagnosis/O of/O probable/B-Factor PML/B-AdverseReaction was/O based/O on/O MRI/O findings/O and/O the/O detection/O of/O JCV/O DNA/O in/O the/O CSF/O in/O the/O absence/B-Negation of/O clinical/O signs/O or/O symptoms/O specific/O to/O PML/B-AdverseReaction ./O
The/O patients/O had/O no/O other/O identified/O systemic/O medical/O conditions/O resulting/O in/O compromised/B-AdverseReaction immune/I-AdverseReaction system/I-AdverseReaction function/O and/O had/O not/O previously/O been/O treated/O with/O natalizumab/B-Negation ,/O which/O has/O a/O known/O association/O with/O PML/B-AdverseReaction ./O
The/O patients/O were/O also/O not/O taking/O any/O immunosuppressive/O or/O immunomodulatory/O medications/O concomitantly/O ./O
At/O the/O first/O sign/O or/O symptom/O suggestive/O of/O PML/O ,/O withhold/O GILENYA/O and/O perform/O an/O appropriate/O diagnostic/O evaluation/O ./O
MRI/O signs/O may/O be/O apparent/O before/O clinical/O symptoms/O ./O
Typical/B-Factor symptoms/O associated/O with/O PML/B-AdverseReaction are/O diverse/O ,/O progress/O over/O days/O to/O weeks/O ,/O and/O include/O progressive/B-AdverseReaction weakness/I-AdverseReaction on/I-AdverseReaction one/I-AdverseReaction side/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction body/I-AdverseReaction or/O clumsiness/B-AdverseReaction of/I-AdverseReaction limbs/I-AdverseReaction ,/O disturbance/B-AdverseReaction of/I-AdverseReaction vision/I-AdverseReaction ,/O and/O changes/B-AdverseReaction in/I-AdverseReaction thinking/I-AdverseReaction ,/O memory/O ,/O and/O orientation/O leading/O to/O confusion/B-AdverseReaction and/O personality/B-AdverseReaction changes/I-AdverseReaction ./O
5.4/O Macular/O Edema/O Fingolimod/O increases/O the/O risk/B-Factor of/O macular/B-AdverseReaction edema/I-AdverseReaction ./O
Perform/O an/O examination/O of/O the/O fundus/O including/O the/O macula/O in/O all/O patients/O before/O starting/O treatment/O ,/O again/O 3/O -/O 4/O months/O after/O starting/O treatment/O ,/O and/O again/O at/O any/O time/O after/O a/O patient/O reports/O visual/O disturbances/O while/O on/O GILENYA/O therapy/O ./O
A/O dose/O -/O dependent/O increase/O in/O the/O risk/B-Factor of/O macular/B-AdverseReaction edema/I-AdverseReaction occurred/O in/O the/O GILENYA/O clinical/O development/O program/O ./O
In/O 2-year/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O studies/O in/O patients/O with/O multiple/O sclerosis/O ,/O macular/B-AdverseReaction edema/I-AdverseReaction with/O or/O without/O visual/B-AdverseReaction symptoms/I-AdverseReaction occurred/O in/O 1.5/O %/O of/O patients/O (/O 11/799/O )/O treated/O with/O fingolimod/O 1.25/O mg/O ,/O 0.5/O %/O of/O patients/O (/O 4/783/O )/O treated/O with/O GILENYA/O 0.5/O mg/O and/O 0.4/O %/O of/O patients/O (/O 3/773/O )/O treated/O with/O placebo/O ./O
Macular/B-AdverseReaction edema/I-AdverseReaction occurred/O predominantly/O during/O the/O first/O 3/O to/O 4/O months/O of/O therapy/O ./O
These/O clinical/O trials/O excluded/O patients/O with/O diabetes/O mellitus/O ,/O a/O known/O risk/O factor/O for/O macular/O edema/O (/O see/O below/O Macular/O Edema/O in/O Patients/O with/O History/O of/O Uveitis/O or/O Diabetes/O Mellitus/O )/O ./O
Symptoms/O of/O macular/B-AdverseReaction edema/I-AdverseReaction included/O blurred/B-AdverseReaction vision/I-AdverseReaction and/O decreased/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction ./O
Routine/O ophthalmological/O examination/O detected/O macular/B-AdverseReaction edema/I-AdverseReaction in/O some/O patients/O with/O no/B-Negation visual/B-AdverseReaction symptoms/I-AdverseReaction ./O
Macular/B-AdverseReaction edema/I-AdverseReaction generally/O partially/O or/O completely/O resolved/O with/O or/O without/O treatment/O after/O drug/O discontinuation/O ./O
Some/O patients/O had/O residual/O visual/B-AdverseReaction acuity/I-AdverseReaction loss/I-AdverseReaction even/O after/O resolution/O of/O macular/B-AdverseReaction edema/I-AdverseReaction ./O
Macular/B-AdverseReaction edema/I-AdverseReaction has/O also/O been/O reported/O in/O patients/O taking/O GILENYA/O 0.5/O mg/O in/O the/O postmarketing/O setting/O ,/O usually/O within/O the/O first/O 6/O months/O of/O treatment/O ./O
Continuation/O of/O GILENYA/O in/O patients/O who/O develop/O macular/B-AdverseReaction edema/I-AdverseReaction has/O not/O been/O evaluated/O ./O
A/O decision/O on/O whether/O or/O not/O to/O discontinue/O GILENYA/O therapy/O should/O include/O an/O assessment/O of/O the/O potential/O benefits/O and/O risks/O for/O the/O individual/O patient/O ./O
The/O risk/O of/O recurrence/O after/O rechallenge/O has/O not/O been/O evaluated/O ./O
Macular/O Edema/O in/O Patients/O with/O History/O of/O Uveitis/O or/O Diabetes/O Mellitus/O Patients/O with/O a/O history/O of/O uveitis/O and/O patients/O with/O diabetes/O mellitus/O are/O at/O increased/O risk/B-Factor of/O macular/B-AdverseReaction edema/I-AdverseReaction during/O GILENYA/O therapy/O ./O
The/O incidence/O of/O macular/B-AdverseReaction edema/I-AdverseReaction is/O also/O increased/O in/O MS/O patients/O with/O a/O history/O of/O uveitis/O ./O
In/O the/O combined/O clinical/O trial/O experience/O with/O all/O doses/O of/O fingolimod/O ,/O the/O rate/O of/O macular/B-AdverseReaction edema/I-AdverseReaction was/O approximately/O 20/O %/O in/O MS/O patients/O with/O a/O history/O of/O uveitis/O versus/O 0.6/O %/O in/O those/O without/O a/O history/O of/O uveitis/O ./O
GILENYA/O has/O not/O been/O tested/O in/O MS/O patients/O with/O diabetes/O mellitus/O ./O
In/O addition/O to/O the/O examination/O of/O the/O fundus/O including/O the/O macula/O prior/O to/O treatment/O and/O at/O 3/O -/O 4/O months/O after/O starting/O treatment/O ,/O MS/O patients/O with/O diabetes/O mellitus/O or/O a/O history/O of/O uveitis/O should/O have/O regular/O follow/O -/O up/O examinations/O ./O
5.5/O Posterior/O Reversible/O Encephalopathy/O Syndrome/O There/O have/O been/O rare/O cases/O of/O posterior/B-AdverseReaction reversible/I-AdverseReaction encephalopathy/I-AdverseReaction syndrome/I-AdverseReaction (/O PRES/B-AdverseReaction )/O reported/O in/O patients/O receiving/O GILENYA/O ./O
Symptoms/O reported/O included/O sudden/O onset/O of/O severe/B-Severity headache/B-AdverseReaction ,/O altered/B-AdverseReaction mental/I-AdverseReaction status/I-AdverseReaction ,/O visual/B-AdverseReaction disturbances/I-AdverseReaction ,/O and/O seizure/B-AdverseReaction ./O
Symptoms/O of/O PRES/B-AdverseReaction are/O usually/O reversible/O but/O may/B-Factor evolve/O into/O ischemic/B-AdverseReaction stroke/I-AdverseReaction or/O cerebral/B-AdverseReaction hemorrhage/I-AdverseReaction ./O
Delay/O in/O diagnosis/O and/O treatment/O may/O lead/O to/O permanent/O neurological/O sequelae/O ./O
If/O PRES/O is/O suspected/O ,/O GILENYA/O should/O be/O discontinued/O ./O
5.6/O Respiratory/O Effects/O Dose/O -/O dependent/O reductions/B-AdverseReaction in/I-AdverseReaction forced/I-AdverseReaction expiratory/I-AdverseReaction volume/I-AdverseReaction over/I-AdverseReaction 1/I-AdverseReaction second/I-AdverseReaction (/O FEV1/O )/O and/O diffusion/O lung/O capacity/O for/O carbon/O monoxide/O (/O DLCO/O )/O were/O observed/O in/O patients/O treated/O with/O GILENYA/O as/O early/O as/O 1/O month/O after/O treatment/O initiation/O ./O
In/O 2-year/O placebo/O -/O controlled/O trials/O ,/O the/O reduction/O from/O baseline/O in/O the/O percent/O of/O predicted/O values/O for/O FEV1/O at/O the/O time/O of/O last/O assessment/O on/O drug/O was/O 2.8/B-Severity %/O for/O GILENYA/O 0.5/O mg/O and/O 1.0/O %/O for/O placebo/O ./O
For/O DLCO/O ,/O the/O reduction/O from/O baseline/O in/O percent/O of/O predicted/O values/O at/O the/O time/O of/O last/O assessment/O on/O drug/O was/O 3.3/B-Severity %/O for/O GILENYA/O 0.5/O mg/O and/O 0.5/O %/O for/O placebo/O ./O
The/O changes/B-AdverseReaction in/I-AdverseReaction FEV1/I-AdverseReaction appear/O to/O be/O reversible/B-Severity after/O treatment/O discontinuation/O ./O
There/O is/O insufficient/O information/O to/O determine/O the/O reversibility/O of/O the/O decrease/B-AdverseReaction of/I-AdverseReaction DLCO/I-AdverseReaction after/O drug/O discontinuation/O ./O
In/O MS/O placebo/O -/O controlled/O trials/O ,/O dyspnea/B-AdverseReaction was/O reported/O in/O 9/O %/O of/O patients/O receiving/O GILENYA/O 0.5/O mg/O and/O 7/O %/O of/O patients/O receiving/O placebo/O ./O
Several/O patients/O discontinued/O GILENYA/O because/O of/O unexplained/O dyspnea/B-AdverseReaction during/O the/O extension/O (/O uncontrolled/O )/O studies/O ./O
GILENYA/O has/O not/O been/O tested/O in/O MS/O patients/O with/O compromised/O respiratory/O function/O ./O
Spirometric/O evaluation/O of/O respiratory/O function/O and/O evaluation/O of/O DLCO/O should/O be/O performed/O during/O therapy/O with/O GILENYA/O if/O clinically/O indicated/O ./O
5.7/O Liver/O Injury/O Elevations/B-AdverseReaction of/I-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction may/B-Factor occur/O in/O patients/O receiving/O GILENYA/O ./O
Recent/O (/O i.e./O ,/O within/O last/O 6/O months/O )/O transaminase/O and/O bilirubin/O levels/O should/O be/O available/O before/O initiation/O of/O GILENYA/O therapy/O ./O
In/O 2-year/O placebo/O -/O controlled/O clinical/O trials/O ,/O elevation/B-AdverseReaction of/I-AdverseReaction liver/I-AdverseReaction transaminases/I-AdverseReaction to/O 3-fold/B-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/I-Severity ULN/O )/O or/O greater/O occurred/O in/O 14/O %/O of/O patients/O treated/O with/O GILENYA/O 0.5/O mg/O and/O 3/O %/O of/O patients/O on/O placebo/O ./O
Elevations/O 5-fold/O the/O ULN/O or/O greater/O occurred/O in/O 4.5/O %/O of/O patients/O on/O GILENYA/O and/O 1/O %/O of/O patients/O on/O placebo/O ./O
The/O majority/O of/O elevations/O occurred/O within/O 6/O to/O 9/O months/O ./O
In/O clinical/O trials/O ,/O GILENYA/O was/O discontinued/O if/O the/O elevation/O exceeded/O 5/O times/O the/O ULN/O ./O
Serum/O transaminase/O levels/O returned/O to/O normal/O within/O approximately/O 2/O months/O after/O discontinuation/O of/O GILENYA/O ./O
Recurrence/O of/O liver/B-AdverseReaction transaminase/I-AdverseReaction elevations/I-AdverseReaction occurred/O with/O rechallenge/O in/O some/O patients/O ./O
Liver/O enzymes/O should/O be/O monitored/O in/O patients/O who/O develop/O symptoms/O suggestive/O of/O hepatic/O dysfunction/O ,/O such/O as/O unexplained/O nausea/O ,/O vomiting/O ,/O abdominal/O pain/O ,/O fatigue/O ,/O anorexia/O ,/O or/O jaundice/O and/or/O dark/O urine/O ./O
GILENYA/O should/O be/O discontinued/O if/O significant/O liver/O injury/O is/O confirmed/O ./O
Patients/O with/O preexisting/O liver/O disease/O may/O be/O at/O increased/O risk/B-Factor of/O developing/O elevated/B-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction when/O taking/O GILENYA/O ./O
Because/O GILENYA/O exposure/O is/O doubled/O in/O patients/O with/O severe/O hepatic/O impairment/O ,/O these/O patients/O should/O be/O closely/O monitored/O ,/O as/O the/O risk/O of/O adverse/O reactions/O is/O greater/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ,/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.8/O Fetal/O Risk/O Based/O on/O animal/B-Animal studies/O ,/O GILENYA/O may/O cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Because/O it/O takes/O approximately/O 2/O months/O to/O eliminate/O GILENYA/O from/O the/O body/O ,/O women/O of/O childbearing/O potential/O should/O use/O effective/O contraception/O to/O avoid/O pregnancy/O during/O and/O for/O 2/O months/O after/O stopping/O GILENYA/O treatment/O ./O
5.9/O Blood/O Pressure/O Effects/O In/O MS/O controlled/O clinical/O trials/O ,/O patients/O treated/O with/O GILENYA/O 0.5/O mg/O had/O an/O average/O increase/O over/O placebo/O of/O approximately/O 3/B-Severity mmHg/I-Severity in/O systolic/O pressure/O ,/O and/O approximately/O 2/B-Severity mmHg/I-Severity in/O diastolic/O pressure/O ,/O first/O detected/O after/O approximately/O 1/O month/O of/O treatment/O initiation/O ,/O and/O persisting/O with/O continued/O treatment/O ./O
Hypertension/B-AdverseReaction was/O reported/O as/O an/O adverse/O reaction/O in/O 8/O %/O of/O patients/O on/O GILENYA/O 0.5/O mg/O and/O in/O 4/O %/O of/O patients/O on/O placebo/O ./O
Blood/O pressure/O should/O be/O monitored/O during/O treatment/O with/O GILENYA/O ./O
5.10/O Immune/O System/O Effects/O Following/O GILENYA/O Discontinuation/O Fingolimod/O remains/O in/O the/O blood/O and/O has/O pharmacodynamic/O effects/O ,/O including/O decreased/B-AdverseReaction lymphocyte/I-AdverseReaction counts/I-AdverseReaction ,/O for/O up/O to/O 2/O months/O following/O the/O last/O dose/O of/O GILENYA/O ./O
Lymphocyte/O counts/O generally/O return/O to/O the/O normal/O range/O within/O 1/O -/O 2/O months/O of/O stopping/O therapy/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
Because/O of/O the/O continuing/O pharmacodynamic/O effects/O of/O fingolimod/O ,/O initiating/O other/O drugs/O during/O this/O period/O warrants/O the/O same/O considerations/O needed/O for/O concomitant/O administration/O (/O e.g./O ,/O risk/B-Factor of/O additive/O immunosuppressant/B-AdverseReaction effects/I-AdverseReaction )/O [/O see/O Drug/O Interactions/O (/O 7/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Diarrhea/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Bullous/O and/O Exfoliative/B-AdverseReaction Skin/I-AdverseReaction Disorders/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Interstitial/B-AdverseReaction Lung/I-AdverseReaction Disease/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Hepatic/B-AdverseReaction Toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Keratitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 20/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O rash/B-AdverseReaction dermatitis/B-AdverseReaction acneiform/I-AdverseReaction ,/O stomatitis/B-AdverseReaction ,/O paronychia/B-AdverseReaction ,/O dry/B-AdverseReaction skin/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O pruritus/B-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Boehringer/O Ingelheim/O Pharmaceuticals/O ,/O Inc./O at/O (/O 800/O )/O 542/O -/O 6257/O or/O (/O 800/O )/O 459/O -/O 9906/O TTY/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O orwww.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O safety/O evaluation/O of/O GILOTRIF/O is/O based/O on/O the/O data/O from/O more/O than/O 3800/O patients/O ,/O including/O 2135/O NSCLC/O patients/O receiving/O GILOTRIF/O monotherapy/O at/O or/O above/O the/O recommended/O dose/O ./O
Controlled/O Study/O The/O data/O in/O Tables/O 1/O and/O 2/O below/O reflect/O exposure/O of/O 229/O EGFR/O -/O TKI/O naive/O GILOTRIF/O -/O treated/O patients/O with/O EGFR/O mutation/O -/O positive/O ,/O metastatic/O ,/O non/O -/O squamous/O ,/O NSCLC/O enrolled/O in/O a/O randomized/O ,/O multicenter/O ,/O open/O -/O label/O trial/O (/O Study/O 1/O )/O ./O
Patients/O received/O GILOTRIF/O 40/O mg/O daily/O until/O documented/O disease/O progression/O or/O intolerance/O to/O the/O therapy/O ./O
A/O total/O of/O 111/O patients/O were/O treated/O with/O pemetrexed/O cisplatin/O ./O
Patients/O were/O treated/O with/O pemetrexed/O 500/O mg/O m2/O followed/O after/O 30/O minutes/O by/O cisplatin/O 75/O mg/O m2/O every/O three/O weeks/O for/O a/O maximum/O of/O six/O treatment/O courses/O ./O
The/O median/O exposure/O was/O 11.0/O months/O for/O patients/O treated/O with/O GILOTRIF/O and/O 3.4/O months/O for/O patients/O treated/O with/O pemetrexed/O cisplatin/O ./O
The/O overall/O trial/O population/O had/O a/O median/O age/O of/O 61/O years/O ;/O 61/O %/O of/O patients/O in/O the/O GILOTRIF/O arm/O and/O 60/O %/O of/O patients/O in/O the/O pemetrexed/O cisplatin/O arm/O were/O younger/O than/O 65/O years/O ./O
A/O total/O of/O 64/O %/O of/O patients/O on/O GILOTRIF/O and/O 67/O %/O of/O pemetrexed/O cisplatin/O patients/O were/O female/O ./O
More/O than/O two/O -/O thirds/O of/O patients/O were/O from/O Asia/O (/O GILOTRIF/O 70/O %/O ;/O pemetrexed/O cisplatin/O 72/O %/O )/O ./O
Serious/O adverse/O reactions/O were/O reported/O in/O 29/O %/O of/O patients/O treated/O with/O GILOTRIF/O ./O
The/O most/O frequent/O serious/O adverse/O reactions/O reported/O in/O patients/O treated/O with/O GILOTRIF/O were/O diarrhea/B-AdverseReaction (/O 6.6/O %/O )/O ;/O vomiting/B-AdverseReaction (/O 4.8/O %/O )/O ;/O and/O dyspnea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O hypokalemia/B-AdverseReaction (/O 1.7/O %/O each/O )/O ./O
Fatal/B-AdverseReaction adverse/O reactions/O in/O GILOTRIF/O -/O treated/O patients/O in/O Study/O 1/O included/O pulmonary/B-AdverseReaction toxicity/I-AdverseReaction ILD/B-AdverseReaction -/I-AdverseReaction like/I-AdverseReaction adverse/O reactions/O (/O 1.3/O %/O )/O ,/O sepsis/B-AdverseReaction (/O 0.43/O %/O )/O ,/O and/O pneumonia/B-AdverseReaction (/O 0.43/O %/O )/O ./O
Dose/O reductions/O due/O to/O adverse/O reactions/O were/O required/O in/O 57/O %/O of/O GILOTRIF/O -/O treated/O patients/O ./O
The/O most/O frequent/O adverse/O reactions/O that/O led/O to/O dose/O reduction/O in/O the/O patients/O treated/O with/O GILOTRIF/O were/O diarrhea/B-AdverseReaction (/O 20/O %/O )/O ,/O rash/B-AdverseReaction acne/B-AdverseReaction (/O 19/O %/O )/O ,/O paronychia/B-AdverseReaction (/O 14/O %/O )/O ,/O and/O stomatitis/B-AdverseReaction (/O 10/O %/O )/O ./O
Discontinuation/O of/O therapy/O in/O GILOTRIF/O -/O treated/O patients/O for/O adverse/O reactions/O was/O 14.0/O %/O ./O
The/O most/O frequent/O adverse/O reactions/O that/O led/O to/O discontinuation/O in/O GILOTRIF/O -/O treated/O patients/O were/O diarrhea/B-AdverseReaction (/O 1.3/O %/O )/O ,/O ILD/B-AdverseReaction (/O 0.9/O %/O )/O ,/O and/O paronychia/B-AdverseReaction (/O 0.9/O %/O )/O ./O
Clinical/O trials/O of/O GILOTRIF/O excluded/O patients/O with/O an/O abnormal/O left/O ventricular/O ejection/O fraction/O (/O LVEF/O )/O ,/O i.e./O ,/O below/O the/O institutional/O lower/O limit/O of/O normal/O ./O
In/O Study/O 1/O ,/O all/O patients/O were/O evaluated/O for/O LVEF/O at/O screening/O and/O every/O 9/O weeks/O thereafter/O in/O the/O GILOTRIF/O -/O treated/O group/O and/O as/O needed/O in/O the/O pemetrexed/O cisplatin/O group/O ./O
More/O GILOTRIF/O -/O treated/O patients/O (/O 2.2/O %/O ;/O n=5/O )/O experienced/O ventricular/B-AdverseReaction dysfunction/I-AdverseReaction (/O defined/O as/O diastolic/B-AdverseReaction dysfunction/I-AdverseReaction ,/O left/B-AdverseReaction ventricular/I-AdverseReaction dysfunction/I-AdverseReaction ,/O or/O ventricular/B-AdverseReaction dilation/I-AdverseReaction ;/O all/O Grade/O 3/O )/O compared/O to/O chemotherapy/O -/O treated/O patients/O (/O 0.9/O %/O ;/O n=1/O )/O ./O
Table/O 1/O Adverse/O Reactions/O Reported/O in/O 10/O %/O of/O GILOTRIF/O -/O Treated/O Patients/O in/O Study/O 1/O None/O of/O the/O adverse/O reactions/O in/O this/O table/O except/O stomatitis/B-AdverseReaction (/O one/O patient/O on/O GILOTRIF/O [/O 0.4/O %/O ]/O )/O were/O Grade/B-Severity 4/I-Severity in/O severity/O 1/O Includes/O stomatitis/B-AdverseReaction ,/O aphthous/B-AdverseReaction stomatitis/I-AdverseReaction ,/O mucosal/B-AdverseReaction inflammation/I-AdverseReaction ,/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ,/O oral/B-AdverseReaction mucosa/I-AdverseReaction erosion/I-AdverseReaction ,/O mucosal/B-AdverseReaction erosion/I-AdverseReaction ,/O mucosal/B-AdverseReaction ulceration/I-AdverseReaction 2/O Includes/O group/O of/O rash/B-AdverseReaction preferred/O terms/O ,/O acne/B-AdverseReaction ,/O acne/B-AdverseReaction pustular/I-AdverseReaction ,/O dermatitis/B-AdverseReaction acneiform/I-AdverseReaction 3/O Includes/O paronychia/B-AdverseReaction ,/O nail/B-AdverseReaction infection/I-AdverseReaction ,/O nail/B-AdverseReaction bed/I-AdverseReaction infection/I-AdverseReaction GILOTRIFn=229/O Pemetrexed/O Cisplatinn=111/O Adverse/O Reaction/O All/O Grades(%/O )/O Grade/O 3*(%/O )/O All/O Grades(%/O )/O Grade/O 3*(%/O )/O Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 96/O 15/O 23/O 2/O Stomatitis/B-AdverseReaction 1/O 71/O 9/O 15/O 1/O Nausea/B-AdverseReaction 25/O 4/O 68/O 4/O Vomiting/B-AdverseReaction 23/O 4/O 47/O 3/O Cheilitis/B-AdverseReaction 12/O 0/O 1/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction Dermatitis/B-AdverseReaction acneiform/I-AdverseReaction 2/O 90/O 16/O 11/O 0/O Pruritus/B-AdverseReaction 21/O 0/O 1/O 0/O Dry/B-AdverseReaction skin/I-AdverseReaction 31/O 0/O 2/O 0/O Infections/O and/O infestations/O Paronychia/B-AdverseReaction 3/O 58/O 11/O 0/O 0/O Cystitis/B-AdverseReaction 13/O 1/O 5/O 0/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 29/O 4/O 55/O 4/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Epistaxis/B-AdverseReaction 17/O 0/O 2/O 1/O Rhinorrhea/B-AdverseReaction 11/O 0/O 6/O 0/O Investigations/O Weight/B-AdverseReaction Decreased/I-AdverseReaction 17/O 1/O 14/O 1/O General/O disorders/O and/O administration/O site/O conditions/O Pyrexia/B-AdverseReaction 12/O 0/O 6/O 0/O Eye/O disorders/O Conjunctivitis/B-AdverseReaction 11/O 0/O 3/O 0/O Table/O 2/O Adverse/O Reactions/O of/O Laboratory/O Abnormalities/O from/O the/O Investigations/O SOC/O Reported/O in/O 5/O %/O of/O GILOTRIF/O -/O Treated/O Patients/O in/O Study/O 1/O 1/O Includes/O hypokalemia/B-AdverseReaction ,/O blood/B-AdverseReaction potassium/I-AdverseReaction decreasedSOC/I-AdverseReaction system/O organ/O class/O GILOTRIFn=229/O Pemetrexed/O Cisplatinn=111/O Adverse/O Reaction/O All/O Grades(%/O )/O Grades/O 3/O -/O 4(%/O )/O All/O Grades(%/O )/O Grades/O 3/O -/O 4(%/O )/O Alanine/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction 11/O 2/O 4/O 0/O Hypokalemia/B-AdverseReaction 1/O 11/O 4/O 5/O 4/O Aspartate/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction 8/O 2/O 2/O 1/O 6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O GILOTRIF/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Pancreatitis/B-AdverseReaction 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Diarrhea/O :/O Diarrhea/B-AdverseReaction may/B-Factor result/O in/O dehydration/B-AdverseReaction and/O renal/B-AdverseReaction failure/I-AdverseReaction ./O
Withhold/O GILOTRIF/O for/O severe/O and/O prolonged/O diarrhea/O not/O responsive/O to/O anti/O -/O diarrheal/O agents/O ./O
(/O 2.3,5.1/O )/O Bullous/O and/O Exfoliative/O Skin/O Disorders/O :/O Severe/B-Severity bullous/O ,/O blistering/O ,/O and/O exfoliating/O lesions/O occurred/O in/O 0.15/O %/O of/O patients/O ./O
Discontinue/O for/O life/O -/O threatening/O cutaneous/O reactions/O ./O
Withhold/O GILOTRIF/O for/O severe/O and/O prolonged/O cutaneous/O reactions/O ./O
(/O 2.3,5.2/O )/O Interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction (/O ILD/B-AdverseReaction )/O :/O Occurs/O in/O 1.5/O %/O of/O patients/O ./O
Withhold/O GILOTRIF/O for/O acute/O onset/O or/O worsening/O of/O pulmonary/O symptoms/O ./O
Discontinue/O GILOTRIF/O if/O ILD/O is/O diagnosed/O ./O
(/O 2.3,5.3/O )/O Hepatic/B-AdverseReaction toxicity/I-AdverseReaction :/O Fatal/B-AdverseReaction hepatic/B-AdverseReaction impairment/I-AdverseReaction occurs/O in/O 0.18/O %/O of/O patients/O ./O
Monitor/O with/O periodic/O liver/O testing/O ./O
Withhold/O or/O discontinue/O GILOTRIF/O for/O severe/O or/O worsening/O liver/O tests/O ./O
(/O 2.3,5.4/O )/O Keratitis/B-AdverseReaction :/O Occurs/O in/O 0.8/O %/O of/O patients/O ./O
Withhold/O GILOTRIF/O for/O keratitis/O evaluation/O ./O
Withhold/O or/O discontinue/O GILOTRIF/O for/O confirmed/O ulcerative/O keratitis/O ./O
(/O 2.3,5.5/O )/O Embryofetal/B-AdverseReaction toxicity/I-AdverseReaction :/O Can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Advise/O females/O of/O the/O potential/O hazard/O to/O the/O fetus/O and/O to/O use/O highly/O effective/O contraception/O ./O
(/O 5.6/O )/O 5.1/O Diarrhea/O Diarrhea/B-AdverseReaction has/O resulted/O in/O dehydration/B-AdverseReaction with/O or/O without/O renal/B-AdverseReaction impairment/I-AdverseReaction ;/O some/O of/O these/O cases/O were/O fatal/B-AdverseReaction ./O
In/O Study/O 1/O ,/O diarrhea/B-AdverseReaction occurred/O in/O 96/O %/O of/O patients/O treated/O with/O GILOTRIF/O (/O n=229/O )/O ,/O of/O which/O 15/O %/O was/O Grade/B-Severity 3/I-Severity in/O severity/O and/O occurred/O within/O the/O first/O 6/O weeks/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Renal/B-AdverseReaction impairment/I-AdverseReaction as/O a/O consequence/O of/O diarrhea/B-AdverseReaction occurred/O in/O 6.1/O %/O of/O patients/O treated/O with/O GILOTRIF/O ,/O out/O of/O which/O 3/O (/O 1.3/O %/O )/O were/O Grade/B-Severity 3/I-Severity ./O
For/O patients/O who/O develop/O prolonged/O Grade/O 2/O diarrhea/O lasting/O more/O than/O 48/O hours/O or/O greater/O than/O or/O equal/O to/O Grade/O 3/O diarrhea/O ,/O withhold/O GILOTRIF/O until/O diarrhea/O resolves/O to/O Grade/O 1/O or/O less/O ,/O and/O resume/O GILOTRIF/O with/O appropriate/O dose/O reduction/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Provide/O patients/O with/O an/O anti/O -/O diarrheal/O agent/O (/O e.g./O ,/O loperamide/O )/O for/O self/O -/O administration/O at/O the/O onset/O of/O diarrhea/O and/O instruct/O patients/O to/O continue/O anti/O -/O diarrheal/O therapy/O until/O loose/O bowel/O movements/O cease/O for/O 12/O hours/O ./O
5.2/O Bullous/O and/O Exfoliative/O Skin/O Disorders/O Grade/B-Severity 3/I-Severity cutaneous/B-AdverseReaction reactions/I-AdverseReaction characterized/O by/O bullous/O ,/O blistering/O ,/O and/O exfoliating/B-AdverseReaction lesions/I-AdverseReaction occurred/O in/O 6/O (/O 0.15/O %/O )/O of/O the/O 3865/O patients/O who/O received/O GILOTRIF/O across/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O Study/O 1/O ,/O the/O overall/O incidence/O of/O cutaneous/B-AdverseReaction reactions/I-AdverseReaction consisting/O of/O rash/B-AdverseReaction ,/O erythema/B-AdverseReaction ,/O and/O acneiform/B-AdverseReaction rash/I-AdverseReaction was/O 90/O %/O ,/O and/O the/O incidence/O of/O Grade/B-Severity 3/I-Severity cutaneous/B-AdverseReaction reactions/I-AdverseReaction was/O 16/O %/O ./O
In/O addition/O ,/O the/O incidence/O of/O Grade/B-Severity 1/I-Severity -/O 3/O palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O was/O 7/O %/O ./O
Discontinue/O GILOTRIF/O in/O patients/O who/O develop/O life/O -/O threatening/O bullous/O ,/O blistering/O ,/O or/O exfoliating/O lesions/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
For/O patients/O who/O develop/O prolonged/O Grade/O 2/O cutaneous/O adverse/O reactions/O lasting/O more/O than/O 7/O days/O ,/O intolerable/O Grade/O 2/O ,/O or/O Grade/O 3/O cutaneous/O reactions/O ,/O withhold/O GILOTRIF/O until/O the/O adverse/O reaction/O resolves/O to/O Grade/O 1/O or/O less/O ,/O and/O resume/O GILOTRIF/O with/O appropriate/O dose/O reduction/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.3/O Interstitial/O Lung/O Disease/O (/O ILD/O )/O ILD/B-AdverseReaction or/O ILD/B-AdverseReaction -/I-AdverseReaction like/I-AdverseReaction adverse/O reactions/O (/O e.g./O ,/O lung/B-AdverseReaction infiltration/I-AdverseReaction ,/O pneumonitis/B-AdverseReaction ,/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction ,/O or/O alveolitis/B-AdverseReaction allergic/I-AdverseReaction )/O occurred/O in/O 1.5/O %/O of/O the/O 3865/O patients/O who/O received/O GILOTRIF/O across/O clinical/O trials/O ;/O of/O these/O ,/O 0.4/O %/O were/O fatal/B-AdverseReaction ./O
The/O incidence/O of/O ILD/B-AdverseReaction appeared/O to/O be/O higher/O in/O patients/O of/O Asian/O ethnicity/O (/O 2.1/O %/O )/O as/O compared/O to/O non/O -/O Asians/O (/O 1.2/O %/O )/O ./O
In/O Study/O 1/O ,/O the/O incidence/O of/O Grade/O =3/O ILD/B-AdverseReaction was/O 1.3/O %/O and/O resulted/O in/O death/B-AdverseReaction in/O 1/O %/O of/O GILOTRIF/O -/O treated/O patients/O ./O
Withhold/O GILOTRIF/O during/O evaluation/O of/O patients/O with/O suspected/O ILD/O ,/O and/O discontinue/O GILOTRIF/O in/O patients/O with/O confirmed/O ILD/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.4/O Hepatic/O Toxicity/O In/O 3865/O patients/O who/O received/O GILOTRIF/O across/O clinical/O trials/O ,/O 10.1/O %/O had/O liver/B-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction ,/O of/O which/O 7/O (/O 0.18/O %/O )/O were/O fatal/B-AdverseReaction ./O
In/O Study/O 1/O ,/O liver/B-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction of/O any/O grade/O occurred/O in/O 17.5/O %/O of/O the/O patients/O treated/O with/O GILOTRIF/O ./O
Obtain/O periodic/O liver/O testing/O in/O patients/O during/O treatment/O with/O GILOTRIF/O ./O
Withhold/O GILOTRIF/O in/O patients/O who/O develop/O worsening/O of/O liver/O function/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
In/O patients/O who/O develop/O severe/O hepatic/O impairment/O while/O taking/O GILOTRIF/O ,/O treatment/O should/O be/O discontinued/O ./O
5.5/O Keratitis/O Keratitis/B-AdverseReaction ,/O characterized/O as/O acute/O or/O worsening/B-AdverseReaction eye/I-AdverseReaction inflammation/I-AdverseReaction ,/O lacrimation/B-AdverseReaction ,/O light/B-AdverseReaction sensitivity/I-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O eye/B-AdverseReaction pain/I-AdverseReaction ,/O and/or/O red/B-AdverseReaction eye/I-AdverseReaction occurred/O in/O 0.8/O %/O of/O patients/O treated/O with/O GILOTRIF/O among/O 3865/O patients/O across/O clinical/O trials/O ./O
Keratitis/B-AdverseReaction was/O reported/O in/O 5/O (/O 2.2/O %/O )/O patients/O in/O Study/O 1/O ,/O with/O Grade/B-Severity 3/I-Severity in/O 1/O (/O 0.4/O %/O )/O ./O
Withhold/O GILOTRIF/O during/O evaluation/O of/O patients/O with/O suspected/O keratitis/O ,/O and/O if/O diagnosis/O of/O ulcerative/O keratitis/O is/O confirmed/O ,/O treatment/O with/O GILOTRIF/O should/O be/O interrupted/O or/O discontinued/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
If/O keratitis/O is/O diagnosed/O ,/O the/O benefits/O and/O risks/O of/O continuing/O treatment/O should/O be/O carefully/O considered/O ./O
GILOTRIF/O should/O be/O used/O with/O caution/O in/O patients/O with/O a/O history/O of/O keratitis/O ,/O ulcerative/O keratitis/O ,/O or/O severe/O dry/O eye/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Contact/O lens/O use/O is/O also/O a/O risk/O factor/O for/O keratitis/O and/O ulceration/O ./O
5.6/O Embryofetal/O Toxicity/O Based/O on/O its/O mechanism/O of/O action/O ,/O GILOTRIF/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Afatinib/O was/O embryotoxic/B-AdverseReaction and/O ,/O in/O animals/O with/O maternal/O toxicity/O ,/O led/O to/O abortions/B-AdverseReaction at/I-AdverseReaction late/I-AdverseReaction gestational/I-AdverseReaction stages/I-AdverseReaction in/O rabbits/B-Animal at/O doses/O of/O 5/O mg/O kg/O (/O approximately/O 0.2/O times/O the/O human/O exposure/O at/O the/O recommended/O dose/O of/O 40/O mg/O daily/O )/O or/O greater/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
Advise/O females/O of/O reproductive/O potential/O to/O use/O highly/O effective/O contraception/O during/O treatment/O ,/O and/O for/O at/O least/O 2/O weeks/O after/O the/O last/O dose/O of/O GILOTRIF/O ./O
Advise/O patients/O to/O contact/O their/O healthcare/O provider/O if/O they/O become/O pregnant/O ,/O or/O if/O pregnancy/O is/O suspected/O ,/O while/O taking/O GILOTRIF/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1and8.6/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O potential/O serious/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Splenic/B-AdverseReaction Rupture/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Acute/B-AdverseReaction Respiratory/I-AdverseReaction Distress/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Serious/B-Severity Allergic/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Use/O in/O Patients/O with/O Sickle/O Cell/O Disease/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Capillary/B-AdverseReaction Leak/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Potential/B-Factor for/O Tumor/B-AdverseReaction Growth/I-AdverseReaction Stimulatory/I-AdverseReaction Effects/I-AdverseReaction on/I-AdverseReaction Malignant/I-AdverseReaction Cells/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O The/O most/O common/O treatment/O -/O emergent/O adverse/O reaction/O that/O occurred/O at/O an/O incidence/O of/O at/O least/O 1/O %/O or/O greater/O in/O patients/O treated/O with/O GRANIX/O at/O the/O recommended/O dose/O and/O was/O numerically/O two/O times/O more/O frequent/O than/O in/O the/O placebo/O group/O was/O bone/B-AdverseReaction pain/I-AdverseReaction ./O
EXCERPT/O :/O Most/O common/O adverse/O reaction/O to/O GRANIX/O is/O bone/B-AdverseReaction pain/I-AdverseReaction (/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O TEVA/O at/O 1/O -/O 866/O -/O 832/O -/O 8537/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
GRANIX/O clinical/O trials/O safety/O data/O are/O based/O upon/O the/O results/O of/O three/O randomized/O clinical/O trials/O in/O patients/O receiving/O myeloablative/O chemotherapy/O for/O breast/O cancer/O (/O N=348/O )/O ,/O lung/O cancer/O (/O N=240/O )/O and/O non/O -/O Hodgkin/O 's/O lymphoma/O (/O N=92/O )/O ./O
In/O the/O breast/O cancer/O study/O ,/O 99/O %/O of/O patients/O were/O female/O ,/O the/O median/O age/O was/O 50/O years/O ,/O and/O 86/O %/O of/O patients/O were/O Caucasian/O ./O
In/O the/O lung/O cancer/O study/O ,/O 80/O %/O of/O patients/O were/O male/O ,/O the/O median/O age/O was/O 58/O years/O ,/O and/O 95/O %/O of/O patients/O were/O Caucasian/O ./O
In/O the/O non/O -/O Hodgkin/O 's/O lymphoma/O study/O ,/O 52/O %/O of/O patients/O were/O male/O ,/O the/O median/O age/O was/O 55/O years/O ,/O and/O 88/O %/O of/O patients/O were/O Caucasian/O ./O
In/O all/O three/O studies/O a/O placebo/O (/O Cycle/O 1/O of/O the/O breast/O cancer/O study/O only/O )/O or/O a/O non/O -/O US/O -/O approved/O filgrastim/O product/O were/O used/O as/O controls/O ./O
Both/O GRANIX/O and/O the/O non/O -/O US/O -/O approved/O filgrastim/O product/O were/O administered/O at/O 5/O mcg/O kg/O subcutaneously/O once/O daily/O beginning/O one/O day/O after/O chemotherapy/O for/O at/O least/O five/O days/O and/O continued/O to/O a/O maximum/O of/O 14/O days/O or/O until/O an/O ANC/O of/O 10,000/O x/O 10/O 6/O /L/O after/O nadir/O was/O reached/O ./O
Bone/B-AdverseReaction pain/I-AdverseReaction was/O the/O most/O frequent/O treatment/O -/O emergent/O adverse/O reaction/O that/O occurred/O in/O at/O least/O 1/O %/O or/O greater/O in/O patients/O treated/O with/O GRANIX/O at/O the/O recommended/O dose/O and/O was/O numerically/O two/O times/O more/O frequent/O than/O in/O the/O placebo/O group/O ./O
The/O overall/O incidence/O of/O bone/B-AdverseReaction pain/I-AdverseReaction in/O Cycle/O 1/O of/O treatment/O was/O 3.4/O %/O (/O 3.4/O %/O GRANIX/O ,/O 1.4/O %/O placebo/O ,/O 7.5/O %/O non/O -/O US/O -/O approved/O filgrastim/O product/O )/O ./O
Leukocytosis/O In/O clinical/O studies/O ,/O leukocytosis/B-AdverseReaction (/O WBC/B-AdverseReaction counts/I-AdverseReaction 100,000/I-AdverseReaction x/I-AdverseReaction 10/I-AdverseReaction 6/I-AdverseReaction /L/O )/O was/O observed/O in/O less/O than/O 1/O %/O patients/O with/O non/O -/O myeloid/O malignancies/O receiving/O GRANIX/O ./O
No/O complications/O attributable/O to/O leukocytosis/B-AdverseReaction were/O reported/O in/O clinical/O studies/O ./O
Additional/O Adverse/O Reactions/O Other/O adverse/O reactions/O known/O to/O occur/O following/O administration/O of/O human/B-DrugClass granulocyte/I-DrugClass colony/I-DrugClass -/I-DrugClass stimulating/O factors/O include/O myalgia/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O Sweet/B-AdverseReaction 's/I-AdverseReaction syndrome/O (/O acute/B-AdverseReaction febrile/I-AdverseReaction neutrophilic/I-AdverseReaction dermatosis/I-AdverseReaction )/O ,/O cutaneous/B-AdverseReaction vasculitis/I-AdverseReaction and/O thrombocytopenia/B-AdverseReaction ./O
6.2/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O a/O potential/O for/O immunogenicity/O ./O
The/O incidence/O of/O antibody/O development/O in/O patients/O receiving/O GRANIX/O has/O not/O been/O adequately/O determined/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Splenic/B-AdverseReaction Rupture/I-AdverseReaction :/O Discontinue/O GRANIX/O if/O suspected/O (/O 5.1/O )/O Acute/B-AdverseReaction Respiratory/I-AdverseReaction Distress/I-AdverseReaction Syndrome/I-AdverseReaction (/O ARDS/B-AdverseReaction )/O :/O Monitor/O for/O and/O manage/O immediately/O ./O
Discontinue/O GRANIX/O if/O suspected/O (/O 5.2/O )/O Allergic/B-AdverseReaction reactions/I-AdverseReaction (/O angioneurotic/B-AdverseReaction edema/I-AdverseReaction ,/O dermatitis/B-AdverseReaction allergic/I-AdverseReaction ,/O drug/B-AdverseReaction hypersensitivity/I-AdverseReaction ,/O hypersensitivity/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O pruritic/B-AdverseReaction rash/I-AdverseReaction and/O urticaria/B-AdverseReaction )/O (/O 5.3/O )/O Sickle/B-AdverseReaction cell/I-AdverseReaction crisis/I-AdverseReaction :/O Severe/B-Severity and/O sometimes/O fatal/B-AdverseReaction crisis/O can/B-Factor occur/O ./O
Discontinue/O GRANIX/O if/O suspected/O (/O 5.4/O )/O Capillary/B-AdverseReaction Leak/I-AdverseReaction Syndrome/I-AdverseReaction :/O Monitor/O if/O symptoms/O develop/O and/O administer/O standard/O symptomatic/O treatment/O (/O 5.5/O )/O 5.1/O Splenic/O Rupture/O Splenic/B-AdverseReaction rupture/I-AdverseReaction ,/O including/O fatal/B-AdverseReaction cases/O ,/O can/B-Factor occur/O following/O administration/O of/O human/O granulocyte/O colony/O -/O stimulating/O factors/O ./O
In/O patients/O who/O report/O upper/O abdominal/O or/O shoulder/O pain/O after/O receiving/O GRANIX/O ,/O discontinue/O GRANIX/O and/O evaluate/O for/O an/O enlarged/O spleen/O or/O splenic/O rupture/O ./O
5.2/O Acute/O Respiratory/O Distress/O Syndrome/O (/O ARDS/O )/O Acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction (/O ARDS/B-AdverseReaction )/O can/O occur/O in/O patients/O receiving/O human/B-DrugClass granulocyte/I-DrugClass colony/I-DrugClass -/I-DrugClass stimulating/O factors/O ./O
Evaluate/O patients/O who/O develop/O fever/O and/O lung/O infiltrates/O or/O respiratory/O distress/O after/O receiving/O GRANIX/O ,/O for/O ARDS/O ./O
Discontinue/O GRANIX/O in/O patients/O with/O ARDS/O ./O
5.3/O Allergic/O Reactions/O Serious/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction including/O anaphylaxis/B-AdverseReaction can/O occur/O in/O patients/O receiving/O human/B-DrugClass granulocyte/I-DrugClass colony/I-DrugClass -/I-DrugClass stimulating/O factors/O ./O
Reactions/O can/O occur/O on/O initial/O exposure/O ./O
The/O administration/O of/O antihistamines/O ,/O steroids/O ,/O bronchodilators/O ,/O and/or/O epinephrine/O may/O reduce/O the/O severity/O of/O the/O reactions/O ./O
Permanently/O discontinue/O GRANIX/O in/O patients/O with/O serious/O allergic/O reactions/O ./O
Do/O not/O administer/O GRANIX/O to/O patients/O with/O a/O history/O of/O serious/O allergic/O reactions/O to/O filgrastim/O or/O pegfilgrastim/O ./O
5.4/O Use/O in/O Patients/O with/O Sickle/O Cell/O Disease/O Severe/O and/O sometimes/O fatal/B-AdverseReaction sickle/B-AdverseReaction cell/I-AdverseReaction crises/I-AdverseReaction can/B-Factor occur/O in/O patients/O with/O sickle/O cell/O disease/O receiving/O human/O granulocyte/O colony/O -/O stimulating/O factors/O ./O
Consider/O the/O potential/O risks/O and/O benefits/O prior/O to/O the/O administration/O of/O human/O granulocyte/O colony/O -/O stimulating/O factors/O in/O patients/O with/O sickle/O cell/O disease/O ./O
Discontinue/O GRANIX/O in/O patients/O undergoing/O a/O sickle/O cell/O crisis/O ./O
5.5/O Capillary/O Leak/O Syndrome/O Capillary/B-AdverseReaction leak/I-AdverseReaction syndrome/I-AdverseReaction (/O CLS/B-AdverseReaction )/O can/O occur/O in/O patients/O receiving/O human/B-DrugClass granulocyte/I-DrugClass colony/I-DrugClass -/I-DrugClass stimulating/O factors/O and/O is/O characterized/O by/O hypotension/B-AdverseReaction ,/O hypoalbuminemia/B-AdverseReaction ,/O edema/B-AdverseReaction and/O hemoconcentration/B-AdverseReaction ./O
Episodes/O vary/O in/O frequency/O ,/O severity/O and/O may/O be/O life/O -/O threatening/O if/O treatment/O is/O delayed/O ./O
Patients/O who/O develop/O symptoms/O of/O capillary/O leak/O syndrome/O should/O be/O closely/O monitored/O and/O receive/O standard/O symptomatic/O treatment/O ,/O which/O may/O include/O a/O need/O for/O intensive/O care/O ./O
5.6/O Potential/O for/O Tumor/O Growth/O Stimulatory/O Effects/O on/O Malignant/O Cells/O The/O granulocyte/O colony/O -/O stimulating/O factor/O (/O G/O -/O CSF/O )/O receptor/O through/O which/O GRANIX/O acts/O has/O been/O found/O on/O tumor/O cell/O lines/O ./O
The/O possibility/B-Factor that/O GRANIX/O acts/O as/O a/O growth/O factor/O for/O any/O tumor/O type/O ,/O including/O myeloid/B-AdverseReaction malignancies/I-AdverseReaction and/O myelodysplasia/B-AdverseReaction ,/O diseases/O for/O which/O GRANIX/O is/O not/O approved/O ,/O can/O not/O be/O excluded/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O described/O in/O more/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O of/O the/O label/O :/O Somnolence/B-AdverseReaction sedation/B-AdverseReaction and/O dizziness/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O RLS/O :/O Most/O common/O adverse/O reactions/O (/O 10/O %/O and/O at/O least/O 2/O times/O the/O rate/O of/O placebo/O )/O were/O somnolence/B-AdverseReaction sedation/B-AdverseReaction and/O dizziness/B-AdverseReaction ./O
(/O 6.1/O )/O PHN/O :/O Most/O common/O adverse/O reactions/O (/O 10/O %/O and/O greater/O than/O placebo/O )/O were/O dizziness/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
(/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O XenoPort/O at/O 1/O -/O 877-XENOPRT/O (/O 1/O -/O 877/O -/O 936/O -/O 6778/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
In/O all/O controlled/O and/O uncontrolled/O trials/O across/O various/O patient/O populations/O ,/O more/O than/O 2,300/O patients/O have/O received/O HORIZANT/O orally/O in/O daily/O doses/O ranging/O from/O 600/O to/O 3,600/O mg/O ./O
Restless/O Legs/O Syndrome/O :/O The/O exposure/O to/O HORIZANT/O in/O 1,201/O patients/O with/O RLS/O included/O 613/O exposed/O for/O at/O least/O 6/O months/O and/O 371/O exposed/O for/O at/O least/O 1/O year/O ./O
HORIZANT/O in/O the/O treatment/O of/O RLS/O was/O studied/O primarily/O in/O placebo/O -/O controlled/O trials/O (/O n/O 642/O )/O ,/O and/O in/O long/O -/O term/O follow/O -/O up/O studies/O ./O
The/O population/O with/O RLS/O ranged/O from/O 18/O to/O 82/O years/O of/O age/O ,/O with/O 60/O %/O being/O female/O and/O 95/O %/O being/O Caucasian/O ./O
The/O safety/O of/O HORIZANT/O in/O doses/O ranging/O from/O 600/O to/O 2,400/O mg/O has/O been/O evaluated/O in/O 515/O patients/O with/O RLS/O in/O 3/O double/O blind/O ,/O placebo/O -/O controlled/O ,/O 12/O week/O clinical/O trials/O ./O
The/O 600-mg/O dose/O was/O studied/O in/O 2/O of/O the/O 3/O studies/O ./O
Eleven/O out/O of/O 163/O (/O 7/O %/O )/O patients/O treated/O with/O 600/O mg/O of/O HORIZANT/O discontinued/O treatment/O due/O to/O adverse/O reactions/O compared/O with/O 10/O of/O the/O 245/O (/O 4/O %/O )/O patients/O who/O received/O placebo/O ./O
The/O most/O commonly/O observed/O adverse/O reactions/O (/O 5/O %/O and/O at/O least/O 2/O times/O the/O rate/O of/O placebo/O )/O in/O these/O trials/O for/O the/O 600/O mg/O dose/O of/O HORIZANT/O were/O somnolence/B-AdverseReaction sedation/B-AdverseReaction and/O dizziness/B-AdverseReaction (/O see/O Table/O 4/O )/O ./O
Table/O 4/O lists/O treatment/O -/O emergent/O adverse/O reactions/O that/O occurred/O in/O 2/O %/O of/O patients/O with/O RLS/O treated/O with/O HORIZANT/O and/O numerically/O greater/O than/O placebo/O ./O
Table/O 4/O ./O
Incidence/O of/O Adverse/O Reactions/O in/O 12/O Week/O RLS/O Studies/O Reported/O in/O 2/O %/O of/O Patients/O Treated/O With/O 600/O or/O 1,200/O mg/O of/O HORIZANT/O and/O Numerically/O Greater/O Than/O Placebo/O Body/O System/O Adverse/O Reaction/O Placebo/O a/O (/O N/O 245)%/O HORIZANT600/O mg/O day/O b/O (/O N/O 163)%/O HORIZANT1,200/O mg/O day/O c/O (/O N/O 269)%/O Nervous/O system/O disorders/O Somnolence/B-AdverseReaction sedation/B-AdverseReaction 6/O 20/O 27/O Dizziness/B-AdverseReaction 4/O 13/O 22/O Headache/B-AdverseReaction 11/O 12/O 15/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 5/O 6/O 7/O Dry/B-AdverseReaction mouth/I-AdverseReaction 2/O 3/O 4/O Flatulence/B-AdverseReaction 1/O 3/O 2/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 4/O 6/O 7/O Irritability/B-AdverseReaction 1/O 4/O 4/O Feeling/B-AdverseReaction drunk/I-AdverseReaction 0/O 1/O 3/O Feeling/B-AdverseReaction abnormal/I-AdverseReaction 1/O 1/O 3/O Peripheral/B-AdverseReaction edema/I-AdverseReaction 1/O 1/O 3/O Metabolism/O and/O nutritional/O disorders/O Weight/B-AdverseReaction increased/I-AdverseReaction 2/O 2/O 3/O Increased/B-AdverseReaction appetite/I-AdverseReaction 1/O 2/O 2/O Ear/O and/O labyrinth/O disorders/O Vertigo/B-AdverseReaction 0/O 1/O 3/O Psychiatric/O disorders/O Depression/B-AdverseReaction 1/O 1/O 3/O Libido/B-AdverseReaction decreased/I-AdverseReaction 1/O 1/O 2/O a/O Placebo/O was/O a/O treatment/O arm/O in/O each/O of/O the/O 3/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O 12-week/O clinical/O trials/O ./O
b/O The/O 600-mg/O dose/O of/O HORIZANT/O was/O a/O treatment/O arm/O in/O 2/O of/O the/O 3/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O 12-week/O clinical/O trials/O ./O
c/O The/O 1,200-mg/O dose/O of/O HORIZANT/O was/O a/O treatment/O arm/O in/O each/O of/O the/O 3/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O 12-week/O clinical/O trials/O ./O
Adverse/O reactions/O reported/O in/O these/O three/O 12/O week/O studies/O in/O 2/O %/O of/O patients/O treated/O with/O 600/O mg/O of/O HORIZANT/O and/O numerically/O greater/O than/O placebo/O were/O balance/B-AdverseReaction disorder/I-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O disorientation/B-AdverseReaction ,/O feeling/B-AdverseReaction drunk/I-AdverseReaction ,/O lethargy/B-AdverseReaction ,/O and/O vertigo/B-AdverseReaction ./O
The/O following/O adverse/O reactions/O were/O dose/O -/O related/O :/O somnolence/B-AdverseReaction sedation/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O feeling/B-AdverseReaction drunk/I-AdverseReaction ,/O libido/B-AdverseReaction decreased/I-AdverseReaction ,/O depression/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O and/O vertigo/B-AdverseReaction ./O
Postherpetic/O Neuralgia/O :/O The/O exposure/O to/O HORIZANT/O in/O 417/O patients/O with/O PHN/O included/O 207/O patients/O exposed/O for/O at/O least/O 3/O months/O ./O
Overall/O ,/O the/O mean/O age/O of/O patients/O in/O the/O PHN/O studies/O ranged/O from/O 61/O to/O 64/O years/O of/O age/O across/O dose/O groups/O ;/O the/O majority/O of/O patients/O were/O male/O (/O 45/O %/O to/O 61/O %/O )/O and/O Caucasian/O (/O 80/O %/O to/O 98/O %/O )/O ./O
The/O safety/O of/O HORIZANT/O in/O doses/O ranging/O from/O 1,200/O to/O 3,600/O mg/O has/O been/O evaluated/O in/O 417/O patients/O with/O PHN/O in/O 3/O clinical/O studies/O ./O
The/O principal/O efficacy/O study/O evaluating/O the/O efficacy/O and/O safety/O of/O HORIZANT/O in/O the/O management/O of/O PHN/O was/O a/O 12-week/O ,/O double/O -/O blind/O ,/O multicenter/O study/O comparing/O 1,200/O mg/O day/O ,/O 2,400/O mg/O day/O and/O 3,600/O mg/O day/O to/O placebo/O ./O
Six/O out/O of/O 107/O (/O 6/O %/O )/O patients/O treated/O with/O 1,200/O mg/O of/O HORIZANT/O discontinued/O treatment/O due/O to/O adverse/O events/O compared/O with/O 12/O of/O the/O 95/O (/O 13/O %/O )/O patients/O who/O received/O placebo/O ./O
The/O most/O commonly/O observed/O adverse/O reactions/O (/O 10/O %/O and/O greater/O than/O placebo/O )/O in/O this/O trial/O for/O the/O 1,200/O mg/O dose/O of/O HORIZANT/O were/O dizziness/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O and/O headache/B-AdverseReaction (/O see/O Table/O 5/O )/O ./O
Table/O 5/O lists/O treatment/O -/O emergent/O adverse/O reactions/O that/O occurred/O in/O 2/O %/O of/O patients/O with/O PHN/O treated/O with/O HORIZANT/O 1,200/O mg/O day/O and/O numerically/O greater/O than/O placebo/O ./O
Table/O 5/O ./O
Incidence/O of/O Adverse/O Reactions/O (/O in/O At/O Least/O 2/O %/O of/O Patients/O Treated/O With/O 1,200/O mg/O day/O of/O HORIZANT/O and/O Numerically/O Greater/O Than/O the/O Placebo/O Rate/O )/O Reported/O in/O All/O Patients/O in/O the/O 12-Week/O PHN/O Study/O Body/O System/O Adverse/O Reaction/O Placebo(N/O 95)%/O HORIZANT1,200/O mg/O day(N/O 107)%/O HORIZANT2,400/O mg/O day(N/O 82)%/O HORIZANT3,600/O mg/O day(N/O 87)%/O Nervous/O System/O Dizziness/B-AdverseReaction 15/O 17/O 26/O 30/O Somnolence/B-AdverseReaction 8/O 10/O 11/O 14/O Headache/B-AdverseReaction 9/O 10/O 10/O 7/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 5/O 8/O 4/O 9/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction Asthenia/B-AdverseReaction 1/O 6/O 4/O 10/O Peripheral/B-AdverseReaction edema/I-AdverseReaction 0/O 6/O 7/O 6/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 2/O 3/O 5/O 7/O Metabolism/O and/O nutritional/O disorders/O Weight/B-AdverseReaction increased/I-AdverseReaction 1/O 3/O 5/O 5/O Eye/O disorders/O Blurred/B-AdverseReaction vision/I-AdverseReaction 0/O 2/O 5/O 2/O The/O following/O adverse/O reactions/O were/O also/O reported/O as/O 2/O %/O at/O 2,400/O mg/O day/O and/or/O 3,600/O mg/O day/O and/O appeared/O to/O be/O dose/O -/O related/O but/O were/O 2/O %/O at/O 1,200/O mg/O day/O :/O balance/B-AdverseReaction disorder/I-AdverseReaction ,/O confusional/B-AdverseReaction state/I-AdverseReaction ,/O depression/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O flatulence/B-AdverseReaction ,/O increased/B-AdverseReaction appetite/I-AdverseReaction ,/O irritability/B-AdverseReaction ,/O and/O vertigo/B-AdverseReaction ./O
Dizziness/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O insomnia/B-AdverseReaction appeared/O to/O show/O a/O dose/O relationship/O ./O
6.2/O Adverse/O Events/O Associated/O With/O Gabapentin/O The/O following/O adverse/O events/O have/O been/O reported/O in/O patients/O receiving/O gabapentin/O ,/O either/O in/O clinical/O trials/O or/O postmarketing/O :/O breast/B-AdverseReaction enlargement/I-AdverseReaction ,/O gynecomastia/B-AdverseReaction ,/O and/O elevated/B-AdverseReaction creatine/I-AdverseReaction kinase/I-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Driving/B-AdverseReaction impairment/I-AdverseReaction :/O Warn/O patients/O not/O to/O drive/O until/O they/O have/O gained/O sufficient/O experience/O with/O HORIZANT/O to/O assess/O whether/O it/O will/O impair/O their/O ability/O to/O drive/O ./O
(/O 5.1/O )/O Somnolence/B-AdverseReaction sedation/B-AdverseReaction and/O dizziness/B-AdverseReaction :/O May/B-Factor impair/O the/O patient/O 's/O ability/O to/O operate/O complex/O machinery/O ./O
(/O 5.2/O )/O HORIZANT/O is/O not/O interchangeable/O with/O other/O gabapentin/O products/O ./O
(/O 5.3/O )/O Suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behaviors/O :/O HORIZANT/O is/O a/O prodrug/O of/O gabapentin/O ,/O an/O antiepileptic/O drug/O (/O AED/O )/O ./O
AEDs/B-DrugClass increase/O the/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behaviors/O ./O
Monitor/O for/O suicidal/O thoughts/O or/O behaviors/O ./O
(/O 5.4/O )/O 5.1/O Effects/O on/O Driving/O HORIZANT/O may/B-Factor cause/O significant/B-Severity driving/B-AdverseReaction impairment/I-AdverseReaction [/O see/O Clinical/O Studies/O (/O 14.3/O )/O ]/O ./O
The/O duration/O of/O driving/B-AdverseReaction impairment/I-AdverseReaction after/O starting/O therapy/O with/O HORIZANT/O is/O unknown/O ./O
Patients/O taking/O HORIZANT/O should/O not/O drive/O until/O they/O have/O gained/O sufficient/O experience/O to/O assess/O whether/O HORIZANT/O impairs/O their/O ability/O to/O drive/O ./O
However/O ,/O prescribers/O and/O patients/O should/O be/O aware/O that/O patients/O '/O ability/O to/O assess/O their/O own/O driving/O competence/O ,/O as/O well/O as/O their/O ability/O to/O assess/O the/O degree/O of/O somnolence/O caused/O by/O HORIZANT/O ,/O can/O be/O imperfect/O ./O
Whether/O the/O impairment/O is/O related/O to/O somnolence/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O or/O other/O effects/O of/O HORIZANT/O is/O unknown/O ./O
5.2/O Somnolence/O Sedation/O and/O Dizziness/O HORIZANT/O causes/O somnolence/B-AdverseReaction sedation/B-AdverseReaction and/O dizziness/B-AdverseReaction (/O see/O Tables/O 4/O and/O 5/O )/O ./O
Patients/O should/O be/O advised/O not/O to/O drive/O a/O car/O or/O operate/O other/O complex/O machinery/O until/O they/O have/O gained/O sufficient/O experience/O on/O HORIZANT/O to/O assess/O whether/O HORIZANT/O impairs/O their/O ability/O to/O perform/O these/O tasks/O ./O
During/O the/O controlled/O trials/O in/O patients/O with/O RLS/O ,/O somnolence/B-AdverseReaction sedation/B-AdverseReaction was/O reported/O in/O 20/O %/O of/O patients/O treated/O with/O 600/O mg/O of/O HORIZANT/O per/O day/O compared/O with/O 6/O %/O of/O patients/O receiving/O placebo/O ./O
In/O those/O patients/O treated/O with/O HORIZANT/O who/O reported/O somnolence/B-AdverseReaction ,/O the/O somnolence/B-AdverseReaction persisted/O during/O treatment/O in/O about/O 30/O %/O ./O
In/O the/O remaining/O patients/O ,/O symptoms/O resolved/O within/O 3/O to/O 4/O weeks/O ./O
Dizziness/B-AdverseReaction was/O reported/O in/O 13/O %/O of/O patients/O receiving/O 600/O mg/O of/O HORIZANT/O per/O day/O compared/O with/O 4/O %/O of/O patients/O receiving/O placebo/O ./O
In/O those/O patients/O treated/O with/O HORIZANT/O who/O reported/O dizziness/B-AdverseReaction ,/O symptoms/O persisted/O during/O treatment/O in/O about/O 20/O %/O ./O
Somnolence/B-AdverseReaction sedation/B-AdverseReaction led/O to/O withdrawal/O in/O 2/O %/O of/O patients/O receiving/O 600/O mg/O of/O HORIZANT/O per/O day/O ./O
Dizziness/B-AdverseReaction led/O to/O withdrawal/O in/O 1/O %/O of/O patients/O receiving/O 600/O mg/O of/O HORIZANT/O per/O day/O ./O
The/O incidence/O of/O these/O adverse/O reactions/O was/O greater/O in/O the/O patients/O receiving/O 1,200/O mg/O per/O day/O ./O
During/O the/O 12-week/O ,/O controlled/O study/O in/O patients/O with/O PHN/O ,/O somnolence/B-AdverseReaction was/O reported/O in/O 10/O %/O of/O patients/O treated/O with/O 1,200/O mg/O of/O HORIZANT/O per/O day/O compared/O with/O 8/O %/O of/O patients/O receiving/O placebo/O ./O
Fatigue/B-AdverseReaction asthenia/B-AdverseReaction was/O reported/O in/O 6/O %/O of/O patients/O treated/O with/O 1,200/O mg/O of/O HORIZANT/O per/O day/O compared/O with/O 1/O %/O of/O patients/O receiving/O placebo/O ./O
In/O those/O patients/O treated/O with/O 1,200/O mg/O of/O HORIZANT/O per/O day/O who/O reported/O somnolence/B-AdverseReaction (/O 10/O %/O )/O ,/O the/O somnolence/B-AdverseReaction persisted/O during/O treatment/O in/O about/O 27/O %/O ./O
In/O the/O remaining/O patients/O ,/O symptoms/O resolved/O within/O 4/O to/O 5/O weeks/O ./O
Dizziness/B-AdverseReaction was/O reported/O in/O 17/O %/O of/O patients/O receiving/O 1,200/O mg/O of/O HORIZANT/O per/O day/O compared/O with/O 15/O %/O of/O patients/O receiving/O placebo/O ./O
In/O those/O patients/O treated/O with/O 1,200/O mg/O of/O HORIZANT/O per/O day/O who/O reported/O dizziness/B-AdverseReaction ,/O symptoms/O persisted/O during/O treatment/O in/O about/O 6/O %/O ./O
Somnolence/B-AdverseReaction led/O to/O withdrawal/O in/O 1/O %/O of/O patients/O receiving/O 1,200/O mg/O of/O HORIZANT/O per/O day/O compared/O with/O 2/O %/O of/O patients/O receiving/O placebo/O ./O
Dizziness/B-AdverseReaction led/O to/O withdrawal/O in/O 2/O %/O of/O patients/O receiving/O 1,200/O mg/O of/O HORIZANT/O per/O day/O compared/O with/O 3/O %/O of/O patients/O receiving/O placebo/O ./O
5.3/O Lack/O of/O Interchangeability/O With/O Gabapentin/O HORIZANT/O is/O not/O interchangeable/O with/O other/O gabapentin/O products/O because/O of/O differing/O pharmacokinetic/O profiles/O ./O
The/O same/O dose/O of/O HORIZANT/O results/O in/O different/O plasma/O concentrations/O of/O gabapentin/O relative/O to/O other/O gabapentin/O products/O ./O
[/O See/O Clinical/O Pharmacology/O (/O 12.3/O )/O ./O
]/O The/O safety/O and/O effectiveness/O of/O HORIZANT/O in/O patients/O with/O epilepsy/O have/O not/O been/O studied/O ./O
5.4/O Suicidal/O Behavior/O and/O Ideation/O HORIZANT/O (/O gabapentin/O enacarbil/O )/O is/O a/O prodrug/O of/O gabapentin/O ,/O an/O antiepileptic/O drug/O (/O AED/O )/O ./O
AEDs/B-DrugClass increase/O the/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O in/O patients/O taking/O these/O drugs/O for/O any/O indication/O ./O
Because/O HORIZANT/O is/O a/O prodrug/O of/O gabapentin/O ,/O HORIZANT/O also/O increases/O this/O risk/O ./O
Patients/O treated/O with/O any/O AED/O for/O any/O indication/O should/O be/O monitored/O for/O the/O emergence/O or/O worsening/O of/O depression/O ,/O suicidal/O thoughts/O or/O behavior/O ,/O and/or/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ./O
Pooled/O analyses/O of/O 199/O placebo/O -/O controlled/O clinical/O trials/O (/O monotherapy/O and/O adjunctive/O therapy/O )/O of/O 11/O different/O AEDs/O showed/O that/O patients/O randomized/O to/O 1/O of/O the/O AEDs/B-DrugClass had/O approximately/O twice/O the/O risk/O [/O adjusted/O relative/O risk/O 1.8/O ,/O 95/O %/O confidence/O interval/O (/O CI/O )/O :/O 1.2/O ,/O 2.7/O ]/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O compared/O with/O patients/O randomized/O to/O placebo/O ./O
In/O these/O trials/O ,/O which/O had/O a/O median/O treatment/O duration/O of/O 12/O weeks/O ,/O the/O estimated/O incidence/O rate/O of/O suicidal/B-AdverseReaction behavior/I-AdverseReaction or/O ideation/O among/O 27,863/O AED/O -/O treated/O patients/O was/O 0.43/O %/O ,/O compared/O with/O 0.24/O %/O among/O 16,029/O placebo/O -/O treated/O patients/O ,/O representing/O an/O increase/O of/O approximately/O 1/O case/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O for/O every/O 530/O patients/O treated/O ./O
There/O were/O 4/O suicides/B-AdverseReaction in/O drug/O -/O treated/O patients/O in/O the/O trials/O and/O none/O in/O placebo/O -/O treated/O patients/O ,/O but/O the/O number/B-Factor is/I-Factor too/I-Factor small/I-Factor to/O allow/O any/O conclusion/O about/O drug/O effect/O on/O suicide/B-AdverseReaction ./O
The/O increased/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O with/O AEDs/B-DrugClass was/O observed/O as/O early/O as/O 1/O week/O after/O starting/O drug/O treatment/O with/O AEDs/O and/O persisted/O for/O the/O duration/O of/O treatment/O assessed/O ./O
Because/O most/O trials/O included/O in/O the/O analysis/O did/O not/O extend/O beyond/O 24/O weeks/O ,/O the/O risk/O of/O suicidal/O thoughts/O or/O behavior/O beyond/O 24/O weeks/O could/O not/O be/O assessed/O ./O
The/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O generally/O consistent/O among/O drugs/O in/O the/O data/O analyzed/O ./O
The/O finding/O of/O increased/O risk/O with/O AEDs/O of/O varying/O mechanisms/O of/O action/O and/O across/O a/O range/O of/O indications/O suggests/O that/O the/O risk/O applies/O to/O all/O AEDs/O used/O for/O any/O indication/O ./O
The/O risk/O did/O not/O vary/O substantially/O by/O age/O (/O 5/O to/O 100/O years/O )/O in/O the/O clinical/O trials/O analyzed/O ./O
Table/O 3/O shows/O absolute/O and/O relative/O risk/O by/O indication/O for/O all/O evaluated/O AEDs/O ./O
Table/O 3/O ./O
Risk/O by/O Indication/O for/O Antiepileptic/O Drugs/O in/O the/O Pooled/O Analysis/O Indication/O PlaceboPatients/O WithEvents/O Per1,000/O Patients/O Drug/O PatientsWith/O Events/O Per1,000/O Patients/O Relative/O Risk/O :/O Incidence/O of/O Eventsin/O DrugPatients/O Incidencein/O Placebo/O Patients/O Risk/O Difference/O :/O Additional/O DrugPatients/O WithEvents/O Per/O 1,000Patients/O Epilepsy/O 1.0/O 3.4/O 3.5/O 2.4/O Psychiatric/O 5.7/O 8.5/O 1.5/O 2.9/O Other/O 1.0/O 1.8/O 1.9/O 0.9/O Total/O 2.4/O 4.3/O 1.8/O 1.9/O The/O relative/O risk/B-Factor for/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O higher/O in/O clinical/O trials/O for/O epilepsy/O than/O in/O clinical/O trials/O for/O psychiatric/O or/O other/O conditions/O ,/O but/O the/O absolute/O risk/O differences/O were/O similar/O for/O the/O epilepsy/O and/O psychiatric/O indications/O ./O
Anyone/O considering/O prescribing/O HORIZANT/O must/O balance/O the/O risk/O of/O suicidal/O thoughts/O or/O behavior/O with/O the/O risk/O of/O untreated/O illness/O ./O
Epilepsy/O and/O many/O other/O illnesses/O for/O which/O AEDs/O are/O prescribed/O are/O themselves/O associated/O with/O morbidity/O and/O mortality/O and/O an/O increased/O risk/O of/O suicidal/O thoughts/O and/O behavior/O ./O
Should/O suicidal/O thoughts/O and/O behavior/O emerge/O during/O treatment/O ,/O the/O prescriber/O needs/O to/O consider/O whether/O the/O emergence/O of/O these/O symptoms/O in/O any/O given/O patient/O may/O be/O related/O to/O the/O illness/O being/O treated/O ./O
Patients/O ,/O their/O caregivers/O ,/O and/O families/O should/O be/O informed/O that/O HORIZANT/O increases/O the/O risk/O of/O suicidal/O thoughts/O and/O behavior/O and/O should/O be/O advised/O of/O the/O need/O to/O be/O alert/O for/O the/O emergence/O or/O worsening/O of/O the/O signs/O and/O symptoms/O of/O depression/O ,/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ,/O or/O the/O emergence/O of/O suicidal/O thoughts/O ,/O behavior/O ,/O or/O thoughts/O about/O self/O -/O harm/O ./O
Behaviors/O of/O concern/O should/O be/O reported/O immediately/O to/O healthcare/O providers/O ./O
5.5/O Drug/O Reaction/O With/O Eosinophilia/O and/O Systemic/O Symptoms/O (/O DRESS)/Multiorgan/O Hypersensitivity/O Drug/B-AdverseReaction Reaction/I-AdverseReaction with/I-AdverseReaction Eosinophilia/I-AdverseReaction and/I-AdverseReaction Systemic/I-AdverseReaction Symptoms/I-AdverseReaction (/O DRESS/B-AdverseReaction )/O ,/O also/O known/O as/O multiorgan/B-AdverseReaction hypersensitivity/I-AdverseReaction ,/O has/O been/O reported/O in/O patients/O taking/O antiepileptic/B-DrugClass drugs/I-DrugClass ,/O including/O gabapentin/O ./O
HORIZANT/O is/O a/O prodrug/O of/O gabapentin/O ./O
Some/O of/O these/O events/O have/O been/O fatal/B-AdverseReaction or/O life/O -/O threatening/O ./O
DRESS/B-AdverseReaction typically/O ,/O although/O not/O exclusively/O ,/O presents/O with/O fever/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/or/O lymphadenopathy/B-AdverseReaction ,/O in/O association/O with/O other/O organ/O system/O involvement/O ,/O such/O as/O hepatitis/B-AdverseReaction ,/O nephritis/B-AdverseReaction ,/O hematological/B-AdverseReaction abnormalities/I-AdverseReaction ,/O myocarditis/B-AdverseReaction ,/O or/O myositis/B-AdverseReaction sometimes/O resembling/O an/O acute/O viral/O infection/O ./O
Eosinophilia/B-AdverseReaction is/O often/O present/O ./O
Because/O this/O disorder/O is/O variable/O in/O its/O expression/O ,/O other/O organ/O systems/O not/O noted/O here/O may/O be/O involved/O ./O
It/O is/O important/O to/O note/O that/O early/O manifestations/O of/O hypersensitivity/B-AdverseReaction ,/O such/O as/O fever/B-AdverseReaction or/O lymphadenopathy/B-AdverseReaction ,/O may/B-Factor be/O present/O even/O though/O rash/B-AdverseReaction is/O not/B-Negation evident/I-Negation ./O
If/O such/O signs/O or/O symptoms/O are/O present/O ,/O the/O patient/O should/O be/O evaluated/O immediately/O ./O
HORIZANT/O should/O be/O discontinued/O if/O an/O alternative/O etiology/O for/O the/O signs/O or/O symptoms/O can/O not/O be/O established/O ./O
5.6/O Discontinuation/O of/O HORIZANT/O When/O discontinuing/O HORIZANT/O ,/O patients/O with/O RLS/O receiving/O 600/O mg/O or/O less/O once/O daily/O can/O discontinue/O the/O drug/O without/O tapering/O ./O
If/O the/O recommended/O dose/O is/O exceeded/O ,/O the/O dose/O should/O be/O reduced/O to/O 600/O mg/O daily/O for/O 1/O week/O prior/O to/O discontinuation/O to/O minimize/O the/O potential/O of/O withdrawal/O seizure/O ./O
In/O patients/O with/O PHN/O receiving/O HORIZANT/O twice/O daily/O ,/O the/O dose/O should/O be/O reduced/O to/O once/O daily/O for/O 1/O week/O prior/O to/O discontinuation/O to/O minimize/O the/O potential/O of/O withdrawal/O seizure/O ,/O see/O Table/O 2/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.7/O Tumorigenic/O Potential/O In/O an/O oral/O carcinogenicity/O study/O ,/O gabapentin/O enacarbil/O increased/O the/O incidence/O of/O pancreatic/B-AdverseReaction acinar/I-AdverseReaction cell/I-AdverseReaction adenoma/I-AdverseReaction and/O carcinoma/O in/O male/O and/O female/O rats/B-Animal [/O see/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
The/O clinical/O significance/O of/O this/O finding/O is/O unknown/O ./O
In/O clinical/O studies/O of/O gabapentin/O as/O adjunctive/O therapy/O in/O epilepsy/O comprising/O 2,085/O patient/O -/O years/O of/O exposure/O in/O patients/O 12/O years/O of/O age/O ,/O new/O tumors/B-AdverseReaction were/O reported/O in/O 10/O patients/O (/O 2/O breast/O ,/O 3/O brain/O ,/O 2/O lung/O ,/O 1/O adrenal/O ,/O 1/O non/B-AdverseReaction -/I-AdverseReaction Hodgkin/O 's/O lymphoma/O ,/O 1/O endometrial/B-AdverseReaction carcinoma/I-AdverseReaction in/I-AdverseReaction situ/I-AdverseReaction )/O ,/O and/O preexisting/O tumors/O worsened/O in/O 11/O patients/O (/O 9/O brain/O ,/O 1/O breast/O ,/O 1/O prostate/O )/O during/O or/O up/O to/O 2/O years/O following/O discontinuation/O of/O gabapentin/O ./O
Without/O knowledge/O of/O the/O background/O incidence/O and/O recurrence/O in/O a/O similar/O population/O not/O treated/O with/O gabapentin/O ,/O it/O is/O impossible/O to/O know/O whether/O the/O incidence/O reported/O in/O this/O cohort/O is/O or/O is/O not/O affected/O by/O treatment/O ./O
6/O ADVERSE/O REACTIONS/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O safety/O of/O INLYTA/O has/O been/O evaluated/O in/O 715/O patients/O in/O monotherapy/O studies/O ,/O which/O included/O 537/O patients/O with/O advanced/O RCC/O ./O
The/O data/O described/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O reflect/O exposure/O to/O INLYTA/O in/O 359/O patients/O with/O advanced/O RCC/O who/O participated/O in/O a/O randomized/O clinical/O study/O versus/O sorafenib/O [/O seeClinical/O Studies/O (/O 14/O )/O ]/O ./O
The/O following/O risks/B-Factor ,/O including/O appropriate/O action/O to/O be/O taken/O ,/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O label/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O -/O 5.13/O )/O ]/O :/O hypertension/B-AdverseReaction ,/O arterial/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction ,/O venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction ,/O hemorrhage/B-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction ,/O gastrointestinal/B-AdverseReaction perforation/I-AdverseReaction and/O fistula/B-AdverseReaction formation/I-AdverseReaction ,/O thyroid/B-AdverseReaction dysfunction/I-AdverseReaction ,/O wound/B-AdverseReaction healing/I-AdverseReaction complications/I-AdverseReaction ,/O RPLS/B-AdverseReaction ,/O proteinuria/B-AdverseReaction ,/O elevation/B-AdverseReaction of/I-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction ,/O hepatic/B-AdverseReaction impairment/I-AdverseReaction and/O fetal/O development/O ./O
EXCERPT/O :/O The/O most/O common/O (/O 20/O %/O )/O adverse/O reactions/O are/O diarrhea/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O palmar/O -/O plantar/O erythrodysesthesia/O (/O hand/O -/O foot/O )/O syndrome/O ,/O weight/B-AdverseReaction decreased/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O and/O constipation/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Pfizer/O ,/O Inc/O at/O 1/O -/O 800/O -/O 438/O -/O 1985/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O The/O median/O duration/O of/O treatment/O was/O 6.4/O months/O (/O range/O 0.03/O to/O 22.0/O )/O for/O patients/O who/O received/O INLYTA/O and/O 5.0/O months/O (/O range/O 0.03/O to/O 20.1/O )/O for/O patients/O who/O received/O sorafenib/O ./O
Dose/O modifications/O or/O temporary/O delay/O of/O treatment/O due/O to/O an/O adverse/O reaction/O occurred/O in/O 199/359/O patients/O (/O 55/O %/O )/O receiving/O INLYTA/O and/O 220/355/O patients/O (/O 62/O %/O )/O receiving/O sorafenib/O ./O
Permanent/O discontinuation/O due/O to/O an/O adverse/O reaction/O occurred/O in/O 34/359/O patients/O (/O 9/O %/O )/O receiving/O INLYTA/O and/O 46/355/O patients/O (/O 13/O %/O )/O receiving/O sorafenib/O ./O
The/O most/O common/O (/O 20/O %/O )/O adverse/O reactions/O observed/O following/O treatment/O with/O INLYTA/O were/O diarrhea/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O palmar/O -/O plantar/O erythrodysesthesia/O (/O hand/O -/O foot/O )/O syndrome/O ,/O weight/B-AdverseReaction decreased/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O and/O constipation/B-AdverseReaction ./O
Table/O 1/O presents/O adverse/O reactions/O reported/O in/O 10/O %/O patients/O who/O received/O INLYTA/O or/O sorafenib/O ./O
Table/O 1/O ./O
Adverse/O Reactions/O Occurring/O in/O 10/O %/O of/O Patients/O Who/O Received/O INLYTA/O or/O Sorafenib/O Adverse/O Reaction/O INLYTA/O Sorafenib/O (/O N=359/O )/O (/O N=355/O )/O All/O Grades/O Grade/O 3/4/O All/O Grades/O Grade/O 3/4/O %/O %/O %/O %/O Diarrhea/B-AdverseReaction 55/O 11/O 53/O 7/O Hypertension/B-AdverseReaction 40/O 16/O 29/O 11/O Fatigue/B-AdverseReaction 39/O 11/O 32/O 5/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 34/O 5/O 29/O 4/O Nausea/B-AdverseReaction 32/O 3/O 22/O 1/O Dysphonia/B-AdverseReaction 31/O 0/O 14/O 0/O Palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O 27/O 5/O 51/O 16/O Weight/B-AdverseReaction decreased/I-AdverseReaction 25/O 2/O 21/O 1/O Vomiting/B-AdverseReaction 24/O 3/O 17/O 1/O Asthenia/B-AdverseReaction 21/O 5/O 14/O 3/O Constipation/B-AdverseReaction 20/O 1/O 20/O 1/O Hypothyroidism/B-AdverseReaction 19/O 1/O 8/O 0/O Cough/B-AdverseReaction 15/O 1/O 17/O 1/O Mucosal/B-AdverseReaction inflammation/I-AdverseReaction 15/O 1/O 12/O 1/O Arthralgia/B-AdverseReaction 15/O 2/O 11/O 1/O Stomatitis/B-AdverseReaction 15/O 1/O 12/O 1/O Dyspnea/B-AdverseReaction 15/O 3/O 12/O 3/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 14/O 2/O 11/O 1/O Headache/B-AdverseReaction 14/O 1/O 11/O 0/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 13/O 1/O 14/O 1/O Rash/B-AdverseReaction 13/O 1/O 32/O 4/O Proteinuria/B-AdverseReaction 11/O 3/O 7/O 2/O Dysgeusia/B-AdverseReaction 11/O 0/O 8/O 0/O Dry/B-AdverseReaction skin/I-AdverseReaction 10/O 0/O 11/O 0/O Dyspepsia/B-AdverseReaction 10/O 0/O 2/O 0/O Pruritus/B-AdverseReaction 7/O 0/O 12/O 0/O Alopecia/B-AdverseReaction 4/O 0/O 32/O 0/O Erythema/B-AdverseReaction 2/O 0/O 10/O 1/O Selected/O adverse/O reactions/O (/O all/O grades/O )/O that/O were/O reported/O in/O 10/O %/O of/O patients/O treated/O with/O INLYTA/O included/O dizziness/B-AdverseReaction (/O 9/O %/O )/O ,/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction (/O 8/O %/O )/O ,/O myalgia/B-AdverseReaction (/O 7/O %/O )/O ,/O dehydration/B-AdverseReaction (/O 6/O %/O )/O ,/O epistaxis/B-AdverseReaction (/O 6/O %/O )/O ,/O anemia/B-AdverseReaction (/O 4/O %/O )/O ,/O hemorrhoids/B-AdverseReaction (/O 4/O %/O )/O ,/O hematuria/B-AdverseReaction (/O 3/O %/O )/O ,/O tinnitus/B-AdverseReaction (/O 3/O %/O )/O ,/O lipase/B-AdverseReaction increased/I-AdverseReaction (/O 3/O %/O )/O ,/O glossodynia/B-AdverseReaction (/O 3/O %/O )/O ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O 2/O %/O )/O ,/O rectal/B-AdverseReaction hemorrhage/I-AdverseReaction (/O 2/O %/O )/O ,/O hemoptysis/B-AdverseReaction (/O 2/O %/O )/O ,/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction (/O 1/O %/O )/O ,/O retinal/B-AdverseReaction -/I-AdverseReaction vein/O occlusion/O thrombosis/O (/O 1/O %/O )/O ,/O polycythemia/B-AdverseReaction (/O 1/O %/O )/O ,/O and/O transient/B-AdverseReaction ischemic/I-AdverseReaction attack/I-AdverseReaction (/O 1/O %/O )/O ./O
Table/O 2/O presents/O the/O most/O common/O laboratory/O abnormalities/O reported/O in/O 10/O %/O patients/O who/O received/O INLYTA/O or/O sorafenib/O ./O
Table/O 2/O ./O
Laboratory/O Abnormalities/O Occurring/O in/O 10/O %/O of/O Patients/O Who/O Received/O INLYTA/O or/O Sorafenib/O Laboratory/O Abnormality/O N/O INLYTA/O N/O Sorafenib/O All/O Grades/O Grade/O 3/4/O All/O Grades/O Grade/O 3/4/O %/O %/O %/O %/O ALP/O :/O alkaline/O phosphatase/O ;/O ALT/O :/O alanine/O aminotransferase/O ;/O AST/O :/O aspartate/O aminotransferase/O Hematology/O Hemoglobin/B-AdverseReaction decreased/I-AdverseReaction 320/O 35/O 1/O 316/O 52/O 4/O Lymphocytes/B-AdverseReaction (/I-AdverseReaction absolute/I-AdverseReaction )/O decreased/O 317/O 33/O 3/O 309/O 36/O 4/O Platelets/B-AdverseReaction decreased/I-AdverseReaction 312/O 15/O 1/O 310/O 14/O 0/O White/B-AdverseReaction blood/I-AdverseReaction cells/I-AdverseReaction decreased/I-AdverseReaction 320/O 11/O 0/O 315/O 16/O 1/O Chemistry/O Creatinine/B-AdverseReaction increased/I-AdverseReaction 336/O 55/O 0/O 318/O 41/O 1/O Bicarbonate/B-AdverseReaction decreased/I-AdverseReaction 314/O 44/O 1/O 291/O 43/O 0/O Hypocalcemia/B-AdverseReaction 336/O 39/O 1/O 319/O 59/O 2/O ALP/B-AdverseReaction increased/I-AdverseReaction 336/O 30/O 1/O 319/O 34/O 1/O Hyperglycemia/B-AdverseReaction 336/O 28/O 2/O 319/O 23/O 2/O Lipase/B-AdverseReaction increased/I-AdverseReaction 338/O 27/O 5/O 319/O 46/O 15/O Amylase/B-AdverseReaction increased/I-AdverseReaction 338/O 25/O 2/O 319/O 33/O 2/O ALT/B-AdverseReaction increased/I-AdverseReaction 331/O 22/O 1/O 313/O 22/O 2/O AST/B-AdverseReaction increased/I-AdverseReaction 331/O 20/O 1/O 311/O 25/O 1/O Hypernatremia/B-AdverseReaction 338/O 17/O 1/O 319/O 13/O 1/O Hypoalbuminemia/B-AdverseReaction 337/O 15/O 1/O 319/O 18/O 1/O Hyperkalemia/B-AdverseReaction 333/O 15/O 3/O 314/O 10/O 3/O Hypoglycemia/B-AdverseReaction 336/O 11/O 1/O 319/O 8/O 1/O Hyponatremia/B-AdverseReaction 338/O 13/O 4/O 319/O 11/O 2/O Hypophosphatemia/B-AdverseReaction 336/O 13/O 2/O 318/O 49/O 16/O Selected/O laboratory/O abnormalities/O (/O all/O grades/O )/O that/O were/O reported/O in/O 10/O %/O of/O patients/O treated/O with/O INLYTA/O included/O hemoglobin/B-AdverseReaction increased/I-AdverseReaction (/O above/O the/O upper/O limit/O of/O normal/O )/O (/O 9/O %/O for/O INLYTA/O versus/O 1/O %/O for/O sorafenib/O )/O and/O hypercalcemia/B-AdverseReaction (/O 6/O %/O for/O INLYTA/O versus/O 2/O %/O for/O sorafenib/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypertension/B-AdverseReaction including/O hypertensive/B-AdverseReaction crisis/I-AdverseReaction has/O been/O observed/O ./O
Blood/O pressure/O should/O be/O well/O -/O controlled/O prior/O to/O initiating/O INLYTA/O ./O
Monitor/O for/O hypertension/O and/O treat/O as/O needed/O ./O
For/O persistent/O hypertension/O despite/O use/O of/O anti/O -/O hypertensive/O medications/O ,/O reduce/O the/O INLYTA/O dose/O ./O
(/O 5.1/O )/O Arterial/O and/O venous/B-AdverseReaction thrombotic/I-AdverseReaction events/I-AdverseReaction have/O been/O observed/O and/O can/B-Factor be/O fatal/B-AdverseReaction ./O
Use/O with/O caution/O in/O patients/O who/O are/O at/O increased/O risk/O for/O these/O events/O ./O
(/O 5.2,5.3/O )/O Hemorrhagic/B-AdverseReaction events/I-AdverseReaction ,/O including/O fatal/B-AdverseReaction events/O ,/O have/O been/O reported/O ./O
INLYTA/O has/O not/O been/O studied/O in/O patients/O with/O evidence/O of/O untreated/O brain/O metastasis/O or/O recent/O active/O gastrointestinal/O bleeding/O and/O should/O not/O be/O used/O in/O those/O patients/O ./O
(/O 5.4/O )/O Cardiac/B-AdverseReaction failure/I-AdverseReaction has/O been/O observed/O and/O can/B-Factor be/O fatal/B-AdverseReaction ./O
Monitor/O for/O signs/O or/O symptoms/O of/O cardiac/O failure/O throughout/O treatment/O with/O INLYTA/O ./O
(/O 5.5/O )/O Gastrointestinal/B-AdverseReaction perforation/I-AdverseReaction and/O fistula/O ,/O including/O death/B-AdverseReaction ,/O have/O occurred/O ./O
Use/O with/O caution/O in/O patients/O at/O risk/O for/O gastrointestinal/O perforation/O or/O fistula/O ./O
(/O 5.6/O )/O Hypothyroidism/B-AdverseReaction requiring/O thyroid/O hormone/O replacement/O has/O been/O reported/O ./O
Monitor/O thyroid/O function/O before/O initiation/O of/O ,/O and/O periodically/O throughout/O ,/O treatment/O with/O INLYTA/O ./O
(/O 5.7/O )/O Stop/O INLYTA/O at/O least/O 24/O hours/O prior/O to/O scheduled/O surgery/O ./O
(/O 5.8/O )/O Reversible/B-AdverseReaction Posterior/I-AdverseReaction Leukoencephalopathy/I-AdverseReaction Syndrome/I-AdverseReaction (/O RPLS/B-AdverseReaction )/O has/O been/O observed/O ./O
Permanently/O discontinue/O INLYTA/O if/O signs/O or/O symptoms/O of/O RPLS/O occur/O ./O
(/O 5.9/O )/O Monitor/O for/O proteinuria/O before/O initiation/O of/O ,/O and/O periodically/O throughout/O ,/O treatment/O with/O INLYTA/O ./O
For/O moderate/O to/O severe/O proteinuria/O ,/O reduce/O the/O dose/O or/O temporarily/O interrupt/O treatment/O with/O INLYTA/O ./O
(/O 5.10/O )/O Liver/B-AdverseReaction enzyme/I-AdverseReaction elevation/I-AdverseReaction has/O been/O observed/O during/O treatment/O with/O INLYTA/O ./O
Monitor/O ALT/O ,/O AST/O and/O bilirubin/O before/O initiation/O of/O ,/O and/O periodically/O throughout/O ,/O treatment/O with/O INLYTA/O ./O
(/O 5.11/O )/O The/O starting/O dose/O of/O INLYTA/O should/O be/O decreased/O if/O used/O in/O patients/O with/O moderate/O hepatic/O impairment/O ./O
INLYTA/O has/O not/O been/O studied/O in/O patients/O with/O severe/O hepatic/O impairment/O ./O
(/O 2.2,5.12/O )/O INLYTA/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O based/O on/O its/O mechanism/O of/O action/O ./O
Women/O of/O childbearing/O potential/O should/O be/O advised/O of/O the/O potential/O hazard/O to/O the/O fetus/O and/O to/O avoid/O becoming/O pregnant/O while/O receiving/O INLYTA/O ./O
(/O 5.13,8.1/O )/O 5.1/O Hypertension/O and/O Hypertensive/O Crisis/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O hypertension/B-AdverseReaction was/O reported/O in/O 145/359/O patients/O (/O 40/O %/O )/O receiving/O INLYTA/O and/O 103/355/O patients/O (/O 29/O %/O )/O receiving/O sorafenib/O ./O
Grade/B-Severity 3/4/I-Severity hypertension/B-AdverseReaction was/O observed/O in/O 56/359/O patients/O (/O 16/O %/O )/O receiving/O INLYTA/O and/O 39/355/O patients/O (/O 11/O %/O )/O receiving/O sorafenib/O ./O
Hypertensive/B-AdverseReaction crisis/I-AdverseReaction was/O reported/O in/O 2/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O none/O of/O the/O patients/O receiving/O sorafenib/O ./O
The/O median/O onset/O time/O for/O hypertension/B-AdverseReaction (/O systolic/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction 150/I-AdverseReaction mmHg/O or/O diastolic/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction 100/I-AdverseReaction mmHg/O )/O was/O within/O the/O first/O month/O of/O the/O start/O of/O INLYTA/O treatment/O and/O blood/B-AdverseReaction pressure/I-AdverseReaction increases/I-AdverseReaction have/O been/O observed/O as/O early/O as/O 4/O days/O after/O starting/O INLYTA/O ./O
Hypertension/B-AdverseReaction was/O managed/O with/O standard/O antihypertensive/O therapy/O ./O
Discontinuation/O of/O INLYTA/O treatment/O due/O to/O hypertension/B-AdverseReaction occurred/O in/O 1/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O none/O of/O the/O patients/O receiving/O sorafenib/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Blood/O pressure/O should/O be/O well/O -/O controlled/O prior/O to/O initiating/O INLYTA/O ./O
Patients/O should/O be/O monitored/O for/O hypertension/O and/O treated/O as/O needed/O with/O standard/O anti/O -/O hypertensive/O therapy/O ./O
In/O the/O case/O of/O persistent/O hypertension/O despite/O use/O of/O anti/O -/O hypertensive/O medications/O ,/O reduce/O the/O INLYTA/O dose/O ./O
Discontinue/O INLYTA/O if/O hypertension/O is/O severe/O and/O persistent/O despite/O anti/O -/O hypertensive/O therapy/O and/O dose/O reduction/O of/O INLYTA/O ,/O and/O discontinuation/O should/O be/O considered/O if/O there/O is/O evidence/O of/O hypertensive/O crisis/O ./O
If/O INLYTA/O is/O interrupted/O ,/O patients/O receiving/O antihypertensive/O medications/O should/O be/O monitored/O for/O hypotension/O [/O seeDosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.2/O Arterial/O Thromboembolic/O Events/O In/O clinical/O trials/O ,/O arterial/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction have/O been/O reported/O ,/O including/O deaths/B-AdverseReaction ./O
In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O Grade/B-Severity 3/4/I-Severity arterial/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction were/O reported/O in/O 4/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O 4/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
Fatal/B-AdverseReaction cerebrovascular/B-AdverseReaction accident/I-AdverseReaction was/O reported/O in/O 1/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O none/O of/O the/O patients/O receiving/O sorafenib/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O clinical/O trials/O with/O INLYTA/O ,/O arterial/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction (/O including/O transient/B-AdverseReaction ischemic/I-AdverseReaction attack/I-AdverseReaction ,/O cerebrovascular/B-AdverseReaction accident/I-AdverseReaction ,/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O and/O retinal/B-AdverseReaction artery/I-AdverseReaction occlusion/I-AdverseReaction )/O were/O reported/O in/O 17/715/O patients/O (/O 2/O %/O )/O ,/O with/O two/O deaths/B-AdverseReaction secondary/O to/O cerebrovascular/B-AdverseReaction accident/I-AdverseReaction ./O
Use/O INLYTA/O with/O caution/O in/O patients/O who/O are/O at/O risk/O for/O ,/O or/O who/O have/O a/O history/O of/O ,/O these/O events/O ./O
INLYTA/O has/O not/O been/O studied/O in/O patients/O who/O had/O an/O arterial/O thromboembolic/O event/O within/O the/O previous/O 12/O months/O ./O
5.3/O Venous/O Thromboembolic/O Events/O In/O clinical/O trials/O ,/O venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction have/O been/O reported/O ,/O including/O deaths/B-AdverseReaction ./O
In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction were/O reported/O in/O 11/359/O patients/O (/O 3/O %/O )/O receiving/O INLYTA/O and/O 2/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
Grade/B-Severity 3/4/I-Severity venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction were/O reported/O in/O 9/359/O patients/O (/O 3/O %/O )/O receiving/O INLYTA/O (/O including/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction ,/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction ,/O retinal/B-AdverseReaction vein/I-AdverseReaction occlusion/I-AdverseReaction and/O retinal/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction )/O and/O 2/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
Fatal/B-AdverseReaction pulmonary/B-AdverseReaction embolism/I-AdverseReaction was/O reported/O in/O 1/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O none/O of/O the/O patients/O receiving/O sorafenib/O ./O
In/O clinical/O trials/O with/O INLYTA/O ,/O venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction were/O reported/O in/O 22/715/O patients/O (/O 3/O %/O )/O ,/O with/O two/O deaths/B-AdverseReaction secondary/O to/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction ./O
Use/O INLYTA/O with/O caution/O in/O patients/O who/O are/O at/O risk/O for/O ,/O or/O who/O have/O a/O history/O of/O ,/O these/O events/O ./O
INLYTA/O has/O not/O been/O studied/O in/O patients/O who/O had/O a/O venous/O thromboembolic/O event/O within/O the/O previous/O 6/O months/O ./O
5.4/O Hemorrhage/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O hemorrhagic/B-AdverseReaction events/I-AdverseReaction were/O reported/O in/O 58/359/O patients/O (/O 16/O %/O )/O receiving/O INLYTA/O and/O 64/355/O patients/O (/O 18/O %/O )/O receiving/O sorafenib/O ./O
Grade/B-Severity 3/4/I-Severity hemorrhagic/B-AdverseReaction events/I-AdverseReaction were/O reported/O in/O 5/359/O (/O 1/O %/O )/O patients/O receiving/O INLYTA/O (/O including/O cerebral/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O hematuria/B-AdverseReaction ,/O hemoptysis/B-AdverseReaction ,/O lower/B-AdverseReaction gastrointestinal/I-AdverseReaction hemorrhage/I-AdverseReaction ,/O and/O melena/B-AdverseReaction )/O and/O 11/355/O (/O 3/O %/O )/O patients/O receiving/O sorafenib/O ./O
Fatal/B-AdverseReaction hemorrhage/B-AdverseReaction was/O reported/O in/O 1/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O (/O gastric/B-AdverseReaction hemorrhage/I-AdverseReaction )/O and/O 3/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
INLYTA/O has/O not/O been/O studied/O in/O patients/O who/O have/O evidence/O of/O untreated/O brain/O metastasis/O or/O recent/O active/O gastrointestinal/O bleeding/O and/O should/O not/O be/O used/O in/O those/O patients/O ./O
If/O any/O bleeding/O requires/O medical/O intervention/O ,/O temporarily/O interrupt/O the/O INLYTA/O dose/O ./O
5.5/O Cardiac/O Failure/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction was/O reported/O in/O 6/359/O patients/O (/O 2/O %/O )/O receiving/O INLYTA/O and/O 3/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
Grade/B-Severity 3/4/I-Severity cardiac/B-AdverseReaction failure/I-AdverseReaction was/O observed/O in/O 2/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O 1/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
Fatal/B-AdverseReaction cardiac/B-AdverseReaction failure/I-AdverseReaction was/O reported/O in/O 2/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O 1/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
Monitor/O for/O signs/O or/O symptoms/O of/O cardiac/O failure/O throughout/O treatment/O with/O INLYTA/O ./O
Management/O of/O cardiac/O failure/O may/O require/O permanent/O discontinuation/O of/O INLYTA/O ./O
5.6/O Gastrointestinal/O Perforation/O and/O Fistula/O Formation/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O gastrointestinal/B-AdverseReaction perforation/I-AdverseReaction was/O reported/O in/O 1/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O none/O of/O the/O patients/O receiving/O sorafenib/O ./O
In/O clinical/O trials/O with/O INLYTA/O ,/O gastrointestinal/B-AdverseReaction perforation/I-AdverseReaction was/O reported/O in/O 5/715/O patients/O (/O 1/O %/O )/O ,/O including/O one/O death/B-AdverseReaction ./O
In/O addition/O to/O cases/O of/O gastrointestinal/B-AdverseReaction perforation/I-AdverseReaction ,/O fistulas/O were/O reported/O in/O 4/715/O patients/O (/O 1/O %/O )/O ./O
Monitor/O for/O symptoms/O of/O gastrointestinal/O perforation/O or/O fistula/O periodically/O throughout/O treatment/O with/O INLYTA/O ./O
5.7/O Thyroid/O Dysfunction/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O hypothyroidism/B-AdverseReaction was/O reported/O in/O 69/359/O patients/O (/O 19/O %/O )/O receiving/O INLYTA/O and/O 29/355/O patients/O (/O 8/O %/O )/O receiving/O sorafenib/O ./O
Hyperthyroidism/B-AdverseReaction was/O reported/O in/O 4/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O 4/355/O patients/O (/O 1/O %/O )/O receiving/O sorafenib/O ./O
In/O patients/O who/O had/O thyroid/O stimulating/O hormone/O (/O TSH/O )/O 5/O muU/O mL/O before/O treatment/O ,/O elevations/B-AdverseReaction of/I-AdverseReaction TSH/I-AdverseReaction to/O 10/I-Severity muU/O mL/O occurred/O in/O 79/245/O patients/O (/O 32/O %/O )/O receiving/O INLYTA/O and/O 25/232/O patients/O (/O 11/O %/O )/O receiving/O sorafenib/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O thyroid/O function/O before/O initiation/O of/O ,/O and/O periodically/O throughout/O ,/O treatment/O with/O INLYTA/O ./O
Treat/O hypothyroidism/O and/O hyperthyroidism/O according/O to/O standard/O medical/O practice/O to/O maintain/O euthyroid/O state/O ./O
5.8/O Wound/O Healing/O Complications/O No/O formal/O studies/O of/O the/O effect/O of/O INLYTA/O on/O wound/O healing/O have/O been/O conducted/O ./O
Stop/O treatment/O with/O INLYTA/O at/O least/O 24/O hours/O prior/O to/O scheduled/O surgery/O ./O
The/O decision/O to/O resume/O INLYTA/O therapy/O after/O surgery/O should/O be/O based/O on/O clinical/O judgment/O of/O adequate/O wound/O healing/O ./O
5.9/O Reversible/O Posterior/O Leukoencephalopathy/O Syndrome/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O reversible/B-AdverseReaction posterior/I-AdverseReaction leukoencephalopathy/I-AdverseReaction syndrome/I-AdverseReaction (/O RPLS/B-AdverseReaction )/O was/O reported/O in/O 1/359/O patients/O (/O 1/O %/O )/O receiving/O INLYTA/O and/O none/O of/O the/O patients/O receiving/O sorafenib/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
There/O were/O two/O additional/O reports/O of/O RPLS/B-AdverseReaction in/O other/O clinical/O trials/O with/O INLYTA/O ./O
RPLS/B-AdverseReaction is/O a/O neurological/O disorder/O which/O can/B-Factor present/O with/O headache/B-AdverseReaction ,/O seizure/B-AdverseReaction ,/O lethargy/B-AdverseReaction ,/O confusion/B-AdverseReaction ,/O blindness/B-AdverseReaction and/O other/O visual/O and/O neurologic/B-AdverseReaction disturbances/I-AdverseReaction ./O
Mild/B-Severity to/I-Severity severe/B-Severity hypertension/B-AdverseReaction may/B-Factor be/O present/O ./O
Magnetic/O resonance/O imaging/O is/O necessary/O to/O confirm/O the/O diagnosis/O of/O RPLS/O ./O
Discontinue/O INLYTA/O in/O patients/O developing/O RPLS/O ./O
The/O safety/O of/O reinitiating/O INLYTA/O therapy/O in/O patients/O previously/O experiencing/O RPLS/O is/O not/O known/O ./O
5.10/O Proteinuria/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O proteinuria/B-AdverseReaction was/O reported/O in/O 39/359/O patients/O (/O 11/O %/O )/O receiving/O INLYTA/O and/O 26/355/O patients/O (/O 7/O %/O )/O receiving/O sorafenib/O ./O
Grade/B-Severity 3/I-Severity proteinuria/B-AdverseReaction was/O reported/O in/O 11/359/O patients/O (/O 3/O %/O )/O receiving/O INLYTA/O and/O 6/355/O patients/O (/O 2/O %/O )/O receiving/O sorafenib/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitoring/O for/O proteinuria/O before/O initiation/O of/O ,/O and/O periodically/O throughout/O ,/O treatment/O with/O INLYTA/O is/O recommended/O ./O
For/O patients/O who/O develop/O moderate/O to/O severe/O proteinuria/O ,/O reduce/O the/O dose/O or/O temporarily/O interrupt/O INLYTA/O treatment/O ./O
5.11/O Elevation/O of/O Liver/O Enzymes/O In/O a/O controlled/O clinical/O study/O with/O INLYTA/O for/O the/O treatment/O of/O patients/O with/O RCC/O ,/O alanine/O aminotransferase/O (/O ALT/O )/O elevations/O of/O all/O grades/O occurred/O in/O 22/O %/O of/O patients/O on/O both/O arms/O ,/O with/O Grade/B-Severity 3/4/I-Severity events/O in/O 1/O %/O of/O patients/O on/O the/O INLYTA/O arm/O and/O 2/O %/O of/O patients/O on/O the/O sorafenib/O arm/O ./O
Monitor/O ALT/O ,/O aspartate/O aminotransferase/O (/O AST/O )/O and/O bilirubin/O before/O initiation/O of/O and/O periodically/O throughout/O treatment/O with/O INLYTA/O ./O
5.12/O Hepatic/O Impairment/O The/O systemic/O exposure/O to/O axitinib/O was/O higher/O in/O subjects/O with/O moderate/O hepatic/O impairment/O (/O Child/O -/O Pugh/O class/O B/O )/O compared/O to/O subjects/O with/O normal/O hepatic/O function/O ./O
A/O dose/O decrease/O is/O recommended/O when/O administering/O INLYTA/O to/O patients/O with/O moderate/O hepatic/O impairment/O (/O Child/O -/O Pugh/O class/O B/O )/O ./O
INLYTA/O has/O not/O been/O studied/O in/O patients/O with/O severe/O hepatic/O impairment/O (/O Child/O -/O Pugh/O class/O C/O )/O [/O seeDosage/O and/O Administration/O (/O 2.2),Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ,/O andClinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.13/O Pregnancy/O INLYTA/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O based/O on/O its/O mechanism/O of/O action/O ./O
There/O are/O no/O adequate/O and/O well/O -/O controlled/O studies/O in/O pregnant/O women/O using/O INLYTA/O ./O
In/O developmental/O toxicity/O studies/O in/O mice/B-Animal ,/O axitinib/O was/O teratogenic/B-AdverseReaction ,/O embryotoxic/B-AdverseReaction and/O fetotoxic/B-AdverseReaction at/O maternal/O exposures/O that/O were/O lower/O than/O human/O exposures/O at/O the/O recommended/O clinical/O dose/O ./O
Women/O of/O childbearing/O potential/O should/O be/O advised/O to/O avoid/O becoming/O pregnant/O while/O receiving/O INLYTA/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O a/O patient/O becomes/O pregnant/O while/O receiving/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O [/O seeUse/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O described/O in/O greater/O detail/O in/O other/O sections/O :/O Severe/B-Severity skin/O and/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O drug/O reactions/O of/O moderate/B-Severity to/I-Severity severe/B-Severity intensity/O (/O at/O least/O 2/O %/O )/O which/O occurred/O at/O a/O higher/O rate/O than/O placebo/O in/O adults/O are/O rash/B-AdverseReaction and/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction ./O
(/O 6.1/O )/O The/O most/O common/O adverse/O drug/O reactions/O in/O at/O least/O 2/O %/O of/O pediatric/O patients/O are/O rash/B-AdverseReaction and/O diarrhea/B-AdverseReaction ./O
(/O 6.2/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Janssen/O Products/O ,/O LP/O at/O 1/O -/O 800-JANSSEN/O (/O 1/O -/O 800/O -/O 526/O -/O 7736/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O :/O Adults/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O safety/O assessment/O is/O based/O on/O all/O data/O from/O 1203/O subjects/O in/O the/O Phase/O 3/O placebo/O -/O controlled/O trials/O ,/O TMC125-C206/O and/O TMC125-C216/O ,/O conducted/O in/O antiretroviral/O treatment/O -/O experienced/O HIV-1-infected/O adult/O subjects/O ,/O 599/O of/O whom/O received/O INTELENCE/O (/O r/O )/O (/O 200/O mg/O twice/O daily/O )/O ./O
In/O these/O pooled/O trials/O ,/O the/O median/O exposure/O for/O subjects/O in/O the/O INTELENCE/O (/O r/O )/O arm/O and/O placebo/O arm/O was/O 52.3/O and/O 51.0/O weeks/O ,/O respectively/O ./O
Discontinuations/O due/O to/O adverse/O drug/O reactions/O (/O ADRs/O )/O were/O 5.2/O %/O in/O the/O INTELENCE/O (/O r/O )/O arm/O and/O 2.6/O %/O in/O the/O placebo/O arm/O ./O
The/O most/O frequently/O reported/O ADR/O at/O least/O Grade/B-Severity 2/I-Severity in/O severity/O was/O rash/B-AdverseReaction (/O 10.0/O %/O )/O ./O
Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O drug/O hypersensitivity/B-AdverseReaction reaction/O and/O erythema/B-AdverseReaction multiforme/I-AdverseReaction were/O reported/O in/O less/O than/O 0.1/O %/O of/O subjects/O during/O clinical/O development/O with/O INTELENCE/O (/O r/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
A/O total/O of/O 2.2/O %/O of/O HIV-1-infected/O subjects/O in/O Phase/O 3/O trials/O receiving/O INTELENCE/O (/O r/O )/O discontinued/O due/O to/O rash/B-AdverseReaction ./O
In/O general/O ,/O in/O clinical/O trials/O ,/O rash/B-AdverseReaction was/O mild/B-Severity to/I-Severity moderate/B-Severity ,/O occurred/O primarily/O in/O the/O second/O week/O of/O therapy/O ,/O and/O was/O infrequent/O after/O Week/O 4/O ./O
Rash/B-AdverseReaction generally/O resolved/O within/O 1/O to/O 2/O weeks/O on/O continued/O therapy/O ./O
The/O incidence/O of/O rash/B-AdverseReaction was/O higher/O in/O women/O compared/O to/O men/O in/O the/O INTELENCE/O (/O r/O )/O arm/O in/O the/O Phase/O 3/O trials/O (/O rash/B-AdverseReaction Grade/B-Severity 2/I-Severity was/O reported/O in/O 9/60/O [/O 15.0/O %/O ]/O women/O versus/O 51/539/O [/O 9.5/O %/O ]/O men/O ;/O discontinuations/O due/O to/O rash/B-AdverseReaction were/O reported/O in/O 3/60/O [/O 5.0/O %/O ]/O women/O versus/O 10/539/O [/O 1.9/O %/O ]/O men/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Patients/O with/O a/O history/O of/O NNRTI/B-DrugClass -/O related/O rash/B-AdverseReaction did/O not/O appear/O to/O be/O at/O increased/O risk/O for/O the/O development/O of/O INTELENCE/O (/O r/O )/O -related/O rash/B-AdverseReaction compared/O to/O patients/O without/O a/O history/O of/O NNRTI/B-DrugClass -/O related/O rash/B-AdverseReaction ./O
Common/O Adverse/O Reactions/O Clinical/O ADRs/O of/O moderate/O intensity/O or/O greater/O (/O greater/O than/O or/O equal/O to/O Grade/O 2/O )/O and/O reported/O in/O at/O least/O 2/O %/O of/O subjects/O treated/O with/O INTELENCE/O (/O r/O )/O and/O occurring/O at/O a/O higher/O rate/O compared/O to/O placebo/O (/O excess/O of/O 1/O %/O )/O are/O presented/O in/O Table/O 1/O ./O
Laboratory/O abnormalities/O considered/O ADRs/O are/O included/O in/O Table/O 2/O ./O
Table/O 1/O :/O Treatment/O -/O Emergent/O Adverse/O ReactionsIncludes/O adverse/O reactions/O at/O least/O possibly/O ,/O probably/O ,/O or/O very/O likely/O related/O to/O the/O drug/O ./O
of/O at/O least/O Moderate/O IntensityIntensities/O are/O defined/O as/O follows/O :/O Moderate/O (/O discomfort/O enough/O to/O cause/O interference/O with/O usual/O activity/O )/O ;/O Severe/O (/O incapacitating/O with/O inability/O to/O work/O or/O do/O usual/O activity/O )/O ./O
(/O Grades/O 2/O to/O 4/O )/O in/O at/O least/O 2/O %/O of/O Adult/O Subjects/O in/O the/O INTELENCE(r/O )/O Treatment/O Groups/O and/O at/O a/O higher/O rate/O compared/O to/O placebo/O (/O excess/O of/O 1/O %/O )/O System/O Organ/O Class/O ,/O Preferred/O Term,%/O Pooled/O TMC125-C206/O and/O TMC125-C216/O Trials/O INTELENCE/O (/O r/O )/O +/O BRN=599/O Placebo/O +/O BRN=604/O N/O total/O number/O of/O subjects/O per/O treatment/O group/O ,/O BR/O background/O regimen/O Nervous/O System/O Disorders/O Peripheral/B-AdverseReaction neuropathy/I-AdverseReaction 4/O %/O 2/O %/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Rash/B-AdverseReaction 10/O %/O 3/O %/O Less/O Common/O Adverse/O Reactions/O Treatment/O -/O emergent/O ADRs/O occurring/O in/O less/O than/O 2/O %/O of/O subjects/O (/O 599/O subjects/O )/O receiving/O INTELENCE/O (/O r/O )/O and/O of/O at/O least/O moderate/O intensity/O (/O greater/O than/O or/O equal/O to/O Grade/O 2/O )/O are/O listed/O below/O by/O body/O system/O :/O Cardiac/O Disorders/O :/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O angina/B-AdverseReaction pectoris/I-AdverseReaction ,/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction Ear/O and/O Labyrinth/O Disorders/O :/O vertigo/B-AdverseReaction Eye/O Disorders/O :/O blurred/B-AdverseReaction vision/I-AdverseReaction Gastrointestinal/O Disorders/O :/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction ,/O flatulence/B-AdverseReaction ,/O gastritis/B-AdverseReaction ,/O abdominal/B-AdverseReaction distension/I-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O hematemesis/B-AdverseReaction ,/O retching/B-AdverseReaction ,/O stomatitis/B-AdverseReaction General/O Disorders/O and/O Administration/O Site/O Conditions/O :/O sluggishness/B-AdverseReaction Hematologic/O Disorders/O :/O hemolytic/B-AdverseReaction anemia/I-AdverseReaction Hepatobiliary/O Disorders/O :/O hepatic/B-AdverseReaction failure/I-AdverseReaction ,/O hepatomegaly/B-AdverseReaction ,/O cytolytic/B-AdverseReaction hepatitis/I-AdverseReaction ,/O hepatic/B-AdverseReaction steatosis/I-AdverseReaction ,/O hepatitis/B-AdverseReaction Immune/O System/O Disorders/O :/O drug/B-AdverseReaction hypersensitivity/I-AdverseReaction ,/O immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction Metabolism/O and/O Nutrition/O Disorders/O :/O diabetes/B-AdverseReaction mellitus/I-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O dyslipidemia/B-AdverseReaction Nervous/O System/O Disorders/O :/O paraesthesia/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O convulsion/B-AdverseReaction ,/O hypoesthesia/B-AdverseReaction ,/O amnesia/B-AdverseReaction ,/O syncope/B-AdverseReaction ,/O disturbance/B-AdverseReaction in/I-AdverseReaction attention/I-AdverseReaction ,/O hypersomnia/B-AdverseReaction ,/O tremor/B-AdverseReaction Psychiatric/O Disorders/O :/O anxiety/B-AdverseReaction ,/O sleep/B-AdverseReaction disorders/I-AdverseReaction ,/O abnormal/B-AdverseReaction dreams/I-AdverseReaction ,/O confusional/B-AdverseReaction state/I-AdverseReaction ,/O disorientation/B-AdverseReaction ,/O nervousness/B-AdverseReaction ,/O nightmares/B-AdverseReaction Renal/O and/O Urinary/O Disorders/O :/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction Reproductive/O System/O and/O Breast/O Disorders/O :/O gynecomastia/B-AdverseReaction Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O :/O exertional/B-AdverseReaction dyspnea/I-AdverseReaction ,/O bronchospasm/B-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O night/B-AdverseReaction sweats/I-AdverseReaction ,/O lipohypertrophy/B-AdverseReaction ,/O prurigo/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O dry/B-AdverseReaction skin/I-AdverseReaction ,/O swelling/B-AdverseReaction face/I-AdverseReaction Additional/O ADRs/O of/O at/O least/O moderate/O intensity/O observed/O in/O other/O trials/O were/O acquired/B-AdverseReaction lipodystrophy/I-AdverseReaction ,/O angioneurotic/B-AdverseReaction edema/I-AdverseReaction ,/O erythema/B-AdverseReaction multiforme/I-AdverseReaction and/O haemorrhagic/B-AdverseReaction stroke/I-AdverseReaction ,/O each/O reported/O in/O no/O more/O than/O 0.5/O %/O of/O subjects/O ./O
Laboratory/O Abnormalities/O in/O Treatment/O -/O Experienced/O Patients/O Selected/O Grade/O 2/O to/O Grade/O 4/O laboratory/O abnormalities/O that/O represent/O a/O worsening/O from/O baseline/O observed/O in/O adult/O subjects/O treated/O with/O INTELENCE/O (/O r/O )/O are/O presented/O in/O Table/O 2/O ./O
Table/O 2/O :/O Selected/O Grade/O 2/O to/O 4/O Laboratory/O Abnormalities/O Observed/O in/O Treatment/O -/O Experienced/O Subjects/O Pooled/O TMC125-C206/O and/O TMC125-C216/O Trials/O Laboratory/O ParameterPreferred/O Term,%/O DAIDS/O Toxicity/O Range/O INTELENCE/O (/O r/O )/O +/O BRN=599/O Placebo/O +/O BRN=604/O ULN/O Upper/O Limit/O of/O Normal/O ,/O BR/O background/O regimen/O GENERAL/O BIOCHEMISTRY/O Pancreatic/O amylase/O Grade/O 2/O 1.5/O -/O 2/O ULN/O 7/O %/O 8/O %/O Grade/O 3/O 2/O -/O 5/O ULN/O 7/O %/O 8/O %/O Grade/O 4/O 5/O ULN/O 2/O %/O 1/O %/O Lipase/O Grade/O 2/O 1.5/O -/O 3/O ULN/O 4/O %/O 6/O %/O Grade/O 3/O 3/O -/O 5/O ULN/O 2/O %/O 2/O %/O Grade/O 4/O 5*ULN/O 1/O %/O 1/O %/O Creatinine/O Grade/O 2/O 1.4/O -/O 1.8/O ULN/O 6/O %/O 5/O %/O Grade/O 3/O 1.9/O -/O 3.4/O ULN/O 2/O %/O 1/O %/O Grade/O 4/O 3.4/O ULN/O 0/O %/O 1/O %/O HEMATOLOGY/O Decreased/B-AdverseReaction hemoglobin/I-AdverseReaction Grade/O 2/O 90/O -/O 99/O g/O L/O 2/O %/O 4/O %/O Grade/O 3/O 70/O -/O 89/O g/O L/O 1/O %/O 1/O %/O Grade/O 4/O 70/O g/O L/O 1/O %/O 1/O %/O White/O blood/O cell/O count/O Grade/O 2/O 1,500/O -/O 1,999/O mm/O 3/O 2/O %/O 3/O %/O Grade/O 3/O 1,000/O -/O 1,499/O mm/O 3/O 1/O %/O 4/O %/O Grade/O 4/O 1,000/O mm/O 3/O 1/O %/O 1/O %/O Neutrophils/O Grade/O 2/O 750/O -/O 999/O mm/O 3/O 5/O %/O 6/O %/O Grade/O 3/O 500/O -/O 749/O mm/O 3/O 4/O %/O 4/O %/O Grade/O 4/O 500/O mm/O 3/O 2/O %/O 3/O %/O Platelet/O count/O Grade/O 2/O 50,000/O -/O 99,999/O mm/O 3/O 3/O %/O 5/O %/O Grade/O 3/O 25,000/O -/O 49,999/O mm/O 3/O 1/O %/O 1/O %/O Grade/O 4/O 25,000/O mm/O 3/O 1/O %/O 1/O %/O LIPIDS/O AND/O GLUCOSE/O Total/O cholesterol/O Grade/O 2/O 6.20/O -/O 7.77/O mmol/O L240/O -/O 300/O mg/O dL/O 20/O %/O 17/O %/O Grade/O 3/O 7.77/O mmol/O L/O 300/O mg/O dL/O 8/O %/O 5/O %/O Low/O density/O lipoprotein/O Grade/O 2/O 4.13/O -/O 4.9/O mmol/O L160/O -/O 190/O mg/O dL/O 13/O %/O 12/O %/O Grade/O 3/O 4.9/O mmol/O L/O 190/O mg/O dL/O 7/O %/O 7/O %/O Triglycerides/O Grade/O 2/O 5.65/O -/O 8.48/O mmol/O L500/O -750/O mg/O dL/O 9/O %/O 7/O %/O Grade/O 3/O 8.49/O -/O 13.56/O mmol/O L751/O -/O 1200/O mg/O dL/O 6/O %/O 4/O %/O Grade/O 4/O 13.56/O mmol/O L/O 1200/O mg/O dL/O 4/O %/O 2/O %/O Elevated/B-AdverseReaction glucose/I-AdverseReaction levels/I-AdverseReaction Grade/O 2/O 6.95/O -/O 13.88/O mmol/O L161/O -/O 250/O mg/O dL/O 15/O %/O 13/O %/O Grade/O 3/O 13.89/O -/O 27.75/O mmol/O L251/O -/O 500/O mg/O dL/O 4/O %/O 2/O %/O Grade/O 4/O 27.75/O mmol/O L/O 500/O mg/O dL/O 0/O %/O 1/O %/O HEPATIC/O PARAMETERS/O Alanine/O amino/O transferase/O Grade/O 2/O 2.6/O -/O 5/O ULN/O 6/O %/O 5/O %/O Grade/O 3/O 5.1/O -/O 10/O ULN/O 3/O %/O 2/O %/O Grade/O 4/O 10/O ULN/O 1/O %/O 1/O %/O Aspartate/O amino/O transferase/O Grade/O 2/O 2.6/O -/O 5/O ULN/O 6/O %/O 8/O %/O Grade/O 3/O 5.1/O -/O 10/O ULN/O 3/O %/O 2/O %/O Grade/O 4/O 10/O ULN/O 1/O %/O 1/O %/O Patients/O co/O -/O infected/O with/O hepatitis/O B/O and/or/O hepatitis/O C/O virus/O In/O Phase/O 3/O trials/O TMC125-C206/O and/O TMC125-C216/O ,/O 139/O subjects/O (/O 12.3/O %/O )/O with/O chronic/O hepatitis/O B/O and/or/O hepatitis/O C/O virus/O co/O -/O infection/O out/O of/O 1129/O subjects/O were/O permitted/O to/O enroll/O ./O
AST/O and/O ALT/B-AdverseReaction abnormalities/I-AdverseReaction occurred/O more/O frequently/O in/O hepatitis/O B/O and/or/O hepatitis/O C/O virus/O co/O -/O infected/O subjects/O for/O both/O treatment/O groups/O ./O
Grade/B-Severity 2/I-Severity or/O higher/O laboratory/O abnormalities/O that/O represent/O a/O worsening/O from/O baseline/O of/O AST/O ,/O ALT/O or/O total/O bilirubin/O occurred/O in/O 27.8/O %/O ,/O 25.0/O %/O and/O 7.1/O %/O respectively/O ,/O of/O INTELENCE/O (/O r/O )/O -treated/O co/O -/O infected/O subjects/O as/O compared/O to/O 6.7/O %/O ,/O 7.5/O %/O and/O 1.8/O %/O of/O non/O -/O co/O -/O infected/O INTELENCE/O (/O r/O )/O -treated/O subjects/O ./O
In/O general/O ,/O adverse/O events/O reported/O by/O INTELENCE/O (/O r/O )/O -treated/O subjects/O with/O hepatitis/O B/O and/or/O hepatitis/O C/O virus/O co/O -/O infection/O were/O similar/O to/O INTELENCE/O (/O r/O )/O -treated/O subjects/O without/O hepatitis/O B/O and/or/O hepatitis/O C/O virus/O co/O -/O infection/O ./O
6.2/O Clinical/O Trials/O Experience/O :/O Pediatric/O Subjects/O (/O 6/O years/O to/O less/O than/O 18/O years/O of/O age/O )/O The/O safety/O assessment/O in/O children/O and/O adolescents/O is/O based/O on/O the/O Week/O 24/O analysis/O of/O the/O single/O -/O arm/O ,/O Phase/O 2/O trial/O TMC125-C213/O in/O which/O 101/O antiretroviral/O treatment/O -/O experienced/O HIV-1/O infected/O subjects/O 6/O years/O to/O less/O than/O 18/O years/O of/O age/O and/O weighing/O at/O least/O 16/O kg/O received/O INTELENCE/O (/O r/O )/O in/O combination/O with/O other/O antiretroviral/O agents/O [/O see/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ./O
The/O frequency/O ,/O type/O and/O severity/O of/O adverse/O drug/O reactions/O in/O pediatric/O subjects/O were/O comparable/O to/O those/O observed/O in/O adult/O subjects/O ,/O except/O for/O rash/B-AdverseReaction which/O was/O observed/O more/O frequently/O in/O pediatric/O subjects/O ./O
The/O most/O common/O adverse/O drug/O reactions/O in/O at/O least/O 2/O %/O of/O pediatric/O subjects/O were/O rash/B-AdverseReaction and/O diarrhea/B-AdverseReaction ./O
Rash/B-AdverseReaction was/O reported/O more/O frequently/O in/O female/O subjects/O than/O in/O male/O subjects/O (/O rash/B-AdverseReaction Grade/B-Severity 2/I-Severity was/O reported/O in/O 13/64/O [/O 20.3/O %/O ]/O females/O versus/O 2/37/O [/O 5.4/O %/O ]/O males/O ;/O discontinuations/O due/O to/O rash/B-AdverseReaction were/O reported/O in/O 4/64/O [/O 6.3/O %/O ]/O females/O versus/O 0/37/O [/O 0/O %/O ]/O males/O )/O ./O
Rash/B-AdverseReaction (/O greater/O than/O or/O equal/O to/O Grade/B-Severity 2/I-Severity )/O occurred/O in/O 15/O %/O of/O pediatric/O subjects/O ./O
In/O the/O majority/O of/O cases/O ,/O rash/B-AdverseReaction was/O mild/B-Severity to/I-Severity moderate/B-Severity ,/O of/O macular/O papular/O type/O ,/O and/O occurred/O in/O the/O second/O week/O of/O therapy/O ./O
Rash/B-AdverseReaction was/O self/O -/O limiting/O and/O generally/O resolved/O within/O 1/O week/O on/O continued/O therapy/O ./O
The/O safety/O profile/O for/O subjects/O who/O completed/O 48/O weeks/O of/O treatment/O was/O similar/O to/O the/O safety/O profile/O for/O subjects/O who/O completed/O 24/O weeks/O of/O treatment/O ./O
6.3/O Postmarketing/O Experience/O The/O following/O events/O have/O been/O identified/O during/O postmarketing/O use/O of/O INTELENCE/O (/O r/O )/O ./O
Because/O these/O events/O are/O reported/O voluntarily/O from/O a/O population/O of/O unknown/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Immune/O System/O Disorders/O :/O Severe/B-Severity hypersensitivity/B-AdverseReaction reactions/O including/O DRESS/B-AdverseReaction and/O cases/O of/O hepatic/B-AdverseReaction failure/I-AdverseReaction have/O been/O reported/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O rhabdomyolysis/B-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O Fatal/B-AdverseReaction cases/O of/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction have/O been/O reported/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Severe/B-Severity ,/O potentially/O life/B-Severity threatening/I-Severity and/O fatal/B-AdverseReaction skin/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O ./O
This/O includes/O cases/O of/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O hypersensitivity/B-AdverseReaction reaction/I-AdverseReaction ,/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction and/O erythema/B-AdverseReaction multiforme/I-AdverseReaction ./O
Immediately/O discontinue/O treatment/O if/O severe/O hypersensitivity/O ,/O severe/O rash/O or/O rash/O with/O systemic/O symptoms/O or/O liver/O transaminase/O elevations/O develops/O and/O monitor/O clinical/O status/O ,/O including/O liver/O transaminases/O closely/O ./O
(/O 5.1/O )/O 5.1/O Severe/O Skin/O and/O Hypersensitivity/O Reactions/O Severe/B-Severity ,/O potentially/B-Factor life/B-Severity -/O threatening/O ,/O and/O fatal/B-AdverseReaction skin/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O ./O
These/O include/O cases/O of/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction and/O erythema/B-AdverseReaction multiforme/I-AdverseReaction ./O
Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction including/O Drug/B-AdverseReaction Rash/I-AdverseReaction with/I-AdverseReaction Eosinophilia/I-AdverseReaction and/I-AdverseReaction Systemic/I-AdverseReaction Symptoms/I-AdverseReaction (/O DRESS/B-AdverseReaction )/O have/O also/O been/O reported/O and/O were/O characterized/O by/O rash/B-AdverseReaction ,/O constitutional/O findings/O ,/O and/O sometimes/O organ/B-AdverseReaction dysfunction/I-AdverseReaction ,/O including/O hepatic/B-AdverseReaction failure/I-AdverseReaction ./O
In/O Phase/O 3/O clinical/O trials/O ,/O Grade/B-Severity 3/I-Severity and/O 4/O rashes/B-AdverseReaction were/O reported/O in/O 1.3/O %/O of/O subjects/O receiving/O INTELENCE/O (/O r/O )/O compared/O to/O 0.2/O %/O of/O placebo/O subjects/O ./O
A/O total/O of/O 2.2/O %/O of/O HIV-1-infected/O subjects/O receiving/O INTELENCE/O (/O r/O )/O discontinued/O from/O Phase/O 3/O trials/O due/O to/O rash/B-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Rash/B-AdverseReaction occurred/O most/O commonly/O during/O the/O first/O 6/O weeks/O of/O therapy/O ./O
The/O incidence/O of/O rash/B-AdverseReaction was/O higher/O in/O females/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O Discontinue/O INTELENCE/O (/O r/O )/O immediately/O if/O signs/O or/O symptoms/O of/O severe/O skin/O reactions/O or/O hypersensitivity/O reactions/O develop/O (/O including/O ,/O but/O not/O limited/O to/O ,/O severe/O rash/O or/O rash/O accompanied/O by/O fever/O ,/O general/O malaise/O ,/O fatigue/O ,/O muscle/O or/O joint/O aches/O ,/O blisters/O ,/O oral/O lesions/O ,/O conjunctivitis/O ,/O facial/O edema/O ,/O hepatitis/O ,/O eosinophilia/O ,/O angioedema/O )/O ./O
Clinical/O status/O including/O liver/O transaminases/O should/O be/O monitored/O and/O appropriate/O therapy/O initiated/O ./O
Delay/O in/O stopping/O INTELENCE/O (/O r/O )/O treatment/O after/O the/O onset/O of/O severe/O rash/O may/O result/O in/O a/O life/O -/O threatening/O reaction/O ./O
5.2/O Fat/O Redistribution/O Redistribution/O accumulation/B-AdverseReaction of/I-AdverseReaction body/I-AdverseReaction fat/I-AdverseReaction ,/O including/O central/B-AdverseReaction obesity/I-AdverseReaction ,/O dorsocervical/B-AdverseReaction fat/I-AdverseReaction enlargement/I-AdverseReaction (/O buffalo/B-AdverseReaction hump/I-AdverseReaction )/O ,/O peripheral/O wasting/O ,/O facial/B-AdverseReaction wasting/I-AdverseReaction ,/O breast/B-AdverseReaction enlargement/I-AdverseReaction ,/O and/O "/O cushingoid/B-AdverseReaction appearance/I-AdverseReaction "/O have/O been/O observed/O in/O patients/O receiving/O antiretroviral/O therapy/O ./O
The/O mechanism/O and/O long/O -/O term/O consequences/O of/O these/O events/O are/O currently/O unknown/O ./O
A/O causal/O relationship/O has/O not/O been/O established/O ./O
5.3/O Immune/O Reconstitution/O Syndrome/O Immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction has/O been/O reported/O in/O patients/O treated/O with/O combination/O antiretroviral/B-DrugClass therapy/O ,/O including/O INTELENCE/O (/O r/O )/O ./O
During/O the/O initial/O phase/O of/O combination/O antiretroviral/O treatment/O ,/O patients/O whose/O immune/O system/O responds/O may/O develop/O an/O inflammatory/B-AdverseReaction response/I-AdverseReaction to/O indolent/O or/O residual/O opportunistic/B-AdverseReaction infections/I-AdverseReaction (/O such/O as/O Mycobacterium/B-AdverseReaction avium/I-AdverseReaction infection/O ,/O cytomegalovirus/B-AdverseReaction ,/O Pneumocystis/B-AdverseReaction jiroveci/I-AdverseReaction pneumonia/O (/O PCP/B-AdverseReaction )/O or/O tuberculosis/B-AdverseReaction )/O ,/O which/O may/O necessitate/O further/O evaluation/O and/O treatment/O ./O
Autoimmune/B-AdverseReaction disorders/I-AdverseReaction (/O such/O as/O Graves/B-AdverseReaction '/I-AdverseReaction disease/O ,/O polymyositis/B-AdverseReaction ,/O and/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O )/O have/O also/O been/O reported/O to/O occur/O in/O the/O setting/O of/O immune/O reconstitution/O ;/O however/O ,/O the/O time/O to/O onset/O is/O more/O variable/O ,/O and/O can/O occur/O many/O months/O after/O initiation/O of/O treatment/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O important/O adverse/O reactions/O are/O described/O below/O and/O elsewhere/O in/O the/O labeling/O :/O Hypotension/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Impairment/B-AdverseReaction in/I-AdverseReaction Renal/I-AdverseReaction Function/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hyperkalemia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Hypoglycemia/B-AdverseReaction with/O Concomitant/O Use/O with/O Insulin/O and/O Insulin/O Secretagogues/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Genital/B-AdverseReaction Mycotic/I-AdverseReaction Infections/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Bone/B-AdverseReaction Fracture/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Increases/B-AdverseReaction in/I-AdverseReaction Low/I-AdverseReaction -/I-AdverseReaction Density/O Lipoprotein/O (/O LDL/O -/O C/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Most/O common/O adverse/O reactions/O associated/O with/O INVOKANA/O (/O 5/O %/O or/O greater/O incidence/O )/O :/O female/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O and/O increased/B-AdverseReaction urination/I-AdverseReaction (/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Janssen/O Pharmaceuticals/O ,/O Inc./O at/O 1/O -/O 800/O -/O 526/O -/O 7736/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Studies/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O the/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Pool/O of/O Placebo/O -/O Controlled/O Trials/O The/O data/O in/O Table/O 1/O is/O derived/O from/O four/O 26-week/O placebo/O -/O controlled/O trials/O ./O
In/O one/O trial/O INVOKANA/O was/O used/O as/O monotherapy/O and/O in/O three/O trials/O INVOKANA/O was/O used/O as/O add/O -/O on/O therapy/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
These/O data/O reflect/O exposure/O of/O 1667/O patients/O to/O INVOKANA/O and/O a/O mean/O duration/O of/O exposure/O to/O INVOKANA/O of/O 24/O weeks/O ./O
Patients/O received/O INVOKANA/O 100/O mg/O (/O N=833/O )/O ,/O INVOKANA/O 300/O mg/O (/O N=834/O )/O or/O placebo/O (/O N=646/O )/O once/O daily/O ./O
The/O mean/O age/O of/O the/O population/O was/O 56/O years/O and/O 2/O %/O were/O older/O than/O 75/O years/O of/O age/O ./O
Fifty/O percent/O (/O 50/O %/O )/O of/O the/O population/O was/O male/O and/O 72/O %/O were/O Caucasian/O ,/O 12/O %/O were/O Asian/O ,/O and/O 5/O %/O were/O Black/O or/O African/O American/O ./O
At/O baseline/O the/O population/O had/O diabetes/O for/O an/O average/O of/O 7.3/O years/O ,/O had/O a/O mean/O HbA1C/O of/O 8.0/O %/O and/O 20/O %/O had/O established/O microvascular/O complications/O of/O diabetes/O ./O
Baseline/O renal/O function/O was/O normal/O or/O mildly/O impaired/O (/O mean/O eGFR/O 88/O mL/O min/1.73/O m/O 2/O )/O ./O
Table/O 1/O shows/O common/O adverse/O reactions/O associated/O with/O the/O use/O of/O INVOKANA/O ./O
These/O adverse/O reactions/O were/O not/O present/O at/O baseline/O ,/O occurred/O more/O commonly/O on/O INVOKANA/O than/O on/O placebo/O ,/O and/O occurred/O in/O at/O least/O 2/O %/O of/O patients/O treated/O with/O either/O INVOKANA/O 100/O mg/O or/O INVOKANA/O 300/O mg/O ./O
Table/O 1/O :/O Adverse/O Reactions/O From/O Pool/O of/O Four/O 26-Week/O Placebo/O -/O Controlled/O Studies/O Reported/O in/O 2/O %/O of/O INVOKANA/O -/O Treated/O PatientsThe/O four/O placebo/O -/O controlled/O trials/O included/O one/O monotherapy/O trial/O and/O three/O add/O -/O on/O combination/O trials/O with/O metformin/O ,/O metformin/O and/O sulfonylurea/O ,/O or/O metformin/O and/O pioglitazone/O ./O
Adverse/O Reaction/O PlaceboN=646/O INVOKANA/O 100/O mgN=833/O INVOKANA/O 300/O mgN=834/O Female/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction 3.2/O %/O 10.4/O %/O 11.4/O %/O Urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction 4.0/O %/O 5.9/O %/O 4.3/O %/O Increased/B-AdverseReaction urination/I-AdverseReaction 0.8/O %/O 5.3/O %/O 4.6/O %/O Male/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction 0.6/O %/O 4.2/O %/O 3.7/O %/O Vulvovaginal/B-AdverseReaction pruritus/I-AdverseReaction 0.0/O %/O 1.6/O %/O 3.0/O %/O Thirst/B-AdverseReaction 0.2/O %/O 2.8/O %/O 2.3/O %/O Constipation/B-AdverseReaction 0.9/O %/O 1.8/O %/O 2.3/O %/O Nausea/B-AdverseReaction 1.5/O %/O 2.2/O %/O 2.3/O %/O Abdominal/B-AdverseReaction pain/I-AdverseReaction was/O also/O more/O commonly/O reported/O in/O patients/O taking/O INVOKANA/O 100/O mg/O (/O 1.8/O %/O )/O ,/O 300/O mg/O (/O 1.7/O %/O )/O than/O in/O patients/O taking/O placebo/O (/O 0.8/O %/O )/O ./O
Pool/O of/O Placebo-/O and/O Active/O -/O Controlled/O Trials/O The/O occurrence/O of/O adverse/O reactions/O for/O canagliflozin/O was/O evaluated/O in/O a/O larger/O pool/O of/O patients/O participating/O in/O placebo-/O and/O active/O -/O controlled/O trials/O ./O
The/O data/O combined/O eight/O clinical/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O and/O reflect/O exposure/O of/O 6177/O patients/O to/O INVOKANA/O ./O
The/O mean/O duration/O of/O exposure/O to/O INVOKANA/O was/O 38/O weeks/O with/O 1832/O individuals/O exposed/O to/O INVOKANA/O for/O greater/O than/O 50/O weeks/O ./O
Patients/O received/O INVOKANA/O 100/O mg/O (/O N=3092/O )/O ,/O INVOKANA/O 300/O mg/O (/O N=3085/O )/O or/O comparator/O (/O N=3262/O )/O once/O daily/O ./O
The/O mean/O age/O of/O the/O population/O was/O 60/O years/O and/O 5/O %/O were/O older/O than/O 75/O years/O of/O age/O ./O
Fifty/O -/O eight/O percent/O (/O 58/O %/O )/O of/O the/O population/O was/O male/O and/O 73/O %/O were/O Caucasian/O ,/O 16/O %/O were/O Asian/O ,/O and/O 4/O %/O were/O Black/O or/O African/O American/O ./O
At/O baseline/O ,/O the/O population/O had/O diabetes/O for/O an/O average/O of/O 11/O years/O ,/O had/O a/O mean/O HbA1C/O of/O 8.0/O %/O and/O 33/O %/O had/O established/O microvascular/O complications/O of/O diabetes/O ./O
Baseline/O renal/O function/O was/O normal/O or/O mildly/O impaired/O (/O mean/O eGFR/O 81/O mL/O min/1.73/O m/O 2/O )/O ./O
The/O types/O and/O frequency/O of/O common/O adverse/O reactions/O observed/O in/O the/O pool/O of/O eight/O clinical/O trials/O were/O consistent/O with/O those/O listed/O in/O Table/O 1/O ./O
In/O this/O pool/O ,/O INVOKANA/O was/O also/O associated/O with/O the/O adverse/O reactions/O of/O fatigue/B-AdverseReaction (/O 1.7/O %/O with/O comparator/O ,/O 2.2/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 2.0/O %/O with/O INVOKANA/O 300/O mg/O )/O and/O loss/B-AdverseReaction of/I-AdverseReaction strength/I-AdverseReaction or/O energy/O (/O i.e./O ,/O asthenia/B-AdverseReaction )/O (/O 0.6/O %/O with/O comparator/O ,/O 0.7/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 1.1/O %/O with/O INVOKANA/O 300/O mg/O )/O ./O
In/O the/O pool/O of/O eight/O clinical/O trials/O ,/O the/O incidence/O rate/O of/O pancreatitis/O (/O acute/O or/O chronic/O )/O was/O 0.9/O ,/O 2.7/O ,/O and/O 0.9/O per/O 1000/O patient/O -/O years/O of/O exposure/O to/O comparator/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
In/O the/O pool/O of/O eight/O clinical/O trials/O ,/O hypersensitivity/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O (/O including/O erythema/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O and/O angioedema/B-AdverseReaction )/O occurred/O in/O 3.0/O %/O ,/O 3.8/O %/O ,/O and/O 4.2/O %/O of/O patients/O receiving/O comparator/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
Five/O patients/O experienced/O serious/B-Severity adverse/O reactions/O of/O hypersensitivity/B-AdverseReaction with/O INVOKANA/O ,/O which/O included/O 4/O patients/O with/O urticaria/B-AdverseReaction and/O 1/O patient/O with/O a/O diffuse/B-AdverseReaction rash/I-AdverseReaction and/O urticaria/B-AdverseReaction occurring/O within/O hours/O of/O exposure/O to/O INVOKANA/O ./O
Among/O these/O patients/O ,/O 2/O patients/O discontinued/O INVOKANA/O ./O
One/O patient/O with/O urticaria/B-AdverseReaction had/O recurrence/O when/O INVOKANA/O was/O re/O -/O initiated/O ./O
Photosensitivity/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O (/O including/O photosensitivity/B-AdverseReaction reaction/I-AdverseReaction ,/O polymorphic/B-AdverseReaction light/I-AdverseReaction eruption/I-AdverseReaction ,/O and/O sunburn/B-AdverseReaction )/O occurred/O in/O 0.1/O %/O ,/O 0.2/O %/O ,/O and/O 0.2/O %/O of/O patients/O receiving/O comparator/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
Other/O adverse/O reactions/O occurring/O more/O frequently/O on/O INVOKANA/O than/O on/O comparator/O were/O :/O Volume/O Depletion/O -/O Related/O Adverse/O Reactions/O INVOKANA/O results/O in/O an/O osmotic/B-AdverseReaction diuresis/I-AdverseReaction ,/O which/O may/B-Factor lead/O to/O reductions/B-AdverseReaction in/I-AdverseReaction intravascular/I-AdverseReaction volume/I-AdverseReaction ./O
In/O clinical/O studies/O ,/O treatment/O with/O INVOKANA/O was/O associated/O with/O a/O dose/O -/O dependent/O increase/O in/O the/O incidence/O of/O volume/B-AdverseReaction depletion/I-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O (/O e.g./O ,/O hypotension/B-AdverseReaction ,/O postural/B-AdverseReaction dizziness/I-AdverseReaction ,/O orthostatic/B-AdverseReaction hypotension/I-AdverseReaction ,/O syncope/B-AdverseReaction ,/O and/O dehydration/B-AdverseReaction )/O ./O
An/O increased/O incidence/O was/O observed/O in/O patients/O on/O the/O 300/O mg/O dose/O ./O
The/O three/O factors/O associated/O with/O the/O largest/O increase/O in/O volume/B-AdverseReaction depletion/I-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O were/O the/O use/O of/O loop/O diuretics/O ,/O moderate/O renal/O impairment/O (/O eGFR/O 30/O to/O less/O than/O 60/O mL/O min/1.73/O m/O 2/O )/O ,/O and/O age/O 75/O years/O and/O older/O (/O Table/O 2/O )/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O and/O Use/O in/O Specific/O Populations/O (/O 8.5/O and/O 8.6/O )/O ]/O ./O
Table/O 2/O :/O Proportion/O of/O Patients/O With/O at/O Least/O One/O Volume/B-AdverseReaction Depletion/I-AdverseReaction -/I-AdverseReaction Related/I-AdverseReaction Adverse/O Reaction/O (/O Pooled/O Results/O from/O 8/O Clinical/O Trials/O )/O Baseline/O Characteristic/O Comparator/O Group%/O INVOKANA/O 100/O mg%/O INVOKANA/O 300/O mg%/O Overall/O population/O 1.5/O %/O 2.3/O %/O 3.4/O %/O 75/O years/O of/O age/O and/O older/O 2.6/O %/O 4.9/O %/O 8.7/O %/O eGFR/B-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 60/I-AdverseReaction mL/I-AdverseReaction min/1.73/I-AdverseReaction m/O 2/O 2.5/O %/O 4.7/O %/O 8.1/O %/O Use/O of/O loop/O diuretic/O 4.7/O %/O 3.2/O %/O 8.8/O %/O Falls/O In/O a/O pool/O of/O nine/O clinical/O trials/O with/O mean/O duration/O of/O exposure/O to/O INVOKANA/O of/O 85/O weeks/O ,/O the/O proportion/O of/O patients/O who/O experienced/O falls/B-AdverseReaction was/O 1.3/O %/O ,/O 1.5/O %/O ,/O and/O 2.1/O %/O with/O comparator/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
The/O higher/O risk/B-Factor of/O falls/B-AdverseReaction for/O patients/O treated/O with/O INVOKANA/O was/O observed/O within/O the/O first/O few/O weeks/O of/O treatment/O ./O
Impairment/O in/O Renal/O Function/O INVOKANA/O is/O associated/O with/O a/O dose/O -/O dependent/O increase/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O a/O concomitant/O fall/B-AdverseReaction in/I-AdverseReaction estimated/I-AdverseReaction GFR/I-AdverseReaction (/O Table/O 3/O )/O ./O
Patients/O with/O moderate/O renal/O impairment/O at/O baseline/O had/O larger/O mean/O changes/O ./O
Table/O 3/O :/O Changes/B-AdverseReaction in/I-AdverseReaction Serum/I-AdverseReaction Creatinine/I-AdverseReaction and/O eGFR/O Associated/O with/O INVOKANA/O in/O the/O Pool/O of/O Four/O Placebo/O -/O Controlled/O Trials/O and/O Moderate/O Renal/O Impairment/O Trial/O PlaceboN=646/O INVOKANA/O 100/O mgN=833/O INVOKANA/O 300/O mgN=834/O Pool/O of/O Four/O Placebo/O -/O Controlled/O Trials/O Baseline/O Creatinine/O (/O mg/O dL/O )/O 0.84/O 0.82/O 0.82/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O 87.0/O 88.3/O 88.8/O Week/O 6/O Change/O Creatinine/O (/O mg/O dL/O )/O 0.01/O 0.03/O 0.05/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O -1.6/O -3.8/O -5.0/O End/O of/O Treatment/O Change/O Creatinine/O (/O mg/O dL/O )/O 0.01/O 0.02/O 0.03/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O -1.6/O -2.3/O -3.4/O PlaceboN=90/O INVOKANA/O 100/O mgN=90/O INVOKANA/O 300/O mgN=89/O Moderate/O Renal/O Impairment/O Trial/O Baseline/O Creatinine/O (/O mg/O dL/O )/O 1.61/O 1.62/O 1.63/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O 40.1/O 39.7/O 38.5/O Week/O 3/O Change/O Creatinine/O (/O mg/O dL/O )/O 0.03/O 0.18/O 0.28/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O -0.7/O -4.6/O -6.2/O End/O of/O Treatment/O Change/O Creatinine/O (/O mg/O dL/O )/O 0.07/O 0.16/O 0.18/O eGFR/O (/O mL/O min/1.73/O m/O 2/O )/O -1.5/O -3.6/O -4.0/O In/O the/O pool/O of/O four/O placebo/O -/O controlled/O trials/O where/O patients/O had/O normal/O or/O mildly/O impaired/O baseline/O renal/O function/O ,/O the/O proportion/O of/O patients/O who/O experienced/O at/O least/O one/O event/O of/O significant/B-Severity renal/B-AdverseReaction function/I-AdverseReaction decline/I-AdverseReaction ,/O defined/O as/O an/O eGFR/B-AdverseReaction below/I-AdverseReaction 80/I-AdverseReaction mL/I-AdverseReaction min/1.73/I-AdverseReaction m/O 2/O and/O 30/O %/O lower/O than/O baseline/O ,/O was/O 2.1/O %/O with/O placebo/O ,/O 2.0/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 4.1/O %/O with/O INVOKANA/O 300/O mg/O ./O
At/O the/O end/O of/O treatment/O ,/O 0.5/O %/O with/O placebo/O ,/O 0.7/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 1.4/O %/O with/O INVOKANA/O 300/O mg/O had/O a/O significant/B-Severity renal/B-AdverseReaction function/I-AdverseReaction decline/I-AdverseReaction ./O
In/O a/O trial/O carried/O out/O in/O patients/O with/O moderate/O renal/O impairment/O with/O a/O baseline/O eGFR/O of/O 30/O to/O less/O than/O 50/O mL/O min/1.73/O m/O 2/O (/O mean/O baseline/O eGFR/O 39/O mL/O min/1.73/O m/O 2/O )/O [/O see/O Clinical/O Studies/O (/O 14.3/O )/O ]/O ,/O the/O proportion/O of/O patients/O who/O experienced/O at/O least/O one/O event/O of/O significant/B-Severity renal/B-AdverseReaction function/I-AdverseReaction decline/I-AdverseReaction ,/O defined/O as/O an/O eGFR/B-AdverseReaction 30/I-AdverseReaction %/I-AdverseReaction lower/I-AdverseReaction than/I-AdverseReaction baseline/O ,/O was/O 6.9/O %/O with/O placebo/O ,/O 18/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 22.5/O %/O with/O INVOKANA/O 300/O mg/O ./O
At/O the/O end/O of/O treatment/O ,/O 4.6/O %/O with/O placebo/O ,/O 3.4/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 2.2/O %/O with/O INVOKANA/O 300/O mg/O had/O a/O significant/B-Severity renal/B-AdverseReaction function/I-AdverseReaction decline/I-AdverseReaction ./O
In/O a/O pooled/O population/O of/O patients/O with/O moderate/O renal/O impairment/O (/O N=1085/O )/O with/O baseline/O eGFR/O of/O 30/O to/O less/O than/O 60/O mL/O min/1.73/O m/O 2/O (/O mean/O baseline/O eGFR/O 48/O mL/O min/1.73/O m/O 2/O )/O ,/O the/O overall/O incidence/O of/O these/O events/O was/O lower/O than/O in/O the/O dedicated/O trial/O but/O a/O dose/O -/O dependent/O increase/O in/O incident/O episodes/O of/O significant/B-Severity renal/B-AdverseReaction function/I-AdverseReaction decline/I-AdverseReaction compared/O to/O placebo/O was/O still/O observed/O ./O
Use/O of/O INVOKANA/O has/O been/O associated/O with/O an/O increased/O incidence/O of/O renal/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O (/O e.g./O ,/O increased/B-AdverseReaction blood/I-AdverseReaction creatinine/I-AdverseReaction ,/O decreased/B-AdverseReaction glomerular/I-AdverseReaction filtration/I-AdverseReaction rate/I-AdverseReaction ,/O renal/B-AdverseReaction impairment/I-AdverseReaction ,/O and/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction )/O ,/O particularly/O in/O patients/O with/O moderate/O renal/O impairment/O ./O
In/O the/O pooled/O analysis/O of/O patients/O with/O moderate/O renal/O impairment/O ,/O the/O incidence/O of/O renal/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O was/O 3.7/O %/O with/O placebo/O ,/O 8.9/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 9.3/O %/O with/O INVOKANA/O 300/O mg/O ./O
Discontinuations/O due/O to/O renal/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O events/O occurred/O in/O 1.0/O %/O with/O placebo/O ,/O 1.2/O %/O with/O INVOKANA/O 100/O mg/O ,/O and/O 1.6/O %/O with/O INVOKANA/O 300/O mg/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Genital/O Mycotic/O Infections/O In/O the/O pool/O of/O four/O placebo/O -/O controlled/O clinical/O trials/O ,/O female/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction (/O e.g./O ,/O vulvovaginal/B-AdverseReaction mycotic/I-AdverseReaction infection/I-AdverseReaction ,/O vulvovaginal/B-AdverseReaction candidiasis/I-AdverseReaction ,/O and/O vulvovaginitis/B-AdverseReaction )/O occurred/O in/O 3.2/O %/O ,/O 10.4/O %/O ,/O and/O 11.4/O %/O of/O females/O treated/O with/O placebo/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
Patients/O with/O a/O history/O of/O genital/O mycotic/O infections/O were/O more/O likely/O to/O develop/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction on/O INVOKANA/O ./O
Female/O patients/O who/O developed/O genital/O mycotic/O infections/O on/O INVOKANA/O were/O more/O likely/O to/O experience/O recurrence/O and/O require/O treatment/O with/O oral/O or/O topical/O antifungal/O agents/O and/O anti/O -/O microbial/O agents/O ./O
In/O females/O ,/O discontinuation/O due/O to/O genital/O mycotic/O infections/O occurred/O in/O 0/O %/O and/O 0.7/O %/O of/O patients/O treated/O with/O placebo/O and/O INVOKANA/O ,/O respectively/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
In/O the/O pool/O of/O four/O placebo/O -/O controlled/O clinical/O trials/O ,/O male/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction (/O e.g./O ,/O candidal/B-AdverseReaction balanitis/I-AdverseReaction ,/O balanoposthitis/B-AdverseReaction )/O occurred/O in/O 0.6/O %/O ,/O 4.2/O %/O ,/O and/O 3.7/O %/O of/O males/O treated/O with/O placebo/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
Male/B-AdverseReaction genital/I-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction occurred/O more/O commonly/O in/O uncircumcised/O males/O and/O in/O males/O with/O a/O prior/O history/O of/O balanitis/O or/O balanoposthitis/O ./O
Male/O patients/O who/O developed/O genital/O mycotic/O infections/O on/O INVOKANA/O were/O more/O likely/O to/O experience/O recurrent/O infections/O (/O 22/O %/O on/O INVOKANA/O versus/O none/O on/O placebo/O )/O ,/O and/O require/O treatment/O with/O oral/O or/O topical/O antifungal/O agents/O and/O anti/O -/O microbial/O agents/O than/O patients/O on/O comparators/O ./O
In/O males/O ,/O discontinuations/O due/O to/O genital/O mycotic/O infections/O occurred/O in/O 0/O %/O and/O 0.5/O %/O of/O patients/O treated/O with/O placebo/O and/O INVOKANA/O ,/O respectively/O ./O
In/O the/O pooled/O analysis/O of/O 8/O controlled/O trials/O ,/O phimosis/B-AdverseReaction was/O reported/O in/O 0.3/O %/O of/O uncircumcised/O male/O patients/O treated/O with/O INVOKANA/O and/O 0.2/O %/O required/O circumcision/O to/O treat/O the/O phimosis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Hypoglycemia/O In/O all/O clinical/O trials/O ,/O hypoglycemia/O was/O defined/O as/O any/O event/O regardless/O of/O symptoms/O ,/O where/O biochemical/O hypoglycemia/O was/O documented/O (/O any/O glucose/O value/O below/O or/O equal/O to/O 70/O mg/O dL/O )/O ./O
Severe/O hypoglycemia/O was/O defined/O as/O an/O event/O consistent/O with/O hypoglycemia/O where/O the/O patient/O required/O the/O assistance/O of/O another/O person/O to/O recover/O ,/O lost/O consciousness/O ,/O or/O experienced/O a/O seizure/O (/O regardless/O of/O whether/O biochemical/O documentation/O of/O a/O low/O glucose/O value/O was/O obtained/O )/O ./O
In/O individual/O clinical/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ,/O episodes/O of/O hypoglycemia/B-AdverseReaction occurred/O at/O a/O higher/O rate/O when/O INVOKANA/O was/O co/O -/O administered/O with/O insulin/O or/O sulfonylureas/O (/O Table/O 4/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Table/O 4/O :/O Incidence/O of/O HypoglycemiaNumber/B-AdverseReaction of/O patients/O experiencing/O at/O least/O one/O event/O of/O hypoglycemia/B-AdverseReaction based/O on/O either/O biochemically/O documented/O episodes/O or/O severe/B-Severity hypoglycemic/B-AdverseReaction events/I-AdverseReaction in/O the/O intent/O -/O to/O -/O treat/O population/O in/O Controlled/O Clinical/O Studies/O Monotherapy(26/O weeks/O )/O Placebo(N=192/O )/O INVOKANA/O 100/O mg(N=195/O )/O INVOKANA/O 300/O mg(N=197/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 5/O (/O 2.6/O )/O 7/O (/O 3.6/O )/O 6/O (/O 3.0/O )/O In/O Combination/O with/O Metformin(26/O weeks/O )/O Placebo/O +/O Metformin(N=183/O )/O INVOKANA/O 100/O mg/O +/O Metformin(N=368/O )/O INVOKANA/O 300/O mg/O +/O Metformin(N=367/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 3/O (/O 1.6/O )/O 16/O (/O 4.3/O )/O 17/O (/O 4.6/O )/O Severe/O [/O N/O (/O %/O )/O ]/O 0/O (/O 0/O )/O 1/O (/O 0.3/O )/O 1/O (/O 0.3/O )/O In/O Combination/O with/O Metformin(52/O weeks/O )/O Glimepiride/O +/O Metformin(N=482/O )/O INVOKANA/O 100/O mg/O +/O Metformin(N=483/O )/O INVOKANA/O 300/O mg/O +/O Metformin(N=485/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 165/O (/O 34.2/O )/O 27/O (/O 5.6/O )/O 24/O (/O 4.9/O )/O Severe/O [/O N/O (/O %/O )/O ]/O 15/O (/O 3.1/O )/O 2/O (/O 0.4/O )/O 3/O (/O 0.6/O )/O In/O Combination/O with/O Sulfonylurea(18/O weeks/O )/O Placebo/O +/O Sulfonylurea(N=69/O )/O INVOKANA/O 100/O mg/O +/O Sulfonylurea(N=74/O )/O INVOKANA/O 300/O mg/O +/O Sulfonylurea(N=72/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 4/O (/O 5.8/O )/O 3/O (/O 4.1/O )/O 9/O (/O 12.5/O )/O In/O Combination/O with/O Metformin/O +/O Sulfonylurea(26/O weeks/O )/O Placebo/O +/O Metformin/O +/O Sulfonylurea(N=156/O )/O INVOKANA/O 100/O mg/O +/O Metformin/O +/O Sulfonylurea(N=157/O )/O INVOKANA/O 300/O mg/O +/O Metformin/O +/O Sulfonylurea(N=156/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 24/O (/O 15.4/O )/O 43/O (/O 27.4/O )/O 47/O (/O 30.1/O )/O Severe/O [/O N/O (/O %/O )/O ]/O 1/O (/O 0.6/O )/O 1/O (/O 0.6/O )/O 0/O In/O Combination/O with/O Metformin/O +/O Sulfonylurea(52/O weeks/O )/O Sitagliptin/O +/O Metformin/O +/O Sulfonylurea(N=378/O )/O INVOKANA/O 300/O mg/O +/O Metformin/O +/O Sulfonylurea(N=377/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 154/O (/O 40.7/O )/O 163/O (/O 43.2/O )/O Severe/O [/O N/O (/O %/O )/O ]/O 13/O (/O 3.4/O )/O 15/O (/O 4.0/O )/O In/O Combination/O with/O Metformin/O +/O Pioglitazone(26/O weeks/O )/O Placebo/O +/O Metformin/O +/O Pioglitazone(N=115/O )/O INVOKANA/O 100/O mg/O +/O Metformin/O +/O Pioglitazone(N=113/O )/O INVOKANA/O 300/O mg/O +/O Metformin/O +/O Pioglitazone(N=114/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 3/O (/O 2.6/O )/O 3/O (/O 2.7/O )/O 6/O (/O 5.3/O )/O In/O Combination/O with/O Insulin(18/O weeks/O )/O Placebo(N=565/O )/O INVOKANA/O 100/O mg(N=566/O )/O INVOKANA/O 300/O mg(N=587/O )/O Overall/O [/O N/O (/O %/O )/O ]/O 208/O (/O 36.8/O )/O 279/O (/O 49.3/O )/O 285/O (/O 48.6/O )/O Severe/O [/O N/O (/O %/O )/O ]/O 14/O (/O 2.5/O )/O 10/O (/O 1.8/O )/O 16/O (/O 2.7/O )/O Bone/O Fracture/O The/O occurrence/O of/O bone/B-AdverseReaction fractures/I-AdverseReaction was/O evaluated/O in/O a/O pool/O of/O nine/O clinical/O trials/O with/O a/O mean/O duration/O of/O exposure/O to/O INVOKANA/O of/O 85/O weeks/O ./O
The/O incidence/O rates/O of/O adjudicated/O bone/B-AdverseReaction fractures/I-AdverseReaction were/O 1.1/O ,/O 1.4/O ,/O and/O 1.5/O per/O 100/O patient/O -/O years/O of/O exposure/O in/O the/O comparator/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O groups/O ,/O respectively/O ./O
Fractures/B-AdverseReaction were/O observed/O as/O early/O as/O 12/O weeks/O after/O treatment/O initiation/O and/O were/O more/O likely/O to/O be/O low/B-Severity trauma/I-Severity (/O e.g./O ,/O fall/O from/O no/O more/O than/O standing/O height/O )/O ,/O and/O affect/O the/O upper/O extremities/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O ./O
Laboratory/O and/O Imaging/O Tests/O Increases/O in/O Serum/O Potassium/O In/O a/O pooled/O population/O of/O patients/O (/O N=723/O )/O with/O moderate/O renal/O impairment/O (/O eGFR/O 45/O to/O less/O than/O 60/O mL/O min/1.73/O m/O 2/O )/O ,/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction potassium/I-AdverseReaction to/O greater/O than/O 5.4/B-Severity mEq/I-Severity L/O and/O 15/B-Severity %/I-Severity above/I-Severity baseline/O occurred/O in/O 5.3/O %/O ,/O 5.0/O %/O ,/O and/O 8.8/O %/O of/O patients/O treated/O with/O placebo/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
Severe/O elevations/O (/O greater/O than/O or/O equal/O to/O 6.5/O mEq/O L/O )/O occurred/O in/O 0.4/O %/O of/O patients/O treated/O with/O placebo/O ,/O no/O patients/O treated/O with/O INVOKANA/O 100/O mg/O ,/O and/O 1.3/O %/O of/O patients/O treated/O with/O INVOKANA/O 300/O mg/O ./O
In/O these/O patients/O ,/O increases/B-AdverseReaction in/I-AdverseReaction potassium/I-AdverseReaction were/O more/O commonly/O seen/O in/O those/O with/O elevated/O potassium/O at/O baseline/O ./O
Among/O patients/O with/O moderate/O renal/O impairment/O ,/O approximately/O 84/O %/O were/O taking/O medications/O that/O interfere/O with/O potassium/O excretion/O ,/O such/O as/O potassium/O -/O sparing/O diuretics/O ,/O angiotensin/O -/O converting/O -/O enzyme/O inhibitors/O ,/O and/O angiotensin/O -/O receptor/O blockers/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O and/O 5.3/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
Increases/O in/O Serum/O Magnesium/O Dose/O -/O related/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction magnesium/I-AdverseReaction were/O observed/O early/O after/O initiation/O of/O INVOKANA/O (/O within/O 6/O weeks/O )/O and/O remained/O elevated/O throughout/O treatment/O ./O
In/O the/O pool/O of/O four/O placebo/O -/O controlled/O trials/O ,/O the/O mean/O percent/O change/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction magnesium/I-AdverseReaction levels/I-AdverseReaction was/O 8.1/O %/O and/O 9.3/O %/O with/O INVOKANA/O 100/O mg/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ,/O compared/O to/O -0.6/O %/O with/O placebo/O ./O
In/O a/O trial/O of/O patients/O with/O moderate/O renal/O impairment/O [/O see/O Clinical/O Studies/O (/O 14.3/O )/O ]/O ,/O serum/B-AdverseReaction magnesium/I-AdverseReaction levels/I-AdverseReaction increased/I-AdverseReaction by/O 0.2/O %/O ,/O 9.2/O %/O ,/O and/O 14.8/O %/O with/O placebo/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
Increases/O in/O Serum/O Phosphate/O Dose/O -/O related/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction phosphate/I-AdverseReaction levels/O were/O observed/O with/O INVOKANA/O ./O
In/O the/O pool/O of/O four/O placebo/O controlled/O trials/O ,/O the/O mean/O percent/O change/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction phosphate/I-AdverseReaction levels/I-AdverseReaction were/O 3.6/O %/O and/O 5.1/O %/O with/O INVOKANA/O 100/O mg/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ,/O compared/O to/O 1.5/O %/O with/O placebo/O ./O
In/O a/O trial/O of/O patients/O with/O moderate/O renal/O impairment/O [/O see/O Clinical/O Studies/O (/O 14.3/O )/O ]/O ,/O the/O mean/O serum/B-AdverseReaction phosphate/I-AdverseReaction levels/I-AdverseReaction increased/I-AdverseReaction by/O 1.2/O %/O ,/O 5.0/O %/O ,/O and/O 9.3/O %/O with/O placebo/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
Increases/O in/O Low/O -/O Density/O Lipoprotein/O Cholesterol/O (/O LDL/O -/O C/O )/O and/O non/O -/O High/O -/O Density/O Lipoprotein/O Cholesterol/O (/O non/O -/O HDL/O -/O C/O )/O In/O the/O pool/O of/O four/O placebo/O -/O controlled/O trials/O ,/O dose/O -/O related/O increases/B-AdverseReaction in/I-AdverseReaction LDL/I-AdverseReaction -/O C/O with/O INVOKANA/O were/O observed/O ./O
Mean/O changes/O (/O percent/O changes/O )/O from/O baseline/O in/O LDL/O -/O C/O relative/O to/O placebo/O were/O 4.4/B-Severity mg/I-Severity dL/O (/O 4.5/O %/O )/O and/O 8.2/B-Severity mg/I-Severity dL/O (/O 8.0/O %/O )/O with/O INVOKANA/O 100/O mg/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ./O
The/O mean/O baseline/O LDL/O -/O C/O levels/O were/O 104/O to/O 110/O mg/O dL/O across/O treatment/O groups/O [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O ./O
Dose/O -/O related/O increases/B-AdverseReaction in/I-AdverseReaction non/I-AdverseReaction -/O HDL/O -/O C/O with/O INVOKANA/O were/O observed/O ./O
Mean/O changes/O (/O percent/O changes/O )/O from/O baseline/O in/O non/O -/O HDL/O -/O C/O relative/O to/O placebo/O were/O 2.1/B-Severity mg/I-Severity dL/O (/O 1.5/O %/O )/O and/O 5.1/B-Severity mg/I-Severity dL/O (/O 3.6/O %/O )/O with/O INVOKANA/O 100/O mg/O and/O 300/O mg/O ,/O respectively/O ./O
The/O mean/O baseline/O non/O -/O HDL/O -/O C/O levels/O were/O 140/O to/O 147/O mg/O dL/O across/O treatment/O groups/O ./O
Increases/O in/O Hemoglobin/O In/O the/O pool/O of/O four/O placebo/O -/O controlled/O trials/O ,/O mean/O changes/O (/O percent/O changes/O )/O from/O baseline/O in/O hemoglobin/O were/O -0.18/O g/O dL/O (/O -1.1/O %/O )/O with/O placebo/O ,/O 0.47/B-Severity g/I-Severity dL/O (/O 3.5/O %/O )/O with/O INVOKANA/O 100/O mg/O ,/O and/O 0.51/B-Severity g/I-Severity dL/O (/O 3.8/O %/O )/O with/O INVOKANA/O 300/O mg/O ./O
The/O mean/O baseline/O hemoglobin/O value/O was/O approximately/O 14.1/O g/O dL/O across/O treatment/O groups/O ./O
At/O the/O end/O of/O treatment/O ,/O 0.8/O %/O ,/O 4.0/O %/O ,/O and/O 2.7/O %/O of/O patients/O treated/O with/O placebo/O ,/O INVOKANA/O 100/O mg/O ,/O and/O INVOKANA/O 300/O mg/O ,/O respectively/O ,/O had/O hemoglobin/B-AdverseReaction above/I-AdverseReaction the/I-AdverseReaction upper/I-AdverseReaction limit/I-AdverseReaction of/I-AdverseReaction normal/I-AdverseReaction ./O
Decreases/O in/O Bone/O Mineral/O Density/O Bone/O mineral/O density/O (/O BMD/O )/O was/O measured/O by/O dual/O -/O energy/O X/O -/O ray/O absorptiometry/O in/O a/O clinical/O trial/O of/O 714/O older/O adults/O (/O mean/O age/O 64/O years/O )/O [/O see/O Clinical/O Studies/O (/O 14.3/O )/O ]/O ./O
At/O 2/O years/O ,/O patients/O randomized/O to/O INVOKANA/O 100/O mg/O and/O INVOKANA/O 300/O mg/O had/O placebo/O -/O corrected/O declines/B-AdverseReaction in/I-AdverseReaction BMD/I-AdverseReaction at/I-AdverseReaction the/I-AdverseReaction total/I-AdverseReaction hip/I-AdverseReaction of/O 0.9/B-Severity %/O and/O 1.2/B-Severity %/O ,/O respectively/O ,/O and/O at/O the/O lumbar/O spine/O of/O 0.3/B-Severity %/O and/O 0.7/B-Severity %/O ,/O respectively/O ./O
Additionally/O ,/O placebo/O -/O adjusted/O BMD/O declines/O were/O 0.1/B-Severity %/O at/O the/O femoral/O neck/O for/O both/O INVOKANA/O doses/O and/O 0.4/B-Severity %/O at/O the/O distal/O forearm/O for/O patients/O randomized/O to/O INVOKANA/O 300/O mg/O ./O
The/O placebo/O -/O adjusted/O change/O at/O the/O distal/O forearm/O for/O patients/O randomized/O to/O INVOKANA/O 100/O mg/O was/O 0/O %/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypotension/B-AdverseReaction :/O Before/O initiating/O INVOKANA/O ,/O assess/O volume/O status/O and/O correct/O hypovolemia/O in/O patients/O with/O renal/O impairment/O ,/O the/O elderly/O ,/O in/O patients/O with/O low/O systolic/O blood/O pressure/O ,/O or/O if/O on/O diuretics/O ,/O ACEi/O ,/O or/O ARB/O ./O
Monitor/O for/O signs/O and/O symptoms/O during/O therapy/O (/O 5.1/O )/O Impairment/B-AdverseReaction in/I-AdverseReaction Renal/I-AdverseReaction Function/I-AdverseReaction :/O Monitor/O renal/O function/O during/O therapy/O ./O
More/O frequent/O monitoring/O is/O recommended/O in/O patients/O with/O eGFR/O below/O 60/O mL/O min/1.73/O m/O 2/O (/O 5.2/O )/O Hyperkalemia/B-AdverseReaction :/O Monitor/O potassium/O levels/O in/O patients/O with/O impaired/O renal/O function/O and/O in/O patients/O predisposed/O to/O hyperkalemia/O (/O 2.2/O ,/O 5.3/O ,/O 6.1/O ,/O 8.6/O )/O Hypoglycemia/B-AdverseReaction :/O Consider/O a/O lower/O dose/O of/O insulin/O or/O the/O insulin/O secretagogue/O to/O reduce/O the/O risk/O of/O hypoglycemia/O when/O used/O in/O combination/O with/O INVOKANA/O (/O 5.4/O )/O Genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction :/O Monitor/O and/O treat/O if/O indicated/O (/O 5.5/O )/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction :/O Discontinue/O INVOKANA/O and/O monitor/O until/O signs/O and/O symptoms/O resolve/O (/O 5.6/O )/O Bone/B-AdverseReaction fracture/I-AdverseReaction :/O Consider/O factors/O that/O contribute/O to/O fracture/O risk/O before/O initiating/O INVOKANA/O (/O 5.7/O )/O Increased/B-AdverseReaction LDL/I-AdverseReaction -/O C/O :/O Monitor/O LDL/O -/O C/O and/O treat/O if/O appropriate/O (/O 5.8/O )/O 5.1/O Hypotension/O INVOKANA/O causes/O intravascular/B-AdverseReaction volume/I-AdverseReaction contraction/I-AdverseReaction ./O
Symptomatic/B-AdverseReaction hypotension/I-AdverseReaction can/B-Factor occur/O after/O initiating/O INVOKANA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O particularly/O in/O patients/O with/O impaired/O renal/O function/O (/O eGFR/O less/O than/O 60/O mL/O min/1.73/O m/O 2/O )/O ,/O elderly/O patients/O ,/O patients/O on/O either/O diuretics/O or/O medications/O that/O interfere/O with/O the/O renin/O -/O angiotensin/O -/O aldosterone/O system/O (/O e.g./O ,/O angiotensin/O -/O converting/O -/O enzyme/O [/O ACE/O ]/O inhibitors/O ,/O angiotensin/O receptor/O blockers/O [/O ARBs/O ]/O )/O ,/O or/O patients/O with/O low/O systolic/O blood/O pressure/O ./O
Before/O initiating/O INVOKANA/O in/O patients/O with/O one/O or/O more/O of/O these/O characteristics/O ,/O volume/O status/O should/O be/O assessed/O and/O corrected/O ./O
Monitor/O for/O signs/O and/O symptoms/O after/O initiating/O therapy/O ./O
5.2/O Impairment/O in/O Renal/O Function/O INVOKANA/O increases/B-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O decreases/B-AdverseReaction eGFR/I-AdverseReaction ./O
Patients/O with/O hypovolemia/O may/O be/O more/O susceptible/O to/O these/O changes/O ./O
Renal/B-AdverseReaction function/I-AdverseReaction abnormalities/I-AdverseReaction can/B-Factor occur/O after/O initiating/O INVOKANA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
More/O frequent/O renal/O function/O monitoring/O is/O recommended/O in/O patients/O with/O an/O eGFR/O below/O 60/O mL/O min/1.73/O m/O 2/O ./O
5.3/O Hyperkalemia/O INVOKANA/O can/B-Factor lead/O to/O hyperkalemia/B-AdverseReaction ./O
Patients/O with/O moderate/O renal/O impairment/O who/O are/O taking/O medications/O that/O interfere/O with/O potassium/O excretion/O ,/O such/O as/O potassium/O -/O sparing/O diuretics/O ,/O or/O medications/O that/O interfere/O with/O the/O renin/O -/O angiotensin/O -/O aldosterone/O system/O are/O at/O an/O increased/O risk/B-Factor of/O developing/O hyperkalemia/B-AdverseReaction [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O serum/O potassium/O levels/O periodically/O after/O initiating/O INVOKANA/O in/O patients/O with/O impaired/O renal/O function/O and/O in/O patients/O predisposed/O to/O hyperkalemia/O due/O to/O medications/O or/O other/O medical/O conditions/O ./O
5.4/O Hypoglycemia/O with/O Concomitant/O Use/O with/O Insulin/O and/O Insulin/O Secretagogues/O Insulin/O and/O insulin/O secretagogues/O are/O known/O to/O cause/O hypoglycemia/O ./O
INVOKANA/O can/O increase/O the/O risk/B-Factor of/O hypoglycemia/B-AdverseReaction when/O combined/O with/O insulin/O or/O an/O insulin/O secretagogue/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Therefore/O ,/O a/O lower/O dose/O of/O insulin/O or/O insulin/O secretagogue/O may/O be/O required/O to/O minimize/O the/O risk/O of/O hypoglycemia/O when/O used/O in/O combination/O with/O INVOKANA/O ./O
5.5/O Genital/O Mycotic/O Infections/O INVOKANA/O increases/O the/O risk/B-Factor of/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction ./O
Patients/O with/O a/O history/O of/O genital/O mycotic/O infections/O and/O uncircumcised/O males/O were/O more/O likely/O to/O develop/O genital/B-AdverseReaction mycotic/I-AdverseReaction infections/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O and/O treat/O appropriately/O ./O
5.6/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction (/O e.g./O ,/O generalized/B-AdverseReaction urticaria/I-AdverseReaction )/O ,/O some/O serious/B-Severity ,/O were/O reported/O with/O INVOKANA/O treatment/O ;/O these/O reactions/O generally/O occurred/O within/O hours/O to/O days/O after/O initiating/O INVOKANA/O ./O
If/O hypersensitivity/O reactions/O occur/O ,/O discontinue/O use/O of/O INVOKANA/O ;/O treat/O and/O monitor/O until/O signs/O and/O symptoms/O resolve/O [/O see/O Contraindications/O (/O 4/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.7/O Bone/O Fracture/O An/O increased/O risk/B-Factor of/O bone/B-AdverseReaction fracture/I-AdverseReaction ,/O occurring/O as/O early/O as/O 12/O weeks/O after/O treatment/O initiation/O ,/O was/O observed/O in/O patients/O using/O INVOKANA/O ./O
Consider/O factors/O that/O contribute/O to/O fracture/O risk/O prior/O to/O initiating/O INVOKANA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.8/O Increases/O in/O Low/O -/O Density/O Lipoprotein/O (/O LDL/O -/O C/O )/O Dose/O -/O related/O increases/B-AdverseReaction in/I-AdverseReaction LDL/I-AdverseReaction -/O C/O occur/O with/O INVOKANA/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O LDL/O -/O C/O and/O treat/O if/O appropriate/O after/O initiating/O INVOKANA/O ./O
5.9/O Macrovascular/O Outcomes/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O INVOKANA/O or/O any/O other/O antidiabetic/O drug/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O another/O section/O of/O the/O label/O :/O Bone/B-AdverseReaction Marrow/I-AdverseReaction Suppression/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Gastrointestinal/B-AdverseReaction Adverse/I-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Renal/B-AdverseReaction Failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Use/O in/O Elderly/O Patients/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Use/O in/O Patients/O with/O Hepatic/O Impairment/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
Embryo/B-AdverseReaction -/I-AdverseReaction Fetal/O Toxicity/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O all/O grades/O adverse/O reactions/O (/O 10/O %/O )/O are/O neutropenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O hematuria/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O dysgeusia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O and/O alopecia/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O sanofi/O -/O aventis/O U.S./O LLC/O at/O 1/O -/O 800/O -/O 633/O -/O 1610/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O the/O adverse/O reaction/O rates/O observed/O can/O not/O be/O directly/O compared/O to/O rates/O in/O other/O trials/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O safety/O of/O JEVTANA/O in/O combination/O with/O prednisone/O was/O evaluated/O in/O 371/O patients/O with/O hormone/O -/O refractory/O metastatic/O prostate/O cancer/O treated/O in/O a/O single/O randomized/O trial/O ,/O compared/O to/O mitoxantrone/O plus/O prednisone/O ./O
Deaths/B-AdverseReaction due/O to/O causes/O other/O than/O disease/O progression/O within/O 30/O days/O of/O last/O study/O drug/O dose/O were/O reported/O in/O 18/O (/O 5/O %/O )/O JEVTANA/O -/O treated/O patients/O and/O 3/O (/O 1/O %/O )/O mitoxantrone/O -/O treated/O patients/O ./O
The/O most/O common/O fatal/B-AdverseReaction adverse/O reactions/O in/O JEVTANA/O -/O treated/O patients/O were/O infections/B-AdverseReaction (/O n=5/O )/O and/O renal/B-AdverseReaction failure/I-AdverseReaction (/O n=4/O )/O ./O
The/O majority/O (/O 4/O of/O 5/O patients/O )/O of/O fatal/B-AdverseReaction infection/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O occurred/O after/O a/O single/O dose/O of/O JEVTANA/O ./O
Other/O fatal/B-AdverseReaction adverse/O reactions/O in/O JEVTANA/O -/O treated/O patients/O included/O ventricular/B-AdverseReaction fibrillation/I-AdverseReaction ,/O cerebral/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O and/O dyspnea/B-AdverseReaction ./O
The/O most/O common/O (/O 10/O %/O )/O grade/B-Severity 1/I-Severity -/O 4/O adverse/O reactions/O were/O anemia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O hematuria/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O dysguesia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O and/O alopecia/B-AdverseReaction ./O
The/O most/O common/O (/O 5/O %/O )/O grade/B-Severity 3/I-Severity -/O 4/O adverse/O reactions/O in/O patients/O who/O received/O JEVTANA/O were/O neutropenia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O asthenia/B-AdverseReaction ./O
Treatment/O discontinuations/O due/O to/O adverse/O drug/O reactions/O occurred/O in/O 18/O %/O of/O patients/O who/O received/O JEVTANA/O and/O 8/O %/O of/O patients/O who/O received/O mitoxantrone/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O treatment/O discontinuation/O in/O the/O JEVTANA/O group/O were/O neutropenia/B-AdverseReaction and/O renal/B-AdverseReaction failure/I-AdverseReaction ./O
Dose/O reductions/O were/O reported/O in/O 12/O %/O of/O JEVTANA/O -/O treated/O patients/O and/O 4/O %/O of/O mitoxantrone/O -/O treated/O patients/O ./O
Dose/O delays/O were/O reported/O in/O 28/O %/O of/O JEVTANA/O -/O treated/O patients/O and/O 15/O %/O of/O mitoxantrone/O -/O treated/O patients/O ./O
Table/O 2/O -/O Incidence/O of/O Reported/O Adverse/O ReactionsGraded/O using/O NCI/O CTCAE/O version/O 3/O and/O Hematologic/B-AdverseReaction Abnormalities/I-AdverseReaction in/O 5/O %/O of/O Patients/O Receiving/O JEVTANA/O in/O Combination/O with/O Prednisone/O or/O Mitoxantrone/O in/O Combination/O with/O Prednisone/O JEVTANA/O 25/O mg/O m/O 2/O every/O 3/O weeks/O with/O prednisone/O 10/O mg/O dailyn=371/O Mitoxantrone/O 12/O mg/O m/O 2/O every/O 3/O weeks/O with/O prednisone/O 10/O mg/O dailyn=371/O Grade/O 1/O -/O 4n/O (/O %/O )/O Grade/O 3/O -/O 4n/O (/O %/O )/O Grade/O 1/O -/O 4n/O (/O %/O )/O Grade/O 3/O -/O 4n/O (/O %/O )/O Any/O Adverse/O Reaction/O Blood/O and/O Lymphatic/O System/O Disorders/O Neutropenia/B-AdverseReaction 347/O (/O 94/O %/O )/O 303/O (/O 82/O %/O )/O 325/O (/O 87/O %/O )/O 215/O (/O 58/O %/O )/O Febrile/B-AdverseReaction Neutropenia/I-AdverseReaction 27/O (/O 7/O %/O )/O 27/O (/O 7/O %/O )/O 5/O (/O 1/O %/O )/O 5/O (/O 1/O %/O )/O Anemia/B-AdverseReaction 361/O (/O 98/O %/O )/O 39/O (/O 11/O %/O )/O 302/O (/O 82/O %/O )/O 18/O (/O 5/O %/O )/O Leukopenia/B-AdverseReaction 355/O (/O 96/O %/O )/O 253/O (/O 69/O %/O )/O 343/O (/O 93/O %/O )/O 157/O (/O 42/O %/O )/O Thrombocytopenia/B-AdverseReaction 176/O (/O 48/O %/O )/O 15/O (/O 4/O %/O )/O 160/O (/O 43/O %/O )/O 6/O (/O 2/O %/O )/O Cardiac/O Disorders/O Arrhythmia/B-AdverseReaction 18/O (/O 5/O %/O )/O 4/O (/O 1/O %/O )/O 6/O (/O 2/O %/O )/O 1/O (/O 1/O %/O )/O Gastrointestinal/O Disorders/O Diarrhea/B-AdverseReaction 173/O (/O 47/O %/O )/O 23/O (/O 6/O %/O )/O 39/O (/O 11/O %/O )/O 1/O (/O 1/O %/O )/O Nausea/B-AdverseReaction 127/O (/O 34/O %/O )/O 7/O (/O 2/O %/O )/O 85/O (/O 23/O %/O )/O 1/O (/O 1/O %/O )/O Vomiting/B-AdverseReaction 83/O (/O 22/O %/O )/O 6/O (/O 2/O %/O )/O 38/O (/O 10/O %/O )/O 0/O Constipation/B-AdverseReaction 76/O (/O 20/O %/O )/O 4/O (/O 1/O %/O )/O 57/O (/O 15/O %/O )/O 2/O (/O 1/O %/O )/O Abdominal/B-AdverseReaction Pain/I-AdverseReaction 64/O (/O 17/O %/O )/O 7/O (/O 2/O %/O )/O 23/O (/O 6/O %/O )/O 0/O Dyspepsia/B-AdverseReaction 36/O (/O 10/O %/O )/O 0/O 9/O (/O 2/O %/O )/O 0/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Fatigue/B-AdverseReaction 136/O (/O 37/O %/O )/O 18/O (/O 5/O %/O )/O 102/O (/O 27/O %/O )/O 11/O (/O 3/O %/O )/O Asthenia/B-AdverseReaction 76/O (/O 20/O %/O )/O 17/O (/O 5/O %/O )/O 46/O (/O 12/O %/O )/O 9/O (/O 2/O %/O )/O Pyrexia/B-AdverseReaction 45/O (/O 12/O %/O )/O 4/O (/O 1/O %/O )/O 23/O (/O 6/O %/O )/O 1/O (/O 1/O %/O )/O Peripheral/B-AdverseReaction Edema/I-AdverseReaction 34/O (/O 9/O %/O )/O 2/O (/O 1/O %/O )/O 34/O (/O 9/O %/O )/O 2/O (/O 1/O %/O )/O Mucosal/B-AdverseReaction Inflammation/I-AdverseReaction 22/O (/O 6/O %/O )/O 1/O (/O 1/O %/O )/O 10/O (/O 3/O %/O )/O 1/O (/O 1/O %/O )/O Pain/B-AdverseReaction 20/O (/O 5/O %/O )/O 4/O (/O 1/O %/O )/O 18/O (/O 5/O %/O )/O 7/O (/O 2/O %/O )/O Infections/O and/O Infestations/O Urinary/B-AdverseReaction Tract/I-AdverseReaction Infection/I-AdverseReaction 29/O (/O 8/O %/O )/O 6/O (/O 2/O %/O )/O 12/O (/O 3/O %/O )/O 4/O (/O 1/O %/O )/O Investigations/O Weight/B-AdverseReaction Decreased/I-AdverseReaction 32/O (/O 9/O %/O )/O 0/O 28/O (/O 8/O %/O )/O 1/O (/O 1/O %/O )/O Metabolism/O and/O Nutrition/O Disorders/O Anorexia/B-AdverseReaction 59/O (/O 16/O %/O )/O 3/O (/O 1/O %/O )/O 39/O (/O 11/O %/O )/O 3/O (/O 1/O %/O )/O Dehydration/B-AdverseReaction 18/O (/O 5/O %/O )/O 8/O (/O 2/O %/O )/O 10/O (/O 3/O %/O )/O 3/O (/O 1/O %/O )/O Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Back/B-AdverseReaction Pain/I-AdverseReaction 60/O (/O 16/O %/O )/O 14/O (/O 4/O %/O )/O 45/O (/O 12/O %/O )/O 11/O (/O 3/O %/O )/O Arthralgia/B-AdverseReaction 39/O (/O 11/O %/O )/O 4/O (/O 1/O %/O )/O 31/O (/O 8/O %/O )/O 4/O (/O 1/O %/O )/O Muscle/B-AdverseReaction Spasms/I-AdverseReaction 27/O (/O 7/O %/O )/O 0/O 10/O (/O 3/O %/O )/O 0/O Nervous/O System/O Disorders/O Peripheral/B-AdverseReaction Neuropathy/I-AdverseReaction 50/O (/O 13/O %/O )/O 3/O (/O 1/O %/O )/O 12/O (/O 3.2/O %/O )/O 3/O (/O 1/O %/O )/O Dysgeusia/B-AdverseReaction 41/O (/O 11/O %/O )/O 0/O 15/O (/O 4/O %/O )/O 0/O Dizziness/B-AdverseReaction 30/O (/O 8/O %/O )/O 0/O 21/O (/O 6/O %/O )/O 2/O (/O 1/O %/O )/O Headache/B-AdverseReaction 28/O (/O 8/O %/O )/O 0/O 19/O (/O 5/O %/O )/O 0/O Renal/O and/O Urinary/O Tract/O Disorders/O Hematuria/B-AdverseReaction 62/O (/O 17/O %/O )/O 7/O (/O 2/O %/O )/O 13/O (/O 4/O %/O )/O 1/O (/O 1/O %/O )/O Dysuria/B-AdverseReaction 25/O (/O 7/O %/O )/O 0/O 5/O (/O 1/O %/O )/O 0/O Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O Dyspnea/B-AdverseReaction 43/O (/O 12/O %/O )/O 4/O (/O 1/O %/O )/O 16/O (/O 4/O %/O )/O 2/O (/O 1/O %/O )/O Cough/B-AdverseReaction 40/O (/O 11/O %/O )/O 0/O 22/O (/O 6/O %/O )/O 0/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Alopecia/B-AdverseReaction 37/O (/O 10/O %/O )/O 0/O 18/O (/O 5/O %/O )/O 0/O Vascular/O Disorders/O Hypotension/B-AdverseReaction 20/O (/O 5/O %/O )/O 2/O (/O 1/O %/O )/O 9/O (/O 2/O %/O )/O 1/O (/O 1/O %/O )/O Median/O Duration/O of/O Treatment/O 6/O cycles/O 4/O cycles/O Neutropenia/O and/O Associated/O Clinical/O Events/O :/O Five/O patients/O experienced/O fatal/B-AdverseReaction infectious/B-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction (/O sepsis/B-AdverseReaction or/O septic/B-AdverseReaction shock/I-AdverseReaction )/O ./O
All/O had/O grade/B-Severity 4/I-Severity neutropenia/B-AdverseReaction and/O one/O had/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ./O
One/O additional/O patient/O 's/O death/B-AdverseReaction was/O attributed/O to/O neutropenia/B-AdverseReaction without/B-Negation a/O documented/O infection/B-AdverseReaction ./O
Twenty/O -/O two/O (/O 6/O %/O )/O patients/O discontinued/O JEVTANA/O treatment/O due/O to/O neutropenia/B-AdverseReaction ,/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O infection/B-AdverseReaction ,/O or/O sepsis/B-AdverseReaction ./O
The/O most/O common/O adverse/O reaction/O leading/O to/O treatment/O discontinuation/O in/O the/O JEVTANA/O group/O was/O neutropenia/B-AdverseReaction (/O 2/O %/O )/O ./O
Hematuria/O :/O Adverse/O events/O of/O hematuria/B-AdverseReaction ,/O including/O those/O requiring/O medical/O intervention/O ,/O were/O more/O common/O in/O JEVTANA/O -/O treated/O patients/O ./O
The/O incidence/O of/O grade/O 2/O hematuria/B-AdverseReaction was/O 6/O %/O in/O JEVTANA/O -/O treated/O patients/O and/O 2/O %/O in/O mitoxantrone/O -/O treated/O patients/O ./O
Other/O factors/O associated/O with/O hematuria/B-AdverseReaction were/O well/O -/O balanced/O between/O arms/O and/O do/O not/O account/O for/O the/O increased/O rate/O of/O hematuria/B-AdverseReaction on/O the/O JEVTANA/O arm/O ./O
Hepatic/O Laboratory/O Abnormalities/O :/O The/O incidences/O of/O grade/B-Severity 3/I-Severity -/O 4/O increased/B-AdverseReaction AST/I-AdverseReaction ,/O increased/B-AdverseReaction ALT/I-AdverseReaction ,/O and/O increased/B-AdverseReaction bilirubin/I-AdverseReaction were/O each/O 1/O %/O ./O
Elderly/O Population/O :/O The/O following/O grade/B-Severity 1/I-Severity -/O 4/O adverse/O reactions/O were/O reported/O at/O rates/O 5/O %/O higher/O in/O patients/O 65/O years/O of/O age/O or/O greater/O compared/O to/O younger/O patients/O :/O fatigue/B-AdverseReaction (/O 40/O %/O vs./O 30/O %/O )/O ,/O neutropenia/B-AdverseReaction (/O 97/O %/O vs./O 89/O %/O )/O ,/O asthenia/B-AdverseReaction (/O 24/O %/O vs./O 15/O %/O )/O ,/O pyrexia/B-AdverseReaction (/O 15/O %/O vs./O 8/O %/O )/O ,/O dizziness/B-AdverseReaction (/O 10/O %/O vs./O 5/O %/O )/O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 10/O %/O vs./O 3/O %/O )/O and/O dehydration/B-AdverseReaction (/O 7/O %/O vs./O 2/O %/O )/O ,/O respectively/O ./O
The/O incidence/O of/O the/O following/O grade/B-Severity 3/I-Severity -/O 4/O adverse/O reactions/O were/O higher/O in/O patients/O 65/O years/O of/O age/O compared/O to/O younger/O patients/O ;/O neutropenia/B-AdverseReaction (/O 87/O %/O vs./O 74/O %/O )/O ,/O and/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction (/O 8/O %/O vs./O 6/O %/O )/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.5/O )/O ]/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O from/O clinical/O trials/O and/or/O post/O -/O marketing/O surveillance/O ./O
Because/O they/O are/O reported/O from/O a/O population/O of/O unknown/O size/O ,/O precise/O estimates/O of/O frequency/O can/O not/O be/O made/O ./O
Gastrointestinal/O :/O Gastritis/B-AdverseReaction ,/O intestinal/B-AdverseReaction obstruction/I-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O NEUTROPENIA/B-AdverseReaction AND/O HYPERSENSITIVITY/B-AdverseReaction WARNING/O :/O NEUTROPENIA/B-AdverseReaction AND/O HYPERSENSITIVITY/B-AdverseReaction EXCERPT/O :/O WARNING/O :/O NEUTROPENIA/B-AdverseReaction AND/O HYPERSENSITIVITY/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Neutropenic/B-AdverseReaction deaths/B-AdverseReaction have/O been/O reported/O ./O
Obtain/O frequent/O blood/O counts/O to/O monitor/O for/O neutropenia/O ./O
Do/O not/O give/O JEVTANA/O if/O neutrophil/O counts/O are/O 1,500/O cells/O mm3/O ./O
(/O 2.2)(4/O )/O Severe/B-Severity hypersensitivity/B-AdverseReaction can/B-Factor occur/O and/O may/B-Factor include/O generalized/B-AdverseReaction rash/I-AdverseReaction erythema/B-AdverseReaction ,/O hypotension/B-AdverseReaction and/O bronchospasm/B-AdverseReaction ./O
Discontinue/O JEVTANA/O immediately/O if/O severe/O reactions/O occur/O and/O administer/O appropriate/O therapy/O ./O
(/O 2.1)(5.2/O )/O Contraindicated/O if/O history/O of/O severe/O hypersensitivity/O reactions/O to/O JEVTANA/O or/O to/O drugs/O formulated/O with/O polysorbate/O 80/O ./O
(/O 4/O )/O Neutropenia/O :/O Neutropenic/B-AdverseReaction deaths/B-AdverseReaction have/O been/O reported/O ./O
In/O order/O to/O monitor/O the/O occurrence/O of/O neutropenia/O ,/O frequent/O blood/O cell/O counts/O should/O be/O performed/O on/O all/O patients/O receiving/O JEVTANA/O ./O
JEVTANA/O is/O contraindicated/O in/O patients/O with/O neutrophil/O counts/O of/O 1,500/O cells/O mm/O 3/O [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Severe/O hypersensitivity/O :/O Severe/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction can/B-Factor occur/O and/O may/B-Factor include/O generalized/B-AdverseReaction rash/I-AdverseReaction erythema/B-AdverseReaction ,/O hypotension/B-AdverseReaction and/O bronchospasm/B-AdverseReaction ./O
Severe/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction require/O immediate/O discontinuation/O of/O the/O JEVTANA/O infusion/O and/O administration/O of/O appropriate/O therapy/O ./O
Patients/O should/O receive/O premedication/O ./O
JEVTANA/O is/O contraindicated/O in/O patients/O who/O have/O a/O history/O of/O severe/O hypersensitivity/O reactions/O to/O cabazitaxel/O or/O to/O other/O drugs/O formulated/O with/O polysorbate/O 80/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ,/O Contraindications/O (/O 4/O )/O ,/O and/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Bone/B-AdverseReaction marrow/I-AdverseReaction suppression/I-AdverseReaction (/O particularly/O neutropenia/B-AdverseReaction )/O and/O its/O clinical/O consequences/O (/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O neutropenic/B-AdverseReaction infections/I-AdverseReaction )/O :/O Monitor/O blood/O counts/O frequently/O to/O determine/O if/O dosage/O modification/O or/O initiation/O of/O G/O -/O CSF/O is/O needed/O ./O
Primary/O prophylaxis/O with/O G/O -/O CSF/O should/O be/O considered/O in/O patients/O with/O high/O -/O risk/O clinical/O features/O ./O
Use/O caution/O in/O patients/O with/O hemoglobin/O 10/O g/O dL./O (/O 2.2/O )/O (/O 4/O )/O (/O 5.1/O )/O Hypersensitivity/B-AdverseReaction :/O Severe/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction can/B-Factor occur/O ./O
Premedicate/O with/O corticosteroids/O and/O H2/O antagonists/O ./O
Discontinue/O infusion/O immediately/O if/O hypersensitivity/O is/O observed/O and/O treat/O as/O indicated/O ./O
(/O 4/O )/O (/O 5.2/O )/O Gastrointestinal/B-AdverseReaction disorders/I-AdverseReaction :/O Nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction may/B-Factor occur/O ./O
Mortality/B-AdverseReaction related/O to/O diarrhea/B-AdverseReaction has/O been/O reported/O ./O
Rehydrate/O and/O treat/O with/O anti/O -/O emetics/O and/O anti/O -/O diarrheals/O as/O needed/O ./O
If/O experiencing/O Grade/O 3/O diarrhea/O ,/O dosage/O should/O be/O modified/O ./O
(/O 2.2/O )/O Deaths/B-AdverseReaction have/O occurred/O due/O to/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O perforation/O and/O neutropenic/B-AdverseReaction enterocolitis/I-AdverseReaction ./O
Delay/O or/O discontinue/O JEVTANA/O ./O
(/O 5.3/O )/O Renal/B-AdverseReaction failure/I-AdverseReaction ,/O including/O cases/O with/O fatal/B-AdverseReaction outcomes/O ,/O has/O been/O reported/O ./O
Identify/O cause/O and/O manage/O aggressively/O ./O
(/O 5.4/O )/O Elderly/O patients/O :/O Patients/O 65/O years/O of/O age/O were/O more/O likely/O to/O experience/O fatal/B-AdverseReaction outcomes/O not/O related/O to/O disease/O progression/O and/O certain/O adverse/O reactions/O ,/O including/O neutropenia/B-AdverseReaction and/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ./O
Monitor/O closely/O ./O
(/O 5.5/O )/O (/O 6/O )/O (/O 8.5/O )/O Hepatic/B-AdverseReaction impairment/I-AdverseReaction :/O Reduce/O the/O JEVTANA/O dose/O to/O 20/O mg/O m/O 2/O in/O patients/O with/O mild/O hepatic/O impairment/O and/O to/O 15/O mg/O m/O 2/O in/O patients/O with/O moderate/O hepatic/O impairment/O ./O
(/O 2.3/O )/O JEVTANA/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
(/O 5.7/O )/O (/O 8.1/O )/O 5.1/O Bone/O Marrow/O Suppression/O Bone/B-AdverseReaction marrow/I-AdverseReaction suppression/I-AdverseReaction manifested/O as/O neutropenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction and/or/O pancytopenia/B-AdverseReaction may/B-Factor occur/O ./O
Neutropenic/B-AdverseReaction deaths/B-AdverseReaction have/O been/O reported/O ./O
In/O the/O randomized/O trial/O ,/O five/O patients/O (/O 1.3/O %/O )/O experienced/O fatal/B-AdverseReaction infectious/B-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction (/O sepsis/B-AdverseReaction or/O septic/B-AdverseReaction shock/I-AdverseReaction )/O ./O
All/O had/O grade/B-Severity 4/I-Severity neutropenia/B-AdverseReaction and/O one/O had/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ./O
One/O additional/O patient/O 's/O death/B-AdverseReaction was/O attributed/O to/O neutropenia/B-AdverseReaction without/B-Negation a/O documented/O infection/B-AdverseReaction ./O
Grade/B-Severity 3/I-Severity -/O 4/O neutropenia/B-AdverseReaction has/O been/O observed/O in/O 82/O %/O of/O patients/O treated/O with/O JEVTANA/O in/O the/O randomized/O trial/O ./O
G/O -/O CSF/O may/O be/O administered/O to/O reduce/O the/O risks/O of/O neutropenia/O complications/O associated/O with/O JEVTANA/O use/O ./O
Primary/O prophylaxis/O with/O G/O -/O CSF/O should/O be/O considered/O in/O patients/O with/O high/O -/O risk/O clinical/O features/O (/O age/O 65/O years/O ,/O poor/O performance/O status/O ,/O previous/O episodes/O of/O febrile/O neutropenia/O ,/O extensive/O prior/O radiation/O ports/O ,/O poor/O nutritional/O status/O ,/O or/O other/O serious/O comorbidities/O )/O that/O predispose/O them/O to/O increased/O complications/O from/O prolonged/O neutropenia/O ./O
Therapeutic/O use/O of/O G/O -/O CSF/O and/O secondary/O prophylaxis/O should/O be/O considered/O in/O all/O patients/O considered/O to/O be/O at/O increased/O risk/O for/O neutropenia/O complications/O ./O
Monitoring/O of/O complete/O blood/O counts/O is/O essential/O on/O a/O weekly/O basis/O during/O cycle/O 1/O and/O before/O each/O treatment/O cycle/O thereafter/O so/O that/O the/O dose/O can/O be/O adjusted/O ,/O if/O needed/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
JEVTANA/O is/O contraindicated/O in/O patients/O with/O neutrophils/O 1,500/O mm/O 3/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
Caution/O is/O recommended/O in/O patients/O with/O hemoglobin/O 10/O g/O dl/O ./O
5.2/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction may/B-Factor occur/O within/O a/O few/O minutes/O following/O the/O initiation/O of/O the/O infusion/O of/O JEVTANA/O ,/O thus/O facilities/O and/O equipment/O for/O the/O treatment/O of/O hypotension/O and/O bronchospasm/O should/O be/O available/O ./O
Severe/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction can/B-Factor occur/O and/O may/B-Factor include/O generalized/B-AdverseReaction rash/I-AdverseReaction erythema/B-AdverseReaction ,/O hypotension/B-AdverseReaction and/O bronchospasm/B-AdverseReaction ./O
Premedicate/O all/O patients/O prior/O to/O the/O initiation/O of/O the/O infusion/O of/O JEVTANA/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
Observe/O patients/O closely/O for/O hypersensitivity/O reactions/O ,/O especially/O during/O the/O first/O and/O second/O infusions/O ./O
Severe/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction require/O immediate/O discontinuation/O of/O the/O JEVTANA/O infusion/O and/O appropriate/O therapy/O ./O
JEVTANA/O is/O contraindicated/O in/O patients/O with/O a/O history/O of/O severe/O hypersensitivity/O reactions/O to/O cabazitaxel/O or/O to/O other/O drugs/O formulated/O with/O polysorbate/O 80/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.3/O Gastrointestinal/O Adverse/O Reactions/O Nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction and/O severe/B-Severity diarrhea/B-AdverseReaction ,/O at/O times/O ,/O may/B-Factor occur/O ./O
Death/B-AdverseReaction related/O to/O diarrhea/B-AdverseReaction and/O electrolyte/B-AdverseReaction imbalance/I-AdverseReaction occurred/O in/O the/O randomized/O clinical/O trial/O ./O
Intensive/O measures/O may/O be/O required/O for/O severe/O diarrhea/O and/O electrolyte/O imbalance/O ./O
Antiemetic/O prophylaxis/O is/O recommended/O ./O
Treat/O patients/O with/O rehydration/O ,/O anti/O -/O diarrheal/O or/O anti/O -/O emetic/O medications/O as/O needed/O ./O
Treatment/O delay/O or/O dosage/O reduction/O may/O be/O necessary/O if/O patients/O experience/O Grade/O 3/O diarrhea/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Gastrointestinal/O (/O GI/O )/O hemorrhage/O and/O perforation/O ,/O ileus/B-AdverseReaction ,/O enterocolitis/B-AdverseReaction ,/O neutropenic/B-AdverseReaction enterocolitis/I-AdverseReaction ,/O including/O fatal/B-AdverseReaction outcome/O ,/O have/O been/O reported/O in/O patients/O treated/O with/O JEVTANA/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
Risk/O may/O be/O increased/O with/O neutropenia/O ,/O age/O ,/O steroid/O use/O ,/O concomitant/O use/O of/O NSAIDs/O ,/O anti/O -/O platelet/O therapy/O or/O anti/O -/O coagulants/O ,/O and/O patients/O with/O a/O prior/O history/O of/O pelvic/O radiotherapy/O ,/O adhesions/O ,/O ulceration/O and/O GI/O bleeding/O ./O
Abdominal/O pain/O and/O tenderness/O ,/O fever/O ,/O persistent/O constipation/O ,/O diarrhea/O ,/O with/O or/O without/O neutropenia/O ,/O may/O be/O early/O manifestations/O of/O serious/O gastrointestinal/O toxicity/O and/O should/O be/O evaluated/O and/O treated/O promptly/O ./O
JEVTANA/O treatment/O delay/O or/O discontinuation/O may/O be/O necessary/O ./O
5.4/O Renal/O Failure/O In/O the/O randomized/O clinical/O trial/O ,/O renal/B-AdverseReaction failure/I-AdverseReaction of/O any/O grade/O occurred/O in/O 4/O %/O of/O the/O patients/O being/O treated/O with/O JEVTANA/O ,/O including/O four/O cases/O with/O fatal/B-AdverseReaction outcome/O ./O
Most/O cases/O occurred/O in/O association/O with/O sepsis/B-AdverseReaction ,/O dehydration/B-AdverseReaction ,/O or/O obstructive/B-AdverseReaction uropathy/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Some/O deaths/B-AdverseReaction due/O to/O renal/B-AdverseReaction failure/I-AdverseReaction did/O not/O have/O a/O clear/O etiology/O ./O
Appropriate/O measures/O should/O be/O taken/O to/O identify/O causes/O of/O renal/O failure/O and/O treat/O aggressively/O ./O
5.5/O Use/O in/O Elderly/O Patients/O In/O the/O randomized/O clinical/O trial/O ,/O 3/O of/O 131/O (/O 2/O %/O )/O patients/O 65/O years/O of/O age/O and/O 15/O of/O 240/O (/O 6/O %/O )/O 65/O years/O of/O age/O died/B-AdverseReaction of/O causes/O other/O than/O disease/O progression/O within/O 30/O days/O of/O the/O last/O cabazitaxel/O dose/O ./O
Patients/O 65/O years/O of/O age/O are/O more/O likely/O to/O experience/O certain/O adverse/O reactions/O ,/O including/O neutropenia/B-AdverseReaction and/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.5/O )/O ]/O ./O
5.6/O Use/O in/O Patients/O with/O Hepatic/O Impairment/O Cabazitaxel/O is/O extensively/O metabolized/O in/O the/O liver/O ./O
JEVTANA/O is/O contraindicated/O in/O patients/O with/O severe/O hepatic/O impairment/O (/O total/O bilirubin/O 3/O ULN/O )/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
Dose/O should/O be/O reduced/O for/O patients/O with/O mild/O (/O total/O bilirubin/O 1/O to/O 1.5/O ULN/O or/O AST/O 1.5/O ULN/O )/O and/O moderate/O (/O total/O bilirubin/O 1.5/O to/O 3.0/O ULN/O and/O any/O AST/O )/O hepatic/O impairment/O ,/O based/O on/O tolerability/O data/O in/O these/O patients/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.7/O )/O ]/O ./O
Administration/O of/O cabazitaxel/O to/O patients/O with/O mild/O and/O moderate/O hepatic/O impairment/O should/O be/O undertaken/O with/O caution/O and/O close/O monitoring/O of/O safety/O ./O
5.7/O Embryo/O -/O Fetal/O Toxicity/O JEVTANA/O is/O not/O indicated/O for/O use/O in/O female/O patients/O ./O
JEVTANA/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
In/O non/O -/O clinical/O studies/O in/O rats/B-Animal and/O rabbits/B-Animal ,/O cabazitaxel/O was/O embryotoxic/B-AdverseReaction ,/O fetotoxic/B-AdverseReaction ,/O and/O abortifacient/B-AdverseReaction at/O exposures/O significantly/O lower/O than/O those/O expected/O at/O the/O recommended/O human/O dose/O level/O ./O
There/O are/O no/O adequate/O and/O well/O -/O controlled/O studies/O in/O pregnant/O women/O using/O JEVTANA/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O ./O
Females/O of/O childbearing/O potential/O should/O be/O advised/O to/O avoid/O becoming/O pregnant/O during/O treatment/O with/O JEVTANA/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O incidence/O 1/O %/O )/O were/O ingrown/B-AdverseReaction toenails/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction dermatitis/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction vesicles/I-AdverseReaction ,/O and/O application/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Valeant/O Pharmaceuticals/O North/O America/O LLC/O at/O 1/O -/O 800/O -/O 321/O -/O 4576/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
In/O two/O clinical/O trials/O ,/O 1227/O subjects/O were/O treated/O with/O JUBLIA/O ,/O 1161/O for/O at/O least/O 24/O weeks/O and/O 780/O for/O 48/O weeks/O ./O
Adverse/O reactions/O reported/O within/O 48/O weeks/O of/O treatment/O and/O in/O at/O least/O 1/O %/O of/O subjects/O treated/O with/O JUBLIA/O and/O those/O reported/O in/O subjects/O treated/O with/O the/O vehicle/O are/O presented/O in/O Table/O 1/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Reported/O by/O at/O Least/O 1/O %/O of/O Subjects/O Treated/O for/O up/O to/O 48/O Weeks/O Adverse/O Event/O ,/O n/O (/O %/O )/O JUBLIAN/O 1227/O VehicleN/O 413/O Ingrown/B-AdverseReaction toenail/I-AdverseReaction 28/O (/O 2.3/O %/O )/O 3/O (/O 0.7/O %/O )/O Application/B-AdverseReaction site/I-AdverseReaction dermatitis/I-AdverseReaction 27/O (/O 2.2/O %/O )/O 1/O (/O 0.2/O %/O )/O Application/B-AdverseReaction site/I-AdverseReaction vesicles/I-AdverseReaction 20/O (/O 1.6/O %/O )/O 0/O (/O 0.0/O %/O )/O Application/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 13/O (/O 1.1/O %/O )/O 1/O (/O 0.2/O %/O )/O 6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reaction/O is/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O label/O :/O Transaminase/B-AdverseReaction Elevations/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O drug/O reactions/O to/O KALYDECO/O (/O occurring/O in/O 8/O %/O of/O patients/O with/O CF/O who/O have/O a/O G551D/O mutation/O in/O the/O CFTR/O gene/O )/O were/O headache/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O nasal/B-AdverseReaction congestion/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O dizziness/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Vertex/O Pharmaceuticals/O Incorporated/O at/O 1/O -/O 877/O -/O 634/O -/O 8789/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O overall/O safety/O profile/O of/O KALYDECO/O is/O based/O on/O pooled/O data/O from/O three/O placebo/O -/O controlled/O clinical/O trials/O conducted/O in/O 353/O patients/O 6/O years/O of/O age/O and/O older/O with/O CF/O who/O had/O a/O G551D/O mutation/O in/O the/O CFTR/O gene/O (/O Trials/O 1/O and/O 2/O )/O or/O were/O homozygous/O for/O the/O F508del/O mutation/O (/O Trial/O 3/O )/O ./O
In/O addition/O ,/O the/O following/O clinical/O trials/O have/O also/O been/O conducted/O [/O see/O Clinical/O Pharmacology/O (/O 12/O )/O and/O Clinical/O Studies/O (/O 14/O )/O ]/O :/O An/O 8-week/O crossover/O design/O trial/O (/O Trial/O 4/O )/O involving/O 39/O patients/O between/O the/O ages/O of/O 6/O and/O 57/O years/O with/O a/O G1244E/O ,/O G1349D/O ,/O G178R/O ,/O G551S/O ,/O G970R/O ,/O S1251N/O ,/O S1255P/O ,/O S549N/O ,/O or/O S549R/O mutation/O in/O the/O CFTR/O gene/O ./O
A/O 24-week/O placebo/O -/O controlled/O trial/O (/O Trial/O 5/O )/O involving/O 69/O patients/O between/O the/O ages/O of/O 6/O and/O 68/O years/O with/O an/O R117H/O mutation/O in/O the/O CFTR/O gene/O ./O
A/O 24-week/O open/O -/O label/O trial/O (/O Trial/O 6/O )/O in/O 34/O patients/O 2/O to/O less/O than/O 6/O years/O of/O age/O ./O
Patients/O eligible/O for/O Trial/O 6/O were/O those/O with/O the/O G551D/O ,/O G1244E/O ,/O G1349D/O ,/O G178R/O ,/O G551S/O ,/O G970R/O ,/O S1251N/O ,/O S1255P/O ,/O S549N/O ,/O or/O S549R/O mutation/O in/O the/O CFTR/O gene/O ./O
Of/O 34/O patients/O enrolled/O ,/O 32/O had/O the/O G551D/O mutation/O and/O 2/O had/O the/O S549N/O mutation/O ./O
Of/O the/O 353/O patients/O included/O in/O the/O pooled/O analyses/O of/O patients/O with/O CF/O who/O had/O either/O a/O G551D/O mutation/O or/O were/O homozygous/O for/O the/O F508del/O mutation/O in/O the/O CFTR/O gene/O ,/O 50/O %/O of/O patients/O were/O female/O and/O 97/O %/O were/O Caucasian/O ;/O 221/O received/O KALYDECO/O ,/O and/O 132/O received/O placebo/O from/O 16/O to/O 48/O weeks/O ./O
The/O proportion/O of/O patients/O who/O prematurely/O discontinued/O study/O drug/O due/O to/O adverse/O reactions/O was/O 2/O %/O for/O KALYDECO/O -/O treated/O patients/O and/O 5/O %/O for/O placebo/O -/O treated/O patients/O ./O
Serious/O adverse/O reactions/O ,/O whether/O considered/O drug/O -/O related/O or/O not/O by/O the/O investigators/O ,/O that/O occurred/O more/O frequently/O in/O KALYDECO/O -/O treated/O patients/O included/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O increased/B-AdverseReaction hepatic/I-AdverseReaction enzymes/I-AdverseReaction ,/O and/O hypoglycemia/B-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O in/O the/O 221/O patients/O treated/O with/O KALYDECO/O were/O headache/B-AdverseReaction (/O 17/O %/O )/O ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 16/O %/O )/O ,/O nasal/B-AdverseReaction congestion/I-AdverseReaction (/O 16/O %/O )/O ,/O nausea/B-AdverseReaction (/O 10/O %/O )/O ,/O rash/B-AdverseReaction (/O 10/O %/O )/O ,/O rhinitis/B-AdverseReaction (/O 6/O %/O )/O ,/O dizziness/B-AdverseReaction (/O 5/O %/O )/O ,/O arthralgia/B-AdverseReaction (/O 5/O %/O )/O ,/O and/O bacteria/B-AdverseReaction in/I-AdverseReaction sputum/I-AdverseReaction (/O 5/O %/O )/O ./O
The/O incidence/O of/O adverse/O reactions/O below/O is/O based/O upon/O two/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O 48-week/O clinical/O trials/O (/O Trials/O 1/O and/O 2/O )/O in/O a/O total/O of/O 213/O patients/O with/O CF/O ages/O 6/O to/O 53/O who/O have/O a/O G551D/O mutation/O in/O the/O CFTR/O gene/O and/O who/O were/O treated/O with/O KALYDECO/O 150/O mg/O orally/O or/O placebo/O twice/O daily/O ./O
Table/O 2/O shows/O adverse/O reactions/O occurring/O in/O 8/O %/O of/O KALYDECO/O -/O treated/O patients/O with/O CF/O who/O have/O a/O G551D/O mutation/O in/O the/O CFTR/O gene/O that/O also/O occurred/O at/O a/O higher/O rate/O than/O in/O the/O placebo/O -/O treated/O patients/O in/O the/O two/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trials/O ./O
Table/O 2/O :/O Incidence/O of/O Adverse/O Drug/O Reactions/O in/O 8/O %/O of/O KALYDECO/O -/O Treated/O Patients/O with/O a/O G551D/O Mutation/O in/O the/O CFTR/O Gene/O and/O Greater/O than/O Placebo/O in/O 2/O Placebo/O -/O Controlled/O Phase/O 3/O Clinical/O Trials/O of/O 48/O Weeks/O Duration/O Adverse/O Reaction(Preferred/O Term/O )/O Incidence/O :/O Pooled/O 48-Week/O Trials/O KALYDECON=109n/O (/O %/O )/O PlaceboN=104n/O (/O %/O )/O Headache/B-AdverseReaction 26/O (/O 24/O )/O 17/O (/O 16/O )/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 24/O (/O 22/O )/O 19/O (/O 18/O )/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 24/O (/O 22/O )/O 14/O (/O 14/O )/O Nasal/B-AdverseReaction congestion/I-AdverseReaction 22/O (/O 20/O )/O 16/O (/O 15/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 17/O (/O 16/O )/O 13/O (/O 13/O )/O Nasopharyngitis/B-AdverseReaction 16/O (/O 15/O )/O 12/O (/O 12/O )/O Diarrhea/B-AdverseReaction 14/O (/O 13/O )/O 10/O (/O 10/O )/O Rash/B-AdverseReaction 14/O (/O 13/O )/O 7/O (/O 7/O )/O Nausea/B-AdverseReaction 13/O (/O 12/O )/O 11/O (/O 11/O )/O Dizziness/B-AdverseReaction 10/O (/O 9/O )/O 1/O (/O 1/O )/O Adverse/O reactions/O in/O the/O 48-week/O clinical/O trials/O that/O occurred/O in/O the/O KALYDECO/O group/O at/O a/O frequency/O of/O 4/O to/O 7/O %/O where/O rates/O exceeded/O that/O in/O the/O placebo/O group/O include/O :/O Infections/O and/O infestations/O :/O rhinitis/B-AdverseReaction Investigations/O :/O aspartate/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O bacteria/B-AdverseReaction in/I-AdverseReaction sputum/I-AdverseReaction ,/O blood/B-AdverseReaction glucose/I-AdverseReaction increased/I-AdverseReaction ,/O hepatic/B-AdverseReaction enzyme/I-AdverseReaction increased/I-AdverseReaction Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O arthralgia/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction chest/I-AdverseReaction pain/I-AdverseReaction ,/O myalgia/B-AdverseReaction Nervous/O system/O disorders/O :/O sinus/B-AdverseReaction headache/I-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O pharyngeal/B-AdverseReaction erythema/I-AdverseReaction ,/O pleuritic/B-AdverseReaction pain/I-AdverseReaction ,/O sinus/B-AdverseReaction congestion/I-AdverseReaction ,/O wheezing/B-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O acne/B-AdverseReaction The/O safety/O profile/O for/O the/O CF/O patients/O enrolled/O in/O the/O other/O clinical/O trials/O (/O Trials/O 3/O -/O 6/O )/O was/O similar/O to/O that/O observed/O in/O the/O 48-week/O ,/O placebo/O -/O controlled/O trials/O (/O Trials/O 1/O and/O 2/O )/O ./O
Laboratory/O Abnormalities/O Transaminase/O Elevations/O :/O In/O Trials/O 1/O ,/O 2/O ,/O and/O 3/O the/O incidence/O of/O maximum/O transaminase/O (/O ALT/O or/O AST/O )/O 8/O ,/O 5/O ,/O or/O 3/O ULN/O was/O 2/O %/O ,/O 2/O %/O ,/O and/O 6/O %/O in/O KALYDECO/O -/O treated/O patients/O and/O 2/O %/O ,/O 2/O %/O ,/O and/O 8/O %/O in/O placebo/O -/O treated/O patients/O ,/O respectively/O ./O
Two/O patients/O (/O 2/O %/O )/O on/O placebo/O and/O 1/O patient/O (/O 0.5/O %/O )/O on/O KALYDECO/O permanently/O discontinued/O treatment/O for/O elevated/B-AdverseReaction transaminases/I-AdverseReaction ,/O all/O 8/I-Severity ULN/O ./O
Two/O patients/O treated/O with/O KALYDECO/O were/O reported/O to/O have/O serious/B-Severity adverse/O reactions/O of/O elevated/B-AdverseReaction liver/I-AdverseReaction transaminases/I-AdverseReaction compared/O to/O none/O on/O placebo/O ./O
Transaminase/O elevations/O were/O more/O common/O in/O patients/O with/O a/O history/O of/O transaminase/O elevations/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
During/O the/O 24-week/O ,/O open/O -/O label/O ,/O clinical/O trial/O in/O 34/O patients/O ages/O 2/O to/O less/O than/O 6/O years/O (/O Trial/O 6/O )/O ,/O where/O patients/O received/O either/O 50/O mg/O (/O less/O than/O 14/O kg/O )/O or/O 75/O mg/O (/O 14/O kg/O or/O greater/O )/O ivacaftor/O granules/O twice/O daily/O ,/O the/O incidence/O of/O patients/O experiencing/O transaminase/B-AdverseReaction elevations/I-AdverseReaction (/O ALT/O or/O AST/O )/O 3/I-Severity ULN/O was/O 14.7/O %/O (/O 5/34/O )/O ./O
All/O 5/O patients/O had/O maximum/O ALT/O or/O AST/B-AdverseReaction levels/I-AdverseReaction 8/I-AdverseReaction ULN/O ,/O which/O returned/O to/O baseline/O levels/O following/O interruption/O of/O KALYDECO/O dosing/O ./O
Transaminase/O elevations/O were/O more/O common/O in/O patients/O who/O had/O abnormal/O transaminases/O at/O baseline/O ./O
KALYDECO/O was/O permanently/O discontinued/O in/O one/O patient/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Elevated/B-AdverseReaction transaminases/I-AdverseReaction (/O ALT/O or/O AST/O )/O :/O Transaminases/O (/O ALT/O and/O AST/O )/O should/O be/O assessed/O prior/O to/O initiating/O KALYDECO/O ,/O every/O 3/O months/O during/O the/O first/O year/O of/O treatment/O ,/O and/O annually/O thereafter/O ./O
In/O patients/O with/O a/O history/O of/O transaminase/O elevations/O ,/O more/O frequent/O monitoring/O of/O liver/O function/O tests/O should/O be/O considered/O ./O
Patients/O who/O develop/O increased/O transaminase/O levels/O should/O be/O closely/O monitored/O until/O the/O abnormalities/O resolve/O ./O
Dosing/O should/O be/O interrupted/O in/O patients/O with/O ALT/O or/O AST/O of/O greater/O than/O 5/O times/O the/O upper/O limit/O of/O normal/O (/O ULN/O )/O ./O
Following/O resolution/O of/O transaminase/O elevations/O ,/O consider/O the/O benefits/O and/O risks/O of/O resuming/O KALYDECO/O dosing/O ./O
(/O 5.1/O ,/O 6/O )/O Use/O with/O CYP3A/O inducers/O :/O Concomitant/O use/O with/O strong/O CYP3A/O inducers/O (/O e.g./O ,/O rifampin/O ,/O St./O John/O 's/O wort/O )/O substantially/O decreases/O exposure/O of/O ivacaftor/O ,/O which/O may/O diminish/O effectiveness/O ./O
Therefore/O ,/O co/O -/O administration/O is/O not/O recommended/O ./O
(/O 5.2/O ,/O 7.2/O ,/O 12.3/O )/O Cataracts/B-AdverseReaction :/O Non/B-AdverseReaction -/I-AdverseReaction congenital/I-AdverseReaction lens/O opacities/O cataracts/O have/O been/O reported/O in/O pediatric/O patients/O treated/O with/O KALYDECO/O ./O
Baseline/O and/O follow/O -/O up/O examinations/O are/O recommended/O in/O pediatric/O patients/O initiating/O KALYDECO/O treatment/O ./O
(/O 5.3/O )/O 5.1/O Transaminase/O (/O ALT/O or/O AST/O )/O Elevations/O Elevated/B-AdverseReaction transaminases/I-AdverseReaction have/O been/O reported/O in/O patients/O with/O CF/O receiving/O KALYDECO/O ./O
It/O is/O recommended/O that/O ALT/O and/O AST/O be/O assessed/O prior/O to/O initiating/O KALYDECO/O ,/O every/O 3/O months/O during/O the/O first/O year/O of/O treatment/O ,/O and/O annually/O thereafter/O ./O
For/O patients/O with/O a/O history/O of/O transaminase/O elevations/O ,/O more/O frequent/O monitoring/O of/O liver/O function/O tests/O should/O be/O considered/O ./O
Patients/O who/O develop/O increased/O transaminase/O levels/O should/O be/O closely/O monitored/O until/O the/O abnormalities/O resolve/O ./O
Dosing/O should/O be/O interrupted/O in/O patients/O with/O ALT/O or/O AST/O of/O greater/O than/O 5/O times/O the/O upper/O limit/O of/O normal/O (/O ULN/O )/O ./O
Following/O resolution/O of/O transaminase/O elevations/O ,/O consider/O the/O benefits/O and/O risks/O of/O resuming/O KALYDECO/O dosing/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
5.2/O Concomitant/O Use/O with/O CYP3A/O Inducers/O Use/O of/O KALYDECO/O with/O strong/O CYP3A/O inducers/O ,/O such/O as/O rifampin/O ,/O substantially/O decreases/O the/O exposure/O of/O ivacaftor/O ,/O which/O may/O reduce/O the/O therapeutic/O effectiveness/O of/O KALYDECO/O ./O
Therefore/O ,/O co/O -/O administration/O of/O KALYDECO/O with/O strong/O CYP3A/O inducers/O (/O e.g./O ,/O rifampin/O ,/O St./O John/O 's/O wort/O )/O is/O not/O recommended/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
5.3/O Cataracts/O Cases/O of/O non/B-AdverseReaction -/I-AdverseReaction congenital/I-AdverseReaction lens/O opacities/O cataracts/O have/O been/O reported/O in/O pediatric/O patients/O treated/O with/O KALYDECO/O ./O
Although/O other/O risk/O factors/O were/O present/O in/O some/O cases/O (/O such/O as/O corticosteroid/O use/O and/or/O exposure/O to/O radiation/O )/O ,/O a/O possible/O risk/O attributable/O to/O KALYDECO/O can/O not/O be/O excluded/O ./O
Baseline/O and/O follow/O -/O up/O ophthalmological/O examinations/O are/O recommended/O in/O pediatric/O patients/O initiating/O KALYDECO/O treatment/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Cardiac/B-AdverseReaction Toxicities/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Acute/B-AdverseReaction Renal/I-AdverseReaction Failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Pulmonary/B-AdverseReaction Toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Pulmonary/B-AdverseReaction Hypertension/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Dyspnea/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Hypertension/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Venous/B-AdverseReaction Thrombosis/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Infusion/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O Thrombocytopenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.10/O )/O ]/O Hepatic/B-AdverseReaction Toxicity/I-AdverseReaction and/O Hepatic/B-AdverseReaction Failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.11/O )/O ]/O Thrombotic/B-AdverseReaction Thrombocytopenic/I-AdverseReaction Purpura/I-AdverseReaction Hemolytic/B-AdverseReaction Uremic/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.12/O )/O ]/O Posterior/B-AdverseReaction Reversible/I-AdverseReaction Encephalopathy/I-AdverseReaction Syndrome/I-AdverseReaction (/O PRES/B-AdverseReaction )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.13/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O events/O occurring/O in/O at/O least/O 20/O %/O of/O patients/O treated/O with/O Kyprolis/O in/O monotherapy/O trials/O :/O anemia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O decreased/B-AdverseReaction platelets/I-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O decreased/B-AdverseReaction lymphocyte/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O decreased/B-AdverseReaction hemoglobin/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O edema/B-AdverseReaction peripheral/I-AdverseReaction ./O
(/O 6/O )/O The/O most/O common/O adverse/O events/O occurring/O in/O at/O least/O 20/O %/O of/O patients/O treated/O with/O Kyprolis/O in/O the/O combination/O therapy/O trial/O :/O decreased/B-AdverseReaction lymphocytes/I-AdverseReaction ,/O decreased/B-AdverseReaction absolute/I-AdverseReaction neutrophil/I-AdverseReaction count/I-AdverseReaction ,/O decreased/B-AdverseReaction phosphorus/I-AdverseReaction ,/O anemia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O decreased/B-AdverseReaction total/I-AdverseReaction white/I-AdverseReaction blood/I-AdverseReaction cell/I-AdverseReaction count/I-AdverseReaction ,/O decreased/B-AdverseReaction platelets/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O muscle/B-AdverseReaction spasm/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O decreased/B-AdverseReaction hemoglobin/I-AdverseReaction ,/O hypokalemia/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Amgen/O Medical/O Information/O at/O 1/O -/O 800/O -/O 77-AMGEN/O (/O 1/O -/O 800/O -/O 772/O -/O 6436/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O ,/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O medical/O practice/O ./O
6.1.1/O Safety/O Experience/O with/O Kyprolis/O in/O Combination/O with/O Lenalidomide/O and/O Dexamethasone/O in/O Patients/O with/O Multiple/O Myeloma/O The/O safety/O of/O Kyprolis/O in/O combination/O with/O lenalidomide/O and/O dexamethasone/O (/O KRd/O )/O was/O evaluated/O in/O an/O open/O -/O label/O randomized/O study/O in/O patients/O with/O relapsed/O multiple/O myeloma/O ./O
Details/O of/O the/O study/O treatment/O are/O described/O in/O Section/O 14.1/O ./O
The/O median/O number/O of/O cycles/O initiated/O was/O 22/O cycles/O for/O the/O KRd/O arm/O and/O 14/O cycles/O for/O the/O Rd/O arm/O ./O
Deaths/B-AdverseReaction due/O to/O adverse/O events/O within/O 30/O days/O of/O the/O last/O dose/O of/O any/O therapy/O in/O the/O KRd/O arm/O occurred/O in/O 27/392/O (/O 7/O %/O )/O patients/O compared/O with/O 27/389/O (/O 7/O %/O )/O patients/O who/O died/B-AdverseReaction due/O to/O adverse/O events/O within/O 30/O days/O of/O the/O last/O dose/O of/O any/O Rd/O therapy/O ./O
The/O most/O common/O cause/O of/O deaths/B-AdverseReaction occurring/O in/O patients/O (/O %/O )/O in/O the/O two/O arms/O (/O KRd/O versus/O Rd/O )/O included/O cardiac/O 10/O (/O 3/O %/O )/O versus/O 7/O (/O 2/O %/O )/O ,/O infection/O 9/O (/O 2/O %/O )/O versus/O 10/O (/O 3/O %/O )/O ,/O renal/O 0/O (/O 0/O %/O )/O versus/O 1/O (/O 1/O %/O )/O ,/O and/O other/O adverse/O events/O 9/O (/O 2/O %/O )/O versus/O 10/O (/O 3/O %/O )/O ./O
Serious/O adverse/O events/O were/O reported/O in/O 60/O %/O of/O the/O patients/O in/O the/O KRd/O arm/O and/O 54/O %/O of/O the/O patients/O in/O the/O Rd/O arm/O ./O
The/O most/O common/O serious/O adverse/O events/O reported/O in/O the/O KRd/O arm/O as/O compared/O with/O the/O Rd/O arm/O were/O pneumonia/B-AdverseReaction (/O 14/O %/O versus/O 11/O %/O )/O ,/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 4/O %/O versus/O 1.5/O %/O )/O ,/O pyrexia/B-AdverseReaction (/O 4/O %/O versus/O 2/O %/O )/O ,/O and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O 3/O %/O versus/O 2/O %/O )/O ./O
Discontinuation/O due/O to/O any/O adverse/O event/O occurred/O in/O 26/O %/O in/O the/O KRd/O arm/O versus/O 25/O %/O in/O the/O Rd/O arm/O ./O
Adverse/O events/O leading/O to/O discontinuation/O of/O Kyprolis/O occurred/O in/O 12/O %/O of/O patients/O and/O the/O most/O common/O events/O included/O pneumonia/B-AdverseReaction (/O 1/O %/O )/O ,/O myocardial/B-AdverseReaction infarction/I-AdverseReaction (/O 0.8/O %/O )/O ,/O and/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 0.8/O %/O )/O ./O
Common/O Adverse/O Events/O (/O 10/O %/O )/O The/O adverse/O events/O in/O the/O first/O 12/O cycles/O of/O therapy/O that/O occurred/O at/O a/O rate/O of/O 10/O %/O or/O greater/O in/O the/O KRd/O arm/O are/O presented/O in/O Table/O 5/O ./O
Table/O 5/O :/O Common/O Adverse/O Events/O (/O 10/O %/O in/O the/O KRd/O Arm/O )/O Occurring/O in/O Cycles/O 1/O -/O 12/O (/O Combination/O Therapy/O )/O KRd/O Kyprolis/O ,/O lenalidomide/O ,/O and/O low/O -/O dose/O dexamethasone/O ;/O Rd/O lenalidomide/O and/O low/O -/O dose/O dexamethasone/O a/O Pneumonia/B-AdverseReaction includes/O preferred/O terms/O of/O pneumonia/B-AdverseReaction ,/O bronchopneumonia/B-AdverseReaction b/O Peripheral/B-AdverseReaction neuropathies/I-AdverseReaction NEC/I-AdverseReaction includes/O preferred/O terms/O under/O HLT/O peripheral/B-AdverseReaction neuropathies/I-AdverseReaction NEC/I-AdverseReaction c/O Dyspnea/B-AdverseReaction includes/O preferred/O terms/O of/O dyspnea/B-AdverseReaction ,/O dyspnea/B-AdverseReaction exertional/I-AdverseReaction d/O Embolic/B-AdverseReaction and/I-AdverseReaction thrombotic/I-AdverseReaction events/I-AdverseReaction ,/I-AdverseReaction venous/O include/O preferred/O terms/O in/O MedDRA/O SMQ/O narrow/O scope/O search/O of/O embolic/B-AdverseReaction and/I-AdverseReaction thrombotic/I-AdverseReaction events/I-AdverseReaction ,/I-AdverseReaction venous/O ./O
e/O Hypertension/B-AdverseReaction includes/O preferred/O terms/O of/O hypertension/B-AdverseReaction ,/O hypertensive/B-AdverseReaction crisis/I-AdverseReaction ,/O hypertensive/B-AdverseReaction emergency/I-AdverseReaction System/O Organ/O Class/O KRd/O Arm(N/O 392/O )/O Rd/O Arm(N/O 389/O )/O Preferred/O Term/O Any/O Grade/O Grade/O 3/O Any/O Grade/O Grade/O 3/O Blood/O and/O Lymphatic/O System/O Disorders/O Anemia/B-AdverseReaction 138/O (/O 35/O %/O )/O 53/O (/O 14/O %/O )/O 127/O (/O 33/O %/O )/O 47/O (/O 12/O %/O )/O Neutropenia/B-AdverseReaction 124/O (/O 32/O %/O )/O 104/O (/O 27/O %/O )/O 115/O (/O 30/O %/O )/O 89/O (/O 23/O %/O )/O Thrombocytopenia/B-AdverseReaction 100/O (/O 26/O %/O )/O 58/O (/O 15/O %/O )/O 75/O (/O 19/O %/O )/O 39/O (/O 10/O %/O )/O Gastrointestinal/O Disorders/O Diarrhea/B-AdverseReaction 115/O (/O 29/O %/O )/O 7/O (/O 2/O %/O )/O 105/O (/O 27/O %/O )/O 12/O (/O 3/O %/O )/O Constipation/B-AdverseReaction 68/O (/O 17/O %/O )/O 0/O 53/O (/O 14/O %/O )/O 1/O (/O 0/O %/O )/O Nausea/B-AdverseReaction 60/O (/O 15/O %/O )/O 1/O (/O 0/O %/O )/O 39/O (/O 10/O %/O )/O 3/O (/O 1/O %/O )/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Fatigue/B-AdverseReaction 109/O (/O 28/O %/O )/O 21/O (/O 5/O %/O )/O 104/O (/O 27/O %/O )/O 20/O (/O 5/O %/O )/O Pyrexia/B-AdverseReaction 93/O (/O 24/O %/O )/O 5/O (/O 1/O %/O )/O 64/O (/O 17/O %/O )/O 1/O (/O 0/O %/O )/O Edema/B-AdverseReaction Peripheral/I-AdverseReaction 63/O (/O 16/O %/O )/O 2/O (/O 1/O %/O )/O 57/O (/O 15/O %/O )/O 2/O (/O 1/O %/O )/O Asthenia/B-AdverseReaction 53/O (/O 14/O %/O )/O 11/O (/O 3/O %/O )/O 46/O (/O 12/O %/O )/O 7/O (/O 2/O %/O )/O Infections/O and/O Infestations/O Upper/B-AdverseReaction Respiratory/I-AdverseReaction Tract/I-AdverseReaction Infection/I-AdverseReaction 85/O (/O 22/O %/O )/O 7/O (/O 2/O %/O )/O 52/O (/O 13/O %/O )/O 3/O (/O 1/O %/O )/O Nasopharyngitis/B-AdverseReaction 63/O (/O 16/O %/O )/O 0/O 43/O (/O 11/O %/O )/O 0/O Bronchitis/B-AdverseReaction 54/O (/O 14/O %/O )/O 5/O (/O 1/O %/O )/O 39/O (/O 10/O %/O )/O 2/O (/O 1/O %/O )/O Pneumoniaa/B-AdverseReaction 54/O (/O 14/O %/O )/O 35/O (/O 9/O %/O )/O 43/O (/O 11/O %/O )/O 27/O (/O 7/O %/O )/O Metabolism/O and/O Nutrition/O Disorders/O Hypokalemia/B-AdverseReaction 78/O (/O 20/O %/O )/O 22/O (/O 6/O %/O )/O 35/O (/O 9/O %/O )/O 12/O (/O 3/O %/O )/O Hypocalcemia/B-AdverseReaction 55/O (/O 14/O %/O )/O 10/O (/O 3/O %/O )/O 39/O (/O 10/O %/O )/O 5/O (/O 1/O %/O )/O Hyperglycemia/B-AdverseReaction 43/O (/O 11/O %/O )/O 18/O (/O 5/O %/O )/O 33/O (/O 9/O %/O )/O 15/O (/O 4/O %/O )/O Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Muscle/B-AdverseReaction Spasms/I-AdverseReaction 88/O (/O 22/O %/O )/O 3/O (/O 1/O %/O )/O 73/O (/O 19/O %/O )/O 3/O (/O 1/O %/O )/O Nervous/O System/O Disorders/O Peripheral/B-AdverseReaction Neuropathies/I-AdverseReaction NECb/I-AdverseReaction 43/O (/O 11/O %/O )/O 7/O (/O 2/O %/O )/O 37/O (/O 10/O %/O )/O 4/O (/O 1/O %/O )/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 63/O (/O 16/O %/O )/O 6/O (/O 2/O %/O )/O 50/O (/O 13/O %/O )/O 8/O (/O 2/O %/O )/O Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O Cough/B-AdverseReaction 85/O (/O 22/O %/O )/O 1/O (/O 0/O %/O )/O 46/O (/O 12/O %/O )/O 0/O Dyspneac/B-AdverseReaction 70/O (/O 18/O %/O )/O 9/O (/O 2/O %/O )/O 58/O (/O 15/O %/O )/O 6/O (/O 2/O %/O )/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Rash/B-AdverseReaction 45/O (/O 12/O %/O )/O 5/O (/O 1/O %/O )/O 53/O (/O 14/O %/O )/O 5/O (/O 1/O %/O )/O Vascular/O Disorders/O Embolic/B-AdverseReaction and/I-AdverseReaction Thrombotic/I-AdverseReaction Events/I-AdverseReaction ,/I-AdverseReaction Venousd/O 49/O (/O 13/O %/O )/O 16/O (/O 4/O %/O )/O 22/O (/O 6/O %/O )/O 9/O (/O 2/O %/O )/O Hypertensione/B-AdverseReaction 41/O (/O 11/O %/O )/O 12/O (/O 3/O %/O )/O 15/O (/O 4/O %/O )/O 4/O (/O 1/O %/O )/O There/O were/O 274/O (/O 70/O %/O )/O patients/O in/O the/O KRd/O arm/O who/O received/O treatment/O beyond/O Cycle/O 12/O ./O
There/O were/O no/O new/O clinically/O relevant/O AEs/O that/O emerged/O in/O the/O later/O treatment/O cycles/O ./O
Adverse/O Reactions/O Occurring/O at/O a/O Frequency/O of/O 10/O %/O Blood/O and/O lymphatic/O system/O disorders/O :/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O lymphopenia/B-AdverseReaction Cardiac/O disorders/O :/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction congestive/I-AdverseReaction ,/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O myocardial/B-AdverseReaction ischemia/I-AdverseReaction Eye/O disorders/O :/O cataract/B-AdverseReaction ,/O vision/B-AdverseReaction blurred/I-AdverseReaction Gastrointestinal/O disorders/O :/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O toothache/B-AdverseReaction General/O disorders/O and/O administration/O site/O conditions/O :/O chills/B-AdverseReaction ,/O infusion/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O multi/B-AdverseReaction -/I-AdverseReaction organ/O failure/O ,/O pain/B-AdverseReaction Infections/O and/O infestations/O :/O influenza/B-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O viral/B-AdverseReaction infection/I-AdverseReaction Metabolism/O and/O nutrition/O disorders/O :/O dehydration/B-AdverseReaction ,/O hyperkalemia/B-AdverseReaction ,/O hyperuricemia/B-AdverseReaction ,/O hypoalbuminemia/B-AdverseReaction ,/O hyponatremia/B-AdverseReaction ,/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O myalgia/B-AdverseReaction Nervous/O system/O disorders/O :/O hypoesthesia/B-AdverseReaction ,/O paresthesia/B-AdverseReaction ,/O deafness/B-AdverseReaction Psychiatric/O disorders/O :/O anxiety/B-AdverseReaction ,/O delirium/B-AdverseReaction Renal/O and/O urinary/O disorders/O :/O renal/B-AdverseReaction failure/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction acute/I-AdverseReaction ,/O renal/B-AdverseReaction impairment/I-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O dysphonia/B-AdverseReaction ,/O epistaxis/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction ,/O pulmonary/B-AdverseReaction edema/I-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O erythema/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O pruritus/B-AdverseReaction Vascular/O disorders/O :/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction ,/O hypotension/B-AdverseReaction Grade/B-Severity 3/I-Severity and/O higher/O adverse/O reactions/O that/O occurred/O during/O Cycles/O 1/O -/O 12/O with/O a/O substantial/O difference/O (/O 2/O %/O )/O between/O the/O two/O arms/O were/O neutropenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O and/O hypophosphatemia/B-AdverseReaction ./O
Laboratory/O Abnormalities/O Table/O 6/O describes/O Grade/O 3/O -/O 4/O laboratory/O abnormalities/O reported/O at/O a/O rate/O of/O 10/O %/O in/O the/O KRd/O arm/O for/O patients/O who/O received/O combination/O therapy/O ./O
Table/O 6/O :/O Grade/O 3/O -/O 4/O Laboratory/O Abnormalities/O (/O 10/O %/O )/O in/O Cycles/O 1/O -/O 12/O (/O Combination/O Therapy/O )/O KRd/O Kyprolis/O ,/O lenalidomide/O ,/O and/O low/O -/O dose/O dexamethasone/O ;/O Rd/O lenalidomide/O and/O low/O -/O dose/O dexamethasone/O Laboratory/O Abnormality/O KRd/O (/O N/O 392/O )/O Rd(N/O 389/O )/O Decreased/B-AdverseReaction Lymphocytes/I-AdverseReaction 182/O (/O 46/O %/O )/O 119/O (/O 31/O %/O )/O Decreased/B-AdverseReaction Absolute/I-AdverseReaction Neutrophil/I-AdverseReaction Count/I-AdverseReaction 152/O (/O 39/O %/O )/O 140/O (/O 36/O %/O )/O Decreased/B-AdverseReaction Phosphorus/I-AdverseReaction 122/O (/O 31/O %/O )/O 106/O (/O 27/O %/O )/O Decreased/B-AdverseReaction Platelets/I-AdverseReaction 101/O (/O 26/O %/O )/O 59/O (/O 15/O %/O )/O Decreased/B-AdverseReaction Total/I-AdverseReaction White/I-AdverseReaction Blood/I-AdverseReaction Cell/I-AdverseReaction Count/I-AdverseReaction 97/O (/O 25/O %/O )/O 71/O (/O 18/O %/O )/O Decreased/B-AdverseReaction Hemoglobin/I-AdverseReaction 58/O (/O 15/O %/O )/O 68/O (/O 18/O %/O )/O Decreased/B-AdverseReaction Potassium/I-AdverseReaction 41/O (/O 11/O %/O )/O 23/O (/O 6/O %/O )/O 6.1.2/O Safety/O Experience/O with/O Kyprolis/O in/O Patients/O with/O Multiple/O Myeloma/O who/O Received/O Monotherapy/O The/O safety/O of/O Kyprolis/O was/O evaluated/O in/O clinical/O trials/O in/O which/O 598/O patients/O with/O relapsed/O and/or/O refractory/O myeloma/O received/O Kyprolis/O monotherapy/O starting/O with/O the/O 20/O mg/O m/O 2/O dose/O in/O Cycle/O 1/O Day/O 1/O and/O escalating/O to/O 27/O mg/O m/O 2/O on/O Cycle/O 1/O Day/O 8/O or/O Cycle/O 2/O Day/O 1/O ./O
The/O median/O age/O of/O these/O patients/O was/O 64/O years/O (/O range/O 32/O -/O 87/O )/O ./O
The/O patients/O received/O a/O median/O of/O 5/O (/O range/O 1/O -/O 20/O )/O prior/O regimens/O ./O
Approximately/O 57/O %/O of/O the/O patients/O were/O male/O ./O
The/O median/O number/O of/O cycles/O initiated/O was/O 4/O (/O range/O 1/O -/O 35/O )/O ./O
Serious/O adverse/O events/O were/O reported/O ,/O regardless/O of/O causality/O ,/O in/O 50/O %/O of/O patients/O in/O the/O pooled/O Kyprolis/O monotherapy/O studies/O (/O n/O 598/O )/O ./O
The/O most/O common/O serious/O adverse/O events/O were/O :/O pneumonia/B-AdverseReaction (/O 8/O %/O )/O ,/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction (/O 5/O %/O )/O ,/O disease/B-AdverseReaction progression/I-AdverseReaction (/O 4/O %/O )/O ,/O pyrexia/B-AdverseReaction (/O 3/O %/O )/O ,/O hypercalcemia/B-AdverseReaction (/O 3/O %/O )/O ,/O congestive/B-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction (/O 3/O %/O )/O ,/O multiple/B-AdverseReaction myeloma/I-AdverseReaction (/O 3/O %/O )/O ,/O anemia/B-AdverseReaction (/O 2/O %/O )/O ,/O and/O dyspnea/B-AdverseReaction (/O 2/O %/O )/O ./O
In/O patients/O treated/O with/O Kyprolis/O ,/O the/O incidence/O of/O serious/O adverse/O events/O was/O higher/O in/O those/O 65/O years/O old/O and/O in/O those/O 75/O years/O old/O [/O see/O Geriatric/O Use/O (/O 8.5/O )/O ]/O ./O
Deaths/B-AdverseReaction due/O to/O adverse/O events/O within/O 30/O days/O of/O the/O last/O dose/O of/O Kyprolis/O occurred/O in/O 30/598/O (/O 5/O %/O )/O patients/O receiving/O Kyprolis/O monotherapy/O ./O
These/O adverse/O events/O were/O related/O to/O cardiac/B-AdverseReaction disorders/I-AdverseReaction in/O 10/O (/O 2/O %/O )/O patients/O ,/O infections/B-AdverseReaction in/O 8/O (/O 1/O %/O )/O patients/O ,/O renal/B-AdverseReaction disorders/I-AdverseReaction in/O 4/O (/O 1/O %/O )/O patients/O ,/O and/O other/O adverse/O events/O in/O 8/O (/O 1/O %/O )/O patients/O ./O
In/O a/O randomized/O trial/O comparing/O Kyprolis/O as/O a/O single/O agent/O versus/O corticosteroids/O with/O optional/O oral/O cyclophosphamide/O for/O patients/O with/O relapsed/O and/O refractory/O multiple/O myeloma/O ,/O mortality/B-AdverseReaction was/O higher/O in/O the/O patients/O treated/O with/O Kyprolis/O in/O comparison/O to/O the/O control/O arm/O in/O the/O subgroup/O of/O 48/O patients/O 75/O years/O of/O age/O ./O
The/O most/O common/O cause/O of/O discontinuation/O due/O to/O an/O adverse/O event/O was/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction (/O 2/O %/O )/O ./O
The/O common/O adverse/O events/O occurring/O at/O a/O rate/O of/O 10/O %/O or/O greater/O with/O Kyprolis/O monotherapy/O are/O presented/O in/O Table/O 7/O ./O
Table/O 7/O :/O Most/O Commonly/O Reported/O Adverse/O Events/O (/O 10/O %/O )/O with/O Kyprolis/O Monotherapy/O a/O Pneumonia/B-AdverseReaction includes/O the/O preferred/O terms/O of/O pneumonia/B-AdverseReaction ,/O bronchopneumonia/B-AdverseReaction ./O
b/O Peripheral/B-AdverseReaction neuropathies/I-AdverseReaction NEC/I-AdverseReaction includes/O the/O preferred/O terms/O under/O HLT/O peripheral/B-AdverseReaction neuropathies/I-AdverseReaction NEC/I-AdverseReaction ./O
c/O Dyspnea/B-AdverseReaction includes/O the/O preferred/O terms/O of/O dyspnea/B-AdverseReaction ,/O dyspnea/B-AdverseReaction exertional/I-AdverseReaction ./O
d/O Hypertension/B-AdverseReaction includes/O the/O preferred/O terms/O of/O hypertension/B-AdverseReaction ,/O hypertensive/B-AdverseReaction crisis/I-AdverseReaction ,/O and/O hypertensive/B-AdverseReaction emergency/I-AdverseReaction ./O
Kyprolis/O Monotherapy20/27/O mg/O m2/O (/O N/O 598/O )/O System/O Organ/O Class/O Any/O Grade/O Grade3/O Blood/O and/O Lymphatic/O System/O Disorders/O Anemia/B-AdverseReaction 291/O (/O 49/O %/O )/O 141/O (/O 24/O %/O )/O Thrombocytopenia/B-AdverseReaction 220/O (/O 37/O %/O )/O 152/O (/O 25/O %/O )/O Neutropenia/B-AdverseReaction 113/O (/O 19/O %/O )/O 63/O (/O 11/O %/O )/O Lymphopenia/B-AdverseReaction 85/O (/O 14/O %/O )/O 73/O (/O 12/O %/O )/O Leukopenia/B-AdverseReaction 61/O (/O 10/O %/O )/O 26/O (/O 4/O %/O )/O Gastrointestinal/O Disorders/O Nausea/B-AdverseReaction 211/O (/O 35/O %/O )/O 7/O (/O 1/O %/O )/O Diarrhea/B-AdverseReaction 160/O (/O 27/O %/O )/O 8/O (/O 1/O %/O )/O Vomiting/B-AdverseReaction 104/O (/O 17/O %/O )/O 4/O (/O 1/O %/O )/O Constipation/B-AdverseReaction 90/O (/O 15/O %/O )/O 1/O (/O 0/O %/O )/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Fatigue/B-AdverseReaction 238/O (/O 40/O %/O )/O 25/O (/O 4/O %/O )/O Pyrexia/B-AdverseReaction 177/O (/O 30/O %/O )/O 11/O (/O 2/O %/O )/O Edema/B-AdverseReaction Peripheral/I-AdverseReaction 118/O (/O 20/O %/O )/O 1/O (/O 0/O %/O )/O Chills/B-AdverseReaction 73/O (/O 12/O %/O )/O 1/O (/O 0/O %/O )/O Asthenia/B-AdverseReaction 71/O (/O 12/O %/O )/O 9/O (/O 2/O %/O )/O Infections/O and/O Infestations/O Upper/B-AdverseReaction Respiratory/I-AdverseReaction Tract/I-AdverseReaction Infection/I-AdverseReaction 112/O (/O 19/O %/O )/O 15/O (/O 3/O %/O )/O Pneumoniaa/B-AdverseReaction 71/O (/O 12/O %/O )/O 54/O (/O 9/O %/O )/O Metabolism/O and/O Nutrition/O Disorders/O Decreased/B-AdverseReaction Appetite/I-AdverseReaction 89/O (/O 15/O %/O )/O 2/O (/O 0/O %/O )/O Hypercalcemia/B-AdverseReaction 68/O (/O 11/O %/O )/O 26/O (/O 4/O %/O )/O Hypokalemia/B-AdverseReaction 61/O (/O 10/O %/O )/O 17/O (/O 3/O %/O )/O Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Back/B-AdverseReaction Pain/I-AdverseReaction 115/O (/O 19/O %/O )/O 19/O (/O 3/O %/O )/O Arthralgia/B-AdverseReaction 83/O (/O 14/O %/O )/O 5/O (/O 1/O %/O )/O Pain/B-AdverseReaction in/I-AdverseReaction Extremity/I-AdverseReaction 69/O (/O 12/O %/O )/O 7/O (/O 1/O %/O )/O Muscle/B-AdverseReaction Spasms/I-AdverseReaction 62/O (/O 10/O %/O )/O 2/O (/O 0/O %/O )/O Musculoskeletal/B-AdverseReaction Pain/I-AdverseReaction 60/O (/O 10/O %/O )/O 12/O (/O 2/O %/O )/O Nervous/O System/O Disorders/O Headache/B-AdverseReaction 141/O (/O 24/O %/O )/O 7/O (/O 1/O %/O )/O Dizziness/B-AdverseReaction 64/O (/O 11/O %/O )/O 5/O (/O 1/O %/O )/O Peripheral/B-AdverseReaction Neuropathies/I-AdverseReaction NECb/I-AdverseReaction 62/O (/O 10/O %/O )/O 5/O (/O 1/O %/O )/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 75/O (/O 13/O %/O )/O 0/O Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O Dyspneac/B-AdverseReaction 202/O (/O 34/O %/O )/O 21/O (/O 4/O %/O )/O Cough/B-AdverseReaction 120/O (/O 20/O %/O )/O 2/O (/O 0/O %/O )/O Epistaxis/B-AdverseReaction 60/O (/O 10/O %/O )/O 5/O (/O 1/O %/O )/O Renal/O Disorders/O Renal/B-AdverseReaction Failure/I-AdverseReaction 76/O (/O 13/O %/O )/O 49/O (/O 8/O %/O )/O Vascular/O Disorders/O Hypertensiond/B-AdverseReaction 90/O (/O 15/O %/O )/O 22/O (/O 4/O %/O )/O Adverse/O Reactions/O Occurring/O at/O a/O Frequency/O of/O 10/O %/O Blood/O and/O lymphatic/O system/O disorders/O :/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction Cardiac/O disorders/O :/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction congestive/I-AdverseReaction ,/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O myocardial/B-AdverseReaction ischemia/I-AdverseReaction Eye/O disorders/O :/O cataract/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction Gastrointestinal/O disorders/O :/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O toothache/B-AdverseReaction General/O disorders/O and/O administration/O site/O conditions/O :/O infusion/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O multi/B-AdverseReaction -/I-AdverseReaction organ/O failure/O ,/O pain/B-AdverseReaction Hepatobiliary/O disorders/O :/O hepatic/B-AdverseReaction failure/I-AdverseReaction Infections/O and/O infestations/O :/O bronchitis/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction Metabolism/O and/O nutrition/O disorders/O :/O hyperglycemia/B-AdverseReaction ,/O hyperkalemia/B-AdverseReaction ,/O hyperuricemia/B-AdverseReaction ,/O hypoalbuminemia/B-AdverseReaction ,/O hypocalcemia/B-AdverseReaction ,/O hypomagnesemia/B-AdverseReaction ,/O hyponatremia/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction Musculoskeletal/O and/O connective/O tissue/O disorders/O :/O musculoskeletal/B-AdverseReaction chest/I-AdverseReaction pain/I-AdverseReaction ,/O myalgia/B-AdverseReaction Nervous/O system/O disorders/O :/O hypoesthesia/B-AdverseReaction ,/O paresthesia/B-AdverseReaction Psychiatric/O disorders/O :/O anxiety/B-AdverseReaction Renal/O and/O urinary/O disorders/O :/O renal/B-AdverseReaction impairment/I-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O dysphonia/B-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O pulmonary/B-AdverseReaction edema/I-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O erythema/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O rash/B-AdverseReaction Vascular/O disorders/O :/O embolic/B-AdverseReaction and/I-AdverseReaction thrombotic/I-AdverseReaction events/I-AdverseReaction ,/I-AdverseReaction venous/O (/O including/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction )/O ,/O hypotension/B-AdverseReaction Grade/B-Severity 3/I-Severity and/O higher/O adverse/O reactions/O occurring/O at/O an/O incidence/O of/O 1/O %/O include/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction ,/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction congestive/I-AdverseReaction ,/O pain/B-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O hyperkalemia/B-AdverseReaction ,/O hyperuricemia/B-AdverseReaction ,/O hypoalbuminemia/B-AdverseReaction ,/O hypocalcemia/B-AdverseReaction ,/O hyponatremia/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction acute/I-AdverseReaction ,/O renal/B-AdverseReaction impairment/I-AdverseReaction ,/O pulmonary/B-AdverseReaction edema/I-AdverseReaction ,/O and/O hypotension/B-AdverseReaction ./O
Laboratory/O Abnormalities/O Table/O 8/O describes/O Grade/O 3/O -/O 4/O laboratory/O abnormalities/O reported/O at/O a/O rate/O of/O 10/O %/O for/O patients/O who/O received/O Kyprolis/O monotherapy/O ./O
Table/O 8/O :/O Grade/O 3/O -/O 4/O Laboratory/O Abnormalities/O (/O 10/O %/O )/O (/O Monotherapy/O )/O Adverse/O Reaction/O Kyprolis(N/O 598/O )/O Decreased/B-AdverseReaction Platelets/I-AdverseReaction 184/O (/O 31/O %/O )/O Decreased/B-AdverseReaction Lymphocytes/I-AdverseReaction 151/O (/O 25/O %/O )/O Decreased/B-AdverseReaction Hemoglobin/I-AdverseReaction 132/O (/O 22/O %/O )/O Decreased/B-AdverseReaction Total/I-AdverseReaction White/I-AdverseReaction Blood/I-AdverseReaction Cell/I-AdverseReaction Count/I-AdverseReaction 71/O (/O 12/O %/O )/O Decreased/B-AdverseReaction Sodium/I-AdverseReaction 69/O (/O 12/O %/O )/O Decreased/B-AdverseReaction Absolute/I-AdverseReaction Neutrophil/I-AdverseReaction Count/I-AdverseReaction 67/O (/O 11/O %/O )/O 6.2/O Post/O -/O marketing/O Experience/O The/O following/O adverse/O reactions/O were/O reported/O in/O the/O post/O -/O marketing/O experience/O with/O Kyprolis/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O :/O dehydration/B-AdverseReaction ,/O thrombotic/B-AdverseReaction thrombocytopenic/I-AdverseReaction purpura/I-AdverseReaction hemolytic/B-AdverseReaction uremic/I-AdverseReaction syndrome/I-AdverseReaction (/O TTP/B-AdverseReaction HUS/B-AdverseReaction )/O ,/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction including/O fatal/B-AdverseReaction outcomes/O ,/O and/O posterior/B-AdverseReaction reversible/I-AdverseReaction encephalopathy/I-AdverseReaction syndrome/I-AdverseReaction (/O PRES/B-AdverseReaction )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Cardiac/B-AdverseReaction toxicities/I-AdverseReaction include/O cardiac/B-AdverseReaction failure/I-AdverseReaction and/O myocardial/B-AdverseReaction infarction/I-AdverseReaction with/O fatal/B-AdverseReaction outcome/O ,/O and/O myocardial/B-AdverseReaction ischemia/I-AdverseReaction ./O
Withhold/O Kyprolis/O and/O evaluate/O promptly/O ./O
(/O 5.1/O )/O Acute/B-AdverseReaction Renal/I-AdverseReaction Failure/I-AdverseReaction :/O Monitor/O serum/O creatinine/O regularly/O (/O 5.2/O )/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction (/O TLS/B-AdverseReaction )/O :/O Administer/O pre/O -/O treatment/O hydration/O ./O
(/O 2.1/O )/O Monitor/O for/O TLS/O ,/O including/O uric/O acid/O levels/O and/O treat/O promptly/O ./O
(/O 5.3/O )/O Pulmonary/B-AdverseReaction Toxicity/I-AdverseReaction :/O including/O Acute/B-AdverseReaction Respiratory/I-AdverseReaction Distress/I-AdverseReaction Syndrome/I-AdverseReaction ,/O acute/B-AdverseReaction respiratory/I-AdverseReaction failure/I-AdverseReaction ,/O and/O acute/B-AdverseReaction diffuse/I-AdverseReaction infiltrative/I-AdverseReaction pulmonary/I-AdverseReaction disease/I-AdverseReaction :/O Withhold/O Kyprolis/O and/O evaluate/O promptly/O (/O 5.4/O )/O Pulmonary/B-AdverseReaction Hypertension/I-AdverseReaction :/O Withhold/O Kyprolis/O and/O evaluate/O (/O 5.5/O )/O Dyspnea/B-AdverseReaction :/O For/O severe/O or/O life/O threatening/O dyspnea/O ,/O withhold/O Kyprolis/O and/O evaluate/O ./O
(/O 5.6/O )/O Hypertension/B-AdverseReaction including/O hypertensive/B-AdverseReaction crisis/I-AdverseReaction :/O Monitor/O blood/O pressure/O regularly/O ./O
If/O hypertension/O can/O not/O be/O adequately/O controlled/O ,/O a/O risk/O -/O benefit/O decision/O on/O continued/O Kyprolis/O therapy/O is/O needed/O ./O
(/O 5.7/O )/O Venous/B-AdverseReaction Thrombosis/I-AdverseReaction :/O Thromboprophylaxis/O is/O recommended/O ./O
(/O 5.8/O )/O Infusion/B-AdverseReaction Reactions/I-AdverseReaction :/O Pre/O -/O medicate/O with/O dexamethasone/O ./O
(/O 2.1/O ,/O 5.9/O )/O Thrombocytopenia/B-AdverseReaction :/O Monitor/O platelet/O counts/O ;/O interrupt/O or/O reduce/O Kyprolis/O dosing/O as/O clinically/O indicated/O ./O
(/O 2.4/O ,/O 5.10/O )/O Hepatic/B-AdverseReaction Toxicity/I-AdverseReaction and/O Hepatic/B-AdverseReaction Failure/I-AdverseReaction :/O Monitor/O liver/O enzymes/O ./O
Withhold/O Kyprolis/O if/O suspected/O ./O
(/O 5.11/O )/O Thrombotic/B-AdverseReaction thrombocytopenic/I-AdverseReaction purpura/I-AdverseReaction hemolytic/B-AdverseReaction uremic/I-AdverseReaction syndrome/I-AdverseReaction (/O TTP/B-AdverseReaction HUS/B-AdverseReaction )/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O TTP/O HUS/O ./O
Discontinue/O Kyprolis/O if/O suspected/O ./O
(/O 5.12/O )/O Posterior/B-AdverseReaction reversible/I-AdverseReaction encephalopathy/I-AdverseReaction syndrome/I-AdverseReaction (/O PRES/B-AdverseReaction )/O :/O Consider/O neuro/O -/O radiological/O imaging/O (/O MRI/O )/O for/O onset/O of/O visual/O or/O neurological/O symptoms/O ;/O discontinue/O Kyprolis/O if/O suspected/O ./O
(/O 5.13/O )/O Embryo/B-AdverseReaction -/I-AdverseReaction fetal/O Toxicity/O :/O Kyprolis/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Females/O of/O reproductive/O potential/O should/O avoid/O becoming/O pregnant/O while/O being/O treated/O ./O
(/O 5.14/O ,/O 8.1/O )/O 5.1/O Cardiac/O Toxicities/O New/O onset/O or/O worsening/B-AdverseReaction of/I-AdverseReaction pre/I-AdverseReaction -/I-AdverseReaction existing/I-AdverseReaction cardiac/O failure/O (/O e.g./O ,/O congestive/B-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction ,/O pulmonary/B-AdverseReaction edema/I-AdverseReaction ,/O decreased/B-AdverseReaction ejection/I-AdverseReaction fraction/I-AdverseReaction )/O ,/O restrictive/B-AdverseReaction cardiomyopathy/I-AdverseReaction ,/O myocardial/B-AdverseReaction ischemia/I-AdverseReaction ,/O and/O myocardial/B-AdverseReaction infarction/I-AdverseReaction including/O fatalities/B-AdverseReaction have/O occurred/O following/O administration/O of/O Kyprolis/O ./O
In/O clinical/O studies/O with/O Kyprolis/O ,/O these/O events/O typically/O occurred/O early/O in/O the/O course/O of/O Kyprolis/O therapy/O (/O 5/O cycles/O )/O ./O
Death/B-AdverseReaction due/O to/O cardiac/B-AdverseReaction arrest/I-AdverseReaction has/O occurred/O within/O a/O day/O of/O Kyprolis/O administration/O ./O
Withhold/O Kyprolis/O for/O Grade/O 3/O or/O 4/O cardiac/O adverse/O events/O until/O recovery/O ,/O and/O consider/O whether/O to/O restart/O Kyprolis/O at/O 1/O dose/O level/O reduction/O based/O on/O a/O benefit/O risk/O assessment/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
While/O adequate/O hydration/O is/O required/O prior/O to/O each/O dose/O in/O Cycle/O 1/O ,/O all/O patients/O should/O also/O be/O monitored/O for/O evidence/O of/O volume/O overload/O ,/O especially/O patients/O at/O risk/O for/O cardiac/O failure/O ./O
Adjust/O total/O fluid/O intake/O as/O clinically/O appropriate/O in/O patients/O with/O baseline/O cardiac/O failure/O or/O who/O are/O at/O risk/O for/O cardiac/O failure/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
In/O patients/O 75/O years/O of/O age/O ,/O the/O risk/O of/O cardiac/O failure/O is/O increased/O ./O
Patients/O with/O New/O York/O Heart/O Association/O Class/O III/O and/O IV/O heart/O failure/O ,/O recent/O myocardial/O infarction/O ,/O and/O conduction/O abnormalities/O uncontrolled/O by/O medications/O were/O not/O eligible/O for/O the/O clinical/O trials/O ./O
These/O patients/O may/O be/O at/O greater/O risk/O for/O cardiac/O complications/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8/O )/O ]/O ./O
5.2/O Acute/O Renal/O Failure/O Cases/O of/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction have/O occurred/O in/O patients/O receiving/O Kyprolis/O ./O
Renal/B-AdverseReaction insufficiency/I-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction (/O renal/B-AdverseReaction impairment/I-AdverseReaction ,/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction )/O have/O occurred/O with/O an/O incidence/O of/O approximately/O 8/O %/O in/O a/O randomized/O controlled/O trial/O ./O
Acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction was/O reported/O more/O frequently/O in/O patients/O with/O advanced/O relapsed/O and/O refractory/O multiple/O myeloma/O who/O received/O Kyprolis/O monotherapy/O ./O
This/O risk/O was/O greater/O in/O patients/O with/O a/O baseline/O reduced/O estimated/O creatinine/O clearance/O (/O calculated/O using/O Cockcroft/O and/O Gault/O equation/O )/O ./O
Monitor/O renal/O function/O with/O regular/O measurement/O of/O the/O serum/O creatinine/O and/or/O estimated/O creatinine/O clearance/O ./O
Reduce/O or/O withhold/O dose/O as/O appropriate/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.3/O Tumor/O Lysis/O Syndrome/O Cases/O of/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction (/O TLS/B-AdverseReaction )/O ,/O including/O fatal/B-AdverseReaction outcomes/O ,/O have/O been/O reported/O in/O patients/O who/O received/O Kyprolis/O ./O
Patients/O with/O multiple/O myeloma/O and/O a/O high/O tumor/O burden/O should/O be/O considered/O to/O be/O at/O greater/O risk/O for/O TLS/O ./O
Ensure/O that/O patients/O are/O well/O hydrated/O before/O administration/O of/O Kyprolis/O in/O Cycle/O 1/O ,/O and/O in/O subsequent/O cycles/O as/O needed/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
Consider/O uric/O acid/O lowering/O drugs/O in/O patients/O at/O risk/O for/O TLS/O ./O
Monitor/O for/O evidence/O of/O TLS/O during/O treatment/O and/O manage/O promptly/O including/O interruption/O of/O Kyprolis/O until/O TLS/O is/O resolved/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.4/O Pulmonary/O Toxicity/O Acute/B-AdverseReaction Respiratory/I-AdverseReaction Distress/I-AdverseReaction Syndrome/I-AdverseReaction (/O ARDS/B-AdverseReaction )/O ,/O acute/B-AdverseReaction respiratory/I-AdverseReaction failure/I-AdverseReaction ,/O and/O acute/B-AdverseReaction diffuse/I-AdverseReaction infiltrative/I-AdverseReaction pulmonary/I-AdverseReaction disease/I-AdverseReaction such/O as/O pneumonitis/B-AdverseReaction and/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction have/O occurred/O in/O less/O than/O 1/O %/O of/O patients/O receiving/O Kyprolis/O ./O
Some/O events/O have/O been/O fatal/B-AdverseReaction ./O
In/O the/O event/O of/O drug/O -/O induced/O pulmonary/O toxicity/O ,/O discontinue/O Kyprolis/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.5/O Pulmonary/O Hypertension/O Pulmonary/B-AdverseReaction arterial/I-AdverseReaction hypertension/I-AdverseReaction (/O PAH/B-AdverseReaction )/O was/O reported/O in/O approximately/O 1/O %/O of/O patients/O treated/O with/O Kyprolis/O and/O was/O Grade/B-Severity 3/I-Severity or/O greater/O in/O less/O than/O 1/O %/O of/O patients/O ./O
Evaluate/O with/O cardiac/O imaging/O and/or/O other/O tests/O as/O indicated/O ./O
Withhold/O Kyprolis/O for/O pulmonary/O hypertension/O until/O resolved/O or/O returned/O to/O baseline/O and/O consider/O whether/O to/O restart/O Kyprolis/O based/O on/O a/O benefit/O risk/O assessment/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.6/O Dyspnea/O Dyspnea/B-AdverseReaction was/O reported/O in/O 28/O %/O of/O patients/O treated/O with/O Kyprolis/O and/O was/O Grade/B-Severity 3/I-Severity or/O greater/O in/O 4/O %/O of/O patients/O ./O
Evaluate/O dyspnea/O to/O exclude/O cardiopulmonary/O conditions/O including/O cardiac/O failure/O and/O pulmonary/O syndromes/O ./O
Stop/O Kyprolis/O for/O Grade/O 3/O or/O 4/O dyspnea/O until/O resolved/O or/O returned/O to/O baseline/O ./O
Consider/O whether/O to/O restart/O Kyprolis/O based/O on/O a/O benefit/O risk/O assessment/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ,/O Warnings/O and/O Precautions/O -/O Cardiac/O Toxicities/O (/O 5.1/O )/O ,/O Pulmonary/O Toxicity/O (/O 5.4/O )/O ,/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.7/O Hypertension/O Hypertension/B-AdverseReaction ,/O including/O hypertensive/B-AdverseReaction crisis/I-AdverseReaction and/O hypertensive/B-AdverseReaction emergency/I-AdverseReaction ,/O has/O been/O observed/O with/O Kyprolis/O ./O
Some/O of/O these/O events/O have/O been/O fatal/B-AdverseReaction ./O
Monitor/O blood/O pressure/O regularly/O in/O all/O patients/O ./O
If/O hypertension/O can/O not/O be/O adequately/O controlled/O ,/O withhold/O Kyprolis/O and/O evaluate/O ./O
Consider/O whether/O to/O restart/O Kyprolis/O based/O on/O a/O benefit/O risk/O assessment/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.8/O Venous/O Thrombosis/O Venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction (/O including/O deep/B-AdverseReaction venous/I-AdverseReaction thrombosis/I-AdverseReaction and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction )/O have/O been/O observed/O with/O Kyprolis/O ./O
In/O the/O combination/O study/O ,/O the/O incidence/O of/O venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction in/O the/O first/O 12/O cycles/O was/O 13/O %/O in/O the/O Kyprolis/O combination/O arm/O versus/O 6/O %/O in/O the/O control/O arm/O ./O
With/O Kyprolis/O monotherapy/O ,/O the/O incidence/O of/O venous/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction was/O 2/O %/O ./O
Thromboprophylaxis/O is/O recommended/O and/O should/O be/O based/O on/O an/O assessment/O of/O the/O patient/O 's/O underlying/O risks/O ,/O treatment/O regimen/O ,/O and/O clinical/O status/O ./O
5.9/O Infusion/O Reactions/O Infusion/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O life/B-Severity -/O threatening/O reactions/O ,/O have/O occurred/O in/O patients/O receiving/O Kyprolis/O ./O
Symptoms/O include/O fever/B-AdverseReaction ,/O chills/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O facial/B-AdverseReaction flushing/I-AdverseReaction ,/O facial/B-AdverseReaction edema/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O weakness/B-AdverseReaction ,/O shortness/B-AdverseReaction of/I-AdverseReaction breath/I-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O syncope/B-AdverseReaction ,/O chest/B-AdverseReaction tightness/I-AdverseReaction ,/O or/O angina/B-AdverseReaction ./O
These/O reactions/O can/O occur/O immediately/O following/O or/O up/O to/O 24/O hours/O after/O administration/O of/O Kyprolis/O ./O
Administer/O dexamethasone/O prior/O to/O Kyprolis/O to/O reduce/O the/O incidence/O and/O severity/O of/O infusion/O reactions/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
Inform/O patients/O of/O the/O risk/O and/O of/O symptoms/O and/O to/O contact/O a/O physician/O immediately/O if/O symptoms/O of/O an/O infusion/O reaction/O occur/O [/O see/O Patient/O Counseling/O Information/O (/O 17/O )/O ]/O ./O
5.10/O Thrombocytopenia/O Kyprolis/O causes/O thrombocytopenia/B-AdverseReaction with/O platelet/B-AdverseReaction nadirs/I-AdverseReaction observed/O between/O Day/O 8/O and/O Day/O 15/O of/O each/O 28-day/O cycle/O with/O recovery/O to/O baseline/O platelet/O count/O usually/O by/O the/O start/O of/O the/O next/O cycle/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Thrombocytopenia/B-AdverseReaction was/O reported/O in/O approximately/O 40/O %/O of/O patients/O in/O clinical/O trials/O with/O Kyprolis/O ./O
Monitor/O platelet/O counts/O frequently/O during/O treatment/O with/O Kyprolis/O ./O
Reduce/O or/O withhold/O dose/O as/O appropriate/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.11/O Hepatic/O Toxicity/O and/O Hepatic/O Failure/O Cases/O of/O hepatic/B-AdverseReaction failure/I-AdverseReaction ,/O including/O fatal/B-AdverseReaction cases/O ,/O have/O been/O reported/O (/O 1/O %/O )/O during/O treatment/O with/O Kyprolis/O ./O
Kyprolis/O can/B-Factor cause/O increased/B-AdverseReaction serum/I-AdverseReaction transaminases/I-AdverseReaction ./O
Monitor/O liver/O enzymes/O regularly/O ./O
Reduce/O or/O withhold/O dose/O as/O appropriate/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.12/O Thrombotic/O Thrombocytopenic/O Purpura/O Hemolytic/O Uremic/O Syndrome/O Cases/O of/O thrombotic/B-AdverseReaction thrombocytopenic/I-AdverseReaction purpura/I-AdverseReaction hemolytic/B-AdverseReaction uremic/I-AdverseReaction syndrome/I-AdverseReaction (/O TTP/B-AdverseReaction HUS/B-AdverseReaction )/O including/O fatal/B-AdverseReaction outcome/O have/O been/O reported/O in/O patients/O who/O received/O Kyprolis/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O TTP/O HUS/O ./O
If/O the/O diagnosis/O is/O suspected/O ,/O stop/O Kyprolis/O and/O evaluate/O ./O
If/O the/O diagnosis/O of/O TTP/O HUS/O is/O excluded/O ,/O Kyprolis/O may/O be/O restarted/O ./O
The/O safety/O of/O reinitiating/O Kyprolis/O therapy/O in/O patients/O previously/O experiencing/O TTP/O HUS/O is/O not/O known/O ./O
5.13/O Posterior/O Reversible/O Encephalopathy/O Syndrome/O (/O PRES/O )/O Cases/O of/O PRES/B-AdverseReaction have/O been/O reported/O in/O patients/O receiving/O Kyprolis/O ./O
Posterior/O reversible/O encephalopathy/O syndrome/O (/O PRES/O )/O ,/O formerly/O termed/O Reversible/O Posterior/O Leukoencephalopathy/O Syndrome/O (/O RPLS/O )/O ,/O is/O a/O neurological/O disorder/O which/O can/O present/O with/O seizure/O ,/O headache/O ,/O lethargy/O ,/O confusion/O ,/O blindness/O ,/O altered/O consciousness/O ,/O and/O other/O visual/O and/O neurological/O disturbances/O ,/O along/O with/O hypertension/O ,/O and/O the/O diagnosis/O is/O confirmed/O by/O neuro/O -/O radiological/O imaging/O (/O MRI/O )/O ./O
Discontinue/O Kyprolis/O if/O PRES/O is/O suspected/O and/O evaluate/O ./O
The/O safety/O of/O reinitiating/O Kyprolis/O therapy/O in/O patients/O previously/O experiencing/O PRES/O is/O not/O known/O ./O
5.14/O Embryo/O -/O fetal/O Toxicity/O Kyprolis/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O based/O on/O its/O mechanism/O of/O action/O and/O findings/O in/O animals/O ./O
There/O are/O no/O adequate/O and/O well/O -/O controlled/O studies/O in/O pregnant/O women/O using/O Kyprolis/O ./O
Carfilzomib/O caused/O embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicity/O in/O pregnant/O rabbits/B-Animal at/O doses/O that/O were/O lower/O than/O in/O patients/O receiving/O the/O recommended/O dose/O ./O
Females/O of/O reproductive/O potential/O should/O be/O advised/O to/O avoid/O becoming/O pregnant/O while/O being/O treated/O with/O Kyprolis/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O the/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O frequently/O reported/O adverse/O reactions/O (/O 5/O %/O )/O in/O clinical/O trials/O were/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction and/O included/O :/O anaphylaxis/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O flushing/B-AdverseReaction feeling/B-AdverseReaction hot/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O decreased/B-AdverseReaction oxygen/I-AdverseReaction saturation/I-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O tachypnea/B-AdverseReaction ,/O chest/B-AdverseReaction discomfort/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O muscle/B-AdverseReaction twitching/I-AdverseReaction ,/O agitation/B-AdverseReaction ,/O cyanosis/B-AdverseReaction ,/O erythema/B-AdverseReaction ,/O hypertension/B-AdverseReaction increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction ,/O pallor/B-AdverseReaction ,/O rigors/B-AdverseReaction ,/O tremor/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O myalgia/B-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Genzyme/O at/O 1/O -/O 800/O -/O 745/O -/O 4447/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O following/O serious/O adverse/O reactions/O are/O described/O below/O and/O elsewhere/O in/O the/O labeling/O :/O Anaphylaxis/O and/O hypersensitivity/O reactions/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
In/O clinical/O trials/O ,/O the/O most/O common/O adverse/O reactions/O (/O 5/O %/O )/O following/O alglucosidase/O alfa/O treatment/O were/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O and/O included/O anaphylaxis/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O flushing/B-AdverseReaction feeling/B-AdverseReaction hot/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O decreased/B-AdverseReaction oxygen/I-AdverseReaction saturation/I-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O tachypnea/B-AdverseReaction ,/O chest/B-AdverseReaction discomfort/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O muscle/B-AdverseReaction twitching/I-AdverseReaction ,/O agitation/B-AdverseReaction ,/O cyanosis/B-AdverseReaction ,/O erythema/B-AdverseReaction ,/O hypertension/B-AdverseReaction increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction ,/O pallor/B-AdverseReaction ,/O rigors/B-AdverseReaction ,/O tremor/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O myalgia/B-AdverseReaction ./O
Clinical/O Trials/O in/O Infantile/O -/O Onset/O and/O Juvenile/O -/O Onset/O Pompe/O Disease/O Two/O multicenter/O ,/O open/O -/O label/O clinical/O trials/O were/O conducted/O in/O 39/O infantile/O -/O onset/O Pompe/O disease/O patients/O ,/O ages/O 1/O month/O to/O 3.5/O years/O old/O ./O
Approximately/O half/O of/O the/O patients/O (/O 54/O %/O )/O were/O male/O ./O
Patients/O were/O treated/O with/O alglucosidase/O alfa/O 20/O or/O 40/O mg/O kg/O every/O other/O week/O for/O periods/O ranging/O from/O 1/O to/O 106/O weeks/O (/O mean/O :/O 61/O weeks/O )/O ./O
The/O most/O serious/O adverse/O reactions/O reported/O with/O alglucosidase/O alfa/O treatment/O included/O anaphylaxis/B-AdverseReaction and/O acute/B-AdverseReaction cardiorespiratory/I-AdverseReaction failure/I-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O requiring/O intervention/O in/O clinical/O trials/O were/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O occurring/O in/O 20/O of/O 39/O (/O 51/O %/O )/O patients/O treated/O with/O alglucosidase/O alfa/O ,/O and/O included/O rash/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O decreased/B-AdverseReaction oxygen/I-AdverseReaction saturation/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O tachypnea/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O hypertension/B-AdverseReaction increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction ,/O pallor/B-AdverseReaction ,/O rigors/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O cyanosis/B-AdverseReaction ,/O agitation/B-AdverseReaction ,/O and/O tremor/B-AdverseReaction ./O
These/O reactions/O were/O more/O likely/O to/O occur/O with/O higher/O infusion/O rates/O ./O
Some/O patients/O who/O were/O pre/O -/O treated/O with/O antihistamines/O ,/O antipyretics/O and/or/O corticosteroids/O still/O experienced/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ./O
Table/O 2/O summarizes/O all/O adverse/O reactions/O occurring/O in/O 5/O %/O of/O patients/O (/O 2/O or/O more/O patients/O )/O treated/O with/O alglucosidase/O alfa/O in/O clinical/O trials/O described/O above/O ./O
Table/O 2/O :/O Adverse/O Reactions/O that/O Occurred/O in/O At/O Least/O 5/O %/O of/O Infantile/O -/O Onset/O Patients/O Treated/O with/O Alglucosidase/O Alfa/O in/O Clinical/O Trials/O Number/O of/O Patients(N=39)n/O (/O %/O )/O Adverse/O Reaction/O 20/O (/O 51/O )/O Rash/B-AdverseReaction (/O including/O rash/B-AdverseReaction erythematous/I-AdverseReaction ,/O rash/B-AdverseReaction macular/I-AdverseReaction and/O maculo/O -/O papular/O )/O 7/O (/O 18/O )/O Pyrexia/B-AdverseReaction 6/O (/O 15/O )/O Urticaria/B-AdverseReaction 5/O (/O 13/O )/O Flushing/B-AdverseReaction 5/O (/O 13/O )/O Hypertension/B-AdverseReaction Increased/B-AdverseReaction Blood/I-AdverseReaction Pressure/I-AdverseReaction 4/O (/O 10/O )/O Decreased/B-AdverseReaction Oxygen/I-AdverseReaction Saturation/I-AdverseReaction 3/O (/O 8)/O Cough/B-AdverseReaction 3/O (/O 8)/O Tachypnea/B-AdverseReaction 3/O (/O 8)/O Tachycardia/B-AdverseReaction 3/O (/O 8)/O Erythema/B-AdverseReaction 2/O (/O 5/O )/O Vomiting/B-AdverseReaction 2/O (/O 5/O )/O Rigors/B-AdverseReaction 2/O (/O 5/O )/O Pallor/B-AdverseReaction 2/O (/O 5/O )/O Cyanosis/B-AdverseReaction 2/O (/O 5/O )/O Agitation/B-AdverseReaction 2/O (/O 5/O )/O Tremor/B-AdverseReaction 2/O (/O 5/O )/O An/O open/O -/O label/O ,/O single/O -/O center/O trial/O was/O conducted/O in/O 18/O treatment/O -/O naive/O infantile/O -/O onset/O Pompe/O disease/O patients/O who/O were/O treated/O exclusively/O with/O alglucosidase/O alfa/O ./O
Adverse/O reactions/O observed/O in/O these/O patients/O were/O similar/O to/O infantile/O -/O onset/O Pompe/O disease/O patients/O who/O received/O alglucosidase/O alfa/O in/O other/O clinical/O trials/O ./O
Additional/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction observed/O in/O infantile/O -/O onset/O Pompe/O disease/O patients/O treated/O in/O other/O clinical/O trials/O and/O expanded/O access/O programs/O with/O alglucosidase/O alfa/O included/O livedo/B-AdverseReaction reticularis/I-AdverseReaction ,/O irritability/B-AdverseReaction ,/O retching/B-AdverseReaction ,/O increased/B-AdverseReaction lacrimation/I-AdverseReaction ,/O ventricular/B-AdverseReaction extrasystoles/I-AdverseReaction ,/O nodal/B-AdverseReaction rhythm/I-AdverseReaction ,/O rales/B-AdverseReaction ,/O respiratory/B-AdverseReaction tract/I-AdverseReaction irritation/I-AdverseReaction ,/O and/O cold/B-AdverseReaction sweat/I-AdverseReaction ./O
Safety/O was/O also/O evaluated/O in/O 99/O patients/O (/O 51/O male/O ,/O 48/O females/O )/O with/O Pompe/O disease/O in/O an/O ongoing/O ,/O open/O -/O label/O ,/O prospective/O study/O in/O patients/O 12/O months/O of/O age/O and/O older/O who/O were/O previously/O treated/O with/O the/O 160/O L/O scale/O of/O alglucosidase/O alfa/O and/O switched/O to/O the/O 4000/O L/O scale/O of/O alglucosidase/O alfa/O ./O
Patients/O were/O aged/O 1/O to/O 18/O years/O with/O a/O median/O duration/O of/O treatment/O of/O 437/O days/O (/O range/O 13/O to/O 466/O days/O )/O ./O
No/O new/O safety/O findings/O were/O observed/O following/O the/O switch/O to/O 4000/O L/O scale/O of/O alglucosidase/O alfa/O ./O
Clinical/O Trials/O in/O Late/O -/O Onset/O Pompe/O Disease/O Assessment/O of/O adverse/O reactions/O in/O patients/O with/O late/O -/O onset/O Pompe/O disease/O is/O based/O on/O the/O exposure/O of/O 90/O patients/O (/O 45/O male/O ,/O 45/O female/O )/O ,/O aged/O 10/O to/O 70/O years/O ,/O to/O 20/O mg/O kg/O alglucosidase/O alfa/O or/O placebo/O in/O a/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trial/O ./O
The/O youngest/O alglucosidase/O alfa/O -/O treated/O patient/O was/O 16/O years/O of/O age/O ,/O and/O the/O youngest/O placebo/O -/O treated/O patient/O was/O 10/O years/O of/O age/O ./O
All/O patients/O were/O naive/O to/O enzyme/O replacement/O therapy/O ./O
Patients/O were/O randomized/O in/O a/O 2:1/O ratio/O and/O received/O alglucosidase/O alfa/O or/O placebo/O every/O other/O week/O for/O 78/O weeks/O (/O 18/O months/O )/O ./O
The/O study/O population/O included/O 34/O males/O and/O 26/O females/O (/O n=60/O )/O in/O the/O alglucosidase/O alfa/O group/O and/O 11/O males/O and/O 19/O females/O (/O n=30/O )/O in/O the/O placebo/O group/O ./O
Two/O patients/O receiving/O alglucosidase/O alfa/O discontinued/O the/O trial/O due/O to/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction ./O
Serious/O adverse/O reactions/O reported/O with/O alglucosidase/O alfa/O included/O anaphylaxis/B-AdverseReaction ,/O which/O presented/O as/O angioedema/B-AdverseReaction ,/O throat/B-AdverseReaction tightness/I-AdverseReaction and/O chest/B-AdverseReaction pain/I-AdverseReaction discomfort/O ./O
One/O patient/O with/O a/O history/O of/O Wolff/O -/O Parkinson/O -/O White/O syndrome/O experienced/O a/O serious/O adverse/O reaction/O of/O supraventricular/B-AdverseReaction tachycardia/I-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O (/O 3/O %/O ;/O 2/O or/O more/O patients/O )/O observed/O in/O alglucosidase/O alfa/O -/O treated/O patients/O were/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction and/O included/O anaphylaxis/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O chest/B-AdverseReaction discomfort/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O flushing/B-AdverseReaction feeling/B-AdverseReaction hot/I-AdverseReaction ,/O increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction ,/O paresthesia/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O local/B-AdverseReaction swelling/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O throat/B-AdverseReaction tightness/I-AdverseReaction ./O
Delayed/O -/O onset/O reactions/O ,/O defined/O as/O adverse/O reactions/O occurring/O 2/O -/O 48/O hours/O after/O completion/O of/O alglucosidase/O alfa/O infusion/O ,/O that/O were/O observed/O in/O 3/O %/O more/O patients/O in/O the/O alglucosidase/O alfa/O -/O treated/O group/O compared/O to/O patients/O in/O the/O placebo/O -/O treated/O group/O in/O the/O controlled/O trial/O ,/O included/O hyperhidrosis/B-AdverseReaction ./O
Additional/O delayed/O -/O onset/O reactions/O occurring/O in/O alglucosidase/O alfa/O -/O treated/O patients/O included/O fatigue/B-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
Patients/O should/O be/O counseled/O about/O the/O possibility/O of/O delayed/O -/O onset/O hypersensitivity/O reactions/O and/O given/O proper/O follow/O -/O up/O instructions/O ./O
Table/O 3/O summarizes/O the/O most/O common/O adverse/O reactions/O that/O occurred/O in/O at/O least/O 3/O %/O of/O alglucosidase/O alfa/O -/O treated/O patients/O and/O with/O a/O higher/O incidence/O than/O the/O placebo/O -/O treated/O patients/O during/O the/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O study/O described/O above/O ./O
Table/O 3/O :/O Adverse/O Reactions/O Occurring/O in/O at/O Least/O 3/O %/O of/O Alglucosidase/O Alfa/O -/O Treated/O Late/O -/O Onset/O Patients/O and/O with/O a/O Higher/O Incidence/O than/O the/O Placebo/O -/O Treated/O Patients/O Adverse/O Reaction/O Alglucosidase/O Alfan=60N/O (/O %/O )/O Placebon=30N/O (/O %/O )/O Hyperhidrosis/B-AdverseReaction 5/O (/O 8.3/O )/O 0/O (/O 0/O )/O Urticaria/B-AdverseReaction 5/O (/O 8.3/O )/O 0/O (/O 0/O )/O Anaphylaxis/B-AdverseReaction 4/O (/O 6.7/O )/O 0/O (/O 0/O )/O Chest/B-AdverseReaction Discomfort/I-AdverseReaction 4/O (/O 6.7/O )/O 1/O (/O 3.3/O )/O Muscle/B-AdverseReaction Twitching/I-AdverseReaction 4/O (/O 6.7/O )/O 1/O (/O 3.3/O )/O Myalgia/B-AdverseReaction 3/O (/O 5.0/O )/O 1/O (/O 3.3/O )/O Flushing/B-AdverseReaction Feeling/B-AdverseReaction Hot/I-AdverseReaction 3/O (/O 5.0/O )/O 0/O (/O 0/O )/O Increased/B-AdverseReaction Blood/I-AdverseReaction Pressure/I-AdverseReaction 3/O (/O 5.0/O )/O 0/O (/O 0/O )/O Vomiting/B-AdverseReaction 3/O (/O 5.0/O )/O 0/O (/O 0/O )/O Edema/B-AdverseReaction ,/I-AdverseReaction Peripheral/O 2/O (/O 3.3/O )/O 0/O (/O 0/O )/O Pruritus/B-AdverseReaction 2/O (/O 3.3/O )/O 0/O (/O 0/O )/O Rash/B-AdverseReaction Papular/I-AdverseReaction 2/O (/O 3.3/O )/O 0/O (/O 0/O )/O Throat/B-AdverseReaction Tightness/I-AdverseReaction 2/O (/O 3.3/O )/O 0/O (/O 0/O )/O In/O clinical/O trials/O ,/O anaphylaxis/B-AdverseReaction and/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction were/O managed/O with/O infusion/O interruption/O ,/O decreased/O infusion/O rate/O ,/O administration/O of/O antihistamines/O ,/O corticosteroids/O ,/O intravenous/O fluids/O ,/O and/or/O oxygen/O ,/O when/O clinically/O indicated/O ./O
In/O some/O cases/O of/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction ,/O epinephrine/O was/O administered/O ./O
Patients/O who/O have/O experienced/O anaphylaxis/O or/O hypersensitivity/O reactions/O should/O be/O treated/O with/O caution/O when/O they/O are/O re/O -/O administered/O alglucosidase/O alfa/O ./O
6.2/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O potential/O for/O immunogenicity/O ./O
The/O data/O reflect/O the/O percentage/O of/O patients/O whose/O test/O results/O were/O considered/O positive/O for/O antibodies/O to/O alglucosidase/O alfa/O using/O an/O enzyme/O -/O linked/O immunosorbent/O assay/O (/O ELISA/O )/O and/O confirmed/O by/O a/O radioimmunoprecipitation/O (/O RIP/O )/O assay/O for/O alglucosidase/O alfa/O -/O specific/O IgG/O antibodies/O ./O
In/O the/O two/O clinical/O trials/O in/O infantile/O -/O onset/O patients/O ,/O the/O majority/O of/O patients/O (/O 34/O of/O 38/O ;/O 89/O %/O )/O tested/O positive/O for/O IgG/O antibodies/O to/O alglucosidase/O alfa/O ./O
There/O is/O evidence/O to/O suggest/O that/O some/O patients/O who/O develop/O high/O sustained/O titers/O of/O anti/O -/O alglucosidase/O alfa/O antibodies/O may/O experience/O reduced/O clinical/O efficacy/O to/O alglucosidase/O alfa/O treatment/O [/O seeWarnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Some/O IgG/O -/O positive/O patients/O in/O clinical/O trials/O who/O were/O retrospectively/O evaluated/O for/O the/O presence/O of/O inhibitory/O antibodies/O tested/O positive/O for/O inhibition/O of/O enzyme/O activity/O and/or/O uptake/O in/O in/O vitro/O assays/O ./O
Furthermore/O ,/O CRIM/O -/O negative/O infants/O have/O shown/O reduced/O clinical/O effect/O in/O the/O presence/O of/O high/B-Severity sustained/I-Severity IgG/B-AdverseReaction antibody/I-AdverseReaction titers/I-AdverseReaction with/I-AdverseReaction inhibitory/I-AdverseReaction activity/I-AdverseReaction ./O
Alglucosidase/O alfa/O -/O treated/O patients/O who/O experience/O a/O decrease/O in/O motor/O function/O should/O be/O tested/O for/O the/O presence/O of/O inhibitory/O antibodies/O that/O neutralize/O enzyme/O uptake/O or/O activity/O ./O
In/O the/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trial/O in/O late/O -/O onset/O patients/O ,/O all/O alglucosidase/O alfa/O -/O treated/O patients/O with/O available/O samples/O (/O N=59/O ,/O 100/O %/O )/O developed/O IgG/O antibodies/O to/O alglucosidase/O alfa/O ./O
Most/O patients/O who/O developed/O IgG/O antibodies/O did/O so/O within/O the/O first/O 3/O months/O of/O exposure/O (/O median/O time/O to/O seroconversion/O was/O 4/O weeks/O )/O ./O
There/O was/O no/O apparent/O association/O between/O mean/O or/O peak/O IgG/O antibody/O titers/O and/O the/O occurrence/O of/O adverse/O reactions/O ./O
None/O of/O the/O 59/O evaluable/O patients/O tested/O positive/O for/O inhibition/O of/O enzyme/O activity/O ./O
Antibody/O titers/O for/O cellular/O uptake/O inhibition/O were/O present/O in/O 18/O of/O 59/O (/O 31/O %/O )/O patients/O by/O Week/O 78/O ./O
All/O other/O patients/O tested/O negative/O for/O inhibition/O of/O cellular/O uptake/O ./O
Patients/O who/O tested/O positive/O for/O uptake/O inhibition/O tended/O to/O have/O higher/O IgG/O titers/O than/O patients/O who/O tested/O negative/O for/O uptake/O inhibition/O ./O
Among/O the/O 32/O patients/O with/O evaluable/O pharmacokinetic/O (/O PK/O )/O samples/O ,/O 5/O patients/O tested/O positive/O for/O uptake/O inhibition/O ./O
The/O clinical/O relevance/O of/O this/O in/O vitro/O inhibition/O is/O not/O fully/O understood/O ./O
The/O clearance/O values/O for/O 4/O of/O these/O 5/O patients/O were/O approximately/O 1.2-/O to/O 1.8-fold/O greater/O in/O the/O presence/O of/O inhibitory/O antibodies/O (/O Week/O 52/O )/O as/O compared/O to/O in/O the/O absence/O of/O inhibitory/O antibodies/O (/O Week/O 0/O )/O [/O seeClinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
Some/O patients/O in/O the/O clinical/O studies/O or/O in/O the/O postmarketing/O setting/O have/O undergone/O testing/O for/O alglucosidase/O alfa/O -/O specific/O IgE/O antibodies/O ./O
Testing/O was/O performed/O in/O patients/O who/O experienced/O moderate/B-Severity to/I-Severity severe/B-Severity or/O recurrent/B-AdverseReaction hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O for/O which/O mast/O -/O cell/O activation/O was/O suspected/O ./O
Some/O of/O the/O patients/O who/O tested/O positive/O for/O alglucosidase/O alfa/O -/O specific/O IgE/O antibodies/O experienced/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction [/O seeBoxed/O WarningandWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Some/O patients/O who/O tested/O positive/O for/O alglucosidase/O alfa/O -/O specific/O IgE/O antibodies/O and/O experienced/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction were/O able/O to/O be/O rechallenged/O with/O alglucosidase/O alfa/O using/O a/O slower/O infusion/O rate/O at/O lower/O starting/O doses/O and/O have/O continued/O to/O receive/O treatment/O under/O close/O clinical/O supervision/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Since/O patients/O who/O develop/O IgE/O antibodies/O to/O alglucosidase/O alfa/O appear/O to/O be/O at/O a/O higher/O risk/O for/O developing/O anaphylaxis/O and/O hypersensitivity/O reactions/O ,/O these/O patients/O should/O be/O monitored/O more/O closely/O during/O administration/O of/O alglucosidase/O alfa/O ./O
The/O detection/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O alglucosidase/O alfa/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
6.3/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O alglucosidase/O alfa/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
In/O postmarketing/O experience/O with/O alglucosidase/O alfa/O ,/O serious/O adverse/O reactions/O have/O been/O reported/O ,/O including/O anaphylaxis/B-AdverseReaction [/O seeBoxed/O WarningandWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Acute/B-AdverseReaction cardiorespiratory/I-AdverseReaction failure/I-AdverseReaction ,/O possibly/O associated/O with/O fluid/B-AdverseReaction overload/I-AdverseReaction ,/O has/O been/O reported/O in/O infantile/O -/O onset/O Pompe/O disease/O patients/O with/O pre/O -/O existing/O hypertrophic/O cardiomyopathy/O [/O seeBoxed/O WarningandWarning/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Recurrent/O reactions/O consisting/O of/O flu/B-AdverseReaction -/I-AdverseReaction like/O illness/O or/O a/O combination/O of/O events/O such/O as/O pyrexia/B-AdverseReaction ,/O chills/B-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O pain/B-AdverseReaction ,/O or/O fatigue/B-AdverseReaction occurring/O after/O completion/O of/O infusions/O and/O lasting/O usually/O for/O 1/O -/O 3/O days/O have/O been/O observed/O in/O some/O patients/O treated/O with/O alglucosidase/O alfa/O ./O
The/O majority/O of/O patients/O were/O able/O to/O be/O rechallenged/O with/O alglucosidase/O alfa/O using/O lower/O doses/O and/or/O pretreatment/O with/O anti/O -/O inflammatory/O drugs/O and/or/O corticosteroids/O and/O were/O able/O to/O continue/O treatment/O under/O close/O clinical/O supervision/O ./O
In/O addition/O to/O the/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction reported/O in/O clinical/O trials/O [/O seeAdverse/O Reactions/O (/O 6.1/O )/O ]/O ,/O the/O following/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O in/O at/O least/O 2/O patients/O and/O included/O :/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction ,/O respiratory/B-AdverseReaction failure/I-AdverseReaction ,/O respiratory/B-AdverseReaction arrest/I-AdverseReaction ,/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O hypoxia/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O wheezing/B-AdverseReaction ,/O convulsions/B-AdverseReaction ,/O peripheral/B-AdverseReaction coldness/I-AdverseReaction ,/O restlessness/B-AdverseReaction ,/O nervousness/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O stridor/B-AdverseReaction ,/O pharyngeal/B-AdverseReaction edema/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O apnea/B-AdverseReaction ,/O muscle/B-AdverseReaction spasm/I-AdverseReaction ,/O and/O conjunctivitis/B-AdverseReaction ./O
In/O addition/O ,/O one/O case/O of/O hyperparathyroidism/B-AdverseReaction has/O been/O reported/O ./O
Systemic/O and/O cutaneous/B-AdverseReaction immune/I-AdverseReaction -/I-AdverseReaction mediated/O reactions/O ,/O including/O proteinuria/B-AdverseReaction and/O nephrotic/B-AdverseReaction syndrome/I-AdverseReaction secondary/O to/O membranous/B-AdverseReaction glomerulonephritis/I-AdverseReaction ,/O and/O necrotizing/B-AdverseReaction skin/I-AdverseReaction lesions/I-AdverseReaction have/O been/O reported/O in/O postmarketing/O safety/O experience/O with/O alglucosidase/O alfa/O [/O seeWarnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O RISK/B-Factor OF/O ANAPHYLAXIS/B-AdverseReaction ,/O HYPERSENSITIVITY/B-AdverseReaction AND/O IMMUNE/B-AdverseReaction -/I-AdverseReaction MEDIATED/O REACTIONS/O ,/O AND/O RISK/B-Factor OF/O CARDIORESPIRATORY/B-AdverseReaction FAILURE/I-AdverseReaction WARNING/O :/O RISK/B-Factor OF/O ANAPHYLAXIS/B-AdverseReaction ,/O HYPERSENSITIVITY/B-AdverseReaction AND/O IMMUNE/B-AdverseReaction -/I-AdverseReaction MEDIATED/O REACTIONS/O ,/O AND/O RISK/B-Factor OF/O CARDIORESPIRATORY/B-AdverseReaction FAILURE/I-AdverseReaction Life/B-Severity -/O threatening/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction and/O severe/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O presenting/O as/O respiratory/B-AdverseReaction distress/I-AdverseReaction ,/O hypoxia/B-AdverseReaction ,/O apnea/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O bradycardia/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O bronchospasm/B-AdverseReaction ,/O throat/B-AdverseReaction tightness/I-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O angioedema/B-AdverseReaction (/O including/O tongue/O or/O lip/B-AdverseReaction swelling/I-AdverseReaction ,/O periorbital/B-AdverseReaction edema/I-AdverseReaction ,/O and/O face/B-AdverseReaction edema/I-AdverseReaction )/O ,/O and/O urticaria/B-AdverseReaction ,/O have/O occurred/O in/O some/O patients/O during/O and/O after/O alglucosidase/O alfa/O infusions/O ./O
Immune/B-AdverseReaction -/I-AdverseReaction mediated/O reactions/O presenting/O as/O proteinuria/B-AdverseReaction ,/O nephrotic/B-AdverseReaction syndrome/I-AdverseReaction ,/O and/O necrotizing/B-AdverseReaction skin/I-AdverseReaction lesions/I-AdverseReaction have/O occurred/O in/O some/O patients/O following/O alglucosidase/O alfa/O treatment/O ./O
Closely/O observe/O patients/O during/O and/O after/O alglucosidase/O alfa/O administration/O and/O be/O prepared/O to/O manage/O anaphylaxis/O and/O hypersensitivity/O reactions/O ./O
Inform/O patients/O of/O the/O signs/O and/O symptoms/O of/O anaphylaxis/O ,/O hypersensitivity/O reactions/O ,/O and/O immune/O -/O mediated/O reactions/O and/O have/O them/O seek/O immediate/O medical/O care/O should/O signs/O and/O symptoms/O occur/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O ,/O 5.2/O )/O ]/O ./O
Infantile/O -/O onset/O Pompe/O disease/O patients/O with/O compromised/O cardiac/O or/O respiratory/O function/O may/B-Factor be/O at/O risk/O of/O serious/B-Severity acute/O exacerbation/O of/O their/O cardiac/O or/O respiratory/O compromise/O due/O to/O fluid/B-AdverseReaction overload/I-AdverseReaction ,/O and/O require/O additional/O monitoring/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
WARNING/O :/O RISK/B-Factor OF/O ANAPHYLAXIS/B-AdverseReaction ,/O HYPERSENSITIVITY/B-AdverseReaction AND/O IMMUNE/B-AdverseReaction -/I-AdverseReaction MEDIATED/O REACTIONS/O ,/O and/O RISK/B-Factor OF/O CARDIORESPIRATORY/B-AdverseReaction FAILURE/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Life/B-Severity -/O threatening/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction and/O severe/B-Severity hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O occurred/O in/O some/O patients/O during/O and/O after/O alglucosidase/O alfa/O infusions/O ./O
Immune/B-AdverseReaction -/I-AdverseReaction mediated/O reactions/O presenting/O as/O proteinuria/B-AdverseReaction ,/O nephrotic/B-AdverseReaction syndrome/I-AdverseReaction ,/O and/O necrotizing/B-AdverseReaction skin/I-AdverseReaction lesions/I-AdverseReaction have/O occurred/O in/O some/O patients/O following/O alglucosidase/O alfa/O treatment/O ./O
Closely/O observe/O patients/O during/O and/O after/O alglucosidase/O alfa/O administration/O and/O be/O prepared/O to/O manage/O anaphylaxis/O and/O hypersensitivity/O reactions/O ./O
Inform/O patients/O of/O the/O signs/O and/O symptoms/O of/O anaphylaxis/O ,/O hypersensitivity/O reactions/O ,/O and/O immune/O -/O mediated/O reactions/O and/O have/O them/O seek/O immediate/O medical/O care/O should/O signs/O and/O symptoms/O occur/O (/O 5.1/O ,/O 5.2/O )/O ./O
Infantile/O -/O onset/O Pompe/O disease/O patients/O with/O compromised/O cardiac/O or/O respiratory/O function/O may/B-Factor be/O at/O risk/O of/O serious/B-Severity acute/O exacerbation/O of/O their/O cardiac/O or/O respiratory/O compromise/O due/O to/O fluid/B-AdverseReaction overload/I-AdverseReaction ,/O and/O require/O additional/O monitoring/O (/O 5.3/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Anaphylaxis/B-AdverseReaction and/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction :/O Life/B-Severity -/O threatening/O anaphylaxis/B-AdverseReaction and/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O observed/O in/O some/O patients/O during/O and/O after/O treatment/O with/O alglucosidase/O alfa/O ./O
Ensure/O that/O appropriate/O medical/O support/O measures/O ,/O including/O cardiopulmonary/O resuscitation/O equipment/O ,/O are/O readily/O available/O ./O
If/O anaphylaxis/O or/O severe/O hypersensitivity/O reactions/O occur/O ,/O immediately/O discontinue/O infusion/O and/O initiate/O appropriate/O medical/O treatment/O (/O 5.1/O )/O ./O
Immune/B-AdverseReaction -/I-AdverseReaction Mediated/O Reactions/O :/O Monitor/O patients/O for/O the/O development/O of/O systemic/O immune/O -/O mediated/O reactions/O involving/O skin/O and/O other/O organs/O (/O 5.2/O )/O ./O
Risk/B-Factor of/O Acute/B-AdverseReaction Cardiorespiratory/I-AdverseReaction Failure/I-AdverseReaction :/O Patients/O with/O compromised/O cardiac/O or/O respiratory/O function/O may/B-Factor be/O at/O risk/O of/O acute/B-AdverseReaction cardiorespiratory/I-AdverseReaction failure/I-AdverseReaction ./O
Caution/O should/O be/O exercised/O when/O administering/O alglucosidase/O alfa/O to/O patients/O susceptible/O to/O fluid/O volume/O overload/O ./O
Appropriate/O medical/O support/O and/O monitoring/O measures/O should/O be/O available/O during/O infusion/O (/O 5.3/O )/O ./O
Risk/B-Factor of/O Cardiac/B-AdverseReaction Arrhythmia/I-AdverseReaction and/O Sudden/B-AdverseReaction Cardiac/I-AdverseReaction Death/I-AdverseReaction during/O General/O Anesthesia/O for/O Central/O Venous/O Catheter/O Placement/O :/O Caution/O should/O be/O used/O when/O administering/O general/O anesthesia/O for/O the/O placement/O of/O a/O central/O venous/O catheter/O intended/O for/O alglucosidase/O alfa/O infusion/O (/O 5.4/O )/O ./O
5.1/O Anaphylaxis/O and/O Hypersensitivity/O Reactions/O Anaphylaxis/B-AdverseReaction and/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O observed/O in/O patients/O during/O and/O up/O to/O 3/O hours/O after/O alglucosidase/O alfa/O infusion/O ./O
Some/O of/O the/O reactions/O were/O life/B-Severity -/O threatening/O and/O included/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction ,/O cardiac/B-AdverseReaction arrest/I-AdverseReaction ,/O respiratory/B-AdverseReaction arrest/I-AdverseReaction ,/O respiratory/B-AdverseReaction distress/I-AdverseReaction ,/O hypoxia/B-AdverseReaction ,/O apnea/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O bradycardia/B-AdverseReaction ,/O tachycardia/B-AdverseReaction ,/O bronchospasm/B-AdverseReaction ,/O throat/B-AdverseReaction tightness/I-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O angioedema/B-AdverseReaction (/O including/O tongue/O or/O lip/B-AdverseReaction swelling/I-AdverseReaction ,/O periorbital/B-AdverseReaction edema/I-AdverseReaction ,/O and/O face/B-AdverseReaction edema/I-AdverseReaction )/O ,/O and/O urticaria/B-AdverseReaction ./O
Other/O accompanying/O reactions/O included/O chest/B-AdverseReaction discomfort/I-AdverseReaction pain/O ,/O wheezing/B-AdverseReaction ,/O tachypnea/B-AdverseReaction ,/O cyanosis/B-AdverseReaction ,/O decreased/B-AdverseReaction oxygen/I-AdverseReaction saturation/I-AdverseReaction ,/O convulsions/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O hypertension/B-AdverseReaction increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction ,/O flushing/B-AdverseReaction feeling/B-AdverseReaction hot/I-AdverseReaction ,/O erythema/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O pallor/B-AdverseReaction ,/O peripheral/B-AdverseReaction coldness/I-AdverseReaction ,/O restlessness/B-AdverseReaction ,/O nervousness/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O and/O paresthesia/B-AdverseReaction ./O
Some/O of/O these/O reactions/O were/O IgE/O -/O mediated/O ./O
If/O anaphylaxis/O or/O severe/O hypersensitivity/O reactions/O occur/O ,/O immediately/O discontinue/O administration/O of/O alglucosidase/O alfa/O ,/O and/O initiate/O appropriate/O medical/O treatment/O ./O
Severe/O reactions/O are/O generally/O managed/O with/O infusion/O interruption/O ,/O administration/O of/O antihistamines/O ,/O corticosteroids/O ,/O intravenous/O fluids/O ,/O and/or/O oxygen/O ,/O when/O clinically/O indicated/O ./O
In/O some/O cases/O of/O anaphylaxis/O ,/O epinephrine/O has/O been/O administered/O ./O
Appropriate/O medical/O support/O ,/O including/O cardiopulmonary/O resuscitation/O equipment/O ,/O should/O be/O readily/O available/O when/O alglucosidase/O alfa/O is/O administered/O ./O
The/O risks/O and/O benefits/O of/O re/O -/O administering/O alglucosidase/O alfa/O following/O an/O anaphylactic/O or/O hypersensitivity/O reaction/O should/O be/O considered/O ./O
Some/O patients/O have/O been/O rechallenged/O and/O have/O continued/O to/O receive/O alglucosidase/O alfa/O under/O close/O clinical/O supervision/O ./O
Extreme/O care/O should/O be/O exercised/O ,/O with/O appropriate/O resuscitation/O measures/O available/O ,/O if/O the/O decision/O is/O made/O to/O re/O -/O administer/O the/O product/O [/O seeAdverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
5.2/O Immune/O -/O Mediated/O Reactions/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction cutaneous/O reactions/O have/O been/O reported/O with/O alglucosidase/O alfa/O including/O necrotizing/B-AdverseReaction skin/I-AdverseReaction lesions/I-AdverseReaction [/O seeAdverse/O Reactions/O (/O 6.3/O )/O ]/O ./O
Systemic/B-AdverseReaction immune/I-AdverseReaction -/I-AdverseReaction mediated/O reactions/O ,/O including/O possible/B-Factor type/B-AdverseReaction III/I-AdverseReaction immune/I-AdverseReaction -/I-AdverseReaction mediated/O reactions/O have/O been/O observed/O with/O alglucosidase/O alfa/O ./O
These/O reactions/O occurred/O several/O weeks/O to/O 3/O years/O after/O initiation/O of/O alglucosidase/O alfa/O infusions/O ./O
Skin/O biopsy/O in/O one/O patient/O demonstrated/O deposition/B-AdverseReaction of/I-AdverseReaction anti/I-AdverseReaction -/I-AdverseReaction rhGAA/O antibodies/O in/O the/O lesion/O ./O
Another/O patient/O developed/O severe/B-Severity inflammatory/B-AdverseReaction arthropathy/I-AdverseReaction in/O association/O with/O pyrexia/B-AdverseReaction and/O elevated/B-AdverseReaction erythrocyte/I-AdverseReaction sedimentation/I-AdverseReaction rate/I-AdverseReaction ./O
Nephrotic/B-AdverseReaction syndrome/I-AdverseReaction secondary/O to/O membranous/B-AdverseReaction glomerulonephritis/I-AdverseReaction was/O observed/O in/O some/O Pompe/O disease/O patients/O treated/O with/O alglucosidase/O alfa/O who/O had/O persistently/O positive/B-AdverseReaction anti/I-AdverseReaction -/I-AdverseReaction rhGAA/I-AdverseReaction IgG/I-AdverseReaction antibody/O titers/O ./O
In/O these/O patients/O ,/O renal/O biopsy/O was/O consistent/O with/O immune/B-AdverseReaction complex/I-AdverseReaction deposition/I-AdverseReaction ./O
Patients/O improved/O following/O treatment/O interruption/O ./O
Therefore/O ,/O patients/O receiving/O alglucosidase/O alfa/O should/O undergo/O periodic/O urinalysis/O [/O seeAdverse/O Reactions/O (/O 6.3/O )/O ]/O ./O
Patients/O should/O be/O monitored/O for/O the/O development/O of/O systemic/O immune/O -/O mediated/O reactions/O involving/O skin/O and/O other/O organs/O while/O receiving/O alglucosidase/O alfa/O ./O
If/O immune/O -/O mediated/O reactions/O occur/O ,/O consider/O discontinuation/O of/O the/O administration/O of/O alglucosidase/O alfa/O ,/O and/O initiate/O appropriate/O medical/O treatment/O ./O
The/O risks/O and/O benefits/O of/O re/O -/O administering/O alglucosidase/O alfa/O following/O an/O immune/O -/O mediated/O reaction/O should/O be/O considered/O ./O
Some/O patients/O have/O been/O able/O to/O be/O rechallenged/O and/O have/O continued/O to/O receive/O alglucosidase/O alfa/O under/O close/O clinical/O supervision/O ./O
5.3/O Risk/O of/O Acute/O Cardiorespiratory/O Failure/O Patients/O with/O acute/O underlying/O respiratory/O illness/O or/O compromised/O cardiac/O and/or/O respiratory/O function/O may/B-Factor be/O at/O risk/O of/O serious/B-Severity exacerbation/O of/O their/O cardiac/O or/O respiratory/O compromise/O during/O infusions/O ./O
Appropriate/O medical/O support/O and/O monitoring/O measures/O should/O be/O readily/O available/O during/O alglucosidase/O alfa/O infusion/O ,/O and/O some/O patients/O may/O require/O prolonged/O observation/O times/O that/O should/O be/O individualized/O based/O on/O the/O needs/O of/O the/O patient/O ./O
Acute/B-AdverseReaction cardiorespiratory/I-AdverseReaction failure/I-AdverseReaction has/O been/O observed/O in/O infantile/O -/O onset/O Pompe/O disease/O patients/O with/O underlying/O cardiac/O hypertrophy/O ,/O possibly/O associated/O with/O fluid/B-AdverseReaction overload/I-AdverseReaction with/O intravenous/O administration/O of/O alglucosidase/O alfa/O [/O seeDosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.4/O Risk/O of/O Cardiac/O Arrhythmia/O and/O Sudden/O Cardiac/O Death/O During/O General/O Anesthesia/O for/O Central/O Venous/O Catheter/O Placement/O Administration/O of/O general/O anesthesia/O can/O be/O complicated/O by/O the/O presence/O of/O severe/O cardiac/O and/O skeletal/O (/O including/O respiratory/O )/O muscle/O weakness/O ./O
Therefore/O ,/O caution/O should/O be/O used/O when/O administering/O general/O anesthesia/O ./O
Ventricular/B-AdverseReaction arrhythmias/I-AdverseReaction and/O bradycardia/B-AdverseReaction ,/O resulting/O in/O cardiac/B-AdverseReaction arrest/I-AdverseReaction or/O death/B-AdverseReaction ,/O or/O requiring/O cardiac/O resuscitation/O or/O defibrillation/O have/O been/O observed/O in/O infantile/O -/O onset/O Pompe/O disease/O patients/O with/O cardiac/O hypertrophy/O during/O general/O anesthesia/O for/O central/O venous/O catheter/O placement/O ./O
5.5/O Risk/O of/O Antibody/O Development/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O potential/O for/O immunogenicity/O ./O
In/O clinical/O studies/O ,/O the/O majority/O of/O patients/O developed/O IgG/O antibodies/O to/O alglucosidase/O alfa/O ,/O typically/O within/O 3/O months/O of/O treatment/O ./O
There/O is/O evidence/O to/O suggest/O that/O some/O patients/O who/O develop/O high/O and/O sustained/O IgG/O antibody/O titers/O may/B-Factor experience/O reduced/B-AdverseReaction clinical/I-AdverseReaction efficacy/I-AdverseReaction to/O alglucosidase/O alfa/O treatment/O ,/O such/O as/O loss/B-AdverseReaction of/I-AdverseReaction motor/I-AdverseReaction function/I-AdverseReaction ,/O ventilator/O dependence/O ,/O or/O death/B-AdverseReaction ./O
The/O effect/O of/O antibody/O development/O on/O the/O long/O term/O efficacy/O of/O alglucosidase/O alfa/O is/O not/O fully/O understood/O ./O
Patients/O should/O be/O monitored/O for/O IgG/O antibody/O formation/O every/O 3/O months/O for/O 2/O years/O and/O then/O annually/O thereafter/O ./O
Testing/O for/O IgG/O titers/O may/O also/O be/O considered/O if/O patients/O develop/O hypersensitivity/O reactions/O ,/O other/O immune/O -/O mediated/O reactions/O ,/O or/O lose/O clinical/O response/O ./O
Patients/O who/O experience/O reduced/O clinical/O response/O may/O also/O be/O tested/O for/O inhibitory/O antibody/O activity/O ./O
Patients/O who/O experience/O anaphylactic/O or/O hypersensitivity/O reactions/O may/O also/O be/O tested/O for/O IgE/O antibodies/O to/O alglucosidase/O alfa/O and/O other/O mediators/O of/O anaphylaxis/O [/O seeAdverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
There/O are/O currently/O no/O marketed/O tests/O for/O antibodies/O against/O alglucosidase/O alfa/O ;/O however/O ,/O a/O testing/O service/O is/O provided/O by/O Genzyme/O ./O
Contact/O your/O local/O Genzyme/O representative/O or/O Genzyme/O Corporation/O at/O 1/O -/O 800/O -/O 745/O -/O 4447/O for/O information/O on/O testing/O and/O to/O obtain/O a/O sample/O collection/O box/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O safety/O concerns/O are/O described/O elsewhere/O in/O the/O label/O :/O New/O or/O worsening/B-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Liver/B-AdverseReaction Injury/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Pulmonary/B-AdverseReaction toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Hypokalemia/B-AdverseReaction and/O hypomagnesemia/B-AdverseReaction with/O potassium/O -/O depleting/O diuretics/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O QT/B-AdverseReaction prolongation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 2/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O and/O asthenia/B-AdverseReaction (/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O sanofi/O -/O aventis/O U.S./O LLC/O at/O 1/O -/O 800/O -/O 633/O -/O 1610/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O The/O safety/O evaluation/O of/O dronedarone/O 400/O mg/O twice/O daily/O in/O patients/O with/O AF/O or/O AFL/O is/O based/O on/O 5/O placebo/O controlled/O studies/O ,/O ATHENA/O ,/O EURIDIS/O ,/O ADONIS/O ,/O ERATO/O and/O DAFNE/O ./O
In/O these/O studies/O ,/O a/O total/O of/O 6285/O patients/O were/O randomized/O and/O treated/O ,/O 3282/O patients/O with/O MULTAQ/O 400/O mg/O twice/O daily/O ,/O and/O 2875/O with/O placebo/O ./O
The/O mean/O exposure/O across/O studies/O was/O 12/O months/O ./O
In/O ATHENA/O ,/O the/O maximum/O follow/O -/O up/O was/O 30/O months/O ./O
In/O clinical/O trials/O ,/O premature/O discontinuation/O because/O of/O adverse/O reactions/O occurred/O in/O 11.8/O %/O of/O the/O dronedarone/O -/O treated/O patients/O and/O in/O 7.7/O %/O of/O the/O placebo/O -/O treated/O group/O ./O
The/O most/O common/O reasons/O for/O discontinuation/O of/O therapy/O with/O MULTAQ/O were/O gastrointestinal/B-AdverseReaction disorders/I-AdverseReaction (/O 3.2/O %/O versus/O 1.8/O %/O in/O the/O placebo/O group/O )/O and/O QT/B-AdverseReaction prolongation/I-AdverseReaction (/O 1.5/O %/O versus/O 0.5/O %/O in/O the/O placebo/O group/O )/O ./O
The/O most/O frequent/O adverse/O reactions/O observed/O with/O MULTAQ/O 400/O mg/O twice/O daily/O in/O the/O 5/O studies/O were/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O and/O asthenia/B-AdverseReaction ./O
Table/O 1/O displays/O adverse/O reactions/O more/O common/O with/O dronedarone/O 400/O mg/O twice/O daily/O than/O with/O placebo/O in/O AF/O or/O AFL/O patients/O ,/O presented/O by/O system/O organ/O class/O and/O by/O decreasing/O order/O of/O frequency/O ./O
Adverse/O laboratory/O and/O ECG/O effects/O are/O presented/O separately/O in/O Table/O 2/O ./O
Table/O 1/O :/O Adverse/O Drug/O Reactions/O that/O Occurred/O in/O at/O Least/O 1/O %/O of/O Patients/O and/O Were/O More/O Frequent/O than/O Placebo/O Placebo/O Dronedarone/O 400/O mg/O twice/O daily/O (/O N=2875/O )/O (/O N=3282/O )/O Gastrointestinal/O Diarrhea/B-AdverseReaction 6/O %/O 9/O %/O Nausea/B-AdverseReaction 3/O %/O 5/O %/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 3/O %/O 4/O %/O Vomiting/B-AdverseReaction 1/O %/O 2/O %/O Dyspeptic/B-AdverseReaction signs/I-AdverseReaction and/I-AdverseReaction symptoms/I-AdverseReaction 1/O %/O 2/O %/O General/O Asthenic/B-AdverseReaction conditions/I-AdverseReaction 5/O %/O 7/O %/O Cardiac/O Bradycardia/B-AdverseReaction 1/O %/O 3/O %/O Skin/O and/O subcutaneous/O tissue/O Including/O rashes/B-AdverseReaction (/O generalized/O ,/O macular/O ,/O maculo/O -/O papular/O ,/O erythematous/O )/O ,/O pruritus/B-AdverseReaction ,/O eczema/B-AdverseReaction ,/O dermatitis/B-AdverseReaction ,/O dermatitis/B-AdverseReaction allergic/I-AdverseReaction 3/O %/O 5/O %/O Photosensitivity/B-AdverseReaction reaction/I-AdverseReaction and/O dysgeusia/B-AdverseReaction have/O also/O been/O reported/O at/O an/O incidence/O less/O than/O 1/O %/O in/O patients/O treated/O with/O MULTAQ/O ./O
The/O following/O laboratory/O data/O ECG/O parameters/O were/O reported/O with/O MULTAQ/O 400/O mg/O twice/O daily/O ./O
Table/O 2/O :/O Laboratory/O data/O ECG/O parameters/O not/O necessarily/O reported/O as/O adverse/O events/O Placebo/O MULTAQ/O 400/O mg/O twice/O daily/O (/O N=2875/O )/O (/O N=3282/O )/O Early/O increases/B-AdverseReaction in/I-AdverseReaction creatinine/I-AdverseReaction 10/O %/O 21/O %/O 51/O %/O (/O N=2237/O )/O (/O N=2701/O )/O QTc/B-AdverseReaction prolonged/I-AdverseReaction 19/O %/O 28/O %/O Assessment/O of/O demographic/O factors/O such/O as/O gender/O or/O age/O on/O the/O incidence/O of/O treatment/O -/O emergent/O adverse/O events/O did/O not/O suggest/O an/O excess/O of/O adverse/O events/O in/O any/O particular/O sub/O -/O group/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O MULTAQ/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O an/O unknown/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Cardiac/O :/O New/O or/O worsening/O heart/B-AdverseReaction failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Atrial/B-AdverseReaction flutter/I-AdverseReaction with/I-AdverseReaction 1:1/I-AdverseReaction atrioventricular/I-AdverseReaction conduction/I-AdverseReaction has/O been/O reported/O very/O rarely/O ./O
Hepatic/O :/O Liver/B-AdverseReaction Injury/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Respiratory/O :/O Interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction including/O pneumonitis/B-AdverseReaction and/O pulmonary/B-AdverseReaction fibrosis/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Immune/O :/O Anaphylactic/B-AdverseReaction reactions/I-AdverseReaction including/O angioedema/B-AdverseReaction Vascular/O :/O Vasculitis/B-AdverseReaction ,/O including/O leukocytoclastic/B-AdverseReaction vasculitis/I-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O INCREASED/O RISK/B-Factor OF/O DEATH/B-AdverseReaction ,/O STROKE/B-AdverseReaction AND/O HEART/B-AdverseReaction FAILURE/I-AdverseReaction IN/O PATIENTS/O WITH/O DECOMPENSATED/O HEART/O FAILURE/O OR/O PERMANENT/O ATRIAL/O FIBRILLATION/O WARNING/O :/O INCREASED/O RISK/B-Factor OF/O DEATH/B-AdverseReaction ,/O STROKE/B-AdverseReaction AND/O HEART/B-AdverseReaction FAILURE/I-AdverseReaction IN/O PATIENTS/O WITH/O DECOMPENSATED/O HEART/O FAILURE/O OR/O PERMANENT/O ATRIAL/O FIBRILLATION/O In/O patients/O with/O symptomatic/O heart/O failure/O and/O recent/O decompensation/O requiring/O hospitalization/O or/O NYHA/O Class/O IV/O heart/O failure/O ;/O MULTAQ/O doubles/O the/O risk/B-Factor of/O death/B-AdverseReaction ./O
(/O 14.3/O )/O MULTAQ/O is/O contraindicated/O in/O patients/O with/O symptomatic/O heart/O failure/O with/O recent/O decompensation/O requiring/O hospitalization/O or/O NYHA/O Class/O IV/O heart/O failure/O ./O
(/O 4/O ,/O 5.1/O )/O In/O patients/O with/O permanent/O atrial/O fibrillation/O ,/O MULTAQ/O doubles/O the/O risk/B-Factor of/O death/B-AdverseReaction ,/O stroke/B-AdverseReaction and/O hospitalization/O for/O heart/B-AdverseReaction failure/I-AdverseReaction ./O
(/O 14.4/O )/O ./O
MULTAQ/O is/O contraindicated/O in/O patients/O in/O atrial/O fibrillation/O (/O AF/O )/O who/O will/O not/O or/O can/O not/O be/O cardioverted/O into/O normal/O sinus/O rhythm/O ./O
(/O 4/O ,/O 5.2/O )/O EXCERPT/O :/O WARNING/O :/O INCREASED/O RISK/B-Factor OF/O DEATH/B-AdverseReaction ,/O STROKE/B-AdverseReaction AND/O HEART/B-AdverseReaction FAILURE/I-AdverseReaction IN/O PATIENTS/O WITH/O DECOMPENSATED/O HEART/O FAILURE/O OR/O PERMANENT/O ATRIAL/O FIBRILLATION/O MULTAQ/O is/O contraindicated/O in/O patients/O with/O symptomatic/O heart/O failure/O with/O recent/O decompensation/O requiring/O hospitalization/O or/O NYHA/O Class/O IV/O heart/O failure/O ./O
MULTAQ/O doubles/O the/O risk/B-Factor of/O death/B-AdverseReaction in/O these/O patients/O (/O 4/O ,/O 5.1/O ,/O 14.3/O )/O ./O
MULTAQ/O is/O contraindicated/O in/O patients/O in/O atrial/O fibrillation/O (/O AF/O )/O who/O will/O not/O or/O can/O not/O be/O cardioverted/O into/O normal/O sinus/O rhythm/O ./O
In/O patients/O with/O permanent/O AF/O ,/O MULTAQ/O doubles/O the/O risk/B-Factor of/O death/B-AdverseReaction ,/O stroke/B-AdverseReaction ,/O and/O hospitalization/O for/O heart/B-AdverseReaction failure/I-AdverseReaction ./O
(/O 4/O ,/O 5.2/O ,/O 14.4/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Determine/O cardiac/O rhythm/O at/O least/O once/O every/O 3/O months/O ./O
If/O AF/O is/O detected/O discontinue/O MULTAQ/O or/O cardiovert/O (/O 5.2/O )/O Ensure/O appropriate/O antithrombotic/O therapy/O prior/O to/O and/O throughout/O MULTAQ/O use/O (/O 5.3/O )/O Liver/B-AdverseReaction injury/I-AdverseReaction :/O if/O hepatic/O injury/O is/O suspected/O ,/O discontinue/O MULTAQ/O (/O 5.5/O )/O If/O pulmonary/O toxicity/O is/O confirmed/O ,/O discontinue/O treatment/O (/O 5.6/O )/O Hypokalemia/B-AdverseReaction and/O hypomagnesemia/B-AdverseReaction :/O Maintain/O potassium/O and/O magnesium/O levels/O within/O the/O normal/O range/O (/O 5.7/O )/O Renal/B-AdverseReaction Impairment/I-AdverseReaction :/O Monitor/O renal/O function/O periodically/O (/O 5.9/O )/O Teratogen/B-AdverseReaction :/O Women/O of/O childbearing/O potential/O should/O use/O effective/O contraception/O while/O using/O MULTAQ/O (/O 5.10/O )/O 5.1/O Cardiovascular/O Death/O in/O NYHA/O Class/O IV/O or/O Decompensated/O Heart/O Failure/O MULTAQ/O is/O contraindicated/O in/O patients/O with/O NYHA/O Class/O IV/O heart/O failure/O or/O symptomatic/O heart/O failure/O with/O recent/O decompensation/O requiring/O hospitalization/O because/O it/O doubles/O the/O risk/B-Factor of/O death/B-AdverseReaction ./O
5.2/O Cardiovascular/O Death/O and/O Heart/O Failure/O in/O Permanent/O AF/O MULTAQ/O doubles/O the/O risk/B-Factor of/O cardiovascular/B-AdverseReaction death/I-AdverseReaction (/O largely/O arrhythmic/O )/O and/O heart/B-AdverseReaction failure/I-AdverseReaction events/I-AdverseReaction in/O patients/O with/O permanent/O AF/O ./O
Patients/O treated/O with/O dronedarone/O should/O undergo/O monitoring/O of/O cardiac/O rhythm/O no/O less/O often/O than/O every/O 3/O months/O ./O
Cardiovert/O patients/O who/O are/O in/O atrial/O fibrillation/O (/O if/O clinically/O indicated/O )/O or/O discontinue/O MULTAQ/O ./O
MULTAQ/O offers/O no/O benefit/O in/O subjects/O in/O permanent/O AF/O ./O
5.3/O Increased/O Risk/O of/O Stroke/O in/O Permanent/O AF/O In/O a/O placebo/O -/O controlled/O study/O in/O patients/O with/O permanent/O atrial/O fibrillation/O ,/O dronedarone/O was/O associated/O with/O an/O increased/O risk/B-Factor of/O stroke/B-AdverseReaction ,/O particularly/O in/O the/O first/O two/O weeks/O of/O therapy/O [/O see/O Clinical/O Studies/O (/O 14.4/O )/O ]/O ./O
MULTAQ/O should/O only/O be/O initiated/O in/O patients/O in/O sinus/O rhythm/O who/O are/O receiving/O appropriate/O antithrombotic/O therapy/O [/O see/O Drug/O interactions/O (/O 7.3/O )/O ]/O ./O
5.4/O New/O Onset/O or/O Worsening/O Heart/O Failure/O New/O onset/O or/O worsening/B-AdverseReaction of/I-AdverseReaction heart/I-AdverseReaction failure/I-AdverseReaction has/O been/O reported/O during/O treatment/O with/O MULTAQ/O in/O the/O postmarketing/O setting/O ./O
In/O a/O placebo/O controlled/O study/O in/O patients/O with/O permanent/O AF/O increased/O rates/O of/O heart/B-AdverseReaction failure/I-AdverseReaction were/O observed/O in/O patients/O with/O normal/O left/O ventricular/O function/O and/O no/O history/O of/O symptomatic/O heart/O failure/O ,/O as/O well/O as/O those/O with/O a/O history/O of/O heart/O failure/O or/O left/O ventricular/O dysfunction/O ./O
Advise/O patients/O to/O consult/O a/O physician/O if/O they/O develop/O signs/O or/O symptoms/O of/O heart/O failure/O ,/O such/O as/O weight/O gain/O ,/O dependent/O edema/O ,/O or/O increasing/O shortness/O of/O breath/O ./O
If/O heart/O failure/O develops/O or/O worsens/O and/O requires/O hospitalization/O ,/O discontinue/O MULTAQ/O ./O
5.5/O Liver/O Injury/O Hepatocellular/B-AdverseReaction liver/I-AdverseReaction injury/I-AdverseReaction ,/O including/O acute/B-AdverseReaction liver/I-AdverseReaction failure/I-AdverseReaction requiring/O transplant/O ,/O has/O been/O reported/O in/O patients/O treated/O with/O MULTAQ/O in/O the/O postmarketing/O setting/O ./O
Advise/O patients/O treated/O with/O MULTAQ/O to/O report/O immediately/O symptoms/O suggesting/O hepatic/O injury/O (/O such/O as/O anorexia/O ,/O nausea/O ,/O vomiting/O ,/O fever/O ,/O malaise/O ,/O fatigue/O ,/O right/O upper/O quadrant/O pain/O ,/O jaundice/O ,/O dark/O urine/O ,/O or/O itching/O )/O ./O
Consider/O obtaining/O periodic/O hepatic/O serum/O enzymes/O ,/O especially/O during/O the/O first/O 6/O months/O of/O treatment/O ,/O but/O it/O is/O not/O known/O whether/O routine/O periodic/O monitoring/O of/O serum/O enzymes/O will/O prevent/O the/O development/O of/O severe/O liver/O injury/O ./O
If/O hepatic/O injury/O is/O suspected/O ,/O promptly/O discontinue/O MULTAQ/O and/O test/O serum/O enzymes/O ,/O aspartate/O aminotransferase/O (/O AST/O )/O ,/O alanine/O aminotransferase/O (/O ALT/O )/O and/O alkaline/O phosphatase/O ,/O as/O well/O as/O serum/O bilirubin/O ,/O to/O establish/O whether/O there/O is/O liver/O injury/O ./O
If/O liver/O injury/O is/O found/O ,/O institute/O appropriate/O treatment/O and/O investigate/O the/O probable/O cause/O ./O
Do/O not/O restart/O MULTAQ/O in/O patients/O without/O another/O explanation/O for/O the/O observed/O liver/O injury/O ./O
5.6/O Pulmonary/O Toxicity/O Cases/O of/O interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction including/O pneumonitis/B-AdverseReaction and/O pulmonary/B-AdverseReaction fibrosis/I-AdverseReaction have/O been/O reported/O in/O patients/O treated/O with/O MULTAQ/O in/O the/O post/O -/O marketing/O setting/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
Onset/O of/O dyspnea/O or/O non/O -/O productive/O cough/O may/O be/O related/O to/O pulmonary/O toxicity/O and/O patients/O should/O be/O carefully/O evaluated/O clinically/O ./O
If/O pulmonary/O toxicity/O is/O confirmed/O ,/O MULTAQ/O should/O be/O discontinued/O ./O
5.7/O Hypokalemia/O and/O Hypomagnesemia/O with/O Potassium/O -/O Depleting/O Diuretics/O Hypokalemia/B-AdverseReaction or/O hypomagnesemia/B-AdverseReaction may/B-Factor occur/O with/O concomitant/O administration/O of/O potassium/O -/O depleting/O diuretics/O ./O
Potassium/O levels/O should/O be/O within/O the/O normal/O range/O prior/O to/O administration/O of/O MULTAQ/O and/O maintained/O in/O the/O normal/O range/O during/O administration/O of/O MULTAQ/O ./O
5.8/O QT/O Interval/O Prolongation/O Dronedarone/O induces/O a/O moderate/B-Severity (/O average/O of/O about/O 10/O ms/O but/O much/O greater/O effects/O have/O been/O observed/O )/O QTc/O (/O Bazett/O )/O prolongation/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O and/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
If/O the/O QTc/O Bazett/O interval/O is/O 500/O ms/O ,/O discontinue/O MULTAQ/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.9/O Renal/O Impairment/O and/O Failure/O Marked/O increase/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction ,/O pre/B-AdverseReaction -/I-AdverseReaction renal/O azotemia/O and/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O often/O in/O the/O setting/O of/O heart/B-AdverseReaction failure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O or/O hypovolemia/B-AdverseReaction ,/O have/O been/O reported/O in/O patients/O taking/O MULTAQ/O ./O
In/O most/O cases/O ,/O these/O effects/O appear/O to/O be/O reversible/O upon/O drug/O discontinuation/O and/O with/O appropriate/O medical/O treatment/O ./O
Monitor/O renal/O function/O periodically/O ./O
Small/O increases/B-AdverseReaction in/I-AdverseReaction creatinine/I-AdverseReaction levels/I-AdverseReaction (/O about/O 0.1/B-Severity mg/I-Severity dL/O )/O following/O dronedarone/O treatment/O initiation/O have/O been/O shown/O to/O be/O a/O result/O of/O inhibition/O of/O creatinine/O 's/O tubular/O secretion/O ./O
The/O elevation/O has/O a/O rapid/O onset/O ,/O reaches/O a/O plateau/O after/O 7/O days/O and/O is/O reversible/O after/O discontinuation/O ./O
5.10/O Women/O of/O Childbearing/O Potential/O Premenopausal/O women/O who/O have/O not/O undergone/O a/O hysterectomy/O or/O oophorectomy/O must/O use/O effective/O contraception/O while/O using/O MULTAQ/O ./O
Dronedarone/O caused/O fetal/B-AdverseReaction harm/I-AdverseReaction in/O animal/B-Animal studies/O at/O doses/O equivalent/O to/O recommended/O human/O doses/O ./O
Counsel/O women/O of/O childbearing/O potential/O regarding/O appropriate/O contraceptive/O choices/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O commonly/O reported/O adverse/O reactions/O were/O :/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction consisting/O of/O erythema/O (/O 1.7/O %/O )/O ,/O irritation/O (/O 1.2/O %/O )/O ,/O and/O pain/O (/O 3.9/O %/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Piramal/O at/O 1/O -/O 855/O -/O 545/O -/O 5245/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rate/O observed/O in/O clinical/O practice/O ./O
The/O overall/O safety/O profile/O of/O Neuraceq/O is/O based/O on/O data/O from/O 978/O administrations/O of/O Neuraceq/O to/O 872/O subjects/O and/O 12/O subjects/O who/O received/O vehicle/O only/O ./O
No/O serious/O adverse/O reactions/O related/O to/O Neuraceq/O administration/O have/O been/O reported/O ./O
The/O most/O frequently/O observed/O adverse/O drug/O reactions/O in/O subjects/O receiving/O Neuraceq/O were/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction consisting/O of/O erythema/O ,/O irritation/O and/O pain/O ./O
All/O adverse/O reactions/O were/O mild/O to/O moderate/O in/O severity/O and/O of/O short/O duration/O ./O
The/O most/O commonly/O reported/O adverse/O reactions/O (/O occurring/O in/O at/O least/O 0.5/O %/O of/O subjects/O )/O during/O Neuraceq/O clinical/O trials/O are/O shown/O in/O Table/O 2/O ./O
Table/O 2/O Adverse/O Reactions/O with/O a/O Frequency/O 0.5/O %/O Reported/O in/O Clinical/O Trials/O (/O n/O 978/O Administrations/O in/O 872/O Subjects/O )/O Adverse/O drug/O reaction/O n/O (/O %/O )/O Injection/O application/B-AdverseReaction site/I-AdverseReaction erythema/I-AdverseReaction 17/O (/O 1.7/O )/O Injection/B-AdverseReaction site/I-AdverseReaction irritation/I-AdverseReaction 12/O (/O 1.2/O )/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 38/O (/O 3.9/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Image/O interpretation/O errors/O (/O especially/O false/O positives/O )/O have/O been/O observed/O (/O 5.1/O )/O ./O
Neuraceq/O ,/O like/O all/O radiopharmaceuticals/O ,/O contributes/O to/O a/O patient/O 's/O long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O ./O
Ensure/O safe/O handling/O to/O protect/O patients/O and/O health/O care/O workers/O from/O unintentional/O radiation/O exposure/O (/O 5.2/O )/O ./O
5.1/O Risk/O for/O Image/O Misinterpretation/O and/O Other/O Errors/O Errors/O may/O occur/O in/O the/O Neuraceq/O estimation/O of/O brain/O neuritic/O beta/O -/O amyloid/O plaque/O density/O during/O image/O interpretation/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Image/O interpretation/O should/O be/O performed/O independently/O of/O the/O patient/O 's/O clinical/O information/O ./O
The/O use/O of/O clinical/O information/O in/O the/O interpretation/O of/O Neuraceq/O images/O has/O not/O been/O evaluated/O and/O may/O lead/O to/O errors/O ./O
Errors/O may/O also/O occur/O in/O cases/O with/O severe/O brain/O atrophy/O that/O limits/O the/O ability/O to/O distinguish/O gray/O and/O white/O matter/O on/O the/O Neuraceq/O scan/O ./O
Errors/O may/O also/O occur/O due/O to/O motion/O artifacts/O that/O result/O in/O image/O distortion/O ./O
Neuraceq/O scan/O results/O are/O indicative/O of/O the/O presence/O of/O brain/O neuritic/O beta/O -/O amyloid/O plaques/O only/O at/O the/O time/O of/O image/O acquisition/O and/O a/O negative/O scan/O result/O does/O not/O preclude/O the/O development/O of/O brain/O neuritic/O beta/O -/O amyloid/O plaques/O in/O the/O future/O ./O
5.2/O Radiation/O Risk/O Neuraceq/O ,/O similar/O to/O other/O radiopharmaceuticals/O ,/O contributes/O to/O a/O patient/O 's/O overall/O long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O ./O
Long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O is/O associated/O with/O an/O increased/O risk/B-Factor of/O cancer/B-AdverseReaction ./O
Ensure/O safe/O handling/O to/O protect/O patients/O and/O health/O care/O workers/O from/O unintentional/O radiation/O exposure/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O with/O NORTHERA/O are/O included/O in/O more/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O of/O the/O label/O :/O Supine/B-AdverseReaction Hypertension/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Hyperpyrexia/B-AdverseReaction and/O Confusion/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O May/B-Factor exacerbate/O existing/O ischemic/O heart/O disease/O ,/O arrhythmias/O ,/O and/O congestive/O heart/O failure/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O EXCERPT/O :/O Headache/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O and/O fatigue/B-AdverseReaction (/O greater/O than/O 5/O %/O )/O (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Lundbeck/O at/O 1/O -/O 800/O -/O 455/O -/O 1141/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O safety/O evaluation/O of/O NORTHERA/O is/O based/O on/O two/O placebo/O -/O controlled/O studies/O 1/O to/O 2/O weeks/O in/O duration/O (/O Studies/O 301/O and/O 302/O )/O ,/O one/O 8-week/O placebo/O -/O controlled/O study/O (/O Study/O 306/O )/O ,/O and/O two/O long/O -/O term/O ,/O open/O -/O label/O extension/O studies/O (/O Studies/O 303/O and/O 304/O )/O ./O
In/O the/O placebo/O -/O controlled/O studies/O ,/O a/O total/O of/O 485/O patients/O with/O Parkinson/O 's/O disease/O ,/O multiple/O system/O atrophy/O ,/O pure/O autonomic/O failure/O ,/O dopamine/O beta/O -/O hydroxylase/O deficiency/O ,/O or/O non/O -/O diabetic/O autonomic/O neuropathy/O were/O randomized/O and/O treated/O ,/O 245/O with/O NORTHERA/O and/O 240/O with/O placebo/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Placebo/O -/O Controlled/O Experience/O The/O most/O commonly/O observed/O adverse/O reactions/O (/O those/O occurring/O at/O an/O incidence/O of/O greater/O than/O 5/O %/O in/O the/O NORTHERA/O group/O and/O with/O at/O least/O a/O 3/O %/O greater/O incidence/O in/O the/O NORTHERA/O group/O than/O in/O the/O placebo/O group/O )/O in/O NORTHERA/O -/O treated/O patients/O during/O the/O three/O placebo/O -/O controlled/O trials/O were/O headache/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O hypertension/B-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O from/O NORTHERA/O were/O hypertension/B-AdverseReaction or/O increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction and/O nausea/B-AdverseReaction ./O
Table/O 1/O ./O
Most/O Common/O Adverse/O Reactions/O Occurring/O More/O Frequently/O in/O the/O NORTHERA/O Group/O Study/O 301/O and/O Study/O 302/O (/O 1/O to/O 2/O Weeks/O Randomized/O Treatment/O )/O Study/O 306/O (/O 8/O to/O 10/O Weeks/O Randomized/O Treatment/O )/O Placebo/O (/O N=132/O )/O n/O (/O %/O )/O NORTHERA/O (/O N=131/O )/O n/O (/O %/O )/O Placebo/O (/O N=108/O )/O n/O (/O %/O )/O NORTHERA/O (/O N=114/O )/O n/O (/O %/O )/O Headache/B-AdverseReaction 4/O (/O 3.0/O )/O 8/O (/O 6.1/O )/O 8/O (/O 7.4/O )/O 15/O (/O 13.2/O )/O Dizziness/B-AdverseReaction 2/O (/O 1.5/O )/O 5/O (/O 3.8/O )/O 5/O (/O 4.6/O )/O 11/O (/O 9.6/O )/O Nausea/B-AdverseReaction 2/O (/O 1.5/O )/O 2/O (/O 1.5/O )/O 5/O (/O 4.6/O )/O 10/O (/O 8.8/O )/O Hypertension/B-AdverseReaction 0/O 2/O (/O 1.5/O )/O 1/O (/O 0.9/O )/O 8/O (/O 7.0/O )/O Note/O :/O n/O number/O of/O patients/O ./O
Table/O displays/O adverse/O reactions/O that/O were/O reported/O in/O greater/O than/O 5/O %/O of/O patients/O in/O the/O NORTHERA/O group/O and/O with/O at/O least/O a/O 3/O %/O greater/O incidence/O in/O the/O NORTHERA/O group/O than/O in/O the/O placebo/O group/O ./O
Long/O -/O Term/O ,/O Open/O -/O Label/O Trials/O with/O NORTHERA/O In/O the/O long/O -/O term/O ,/O open/O -/O label/O extension/O studies/O ,/O a/O total/O of/O 422/O patients/O ,/O mean/O age/O 65/O years/O ,/O were/O treated/O with/O NORTHERA/O for/O a/O mean/O total/O exposure/O of/O approximately/O one/O year/O ./O
The/O commonly/O reported/O adverse/O events/O were/O falls/B-AdverseReaction (/O 24/O %/O )/O ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infections/I-AdverseReaction (/O 15/O %/O )/O ,/O headache/B-AdverseReaction (/O 13/O %/O )/O ,/O syncope/B-AdverseReaction (/O 13/O %/O )/O ,/O and/O dizziness/B-AdverseReaction (/O 10/O %/O )/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O SUPINE/B-AdverseReaction HYPERTENSION/I-AdverseReaction WARNING/O :/O SUPINE/B-AdverseReaction HYPERTENSION/I-AdverseReaction Monitor/O supine/O blood/O pressure/O prior/O to/O and/O during/O treatment/O and/O more/O frequently/O when/O increasing/O doses/O ./O
Elevating/O the/O head/O of/O the/O bed/O lessens/O the/O risk/O of/O supine/O hypertension/O ,/O and/O blood/O pressure/O should/O be/O measured/O in/O this/O position/O ./O
If/O supine/O hypertension/O can/O not/O be/O managed/O by/O elevation/O of/O the/O head/O of/O the/O bed/O ,/O reduce/O or/O discontinue/O NORTHERA/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O SUPINE/B-AdverseReaction HYPERTENSION/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Monitor/O supine/O blood/O pressure/O prior/O to/O and/O during/O treatment/O and/O more/O frequently/O when/O increasing/O doses/O ./O
Elevating/O the/O head/O of/O the/O bed/O lessens/O the/O risk/O of/O supine/O hypertension/O ,/O and/O blood/O pressure/O should/O be/O measured/O in/O this/O position/O ./O
If/O supine/O hypertension/O can/O not/O be/O managed/O by/O elevation/O of/O the/O head/O of/O the/O bed/O ,/O reduce/O or/O discontinue/O NORTHERA/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O NORTHERA/O can/B-Factor cause/O supine/B-AdverseReaction hypertension/I-AdverseReaction and/O may/B-Factor increase/O cardiovascular/B-AdverseReaction risk/I-AdverseReaction if/O supine/B-AdverseReaction hypertension/I-AdverseReaction is/O not/O well/O -/O managed/O (/O 5.1/O )/O ./O
Hyperpyrexia/B-AdverseReaction and/O confusion/B-AdverseReaction (/O 5.2/O )/O May/B-Factor exacerbate/O symptoms/O in/O patients/O with/O existing/O ischemic/O heart/O disease/O ,/O arrhythmias/O ,/O and/O congestive/O heart/O failure/O (/O 5.3/O )/O Allergic/B-AdverseReaction reactions/I-AdverseReaction (/O 5.4/O )/O 5.1/O Supine/O Hypertension/O NORTHERA/O therapy/O may/B-Factor cause/O or/O exacerbate/O supine/B-AdverseReaction hypertension/I-AdverseReaction in/O patients/O with/O NOH/O ./O
Patients/O should/O be/O advised/O to/O elevate/O the/O head/O of/O the/O bed/O when/O resting/O or/O sleeping/O ./O
Monitor/O blood/O pressure/O ,/O both/O in/O the/O supine/O position/O and/O in/O the/O recommended/O head/O -/O elevated/O sleeping/O position/O ./O
Reduce/O or/O discontinue/O NORTHERA/O if/O supine/O hypertension/O persists/O ./O
If/O supine/O hypertension/O is/O not/O well/O -/O managed/O ,/O NORTHERA/O may/O increase/O the/O risk/O of/O cardiovascular/O events/O ./O
5.2/O Hyperpyrexia/O and/O Confusion/O Post/O -/O marketing/O cases/O of/O a/O symptom/O complex/O resembling/O neuroleptic/B-AdverseReaction malignant/I-AdverseReaction syndrome/I-AdverseReaction (/O NMS/B-AdverseReaction )/O have/O been/O reported/O with/O NORTHERA/O use/O during/O post/O -/O marketing/O surveillance/O in/O Japan/O ./O
Observe/O patients/O carefully/O when/O the/O dosage/O of/O NORTHERA/O is/O changed/O or/O when/O concomitant/O levodopa/O is/O reduced/O abruptly/O or/O discontinued/O ,/O especially/O if/O the/O patient/O is/O receiving/O neuroleptics/O ./O
NMS/B-AdverseReaction is/O an/O uncommon/O but/O life/B-Severity -/O threatening/O syndrome/O characterized/O by/O fever/B-AdverseReaction or/O hyperthermia/B-AdverseReaction ,/O muscle/B-AdverseReaction rigidity/I-AdverseReaction ,/O involuntary/B-AdverseReaction movements/I-AdverseReaction ,/O altered/B-AdverseReaction consciousness/I-AdverseReaction ,/O and/O mental/B-AdverseReaction status/I-AdverseReaction changes/I-AdverseReaction ./O
The/O early/O diagnosis/O of/O this/O condition/O is/O important/O for/O the/O appropriate/O management/O of/O these/O patients/O ./O
5.3/O Ischemic/O Heart/O Disease/O ,/O Arrhythmias/O ,/O and/O Congestive/O Heart/O Failure/O NORTHERA/O may/B-Factor exacerbate/O existing/O ischemic/O heart/O disease/O ,/O arrhythmias/O ,/O and/O congestive/O heart/O failure/O ./O
Careful/O consideration/O should/O be/O given/O to/O this/O potential/O risk/O prior/O to/O initiating/O therapy/O in/O patients/O with/O these/O conditions/O ./O
5.4/O Allergic/O Reactions/O This/O product/O contains/O FD&C/O Yellow/O No/O ./O
5/O (/O tartrazine/O )/O which/O may/B-Factor cause/O allergic/B-AdverseReaction -/I-AdverseReaction type/O reactions/O (/O including/O bronchial/B-AdverseReaction asthma/I-AdverseReaction )/O in/O certain/O susceptible/O persons/O ./O
Although/O the/O overall/O incidence/O of/O FD&C/O Yellow/O No/O ./O
5/O (/O tartrazine/O )/O sensitivity/O in/O the/O general/O population/O is/O low/O ,/O it/O is/O frequently/O seen/O in/O patients/O who/O also/O have/O aspirin/O hypersensitivity/O ./O
6/O ADVERSE/O REACTIONS/O The/O most/O serious/O adverse/O reactions/O reported/O with/O NULOJIX/O are/O :/O PTLD/B-AdverseReaction ,/O predominantly/O CNS/B-AdverseReaction PTLD/I-AdverseReaction ,/O and/O other/O malignancies/B-AdverseReaction [/O see/O Boxed/O Warning/O and/O Warnings/O and/O Precautions/O (/O 5.1/O ,/O 5.3/O )/O ]/O Serious/B-Severity infections/B-AdverseReaction ,/O including/O JC/B-AdverseReaction virus/I-AdverseReaction -/O associated/O PML/B-AdverseReaction and/O polyoma/B-AdverseReaction virus/I-AdverseReaction nephropathy/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O ,/O 5.5/O ,/O 5.6/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 20/O %/O on/O NULOJIX/O treatment/O )/O are/O anemia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O graft/B-AdverseReaction dysfunction/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O hyperkalemia/B-AdverseReaction ,/O and/O leukopenia/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bristol/O -/O Myers/O Squibb/O at/O 1/O -/O 800/O -/O 721/O -/O 5072/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Studies/O Experience/O The/O data/O described/O below/O primarily/O derive/O from/O two/O randomized/O ,/O active/O -/O controlled/O three/O -/O year/O trials/O of/O NULOJIX/O in/O de/O novo/O kidney/O transplant/O patients/O ./O
In/O Study/O 1/O and/O Study/O 2/O ,/O NULOJIX/O was/O studied/O at/O the/O recommended/O dose/O and/O frequency/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O in/O a/O total/O of/O 401/O patients/O compared/O to/O a/O cyclosporine/O control/O regimen/O in/O a/O total/O of/O 405/O patients/O ./O
These/O two/O trials/O also/O included/O a/O total/O of/O 403/O patients/O treated/O with/O a/O NULOJIX/O regimen/O of/O higher/O cumulative/O dose/O and/O more/O frequent/O dosing/O than/O recommended/O [/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
All/O patients/O also/O received/O basiliximab/O induction/O ,/O mycophenolate/O mofetil/O ,/O and/O corticosteroids/O ./O
Patients/O were/O treated/O and/O followed/O for/O 3/O years/O ./O
CNS/B-AdverseReaction PTLD/I-AdverseReaction ,/O PML/B-AdverseReaction ,/O and/O other/O CNS/B-AdverseReaction infections/I-AdverseReaction were/O more/O frequently/O observed/O in/O association/O with/O a/O NULOJIX/O regimen/O of/O higher/O cumulative/O dose/O and/O more/O frequent/O dosing/O compared/O to/O the/O recommended/O regimen/O ;/O therefore/O ,/O administration/O of/O higher/O than/O the/O recommended/O doses/O and/or/O more/O frequent/O dosing/O of/O NULOJIX/O is/O not/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
The/O average/O age/O of/O patients/O in/O Studies/O 1/O and/O 2/O in/O the/O NULOJIX/O recommended/O dose/O and/O cyclosporine/O control/O regimens/O was/O 49/O years/O ,/O ranging/O from/O 18/O to/O 79/O years/O ./O
Approximately/O 70/O %/O of/O patients/O were/O male/O ;/O 67/O %/O were/O white/O ,/O 11/O %/O were/O black/O ,/O and/O 22/O %/O other/O races/O ./O
About/O 25/O %/O of/O patients/O were/O from/O the/O United/O States/O and/O 75/O %/O from/O other/O countries/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O the/O adverse/O reaction/O rates/O observed/O can/O not/O be/O directly/O compared/O to/O rates/O in/O other/O trials/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O most/O commonly/O reported/O adverse/O reactions/O occurring/O in/O 20/O %/O of/O patients/O treated/O with/O the/O recommended/O dose/O and/O frequency/O of/O NULOJIX/O were/O anemia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O graft/B-AdverseReaction dysfunction/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O hyperkalemia/B-AdverseReaction ,/O and/O leukopenia/B-AdverseReaction ./O
The/O proportion/O of/O patients/O who/O discontinued/O treatment/O due/O to/O adverse/O reactions/O was/O 13/O %/O for/O the/O recommended/O NULOJIX/O regimen/O and/O 19/O %/O for/O the/O cyclosporine/O control/O arm/O through/O three/O years/O of/O treatment/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O in/O NULOJIX/O -/O treated/O patients/O were/O cytomegalovirus/B-AdverseReaction infection/I-AdverseReaction (/O 1.5/O %/O )/O and/O complications/B-AdverseReaction of/I-AdverseReaction transplanted/I-AdverseReaction kidney/I-AdverseReaction (/O 1.5/O %/O )/O ./O
Information/O on/O selected/O significant/O adverse/O reactions/O observed/O during/O clinical/O trials/O is/O summarized/O below/O ./O
Post/O -/O Transplant/O Lymphoproliferative/O Disorder/O Reported/O cases/O of/O post/B-AdverseReaction -/I-AdverseReaction transplant/I-AdverseReaction lymphoproliferative/O disorder/O (/O PTLD/B-AdverseReaction )/O up/O to/O 36/O months/O post/O transplant/O were/O obtained/O for/O NULOJIX/O by/O pooling/O both/O dosage/O regimens/O of/O NULOJIX/O in/O Studies/O 1/O and/O 2/O (/O 804/O patients/O )/O with/O data/O from/O a/O third/O study/O in/O kidney/O transplantation/O (/O Study/O 3/O ,/O 145/O patients/O )/O which/O evaluated/O two/O NULOJIX/O dosage/O regimens/O similar/O ,/O but/O slightly/O different/O ,/O from/O those/O of/O Studies/O 1/O and/O 2/O (/O see/O Table/O 2/O )/O ./O
The/O total/O number/O of/O NULOJIX/O patients/O from/O these/O three/O studies/O (/O 949/O )/O was/O compared/O to/O the/O pooled/O cyclosporine/O control/O groups/O from/O all/O three/O studies/O (/O 476/O patients/O )/O ./O
Among/O 401/O patients/O in/O Studies/O 1/O and/O 2/O treated/O with/O the/O recommended/O regimen/O of/O NULOJIX/O and/O the/O 71/O patients/O in/O Study/O 3/O treated/O with/O a/O very/O similar/O (/O but/O non/O -/O identical/O )/O NULOJIX/O regimen/O ,/O there/O were/O 5/O cases/O of/O PTLD/B-AdverseReaction :/O 3/O in/O EBV/O seropositive/O patients/O and/O 2/O in/O EBV/O seronegative/O patients/O ./O
Two/O of/O the/O 5/O cases/O presented/O with/O CNS/O involvement/O ./O
Among/O the/O 477/O patients/O in/O Studies/O 1/O ,/O 2/O ,/O and/O 3/O treated/O with/O the/O NULOJIX/O regimen/O of/O higher/O cumulative/O dose/O and/O more/O frequent/O dosing/O than/O recommended/O ,/O there/O were/O 8/O cases/O of/O PTLD/B-AdverseReaction :/O 2/O in/O EBV/O seropositive/O patients/O and/O 6/O in/O EBV/O seronegative/O or/O serostatus/O unknown/O patients/O ./O
Six/O of/O the/O 8/O cases/O presented/O with/O CNS/O involvement/O ./O
Therefore/O ,/O administration/O of/O higher/O than/O the/O recommended/O doses/O or/O more/O frequent/O dosing/O of/O NULOJIX/O is/O not/O recommended/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.1/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ./O
]/O One/O of/O the/O 476/O patients/O treated/O with/O cyclosporine/O developed/O PTLD/B-AdverseReaction ,/O without/O CNS/O involvement/O ./O
All/O cases/O of/O PTLD/B-AdverseReaction reported/O up/O to/O 36/O months/O post/O transplant/O in/O NULOJIX-/O or/O cyclosporine/O -/O treated/O patients/O presented/O within/O 18/O months/O of/O transplantation/O ./O
Overall/O ,/O the/O rate/O of/O PTLD/B-AdverseReaction in/O 949/O patients/O treated/O with/O any/O of/O the/O NULOJIX/O regimens/O was/O 9-fold/O higher/O in/O those/O who/O were/O EBV/O seronegative/O or/O EBV/O serostatus/O unknown/O (/O 8/139/O )/O compared/O to/O those/O who/O were/O EBV/O seropositive/O (/O 5/810/O patients/O )/O ./O
Therefore/O NULOJIX/O is/O recommended/O for/O use/O only/O in/O patients/O who/O are/O EBV/O seropositive/O [/O see/O Boxed/O Warning/O and/O Contraindications/O (/O 4/O )/O ]/O ./O
Table/O 2/O :/O Summary/O of/O PTLD/B-AdverseReaction Reported/O in/O Studies/O 1/O ,/O 2/O ,/O and/O 3/O Through/O Three/O Years/O of/O Treatment/O NULOJIX/O Non/O -/O Recommended/O Regimen/O (/O N=477/O )/O NULOJIX/O Recommended/O Regimen/O (/O N=472/O )/O Cyclosporine/O (/O N=476/O )/O Trial/O EBV/O Positive/O (/O n=406/O )/O EBV/O Negative/O (/O n=43/O )/O EBV/O Unknown/O (/O n=28/O )/O EBV/O Positive/O (/O n=404/O )/O EBV/O Negative/O (/O n=48/O )/O EBV/O Unknown/O (/O n=20/O )/O EBV/O Positive/O (/O n=399/O )/O EBV/O Negative/O (/O n=57/O )/O EBV/O Unknown/O (/O n=20/O )/O Regimen/O with/O higher/O cumulative/O dose/O and/O more/O frequent/O dosing/O than/O the/O recommended/O NULOJIX/O regimen/O ./O
In/O Studies/O 1/O and/O 2/O the/O NULOJIX/O regimen/O is/O identical/O to/O the/O recommended/O regimen/O ,/O but/O is/O slightly/O different/O in/O Study/O 3/O ./O
Study/O 1/O CNS/B-AdverseReaction PTLD/I-AdverseReaction 1/O 1/O Non/B-AdverseReaction -/O CNSPTLD/O 1/O 2/O 1/O Study/O 2/O CNS/B-AdverseReaction PTLD/I-AdverseReaction 1/O 1/O 1/O 1/O Non/B-AdverseReaction -/O CNSPTLD/O 1/O Study/O 3/O CNS/B-AdverseReaction PTLD/I-AdverseReaction 2/O Non/B-AdverseReaction -/O CNSPTLD/O 1/O Total/O (/O %/O )/O 2/O (/O 0.5/O )/O 5/O (/O 11.6/O )/O 1/O (/O 3.6/O )/O 3/O (/O 0.7/O )/O 2/O (/O 4.1/O )/O 0/O 0/O 1/O (/O 1.8/O )/O 0/O EBV/O Seropositive/O Subpopulation/O Among/O the/O 806/O EBV/O seropositive/O patients/O with/O known/O CMV/O serostatus/O treated/O with/O either/O NULOJIX/O regimen/O in/O Studies/O 1/O ,/O 2/O ,/O and/O 3/O ,/O two/O percent/O (/O 2/O %/O ;/O 4/210/O )/O of/O CMV/O seronegative/O patients/O developed/O PTLD/B-AdverseReaction compared/O to/O 0.2/O %/O (/O 1/596/O )/O of/O CMV/O seropositive/O patients/O ./O
Among/O the/O 404/O EBV/O seropositive/O recipients/O treated/O with/O the/O recommended/O dosage/O regimen/O of/O NULOJIX/O ,/O three/O PTLD/B-AdverseReaction cases/O were/O detected/O among/O 99/O CMV/O seronegative/O patients/O (/O 3/O %/O )/O and/O there/O was/O no/O case/O detected/O among/O 303/O CMV/O seropositive/O patients/O ./O
The/O clinical/O significance/O of/O CMV/O serology/O as/O a/O risk/O factor/O for/O PTLD/B-AdverseReaction remains/O to/O be/O determined/O ;/O however/O ,/O these/O findings/O should/O be/O considered/O when/O prescribing/O NULOJIX/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Other/O Malignancies/O Malignancies/B-AdverseReaction ,/O excluding/B-Negation non/B-AdverseReaction -/I-AdverseReaction melanoma/I-AdverseReaction skin/O cancer/O and/O PTLD/B-AdverseReaction ,/O were/O reported/O in/O Study/O 1/O and/O Study/O 2/O in/O 3.5/O %/O (/O 14/401/O )/O of/O patients/O treated/O with/O the/O recommended/O NULOJIX/O regimen/O and/O 3.7/O %/O (/O 15/405/O )/O of/O patients/O treated/O with/O the/O cyclosporine/O control/O regimen/O ./O
Non/B-AdverseReaction -/I-AdverseReaction melanoma/I-AdverseReaction skin/O cancer/O was/O reported/O in/O 1.5/O %/O (/O 6/401/O )/O of/O patients/O treated/O with/O the/O recommended/O NULOJIX/O regimen/O and/O in/O 3.7/O %/O (/O 15/405/O )/O of/O patients/O treated/O with/O cyclosporine/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Progressive/O Multifocal/O Leukoencephalopathy/O Two/O fatal/B-AdverseReaction cases/O of/O progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O have/O been/O reported/O among/O 1096/O patients/O treated/O with/O a/O NULOJIX/O -/O containing/O regimen/O :/O one/O patient/O in/O clinical/O trials/O of/O kidney/O transplant/O (/O Studies/O 1/O ,/O 2/O ,/O and/O 3/O described/O above/O )/O and/O one/O patient/O in/O a/O trial/O of/O liver/O transplant/O (/O trial/O of/O 250/O patients/O )/O ./O
No/B-Negation cases/O of/O PML/B-AdverseReaction were/O reported/O in/O patients/O treated/O with/O the/O recommended/O NULOJIX/O regimen/O or/O the/O control/O regimen/O in/O these/O trials/O ./O
The/O kidney/O transplant/O recipient/O was/O treated/O with/O the/O NULOJIX/O regimen/O of/O higher/O cumulative/O dose/O and/O more/O frequent/O dosing/O than/O recommended/O ,/O mycophenolate/O mofetil/O (/O MMF/O )/O ,/O and/O corticosteroids/O for/O 2/O years/O ./O
The/O liver/O transplant/O recipient/O was/O treated/O with/O 6/O months/O of/O a/O NULOJIX/O dosage/O regimen/O that/O was/O more/O intensive/O than/O that/O studied/O in/O kidney/O transplant/O recipients/O ,/O MMF/O at/O doses/O higher/O than/O the/O recommended/O dose/O ,/O and/O corticosteroids/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Bacterial/O ,/O Mycobacterial/O ,/O Viral/O ,/O and/O Fungal/O Infections/O Adverse/O reactions/O of/O infectious/B-AdverseReaction etiology/I-AdverseReaction were/O reported/O based/O on/O clinical/O assessment/O by/O physicians/O ./O
The/O causative/O organisms/O for/O these/O reactions/O are/O identified/O when/O provided/O by/O the/O physician/O ./O
The/O overall/O number/O of/O infections/B-AdverseReaction ,/O serious/B-Severity infections/B-AdverseReaction ,/O and/O select/O infections/B-AdverseReaction with/O identified/O etiology/O reported/O in/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O or/O the/O cyclosporine/O control/O in/O Studies/O 1/O and/O 2/O are/O shown/O in/O Table/O 3/O ./O
Fungal/B-AdverseReaction infections/I-AdverseReaction were/O reported/O in/O 18/O %/O of/O patients/O receiving/O NULOJIX/O compared/O to/O 22/O %/O receiving/O cyclosporine/O ,/O primarily/O due/O to/O skin/O and/O mucocutaneous/B-AdverseReaction fungal/I-AdverseReaction infections/I-AdverseReaction ./O
Tuberculosis/B-AdverseReaction and/O herpes/B-AdverseReaction infections/I-AdverseReaction were/O reported/O more/O frequently/O in/O patients/O receiving/O NULOJIX/O than/O cyclosporine/O ./O
Of/O the/O patients/O who/O developed/O tuberculosis/B-AdverseReaction through/O 3/O years/O ,/O all/O but/O one/O NULOJIX/O patient/O lived/O in/O countries/O with/O a/O high/O prevalence/O of/O tuberculosis/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Table/O 3/O :/O Overall/O Infections/B-AdverseReaction and/O Select/O Infections/B-AdverseReaction with/O Identified/O Etiology/O by/O Treatment/O Group/O following/O One/O and/O Three/O Years/O of/O Treatment/O in/O Studies/O 1/O and/O 2/O Up/O to/O Year/O 1/O Up/O to/O Year/O 3/O NULOJIX/O Recommended/O Regimen/O N=401/O n/O (/O %/O )/O Cyclosporine/O N=405/O n/O (/O %/O )/O NULOJIX/O Recommended/O Regimen/O N=401/O n/O (/O %/O )/O Cyclosporine/O N=405/O n/O (/O %/O )/O Studies/O 1/O and/O 2/O were/O not/O designed/O to/O support/O comparative/O claims/O for/O NULOJIX/O for/O the/O adverse/O reactions/O reported/O in/O this/O table/O ./O
Median/O exposure/O in/O days/O for/O pooled/O studies/O :/O 1203/O for/O NULOJIX/O recommended/O regimen/O and/O 1163/O for/O cyclosporine/O in/O Studies/O 1/O and/O 2/O ./O
?/O All/O infections/B-AdverseReaction include/O bacterial/O ,/O viral/O ,/O fungal/O ,/O and/O other/O organisms/O ./O
For/O infectious/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ,/O the/O causative/O organism/O is/O reported/O if/O specified/O by/O the/O physician/O in/O the/O clinical/O trials/O ./O
S/O A/O medically/O important/O event/O that/O may/O be/O life/O -/O threatening/O or/O result/O in/O death/B-AdverseReaction or/O hospitalization/O or/O prolongation/O of/O existing/O hospitalization/O ./O
Infections/B-AdverseReaction not/O meeting/O these/O criteria/O are/O considered/O non/O -/O serious/O ./O
BK/B-AdverseReaction virus/I-AdverseReaction -/I-AdverseReaction associated/O nephropathy/O was/O reported/O in/O 6/O NULOJIX/O patients/O (/O 4/O of/O which/O resulted/O in/O graft/O loss/O )/O and/O 6/O cyclosporine/O patients/O (/O none/O of/O which/O resulted/O in/O graft/O loss/O )/O by/O Year/O 3/O ./O
#/O Most/O herpes/B-AdverseReaction infections/I-AdverseReaction were/O non/B-Severity -/O serious/O and/O 1/O led/O to/O treatment/O discontinuation/O ./O
All/O infections/B-AdverseReaction ?/O 287/O (/O 72/O )/O 299/O (/O 74/O )/O 329/O (/O 82/O )/O 327/O (/O 81/O )/O Serious/B-Severity infectionsS/B-AdverseReaction 98/O (/O 24/O )/O 113/O (/O 28/O )/O 144/O (/O 36/O )/O 157/O (/O 39/O )/O CMV/O 44/O (/O 11/O )/O 52/O (/O 13/O )/O 53/O (/O 13/O )/O 56/O (/O 14/O )/O Polyoma/O virus/O 10/O (/O 3/O )/O 23/O (/O 6/O )/O 17/O (/O 4/O )/O 27/O (/O 7/O )/O Herpes/O #/O 27/O (/O 7/O )/O 26/O (/O 6/O )/O 55/O (/O 14/O )/O 46/O (/O 11/O )/O Tuberculosis/B-AdverseReaction 2/O (/O 1/O )/O 1/O (/O 1/O )/O 6/O (/O 2/O )/O 1/O (/O 1/O )/O Infections/O Reported/O in/O the/O CNS/O Following/O three/O years/O of/O treatment/O in/O Studies/O 1/O and/O 2/O ,/O cryptococcal/B-AdverseReaction meningitis/I-AdverseReaction was/O reported/O in/O one/O patient/O out/O of/O 401/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O (/O 0.2/O %/O )/O and/O one/O patient/O out/O of/O the/O 405/O treated/O with/O the/O cyclosporine/O control/O (/O 0.2/O %/O )/O ./O
Six/O patients/O out/O of/O the/O 403/O who/O were/O treated/O with/O the/O NULOJIX/O regimen/O of/O higher/O cumulative/O dose/O and/O more/O frequent/O dosing/O than/O recommended/O in/O Studies/O 1/O and/O 2/O (/O 1.5/O %/O )/O were/O reported/O to/O have/O developed/O CNS/B-AdverseReaction infections/I-AdverseReaction ,/O including/O 2/O cases/O of/O cryptococcal/B-AdverseReaction meningitis/I-AdverseReaction ,/O one/O case/O of/O Chagas/B-AdverseReaction encephalitis/I-AdverseReaction with/O cryptococcal/B-AdverseReaction meningitis/I-AdverseReaction ,/O one/O case/O of/O cerebral/B-AdverseReaction aspergillosis/I-AdverseReaction ,/O one/O case/O of/O West/B-AdverseReaction Nile/I-AdverseReaction encephalitis/I-AdverseReaction ,/O and/O one/O case/O of/O PML/B-AdverseReaction (/O discussed/O above/O )/O ./O
Infusion/O Reactions/O There/O were/O no/B-Negation reports/O of/O anaphylaxis/B-AdverseReaction or/O drug/B-AdverseReaction hypersensitivity/I-AdverseReaction in/O patients/O treated/O with/O NULOJIX/O in/O Studies/O 1/O and/O 2/O through/O three/O years/O ./O
Infusion/B-AdverseReaction -/I-AdverseReaction related/O reactions/O within/O one/O hour/O of/O infusion/O were/O reported/O in/O 5/O %/O of/O patients/O treated/O with/O the/O recommended/O dose/O of/O NULOJIX/O ,/O similar/O to/O the/O placebo/O rate/O ./O
No/O serious/O events/O were/O reported/O through/O Year/O 3/O ./O
The/O most/O frequent/O reactions/O were/O hypotension/B-AdverseReaction and/O hypertension/B-AdverseReaction ./O
Proteinuria/O At/O Month/O 1/O after/O transplantation/O in/O Studies/O 1/O and/O 2/O ,/O the/O frequency/O of/O 2/B-Severity +/O proteinuria/B-AdverseReaction on/O urine/O dipstick/O in/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O was/O 33/O %/O (/O 130/390/O )/O and/O 28/O %/O (/O 107/384/O )/O in/O patients/O treated/O with/O the/O cyclosporine/O control/O regimen/O ./O
The/O frequency/O of/O 2/B-Severity +/O proteinuria/B-AdverseReaction was/O similar/O between/O the/O two/O treatment/O groups/O between/O one/O and/O three/O years/O after/O transplantation/O (/O 10/O %/O in/O both/O studies/O )/O ./O
There/O were/O no/O differences/O in/O the/O occurrence/O of/O 3/B-Severity +/O proteinuria/B-AdverseReaction (/O 4/O %/O in/O both/O studies/O )/O at/O any/O time/O point/O ,/O and/O no/B-Negation patients/O experienced/O 4/B-Severity +/O proteinuria/B-AdverseReaction ./O
The/O clinical/O significance/O of/O this/O increase/O in/O early/B-AdverseReaction proteinuria/I-AdverseReaction is/O unknown/O ./O
Immunogenicity/O Antibodies/O directed/O against/O the/O belatacept/O molecule/O were/O assessed/O in/O 398/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O in/O Studies/O 1/O and/O 2/O (/O 212/O of/O these/O patients/O were/O treated/O for/O at/O least/O 2/O years/O )/O ./O
Of/O the/O 372/O patients/O with/O immunogenicity/O assessment/O at/O baseline/O (/O prior/O to/O receiving/O belatacept/O treatment/O )/O ,/O 29/O patients/O tested/O positive/O for/O anti/O -/O belatacept/O antibodies/O ;/O 13/O of/O these/O patients/O had/O antibodies/O to/O the/O modified/O cytotoxic/O T/O -/O lymphocyte/O -/O associated/O antigen/O 4/O (/O CTLA-4/O )/O ./O
Anti/O -/O belatacept/O antibody/O titers/O did/O not/O increase/O during/O treatment/O in/O these/O 29/O patients/O ./O
Eight/O (/O 2/O %/O )/O patients/O developed/O antibodies/O during/O treatment/O with/O the/O NULOJIX/O recommended/O regimen/O ./O
In/O the/O patients/O who/O developed/O antibodies/O during/O treatment/O ,/O the/O median/O titer/O (/O by/O dilution/O method/O )/O was/O 8/O ,/O with/O a/O range/O of/O 5/O to/O 80/O ./O
Of/O 56/O patients/O who/O tested/O negative/O for/O antibodies/O during/O treatment/O and/O reassessed/O approximately/O 7/O half/O -/O lives/O after/O discontinuation/O of/O NULOJIX/O ,/O 1/O tested/O antibody/O positive/O ./O
Anti/O -/O belatacept/O antibody/O development/O was/O not/O associated/O with/O altered/O clearance/O of/O belatacept/O ./O
Samples/O from/O 6/O patients/O with/O confirmed/O binding/O activity/O to/O the/O modified/O cytotoxic/O T/O -/O lymphocyte/O -/O associated/O antigen/O 4/O (/O CTLA-4/O )/O region/O of/O the/O belatacept/O molecule/O were/O assessed/O by/O an/O in/O vitro/O bioassay/O for/O the/O presence/O of/O neutralizing/O antibodies/O ./O
Three/O of/O these/O 6/O patients/O tested/O positive/O for/O neutralizing/O antibodies/O ./O
However/O ,/O the/O development/O of/O neutralizing/O antibodies/O may/O be/O underreported/O due/O to/O lack/O of/O assay/O sensitivity/O ./O
The/O clinical/O impact/O of/O anti/O -/O belatacept/O antibodies/O (/O including/O neutralizing/O anti/O -/O belatacept/O antibodies/O )/O could/O not/O be/O determined/O in/O the/O studies/O ./O
The/O data/O reflect/O the/O percentage/O of/O patients/O whose/O test/O results/O were/O positive/O for/O antibodies/O to/O belatacept/O in/O specific/O assays/O ./O
The/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O assay/O sensitivity/O and/O specificity/O ,/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O belatacept/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
New/O -/O Onset/O Diabetes/O After/O Transplantation/O The/O incidence/O of/O new/B-AdverseReaction -/I-AdverseReaction onset/I-AdverseReaction diabetes/I-AdverseReaction after/O transplantation/O (/O NODAT/B-AdverseReaction )/O was/O defined/O in/O Studies/O 1/O and/O 2/O as/O use/O of/O an/O antidiabetic/O agent/O for/O 30/O days/O or/O 2/O fasting/O plasma/O glucose/O values/O 126/O mg/O dL/O (/O 7.0/O mmol/O L/O )/O post/O -/O transplantation/O ./O
Of/O the/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O ,/O 5/O %/O (/O 14/304/O )/O developed/O NODAT/B-AdverseReaction by/O the/O end/O of/O one/O year/O compared/O to/O 10/O %/O (/O 27/280/O )/O of/O patients/O on/O the/O cyclosporine/O control/O regimen/O ./O
However/O ,/O by/O the/O end/O of/O the/O third/O year/O ,/O the/O cumulative/O incidence/O of/O NODAT/B-AdverseReaction was/O 8/O %/O (/O 24/304/O )/O in/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O and/O 10/O %/O (/O 29/280/O )/O in/O patients/O treated/O with/O the/O cyclosporine/O regimen/O ./O
Hypertension/O Blood/O pressure/O and/O use/O of/O antihypertensive/O medications/O were/O reported/O in/O Studies/O 1/O and/O 2/O ./O
By/O Year/O 3/O ,/O one/O or/O more/O antihypertensive/O medications/O were/O used/O in/O 85/O %/O of/O NULOJIX/O -/O treated/O patients/O and/O 92/O %/O of/O cyclosporine/O -/O treated/O patients/O ./O
At/O one/O year/O after/O transplantation/O ,/O systolic/O blood/O pressures/O were/O 8/O mmHg/O lower/O and/O diastolic/O blood/O pressures/O were/O 3/O mmHg/O lower/O in/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O compared/O to/O the/O cyclosporine/O control/O regimen/O ./O
At/O three/O years/O after/O transplantation/O ,/O systolic/O blood/O pressures/O were/O 6/O mmHg/O lower/O and/O diastolic/O blood/O pressures/O were/O 3/O mmHg/O lower/O in/O NULOJIX/O -/O treated/O patients/O compared/O to/O cyclosporine/O -/O treated/O patients/O ./O
Hypertension/B-AdverseReaction was/O reported/O as/O an/O adverse/O reaction/O in/O 32/O %/O of/O NULOJIX/O -/O treated/O patients/O and/O 37/O %/O of/O cyclosporine/O -/O treated/O patients/O (/O see/O Table/O 4/O )/O ./O
Dyslipidemia/O Mean/O values/O of/O total/O cholesterol/O ,/O HDL/O ,/O LDL/O ,/O and/O triglycerides/O were/O reported/O in/O Studies/O 1/O and/O 2/O ./O
At/O one/O year/O after/O transplantation/O these/O values/O were/O 183/O mg/O dL/O ,/O 50/O mg/O dL/O ,/O 102/O mg/O dL/O ,/O and/O 151/O mg/O dL/O ,/O respectively/O ,/O in/O 401/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O and/O 196/O mg/O dL/O ,/O 48/O mg/O dL/O ,/O 108/O mg/O dL/O ,/O and/O 195/O mg/O dL/O ,/O respectively/O ,/O in/O 405/O patients/O treated/O with/O the/O cyclosporine/O control/O regimen/O ./O
At/O three/O years/O after/O transplantation/O ,/O the/O total/O cholesterol/O ,/O HDL/O ,/O LDL/O ,/O and/O triglycerides/O were/O 176/O mg/O dL/O ,/O 49/O mg/O dL/O ,/O 100/O mg/O dL/O ,/O and/O 141/O mg/O dL/O ,/O respectively/O ,/O in/O NULOJIX/O -/O treated/O patients/O compared/O to/O 193/O mg/O dL/O ,/O 48/O mg/O dL/O ,/O 106/O mg/O dL/O ,/O and/O 180/O mg/O dL/O in/O cyclosporine/O -/O treated/O patients/O ./O
The/O clinical/O significance/O of/O the/O lower/O mean/O triglyceride/O values/O in/O NULOJIX/O -/O treated/O patients/O at/O one/O and/O three/O years/O is/O unknown/O ./O
Other/O Adverse/O Reactions/O Adverse/O reactions/O that/O occurred/O at/O a/O frequency/O of/O 10/O %/O in/O patients/O treated/O with/O the/O NULOJIX/O recommended/O regimen/O or/O cyclosporine/O control/O regimen/O in/O Studies/O 1/O and/O 2/O through/O three/O years/O are/O summarized/O by/O preferred/O term/O in/O decreasing/O order/O of/O frequency/O within/O Table/O 4/O ./O
Table/O 4/O :/O Adverse/O Reactions/O Reported/O by/O 10/O %/O of/O Patients/O Treated/O with/O Either/O the/O NULOJIX/O Recommended/O Regimen/O or/O Control/O in/O Studies/O 1/O and/O 2/O Through/O Three/O Years/O ,/O Adverse/O Reaction/O NULOJIX/O Recommended/O Regimen/O N=401/O %/O Cyclosporine/O N=405/O %/O All/O randomized/O and/O transplanted/O patients/O in/O Studies/O 1/O and/O 2/O ./O
Studies/O 1/O and/O 2/O were/O not/O designed/O to/O support/O comparative/O claims/O for/O NULOJIX/O for/O the/O adverse/O reactions/O reported/O in/O this/O table/O ./O
Infections/O and/O Infestations/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 37/O 36/O Upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction 15/O 16/O Nasopharyngitis/B-AdverseReaction 13/O 16/O Cytomegalovirus/B-AdverseReaction infection/I-AdverseReaction 12/O 12/O Influenza/B-AdverseReaction 11/O 8/O Bronchitis/B-AdverseReaction 10/O 7/O Gastrointestinal/O Disorders/O Diarrhea/B-AdverseReaction 39/O 36/O Constipation/B-AdverseReaction 33/O 35/O Nausea/B-AdverseReaction 24/O 27/O Vomiting/B-AdverseReaction 22/O 20/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 19/O 16/O Abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction 9/O 10/O Metabolism/O and/O Nutrition/O Disorders/O Hyperkalemia/B-AdverseReaction 20/O 20/O Hypokalemia/B-AdverseReaction 21/O 14/O Hypophosphatemia/B-AdverseReaction 19/O 13/O Dyslipidemia/B-AdverseReaction 19/O 24/O Hyperglycemia/B-AdverseReaction 16/O 17/O Hypocalcemia/B-AdverseReaction 13/O 11/O Hypercholesterolemia/B-AdverseReaction 11/O 11/O Hypomagnesemia/B-AdverseReaction 7/O 10/O Hyperuricemia/B-AdverseReaction 5/O 12/O Procedural/O Complications/O Graft/B-AdverseReaction dysfunction/I-AdverseReaction 25/O 34/O General/O Disorders/O Peripheral/B-AdverseReaction edema/I-AdverseReaction 34/O 42/O Pyrexia/B-AdverseReaction 28/O 26/O Blood/O and/O Lymphatic/O System/O Disorders/O Anemia/B-AdverseReaction 45/O 44/O Leukopenia/B-AdverseReaction 20/O 23/O Renal/O and/O Urinary/O Disorders/O Hematuria/B-AdverseReaction 16/O 18/O Proteinuria/B-AdverseReaction 16/O 12/O Dysuria/B-AdverseReaction 11/O 11/O Renal/B-AdverseReaction tubular/I-AdverseReaction necrosis/I-AdverseReaction 9/O 13/O Vascular/O Disorders/O Hypertension/B-AdverseReaction 32/O 37/O Hypotension/B-AdverseReaction 18/O 12/O Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O Cough/B-AdverseReaction 24/O 18/O Dyspnea/B-AdverseReaction 12/O 15/O Investigations/O Blood/B-AdverseReaction creatinine/I-AdverseReaction increased/I-AdverseReaction 15/O 20/O Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Arthralgia/B-AdverseReaction 17/O 13/O Back/B-AdverseReaction pain/I-AdverseReaction 13/O 13/O Nervous/O System/O Disorders/O Headache/B-AdverseReaction 21/O 18/O Dizziness/B-AdverseReaction 9/O 10/O Tremor/B-AdverseReaction 8/O 17/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Acne/B-AdverseReaction 8/O 11/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 15/O 18/O Anxiety/B-AdverseReaction 10/O 11/O Selected/O adverse/O reactions/O occurring/O in/O 10/O %/O from/O NULOJIX/O -/O treated/O patients/O in/O either/O regimen/O through/O three/O years/O in/O Studies/O 1/O and/O 2/O are/O listed/O below/O :/O Immune/O System/O Disorders/O :/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O Infections/O and/O Infestations/O :/O see/O Table/O 3/O Gastrointestinal/O Disorders/O :/O stomatitis/B-AdverseReaction ,/O including/O aphthous/B-AdverseReaction stomatitis/I-AdverseReaction Injury/O ,/O Poisoning/O ,/O and/O Procedural/O Complications/O :/O chronic/B-AdverseReaction allograft/I-AdverseReaction nephropathy/I-AdverseReaction ,/O complications/B-AdverseReaction of/I-AdverseReaction transplanted/I-AdverseReaction kidney/I-AdverseReaction ,/O including/O wound/B-AdverseReaction dehiscence/I-AdverseReaction ,/O arteriovenous/B-AdverseReaction fistula/I-AdverseReaction thrombosis/I-AdverseReaction Blood/O and/O Lymphatic/O System/O Disorders/O :/O neutropenia/B-AdverseReaction Renal/O and/O Urinary/O Disorders/O :/O renal/B-AdverseReaction impairment/I-AdverseReaction ,/O including/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O renal/B-AdverseReaction artery/I-AdverseReaction stenosis/I-AdverseReaction ,/O urinary/B-AdverseReaction incontinence/I-AdverseReaction ,/O hydronephrosis/B-AdverseReaction Vascular/O Disorders/O :/O hematoma/B-AdverseReaction ,/O lymphocele/B-AdverseReaction Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O alopecia/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction Cardiac/O Disorders/O :/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction BOXED/O WARNING/O :/O WARNING/O :/O POST/B-AdverseReaction -/I-AdverseReaction TRANSPLANT/I-AdverseReaction LYMPHOPROLIFERATIVE/O DISORDER/O ,/O OTHER/O MALIGNANCIES/B-AdverseReaction ,/O AND/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction WARNING/O :/O POST/B-AdverseReaction -/I-AdverseReaction TRANSPLANT/I-AdverseReaction LYMPHOPROLIFERATIVE/O DISORDER/O ,/O OTHER/O MALIGNANCIES/B-AdverseReaction ,/O AND/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction Increased/O risk/B-Factor for/O developing/O post/B-AdverseReaction -/I-AdverseReaction transplant/I-AdverseReaction lymphoproliferative/O disorder/O (/O PTLD/B-AdverseReaction )/O ,/O predominantly/O involving/O the/O central/O nervous/O system/O (/O CNS/O )/O ./O
Recipients/O without/O immunity/O to/O Epstein/O -/O Barr/O virus/O (/O EBV/O )/O are/O at/O a/O particularly/O increased/O risk/O ;/O therefore/O ,/O use/O in/O EBV/O seropositive/O patients/O only/O ./O
Do/O not/O use/O NULOJIX/O in/O transplant/O recipients/O who/O are/O EBV/O seronegative/O or/O with/O unknown/O EBV/O serostatus/O [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Only/O physicians/O experienced/O in/O immunosuppressive/O therapy/O and/O management/O of/O kidney/O transplant/O patients/O should/O prescribe/O NULOJIX/O ./O
Patients/O receiving/O the/O drug/O should/O be/O managed/O in/O facilities/O equipped/O and/O staffed/O with/O adequate/O laboratory/O and/O supportive/O medical/O resources/O ./O
The/O physician/O responsible/O for/O maintenance/O therapy/O should/O have/O complete/O information/O requisite/O for/O the/O follow/O -/O up/O of/O the/O patient/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Increased/B-AdverseReaction susceptibility/I-AdverseReaction to/I-AdverseReaction infection/I-AdverseReaction and/O the/O possible/O development/O of/O malignancies/B-AdverseReaction may/B-Factor result/O from/O immunosuppression/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O ,/O 5.3/O ,/O 5.4/O ,/O 5.5/O )/O ]/O ./O
Use/O in/O liver/O transplant/O patients/O is/O not/O recommended/O due/O to/O an/O increased/O risk/O of/O graft/O loss/O and/O death/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O POST/B-AdverseReaction -/I-AdverseReaction TRANSPLANT/I-AdverseReaction LYMPHOPROLIFERATIVE/O DISORDER/O ,/O OTHER/O MALIGNANCIES/B-AdverseReaction ,/O AND/O SERIOUS/B-Severity INFECTIONS/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Increased/O risk/B-Factor for/O developing/O post/B-AdverseReaction -/I-AdverseReaction transplant/I-AdverseReaction lymphoproliferative/O disorder/O (/O PTLD/B-AdverseReaction )/O ,/O predominantly/O involving/O the/O central/O nervous/O system/O (/O CNS/O )/O ./O
Recipients/O without/O immunity/O to/O Epstein/O -/O Barr/O virus/O (/O EBV/O )/O are/O at/O a/O particularly/O increased/O risk/O ;/O therefore/O ,/O use/O in/O EBV/O seropositive/O patients/O only/O ./O
Do/O not/O use/O NULOJIX/O in/O transplant/O recipients/O who/O are/O EBV/O seronegative/O or/O with/O unknown/O serostatus/O ./O
(/O 4/O ,/O 5.1/O )/O Only/O physicians/O experienced/O in/O immunosuppressive/O therapy/O and/O management/O of/O kidney/O transplant/O patients/O should/O prescribe/O NULOJIX/O ./O
(/O 5.2/O )/O Increased/B-AdverseReaction susceptibility/I-AdverseReaction to/I-AdverseReaction infection/I-AdverseReaction and/O the/O possible/O development/O of/O malignancies/B-AdverseReaction may/B-Factor result/O from/O immunosuppression/O ./O
(/O 5.1/O ,/O 5.3/O ,/O 5.4/O ,/O 5.5/O )/O Use/O in/O liver/O transplant/O patients/O is/O not/O recommended/O due/O to/O an/O increased/O risk/O of/O graft/O loss/O and/O death/O ./O
(/O 5.6/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Post/B-AdverseReaction -/I-AdverseReaction Transplant/I-AdverseReaction Lymphoproliferative/O Disorder/O (/O PTLD/B-AdverseReaction )/O :/O increased/O risk/B-Factor ,/O predominantly/O involving/O the/O CNS/O ;/O monitor/O for/O new/O or/O worsening/O neurological/O ,/O cognitive/O ,/O or/O behavioral/O signs/O and/O symptoms/O ./O
(/O Boxed/O Warning/O ,/O 4/O ,/O 5.1/O ,/O 5.6/O )/O Other/O malignancies/B-AdverseReaction :/O increased/O risk/O with/O all/O immunosuppressants/B-DrugClass ;/O appears/O related/O to/O intensity/O and/O duration/O of/O use/O ./O
Avoid/O prolonged/O exposure/O to/O UV/O light/O and/O sunlight/O ./O
(/O 5.3/O )/O Progressive/B-AdverseReaction Multifocal/I-AdverseReaction Leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O :/O increased/O risk/B-Factor ;/O consider/O in/O the/O diagnosis/O of/O patients/O reporting/O new/O or/O worsening/O neurological/O ,/O cognitive/O ,/O or/O behavioral/O signs/O and/O symptoms/O ./O
Recommended/O doses/O of/O immunosuppressants/O should/O not/O be/O exceeded/O ./O
(/O 5.4/O )/O Other/O serious/B-Severity infections/B-AdverseReaction :/O increased/O risk/B-Factor of/O bacterial/O ,/O viral/O ,/O fungal/O ,/O and/O protozoal/B-AdverseReaction infections/I-AdverseReaction ,/O including/O opportunistic/B-AdverseReaction infections/I-AdverseReaction and/O tuberculosis/B-AdverseReaction ./O
Some/O infections/B-AdverseReaction were/O fatal/B-AdverseReaction ./O
Polyoma/B-AdverseReaction virus/I-AdverseReaction -/I-AdverseReaction associated/O nephropathy/O can/B-Factor lead/O to/O kidney/B-AdverseReaction graft/I-AdverseReaction loss/I-AdverseReaction ;/O consider/O reduction/O in/O immunosuppression/O ./O
Evaluate/O for/O tuberculosis/O and/O initiate/O treatment/O for/O latent/O infection/O prior/O to/O NULOJIX/O use/O ./O
Cytomegalovirus/O and/O pneumocystis/O prophylaxis/O are/O recommended/O after/O transplantation/O ./O
(/O 5.1/O ,/O 5.4/O ,/O 5.5/O )/O Liver/O transplant/O :/O use/O is/O not/O recommended/O ./O
(/O 5.6/O )/O Acute/O Rejection/O and/O Graft/B-AdverseReaction Loss/I-AdverseReaction with/O Corticosteroid/O Minimization/O :/O corticosteroid/O utilization/O should/O be/O consistent/O with/O the/O NULOJIX/O clinical/O trial/O experience/O ./O
(/O 2.1/O ,/O 5.7/O ,/O 14.1/O )/O Immunizations/O :/O avoid/O use/O of/O live/O vaccines/O during/O treatment/O ./O
(/O 5.8/O )/O 5.1/O Post/O -/O Transplant/O Lymphoproliferative/O Disorder/O NULOJIX/O -/O treated/O patients/O have/O an/O increased/O risk/B-Factor for/O developing/O post/B-AdverseReaction -/I-AdverseReaction transplant/I-AdverseReaction lymphoproliferative/O disorder/O (/O PTLD/B-AdverseReaction )/O ,/O predominantly/O involving/O the/O CNS/O ,/O compared/O to/O patients/O on/O a/O cyclosporine/O -/O based/O regimen/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O and/O Table/O 2/O ]/O ./O
As/O the/O total/O burden/O of/O immunosuppression/O is/O a/O risk/O factor/O for/O PTLD/O ,/O higher/O than/O the/O recommended/O doses/O or/O more/O frequent/O dosing/O of/O NULOJIX/O and/O higher/O than/O recommended/O doses/O of/O concomitant/O immunosuppressive/O agents/O are/O not/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O and/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
Physicians/O should/O consider/O PTLD/O in/O patients/O reporting/O new/O or/O worsening/O neurological/O ,/O cognitive/O ,/O or/O behavioral/O signs/O or/O symptoms/O ./O
EBV/O Serostatus/O The/O risk/B-Factor of/O PTLD/B-AdverseReaction was/O higher/O in/O EBV/O seronegative/O patients/O compared/O to/O EBV/O seropositive/O patients/O ./O
EBV/O seropositive/O patients/O are/O defined/O as/O having/O evidence/O of/O acquired/O immunity/O shown/O by/O the/O presence/O of/O IgG/O antibodies/O to/O viral/O capsid/O antigen/O (/O VCA/O )/O and/O EBV/O nuclear/O antigen/O (/O EBNA/O )/O ./O
Epstein/O -/O Barr/O virus/O serology/O should/O be/O ascertained/O before/O starting/O administration/O of/O NULOJIX/O ,/O and/O only/O patients/O who/O are/O EBV/O seropositive/O should/O receive/O NULOJIX/O ./O
Transplant/O recipients/O who/O are/O EBV/O seronegative/O ,/O or/O with/O unknown/O serostatus/O ,/O should/O not/O receive/O NULOJIX/O [/O see/O Boxed/O Warning/O and/O Contraindications/O (/O 4/O )/O ]/O ./O
Other/O Risk/O Factors/O Other/O known/O risk/O factors/O for/O PTLD/O include/O cytomegalovirus/O (/O CMV/O )/O infection/O and/O T/O -/O cell/O -/O depleting/O therapy/O ./O
T/O -/O cell/O -/O depleting/O therapies/O to/O treat/O acute/O rejection/O should/O be/O used/O cautiously/O ./O
CMV/O prophylaxis/O is/O recommended/O for/O at/O least/O 3/O months/O after/O transplantation/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Patients/O who/O are/O EBV/O seropositive/O and/O CMV/O seronegative/O may/O be/O at/O increased/O risk/O for/O PTLD/O compared/O to/O patients/O who/O are/O EBV/O seropositive/O and/O CMV/O seropositive/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Since/O CMV/O seronegative/O patients/O are/O at/O increased/O risk/O for/O CMV/O disease/O (/O a/O known/O risk/O factor/O for/O PTLD/O )/O ,/O the/O clinical/O significance/O of/O CMV/O serology/O for/O PTLD/O remains/O to/O be/O determined/O ;/O however/O ,/O these/O findings/O should/O be/O considered/O when/O prescribing/O NULOJIX/O ./O
5.2/O Management/O of/O Immunosuppression/O Only/O physicians/O experienced/O in/O management/O of/O systemic/O immunosuppressant/O therapy/O in/O transplantation/O should/O prescribe/O NULOJIX/O ./O
Patients/O receiving/O the/O drug/O should/O be/O managed/O in/O facilities/O equipped/O and/O staffed/O with/O adequate/O laboratory/O and/O supportive/O medical/O resources/O ./O
The/O physician/O responsible/O for/O the/O maintenance/O therapy/O should/O have/O complete/O information/O requisite/O for/O the/O follow/O -/O up/O of/O the/O patient/O [/O see/O Boxed/O Warning/O ]/O ./O
5.3/O Other/O Malignancies/O Patients/O receiving/O immunosuppressants/O ,/O including/O NULOJIX/O ,/O are/O at/O increased/O risk/O of/O developing/O malignancies/B-AdverseReaction ,/O in/O addition/O to/O PTLD/B-AdverseReaction ,/O including/O the/O skin/O [/O see/O Boxed/O Warning/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Exposure/O to/O sunlight/O and/O ultraviolet/O (/O UV/O )/O light/O should/O be/O limited/O by/O wearing/O protective/O clothing/O and/O using/O a/O sunscreen/O with/O a/O high/O protection/O factor/O ./O
5.4/O Progressive/O Multifocal/O Leukoencephalopathy/O Progressive/O multifocal/O leukoencephalopathy/O (/O PML/O )/O is/O an/O often/O rapidly/O progressive/O and/O fatal/O opportunistic/O infection/O of/O the/O CNS/O that/O is/O caused/O by/O the/O JC/O virus/O ,/O a/O human/O polyoma/O virus/O ./O
In/O clinical/O trials/O with/O NULOJIX/O ,/O two/O cases/O of/O PML/B-AdverseReaction were/O reported/O in/O patients/O receiving/O NULOJIX/O at/O higher/O cumulative/O doses/O and/O more/O frequently/O than/O the/O recommended/O regimen/O ,/O along/O with/O mycophenolate/O mofetil/O (/O MMF/O )/O and/O corticosteroids/O ;/O one/O case/O occurred/O in/O a/O kidney/O transplant/O recipient/O and/O the/O second/O case/O occurred/O in/O a/O liver/O transplant/O recipient/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
As/O PML/O has/O been/O associated/O with/O high/O levels/O of/O overall/O immunosuppression/O ,/O the/O recommended/O doses/O and/O frequency/O of/O NULOJIX/O and/O concomitant/O immunosuppressives/O ,/O including/O MMF/O ,/O should/O not/O be/O exceeded/O ./O
Physicians/O should/O consider/O PML/O in/O the/O differential/O diagnosis/O in/O patients/O with/O new/O or/O worsening/O neurological/O ,/O cognitive/O ,/O or/O behavioral/O signs/O or/O symptoms/O ./O
PML/O is/O usually/O diagnosed/O by/O brain/O imaging/O ,/O cerebrospinal/O fluid/O (/O CSF/O )/O testing/O for/O JC/O viral/O DNA/O by/O polymerase/O chain/O reaction/O (/O PCR/O )/O ,/O and/or/O brain/O biopsy/O ./O
Consultation/O with/O a/O specialist/O (/O e.g./O ,/O neurologist/O and/or/O infectious/O disease/O )/O should/O be/O considered/O for/O any/O suspected/O or/O confirmed/O cases/O of/O PML/O ./O
If/O PML/O is/O diagnosed/O ,/O consideration/O should/O be/O given/O to/O reduction/O or/O withdrawal/O of/O immunosuppression/O taking/O into/O account/O the/O risk/O to/O the/O allograft/O ./O
5.5/O Other/O Serious/O Infections/O Patients/O receiving/O immunosuppressants/O ,/O including/O NULOJIX/O ,/O are/O at/O increased/O risk/B-Factor of/O developing/O bacterial/O ,/O viral/O (/O cytomegalovirus/O [/O CMV/O ]/O and/O herpes/O )/O ,/O fungal/O ,/O and/O protozoal/B-AdverseReaction infections/I-AdverseReaction ,/O including/O opportunistic/B-AdverseReaction infections/I-AdverseReaction ./O
These/O infections/B-AdverseReaction may/O lead/O to/O serious/B-Severity ,/O including/O fatal/B-AdverseReaction ,/O outcomes/O [/O see/O Boxed/O Warning/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Prophylaxis/O for/O cytomegalovirus/O is/O recommended/O for/O at/O least/O 3/O months/O after/O transplantation/O ./O
Prophylaxis/O for/O Pneumocystis/O jiroveci/O is/O recommended/O after/O transplantation/O ./O
Tuberculosis/O Tuberculosis/B-AdverseReaction was/O more/O frequently/O observed/O in/O patients/O receiving/O NULOJIX/O than/O cyclosporine/O in/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Patients/O should/O be/O evaluated/O for/O tuberculosis/O and/O tested/O for/O latent/O infection/O prior/O to/O initiating/O NULOJIX/O ./O
Treatment/O of/O latent/O tuberculosis/O infection/O should/O be/O initiated/O prior/O to/O NULOJIX/O use/O ./O
Polyoma/O Virus/O Nephropathy/O In/O addition/O to/O cases/O of/O JC/B-AdverseReaction virus/I-AdverseReaction -/O associated/O PML/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ,/O cases/O of/O polyoma/B-AdverseReaction virus/I-AdverseReaction -/I-AdverseReaction associated/O nephropathy/O (/O PVAN/B-AdverseReaction )/O ,/O mostly/O due/O to/O BK/B-AdverseReaction virus/I-AdverseReaction infection/I-AdverseReaction ,/O have/O been/O reported/O ./O
PVAN/B-AdverseReaction is/O associated/O with/O serious/O outcomes/O ;/O including/O deteriorating/B-AdverseReaction renal/I-AdverseReaction function/I-AdverseReaction and/O kidney/B-AdverseReaction graft/I-AdverseReaction loss/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Patient/O monitoring/O may/O help/O detect/O patients/O at/O risk/O for/O PVAN/O ./O
Reductions/O in/O immunosuppression/O should/O be/O considered/O for/O patients/O who/O develop/O evidence/O of/O PVAN/O ./O
Physicians/O should/O also/O consider/O the/O risk/O that/O reduced/O immunosuppression/O represents/O to/O the/O functioning/O allograft/O ./O
5.6/O Liver/O Transplant/O Use/O of/O NULOJIX/O in/O liver/O transplant/O patients/O is/O not/O recommended/O [/O see/O Boxed/O Warning/O ]/O ./O
In/O a/O clinical/O trial/O of/O liver/O transplant/O patients/O ,/O use/O of/O NULOJIX/O regimens/O with/O more/O frequent/O administration/O of/O belatacept/O than/O any/O of/O those/O studied/O in/O kidney/O transplant/O ,/O along/O with/O mycophenolate/O mofetil/O (/O MMF/O )/O and/O corticosteroids/O ,/O was/O associated/O with/O a/O higher/O rate/O of/O graft/B-AdverseReaction loss/I-AdverseReaction and/O death/B-AdverseReaction compared/O to/O the/O tacrolimus/O control/O arms/O ./O
In/O addition/O ,/O two/O cases/O of/O PTLD/B-AdverseReaction involving/O the/O liver/O allograft/O (/O one/O fatal/B-AdverseReaction )/O and/O one/O fatal/B-AdverseReaction case/O of/O PML/B-AdverseReaction were/O observed/O among/O the/O 147/O patients/O randomized/O to/O NULOJIX/O ./O
The/O two/O cases/O of/O PTLD/B-AdverseReaction were/O reported/O among/O the/O 140/O EBV/O seropositive/O patients/O (/O 1.4/O %/O )/O ./O
The/O fatal/B-AdverseReaction case/O of/O PML/B-AdverseReaction was/O reported/O in/O a/O patient/O receiving/O higher/O than/O recommended/O doses/O of/O NULOJIX/O and/O MMF/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
5.7/O Acute/O Rejection/O and/O Graft/O Loss/O with/O Corticosteroid/O Minimization/O In/O postmarketing/O experience/O ,/O use/O of/O NULOJIX/O in/O conjunction/O with/O basiliximab/O induction/O ,/O MMF/O ,/O and/O corticosteroid/O minimization/O to/O 5/O mg/O per/O day/O between/O Day/O 3/O and/O Week/O 6/O post/O -/O transplant/O was/O associated/O with/O an/O increased/O rate/O and/O grade/O of/O acute/O rejection/O ,/O particularly/O Grade/B-Severity III/I-Severity rejection/O ./O
These/O Grade/B-Severity III/I-Severity rejections/O occurred/O in/O patients/O with/O 4/O to/O 6/O HLA/O mismatches/O ./O
Graft/B-AdverseReaction loss/I-AdverseReaction was/O a/O consequence/O of/O Grade/B-Severity III/I-Severity rejection/O in/O some/O patients/O ./O
Corticosteroid/O utilization/O should/O be/O consistent/O with/O the/O NULOJIX/O clinical/O trial/O experience/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O and/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
5.8/O Immunizations/O The/O use/O of/O live/O vaccines/O should/O be/O avoided/O during/O treatment/O with/O NULOJIX/O ,/O including/O but/O not/O limited/O to/O the/O following/O :/O intranasal/O influenza/O ,/O measles/O ,/O mumps/O ,/O rubella/O ,/O oral/O polio/O ,/O BCG/O ,/O yellow/O fever/O ,/O varicella/O ,/O and/O TY21a/O typhoid/O vaccines/O ./O
6/O ADVERSE/O REACTIONS/O Clinically/O significant/O adverse/O reactions/O that/O appear/O in/O other/O sections/O of/O the/O labeling/O include/O the/O following/O :/O Somnolence/B-AdverseReaction or/O Sedation/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Potentiation/B-AdverseReaction of/I-AdverseReaction Sedation/I-AdverseReaction from/O Concomitant/O Use/O with/O Central/O Nervous/O System/O Depressants/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Withdrawal/O Symptoms/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Serious/B-Severity Dermatological/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Physical/O and/O Psychological/B-AdverseReaction Dependence/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Suicidal/B-AdverseReaction Behavior/I-AdverseReaction and/O Ideation/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O EXCERPT/O :/O Adverse/O reactions/O that/O occurred/O at/O least/O 10/O %/O more/O frequently/O than/O placebo/O in/O any/O ONFI/O dose/O included/O constipation/B-AdverseReaction ,/O somnolence/B-AdverseReaction or/O sedation/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O lethargy/B-AdverseReaction ,/O and/O drooling/B-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Lundbeck/O at/O 1/O -/O 800/O -/O 455/O -/O 1141/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
During/O its/O development/O for/O the/O adjunctive/O treatment/O of/O seizures/O associated/O with/O LGS/O ,/O ONFI/O was/O administered/O to/O 333/O healthy/O volunteers/O and/O 300/O patients/O with/O a/O current/O or/O prior/O diagnosis/O of/O LGS/O ,/O including/O 197/O patients/O treated/O for/O 12/O months/O or/O more/O ./O
The/O conditions/O and/O duration/O of/O exposure/O varied/O greatly/O and/O included/O single-/O and/O multiple/O -/O dose/O clinical/O pharmacology/O studies/O in/O healthy/O volunteers/O and/O two/O double/O -/O blind/O studies/O in/O patients/O with/O LGS/O (/O Study/O 1/O and/O 2/O )/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Only/O Study/O 1/O included/O a/O placebo/O group/O ,/O allowing/O comparison/O of/O adverse/O reaction/O rates/O on/O ONFI/O at/O several/O doses/O to/O placebo/O ./O
Adverse/O Reactions/O Leading/O to/O Discontinuation/O in/O an/O LGS/O Placebo/O Controlled/O Clinical/O Trial/O (/O Study/O 1/O )/O The/O adverse/O reactions/O associated/O with/O ONFI/O treatment/O discontinuation/O in/O 1/O %/O of/O patients/O in/O decreasing/O order/O of/O frequency/O included/O lethargy/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O ataxia/B-AdverseReaction ,/O aggression/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O insomnia/B-AdverseReaction ./O
Most/O Common/O Adverse/O Reactions/O in/O an/O LGS/O Placebo/O Controlled/O Clinical/O Trial/O (/O Study/O 1/O )/O Table/O 3/O lists/O the/O adverse/O reactions/O that/O occurred/O in/O 5/O %/O of/O ONFI/O treated/O patients/O (/O at/O any/O dose/O )/O ,/O and/O at/O a/O rate/O greater/O than/O placebo/O treated/O patients/O ,/O in/O the/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O parallel/O group/O clinical/O study/O of/O adjunctive/O AED/O therapy/O for/O 15/O weeks/O (/O Study/O 1/O )/O ./O
Table/O 3/O ./O
Adverse/O Reactions/O Reported/O for/O 5/O %/O of/O Patients/O and/O More/O Frequently/O than/O Placebo/O in/O Any/O Treatment/O Group/O a/O Maximum/O daily/O dose/O of/O 5/O mg/O for/O 30/O kg/O body/O weight/O ;/O 10/O mg/O for/O 30/O kg/O body/O weight/O b/O Maximum/O daily/O dose/O of/O 10/O mg/O for/O 30/O kg/O body/O weight/O ;/O 20/O mg/O for/O 30/O kg/O body/O weight/O c/O Maximum/O daily/O dose/O of/O 20/O mg/O for/O 30/O kg/O body/O weight/O ;/O 40/O mg/O for/O 30/O kg/O body/O weight/O Placebo/O N=59/O %/O ONFI/O Dose/O Level/O All/O ONFI/O N=179/O %/O Low/O a/O N=58/O %/O Medium/O b/O N=62/O %/O High/O c/O N=59/O %/O Gastrointestinal/O Disorders/O Vomiting/B-AdverseReaction 5/O 9/O 5/O 7/O 7/O Constipation/B-AdverseReaction 0/O 2/O 2/O 10/O 5/O Dysphagia/B-AdverseReaction 0/O 0/O 0/O 5/O 2/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Pyrexia/B-AdverseReaction 3/O 17/O 10/O 12/O 13/O Irritability/B-AdverseReaction 5/O 3/O 11/O 5/O 7/O Fatigue/B-AdverseReaction 2/O 5/O 5/O 3/O 5/O Infections/O and/O Infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 10/O 10/O 13/O 14/O 12/O Pneumonia/B-AdverseReaction 2/O 3/O 3/O 7/O 4/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 0/O 2/O 5/O 5/O 4/O Bronchitis/B-AdverseReaction 0/O 2/O 0/O 5/O 2/O Metabolism/O and/O Nutrition/O Disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 3/O 3/O 0/O 7/O 3/O Increased/B-AdverseReaction appetite/I-AdverseReaction 0/O 2/O 3/O 5/O 3/O Nervous/O System/O Disorders/O Somnolence/B-AdverseReaction or/O Sedation/B-AdverseReaction 15/O 17/O 27/O 32/O 26/O Somnolence/B-AdverseReaction 12/O 16/O 24/O 25/O 22/O Sedation/B-AdverseReaction 3/O 2/O 3/O 9/O 5/O Lethargy/B-AdverseReaction 5/O 10/O 5/O 15/O 10/O Drooling/B-AdverseReaction 3/O 0/O 13/O 14/O 9/O Ataxia/B-AdverseReaction 3/O 3/O 2/O 10/O 5/O Psychomotor/B-AdverseReaction hyperactivity/I-AdverseReaction 3/O 3/O 3/O 5/O 4/O Dysarthria/B-AdverseReaction 0/O 2/O 2/O 5/O 3/O Psychiatric/O Disorders/O Aggression/B-AdverseReaction 5/O 3/O 8/O 14/O 8/O Insomnia/B-AdverseReaction 2/O 2/O 5/O 7/O 5/O Respiratory/O Disorders/O Cough/B-AdverseReaction 0/O 3/O 5/O 7/O 5/O 6.2/O Post/O Marketing/O Experience/O These/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ;/O therefore/O ,/O it/O is/O not/O possible/O to/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Adverse/O reactions/O are/O categorized/O by/O system/O organ/O class/O ./O
Blood/O Disorders/O :/O Anemia/B-AdverseReaction ,/O eosinophilia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction Eye/O Disorders/O :/O Diplopia/B-AdverseReaction ,/O vision/B-AdverseReaction blurred/I-AdverseReaction Gastrointestinal/O Disorders/O :/O Abdominal/B-AdverseReaction distention/I-AdverseReaction General/O Disorders/O and/O Administration/O Site/O Conditions/O :/O Hypothermia/B-AdverseReaction Investigations/O :/O Hepatic/B-AdverseReaction enzyme/I-AdverseReaction increased/I-AdverseReaction Musculoskeletal/O :/O Muscle/B-AdverseReaction spasms/I-AdverseReaction Psychiatric/O Disorders/O :/O Agitation/B-AdverseReaction ,/O anxiety/B-AdverseReaction ,/O apathy/B-AdverseReaction ,/O confusional/B-AdverseReaction state/I-AdverseReaction ,/O depression/B-AdverseReaction ,/O delirium/B-AdverseReaction ,/O delusion/B-AdverseReaction ,/O hallucination/B-AdverseReaction Renal/O and/O Urinary/O Disorders/O :/O Urinary/B-AdverseReaction retention/I-AdverseReaction Respiratory/O Disorders/O :/O Aspiration/B-AdverseReaction ,/O respiratory/B-AdverseReaction depression/I-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O Rash/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O angioedema/B-AdverseReaction ,/O and/O facial/O and/O lip/B-AdverseReaction edema/I-AdverseReaction 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Somnolence/B-AdverseReaction or/O Sedation/B-AdverseReaction :/O Monitor/O for/O central/O nervous/O system/O (/O CNS/O )/O depression/O ./O
Risk/O may/O be/O increased/O with/O concomitant/O use/O of/O other/O CNS/O depressants/O ./O
(/O 5.1/O ,/O 5.2/O )/O Withdrawal/O :/O Symptoms/O may/O occur/O with/O rapid/O dose/O reduction/O or/O discontinuation/O ./O
Discontinue/O ONFI/O gradually/O ./O
(/O 5.3/O )/O Serious/B-Severity Dermatological/B-AdverseReaction Reactions(including/I-AdverseReaction Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O and/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis):Discontinue/I-AdverseReaction ONFI/O at/O first/O sign/O of/O rash/O unless/O the/O rash/O is/O clearly/O not/O drug/O -/O related/O ./O
(/O 5.4/O )/O Physical/O and/O Psychological/B-AdverseReaction Dependence/I-AdverseReaction :/O Monitor/O patients/O with/O a/O history/O of/O substance/O abuse/O for/O signs/O of/O habituation/O and/O dependence/O (/O 5.5/O ,/O 9/O )/O Suicidal/B-AdverseReaction Behavior/I-AdverseReaction and/O Ideation/O :/O Monitor/O for/O suicidal/O thoughts/O or/O behaviors/O (/O 5.6/O )/O 5.1/O Somnolence/O or/O Sedation/O ONFI/O causes/O somnolence/B-AdverseReaction and/O sedation/B-AdverseReaction ./O
In/O clinical/O trials/O ,/O somnolence/B-AdverseReaction or/O sedation/B-AdverseReaction was/O reported/O at/O all/O effective/O doses/O and/O was/O dose/O -/O related/O ./O
In/O general/O ,/O somnolence/B-AdverseReaction and/O sedation/B-AdverseReaction begin/O within/O the/O first/O month/O of/O treatment/O and/O may/O diminish/O with/O continued/O treatment/O ./O
Prescribers/O should/O monitor/O patients/O for/O somnolence/O and/O sedation/O ,/O particularly/O with/O concomitant/O use/O of/O other/O central/O nervous/O system/O depressants/O ./O
Prescribers/O should/O caution/O patients/O against/O engaging/O in/O hazardous/O activities/O requiring/O mental/O alertness/O ,/O such/O as/O operating/O dangerous/O machinery/O or/O motor/O vehicles/O ,/O until/O the/O effect/O of/O ONFI/O is/O known/O ./O
5.2/O Potentiation/O of/O Sedation/O from/O Concomitant/O Use/O with/O Central/O Nervous/O System/O Depressants/O Since/O ONFI/O has/O a/O central/O nervous/O system/O (/O CNS/O )/O depressant/O effect/O ,/O patients/O or/O their/O caregivers/O should/O be/O cautioned/O against/O simultaneous/O use/O with/O other/O CNS/O depressant/O drugs/O or/O alcohol/O ,/O and/O cautioned/O that/O the/O effects/O of/O other/O CNS/O depressant/O drugs/O or/O alcohol/O may/O be/O potentiated/O ./O
5.3/O Withdrawal/O Symptoms/O Abrupt/O discontinuation/O of/O ONFI/O should/O be/O avoided/O ./O
ONFI/O should/O be/O tapered/O by/O decreasing/O the/O dose/O every/O week/O by/O 5/O -/O 10/O mg/O day/O until/O discontinuation/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Withdrawal/O symptoms/O occurred/O following/O abrupt/O discontinuation/O of/O ONFI/O ;/O the/O risk/O of/O withdrawal/O symptoms/O is/O greater/O with/O higher/O doses/O ./O
As/O with/O all/O antiepileptic/O drugs/O ,/O ONFI/O should/O be/O withdrawn/O gradually/O to/O minimize/O the/O risk/O of/O precipitating/O seizures/O ,/O seizure/O exacerbation/O ,/O or/O status/O epilepticus/O ./O
Withdrawal/O symptoms/O (/O e.g./O ,/O convulsions/O ,/O psychosis/O ,/O hallucinations/O ,/O behavioral/O disorder/O ,/O tremor/O ,/O and/O anxiety/O )/O have/O been/O reported/O following/O abrupt/O discontinuance/O of/O benzodiazepines/O ./O
The/O more/O severe/O withdrawal/O symptoms/O have/O usually/O been/O limited/O to/O patients/O who/O received/O excessive/O doses/O over/O an/O extended/O period/O of/O time/O ,/O followed/O by/O an/O abrupt/O discontinuation/O ./O
Generally/O milder/O withdrawal/O symptoms/O (/O e.g./O ,/O dysphoria/O ,/O anxiety/O ,/O and/O insomnia/O )/O have/O been/O reported/O following/O abrupt/O discontinuance/O of/O benzodiazepines/O taken/O continuously/O at/O therapeutic/O doses/O for/O several/O months/O ./O
5.4/O Serious/O Dermatological/O Reactions/O Serious/B-Severity skin/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O (/O SJS/B-AdverseReaction )/O and/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction (/O TEN/B-AdverseReaction )/O ,/O have/O been/O reported/O with/O ONFI/O in/O both/O children/O and/O adults/O during/O the/O post/O -/O marketing/O period/O ./O
Patients/O should/O be/O closely/O monitored/O for/O signs/O or/O symptoms/O of/O SJS/O TEN/O ,/O especially/O during/O the/O first/O 8/O weeks/O of/O treatment/O initiation/O or/O when/O re/O -/O introducing/O therapy/O ./O
ONFI/O should/O be/O discontinued/O at/O the/O first/O sign/O of/O rash/O ,/O unless/O the/O rash/O is/O clearly/O not/O drug/O -/O related/O ./O
If/O signs/O or/O symptoms/O suggest/O SJS/O TEN/O ,/O use/O of/O this/O drug/O should/O not/O be/O resumed/O and/O alternative/O therapy/O should/O be/O considered/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.5/O Physical/O and/O Psychological/O Dependence/O Patients/O with/O a/O history/O of/O substance/O abuse/O should/O be/O under/O careful/O surveillance/O when/O receiving/O ONFI/O or/O other/O psychotropic/O agents/O because/O of/O the/O predisposition/O of/O such/O patients/O to/O habituation/O and/O dependence/O [/O see/O Drug/O Abuse/O and/O Dependence/O (/O 9/O )/O ]/O ./O
5.6/O Suicidal/O Behavior/O and/O Ideation/O Antiepileptic/O drugs/O (/O AEDs/O )/O ,/O including/O ONFI/O ,/O increase/O the/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O in/O patients/O taking/O these/O drugs/O for/O any/O indication/O ./O
Patients/O treated/O with/O any/O AED/O for/O any/O indication/O should/O be/O monitored/O for/O the/O emergence/O or/O worsening/O of/O depression/O ,/O suicidal/O thoughts/O or/O behavior/O ,/O and/or/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ./O
Pooled/O analyses/O of/O 199/O placebo/O -/O controlled/O clinical/O trials/O (/O mono-/O and/O adjunctive/O therapy/O )/O of/O 11/O different/O AEDs/B-DrugClass showed/O that/O patients/O randomized/O to/O one/O of/O the/O AEDs/O had/O approximately/O twice/O the/O risk/O (/O adjusted/O relative/O risk/O 1.8/O ,/O 95/O %/O confidence/O interval/O [/O CI/O ]/O :/O 1.2/O ,/O 2.7/O )/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O compared/O to/O patients/O randomized/O to/O placebo/O ./O
In/O these/O trials/O ,/O which/O had/O a/O median/O treatment/O duration/O of/O 12/O weeks/O ,/O the/O estimated/O incidence/O rate/O of/O suicidal/B-AdverseReaction behavior/I-AdverseReaction or/O ideation/O among/O 27,863/O AED/B-DrugClass treated/O patients/O was/O 0.43/O %/O ,/O compared/O to/O 0.24/O %/O among/O 16,029/O placebo/O treated/O patients/O ,/O representing/O an/O increase/O of/O approximately/O one/O case/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction or/O behavior/O for/O every/O 530/O patients/O treated/O ./O
There/O were/O four/O suicides/B-AdverseReaction in/O drug/O treated/O patients/O in/O the/O trials/O and/O none/O in/O placebo/O treated/O patients/O ,/O but/O the/O number/O is/O too/O small/O to/O allow/O any/O conclusion/O about/O drug/O effect/O on/O suicide/B-AdverseReaction ./O
The/O increased/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O with/O AEDs/B-DrugClass was/O observed/O as/O early/O as/O one/O week/O after/O starting/O drug/O treatment/O with/O AEDs/O and/O persisted/O for/O the/O duration/O of/O treatment/O assessed/O ./O
Because/O most/O trials/O included/O in/O the/O analysis/O did/O not/O extend/O beyond/O 24/O weeks/O ,/O the/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O beyond/O 24/O weeks/O could/O not/O be/O assessed/O ./O
The/O risk/B-Factor of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O generally/O consistent/O among/O drugs/O in/O the/O data/O analyzed/O ./O
The/O finding/O of/O increased/O risk/O with/O AEDs/O of/O varying/O mechanisms/O of/O action/O and/O across/O a/O range/O of/O indications/O suggests/O that/O the/O risk/O applies/O to/O all/O AEDs/O used/O for/O any/O indication/O ./O
The/O risk/O did/O not/O vary/O substantially/O by/O age/O (/O 5/O -/O 100/O years/O )/O in/O the/O clinical/O trials/O analyzed/O ./O
Table/O 2/O shows/O absolute/O and/O relative/O risk/O by/O indication/O for/O all/O evaluated/O AEDs/O ./O
Table/O 2/O ./O
Risk/O by/O Indication/O for/O Antiepileptic/O Drugs/O in/O the/O Pooled/O Analysis/O Indication/O Placebo/O Patients/O with/O Events/O per/O 1000/O Patients/O Drug/O Patients/O with/O Events/O per/O 1000/O Patients/O Relative/O Risk/O :/O Incidence/O of/O Drug/O Events/O in/O Drug/O Patients/O Incidencein/O Placebo/O Patients/O Risk/O Difference/O :/O Additional/O Drug/O Patients/O with/O Events/O per/O 1000/O Patients/O Epilepsy/O 1.0/O 3.4/O 3.5/O 2.4/O Psychiatric/O 5.7/O 8.5/O 1.5/O 2.9/O Other/O 1.0/O 1.8/O 1.9/O 0.9/O Total/O 2.4/O 4.3/O 1.8/O 1.9/O The/O relative/O risk/B-Factor for/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction or/O behavior/O was/O higher/O in/O clinical/O trials/O for/O epilepsy/O than/O in/O clinical/O trials/O for/O psychiatric/O or/O other/O conditions/O ,/O but/O the/O absolute/O risk/O differences/O were/O similar/O for/O the/O epilepsy/O and/O psychiatric/O indications/O ./O
Anyone/O considering/O prescribing/O ONFI/O or/O any/O other/O AED/O must/O balance/O the/O risk/O of/O suicidal/O thoughts/O or/O behavior/O with/O the/O risk/O of/O untreated/O illness/O ./O
Epilepsy/O and/O many/O other/O illnesses/O for/O which/O AEDs/O are/O prescribed/O are/O themselves/O associated/O with/O morbidity/O and/O mortality/O and/O an/O increased/O risk/O of/O suicidal/O thoughts/O and/O behavior/O ./O
Should/O suicidal/O thoughts/O and/O behavior/O emerge/O during/O treatment/O ,/O the/O prescriber/O needs/O to/O consider/O whether/O the/O emergence/O of/O these/O symptoms/O in/O any/O given/O patient/O may/O be/O related/O to/O the/O illness/O being/O treated/O ./O
Patients/O ,/O their/O caregivers/O ,/O and/O families/O should/O be/O informed/O that/O AEDs/O increase/O the/O risk/O of/O suicidal/O thoughts/O and/O behavior/O and/O should/O be/O advised/O of/O the/O need/O to/O be/O alert/O for/O the/O emergence/O or/O worsening/O of/O the/O signs/O and/O symptoms/O of/O depression/O ,/O any/O unusual/O changes/O in/O mood/O or/O behavior/O ,/O or/O the/O emergence/O of/O suicidal/O thoughts/O ,/O behavior/O ,/O or/O thoughts/O about/O self/O -/O harm/O ./O
Behaviors/O of/O concern/O should/O be/O reported/O immediately/O to/O healthcare/O providers/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Psoriatic/O Arthritis/O :/O The/O most/O common/O adverse/O reactions/O (/O 5/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O headache/B-AdverseReaction (/O 6.1/O )/O Psoriasis/O :/O The/O most/O common/O adverse/O reactions/O (/O 5/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O and/O headache/B-AdverseReaction ,/O including/O tension/B-AdverseReaction headache/I-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Celgene/O Corporation/O at/O 1/O -/O 888/O -/O 423/O -/O 5436/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trial/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Psoriatic/O Arthritis/O Clinical/O Trials/O OTEZLA/O was/O evaluated/O in/O 3/O multicenter/O ,/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trials/O [/O Studies/O PsA-1/O ,/O PsA-2/O ,/O and/O PsA-3/O ]/O of/O similar/O design/O in/O adult/O patients/O with/O active/O psoriatic/O arthritis/O [/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
Across/O the/O 3/O studies/O ,/O there/O were/O 1493/O patients/O randomized/O equally/O to/O placebo/O ,/O OTEZLA/O 20/O mg/O twice/O daily/O or/O OTEZLA/O 30/O mg/O twice/O daily/O ./O
Titration/O was/O used/O over/O the/O first/O 5/O days/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
Placebo/O patients/O whose/O tender/O and/O swollen/O joint/O counts/O had/O not/O improved/O by/O at/O least/O 20/O %/O were/O re/O -/O randomized/O 1:1/O in/O a/O blinded/O fashion/O to/O either/O OTEZLA/O 20/O mg/O twice/O daily/O or/O 30/O mg/O twice/O daily/O at/O week/O 16/O while/O OTEZLA/O patients/O remained/O on/O their/O initial/O treatment/O ./O
Patients/O ranged/O in/O age/O from/O 18/O to/O 83/O years/O ,/O with/O an/O overall/O median/O age/O of/O 51/O years/O ./O
The/O majority/O of/O the/O most/O common/O adverse/O reactions/O presented/O inTable/O 2occurred/O within/O the/O first/O 2/O weeks/O of/O treatment/O and/O tended/O to/O resolve/O over/O time/O with/O continued/O dosing/O ./O
Diarrhea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction were/O the/O most/O commonly/O reported/O adverse/O reactions/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O for/O patients/O taking/O OTEZLA/O were/O nausea/B-AdverseReaction (/O 1.8/O %/O )/O ,/O diarrhea/B-AdverseReaction (/O 1.8/O %/O )/O ,/O and/O headache/B-AdverseReaction (/O 1.2/O %/O )/O ./O
The/O proportion/O of/O patients/O with/O psoriatic/O arthritis/O who/O discontinued/O treatment/O due/O to/O any/O adverse/O reaction/O was/O 4.6/O %/O for/O patients/O taking/O OTEZLA/O 30/O mg/O twice/O daily/O and/O 1.2/O %/O for/O placebo/O -/O treated/O patients/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Reported/O in/O 2/O %/O of/O Patients/O on/O OTEZLA/O 30/O mg/O Twice/O Daily/O and/O 1/O %/O Than/O That/O Observed/O in/O Patients/O on/O Placebo/O for/O up/O to/O Day/O 112/O (/O Week/O 16/O )/O a/O Of/O the/O reported/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ,/O 1/O subject/O experienced/O a/O serious/B-Severity adverse/O reaction/O of/O nausea/B-AdverseReaction and/O vomiting/B-AdverseReaction in/O OTEZLA/O 30/O mg/O twice/O daily/O ;/O 1/O subject/O treated/O with/O OTEZLA/O 20/O mg/O twice/O daily/O experienced/O a/O serious/B-Severity adverse/O reaction/O of/O diarrhea/B-AdverseReaction ;/O 1/O patient/O treated/O with/O OTEZLA/O 30/O mg/O twice/O daily/O experienced/O a/O serious/B-Severity adverse/O reaction/O of/O headache/B-AdverseReaction ./O
b/O Of/O the/O reported/O adverse/O drug/O reactions/O none/O were/O serious/O ./O
c/O n/O (/O %/O )/O indicates/O number/O of/O patients/O and/O percent/O ./O
Placebo/O OTEZLA/O 30/O mg/O BID/O Preferred/O Term/O Day/O 1/O to/O 5(N=495)n/O (/O %/O )/O c/O Day/O 6/O to/O Day/O 112(N=490)n/O (/O %/O )/O Day/O 1/O to/O 5(N=497)n/O (/O %/O )/O Day/O 6/O to/O Day/O 112(N=493)n/O (/O %/O )/O Diarrhea/B-AdverseReaction a/O 6/O (/O 1.2/O )/O 8/O (/O 1.6/O )/O 46/O (/O 9.3/O )/O 38/O (/O 7.7/O )/O Nausea/B-AdverseReaction a/O 7/O (/O 1.4/O )/O 15/O (/O 3.1/O )/O 37/O (/O 7.4/O )/O 44/O (/O 8.9/O )/O Headache/B-AdverseReaction a/O 9/O (/O 1.8/O )/O 11/O (/O 2.2/O )/O 24/O (/O 4.8/O )/O 29/O (/O 5.9/O )/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tractinfection/I-AdverseReaction b/O 3/O (/O 0.6/O )/O 9/O (/O 1.8/O )/O 3/O (/O 0.6/O )/O 19/O (/O 3.9/O )/O Vomiting/B-AdverseReaction a/O 2/O (/O 0.4/O )/O 2/O (/O 0.4/O )/O 4/O (/O 0.8/O )/O 16/O (/O 3.2/O )/O Nasopharyngitis/B-AdverseReaction b/O 1/O (/O 0.2/O )/O 8/O (/O 1.6/O )/O 1/O (/O 0.2/O )/O 13/O (/O 2.6/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction b/O 0/O (/O 0.0/O )/O 1/O (/O 0.2/O )/O 3/O (/O 0.6/O )/O 10/O (/O 2.0/O )/O Other/O adverse/O reactions/O reported/O in/O patients/O on/O OTEZLA/O in/O clinical/O studies/O including/O extension/O studies/O :/O Immune/O system/O disorders/O :/O Hypersensitivity/B-AdverseReaction Investigations/O :/O Weight/B-AdverseReaction decrease/I-AdverseReaction Gastrointestinal/O Disorders/O :/O Frequent/B-AdverseReaction bowel/I-AdverseReaction movement/I-AdverseReaction ,/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction Metabolism/O and/O Nutrition/O Disorders/O :/O Decreased/B-AdverseReaction appetite/I-AdverseReaction Nervous/O System/O Disorders/O :/O Migraine/B-AdverseReaction Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O :/O Cough/B-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O Rash*1/B-AdverseReaction patient/O treated/O with/O OTEZLA/O 30/O mg/O twice/O daily/O experienced/O a/O serious/O adverse/O reaction/O ./O
Psoriasis/O Clinical/O Trials/O The/O safety/O of/O OTEZLA/O (/O r/O )/O was/O assessed/O in/O 1426/O subjects/O in/O 3/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trials/O in/O adult/O subjects/O with/O moderate/O to/O severe/O plaque/O psoriasis/O who/O were/O candidates/O for/O phototherapy/O or/O systemic/O therapy/O ./O
Subjects/O were/O randomized/O to/O receive/O OTEZLA/O 30/O mg/O twice/O daily/O or/O placebo/O twice/O daily/O ./O
Titration/O was/O used/O over/O the/O first/O 5/O days/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
Subjects/O ranged/O in/O age/O from/O 18/O to/O 83/O years/O ,/O with/O an/O overall/O median/O age/O of/O 46/O years/O ./O
Diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction were/O the/O most/O commonly/O reported/O adverse/O reactions/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O for/O subjects/O taking/O OTEZLA/O were/O nausea/B-AdverseReaction (/O 1.6/O %/O )/O ,/O diarrhea/B-AdverseReaction (/O 1.0/O %/O )/O ,/O and/O headache/B-AdverseReaction (/O 0.8/O %/O )/O ./O
The/O proportion/O of/O subjects/O with/O psoriasis/O who/O discontinued/O treatment/O due/O to/O any/O adverse/O reaction/O was/O 6.1/O %/O for/O subjects/O treated/O with/O OTEZLA/O 30/O mg/O twice/O daily/O and/O 4.1/O %/O for/O placebo/O -/O treated/O subjects/O ./O
Table/O 3/O :/O Adverse/O Reactions/O Reported/O in/O 1/O %/O of/O Subjects/O on/O OTEZLA/O and/O With/O Greater/O Frequency/O Than/O in/O Subjects/O on/O Placebo/O ;/O up/O to/O Day/O 112/O (/O Week/O 16/O )/O Two/O subjects/O treated/O with/O OTEZLA/O experienced/O serious/B-Severity adverse/O reaction/O of/O abdominal/B-AdverseReaction pain/I-AdverseReaction ./O
Preferred/O Term/O Placebo/O (/O N=506)n/O (/O %/O )/O OTEZLA/O 30/O mg/O BID/O (/O N=920)n/O (/O %/O )/O Diarrhea/B-AdverseReaction 32/O (/O 6/O )/O 160/O (/O 17/O )/O Nausea/B-AdverseReaction 35/O (/O 7/O )/O 155/O (/O 17/O )/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 31/O (/O 6/O )/O 84/O (/O 9/O )/O Tension/B-AdverseReaction headache/I-AdverseReaction 21/O (/O 4/O )/O 75/O (/O 8)/O Headache/B-AdverseReaction 19/O (/O 4/O )/O 55/O (/O 6/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 11/O (/O 2/O )/O 39/O (/O 4/O )/O Vomiting/B-AdverseReaction 8/O (/O 2/O )/O 35/O (/O 4/O )/O Fatigue/B-AdverseReaction 9/O (/O 2/O )/O 29/O (/O 3/O )/O Dyspepsia/B-AdverseReaction 6/O (/O 1/O )/O 29/O (/O 3/O )/O Decrease/B-AdverseReaction appetite/I-AdverseReaction 5/O (/O 1/O )/O 26/O (/O 3/O )/O Insomnia/B-AdverseReaction 4/O (/O 1/O )/O 21/O (/O 2/O )/O Back/B-AdverseReaction pain/I-AdverseReaction 4/O (/O 1/O )/O 20/O (/O 2/O )/O Migraine/B-AdverseReaction 5/O (/O 1/O )/O 19/O (/O 2/O )/O Frequent/B-AdverseReaction bowel/I-AdverseReaction movements/I-AdverseReaction 1/O (/O 0/O )/O 17/O (/O 2/O )/O Depression/B-AdverseReaction 2/O (/O 0/O )/O 12/O (/O 1/O )/O Bronchitis/B-AdverseReaction 2/O (/O 0/O )/O 12/O (/O 1/O )/O Tooth/B-AdverseReaction abscess/I-AdverseReaction 0/O (/O 0/O )/O 10/O (/O 1/O )/O Folliculitis/B-AdverseReaction 0/O (/O 0/O )/O 9/O (/O 1/O )/O Sinus/B-AdverseReaction headache/I-AdverseReaction 0/O (/O 0/O )/O 9/O (/O 1/O )/O Severe/O worsening/O of/O psoriasis/O (/O rebound/O )/O occurred/O in/O 0.3/O %/O (/O 4/1184/O )/O subjects/O following/O discontinuation/O of/O treatment/O with/O OTEZLA/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Depression/B-AdverseReaction :/O Advise/O patients/O ,/O their/O caregivers/O ,/O and/O families/O to/O be/O alert/O for/O the/O emergence/O or/O worsening/O of/O depression/O ,/O suicidal/O thoughts/O or/O other/O mood/O changes/O and/O if/O such/O changes/O occur/O to/O contact/O their/O healthcare/O provider/O ./O
Carefully/O weigh/O risks/O and/O benefits/O of/O treatment/O with/O OTEZLA/O in/O patients/O with/O a/O history/O of/O depression/O and/or/O suicidal/O thoughts/O or/O behavior/O ./O
(/O 5.1/O )/O Weight/B-AdverseReaction Decrease/I-AdverseReaction :/O Monitor/O weight/O regularly/O ./O
If/O unexplained/O or/O clinically/O significant/O weight/O loss/O occurs/O ,/O evaluate/O weight/O loss/O and/O consider/O discontinuation/O of/O OTEZLA/O (/O 5.2/O )/O Drug/O Interactions/O :/O Use/O with/O strong/O cytochrome/O P450/O enzyme/O inducers/O (/O e.g./O ,/O rifampin/O ,/O phenobarbital/O ,/O carbamazepine/O ,/O phenytoin/O )/O is/O not/O recommended/O because/O loss/O of/O efficacy/O may/O occur/O (/O 5.3,7.1/O )/O 5.1/O Depression/O Treatment/O with/O OTEZLA/O is/O associated/O with/O an/O increase/O in/O adverse/O reactions/O of/O depression/B-AdverseReaction ./O
Before/O using/O OTEZLA/O in/O patients/O with/O a/O history/O of/O depression/O and/or/O suicidal/O thoughts/O or/O behavior/O prescribers/O should/O carefully/O weigh/O the/O risks/O and/O benefits/O of/O treatment/O with/O OTEZLA/O in/O such/O patients/O ./O
Patients/O ,/O their/O caregivers/O ,/O and/O families/O should/O be/O advised/O of/O the/O need/O to/O be/O alert/O for/O the/O emergence/O or/O worsening/O of/O depression/O ,/O suicidal/O thoughts/O or/O other/O mood/O changes/O ,/O and/O if/O such/O changes/O occur/O to/O contact/O their/O healthcare/O provider/O ./O
Prescribers/O should/O carefully/O evaluate/O the/O risks/O and/O benefits/O of/O continuing/O treatment/O with/O OTEZLA/O if/O such/O events/O occur/O ./O
Psoriatic/O arthritis/O :/O During/O the/O 0/O to/O 16/O week/O placebo/O -/O controlled/O period/O of/O the/O 3/O controlled/O clinical/O trials/O ,/O 1.0/O %/O (/O 10/998/O )/O of/O subjects/O treated/O with/O OTEZLA/O reported/O depression/B-AdverseReaction or/O depressed/B-AdverseReaction mood/I-AdverseReaction compared/O to/O 0.8/O %/O (/O 4/495/O )/O treated/O with/O placebo/O ./O
During/O the/O clinical/O trials/O ,/O 0.3/O %/O (/O 4/1441/O )/O of/O subjects/O treated/O with/O OTEZLA/O discontinued/O treatment/O due/O to/O depression/B-AdverseReaction or/O depressed/B-AdverseReaction mood/I-AdverseReaction compared/O with/O none/O in/O placebo/O treated/O subjects/O (/O 0/495/O )/O ./O
Depression/B-AdverseReaction was/O reported/O as/O serious/B-Severity in/O 0.2/O %/O (/O 3/1441/O )/O of/O subjects/O exposed/O to/O OTEZLA/O ,/O compared/O to/O none/O in/O placebo/O -/O treated/O subjects/O (/O 0/495/O )/O ./O
Instances/O of/O suicidal/B-AdverseReaction ideation/I-AdverseReaction and/O behavior/O have/O been/O observed/O in/O 0.2/O %/O (/O 3/1441/O )/O of/O subjects/O while/O receiving/O OTEZLA/O ,/O compared/O to/O none/O in/O placebo/O treated/O subjects/O (/O 0/495/O )/O ./O
In/O the/O clinical/O trials/O ,/O 2/O subjects/O who/O received/O placebo/O committed/O suicide/B-AdverseReaction compared/O to/O none/B-Negation in/O OTEZLA/O -/O treated/O subjects/O ./O
Psoriasis/O :/O During/O the/O 0/O to/O 16/O week/O placebo/O -/O controlled/O period/O of/O the/O 3/O controlled/O clinical/O trials/O ,/O 1.3/O %/O (/O 12/920/O )/O of/O subjects/O treated/O with/O OTEZLA/O reported/O depression/B-AdverseReaction compared/O to/O 0.4/O %/O (/O 2/506/O )/O treated/O with/O placebo/O ./O
During/O the/O clinical/O trials/O ,/O 0.1/O %/O (/O 1/1308/O )/O of/O subjects/O treated/O with/O OTEZLA/O discontinued/O treatment/O due/O to/O depression/B-AdverseReaction compared/O with/O none/O in/O placebo/O -/O treated/O subjects(0/506/O )/O ./O
Depression/B-AdverseReaction was/O reported/O as/O serious/B-Severity in/O 0.1/O %/O (/O 1/1308/O )/O of/O subjects/O exposed/O to/O OTEZLA/O ,/O compared/O to/O none/O in/O placebo/O -/O treated/O subjects/O (/O 0/506/O )/O ./O
Instances/O of/O suicidal/B-AdverseReaction behavior/I-AdverseReaction have/O been/O observed/O in/O 0.1/O %/O (/O 1/1308/O )/O of/O subjects/O while/O receiving/O OTEZLA/O ,/O compared/O to/O 0.2/O %/O (/O 1/506/O )/O in/O placebo/O -/O treated/O subjects/O ./O
In/O the/O clinical/O trials/O ,/O one/O subject/O treated/O with/O OTEZLA/O attempted/B-AdverseReaction suicide/I-AdverseReaction while/O one/O who/O received/O placebo/B-Factor committed/O suicide/B-AdverseReaction ./O
5.2/O Weight/O Decrease/O During/O the/O controlled/O period/O of/O the/O studies/O in/O psoriatic/O arthritis/O (/O PsA/O )/O ,/O weight/B-AdverseReaction decrease/I-AdverseReaction between/O 5%-10/O %/O of/O body/O weight/O was/O reported/O in/O 10/O %/O (/O 49/497/O )/O of/O subjects/O treated/O with/O OTEZLA/O 30/O mg/O twice/O daily/O compared/O to/O 3.3/O %/O (/O 16/495/O )/O treated/O with/O placebo/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
During/O the/O controlled/O period/O of/O the/O trials/O in/O psoriasis/O ,/O weight/B-AdverseReaction decrease/I-AdverseReaction between/B-Severity 5%-10/I-Severity %/I-Severity of/I-Severity body/I-Severity weight/O occurred/O in/O 12/O %/O (/O 96/784/O )/O of/O subjects/O treated/O with/O OTEZLA/O compared/O to/O 5/O %/O (/O 19/382/O )/O treated/O with/O placebo/O ./O
Weight/B-AdverseReaction decrease/I-AdverseReaction of/O 10/B-Severity %/I-Severity of/I-Severity body/I-Severity weight/O occurred/O in/O 2/O %/O (/O 16/784/O )/O of/O subjects/O treated/O with/O OTEZLA/O 30/O mg/O twice/O daily/O compared/O to/O 1/O %/O (/O 3/382/O )/O subjects/O treated/O with/O placebo/O ./O
Patients/O treated/O with/O OTEZLA/O should/O have/O their/O weight/O monitored/O regularly/O ./O
If/O unexplained/O or/O clinically/O significant/O weight/O loss/O occurs/O ,/O weight/O loss/O should/O be/O evaluated/O ,/O and/O discontinuation/O of/O OTEZLA/O should/O be/O considered/O ./O
5.3/O Drug/O Interactions/O Co/O -/O administration/O of/O strong/O cytochrome/O P450/O enzyme/O inducer/O ,/O rifampin/O ,/O resulted/O in/O a/O reduction/O of/O systemic/O exposure/O of/O apremilast/O ,/O which/O may/O result/O in/O a/O loss/O of/O efficacy/O of/O OTEZLA/O ./O
Therefore/O ,/O the/O use/O of/O cytochrome/O P450/O enzyme/O inducers/O (/O e.g./O ,/O rifampin/O ,/O phenobarbital/O ,/O carbamazepine/O ,/O phenytoin/O )/O with/O OTEZLA/O is/O not/O recommended/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O most/O serious/O adverse/O reactions/O reported/O with/O PRADAXA/O were/O related/O to/O bleeding/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 15/O %/O )/O are/O gastritis/B-AdverseReaction -/O like/O symptoms/O and/O bleeding/B-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Boehringer/O Ingelheim/O Pharmaceuticals/O ,/O Inc./O at/O (/O 800/O )/O 542/O -/O 6257/O or/O (/O 800/O )/O 459/O -/O 9906/O TTY/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reactions/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Reduction/O of/O Risk/O of/O Stroke/O and/O Systemic/O Embolism/O in/O Non/O -/O valvular/O Atrial/O Fibrillation/O The/O RE/O -/O LY/O (/O Randomized/O Evaluation/O of/O Long/O -/O term/O Anticoagulant/O Therapy/O )/O study/O provided/O safety/O information/O on/O the/O use/O of/O two/O doses/O of/O PRADAXA/O and/O warfarin/O [/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
The/O numbers/O of/O patients/O and/O their/O exposures/O are/O described/O in/O Table/O 1/O ./O
Limited/O information/O is/O presented/O on/O the/O 110/O mg/O dosing/O arm/O because/O this/O dose/O is/O not/O approved/O ./O
Table/O 1/O Summary/O of/O Treatment/O Exposure/O in/O RE/O -/O LY/O PRADAXA/O 110/O mg/O twice/O daily/O PRADAXA/O 150/O mg/O twice/O daily/O Warfarin/O Total/O number/O treated/O 5983/O 6059/O 5998/O Exposure/O 12/O months/O 4936/O 4939/O 5193/O 24/O months/O 2387/O 2405/O 2470/O Mean/O exposure/O (/O months/O )/O 20.5/O 20.3/O 21.3/O Total/O patient/O -/O years/O 10,242/O 10,261/O 10,659/O Drug/O Discontinuation/O in/O RE/O -/O LY/O The/O rates/O of/O adverse/O reactions/O leading/O to/O treatment/O discontinuation/O were/O 21/O %/O for/O PRADAXA/O 150/O mg/O and/O 16/O %/O for/O warfarin/O ./O
The/O most/O frequent/O adverse/O reactions/O leading/O to/O discontinuation/O of/O PRADAXA/O were/O bleeding/B-AdverseReaction and/O gastrointestinal/B-AdverseReaction events/I-AdverseReaction (/O i.e./O ,/O dyspepsia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction ,/O gastrointestinal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction )/O ./O
Bleeding/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Table/O 2/O shows/O the/O number/O of/O adjudicated/O major/B-Severity bleeding/B-AdverseReaction events/O during/O the/O treatment/O period/O in/O the/O RE/O -/O LY/O study/O ,/O with/O the/O bleeding/B-AdverseReaction rate/O per/O 100/O subject/O -/O years/O (/O %/O )/O ./O
Major/B-Severity bleeding/B-AdverseReaction is/O defined/O as/O bleeding/B-AdverseReaction accompanied/O by/O one/O or/O more/O of/O the/O following/O :/O a/O decrease/B-AdverseReaction in/I-AdverseReaction hemoglobin/I-AdverseReaction of/O 2/B-Severity g/I-Severity dL/O ,/O a/O transfusion/O of/O 2/O units/O of/O packed/O red/O blood/O cells/O ,/O bleeding/B-AdverseReaction at/I-AdverseReaction a/I-AdverseReaction critical/I-AdverseReaction site/I-AdverseReaction or/O with/O a/O fatal/B-AdverseReaction outcome/O ./O
Intracranial/B-AdverseReaction hemorrhage/I-AdverseReaction included/O intracerebral/O (/O hemorrhagic/B-AdverseReaction stroke/I-AdverseReaction )/O ,/O subarachnoid/O ,/O and/O subdural/B-AdverseReaction bleeds/I-AdverseReaction ./O
Table/O 2/O Adjudicated/O Major/B-Severity Bleeding/B-AdverseReaction Events/O in/O Treated/O Patientsa/O aPatients/O during/O treatment/O or/O within/O 2/O days/O of/O stopping/O study/O treatment/O ./O
Major/B-Severity bleeding/B-AdverseReaction events/O within/O each/O subcategory/O were/O counted/O once/O per/O patient/O ,/O but/O patients/O may/O have/O contributed/O events/O to/O multiple/O subcategories/O ./O
bAnnual/O event/O rate/O per/O 100/O pt/O -/O years/O 100/O number/O of/O subjects/O with/O event/O subject/O -/O years/O ./O
Subject/O -/O years/O is/O defined/O as/O cumulative/O number/O of/O days/O from/O first/O drug/O intake/O to/O event/O date/O ,/O date/O of/O last/O drug/O intake/O +/O 2/O ,/O death/O date/O (/O whatever/O occurred/O first/O )/O across/O all/O treated/O subjects/O divided/O by/O 365.25/O ./O
In/O case/O of/O recurrent/O events/O of/O the/O same/O category/O ,/O the/O first/O event/O was/O considered/O ./O
cDefined/O as/O bleeding/B-AdverseReaction accompanied/O by/O one/O or/O more/O of/O the/O following/O :/O a/O decrease/B-AdverseReaction in/I-AdverseReaction hemoglobin/I-AdverseReaction of/O 2/B-Severity g/I-Severity dL/O ,/O a/O transfusion/O of/O 2/O or/O more/O units/O of/O packed/O red/O blood/O cells/O ,/O bleeding/B-AdverseReaction at/I-AdverseReaction a/I-AdverseReaction critical/I-AdverseReaction site/I-AdverseReaction or/O with/O fatal/B-AdverseReaction outcome/O ./O
dIntracranial/O bleed/O included/O intracerebral/O (/O hemorrhagic/B-AdverseReaction stroke/I-AdverseReaction )/O ,/O subarachnoid/O ,/O and/O subdural/B-AdverseReaction bleeds/I-AdverseReaction ./O
eOn/O -/O treatment/O analysis/O based/O on/O the/O safety/O population/O ,/O compared/O to/O ITT/O analysis/O presented/O in/O Section/O 14/O Clinical/O Studies/O ./O
fFatal/O bleed/B-AdverseReaction :/O Adjudicated/O major/B-Severity bleed/B-AdverseReaction as/O defined/O above/O with/O investigator/O reported/O fatal/B-AdverseReaction outcome/O and/O adjudicated/O death/B-AdverseReaction with/O primary/O cause/O from/O bleeding/B-AdverseReaction ./O
gNon/O -/O intracranial/O fatal/B-AdverseReaction bleed/O :/O Adjudicated/O major/B-Severity bleed/B-AdverseReaction as/O defined/O above/O and/O adjudicated/O death/B-AdverseReaction with/O primary/O cause/O from/O bleeding/B-AdverseReaction but/O without/B-Negation symptomatic/B-AdverseReaction intracranial/I-AdverseReaction bleed/I-AdverseReaction based/O on/O investigator/O 's/O clinical/O assessment/O ./O
Event/O PRADAXA/O 150/O mgN/O 6059n/O (/O %/O /year/O b/O )/O WarfarinN/O 5998n/O (/O %/O /year/O b/O )/O PRADAXA/O 150/O mgvs/O ./O
WarfarinHR/O (/O 95/O %/O CI/O )/O Major/B-Severity Bleeding/B-AdverseReaction c/O 350/O (/O 3.47/O )/O 374/O (/O 3.58/O )/O 0.97/O (/O 0.84/O ,/O 1.12/O )/O Intracranial/B-AdverseReaction Hemorrhage/I-AdverseReaction (/O ICH/B-AdverseReaction )/O d/O 23/O (/O 0.22/O )/O 82/O (/O 0.77/O )/O 0.29/O (/O 0.18/O ,/O 0.46/O )/O Hemorrhagic/B-AdverseReaction Stroke/I-AdverseReaction e/O 6/O (/O 0.06/O )/O 40/O (/O 0.37/O )/O 0.16/O (/O 0.07/O ,/O 0.37/O )/O Other/O ICH/B-AdverseReaction 17/O (/O 0.17/O )/O 46/O (/O 0.43/O )/O 0.38/O (/O 0.22/O ,/O 0.67/O )/O Gastrointestinal/O 162/O (/O 1.59/O )/O 111/O (/O 1.05/O )/O 1.51/O (/O 1.19/O ,/O 1.92/O )/O Fatal/B-AdverseReaction Bleeding/B-AdverseReaction f/O 7/O (/O 0.07/O )/O 16/O (/O 0.15/O )/O 0.45/O (/O 0.19/O ,/O 1.10/O )/O ICH/B-AdverseReaction 3/O (/O 0.03/O )/O 9/O (/O 0.08/O )/O 0.35/O (/O 0.09/O ,/O 1.28/O )/O Non/O -/O intracranial/O g/O 4/O (/O 0.04/O )/O 7/O (/O 0.07/O )/O 0.59/O (/O 0.17/O ,/O 2.02/O )/O There/O was/O a/O higher/O rate/O of/O any/O gastrointestinal/B-AdverseReaction bleeds/I-AdverseReaction in/O patients/O receiving/O PRADAXA/O 150/O mg/O than/O in/O patients/O receiving/O warfarin/O (/O 6.6/O %/O vs./O 4.2/O %/O ,/O respectively/O )/O ./O
The/O risk/B-Factor of/O major/B-Severity bleeds/B-AdverseReaction was/O similar/O with/O PRADAXA/O 150/O mg/O and/O warfarin/O across/O major/O subgroups/O defined/O by/O baseline/O characteristics/O (/O see/O Figure/O 1/O )/O ,/O with/O the/O exception/O of/O age/O ,/O where/O there/O was/O a/O trend/O towards/O a/O higher/O incidence/O of/O major/B-Severity bleeding/B-AdverseReaction on/O PRADAXA/O (/O hazard/O ratio/O 1.2/O ,/O 95/O %/O CI/O :/O 1.0/O to/O 1.5/O )/O for/O patients/O 75/O years/O of/O age/O ./O
Figure/O 1/O Adjudicated/O Major/B-Severity Bleeding/B-AdverseReaction by/O Baseline/O Characteristics/O Including/O Hemorrhagic/O Stroke/O Treated/O Patients/O Note/O :/O The/O figure/O above/O presents/O effects/O in/O various/O subgroups/O all/O of/O which/O are/O baseline/O characteristics/O and/O all/O of/O which/O were/O pre/O -/O specified/O ./O
The/O 95/O %/O confidence/O limits/O that/O are/O shown/O do/O not/O take/O into/O account/O how/O many/O comparisons/O were/O made/O ,/O nor/O do/O they/O reflect/O the/O effect/O of/O a/O particular/O factor/O after/O adjustment/O for/O all/O other/O factors/O ./O
Apparent/O homogeneity/O or/O heterogeneity/O among/O groups/O should/O not/O be/O over/O -/O interpreted/O ./O
Figure/O 1/O Gastrointestinal/O Adverse/O Reactions/O Patients/O on/O PRADAXA/O 150/O mg/O had/O an/O increased/O incidence/O of/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction (/O 35/O %/O vs./O 24/O %/O on/O warfarin/O )/O ./O
These/O were/O commonly/O dyspepsia/B-AdverseReaction (/O including/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ,/O and/O epigastric/B-AdverseReaction discomfort/I-AdverseReaction )/O and/O gastritis/B-AdverseReaction -/O like/O symptoms/O (/O including/O GERD/B-AdverseReaction ,/O esophagitis/B-AdverseReaction ,/O erosive/B-AdverseReaction gastritis/I-AdverseReaction ,/O gastric/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O hemorrhagic/B-AdverseReaction gastritis/I-AdverseReaction ,/O hemorrhagic/B-AdverseReaction erosive/I-AdverseReaction gastritis/I-AdverseReaction ,/O and/O gastrointestinal/B-AdverseReaction ulcer/I-AdverseReaction )/O ./O
Hypersensitivity/O Reactions/O In/O the/O RE/O -/O LY/O study/O ,/O drug/O hypersensitivity/B-AdverseReaction (/O including/O urticaria/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O pruritus/B-AdverseReaction )/O ,/O allergic/B-AdverseReaction edema/I-AdverseReaction ,/O anaphylactic/B-AdverseReaction reaction/I-AdverseReaction ,/O and/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction were/O reported/O in/O 0.1/O %/O of/O patients/O receiving/O PRADAXA/O ./O
Treatment/O and/O Reduction/O in/O the/O Risk/O of/O Recurrence/O of/O Deep/O Venous/O Thrombosis/O and/O Pulmonary/O Embolism/O PRADAXA/O was/O studied/O in/O 4387/O patients/O in/O 4/O pivotal/O ,/O parallel/O ,/O randomized/O ,/O double/O -/O blind/O trials/O ./O
Three/O of/O these/O trials/O were/O active/O -/O controlled/O (/O warfarin/O )/O (/O RE/O -/O COVER/O ,/O RE/O -/O COVER/O II/O ,/O and/O RE/O -/O MEDY/O )/O ,/O and/O one/O study/O (/O RE/O -/O SONATE/O )/O was/O placebo/O -/O controlled/O ./O
The/O demographic/O characteristics/O were/O similar/O among/O the/O 4/O pivotal/O studies/O and/O between/O the/O treatment/O groups/O within/O these/O studies/O ./O
Approximately/O 60/O %/O of/O the/O treated/O patients/O were/O male/O ,/O with/O a/O mean/O age/O of/O 55.1/O years/O ./O
The/O majority/O of/O the/O patients/O were/O white/O (/O 87.7/O %/O )/O ,/O 10.3/O %/O were/O Asian/O ,/O and/O 1.9/O %/O were/O black/O with/O a/O mean/O CrCl/O of/O 105.6/O mL/O min/O ./O
Bleeding/B-AdverseReaction events/O for/O the/O 4/O pivotal/O studies/O were/O classified/O as/O major/B-Severity bleeding/B-AdverseReaction events/O if/O at/O least/O one/O of/O the/O following/O criteria/O applied/O :/O fatal/B-AdverseReaction bleeding/B-AdverseReaction ,/O symptomatic/B-AdverseReaction bleeding/I-AdverseReaction in/I-AdverseReaction a/I-AdverseReaction critical/I-AdverseReaction area/I-AdverseReaction or/O organ/O (/O intraocular/O ,/O intracranial/O ,/O intraspinal/O or/O intramuscular/O with/O compartment/B-AdverseReaction syndrome/I-AdverseReaction ,/O retroperitoneal/B-AdverseReaction bleeding/I-AdverseReaction ,/O intra/B-AdverseReaction -/I-AdverseReaction articular/O bleeding/O ,/O or/O pericardial/B-AdverseReaction bleeding/I-AdverseReaction )/O ,/O bleeding/B-AdverseReaction causing/O a/O fall/B-AdverseReaction in/I-AdverseReaction hemoglobin/I-AdverseReaction level/I-AdverseReaction of/O 2.0/B-Severity g/I-Severity dL/O (/O 1.24/O mmol/O L/O or/O more/O ,/O or/O leading/O to/O transfusion/O of/O 2/O or/O more/O units/O of/O whole/O blood/O or/O red/O cells/O )/O ./O
RE/O -/O COVER/O and/O RE/O -/O COVER/O II/O studies/O compared/O PRADAXA/O 150/O mg/O twice/O daily/O and/O warfarin/O for/O the/O treatment/O of/O deep/O vein/O thrombosis/O and/O pulmonary/O embolism/O ./O
Patients/O received/O 5/O -/O 10/O days/O of/O an/O approved/O parenteral/O anticoagulant/O therapy/O followed/O by/O 6/O months/O ,/O with/O mean/O exposure/O of/O 164/O days/O ,/O of/O oral/O only/O treatment/O ;/O warfarin/O was/O overlapped/O with/O parenteral/O therapy/O ./O
Table/O 3/O shows/O the/O number/O of/O patients/O experiencing/O bleeding/B-AdverseReaction events/O in/O the/O pooled/O analysis/O of/O RE/O -/O COVER/O and/O RE/O -/O COVER/O II/O studies/O during/O the/O full/O treatment/O including/O parenteral/O and/O oral/O only/O treatment/O periods/O after/O randomization/O ./O
Table/O 3/O Bleeding/B-AdverseReaction Events/O in/O RE/O -/O COVER/O and/O RE/O -/O COVER/O II/O Treated/O Patients/O Note/O :/O MBE/B-AdverseReaction can/O belong/O to/O more/O than/O one/O criterion/O ./O
a/O Patients/O with/O at/O least/O one/O MBE/B-AdverseReaction ./O
b/O Bleeding/B-AdverseReaction site/O based/O on/O investigator/O assessment/O ./O
Patients/O can/O have/O more/O than/O one/O site/O of/O bleeding/B-AdverseReaction ./O
c/O Confidence/O interval/O Patients/O Major/B-Severity bleeding/B-AdverseReaction event/O a/O Bleeding/B-AdverseReaction sites/O for/O MBE/B-AdverseReaction b/O Clinically/O relevant/O non/B-Severity -/O major/O bleeding/B-AdverseReaction Any/O bleeding/B-AdverseReaction The/O rate/O of/O any/O gastrointestinal/B-AdverseReaction bleeds/I-AdverseReaction in/O patients/O receiving/O PRADAXA/O 150/O mg/O in/O the/O full/O treatment/O period/O was/O 3.1/O %/O (/O 2.4/O %/O on/O warfarin/O )/O ./O
The/O RE/O -/O MEDY/O and/O RE/O -/O SONATE/O studies/O provided/O safety/O information/O on/O the/O use/O of/O PRADAXA/O for/O the/O reduction/O in/O the/O risk/O of/O recurrence/O of/O deep/O vein/O thrombosis/O and/O pulmonary/O embolism/O ./O
RE/O -/O MEDY/O was/O an/O active/O -/O controlled/O study/O (/O warfarin/O )/O in/O which/O 1430/O patients/O received/O PRADAXA/O 150/O mg/O twice/O daily/O following/O 3/O to/O 12/O months/O of/O oral/O anticoagulant/O regimen/O ./O
Patients/O in/O the/O treatment/O studies/O who/O rolled/O over/O into/O the/O RE/O -/O MEDY/O study/O had/O a/O combined/O treatment/O duration/O of/O up/O to/O more/O than/O 3/O years/O ,/O with/O mean/O exposure/O of/O 473/O days/O ./O
Table/O 4/O shows/O the/O number/O of/O patients/O experiencing/O bleeding/B-AdverseReaction events/O in/O the/O study/O ./O
Table/O 4/O Bleeding/B-AdverseReaction Events/O in/O RE/O -/O MEDY/O Treated/O Patients/O Note/O :/O MBE/B-AdverseReaction can/O belong/O to/O more/O than/O one/O criterion/O ./O
a/O Patients/O with/O at/O least/O one/O MBE/B-AdverseReaction ./O
b/O Bleeding/B-AdverseReaction site/O based/O on/O investigator/O assessment/O ./O
Patients/O can/O have/O more/O than/O one/O site/O of/O bleeding/B-AdverseReaction ./O
c/O Confidence/O interval/O Patients/O Major/B-Severity bleeding/B-AdverseReaction event/O a/O Bleeding/B-AdverseReaction sites/O for/O MBE/B-AdverseReaction b/O Clinically/O relevant/O non/B-Severity -/O major/O bleeding/B-AdverseReaction Any/O bleeding/B-AdverseReaction In/O the/O RE/O -/O MEDY/O study/O ,/O the/O rate/O of/O any/O gastrointestinal/B-AdverseReaction bleeds/I-AdverseReaction in/O patients/O receiving/O PRADAXA/O 150/O mg/O was/O 3.1/O %/O (/O 2.2/O %/O on/O warfarin/O )/O ./O
RE/O -/O SONATE/O was/O a/O placebo/O -/O controlled/O study/O in/O which/O 684/O patients/O received/O PRADAXA/O 150/O mg/O twice/O daily/O following/O 6/O to/O 18/O months/O of/O oral/O anticoagulant/O regimen/O ./O
Patients/O in/O the/O treatment/O studies/O who/O rolled/O over/O into/O the/O RE/O -/O SONATE/O study/O had/O combined/O treatment/O duration/O up/O to/O 9/O months/O ,/O with/O mean/O exposure/O of/O 165/O days/O ./O
Table/O 5/O shows/O the/O number/O of/O patients/O experiencing/O bleeding/B-AdverseReaction events/O in/O the/O study/O ./O
Table/O 5/O Bleeding/B-AdverseReaction Events/O in/O RE/O -/O SONATE/O Treated/O Patients/O Note/O :/O MBE/B-AdverseReaction can/O belong/O to/O more/O than/O one/O criterion/O ./O
a/O Patients/O with/O at/O least/O one/O MBE/B-AdverseReaction ./O
b/O Bleeding/B-AdverseReaction site/O based/O on/O investigator/O assessment/O ./O
Patients/O can/O have/O more/O than/O one/O site/O of/O bleeding/B-AdverseReaction ./O
c/O Confidence/O interval/O Patients/O Major/B-Severity bleeding/B-AdverseReaction event/O a/O Clinically/O relevant/O non/B-Severity -/O major/O bleeding/B-AdverseReaction Any/O bleeding/B-AdverseReaction In/O the/O RE/O -/O SONATE/O study/O ,/O the/O rate/O of/O any/O gastrointestinal/B-AdverseReaction bleeds/I-AdverseReaction in/O patients/O receiving/O PRADAXA/O 150/O mg/O was/O 0.7/O %/O (/O 0.3/O %/O on/O placebo/O )/O ./O
Clinical/O Myocardial/O Infarction/O Events/O In/O the/O active/O -/O controlled/O VTE/O studies/O ,/O a/O higher/O rate/O of/O clinical/O myocardial/B-AdverseReaction infarction/I-AdverseReaction was/O reported/O in/O patients/O who/O received/O PRADAXA/O [/O 20/O (/O 0.66/O per/O 100/O patient/O -/O years/O )/O ]/O than/O in/O those/O who/O received/O warfarin/O [/O 5/O (/O 0.17/O per/O 100/O patient/O -/O years/O )/O ]/O ./O
In/O the/O placebo/O -/O controlled/O study/O ,/O a/O similar/O rate/O of/O non/B-Severity -/O fatal/O and/O fatal/B-AdverseReaction clinical/O myocardial/B-AdverseReaction infarction/I-AdverseReaction was/O reported/O in/O patients/O who/O received/O PRADAXA/O [/O 1/O (/O 0.32/O per/O 100/O patient/O -/O years/O )/O ]/O and/O in/O those/O who/O received/O placebo/O [/O 1/O (/O 0.34/O per/O 100/O patient/O -/O years/O )/O ]/O ./O
Gastrointestinal/O Adverse/O Reactions/O In/O the/O four/O pivotal/O studies/O ,/O patients/O on/O PRADAXA/O 150/O mg/O had/O a/O similar/O incidence/O of/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction (/O 24.7/O %/O vs./O 22.7/O %/O on/O warfarin/O )/O ./O
Dyspepsia/B-AdverseReaction (/O including/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ,/O and/O epigastric/B-AdverseReaction discomfort/I-AdverseReaction )/O occurred/O in/O patients/O on/O PRADAXA/O in/O 7.5/O %/O vs./O 5.5/O %/O on/O warfarin/O ,/O and/O gastritis/B-AdverseReaction -/O like/O symptoms/O (/O including/O gastritis/B-AdverseReaction ,/O GERD/B-AdverseReaction ,/O esophagitis/B-AdverseReaction ,/O erosive/B-AdverseReaction gastritis/I-AdverseReaction and/O gastric/B-AdverseReaction hemorrhage/I-AdverseReaction )/O occurred/O at/O 3.0/O %/O vs./O 1.7/O %/O ,/O respectively/O ./O
Hypersensitivity/O Reactions/O In/O the/O 4/O pivotal/O studies/O ,/O drug/O hypersensitivity/B-AdverseReaction (/O including/O urticaria/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O pruritus/B-AdverseReaction )/O ,/O allergic/B-AdverseReaction edema/I-AdverseReaction ,/O anaphylactic/B-AdverseReaction reaction/I-AdverseReaction ,/O and/O anaphylactic/B-AdverseReaction shock/I-AdverseReaction were/O reported/O in/O 0.1/O %/O of/O patients/O receiving/O PRADAXA/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O PRADAXA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O PRADAXA/O :/O angioedema/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O esophageal/B-AdverseReaction ulcer/I-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O PRADAXA/O INCREASES/O THE/O RISK/O OF/O THROMBOTIC/O EVENTS/O ,/O (/O B/O )/O SPINAL/O EPIDURAL/B-AdverseReaction HEMATOMA/I-AdverseReaction WARNING/O :/O (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O PRADAXA/O INCREASES/O THE/O RISK/O OF/O THROMBOTIC/O EVENTS/O ,/O (/O B/O )/O SPINAL/O EPIDURAL/B-AdverseReaction HEMATOMA/I-AdverseReaction (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O PRADAXA/O INCREASES/O THE/O RISK/O OF/O THROMBOTIC/O EVENTSPremature/O discontinuation/O of/O any/O oral/O anticoagulant/O ,/O including/O PRADAXA/O ,/O increases/O the/O risk/O of/O thrombotic/O events/O ./O
If/O anticoagulation/O with/O PRADAXA/O is/O discontinued/O for/O a/O reason/O other/O than/O pathological/O bleeding/O or/O completion/O of/O a/O course/O of/O therapy/O ,/O consider/O coverage/O with/O another/O anticoagulant/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O ,/O 2.5/O ,/O 2.6/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
(/O B/O )/O SPINAL/O EPIDURAL/O HEMATOMAEpidural/O or/O spinal/B-AdverseReaction hematomas/I-AdverseReaction may/B-Factor occur/O in/O patients/O treated/O with/O PRADAXA/O who/O are/O receiving/O neuraxial/O anesthesia/O or/O undergoing/O spinal/O puncture/O ./O
These/O hematomas/B-AdverseReaction may/B-Factor result/O in/O long/O -/O term/O or/O permanent/B-AdverseReaction paralysis/O ./O
Consider/O these/O risks/O when/O scheduling/O patients/O for/O spinal/O procedures/O ./O
Factors/O that/O can/O increase/O the/O risk/O of/O developing/O epidural/O or/O spinal/O hematomas/O in/O these/O patients/O include/O :/O use/O of/O indwelling/O epidural/O catheters/O concomitant/O use/O of/O other/O drugs/O that/O affect/O hemostasis/O ,/O such/O as/O non/O -/O steroidal/O anti/O -/O inflammatory/O drugs/O (/O NSAIDs/O )/O ,/O platelet/O inhibitors/O ,/O other/O anticoagulants/O a/O history/O of/O traumatic/O or/O repeated/O epidural/O or/O spinal/O punctures/O a/O history/O of/O spinal/O deformity/O or/O spinal/O surgery/O optimal/O timing/O between/O the/O administration/O of/O PRADAXA/O and/O neuraxial/O procedures/O is/O not/O known/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Monitor/O patients/O frequently/O for/O signs/O and/O symptoms/O of/O neurological/O impairment/O ./O
If/O neurological/O compromise/O is/O noted/O ,/O urgent/O treatment/O is/O necessary/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O .Consider/O the/O benefits/O and/O risks/O before/O neuraxial/O intervention/O in/O patients/O anticoagulated/O or/O to/O be/O anticoagulated/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O PRADAXA/O INCREASES/O THE/O RISK/O OF/O THROMBOTIC/O EVENTS/O ,/O and/O (/O B/O )/O SPINAL/O EPIDURAL/B-AdverseReaction HEMATOMA/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O (/O A/O )/O PREMATURE/O DISCONTINUATION/O OF/O PRADAXA/O INCREASES/O THE/O RISK/O OF/O THROMBOTIC/O EVENTS/O :/O Premature/O discontinuation/O of/O any/O oral/O anticoagulant/O ,/O including/O PRADAXA/O ,/O increases/O the/O risk/O of/O thrombotic/O events/O ./O
To/O reduce/O this/O risk/O ,/O consider/O coverage/O with/O another/O anticoagulant/O if/O PRADAXA/O is/O discontinued/O for/O a/O reason/O other/O than/O pathological/O bleeding/O or/O completion/O of/O a/O course/O of/O therapy/O (/O 2.4/O ,/O 2.5/O ,/O 2.6/O ,/O 5.1/O )/O ./O
(/O B/O )/O SPINAL/O EPIDURAL/O HEMATOMA/O :/O Epidural/O or/O spinal/B-AdverseReaction hematomas/I-AdverseReaction may/B-Factor occur/O in/O patients/O treated/O with/O PRADAXA/O who/O are/O receiving/O neuraxial/O anesthesia/O or/O undergoing/O spinal/O puncture/O ./O
These/O hematomas/B-AdverseReaction may/B-Factor result/O in/O long/O -/O term/O or/O permanent/B-AdverseReaction paralysis/I-AdverseReaction (/O 5.3/O )/O ./O
Monitor/O patients/O frequently/O for/O signs/O and/O symptoms/O of/O neurological/O impairment/O and/O if/O observed/O ,/O treat/O urgently/O ./O
Consider/O the/O benefits/O and/O risks/O before/O neuraxial/O intervention/O in/O patients/O who/O are/O or/O who/O need/O to/O be/O anticoagulated/O (/O 5.3/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Bleeding/B-AdverseReaction :/O PRADAXA/O can/B-Factor cause/O serious/B-Severity and/O fatal/B-AdverseReaction bleeding/B-AdverseReaction (/O 5.2/O )/O Bioprosthetic/O heart/O valves/O :/O PRADAXA/O use/O not/O recommended/O (/O 5.4/O )/O 5.1/O Increased/O Risk/O of/O Thrombotic/O Events/O after/O Premature/O Discontinuation/O Premature/O discontinuation/O of/O any/O oral/O anticoagulant/O ,/O including/O PRADAXA/O ,/O in/O the/O absence/O of/O adequate/O alternative/O anticoagulation/O increases/O the/O risk/O of/O thrombotic/O events/O ./O
If/O PRADAXA/O is/O discontinued/O for/O a/O reason/O other/O than/O pathological/O bleeding/O or/O completion/O of/O a/O course/O of/O therapy/O ,/O consider/O coverage/O with/O another/O anticoagulant/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O ,/O 2.5/O ,/O 2.6/O )/O ]/O ./O
5.2/O Risk/O of/O Bleeding/O PRADAXA/O increases/O the/O risk/B-Factor of/O bleeding/B-AdverseReaction and/O can/B-Factor cause/O significant/B-Severity and/O ,/O sometimes/O ,/O fatal/B-AdverseReaction bleeding/B-AdverseReaction ./O
Promptly/O evaluate/O any/O signs/O or/O symptoms/O of/O blood/O loss/O (/O e.g./O ,/O a/O drop/O in/O hemoglobin/O and/or/O hematocrit/O or/O hypotension/O )/O ./O
Discontinue/O PRADAXA/O in/O patients/O with/O active/O pathological/O bleeding/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Risk/O factors/O for/O bleeding/O include/O the/O concomitant/O use/O of/O other/O drugs/O that/O increase/O the/O risk/O of/O bleeding/O (/O e.g./O ,/O anti/O -/O platelet/O agents/O ,/O heparin/O ,/O fibrinolytic/O therapy/O ,/O and/O chronic/O use/O of/O NSAIDs/O )/O ./O
PRADAXA/O 's/O anticoagulant/O activity/O and/O half/O -/O life/O are/O increased/O in/O patients/O with/O renal/O impairment/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
Reversal/O of/O Anticoagulant/O Effect/O :/O A/O specific/O reversal/O agent/O for/O dabigatran/O is/O not/O available/O ./O
Hemodialysis/O can/O remove/O dabigatran/O ;/O however/O the/O clinical/O experience/O supporting/O the/O use/O of/O hemodialysis/O as/O a/O treatment/O for/O bleeding/O is/O limited/O [/O see/O Overdosage/O (/O 10/O )/O ]/O ./O
Activated/O prothrombin/O complex/O concentrates/O (/O aPCCs/O ,/O e.g./O ,/O FEIBA/O )/O ,/O or/O recombinant/O Factor/O VIIa/O ,/O or/O concentrates/O of/O coagulation/O factors/O II/O ,/O IX/O or/O X/O may/O be/O considered/O but/O their/O use/O has/O not/O been/O evaluated/O in/O clinical/O trials/O ./O
Protamine/O sulfate/O and/O vitamin/O K/O are/O not/O expected/O to/O affect/O the/O anticoagulant/O activity/O of/O dabigatran/O ./O
Consider/O administration/O of/O platelet/O concentrates/O in/O cases/O where/O thrombocytopenia/O is/O present/O or/O long/O -/O acting/O antiplatelet/O drugs/O have/O been/O used/O ./O
5.3/O Spinal/O Epidural/O Anesthesia/O or/O Puncture/O When/O neuraxial/O anesthesia/O (/O spinal/O epidural/O anesthesia/O )/O or/O spinal/O puncture/O is/O employed/O ,/O patients/O treated/O with/O anticoagulant/B-DrugClass agents/I-DrugClass are/O at/O risk/O of/O developing/O an/O epidural/O or/O spinal/B-AdverseReaction hematoma/I-AdverseReaction which/O can/O result/O in/O long/O -/O term/O or/O permanent/B-AdverseReaction paralysis/B-AdverseReaction [/O see/O Boxed/O Warning/O ]/O ./O
To/O reduce/O the/O potential/O risk/O of/O bleeding/O associated/O with/O the/O concurrent/O use/O of/O dabigatran/O and/O epidural/O or/O spinal/O anesthesia/O analgesia/O or/O spinal/O puncture/O ,/O consider/O the/O pharmacokinetic/O profile/O of/O dabigatran/O [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
Placement/O or/O removal/O of/O an/O epidural/O catheter/O or/O lumbar/O puncture/O is/O best/O performed/O when/O the/O anticoagulant/O effect/O of/O dabigatran/O is/O low/O ;/O however/O ,/O the/O exact/O timing/O to/O reach/O a/O sufficiently/O low/O anticoagulant/O effect/O in/O each/O patient/O is/O not/O known/O ./O
Should/O the/O physician/O decide/O to/O administer/O anticoagulation/O in/O the/O context/O of/O epidural/O or/O spinal/O anesthesia/O analgesia/O or/O lumbar/O puncture/O ,/O monitor/O frequently/O to/O detect/O any/O signs/O or/O symptoms/O of/O neurological/O impairment/O ,/O such/O as/O midline/O back/O pain/O ,/O sensory/O and/O motor/O deficits/O (/O numbness/O ,/O tingling/O ,/O or/O weakness/O in/O lower/O limbs/O )/O ,/O bowel/O and/or/O bladder/O dysfunction/O ./O
Instruct/O patients/O to/O immediately/O report/O if/O they/O experience/O any/O of/O the/O above/O signs/O or/O symptoms/O ./O
If/O signs/O or/O symptoms/O of/O spinal/O hematoma/O are/O suspected/O ,/O initiate/O urgent/O diagnosis/O and/O treatment/O including/O consideration/O for/O spinal/O cord/O decompression/O even/O though/O such/O treatment/O may/O not/O prevent/O or/O reverse/O neurological/O sequelae/O ./O
5.4/O Thromboembolic/O and/O Bleeding/O Events/O in/O Patients/O with/O Prosthetic/O Heart/O Valves/O The/O safety/O and/O efficacy/O of/O PRADAXA/O in/O patients/O with/O bileaflet/O mechanical/O prosthetic/O heart/O valves/O was/O evaluated/O in/O the/O RE/O -/O ALIGN/O trial/O ,/O in/O which/O patients/O with/O bileaflet/O mechanical/O prosthetic/O heart/O valves/O (/O recently/O implanted/O or/O implanted/O more/O than/O three/O months/O prior/O to/O enrollment/O )/O were/O randomized/O to/O dose/O adjusted/O warfarin/O or/O 150/O ,/O 220/O ,/O or/O 300/O mg/O of/O PRADAXA/O twice/O a/O day/O ./O
RE/O -/O ALIGN/O was/O terminated/O early/O due/O to/O the/O occurrence/O of/O significantly/O more/O thromboembolic/B-AdverseReaction events/I-AdverseReaction (/O valve/O thrombosis/O ,/O stroke/O ,/O transient/B-AdverseReaction ischemic/I-AdverseReaction attack/I-AdverseReaction ,/O and/O myocardial/B-AdverseReaction infarction/I-AdverseReaction )/O and/O an/O excess/O of/O major/B-Severity bleeding/B-AdverseReaction (/O predominantly/O post/O -/O operative/O pericardial/B-AdverseReaction effusions/I-AdverseReaction requiring/O intervention/O for/O hemodynamic/O compromise/O )/O in/O the/O PRADAXA/O treatment/O arm/O as/O compared/O to/O the/O warfarin/O treatment/O arm/O ./O
These/O bleeding/B-AdverseReaction and/O thromboembolic/B-AdverseReaction events/I-AdverseReaction were/O seen/O both/O in/O patients/O who/O were/O initiated/O on/O PRADAXA/O post/O -/O operatively/O within/O three/O days/O of/O mechanical/O bileaflet/O valve/O implantation/O ,/O as/O well/O as/O in/O patients/O whose/O valves/O had/O been/O implanted/O more/O than/O three/O months/O prior/O to/O enrollment/O ./O
Therefore/O ,/O the/O use/O of/O PRADAXA/O is/O contraindicated/O in/O patients/O with/O mechanical/O prosthetic/O valves/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
The/O use/O of/O PRADAXA/O for/O the/O prophylaxis/O of/O thromboembolic/O events/O in/O patients/O with/O atrial/O fibrillation/O in/O the/O setting/O of/O other/O forms/O of/O valvular/O heart/O disease/O ,/O including/O the/O presence/O of/O a/O bioprosthetic/O heart/O valve/O ,/O has/O not/O been/O studied/O and/O is/O not/O recommended/O ./O
5.5/O Effect/O of/O P/O -/O gp/O Inducers/O and/O Inhibitors/O on/O Dabigatran/O Exposure/O The/O concomitant/O use/O of/O PRADAXA/O with/O P/O -/O gp/O inducers/O (/O e.g./O ,/O rifampin/O )/O reduces/O exposure/O to/O dabigatran/O and/O should/O generally/O be/O avoided/O [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
P/O -/O gp/O inhibition/O and/O impaired/O renal/O function/O are/O the/O major/O independent/O factors/O that/O result/O in/O increased/O exposure/O to/O dabigatran/O [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
Concomitant/O use/O of/O P/O -/O gp/O inhibitors/O in/O patients/O with/O renal/O impairment/O is/O expected/O to/O produce/O increased/O exposure/O of/O dabigatran/O compared/O to/O that/O seen/O with/O either/O factor/O alone/O ./O
Reduction/O of/O Risk/O of/O Stroke/O and/O Systemic/O Embolism/O in/O Non/O -/O valvular/O Atrial/O Fibrillation/O Reduce/O the/O dose/O of/O PRADAXA/O to/O 75/O mg/O twice/O daily/O when/O dronedarone/O or/O systemic/O ketoconazole/O is/O coadministered/O with/O PRADAXA/O in/O patients/O with/O moderate/O renal/O impairment/O (/O CrCl/O 30/O -/O 50/O mL/O min/O )/O ./O
Avoid/O use/O of/O PRADAXA/O and/O P/O -/O gp/O inhibitors/O in/O patients/O with/O severe/O renal/O impairment/O (/O CrCl/O 15/O -/O 30/O mL/O min/O )/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
Treatment/O and/O Reduction/O in/O the/O Risk/O of/O Recurrence/O of/O Deep/O Venous/O Thrombosis/O and/O Pulmonary/O Embolism/O Avoid/O use/O of/O PRADAXA/O and/O concomitant/O P/O -/O gp/O inhibitors/O in/O patients/O with/O CrCl/O 50/O mL/O min/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O and/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O label/O ./O
Hypersensitivity/B-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O ]/O Suicidal/B-AdverseReaction Thoughts/I-AdverseReaction and/O Behaviors/O in/O Adolescents/O and/O Young/O Adults/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Serotonin/B-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Elevated/B-AdverseReaction Blood/I-AdverseReaction Pressure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Abnormal/B-AdverseReaction Bleeding/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Angle/B-AdverseReaction Closure/I-AdverseReaction Glaucoma/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Activation/O of/O Mania/B-AdverseReaction Hypomania/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Discontinuation/B-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Seizure/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Hyponatremia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O Interstitial/B-AdverseReaction Lung/I-AdverseReaction Disease/I-AdverseReaction and/O Eosinophilic/B-AdverseReaction Pneumonia/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.10/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 5/O %/O and/O twice/O the/O rate/O of/O placebo/O in/O the/O 50/O or/O 100/O mg/O dose/O groups/O )/O were/O :/O nausea/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O anxiety/B-AdverseReaction ,/O and/O specific/O male/B-AdverseReaction sexual/I-AdverseReaction function/I-AdverseReaction disorders/I-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Wyeth/O Pharmaceuticals/O Inc./O ,/O a/O subsidiary/O of/O Pfizer/O Inc./O ,/O at/O 1/O -/O 800/O -/O 438/O -/O 1985/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Studies/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Patient/O exposure/O PRISTIQ/O was/O evaluated/O for/O safety/O in/O 8,394/O patients/O diagnosed/O with/O major/O depressive/O disorder/O who/O participated/O in/O multiple/O -/O dose/O pre/O -/O marketing/O studies/O ,/O representing/O 2,784/O patient/O -/O years/O of/O exposure/O ./O
Of/O the/O total/O 8,394/O patients/O exposed/O to/O at/O least/O one/O dose/O of/O PRISTIQ/O ;/O 2,116/O were/O exposed/O to/O PRISTIQ/O for/O 6/O months/O ,/O representing/O 1,658/O patient/O -/O years/O of/O exposure/O ,/O and/O 421/O were/O exposed/O for/O one/O year/O ,/O representing/O 416/O patient/O -/O years/O of/O exposure/O ./O
Adverse/O reactions/O reported/O as/O reasons/O for/O discontinuation/O of/O treatment/O In/O the/O pre/O -/O marketing/O pooled/O 8-week/O placebo/O -/O controlled/O studies/O in/O patients/O with/O MDD/O ,/O 1,834/O patients/O were/O exposed/O to/O PRISTIQ/O (/O 50/O to/O 400/O mg/O )/O ./O
Of/O the/O 1,834/O patients/O ,/O 12/O %/O discontinued/O treatment/O due/O to/O an/O adverse/O reaction/O ,/O compared/O with/O 3/O %/O of/O the/O 1,116/O placebo/O -/O treated/O patients/O ./O
At/O the/O recommended/O dose/O of/O 50/O mg/O ,/O the/O discontinuation/O rate/O due/O to/O an/O adverse/O reaction/O for/O PRISTIQ/O (/O 4.1/O %/O )/O was/O similar/O to/O the/O rate/O for/O placebo/O (/O 3.8/O %/O )/O ./O
For/O the/O 100/O mg/O dose/O of/O PRISTIQ/O the/O discontinuation/O rate/O due/O to/O an/O adverse/O reaction/O was/O 8.7/O %/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O in/O at/O least/O 2/O %/O and/O at/O a/O rate/O greater/O than/O placebo/O of/O the/O PRISTIQ/O treated/O patients/O in/O the/O short/O -/O term/O studies/O ,/O up/O to/O 8/O weeks/O ,/O were/O :/O nausea/B-AdverseReaction (/O 4/O %/O )/O ;/O dizziness/B-AdverseReaction ,/O headache/B-AdverseReaction and/O vomiting/B-AdverseReaction (/O 2/O %/O each/O )/O ./O
In/O a/O longer/O -/O term/O study/O ,/O up/O to/O 9/O months/O ,/O the/O most/O common/O was/O vomiting/B-AdverseReaction (/O 2/O %/O )/O ./O
Common/O adverse/O reactions/O in/O placebo/O -/O controlled/O MDD/O studies/O The/O most/O commonly/O observed/O adverse/O reactions/O in/O PRISTIQ/O treated/O MDD/O patients/O in/O pre/O -/O marketing/O pooled/O 8-week/O ,/O placebo/O -/O controlled/O ,/O fixed/O -/O dose/O studies/O (/O incidence/O 5/O %/O and/O at/O least/O twice/O the/O rate/O of/O placebo/O in/O the/O 50/O or/O 100/O mg/O dose/O groups/O )/O were/O :/O nausea/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O anxiety/B-AdverseReaction ,/O and/O specific/O male/B-AdverseReaction sexual/I-AdverseReaction function/I-AdverseReaction disorders/I-AdverseReaction ./O
Table/O 2/O shows/O the/O incidence/O of/O common/O adverse/O reactions/O that/O occurred/O in/O 2/O %/O of/O PRISTIQ/O treated/O MDD/O patients/O and/O twice/O the/O rate/O of/O placebo/O at/O any/O dose/O in/O the/O pre/O -/O marketing/O pooled/O 8-week/O ,/O placebo/O -/O controlled/O ,/O fixed/O dose/O clinical/O studies/O Table/O 2/O :/O Common/O Adverse/O Reactions/O (/O 2/O %/O in/O any/O Fixed/O -/O Dose/O Group/O and/O Twice/O the/O Rate/O of/O Placebo/O )/O in/O Pre/O -/O marketing/O Pooled/O MDD/O 8-Week/O Placebo/O -/O Controlled/O Studies/O Percentage/O of/O Patients/O Reporting/O Reaction/O PRISTIQ/O System/O Organ/O Class/O Preferred/O Term/O Placebo/O (/O n=636/O )/O 50/O mg/O (/O n=317/O )/O 100/O mg/O (/O n=424/O )/O 200/O mg/O (/O n=307/O )/O 400/O mg/O (/O n=317/O )/O Cardiac/O disorders/O Blood/B-AdverseReaction pressure/I-AdverseReaction increased/I-AdverseReaction 1/O 1/O 1/O 2/O 2/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 10/O 22/O 26/O 36/O 41/O Dry/B-AdverseReaction mouth/I-AdverseReaction 9/O 11/O 17/O 21/O 25/O Constipation/B-AdverseReaction 4/O 9/O 9/O 10/O 14/O Vomiting/B-AdverseReaction 3/O 3/O 4/O 6/O 9/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 4/O 7/O 7/O 10/O 11/O Chills/B-AdverseReaction 1/O 1/O 1/O 3/O 4/O Feeling/B-AdverseReaction jittery/I-AdverseReaction 1/O 1/O 2/O 3/O 3/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 2/O 5/O 8/O 10/O 10/O Nervous/O system/O disorders/O Dizziness/B-AdverseReaction 5/O 13/O 10/O 15/O 16/O Somnolence/B-AdverseReaction 4/O 4/O 9/O 12/O 12/O Tremor/B-AdverseReaction 2/O 2/O 3/O 9/O 9/O Disturbance/B-AdverseReaction in/I-AdverseReaction attention/I-AdverseReaction 1/O 1/O 1/O 2/O 1/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 6/O 9/O 12/O 14/O 15/O Anxiety/B-AdverseReaction 2/O 3/O 5/O 4/O 4/O Nervousness/B-AdverseReaction 1/O 1/O 1/O 2/O 2/O Abnormal/B-AdverseReaction dreams/I-AdverseReaction 1/O 2/O 3/O 2/O 4/O Renal/O and/O urinary/O disorders/O Urinary/B-AdverseReaction hesitation/I-AdverseReaction 0/O 1/O 1/O 2/O 2/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Yawning/B-AdverseReaction 1/O 1/O 1/O 4/O 3/O Skin/O and/O subcutaneous/O tissue/O disorders/O Hyperhidrosis/B-AdverseReaction 4/O 10/O 11/O 18/O 21/O Special/O Senses/O Vision/B-AdverseReaction blurred/I-AdverseReaction 1/O 3/O 4/O 4/O 4/O Mydriasis/B-AdverseReaction 1/O 2/O 2/O 6/O 6/O Vertigo/B-AdverseReaction 1/O 2/O 1/O 5/O 3/O Tinnitus/B-AdverseReaction 1/O 2/O 1/O 1/O 2/O Dysgeusia/B-AdverseReaction 1/O 1/O 1/O 1/O 2/O Vascular/O disorders/O Hot/B-AdverseReaction flush/I-AdverseReaction 1/O 1/O 1/O 2/O 2/O Sexual/O function/O adverse/O reactions/O Table/O 3/O shows/O the/O incidence/O of/O sexual/B-AdverseReaction function/I-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction that/O occurred/O in/O 2/O %/O of/O PRISTIQ/O treated/O MDD/O patients/O in/O any/O fixed/O -/O dose/O group/O (/O pre/O -/O marketing/O pooled/O 8-week/O ,/O placebo/O -/O controlled/O ,/O fixed/O -dose/O ,/O clinical/O studies/O )/O ./O
Table/O 3/O :/O Sexual/B-AdverseReaction Function/I-AdverseReaction Adverse/I-AdverseReaction Reactions/I-AdverseReaction (/O 2/O %/O in/O Men/O or/O Women/O in/O any/O PRISTIQ/O Group/O )/O During/O the/O On/O -/O Therapy/O Period/O PRISTIQ/O Placebo(n=239/O )/O 50/O mg(n=108/O )/O 100/O mg(n=157/O )/O 200/O mg(n=131/O )/O 400/O mg(n=154/O )/O Men/O only/O Anorgasmia/B-AdverseReaction 0/O 0/O 3/O 5/O 8/O Libido/B-AdverseReaction decreased/I-AdverseReaction 1/O 4/O 5/O 6/O 3/O Orgasm/B-AdverseReaction abnormal/I-AdverseReaction 0/O 0/O 1/O 2/O 3/O Ejaculation/B-AdverseReaction delayed/I-AdverseReaction 1/O 1/O 5/O 7/O 6/O Erectile/B-AdverseReaction dysfunction/I-AdverseReaction 1/O 3/O 6/O 8/O 11/O Ejaculation/B-AdverseReaction disorder/I-AdverseReaction 0/O 0/O 1/O 2/O 5/O Ejaculation/B-AdverseReaction failure/I-AdverseReaction 0/O 1/O 0/O 2/O 2/O Sexual/B-AdverseReaction dysfunction/I-AdverseReaction 0/O 1/O 0/O 0/O 2/O PRISTIQ/O Placebo(n=397/O )/O 50/O mg(n=209/O )/O 100/O mg(n=267/O )/O 200/O mg(n=176/O )/O 400/O mg(n=163/O )/O Women/O only/O Anorgasmia/B-AdverseReaction 0/O 1/O 1/O 0/O 3/O Other/O adverse/O reactions/O observed/O in/O premarketing/O and/O postmarketing/O clinical/O studies/O Other/O infrequent/O adverse/O reactions/O ,/O not/O described/O elsewhere/O in/O the/O label/O ,/O occurring/O at/O an/O incidence/O of/O 2/O %/O in/O MDD/O patients/O treated/O with/O PRISTIQ/O were/O :/O Cardiac/O disorders/O -/O Tachycardia/B-AdverseReaction ./O
General/O disorders/O and/O administration/O site/O conditions/O -/O Asthenia/B-AdverseReaction ./O
Investigations/O -/O Weight/B-AdverseReaction increased/I-AdverseReaction ,/O liver/B-AdverseReaction function/I-AdverseReaction test/I-AdverseReaction abnormal/I-AdverseReaction ,/O blood/B-AdverseReaction prolactin/I-AdverseReaction increased/I-AdverseReaction ./O
Musculoskeletal/O and/O connective/O tissue/O disorders/O -/O Musculoskeletal/B-AdverseReaction stiffness/I-AdverseReaction ./O
Nervous/O system/O disorders/O -/O Syncope/B-AdverseReaction ,/O convulsion/B-AdverseReaction ,/O dystonia/B-AdverseReaction ./O
Psychiatric/O disorders/O -/O Depersonalization/B-AdverseReaction ,/O bruxism/B-AdverseReaction ./O
Renal/O and/O urinary/O disorders/O -/O Urinary/B-AdverseReaction retention/I-AdverseReaction ./O
Skin/O and/O subcutaneous/O tissue/O disorders/O -/O Rash/B-AdverseReaction ,/O alopecia/B-AdverseReaction ,/O photosensitivity/B-AdverseReaction reaction/O ,/O angioedema/B-AdverseReaction ./O
In/O clinical/O studies/O ,/O there/O were/O uncommon/O reports/O of/O ischemic/B-AdverseReaction cardiac/I-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O myocardial/B-AdverseReaction ischemia/I-AdverseReaction ,/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O and/O coronary/B-AdverseReaction occlusion/I-AdverseReaction requiring/O revascularization/O ;/O these/O patients/O had/O multiple/O underlying/O cardiac/O risk/O factors/O ./O
More/O patients/O experienced/O these/O events/O during/O PRISTIQ/O treatment/O as/O compared/O to/O placebo/O ./O
Laboratory/O ,/O ECG/O and/O vital/O sign/O changes/O observed/O in/O MDD/O clinical/O studies/O The/O following/O changes/O were/O observed/O in/O pre/O -/O marketing/O placebo/O -/O controlled/O ,/O short/O -/O term/O MDD/O studies/O with/O PRISTIQ/O ./O
Lipids/O Elevations/B-AdverseReaction in/I-AdverseReaction fasting/I-AdverseReaction serum/I-AdverseReaction total/I-AdverseReaction cholesterol/I-AdverseReaction ,/O LDL/O (/O low/O density/O lipoproteins/O )/O cholesterol/O ,/O and/O triglycerides/O occurred/O in/O the/O controlled/O studies/O ./O
Some/O of/O these/O abnormalities/O were/O considered/O potentially/O clinically/O significant/O ./O
The/O percentage/O of/O patients/O who/O exceeded/O a/O predetermined/O threshold/O value/O is/O shown/O in/O Table/O 4/O ./O
Table/O 4/O :/O Incidence/O (/O %/O )/O of/O Patients/O With/O Lipid/B-AdverseReaction Abnormalities/I-AdverseReaction of/O Potential/O Clinical/O Significance/O PRISTIQ/O Placebo/O 50/O mg/O 100/O mg/O 200/O mg/O 400/O mg/O Total/O Cholesterol*(Increase/O of/O 50/O mg/O dl/O and/O an/O absolute/O value/O of/O 261/O mg/O dl/O )/O 2/O 3/O 4/O 4/O 10/O LDL/O Cholesterol*(Increase/O 50/O mg/O dl/O and/O an/O absolute/O value/O of/O 190/O mg/O dl/O )/O 0/O 1/O 0/O 1/O 2/O Triglycerides/O ,/O fasting*(Fasting/O :/O 327/O mg/O dl/O )/O 3/O 2/O 1/O 4/O 6/O Proteinuria/O Proteinuria/B-AdverseReaction ,/O greater/O than/O or/O equal/O to/O trace/O ,/O was/O observed/O in/O the/O pre/O -/O marketing/O fixed/O -/O dose/O controlled/O studies/O (/O see/O Table/O 5/O )/O ./O
This/O proteinuria/B-AdverseReaction was/O not/B-Negation associated/O with/O increases/B-AdverseReaction in/I-AdverseReaction BUN/I-AdverseReaction or/O creatinine/O and/O was/O generally/O transient/B-Severity ./O
Table/O 5/O :/O Incidence/O (/O %/O )/O of/O Patients/O with/O Proteinuria/B-AdverseReaction in/O the/O Fixed/O -/O dose/O Clinical/O Studies/O PRISTIQ/O Placebo/O 50/O mg/O 100/O mg/O 200/O mg/O 400/O mg/O Proteinuria/B-AdverseReaction 4/O 6/O 8/O 5/O 7/O Vital/O sign/O changes/O Table/O 6/O summarizes/O the/O changes/O that/O were/O observed/O in/O placebo/O -/O controlled/O ,/O short/O -/O term/O ,/O pre/O -/O marketing/O studies/O with/O PRISTIQ/O in/O patients/O with/O MDD/O (/O doses/O 50/O to/O 400/O mg/O )/O ./O
Table/O 6/O :/O Mean/O Changes/O in/O Vital/O Signs/O at/O Final/O on/O Therapy/O for/O All/O Short/O -/O term/O ,/O Fixed/O -/O dose/O Controlled/O Studies/O PRISTIQ/O Placebo/O 50/O mg/O 100/O mg/O 200/O mg/O 400/O mg/O Blood/O pressure/O Supine/O systolic/O bp/O (/O mm/O Hg/O )/O -1.4/O 1.2/O 2.0/O 2.5/O 2.1/O Supine/O diastolic/O bp/O (/O mm/O Hg/O )/O -0.6/O 0.7/O 0.8/O 1.8/O 2.3/O Pulse/O rate/O Supine/O pulse/O (/O bpm/O )/O -0.3/O 1.3/O 1.3/O 0.9/O 4.1/O Weight/O (/O kg/O )/O 0.0/O -0.4/O -0.6/O -0.9/O -1.1/O Treatment/O with/O PRISTIQ/O at/O all/O doses/O from/O 50/O mg/O per/O day/O to/O 400/O mg/O per/O day/O in/O controlled/O studies/O was/O associated/O with/O sustained/B-Severity hypertension/B-AdverseReaction ,/O defined/O as/O treatment/O -/O emergent/O supine/O diastolic/O blood/O pressure/O (/O SDBP/O )/O 90/O mm/O Hg/O and/O 10/O mm/O Hg/O above/O baseline/O for/O 3/O consecutive/O on/O -/O therapy/O visits/O (/O see/O Table/O 7/O )/O ./O
Analyses/O of/O patients/O in/O PRISTIQ/O pre/O -/O marketing/O short/O -/O term/O controlled/O studies/O who/O met/O criteria/O for/O sustained/B-Severity hypertension/B-AdverseReaction revealed/O a/O consistent/O increase/O in/O the/O proportion/O of/O patients/O who/O developed/O sustained/B-Severity hypertension/B-AdverseReaction ./O
This/O was/O seen/O at/O all/O doses/O with/O a/O suggestion/O of/O a/O higher/O rate/O at/O 400/O mg/O per/O day/O ./O
Table/O 7/O :/O Proportion/O of/O Patients/O with/O Sustained/B-Severity Elevation/B-AdverseReaction of/I-AdverseReaction Supine/I-AdverseReaction Diastolic/I-AdverseReaction Blood/I-AdverseReaction Pressure/I-AdverseReaction Treatment/O Group/O Proportion/O of/O Patients/O with/O Sustained/O Hypertension/O Placebo/O 0.5/O %/O PRISTIQ/O 50/O mg/O per/O day/O 1.3/O %/O PRISTIQ/O 100/O mg/O per/O day/O 0.7/O %/O PRISTIQ/O 200/O mg/O per/O day/O 1.1/O %/O PRISTIQ/O 400/O mg/O per/O day/O 2.3/O %/O Orthostatic/O hypotension/O In/O the/O pre/O -/O marketing/O short/O -/O term/O ,/O placebo/O -/O controlled/O clinical/O studies/O with/O doses/O of/O 50/O to/O 400/O mg/O ,/O systolic/B-AdverseReaction orthostatic/I-AdverseReaction hypotension/I-AdverseReaction (/O decrease/O 30/O mm/O Hg/O from/O supine/O to/O standing/O position/O )/O occurred/O more/O frequently/O in/O patients/O 65/O years/O of/O age/O receiving/O PRISTIQ/O (/O 8/O %/O ,/O 7/87/O )/O versus/O placebo/O (/O 2.5/O %/O ,/O 1/40/O )/O ,/O compared/O to/O patients/O 65/O years/O of/O age/O receiving/O PRISTIQ/O (/O 0.9/O %/O ,/O 18/1,937/O )/O versus/O placebo/O (/O 0.7/O %/O ,/O 8/1,218/O )/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reaction/O has/O been/O identified/O during/O post/O -/O approval/O use/O of/O PRISTIQ/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O :/O Skin/O and/O subcutaneous/O tissue/O disorders/O -/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O SUICIDAL/B-AdverseReaction THOUGHTS/I-AdverseReaction AND/O BEHAVIORS/O WARNING/O :/O SUICIDAL/B-AdverseReaction THOUGHTS/I-AdverseReaction AND/O BEHAVIORS/O Antidepressants/B-DrugClass increased/O the/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction and/O behavior/O in/O children/O ,/O adolescents/O ,/O and/O young/O adults/O in/O short/O -/O term/O studies/O ./O
These/O studies/O did/O not/B-Negation show/O an/O increase/O in/O the/O risk/O of/O suicidal/B-AdverseReaction thoughts/I-AdverseReaction and/O behavior/O with/O antidepressant/O use/O in/O patients/O over/O age/O 24/O ;/O there/O was/O a/O reduction/O in/O risk/O with/O antidepressant/O use/O in/O patients/O aged/O 65/O and/O older/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
In/O patients/O of/O all/O ages/O who/O are/O started/O on/O antidepressant/O therapy/O ,/O monitor/O closely/O for/O worsening/O ,/O and/O for/O emergence/O of/O suicidal/O thoughts/O and/O behaviors/O ./O
Advise/O families/O and/O caregivers/O of/O the/O need/O for/O close/O observation/O and/O communication/O with/O the/O prescriber/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
PRISTIQ/O is/O not/O approved/O for/O use/O in/O pediatric/O patients/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.4/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O SUICIDAL/B-AdverseReaction THOUGHTS/I-AdverseReaction AND/O BEHAVIORS/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Increased/O risk/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction and/O behavior/O in/O children/O ,/O adolescents/O and/O young/O adults/O taking/O antidepressants/B-DrugClass (/O 5.1/O )/O ./O
Monitor/O for/O worsening/O and/O emergence/O of/O suicidal/O thoughts/O and/O behaviors/O (/O 5.1/O )/O ./O
PRISTIQ/O is/O not/O approved/O for/O use/O in/O pediatric/O patients/O (/O 8.4/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Clinical/B-AdverseReaction Worsening/I-AdverseReaction Suicide/B-AdverseReaction Risk/I-AdverseReaction :/O Monitor/O for/O clinical/O worsening/O and/O suicide/O risk/O (/O 5.1/O )/O ./O
Serotonin/B-AdverseReaction Syndrome/I-AdverseReaction :/O Serotonin/B-AdverseReaction syndrome/I-AdverseReaction has/O been/O reported/O with/O SSRIs/O and/O SNRIs/O ,/O including/O with/O PRISTIQ/O ,/O both/O when/O taken/O alone/O ,/O but/O especially/O when/O co/O -/O administered/O with/O other/O serotonergic/O agents/O (/O including/O triptans/O ,/O tricyclic/O antidepressants/O ,/O fentanyl/O ,/O lithium/O ,/O tramadol/O ,/O tryptophan/O ,/O buspirone/O ,/O and/O St./O John/O 's/O Wort/O )/O ./O
If/O such/O symptoms/O occur/O ,/O discontinue/O PRISTIQ/O and/O initiate/O supportive/O treatment/O ./O
If/O concomitant/O use/O of/O PRISTIQ/O with/O other/O serotonergic/O drugs/O is/O clinically/O warranted/O ,/O patients/O should/O be/O made/O aware/O of/O a/O potential/O increased/O risk/O for/O serotonin/O syndrome/O ,/O particularly/O during/O treatment/O initiation/O and/O dose/O increases/O (/O 5.2/O )/O ./O
Elevated/B-AdverseReaction Blood/I-AdverseReaction Pressure/I-AdverseReaction :/O Control/O hypertension/O before/O initiating/O treatment/O ./O
Monitor/O blood/O pressure/O regularly/O during/O treatment/O (/O 5.3/O )/O ./O
Abnormal/B-AdverseReaction Bleeding/I-AdverseReaction :/O PRISTIQ/O may/B-Factor increase/O risk/O of/O bleeding/B-AdverseReaction events/O ./O
Caution/O patients/O about/O risk/O of/O bleeding/O associated/O with/O concomitant/O use/O of/O PRISTIQ/O and/O NSAIDs/O ,/O aspirin/O ,/O or/O other/O drugs/O that/O affect/O coagulation/O (/O 5.4/O )/O ./O
Angle/B-AdverseReaction Closure/I-AdverseReaction Glaucoma/I-AdverseReaction :/O Angle/B-AdverseReaction closure/I-AdverseReaction glaucoma/I-AdverseReaction has/O occurred/O in/O patients/O with/O untreated/O anatomically/O narrow/O angles/O treated/O with/O antidepressants/B-DrugClass ./O
(/O 5.5/O )/O Activation/B-AdverseReaction of/I-AdverseReaction Mania/I-AdverseReaction Hypomania/O :/O Use/O cautiously/O in/O patients/O with/O Bipolar/O Disorder/O ./O
Caution/O patients/O about/O risk/O of/O activation/O of/O mania/O hypomania/O (/O 5.6/O )/O ./O
Discontinuation/B-AdverseReaction Syndrome/I-AdverseReaction :/O Taper/O dose/O when/O possible/O and/O monitor/O for/O discontinuation/O symptoms/O (/O 5.7/O )/O ./O
Seizure/B-AdverseReaction :/O Can/O occur/O ./O
Use/O cautiously/O in/O patients/O with/O seizure/O disorder/O (/O 5.8/O )/O ./O
Hyponatremia/B-AdverseReaction :/O Can/O occur/O in/O association/O with/O SIADH/O (/O 5.9/O )/O ./O
Interstitial/B-AdverseReaction Lung/I-AdverseReaction Disease/I-AdverseReaction and/O Eosinophilic/B-AdverseReaction Pneumonia/I-AdverseReaction :/O Can/O occur/O (/O 5.10/O )/O ./O
5.1/O Suicidal/O Thoughts/O and/O Behaviors/O in/O Children/O ,/O Adolescents/O and/O Young/O Adults/O Patients/O with/O major/O depressive/O disorder/O (/O MDD/O )/O ,/O both/O adult/O and/O pediatric/O ,/O may/O experience/O worsening/O of/O their/O depression/O and/or/O the/O emergence/O of/O suicidal/O ideation/O and/O behavior/O (/O suicidality/O )/O or/O unusual/O changes/O in/O behavior/O ,/O whether/O or/O not/O they/O are/O taking/O antidepressant/O medications/O ,/O and/O this/O risk/O may/O persist/O until/O significant/O remission/O occurs/O ./O
Suicide/O is/O a/O known/O risk/O of/O depression/O and/O certain/O other/O psychiatric/O disorders/O ,/O and/O these/O disorders/O themselves/O are/O the/O strongest/O predictors/O of/O suicide/O ./O
There/O has/O been/O a/O long/O -/O standing/O concern/O ,/O however/O ,/O that/O antidepressants/B-DrugClass may/O have/O a/O role/O in/O inducing/O worsening/B-AdverseReaction of/I-AdverseReaction depression/I-AdverseReaction and/O the/O emergence/O of/O suicidality/B-AdverseReaction in/O certain/O patients/O during/O the/O early/O phases/O of/O treatment/O ./O
Pooled/O analyses/O of/O short/O -/O term/O placebo/O -/O controlled/O studies/O of/O antidepressant/B-DrugClass drugs/I-DrugClass (/O SSRIs/O and/O others/O )/O showed/O that/O these/O drugs/O increase/O the/O risk/O of/O suicidal/B-AdverseReaction thinking/I-AdverseReaction and/O behavior/O (/O suicidality/B-AdverseReaction )/O in/O children/O ,/O adolescents/O ,/O and/O young/O adults/O (/O ages/O 18/O to/O 24/O )/O with/O major/O depressive/O disorder/O (/O MDD/O )/O and/O other/O psychiatric/O disorders/O ./O
Short/O -/O term/O studies/O did/O not/B-Negation show/O an/O increase/O in/O the/O risk/O of/O suicidality/B-AdverseReaction with/O antidepressants/O compared/O to/O placebo/O in/O adults/O beyond/O age/O 24/O ;/O there/O was/O a/O reduction/O with/O antidepressants/O compared/O to/O placebo/O in/O adults/O aged/O 65/O and/O older/O ./O
The/O pooled/O analyses/O of/O placebo/O -/O controlled/O studies/O in/O children/O and/O adolescents/O with/O MDD/O ,/O obsessive/O compulsive/O disorder/O (/O OCD/O )/O ,/O or/O other/O psychiatric/O disorders/O included/O a/O total/O of/O 24/O short/O -/O term/O studies/O of/O 9/O antidepressant/O drugs/O in/O over/O 4,400/O patients/O ./O
The/O pooled/O analyses/O of/O placebo/O -/O controlled/O studies/O in/O adults/O with/O MDD/O or/O other/O psychiatric/O disorders/O included/O a/O total/O of/O 295/O short/O -/O term/O studies/O (/O median/O duration/O of/O 2/O months/O )/O of/O 11/O antidepressant/O drugs/O in/O over/O 77,000/O patients/O ./O
There/O was/O considerable/O variation/O in/O risk/O of/O suicidality/B-AdverseReaction among/O drugs/B-DrugClass ,/O but/O a/O tendency/O toward/O an/O increase/O in/O the/O younger/O patients/O for/O almost/O all/O drugs/O studied/O ./O
There/O were/O differences/O in/O absolute/O risk/O of/O suicidality/B-AdverseReaction across/O the/O different/O indications/O ,/O with/O the/O highest/O incidence/O in/O MDD/O ./O
The/O risk/O differences/O (/O drug/O vs./O placebo/O )/O ,/O however/O ,/O were/O relatively/O stable/O within/O age/O strata/O and/O across/O indications/O ./O
These/O risk/O differences/O (/O drug/O -/O placebo/O difference/O in/O the/O number/O of/O cases/O of/O suicidality/B-AdverseReaction per/O 1,000/O patients/O treated/O )/O are/O provided/O in/O Table/O 1/O ./O
Table/O 1/O Age/O Range/O Drug/O -/O Placebo/O Difference/O in/O Number/O of/O Cases/O of/O Suicidality/B-AdverseReaction per/O 1,000/O Patients/O Treated/O Increases/O Compared/O to/O Placebo/O 18/O 14/O additional/O cases/O 18/O to/O 24/O 5/O additional/O cases/O Decreases/O Compared/O to/O Placebo/O 25/O to/O 64/O 1/O fewer/O case/O 65/O 6/O fewer/O cases/O No/B-Negation suicides/B-AdverseReaction occurred/O in/O any/O of/O the/O pediatric/O studies/O ./O
There/O were/O suicides/B-AdverseReaction in/O the/O adult/O studies/O ,/O but/O the/O number/O was/O not/O sufficient/O to/O reach/O any/O conclusion/O about/O drug/O effect/O on/O suicide/O ./O
It/O is/O unknown/O whether/O the/O suicidality/B-AdverseReaction risk/B-Factor extends/O to/O longer/O -/O term/O use/O ,/O i.e./O ,/O beyond/O several/O months/O ./O
However/O ,/O there/O is/O substantial/O evidence/O from/O placebo/O -/O controlled/O maintenance/O studies/O in/O adults/O with/O depression/O that/O the/O use/O of/O antidepressants/O can/O delay/O the/O recurrence/O of/O depression/O ./O
All/O patients/O being/O treated/O with/O antidepressants/O for/O any/O indication/O should/O be/O monitored/O appropriately/O and/O observed/O closely/O for/O clinical/O worsening/O ,/O suicidality/O ,/O and/O unusual/O changes/O in/O behavior/O ,/O especially/O during/O the/O initial/O few/O months/O of/O a/O course/O of/O drug/O therapy/O ,/O or/O at/O times/O of/O dose/O changes/O ,/O either/O increases/O or/O decreases/O ./O
The/O following/O symptoms/O ,/O anxiety/B-AdverseReaction ,/O agitation/B-AdverseReaction ,/O panic/B-AdverseReaction attacks/I-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O irritability/B-AdverseReaction ,/O hostility/B-AdverseReaction ,/O aggressiveness/B-AdverseReaction ,/O impulsivity/B-AdverseReaction ,/O akathisia/B-AdverseReaction (/O psychomotor/B-AdverseReaction restlessness/I-AdverseReaction )/O ,/O hypomania/B-AdverseReaction ,/O and/O mania/B-AdverseReaction ,/O have/O been/O reported/O in/O adult/O and/O pediatric/O patients/O being/O treated/O with/O antidepressants/B-DrugClass for/O major/O depressive/O disorder/O as/O well/O as/O for/O other/O indications/O ,/O both/O psychiatric/O and/O nonpsychiatric/O ./O
Although/O a/O causal/O link/O between/O the/O emergence/O of/O such/O symptoms/O and/O either/O the/O worsening/B-AdverseReaction of/I-AdverseReaction depression/I-AdverseReaction and/or/O the/O emergence/O of/O suicidal/B-AdverseReaction impulses/I-AdverseReaction has/O not/B-Negation been/I-Negation established/I-Negation ,/O there/O is/O concern/O that/O such/O symptoms/O may/B-Factor represent/O precursors/O to/O emerging/O suicidality/B-AdverseReaction ./O
Consideration/O should/O be/O given/O to/O changing/O the/O therapeutic/O regimen/O ,/O including/O possibly/O discontinuing/O the/O medication/O ,/O in/O patients/O whose/O depression/O is/O persistently/O worse/O ,/O or/O who/O are/O experiencing/O emergent/O suicidality/O or/O symptoms/O that/O might/O be/O precursors/O to/O worsening/O depression/O or/O suicidality/O ,/O especially/O if/O these/O symptoms/O are/O severe/O ,/O abrupt/O in/O onset/O ,/O or/O were/O not/O part/O of/O the/O patient/O 's/O presenting/O symptoms/O ./O
If/O the/O decision/O has/O been/O made/O to/O discontinue/O treatment/O ,/O medication/O should/O be/O tapered/O ,/O as/O rapidly/O as/O is/O feasible/O ,/O but/O with/O recognition/O that/O abrupt/O discontinuation/O can/O be/O associated/O with/O certain/O symptoms/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.7/O )/O for/O a/O description/O of/O the/O risks/O of/O discontinuation/O of/O PRISTIQ/O ]/O ./O
Families/O and/O caregivers/O of/O patients/O being/O treated/O with/O antidepressants/O for/O major/O depressive/O disorder/O or/O other/O indications/O ,/O both/O psychiatric/O and/O nonpsychiatric/O ,/O should/O be/O alerted/O about/O the/O need/O to/O monitor/O patients/O for/O the/O emergence/O of/O agitation/O ,/O irritability/O ,/O unusual/O changes/O in/O behavior/O ,/O and/O the/O other/O symptoms/O described/O above/O ,/O as/O well/O as/O the/O emergence/O of/O suicidality/O ,/O and/O to/O report/O such/O symptoms/O immediately/O to/O healthcare/O providers/O ./O
Such/O monitoring/O should/O include/O daily/O observation/O by/O families/O and/O caregivers/O ./O
Prescriptions/O for/O PRISTIQ/O should/O be/O written/O for/O the/O smallest/O quantity/O of/O tablets/O consistent/O with/O good/O patient/O management/O ,/O in/O order/O to/O reduce/O the/O risk/O of/O overdose/O ./O
Screening/O patients/O for/O bipolar/O disorder/O A/O major/O depressive/O episode/O may/O be/O the/O initial/O presentation/O of/O bipolar/O disorder/O ./O
It/O is/O generally/O believed/O (/O though/O not/O established/O in/O controlled/O studies/O )/O that/O treating/O such/O an/O episode/O with/O an/O antidepressant/B-DrugClass alone/O may/O increase/O the/O likelihood/O of/O precipitation/O of/O a/O mixed/O manic/O episode/O in/O patients/O at/O risk/O for/O bipolar/O disorder/O ./O
Whether/O any/O of/O the/O symptoms/O described/O above/O represent/O such/O a/O conversion/O is/O unknown/O ./O
However/O ,/O prior/O to/O initiating/O treatment/O with/O an/O antidepressant/O ,/O patients/O with/O depressive/O symptoms/O should/O be/O adequately/O screened/O to/O determine/O if/O they/O are/O at/O risk/O for/O bipolar/O disorder/O ;/O such/O screening/O should/O include/O a/O detailed/O psychiatric/O history/O ,/O including/O a/O family/O history/O of/O suicide/O ,/O bipolar/O disorder/O ,/O and/O depression/O ./O
It/O should/O be/O noted/O that/O PRISTIQ/O is/O not/O approved/O for/O use/O in/O treating/O bipolar/O depression/O ./O
5.2/O Serotonin/O Syndrome/O The/O development/O of/O a/O potentially/B-Factor life/B-Severity -/O threatening/O serotonin/B-AdverseReaction syndrome/I-AdverseReaction has/O been/O reported/O with/O SNRIs/O and/O SSRIs/O ,/O including/O PRISTIQ/O ,/O alone/O but/O particularly/O with/O concomitant/O use/O of/O other/O serotonergic/O drugs/O (/O including/O triptans/O ,/O tricyclic/O antidepressants/O ,/O fentanyl/O ,/O lithium/O ,/O tramadol/O ,/O tryptophan/O ,/O buspirone/O ,/O and/O St./O John/O 's/O Wort/O )/O ,/O and/O with/O drugs/O that/O impair/O metabolism/O of/O serotonin/O (/O in/O particular/O ,/O MAOIs/O ,/O both/O those/O intended/O to/O treat/O psychiatric/O disorders/O and/O also/O others/O ,/O such/O as/O linezolid/O and/O intravenous/O methylene/O blue/O )/O ./O
Serotonin/B-AdverseReaction syndrome/I-AdverseReaction symptoms/O may/B-Factor include/O mental/B-AdverseReaction status/I-AdverseReaction changes/I-AdverseReaction (/O e.g./O ,/O agitation/B-AdverseReaction ,/O hallucinations/B-AdverseReaction ,/O delirium/B-AdverseReaction ,/O and/O coma/B-AdverseReaction )/O ,/O autonomic/B-AdverseReaction instability/I-AdverseReaction (/O e.g./O ,/O tachycardia/B-AdverseReaction ,/O labile/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O diaphoresis/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O hyperthermia/B-AdverseReaction )/O ,/O neuromuscular/B-AdverseReaction symptoms/I-AdverseReaction (/O e.g./O ,/O tremor/B-AdverseReaction ,/O rigidity/B-AdverseReaction ,/O myoclonus/B-AdverseReaction ,/O hyperreflexia/B-AdverseReaction ,/O incoordination/B-AdverseReaction )/O ,/O seizures/B-AdverseReaction ,/O and/or/O gastrointestinal/B-AdverseReaction symptoms/I-AdverseReaction (/O e.g./O ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O diarrhea/B-AdverseReaction )/O ./O
Patients/O should/O be/O monitored/O for/O the/O emergence/O of/O serotonin/O syndrome/O ./O
The/O concomitant/O use/O of/O PRISTIQ/O with/O MAOIs/O intended/O to/O treat/O psychiatric/O disorders/O is/O contraindicated/O ./O
PRISTIQ/O should/O also/O not/O be/O started/O in/O a/O patient/O who/O is/O being/O treated/O with/O MAOIs/O such/O as/O linezolid/O or/O intravenous/O methylene/O blue/O ./O
All/O reports/O with/O methylene/O blue/O that/O provided/O information/O on/O the/O route/O of/O administration/O involved/O intravenous/O administration/O in/O the/O dose/O range/O of/O 1/O mg/O kg/O to/O 8/O mg/O kg/O ./O
No/O reports/O involved/O the/O administration/O of/O methylene/O blue/O by/O other/O routes/O (/O such/O as/O oral/O tablets/O or/O local/O tissue/O injection/O )/O or/O at/O lower/O doses/O ./O
There/O may/O be/O circumstances/O when/O it/O is/O necessary/O to/O initiate/O treatment/O with/O a/O MAOI/O such/O as/O linezolid/O or/O intravenous/O methylene/O blue/O in/O a/O patient/O taking/O PRISTIQ/O ./O
PRISTIQ/O should/O be/O discontinued/O before/O initiating/O treatment/O with/O the/O MAOI/O [/O see/O Contraindications/O (/O 4.2/O )/O and/O Dosage/O and/O Administration/O (/O 2.6/O )/O ]/O ./O
If/O concomitant/O use/O of/O PRISTIQ/O with/O other/O serotonergic/O drugs/O ,/O including/O triptans/O ,/O tricyclic/O antidepressants/O ,/O fentanyl/O ,/O lithium/O ,/O tramadol/O ,/O buspirone/O ,/O tryptophan/O ,/O and/O St./O John/O 's/O Wort/O is/O clinically/O warranted/O ,/O patients/O should/O be/O made/O aware/O of/O a/O potential/O increased/O risk/O for/O serotonin/O syndrome/O ,/O particularly/O during/O treatment/O initiation/O and/O dose/O increases/O ./O
Treatment/O with/O PRISTIQ/O and/O any/O concomitant/O serotonergic/O agents/O should/O be/O discontinued/O immediately/O if/O the/O above/O events/O occur/O and/O supportive/O symptomatic/O treatment/O should/O be/O initiated/O ./O
5.3/O Elevated/O Blood/O Pressure/O Patients/O receiving/O PRISTIQ/O should/O have/O regular/O monitoring/O of/O blood/O pressure/O since/O increases/B-AdverseReaction in/I-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction were/O observed/O in/O clinical/O studies/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Pre/O -/O existing/O hypertension/O should/O be/O controlled/O before/O initiating/O treatment/O with/O PRISTIQ/O ./O
Caution/O should/O be/O exercised/O in/O treating/O patients/O with/O pre/O -/O existing/O hypertension/O ,/O cardiovascular/O ,/O or/O cerebrovascular/O conditions/O that/O might/O be/O compromised/O by/O increases/O in/O blood/O pressure/O ./O
Cases/O of/O elevated/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction requiring/O immediate/O treatment/O have/O been/O reported/O with/O PRISTIQ/O ./O
Sustained/B-Severity blood/B-AdverseReaction pressure/I-AdverseReaction increases/I-AdverseReaction could/O have/O adverse/O consequences/O ./O
For/O patients/O who/O experience/O a/O sustained/O increase/O in/O blood/O pressure/O while/O receiving/O PRISTIQ/O ,/O either/O dose/O reduction/O or/O discontinuation/O should/O be/O considered/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.4/O Abnormal/O Bleeding/O SSRIs/O and/O SNRIs/O ,/O including/O PRISTIQ/O ,/O may/O increase/O the/O risk/B-Factor of/O bleeding/B-AdverseReaction events/O ./O
Concomitant/O use/O of/O aspirin/O ,/O nonsteroidal/O anti/O -/O inflammatory/O drugs/O ,/O warfarin/O ,/O and/O other/O anticoagulants/O may/O add/O to/O this/O risk/O ./O
Case/O reports/O and/O epidemiological/O studies/O (/O case/O -/O control/O and/O cohort/O design/O )/O have/O demonstrated/O an/O association/O between/O use/O of/O drugs/B-DrugClass that/I-DrugClass interfere/I-DrugClass with/I-DrugClass serotonin/I-DrugClass reuptake/I-DrugClass and/O the/O occurrence/O of/O gastrointestinal/B-AdverseReaction bleeding/I-AdverseReaction ./O
Bleeding/B-AdverseReaction events/O related/O to/O SSRIs/O and/O SNRIs/B-DrugClass have/O ranged/O from/O ecchymosis/B-AdverseReaction ,/O hematoma/B-AdverseReaction ,/O epistaxis/B-AdverseReaction ,/O and/O petechiae/B-AdverseReaction to/O life/B-Severity -/O threatening/O hemorrhages/B-AdverseReaction ./O
Patients/O should/O be/O cautioned/O about/O the/O risk/O of/O bleeding/O associated/O with/O the/O concomitant/O use/O of/O PRISTIQ/O and/O NSAIDs/O ,/O aspirin/O ,/O or/O other/O drugs/O that/O affect/O coagulation/O or/O bleeding/O ./O
5.5/O Angle/O Closure/O Glaucoma/O Angle/B-AdverseReaction -/I-AdverseReaction Closure/O Glaucoma/O :/O The/O pupillary/O dilation/O that/O occurs/O following/O use/O of/O many/O antidepressant/O drugs/O including/O Pristiq/O may/B-Factor trigger/O an/O angle/B-AdverseReaction closure/I-AdverseReaction attack/I-AdverseReaction in/O a/O patient/O with/O anatomically/O narrow/O angles/O who/O does/O not/O have/O a/O patent/O iridectomy/O ./O
5.6/O Activation/O of/O Mania/O Hypomania/O During/O all/O MDD/O phase/O 2/O and/O phase/O 3/O studies/O ,/O mania/B-AdverseReaction was/O reported/O for/O approximately/O 0.02/O %/O of/O patients/O treated/O with/O PRISTIQ/O ./O
Activation/B-AdverseReaction of/I-AdverseReaction mania/I-AdverseReaction hypomania/O has/O also/O been/O reported/O in/O a/O small/O proportion/O of/O patients/O with/O major/O affective/O disorder/O who/O were/O treated/O with/O other/O marketed/O antidepressants/B-DrugClass ./O
As/O with/O all/O antidepressants/O ,/O PRISTIQ/O should/O be/O used/O cautiously/O in/O patients/O with/O a/O history/O or/O family/O history/O of/O mania/O or/O hypomania/O ./O
5.7/O Discontinuation/O Syndrome/O Discontinuation/O symptoms/O have/O been/O systematically/O and/O prospectively/O evaluated/O in/O patients/O treated/O with/O PRISTIQ/O during/O clinical/O studies/O in/O Major/O Depressive/O Disorder/O ./O
Abrupt/O discontinuation/O or/O dose/O reduction/O has/O been/O associated/O with/O the/O appearance/O of/O new/O symptoms/O that/O include/O dizziness/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O irritability/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O anxiety/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O abnormal/B-AdverseReaction dreams/I-AdverseReaction ,/O and/O hyperhidrosis/B-AdverseReaction ./O
In/O general/O ,/O discontinuation/O events/O occurred/O more/O frequently/O with/O longer/O duration/O of/O therapy/O ./O
During/O marketing/O of/O SNRIs/O (/O Serotonin/O and/O Norepinephrine/O Reuptake/O Inhibitors/O )/O ,/O and/O SSRIs/O (/O Selective/O Serotonin/O Reuptake/O Inhibitors/O )/O ,/O there/O have/O been/O spontaneous/O reports/O of/O adverse/O events/O occurring/O upon/O discontinuation/O of/O these/O drugs/O ,/O particularly/O when/O abrupt/O ,/O including/O the/O following/O :/O dysphoric/O mood/O ,/O irritability/O ,/O agitation/O ,/O dizziness/O ,/O sensory/O disturbances/O (/O e.g./O ,/O paresthesia/O ,/O such/O as/O electric/O shock/O sensations/O )/O ,/O anxiety/O ,/O confusion/O ,/O headache/O ,/O lethargy/O ,/O emotional/O lability/O ,/O insomnia/O ,/O hypomania/O ,/O tinnitus/O ,/O and/O seizures/O ./O
While/O these/O events/O are/O generally/O self/O -/O limiting/O ,/O there/O have/O been/O reports/O of/O serious/O discontinuation/O symptoms/O ./O
Patients/O should/O be/O monitored/O for/O these/O symptoms/O when/O discontinuing/O treatment/O with/O PRISTIQ/O ./O
A/O gradual/O reduction/O in/O the/O dose/O rather/O than/O abrupt/O cessation/O is/O recommended/O whenever/O possible/O ./O
If/O intolerable/O symptoms/O occur/O following/O a/O decrease/O in/O the/O dose/O or/O upon/O discontinuation/O of/O treatment/O ,/O then/O resuming/O the/O previously/O prescribed/O dose/O may/O be/O considered/O ./O
Subsequently/O ,/O the/O physician/O may/O continue/O decreasing/O the/O dose/O ,/O but/O at/O a/O more/O gradual/O rate/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.8/O Seizure/O Cases/O of/O seizure/B-AdverseReaction have/O been/O reported/O in/O pre/O -/O marketing/O clinical/O studies/O with/O PRISTIQ/O ./O
PRISTIQ/O has/O not/O been/O systematically/O evaluated/O in/O patients/O with/O a/O seizure/O disorder/O ./O
Patients/O with/O a/O history/O of/O seizures/O were/O excluded/O from/O pre/O -/O marketing/O clinical/O studies/O ./O
PRISTIQ/O should/O be/O prescribed/O with/O caution/O in/O patients/O with/O a/O seizure/O disorder/O ./O
5.9/O Hyponatremia/O Hyponatremia/B-AdverseReaction may/B-Factor occur/O as/O a/O result/O of/O treatment/O with/O SSRIs/O and/O SNRIs/O ,/O including/O PRISTIQ/O ./O
In/O many/O cases/O ,/O this/O hyponatremia/B-AdverseReaction appears/O to/O be/O the/O result/O of/O the/O syndrome/B-AdverseReaction of/I-AdverseReaction inappropriate/I-AdverseReaction antidiuretic/I-AdverseReaction hormone/I-AdverseReaction secretion/I-AdverseReaction (/O SIADH/B-AdverseReaction )/O ./O
Cases/O with/O serum/B-AdverseReaction sodium/I-AdverseReaction lower/I-AdverseReaction than/I-AdverseReaction 110/I-AdverseReaction mmol/I-AdverseReaction L/O have/O been/O reported/O ./O
Elderly/O patients/O may/O be/O at/O greater/O risk/O of/O developing/O hyponatremia/B-AdverseReaction with/O SSRIs/O and/O SNRIs/B-DrugClass ./O
Also/O ,/O patients/O taking/O diuretics/O or/O who/O are/O otherwise/O volume/O depleted/O can/O be/O at/O greater/O risk/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.5/O )/O and/O Clinical/O Pharmacology/O (/O 12.6/O )/O ]/O ./O
Discontinuation/O of/O PRISTIQ/O should/O be/O considered/O in/O patients/O with/O symptomatic/O hyponatremia/O and/O appropriate/O medical/O intervention/O should/O be/O instituted/O ./O
Signs/O and/O symptoms/O of/O hyponatremia/B-AdverseReaction include/O headache/B-AdverseReaction ,/O difficulty/B-AdverseReaction concentrating/I-AdverseReaction ,/O memory/B-AdverseReaction impairment/I-AdverseReaction ,/O confusion/B-AdverseReaction ,/O weakness/B-AdverseReaction ,/O and/O unsteadiness/B-AdverseReaction ,/O which/O can/B-Factor lead/O to/O falls/B-AdverseReaction ./O
Signs/O and/O symptoms/O associated/O with/O more/O severe/O and/or/O acute/O cases/O have/O included/O hallucination/B-AdverseReaction ,/O syncope/B-AdverseReaction ,/O seizure/B-AdverseReaction ,/O coma/B-AdverseReaction ,/O respiratory/B-AdverseReaction arrest/I-AdverseReaction ,/O and/O death/B-AdverseReaction ./O
5.10/O Interstitial/O Lung/O Disease/O and/O Eosinophilic/O Pneumonia/O Interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction and/O eosinophilic/B-AdverseReaction pneumonia/I-AdverseReaction associated/O with/O venlafaxine/B-DrugClass (/O the/O parent/O drug/O of/O PRISTIQ/O )/O therapy/O have/O been/O rarely/O reported/O ./O
The/O possibility/O of/O these/O adverse/O events/O should/O be/O considered/O in/O patients/O treated/O with/O PRISTIQ/O who/O present/O with/O progressive/O dyspnea/O ,/O cough/O ,/O or/O chest/O discomfort/O ./O
Such/O patients/O should/O undergo/O a/O prompt/O medical/O evaluation/O ,/O and/O discontinuation/O of/O PRISTIQ/O should/O be/O considered/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O below/O and/O also/O elsewhere/O in/O the/O labeling/O :/O Hypocalcemia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Serious/B-Severity Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Dermatologic/B-AdverseReaction Adverse/I-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Osteonecrosis/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction Jaw/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Atypical/O Subtrochanteric/O and/O Diaphyseal/O Femoral/O Fractures/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O The/O most/O common/O adverse/O reactions/O reported/O with/O Prolia/O in/O patients/O with/O postmenopausal/O osteoporosis/O are/O back/B-AdverseReaction pain/I-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O and/O cystitis/B-AdverseReaction ./O
The/O most/O common/O adverse/O reactions/O reported/O with/O Prolia/O in/O men/O with/O osteoporosis/O are/O back/B-AdverseReaction pain/I-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O and/O nasopharyngitis/B-AdverseReaction ./O
The/O most/O common/O (/O per/O patient/O incidence/O 10/O %/O )/O adverse/O reactions/O reported/O with/O Prolia/O in/O patients/O with/O bone/O loss/O receiving/O androgen/O deprivation/O therapy/O for/O prostate/O cancer/O or/O adjuvant/O aromatase/O inhibitor/O therapy/O for/O breast/O cancer/O are/O arthralgia/B-AdverseReaction and/O back/B-AdverseReaction pain/I-AdverseReaction ./O
Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction and/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction have/O also/O been/O reported/O in/O clinical/O trials/O ./O
The/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O of/O Prolia/O in/O patients/O with/O postmenopausal/O osteoporosis/O are/O back/B-AdverseReaction pain/I-AdverseReaction and/O constipation/B-AdverseReaction ./O
The/O Prolia/O Postmarketing/O Active/O Safety/O Surveillance/O Program/O is/O available/O to/O collect/O information/O from/O prescribers/O on/O specific/O adverse/O events/O ./O
Please/O see/O www.proliasafety.com/O or/O call/O 1/O -/O 800/O -/O 772/O -/O 6436/O for/O more/O information/O about/O this/O program/O ./O
EXCERPT/O :/O Postmenopausal/O osteoporosis/O :/O Most/O common/O adverse/O reactions/O (/O 5/O %/O and/O more/O common/O than/O placebo/O )/O were/O :/O back/B-AdverseReaction pain/I-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O cystitis/B-AdverseReaction ./O
Pancreatitis/B-AdverseReaction has/O been/O reported/O in/O clinical/O trials/O (/O 6.1/O )/O Male/O Osteoporosis/O :/O Most/O common/O adverse/O reactions/O (/O 5/O %/O and/O more/O common/O than/O placebo/O )/O were/O :/O back/B-AdverseReaction pain/I-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O and/O nasopharyngitis/B-AdverseReaction (/O 6.1/O )/O Bone/O loss/O due/O to/O hormone/O ablation/O for/O cancer/O :/O Most/O common/O adverse/O reactions/O (/O 10/O %/O and/O more/O common/O than/O placebo/O )/O were/O :/O arthralgia/B-AdverseReaction and/O back/B-AdverseReaction pain/I-AdverseReaction ./O
Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction and/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction have/O also/O been/O reported/O in/O clinical/O trials/O (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Amgen/O Inc./O at/O 1/O -/O 800/O -/O 77-AMGEN/O (/O 1/O -/O 800/O -/O 772/O -/O 6436/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O studies/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O studies/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Treatment/O of/O Postmenopausal/O Women/O with/O Osteoporosis/O The/O safety/O of/O Prolia/O in/O the/O treatment/O of/O postmenopausal/O osteoporosis/O was/O assessed/O in/O a/O 3-year/O ,/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O multinational/O study/O of/O 7808/O postmenopausal/O women/O aged/O 60/O to/O 91/O years/O ./O
A/O total/O of/O 3876/O women/O were/O exposed/O to/O placebo/O and/O 3886/O women/O were/O exposed/O to/O Prolia/O administered/O subcutaneously/O once/O every/O 6/O months/O as/O a/O single/O 60/O mg/O dose/O ./O
All/O women/O were/O instructed/O to/O take/O at/O least/O 1000/O mg/O of/O calcium/O and/O 400/O IU/O of/O vitamin/O D/O supplementation/O per/O day/O ./O
The/O incidence/O of/O all/O -/O cause/O mortality/B-AdverseReaction was/O 2.3/O %/O (/O n/O 90/O )/O in/O the/O placebo/O group/O and/O 1.8/O %/O (/O n/O 70/O )/O in/O the/O Prolia/O group/O ./O
The/O incidence/O of/O nonfatal/O serious/O adverse/O events/O was/O 24.2/O %/O in/O the/O placebo/O group/O and/O 25.0/O %/O in/O the/O Prolia/O group/O ./O
The/O percentage/O of/O patients/O who/O withdrew/O from/O the/O study/O due/O to/O adverse/O events/O was/O 2.1/O %/O and/O 2.4/O %/O for/O the/O placebo/O and/O Prolia/O groups/O ,/O respectively/O ./O
Adverse/O reactions/O reported/O in/O 2/O %/O of/O postmenopausal/O women/O with/O osteoporosis/O and/O more/O frequently/O in/O the/O Prolia/O -/O treated/O women/O than/O in/O the/O placebo/O -/O treated/O women/O are/O shown/O in/O the/O table/O below/O ./O
Table/O 1/O ./O
Adverse/O Reactions/O Occurring/O in/O 2/O %/O of/O Patients/O with/O Osteoporosis/O and/O More/O Frequently/O than/O in/O Placebo/O -/O treated/O Patients/O SYSTEM/O ORGAN/O CLASS/O Preferred/O Term/O Prolia(N/O 3886)n/O (/O %/O )/O Placebo(N/O 3876)n/O (/O %/O )/O BLOOD/O AND/O LYMPHATIC/O SYSTEM/O DISORDERS/O Anemia/B-AdverseReaction 129/O (/O 3.3/O )/O 107/O (/O 2.8/O )/O CARDIAC/O DISORDERS/O Angina/B-AdverseReaction pectoris/I-AdverseReaction 101/O (/O 2.6/O )/O 87/O (/O 2.2/O )/O Atrial/B-AdverseReaction fibrillation/I-AdverseReaction 79/O (/O 2.0/O )/O 77/O (/O 2.0/O )/O EAR/O AND/O LABYRINTH/O DISORDERS/O Vertigo/B-AdverseReaction 195/O (/O 5.0/O )/O 187/O (/O 4.8/O )/O GASTROINTESTINAL/O DISORDERS/O Abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction 129/O (/O 3.3/O )/O 111/O (/O 2.9/O )/O Flatulence/B-AdverseReaction 84/O (/O 2.2/O )/O 53/O (/O 1.4/O )/O Gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction 80/O (/O 2.1/O )/O 66/O (/O 1.7/O )/O GENERAL/O DISORDERS/O AND/O ADMINISTRATION/O SITE/O CONDITIONS/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 189/O (/O 4.9/O )/O 155/O (/O 4.0/O )/O Asthenia/B-AdverseReaction 90/O (/O 2.3/O )/O 73/O (/O 1.9/O )/O INFECTIONS/O AND/O INFESTATIONS/O Cystitis/B-AdverseReaction 228/O (/O 5.9/O )/O 225/O (/O 5.8/O )/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 190/O (/O 4.9/O )/O 167/O (/O 4.3/O )/O Pneumonia/B-AdverseReaction 152/O (/O 3.9/O )/O 150/O (/O 3.9/O )/O Pharyngitis/B-AdverseReaction 91/O (/O 2.3/O )/O 78/O (/O 2.0/O )/O Herpes/B-AdverseReaction zoster/I-AdverseReaction 79/O (/O 2.0/O )/O 72/O (/O 1.9/O )/O METABOLISM/O AND/O NUTRITION/O DISORDERS/O Hypercholesterolemia/B-AdverseReaction 280/O (/O 7.2/O )/O 236/O (/O 6.1/O )/O MUSCULOSKELETAL/O AND/O CONNECTIVE/O TISSUE/O DISORDERS/O Back/B-AdverseReaction pain/I-AdverseReaction 1347/O (/O 34.7/O )/O 1340/O (/O 34.6/O )/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 453/O (/O 11.7/O )/O 430/O (/O 11.1/O )/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 297/O (/O 7.6/O )/O 291/O (/O 7.5/O )/O Bone/B-AdverseReaction pain/I-AdverseReaction 142/O (/O 3.7/O )/O 117/O (/O 3.0/O )/O Myalgia/B-AdverseReaction 114/O (/O 2.9/O )/O 94/O (/O 2.4/O )/O Spinal/B-AdverseReaction osteoarthritis/I-AdverseReaction 82/O (/O 2.1/O )/O 64/O (/O 1.7/O )/O NERVOUS/O SYSTEM/O DISORDERS/O Sciatica/B-AdverseReaction 178/O (/O 4.6/O )/O 149/O (/O 3.8/O )/O PSYCHIATRIC/O DISORDERS/O Insomnia/B-AdverseReaction 126/O (/O 3.2/O )/O 122/O (/O 3.1/O )/O SKIN/O AND/O SUBCUTANEOUS/O TISSUE/O DISORDERS/O Rash/B-AdverseReaction 96/O (/O 2.5/O )/O 79/O (/O 2.0/O )/O Pruritus/B-AdverseReaction 87/O (/O 2.2/O )/O 82/O (/O 2.1/O )/O Hypocalcemia/B-AdverseReaction Decreases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction calcium/I-AdverseReaction levels/I-AdverseReaction to/O less/O than/O 8.5/O mg/O dL/O at/O any/O visit/O were/O reported/O in/O 0.4/O %/O women/O in/O the/O placebo/O group/O and/O 1.7/O %/O women/O in/O the/O Prolia/O group/O ./O
The/O nadir/O in/O serum/O calcium/O level/O occurs/O at/O approximately/O day/O 10/O after/O Prolia/O dosing/O in/O subjects/O with/O normal/O renal/O function/O ./O
In/O clinical/O studies/O ,/O subjects/O with/O impaired/O renal/O function/O were/O more/O likely/O to/O have/O greater/O reductions/O in/O serum/O calcium/O levels/O compared/O to/O subjects/O with/O normal/O renal/O function/O ./O
In/O a/O study/O of/O 55/O subjects/O with/O varying/O degrees/O of/O renal/O function/O ,/O serum/O calcium/O levels/O 7.5/O mg/O dL/O or/O symptomatic/B-AdverseReaction hypocalcemia/I-AdverseReaction were/O observed/O in/O 5/O subjects/O ./O
These/O included/O no/O subjects/O in/O the/O normal/O renal/O function/O group/O ,/O 10/O %/O of/O subjects/O in/O the/O creatinine/O clearance/O 50/O to/O 80/O mL/O min/O group/O ,/O 29/O %/O of/O subjects/O in/O the/O creatinine/O clearance/O 30/O mL/O min/O group/O ,/O and/O 29/O %/O of/O subjects/O in/O the/O hemodialysis/O group/O ./O
These/O subjects/O did/O not/O receive/O calcium/O and/O vitamin/O D/O supplementation/O ./O
In/O a/O study/O of/O 4550/O postmenopausal/O women/O with/O osteoporosis/O ,/O the/O mean/O change/O from/O baseline/O in/O serum/O calcium/O level/O 10/O days/O after/O Prolia/O dosing/O was/O -5.5/O %/O in/O subjects/O with/O creatinine/O clearance/O 30/O mL/O min/O vs./O -3.1/O %/O in/O subjects/O with/O creatinine/O clearance/O 30/O mL/O min/O ./O
Serious/O Infections/O Receptor/O activator/O of/O nuclear/O factor/O kappa/O -/O B/O ligand/O (/O RANKL/O )/O is/O expressed/O on/O activated/O T/O and/O B/O lymphocytes/O and/O in/O lymph/O nodes/O ./O
Therefore/O ,/O a/O RANKL/O inhibitor/O such/O as/O Prolia/O may/O increase/O the/O risk/B-Factor of/O infection/B-AdverseReaction ./O
In/O the/O clinical/O study/O of/O 7808/O postmenopausal/O women/O with/O osteoporosis/O ,/O the/O incidence/O of/O infections/B-AdverseReaction resulting/O in/O death/B-AdverseReaction was/O 0.2/O %/O in/O both/O placebo/O and/O Prolia/O treatment/O groups/O ./O
However/O ,/O the/O incidence/O of/O nonfatal/O serious/B-Severity infections/B-AdverseReaction was/O 3.3/O %/O in/O the/O placebo/O and/O 4.0/O %/O in/O the/O Prolia/O groups/O ./O
Hospitalizations/O due/O to/O serious/B-Severity infections/B-AdverseReaction in/I-AdverseReaction the/I-AdverseReaction abdomen/I-AdverseReaction (/O 0.7/O %/O placebo/O vs./O 0.9/O %/O Prolia/O )/O ,/O urinary/O tract/O (/O 0.5/O %/O placebo/O vs./O 0.7/O %/O Prolia/O )/O ,/O and/O ear/O (/O 0.0/O %/O placebo/O vs./O 0.1/O %/O Prolia/O )/O were/O reported/O ./O
Endocarditis/B-AdverseReaction was/O reported/O in/O no/O placebo/O patients/O and/O 3/O patients/O receiving/O Prolia/O ./O
Skin/B-AdverseReaction infections/I-AdverseReaction ,/O including/O erysipelas/B-AdverseReaction and/O cellulitis/B-AdverseReaction ,/O leading/O to/O hospitalization/O were/O reported/O more/O frequently/O in/O patients/O treated/O with/O Prolia/O (/O 0.1/O %/O placebo/O vs./O 0.4/O %/O Prolia/O )/O ./O
The/O incidence/O of/O opportunistic/B-AdverseReaction infections/I-AdverseReaction was/O similar/O to/O that/O reported/O with/O placebo/O ./O
Dermatologic/O Reactions/O A/O significantly/O higher/O number/O of/O patients/O treated/O with/O Prolia/O developed/O epidermal/O and/O dermal/B-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction (/O such/O as/O dermatitis/B-AdverseReaction ,/O eczema/B-AdverseReaction ,/O and/O rashes/B-AdverseReaction )/O ,/O with/O these/O events/O reported/O in/O 8.2/O %/O of/O the/O placebo/O and/O 10.8/O %/O of/O the/O Prolia/O groups/O (/O p/O 0.0001/O )/O ./O
Most/O of/O these/O events/O were/O not/O specific/O to/O the/O injection/O site/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O ./O
Osteonecrosis/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction Jaw/I-AdverseReaction ONJ/B-AdverseReaction has/O been/O reported/O in/O the/O osteoporosis/O clinical/O trial/O program/O in/O patients/O treated/O with/O Prolia/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Atypical/O Subtrochanteric/O and/O Diaphyseal/O Fractures/O In/O the/O osteoporosis/O clinical/O trial/O program/O ,/O atypical/B-AdverseReaction femoral/I-AdverseReaction fractures/I-AdverseReaction were/O reported/O in/O patients/O treated/O with/O Prolia/O ./O
The/O duration/O of/O Prolia/O exposure/O to/O time/O of/O atypical/B-AdverseReaction femoral/I-AdverseReaction fracture/I-AdverseReaction diagnosis/O was/O as/O early/O as/O 21/2/O years/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
Pancreatitis/O Pancreatitis/B-AdverseReaction was/O reported/O in/O 4/O patients/O (/O 0.1/O %/O )/O in/O the/O placebo/O and/O 8/O patients/O (/O 0.2/O %/O )/O in/O the/O Prolia/O groups/O ./O
Of/O these/O reports/O ,/O 1/O patient/O in/O the/O placebo/O group/O and/O all/O 8/O patients/O in/O the/O Prolia/O group/O had/O serious/O events/O ,/O including/O one/O death/B-AdverseReaction in/O the/O Prolia/O group/O ./O
Several/O patients/O had/O a/O prior/O history/O of/O pancreatitis/O ./O
The/O time/O from/O product/O administration/O to/O event/O occurrence/O was/O variable/O ./O
New/O Malignancies/O The/O overall/O incidence/O of/O new/O malignancies/B-AdverseReaction was/O 4.3/O %/O in/O the/O placebo/O and/O 4.8/O %/O in/O the/O Prolia/O groups/O ./O
New/O malignancies/O related/O to/O the/O breast/O (/O 0.7/O %/O placebo/O vs./O 0.9/O %/O Prolia/O )/O ,/O reproductive/O system/O (/O 0.2/O %/O placebo/O vs./O 0.5/O %/O Prolia/O )/O ,/O and/O gastrointestinal/O system/O (/O 0.6/O %/O placebo/O vs./O 0.9/O %/O Prolia/O )/O were/O reported/O ./O
A/O causal/O relationship/O to/O drug/O exposure/O has/O not/O been/O established/O ./O
Treatment/O to/O Increase/O Bone/O Mass/O in/O Men/O with/O Osteoporosis/O The/O safety/O of/O Prolia/O in/O the/O treatment/O of/O men/O with/O osteoporosis/O was/O assessed/O in/O a/O 1-year/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O study/O ./O
A/O total/O of/O 120/O men/O were/O exposed/O to/O placebo/O and/O 120/O men/O were/O exposed/O to/O Prolia/O administered/O subcutaneously/O once/O every/O 6/O months/O as/O a/O single/O 60/O mg/O dose/O ./O
All/O men/O were/O instructed/O to/O take/O at/O least/O 1000/O mg/O of/O calcium/O and/O 800/O IU/O of/O vitamin/O D/O supplementation/O per/O day/O ./O
The/O incidence/O of/O all/O -/O cause/O mortality/B-AdverseReaction was/O 0.8/O %/O (/O n/O 1/O )/O in/O the/O placebo/O group/O and/O 0.8/O %/O (/O n/O 1/O )/O in/O the/O Prolia/O group/O ./O
The/O incidence/O of/O nonfatal/O serious/O adverse/O events/O was/O 7.5/O %/O in/O the/O placebo/O group/O and/O 8.3/O %/O in/O the/O Prolia/O group/O ./O
The/O percentage/O of/O patients/O who/O withdrew/O from/O the/O study/O due/O to/O adverse/O events/O was/O 0/O %/O and/O 2.5/O %/O for/O the/O placebo/O and/O Prolia/O groups/O ,/O respectively/O ./O
Adverse/O reactions/O reported/O in/O 5/O %/O of/O men/O with/O osteoporosis/O and/O more/O frequently/O with/O Prolia/O than/O in/O the/O placebo/O -/O treated/O patients/O were/O :/O back/B-AdverseReaction pain/I-AdverseReaction (/O 6.7/O %/O placebo/O vs./O 8.3/O %/O Prolia/O )/O ,/O arthralgia/B-AdverseReaction (/O 5.8/O %/O placebo/O vs./O 6.7/O %/O Prolia/O )/O ,/O and/O nasopharyngitis/B-AdverseReaction (/O 5.8/O %/O placebo/O vs./O 6.7/O %/O Prolia/O )/O ./O
Serious/O Infections/O S/B-Severity erious/O infection/B-AdverseReaction was/O reported/O in/O 1/O patient/O (/O 0.8/O %/O )/O in/O the/O placebo/O group/O and/O no/B-Negation patients/O in/O the/O Prolia/O group/O ./O
Dermatologic/O Reactions/O Epidermal/O and/O dermal/B-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction (/O such/O as/O dermatitis/B-AdverseReaction ,/O eczema/B-AdverseReaction ,/O and/O rashes/B-AdverseReaction )/O were/O reported/O in/O 4/O patients/O (/O 3.3/O %/O )/O in/O the/O placebo/O group/O and/O 5/O patients/O (/O 4.2/O %/O )/O in/O the/O Prolia/O group/O ./O
Osteonecrosis/O of/O the/O Jaw/O No/B-Negation cases/O of/O ONJ/B-AdverseReaction were/O reported/O ./O
Pancreatitis/O Pancreatitis/B-AdverseReaction was/O reported/O in/O 1/O patient/O (/O 0.8/O %/O )/O in/O the/O placebo/O group/O and/O 1/O patient/O (/O 0.8/O %/O )/O in/O the/O Prolia/O group/O ./O
New/O Malignancies/O New/O malignancies/B-AdverseReaction were/O reported/O in/O no/O patients/O in/O the/O placebo/O group/O and/O 4/O (/O 3.3/O %/O )/O patients/O (/O 3/O prostate/B-AdverseReaction cancers/I-AdverseReaction ,/O 1/O basal/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction )/O in/O the/O Prolia/O group/O ./O
Treatment/O of/O Bone/O Loss/O in/O Patients/O Receiving/O Androgen/O Deprivation/O Therapy/O for/O Prostate/O Cancer/O or/O Adjuvant/O Aromatase/O Inhibitor/O Therapy/O for/O Breast/O Cancer/O The/O safety/O of/O Prolia/O in/O the/O treatment/O of/O bone/O loss/O in/O men/O with/O nonmetastatic/O prostate/O cancer/O receiving/O androgen/O deprivation/O therapy/O (/O ADT/O )/O was/O assessed/O in/O a/O 3-year/O ,/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O multinational/O study/O of/O 1468/O men/O aged/O 48/O to/O 97/O years/O ./O
A/O total/O of/O 725/O men/O were/O exposed/O to/O placebo/O and/O 731/O men/O were/O exposed/O to/O Prolia/O administered/O once/O every/O 6/O months/O as/O a/O single/O 60/O mg/O subcutaneous/O dose/O ./O
All/O men/O were/O instructed/O to/O take/O at/O least/O 1000/O mg/O of/O calcium/O and/O 400/O IU/O of/O vitamin/O D/O supplementation/O per/O day/O ./O
The/O incidence/O of/O serious/O adverse/O events/O was/O 30.6/O %/O in/O the/O placebo/O group/O and/O 34.6/O %/O in/O the/O Prolia/O group/O ./O
The/O percentage/O of/O patients/O who/O withdrew/O from/O the/O study/O due/O to/O adverse/O events/O was/O 6.1/O %/O and/O 7.0/O %/O for/O the/O placebo/O and/O Prolia/O groups/O ,/O respectively/O ./O
The/O safety/O of/O Prolia/O in/O the/O treatment/O of/O bone/O loss/O in/O women/O with/O nonmetastatic/O breast/O cancer/O receiving/O aromatase/O inhibitor/O (/O AI/O )/O therapy/O was/O assessed/O in/O a/O 2-year/O ,/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O multinational/O study/O of/O 252/O postmenopausal/O women/O aged/O 35/O to/O 84/O years/O ./O
A/O total/O of/O 120/O women/O were/O exposed/O to/O placebo/O and/O 129/O women/O were/O exposed/O to/O Prolia/O administered/O once/O every/O 6/O months/O as/O a/O single/O 60/O mg/O subcutaneous/O dose/O ./O
All/O women/O were/O instructed/O to/O take/O at/O least/O 1000/O mg/O of/O calcium/O and/O 400/O IU/O of/O vitamin/O D/O supplementation/O per/O day/O ./O
The/O incidence/O of/O serious/O adverse/O events/O was/O 9.2/O %/O in/O the/O placebo/O group/O and/O 14.7/O %/O in/O the/O Prolia/O group/O ./O
The/O percentage/O of/O patients/O who/O withdrew/O from/O the/O study/O due/O to/O adverse/O events/O was/O 4.2/O %/O and/O 0.8/O %/O for/O the/O placebo/O and/O Prolia/O groups/O ,/O respectively/O ./O
Adverse/O reactions/O reported/O in/O 10/O %/O of/O Prolia/O -/O treated/O patients/O receiving/O ADT/O for/O prostate/O cancer/O or/O adjuvant/O AI/O therapy/O for/O breast/O cancer/O ,/O and/O more/O frequently/O than/O in/O the/O placebo/O -/O treated/O patients/O were/O :/O arthralgia/B-AdverseReaction (/O 13.0/O %/O placebo/O vs./O 14.3/O %/O Prolia/O )/O and/O back/B-AdverseReaction pain/I-AdverseReaction (/O 10.5/O %/O placebo/O vs./O 11.5/O %/O Prolia/O )/O ./O
Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction (/O 7.7/O %/O placebo/O vs./O 9.9/O %/O Prolia/O )/O and/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction (/O 3.8/O %/O placebo/O vs./O 6.0/O %/O Prolia/O )/O have/O also/O been/O reported/O in/O clinical/O trials/O ./O
Additionally/O in/O Prolia/O -/O treated/O men/O with/O nonmetastatic/O prostate/O cancer/O receiving/O ADT/O ,/O a/O greater/O incidence/O of/O cataracts/B-AdverseReaction was/O observed/O (/O 1.2/O %/O placebo/O vs./O 4.7/O %/O Prolia/O )/O ./O
Hypocalcemia/B-AdverseReaction (/O serum/O calcium/O 8.4/O mg/O dL/O )/O was/O reported/O only/O in/O Prolia/O -/O treated/O patients/O (/O 2.4/O %/O vs./O 0/O %/O )/O at/O the/O month/O 1/O visit/O ./O
6.2/O Postmarketing/O Experience/O Because/O postmarketing/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O Prolia/O :/O Drug/O -/O related/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction :/O anaphylaxis/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O facial/B-AdverseReaction swelling/I-AdverseReaction ,/O and/O erythema/B-AdverseReaction Hypocalcemia/B-AdverseReaction :/O severe/B-Severity symptomatic/B-AdverseReaction hypocalcemia/B-AdverseReaction Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O including/O severe/B-Severity cases/O Parathyroid/O Hormone/O (/O PTH/O )/O :/O Marked/B-Severity elevation/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction PTH/I-AdverseReaction in/O patients/O with/O severe/O renal/O impairment/O (/O creatinine/O clearance/O 30/O mL/O min/O )/O or/O receiving/O dialysis/O ./O
6.3/O Immunogenicity/O Denosumab/O is/O a/O human/O monoclonal/O antibody/O ./O
As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O potential/O for/O immunogenicity/O ./O
Using/O an/O electrochemiluminescent/O bridging/O immunoassay/O ,/O less/O than/O 1/O %/O (/O 55/O out/O of/O 8113/O )/O of/O patients/O treated/O with/O Prolia/O for/O up/O to/O 5/O years/O tested/O positive/O for/O binding/O antibodies/O (/O including/O pre/O -/O existing/O ,/O transient/O ,/O and/O developing/O antibodies/O )/O ./O
None/O of/O the/O patients/O tested/O positive/O for/O neutralizing/O antibodies/O ,/O as/O was/O assessed/O using/O a/O chemiluminescent/O cell/O -/O based/O in/O vitro/O biological/O assay/O ./O
No/B-Negation evidence/O of/O altered/O pharmacokinetic/O profile/O ,/O toxicity/B-AdverseReaction profile/O ,/O or/O clinical/O response/O was/O associated/O with/O binding/O antibody/O development/O ./O
The/O incidence/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O a/O positive/O antibody/O (/O including/O neutralizing/O antibody/O )/O test/O result/O may/O be/O influenced/O by/O several/O factors/O ,/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O antibodies/O to/O denosumab/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Same/O Active/O Ingredient/O :/O Patients/O receiving/O Prolia/O should/O not/O receive/O XGEVA/O (/O r/O )/O (/O 5.1/O )/O Hypersensitivity/B-AdverseReaction including/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction may/O occur/O ./O
Discontinue/O permanently/O if/O a/O clinically/O significant/O reaction/O occurs/O (/O 5.2/O )/O Hypocalcemia/B-AdverseReaction :/O Must/O be/O corrected/O before/O initiating/O Prolia/O ./O
May/O worsen/O ,/O especially/O in/O patients/O with/O renal/O impairment/O ./O
Adequately/O supplement/O patients/O with/O calcium/O and/O vitamin/O D/O (/O 5.3/O )/O Osteonecrosis/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction jaw/I-AdverseReaction :/O Has/O been/O reported/O with/O Prolia/O ./O
Monitor/O for/O symptoms/O (/O 5.4/O )/O Atypical/B-AdverseReaction femoral/I-AdverseReaction fractures/I-AdverseReaction :/O Have/O been/O reported/O ./O
Evaluate/O patients/O with/O thigh/O or/O groin/O pain/O to/O rule/O out/O a/O femoral/O fracture/O (/O 5.5/O )/O Serious/B-Severity infections/B-AdverseReaction including/O skin/B-AdverseReaction infections/I-AdverseReaction :/O May/O occur/O ,/O including/O those/O leading/O to/O hospitalization/O ./O
Advise/O patients/O to/O seek/O prompt/O medical/O attention/O if/O they/O develop/O signs/O or/O symptoms/O of/O infection/O ,/O including/O cellulitis/O (/O 5.6/O )/O Dermatologic/B-AdverseReaction reactions/I-AdverseReaction :/O Dermatitis/B-AdverseReaction ,/O rashes/B-AdverseReaction ,/O and/O eczema/B-AdverseReaction have/O been/O reported/O ./O
Consider/O discontinuing/O Prolia/O if/O severe/O symptoms/O develop/O (/O 5.7/O )/O Severe/B-Severity Bone/O ,/O Joint/O ,/O Muscle/B-AdverseReaction Pain/I-AdverseReaction may/O occur/O ./O
Discontinue/O use/O if/O severe/O symptoms/O develop/O (/O 5.8/O )/O Suppression/B-AdverseReaction of/I-AdverseReaction bone/I-AdverseReaction turnover/I-AdverseReaction :/O Significant/O suppression/O has/O been/O demonstrated/O ./O
Monitor/O for/O consequences/O of/O bone/O oversuppression/O (/O 5.9/O )/O 5.1/O Drug/O Products/O with/O Same/O Active/O Ingredient/O Prolia/O contains/O the/O same/O active/O ingredient/O (/O denosumab/O )/O found/O in/O Xgeva/O ./O
Patients/O receiving/O Prolia/O should/O not/O receive/O Xgeva/O ./O
5.2/O Hypersensitivity/O Clinically/O significant/O hypersensitivity/B-AdverseReaction including/O anaphylaxis/B-AdverseReaction has/O been/O reported/O with/O Prolia/O ./O
Symptoms/O have/O included/O hypotension/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O throat/B-AdverseReaction tightness/I-AdverseReaction ,/O facial/O and/O upper/B-AdverseReaction airway/I-AdverseReaction edema/I-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O and/O urticaria/B-AdverseReaction ./O
If/O an/O anaphylactic/O or/O other/O clinically/O significant/O allergic/O reaction/O occurs/O ,/O initiate/O appropriate/O therapy/O and/O discontinue/O further/O use/O of/O Prolia/O [/O see/O Contraindications/O (/O 4.3/O )/O ,/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
5.3/O Hypocalcemia/O and/O Mineral/O Metabolism/O Hypocalcemia/O may/B-Factor be/O exacerbated/O by/O the/O use/O of/O Prolia/O ./O
Pre/O -/O existing/O hypocalcemia/O must/O be/O corrected/O prior/O to/O initiating/O therapy/O with/O Prolia/O ./O
In/O patients/O predisposed/O to/O hypocalcemia/O and/O disturbances/O of/O mineral/O metabolism/O (/O e.g./O history/O of/O hypoparathyroidism/O ,/O thyroid/O surgery/O ,/O parathyroid/O surgery/O ,/O malabsorption/O syndromes/O ,/O excision/O of/O small/O intestine/O ,/O severe/O renal/O impairment/O [/O creatinine/O clearance/O 30/O mL/O min/O ]/O or/O receiving/O dialysis/O )/O ,/O clinical/O monitoring/O of/O calcium/O and/O mineral/O levels/O (/O phosphorus/O and/O magnesium/O )/O is/O highly/O recommended/O within/O 14/O days/O of/O Prolia/O injection/O ./O
In/O some/O postmarketing/O cases/O ,/O hypocalcemia/B-AdverseReaction persisted/O for/O weeks/O or/O months/O and/O required/O frequent/O monitoring/O and/O intravenous/O and/or/O oral/O calcium/O replacement/O ,/O with/O or/O without/O vitamin/O D./O Hypocalcemia/B-AdverseReaction following/O Prolia/O administration/O is/O a/O significant/O risk/O in/O patients/O with/O severe/O renal/O impairment/O [/O creatinine/O clearance/O 30/O mL/O min/O ]/O or/O receiving/O dialysis/O ./O
These/O patients/O may/B-Factor also/O develop/O marked/B-Severity elevations/B-AdverseReaction of/I-AdverseReaction serum/I-AdverseReaction parathyroid/I-AdverseReaction hormone/I-AdverseReaction (/O PTH/O )/O ./O
Instruct/O all/O patients/O with/O severe/O renal/O impairment/O ,/O including/O those/O receiving/O dialysis/O ,/O about/O the/O symptoms/O of/O hypocalcemia/O and/O the/O importance/O of/O maintaining/O calcium/O levels/O with/O adequate/O calcium/O and/O vitamin/O D/O supplementation/O ./O
Adequately/O supplement/O all/O patients/O with/O calcium/O and/O vitamin/O D/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ,/O Contraindications/O (/O 4.1/O )/O ,/O Adverse/O Reactions/O (/O 6.1/O )/O ,/O and/O Patient/O Counseling/O Information/O (/O 17.3/O )/O ]/O ./O
5.4/O Osteonecrosis/O of/O the/O Jaw/O Osteonecrosis/O of/O the/O jaw/O (/O ONJ/O )/O ,/O which/O can/O occur/O spontaneously/O ,/O is/O generally/O associated/O with/O tooth/O extraction/O and/or/O local/O infection/O with/O delayed/O healing/O ./O
ONJ/B-AdverseReaction has/O been/O reported/O in/O patients/O receiving/O denosumab/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
A/O routine/O oral/O exam/O should/O be/O performed/O by/O the/O prescriber/O prior/O to/O initiation/O of/O Prolia/O treatment/O ./O
A/O dental/O examination/O with/O appropriate/O preventive/O dentistry/O is/O recommended/O prior/O to/O treatment/O with/O Prolia/O in/O patients/O with/O risk/O factors/O for/O ONJ/O such/O as/O invasive/O dental/O procedures/O (/O e.g./O tooth/O extraction/O ,/O dental/O implants/O ,/O oral/O surgery/O )/O ,/O diagnosis/O of/O cancer/O ,/O concomitant/O therapies/O (/O e.g./O chemotherapy/O ,/O corticosteroids/O ,/O angiogenesis/O inhibitors/O )/O ,/O poor/O oral/O hygiene/O ,/O and/O co/O -/O morbid/O disorders/O (/O e.g./O periodontal/O and/or/O other/O pre/O -/O existing/O dental/O disease/O ,/O anemia/O ,/O coagulopathy/O ,/O infection/O ,/O ill/O -/O fitting/O dentures/O )/O ./O
Good/O oral/O hygiene/O practices/O should/O be/O maintained/O during/O treatment/O with/O Prolia/O ./O
Concomitant/O administration/O of/O drugs/O associated/O with/O ONJ/O may/O increase/O the/O risk/O of/O developing/O ONJ/O ./O
For/O patients/O requiring/O invasive/O dental/O procedures/O ,/O clinical/O judgment/O of/O the/O treating/O physician/O and/or/O oral/O surgeon/O should/O guide/O the/O management/O plan/O of/O each/O patient/O based/O on/O individual/O benefit/O -/O risk/O assessment/O ./O
Patients/O who/O are/O suspected/O of/O having/O or/O who/O develop/O ONJ/O while/O on/O Prolia/O should/O receive/O care/O by/O a/O dentist/O or/O an/O oral/O surgeon/O ./O
In/O these/O patients/O ,/O extensive/O dental/O surgery/O to/O treat/O ONJ/O may/O exacerbate/O the/O condition/O ./O
Discontinuation/O of/O Prolia/O therapy/O should/O be/O considered/O based/O on/O individual/O benefit/O -/O risk/O assessment/O ./O
5.5/O Atypical/O Subtrochanteric/O and/O Diaphyseal/O Femoral/O Fractures/O Atypical/O low/O -/O energy/O or/O low/O trauma/O fractures/O of/O the/O shaft/O have/O been/O reported/O in/O patients/O receiving/O Prolia/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
These/O fractures/O can/O occur/O anywhere/O in/O the/O femoral/O shaft/O from/O just/O below/O the/O lesser/O trochanter/O to/O above/O the/O supracondylar/O flare/O and/O are/O transverse/O or/O short/O oblique/O in/O orientation/O without/O evidence/O of/O comminution/O ./O
Causality/O has/O not/O been/O established/O as/O these/O fractures/O also/O occur/O in/O osteoporotic/O patients/O who/O have/O not/O been/O treated/O with/O anti/O -/O resorptive/O agents/O ./O
Atypical/B-AdverseReaction femoral/I-AdverseReaction fractures/I-AdverseReaction most/O commonly/O occur/O with/O minimal/O or/O no/O trauma/O to/O the/O affected/O area/O ./O
They/O may/O be/O bilateral/O and/O many/O patients/O report/O prodromal/O pain/O in/O the/O affected/O area/O ,/O usually/O presenting/O as/O dull/O ,/O aching/O thigh/B-AdverseReaction pain/I-AdverseReaction ,/O weeks/O to/O months/O before/O a/O complete/O fracture/O occurs/O ./O
A/O number/O of/O reports/O note/O that/O patients/O were/O also/O receiving/O treatment/O with/O glucocorticoids/O (/O e.g./O prednisone/O )/O at/O the/O time/O of/O fracture/O ./O
During/O Prolia/O treatment/O ,/O patients/O should/O be/O advised/O to/O report/O new/O or/O unusual/O thigh/O ,/O hip/O ,/O or/O groin/O pain/O ./O
Any/O patient/O who/O presents/O with/O thigh/O or/O groin/O pain/O should/O be/O suspected/O of/O having/O an/O atypical/O fracture/O and/O should/O be/O evaluated/O to/O rule/O out/O an/O incomplete/O femur/O fracture/O ./O
Patient/O presenting/O with/O an/O atypical/O femur/O fracture/O should/O also/O be/O assessed/O for/O symptoms/O and/O signs/O of/O fracture/O in/O the/O contralateral/O limb/O ./O
Interruption/O of/O Prolia/O therapy/O should/O be/O considered/O ,/O pending/O a/O risk/O benefit/O assessment/O ,/O on/O an/O individual/O basis/O ./O
5.6/O Serious/O Infections/O In/O a/O clinical/O trial/O of/O over/O 7800/O women/O with/O postmenopausal/O osteoporosis/O ,/O serious/B-Severity infections/B-AdverseReaction leading/O to/O hospitalization/O were/O reported/O more/O frequently/O in/O the/O Prolia/O group/O than/O in/O the/O placebo/O group/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Serious/B-Severity skin/B-AdverseReaction infections/I-AdverseReaction ,/O as/O well/O as/O infections/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction abdomen/I-AdverseReaction ,/O urinary/O tract/O ,/O and/O ear/O ,/O were/O more/O frequent/O in/O patients/O treated/O with/O Prolia/O ./O
Endocarditis/B-AdverseReaction was/O also/O reported/O more/O frequently/O in/O Prolia/O -/O treated/O patients/O ./O
The/O incidence/O of/O opportunistic/B-AdverseReaction infections/I-AdverseReaction was/O similar/O between/O placebo/O and/O Prolia/O groups/O ,/O and/O the/O overall/O incidence/O of/O infections/B-AdverseReaction was/O similar/O between/O the/O treatment/O groups/O ./O
Advise/O patients/O to/O seek/O prompt/O medical/O attention/O if/O they/O develop/O signs/O or/O symptoms/O of/O severe/O infection/O ,/O including/O cellulitis/O ./O
Patients/O on/O concomitant/O immunosuppressant/O agents/O or/O with/O impaired/O immune/O systems/O may/B-Factor be/O at/O increased/O risk/O for/O serious/B-Severity infections/B-AdverseReaction ./O
Consider/O the/O benefit/O -/O risk/O profile/O in/O such/O patients/O before/O treating/O with/O Prolia/O ./O
In/O patients/O who/O develop/O serious/O infections/O while/O on/O Prolia/O ,/O prescribers/O should/O assess/O the/O need/O for/O continued/O Prolia/O therapy/O ./O
5.7/O Dermatologic/O Adverse/O Reactions/O In/O a/O large/O clinical/O trial/O of/O over/O 7800/O women/O with/O postmenopausal/O osteoporosis/O ,/O epidermal/O and/O dermal/B-AdverseReaction adverse/I-AdverseReaction events/I-AdverseReaction such/O as/O dermatitis/B-AdverseReaction ,/O eczema/B-AdverseReaction ,/O and/O rashes/B-AdverseReaction occurred/O at/O a/O significantly/O higher/O rate/O in/O the/O Prolia/O group/O compared/O to/O the/O placebo/O group/O ./O
Most/O of/O these/O events/O were/O not/O specific/O to/O the/O injection/O site/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Consider/O discontinuing/O Prolia/O if/O severe/O symptoms/O develop/O ./O
5.8/O Musculoskeletal/O Pain/O In/O post/O -/O marketing/O experience/O ,/O severe/B-Severity and/O occasionally/O incapacitating/B-Severity bone/O ,/O joint/O ,/O and/or/O muscle/B-AdverseReaction pain/I-AdverseReaction has/O been/O reported/O in/O patients/O taking/O Prolia/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
The/O time/O to/O onset/O of/O symptoms/O varied/O from/O one/O day/O to/O several/O months/O after/O starting/O Prolia/O ./O
Consider/O discontinuing/O use/O if/O severe/O symptoms/O develop/O [/O see/O Patient/O Counseling/O Information/O (/O 17.8/O )/O ]/O ./O
5.9/O Suppression/O of/O Bone/O Turnover/O In/O clinical/O trials/O in/O women/O with/O postmenopausal/O osteoporosis/O ,/O treatment/O with/O Prolia/O resulted/O in/O significant/O suppression/B-AdverseReaction of/I-AdverseReaction bone/I-AdverseReaction remodeling/I-AdverseReaction as/O evidenced/O by/O markers/O of/O bone/O turnover/O and/O bone/O histomorphometry/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O and/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
The/O significance/O of/O these/O findings/O and/O the/O effect/O of/O long/O -/O term/O treatment/O with/O Prolia/O are/O unknown/O ./O
The/O long/O -/O term/O consequences/O of/O the/O degree/O of/O suppression/B-AdverseReaction of/I-AdverseReaction bone/I-AdverseReaction remodeling/I-AdverseReaction observed/O with/O Prolia/O may/B-Factor contribute/O to/O adverse/O outcomes/O such/O as/O osteonecrosis/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction jaw/I-AdverseReaction ,/O atypical/B-AdverseReaction fractures/I-AdverseReaction ,/O and/O delayed/B-AdverseReaction fracture/I-AdverseReaction healing/I-AdverseReaction ./O
Monitor/O patients/O for/O these/O consequences/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O associated/O with/O PROMACTA/O are/O described/O in/O other/O sections/O ./O
Hepatic/B-AdverseReaction Decompensation/I-AdverseReaction in/O Patients/O with/O Chronic/O Hepatitis/O C/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Thrombotic/O Thromboembolic/B-AdverseReaction Complications/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Cataracts/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O In/O adult/O patients/O with/O ITP/O ,/O the/O most/O common/O adverse/O reactions/O (/O greater/O than/O or/O equal/O to/O 5/O %/O and/O greater/O than/O placebo/O )/O were/O :/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O increased/B-AdverseReaction ALT/I-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O and/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
(/O 6.1/O )/O In/O pediatric/O patients/O age/O 6/O years/O and/O older/O with/O ITP/O ,/O the/O most/O common/O adverse/O reactions/O (/O greater/O than/O or/O equal/O to/O 10/O %/O and/O greater/O than/O placebo/O )/O were/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O and/O rhinitis/B-AdverseReaction ./O
(/O 6.1/O )/O In/O patients/O with/O chronic/O hepatitis/O C/O -/O associated/O thrombocytopenia/O ,/O the/O most/O common/O adverse/O reactions/O (/O greater/O than/O or/O equal/O to/O 10/O %/O and/O greater/O than/O placebo/O )/O were/O :/O anemia/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O influenza/B-AdverseReaction -/I-AdverseReaction like/O illness/O ,/O asthenia/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O chills/B-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O alopecia/B-AdverseReaction ,/O and/O peripheral/B-AdverseReaction edema/I-AdverseReaction ./O
(/O 6.1/O )/O In/O patients/O with/O severe/O aplastic/O anemia/O ,/O the/O most/O common/O adverse/O reactions/O (/O greater/O than/O or/O equal/O to/O 20/O %/O )/O were/O :/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
(/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GlaxoSmithKline/O at/O 1/O -/O 888/O -/O 825/O -/O 5249/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Chronic/O Immune/O (/O Idiopathic/O )/O Thrombocytopenia/O :/O Adults/O :/O In/O clinical/O trials/O ,/O hemorrhage/B-AdverseReaction was/O the/O most/O common/O serious/O adverse/O reaction/O and/O most/O hemorrhagic/B-AdverseReaction reactions/I-AdverseReaction followed/O discontinuation/O of/O PROMACTA/O ./O
Other/O serious/O adverse/O reactions/O included/O thrombotic/O thromboembolic/B-AdverseReaction complications/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
The/O data/O described/O below/O reflect/O exposure/O of/O PROMACTA/O to/O 446/O patients/O with/O chronic/O ITP/O aged/O 18/O to/O 85/O years/O ,/O of/O whom/O 65/O %/O were/O female/O ,/O across/O the/O ITP/O clinical/O development/O program/O including/O three/O placebo/O -/O controlled/O trials/O ./O
PROMACTA/O was/O administered/O to/O 277/O patients/O for/O at/O least/O 6/O months/O and/O 202/O patients/O for/O at/O least/O 1/O year/O ./O
Table/O 4/O presents/O the/O most/O common/O adverse/O drug/O reactions/O (/O experienced/O by/O greater/O than/O or/O equal/O to/O 3/O %/O of/O patients/O receiving/O PROMACTA/O )/O from/O the/O three/O placebo/O -/O controlled/O trials/O ,/O with/O a/O higher/O incidence/O in/O PROMACTA/O versus/O placebo/O ./O
Table/O 4/O ./O
Adverse/O Reactions/O (/O =3/O %/O )/O from/O Three/O Placebo/O -/O controlled/O Trials/O in/O Adults/O with/O Chronic/O Immune/O (/O Idiopathic/O )/O Thrombocytopenia/O Adverse/O Reaction/O PROMACTA/O 50/O mg/O n/O 241/O (/O %/O )/O Placebo/O n/O 128/O (/O %/O )/O Nausea/B-AdverseReaction 9/O 3/O Diarrhea/B-AdverseReaction 9/O 7/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 7/O 6/O Vomiting/B-AdverseReaction 6/O 1/O Increased/B-AdverseReaction ALT/I-AdverseReaction 5/O 3/O Myalgia/B-AdverseReaction 5/O 2/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 5/O 3/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 4/O 3/O Increased/B-AdverseReaction AST/I-AdverseReaction 4/O 2/O Pharyngitis/B-AdverseReaction 4/O 2/O Back/B-AdverseReaction pain/I-AdverseReaction 3/O 2/O Influenza/B-AdverseReaction 3/O 2/O Paresthesia/B-AdverseReaction 3/O 2/O Rash/B-AdverseReaction 3/O 2/O In/O the/O three/O controlled/O clinical/O chronic/O ITP/O trials/O ,/O alopecia/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O blood/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction increased/I-AdverseReaction ,/O and/O dry/B-AdverseReaction mouth/I-AdverseReaction were/O the/O adverse/O reactions/O reported/O in/O 2/O %/O of/O patients/O treated/O with/O PROMACTA/O and/O in/O no/O patients/O who/O received/O placebo/O ./O
Among/O 299/O patients/O with/O chronic/O ITP/O who/O received/O PROMACTA/O in/O the/O single/O -/O arm/O extension/O trial/O ,/O the/O adverse/O reactions/O occurred/O in/O a/O pattern/O similar/O to/O that/O seen/O in/O the/O placebo/O -/O controlled/O trials/O ./O
Table/O 5/O presents/O the/O most/O common/O treatment/O -/O related/O adverse/O reactions/O (/O experienced/O by/O greater/O than/O or/O equal/O to/O 3/O %/O of/O patients/O receiving/O PROMACTA/O )/O from/O the/O extension/O trial/O ./O
Table/O 5/O ./O
Treatment/O -/O related/O Adverse/O Reactions/O (/O =3/O %/O )/O from/O Extension/O Trial/O in/O Adults/O with/O Chronic/O Immune/O (/O Idiopathic/O )/O Thrombocytopenia/O Adverse/O Reaction/O PROMACTA/O 50/O mg/O n/O 299/O (/O %/O )/O Headache/B-AdverseReaction 10/O Hyperbilirubinemia/B-AdverseReaction 6/O ALT/B-AdverseReaction increased/I-AdverseReaction 6/O Cataract/B-AdverseReaction 5/O AST/B-AdverseReaction increased/I-AdverseReaction 4/O Fatigue/B-AdverseReaction 4/O Nausea/B-AdverseReaction 4/O In/O the/O three/O controlled/O chronic/O ITP/O trials/O ,/O serum/B-AdverseReaction liver/I-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction (/O predominantly/O Grade/B-Severity 2/I-Severity or/O less/O in/O severity/O )/O were/O reported/O in/O 11/O %/O and/O 7/O %/O of/O patients/O for/O PROMACTA/O and/O placebo/O ,/O respectively/O ./O
Four/O patients/O (/O 1/O %/O )/O treated/O with/O PROMACTA/O and/O three/O patients/O in/O the/O placebo/O group/O (/O 2/O %/O )/O discontinued/O treatment/O due/O to/O hepatobiliary/B-AdverseReaction laboratory/I-AdverseReaction abnormalities/I-AdverseReaction ./O
Seven/O of/O the/O patients/O treated/O with/O PROMACTA/O in/O the/O controlled/O trials/O with/O hepatobiliary/B-AdverseReaction laboratory/I-AdverseReaction abnormalities/I-AdverseReaction were/O re/O -/O exposed/O to/O PROMACTA/O in/O the/O extension/O trial/O ./O
Six/O of/O these/O patients/O again/O experienced/O liver/B-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction (/O predominantly/O Grade/B-Severity 1/I-Severity )/O resulting/O in/O discontinuation/O of/O PROMACTA/O in/O one/O patient/O ./O
In/O the/O extension/O chronic/O ITP/O trial/O ,/O one/O additional/O patient/O had/O PROMACTA/O discontinued/O due/O to/O liver/B-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction (/O less/O than/O or/O equal/O to/O Grade/B-Severity 3/I-Severity )/O ./O
In/O a/O placebo/O -/O controlled/O trial/O of/O PROMACTA/O in/O patients/O with/O chronic/O liver/O diseaseand/O thrombocytopenia/O not/O related/O to/O ITP/O ,/O six/O patients/O treated/O with/O PROMACTA/O and/O one/O patient/O in/O the/O placebo/O group/O developed/O portal/B-AdverseReaction vein/I-AdverseReaction thromboses/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Pediatric/O Patients/O :/O The/O data/O described/O below/O reflect/O median/O exposure/O to/O PROMACTA/O of/O 91/O days/O for/O 82/O pediatric/O patients/O (/O aged/O 6/O to/O 17/O years/O )/O with/O chronic/O ITP/O ,/O of/O whom/O 52/O %/O were/O female/O ,/O across/O the/O randomized/O phase/O of/O two/O placebo/O -/O controlled/O trials/O ./O
Table/O 6/O presents/O the/O most/O common/O adverse/O drug/O reactions/O (/O experienced/O by/O greater/O than/O or/O equal/O to/O 3/O %/O of/O pediatric/O patients/O 6/O years/O and/O older/O receiving/O PROMACTA/O )/O across/O the/O two/O placebo/O -/O controlled/O trials/O ,/O with/O a/O higher/O incidence/O for/O PROMACTA/O versus/O placebo/O ./O
Table/O 6/O ./O
Adverse/O Reactions/O (/O =3/O %/O )/O with/O a/O Higher/O Incidence/O for/O PROMACTA/O versus/O Placebo/O from/O Two/O Placebo/O -/O controlled/O Trials/O in/O Pediatric/O Patients/O 6/O Years/O and/O Older/O with/O Chronic/O Immune/O (/O Idiopathic/O )/O Thrombocytopenia/O PROMACTA/O Placebo/O n/O 82/O n/O 40/O Adverse/O Reaction/O (/O %/O )/O (/O %/O )/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 16/O 5/O Nasopharyngitis/B-AdverseReaction 12/O 5/O Rhinitis/B-AdverseReaction 11/O 8/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 9/O 5/O Cough/B-AdverseReaction 9/O 0/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 9/O 3/O Toothache/B-AdverseReaction 6/O 0/O AST/B-AdverseReaction increased/I-AdverseReaction 5/O 0/O Diarrhea/B-AdverseReaction 5/O 3/O Rash/B-AdverseReaction 5/O 3/O ALT/B-AdverseReaction increaseda/I-AdverseReaction 6/O 0/O Vitamin/B-AdverseReaction D/I-AdverseReaction deficiency/I-AdverseReaction 4/O 0/O a/O Includes/O adverse/O reactions/O or/O laboratory/O abnormalities/O 3/O x/O ULN/O ./O
Chronic/O Hepatitis/O C/O -/O associated/O Thrombocytopenia/O :/O In/O the/O two/O placebo/O -/O controlled/O trials/O ,/O 955/O patients/O with/O chronic/O hepatitis/O C/O -/O associated/O thrombocytopenia/O received/O PROMACTA/O ./O
Table/O 7/O presents/O the/O most/O common/O adverse/O drug/O reactions/O (/O experienced/O by/O greater/O than/O or/O equal/O to/O 10/O %/O of/O patients/O receiving/O PROMACTA/O compared/O with/O placebo/O )/O ./O
Table/O 7/O ./O
Adverse/O Reactions/O (/O 10/O %/O and/O Greater/O than/O Placebo/O )/O from/O Two/O Placebo/O -/O controlled/O Trials/O in/O Adults/O with/O Chronic/O Hepatitis/O C/O Adverse/O Reaction/O PROMACTA/O +/O Peginterferon/O Ribavirin/O n/O 955/O (/O %/O )/O Placebo/O +/O Peginterferon/O Ribavirin/O n/O 484/O (/O %/O )/O Anemia/B-AdverseReaction 40/O 35/O Pyrexia/B-AdverseReaction 30/O 24/O Fatigue/B-AdverseReaction 28/O 23/O Headache/B-AdverseReaction 21/O 20/O Nausea/B-AdverseReaction 19/O 14/O Diarrhea/B-AdverseReaction 19/O 11/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 18/O 14/O Influenza/B-AdverseReaction -/I-AdverseReaction like/O illness/O 18/O 16/O Asthenia/B-AdverseReaction 16/O 13/O Insomnia/B-AdverseReaction 16/O 15/O Cough/B-AdverseReaction 15/O 12/O Pruritus/B-AdverseReaction 15/O 13/O Chills/B-AdverseReaction 14/O 9/O Myalgia/B-AdverseReaction 12/O 10/O Alopecia/B-AdverseReaction 10/O 6/O Peripheral/B-AdverseReaction edema/I-AdverseReaction 10/O 5/O In/O the/O two/O controlled/O clinical/O trials/O in/O patients/O with/O chronic/O hepatitis/O C/O ,/O hyperbilirubinemia/B-AdverseReaction was/O reported/O in/O 8/O %/O of/O patients/O receiving/O PROMACTA/O compared/O with/O 3/O %/O for/O placebo/O ./O
Total/B-AdverseReaction bilirubin/I-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction or/I-AdverseReaction equal/I-AdverseReaction to/I-AdverseReaction 1.5/I-AdverseReaction x/I-AdverseReaction ULN/I-AdverseReaction was/O reported/O in/O 76/O %/O and/O 50/O %/O of/O patients/O receiving/O PROMACTA/O and/O placebo/O ,/O respectively/O ./O
ALT/O or/O AST/B-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction or/I-AdverseReaction equal/I-AdverseReaction to/I-AdverseReaction 3/I-AdverseReaction x/I-AdverseReaction ULN/I-AdverseReaction was/O reported/O in/O 34/O %/O and/O 38/O %/O of/O patients/O for/O PROMACTA/O and/O placebo/O ,/O respectively/O ./O
Severe/O Aplastic/O Anemia/O :/O In/O the/O single/O -/O arm/O ,/O open/O -/O label/O trial/O ,/O 43/O patients/O with/O severe/O aplastic/O anemia/O received/O PROMACTA/O ./O
Eleven/O patients/O (/O 26/O %/O )/O were/O treated/O for/O greater/O than/O 6/O months/O and/O 7/O patients/O (/O 16/O %/O )/O were/O treated/O for/O greater/O than/O 1/O year/O ./O
The/O most/O common/O adverse/O reactions/O (/O greater/O than/O or/O equal/O to/O 20/O %/O )/O were/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
Table/O 8/O ./O
Adverse/O Reactions/O (/O 10/O %/O )/O from/O One/O Open/O -/O label/O Trial/O in/O Adults/O with/O Severe/O Aplastic/O Anemia/O Adverse/O Reaction/O PROMACTA/O (/O n/O 43/O )/O (/O %/O )/O Nausea/B-AdverseReaction 33/O Fatigue/B-AdverseReaction 28/O Cough/B-AdverseReaction 23/O Diarrhea/B-AdverseReaction 21/O Headache/B-AdverseReaction 21/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 19/O Dyspnea/B-AdverseReaction 14/O Pyrexia/B-AdverseReaction 14/O Dizziness/B-AdverseReaction 14/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 14/O Febrile/B-AdverseReaction neutropenia/I-AdverseReaction 14/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 12/O Ecchymosis/B-AdverseReaction 12/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 12/O Transaminases/B-AdverseReaction increased/I-AdverseReaction 12/O Arthralgia/B-AdverseReaction 12/O Rhinorrhea/B-AdverseReaction 12/O In/O this/O trial/O ,/O patients/O had/O bone/O marrow/O aspirates/O evaluated/O for/O cytogenetic/O abnormalities/O ./O
Eight/O patients/O had/O a/O new/O cytogenetic/B-AdverseReaction abnormality/I-AdverseReaction reported/O on/O therapy/O ,/O including/O 5/O patients/O who/O had/O complex/O changes/B-AdverseReaction in/I-AdverseReaction chromosome/I-AdverseReaction 7/I-AdverseReaction ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O PROMACTA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O the/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Vascular/O Disorders/O :/O Thrombotic/B-AdverseReaction microangiopathy/I-AdverseReaction with/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O RISK/B-Factor FOR/O HEPATIC/B-AdverseReaction DECOMPENSATION/I-AdverseReaction IN/O PATIENTS/O WITH/O CHRONIC/O HEPATITIS/O C/O WARNING/O :/O RISK/B-Factor FOR/O HEPATIC/B-AdverseReaction DECOMPENSATION/I-AdverseReaction IN/O PATIENTS/O WITH/O CHRONIC/O HEPATITIS/O C/O In/O patients/O with/O chronic/O hepatitis/O C/O ,/O PROMACTA/O (/O r/O )/O in/O combination/O with/O interferon/O and/O ribavirin/O may/O increase/O the/O risk/B-Factor of/O hepatic/B-AdverseReaction decompensation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O RISK/B-Factor FOR/O HEPATIC/B-AdverseReaction DECOMPENSATION/I-AdverseReaction IN/O PATIENTS/O WITH/O CHRONIC/O HEPATITIS/O C/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
In/O patients/O with/O chronic/O hepatitis/O C/O ,/O PROMACTA/O in/O combination/O with/O interferon/O and/O ribavirin/O may/O increase/O the/O risk/B-Factor of/O hepatic/B-AdverseReaction decompensation/I-AdverseReaction ./O
(/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hepatotoxicity/B-AdverseReaction :/O Monitor/O liver/O function/O before/O and/O during/O therapy/O ./O
(/O 5.2/O )/O Thrombotic/O Thromboembolic/B-AdverseReaction Complications/I-AdverseReaction :/O Portal/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction has/O been/O reported/O in/O patients/O with/O chronic/O liver/O disease/O receiving/O PROMACTA/O ./O
Monitor/O platelet/O counts/O regularly/O ./O
(/O 5.3/O )/O 5.1/O Hepatic/O Decompensation/O in/O Patients/O with/O Chronic/O Hepatitis/O C/O In/O patients/O with/O chronic/O hepatitis/O C/O ,/O PROMACTA/O in/O combination/O with/O interferon/O and/O ribavirin/O may/O increase/O the/O risk/B-Factor of/O hepatic/B-AdverseReaction decompensation/I-AdverseReaction ./O
In/O two/O controlled/O clinical/O trials/O in/O patients/O with/O chronic/O hepatitis/O C/O and/O thrombocytopenia/O ,/O ascites/B-AdverseReaction and/O encephalopathy/B-AdverseReaction occurred/O more/O frequently/O on/O the/O arm/O receiving/O treatment/O with/O PROMACTA/O plus/O antivirals/O (/O 7/O %/O )/O than/O the/O placebo/O plus/O antivirals/O arm/O (/O 4/O %/O )/O ./O
Patients/O with/O low/O albumin/O levels/O (/O less/O than/O 3.5/O g/O dL/O )/O or/O Model/O for/O End/O -/O Stage/O Liver/O Disease/O (/O MELD/O )/O score/O greater/O than/O or/O equal/O to/O 10/O at/O baseline/O had/O a/O greater/O risk/B-Factor for/O hepatic/B-AdverseReaction decompensation/I-AdverseReaction on/O the/O arm/O receiving/O treatment/O with/O PROMACTA/O plus/O antivirals/O ./O
Discontinue/O PROMACTA/O if/O antiviral/O therapy/O is/O discontinued/O ./O
5.2/O Hepatotoxicity/O PROMACTA/O can/B-Factor cause/O liver/B-AdverseReaction enzyme/I-AdverseReaction elevations/I-AdverseReaction [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Measure/O serum/O ALT/O ,/O AST/O ,/O and/O bilirubin/O prior/O to/O initiation/O of/O PROMACTA/O ,/O every/O 2/O weeks/O during/O the/O dose/O adjustment/O phase/O ,/O and/O monthly/O following/O establishment/O of/O a/O stable/O dose/O ./O
PROMACTA/O inhibits/O UDP/O -/O glucuronosyltransferase/O (/O UGT)1A1/O and/O organic/O anion/O -/O transporting/O polypeptide/O (/O OATP)1B1/O ,/O which/O may/B-Factor lead/O to/O indirect/B-AdverseReaction hyperbilirubinemia/I-AdverseReaction ./O
If/O bilirubin/O is/O elevated/O ,/O perform/O fractionation/O ./O
Evaluate/O abnormal/O serum/O liver/O tests/O with/O repeat/O testing/O within/O 3/O to/O 5/O days/O ./O
If/O the/O abnormalities/O are/O confirmed/O ,/O monitor/O serum/O liver/O tests/O weekly/O until/O resolved/O or/O stabilized/O ./O
Discontinue/O PROMACTA/O if/O ALT/O levels/O increase/O to/O greater/O than/O or/O equal/O to/O 3/O x/O ULN/O in/O patients/O with/O normal/O liver/O function/O or/O greater/O than/O or/O equal/O to/O 3/O x/O baseline/O in/O patients/O with/O pre/O -/O treatment/O elevations/O in/O transaminases/O and/O are/O :/O progressively/O increasing/O ,/O or/O persistent/O for/O greater/O than/O or/O equal/O to/O 4/O weeks/O ,/O or/O accompanied/O by/O increased/O direct/O bilirubin/O ,/O or/O accompanied/O by/O clinical/O symptoms/O of/O liver/O injury/O or/O evidence/O for/O hepatic/O decompensation/O ./O
If/O the/O potential/O benefit/O for/O reinitiating/O treatment/O with/O PROMACTA/O is/O considered/O to/O outweigh/O the/O risk/O for/O hepatotoxicity/O ,/O then/O consider/O cautiously/O reintroducing/O PROMACTA/O and/O measure/O serum/O liver/O tests/O weekly/O during/O the/O dose/O adjustment/O phase/O ./O
Hepatotoxicity/B-AdverseReaction may/B-Factor reoccur/O if/O PROMACTA/O is/O reinitiated/O ./O
If/O liver/O test/O abnormalities/O persist/O ,/O worsen/O or/O recur/O ,/O then/O permanently/O discontinue/O PROMACTA/O ./O
5.3/O Thrombotic/O Thromboembolic/O Complications/O In/O two/O controlled/O clinical/O trials/O in/O patients/O with/O chronic/O hepatitis/O C/O and/O thrombocytopenia/O ,/O 3/O %/O (/O 31/955/O )/O treated/O with/O PROMACTA/O experienced/O a/O thrombotic/B-AdverseReaction event/I-AdverseReaction compared/O with/O 1/O %/O (/O 5/484/O )/O on/O placebo/O ./O
The/O majority/O of/O events/O were/O of/O the/O portal/O venous/O system/O (/O 1/O %/O in/O patients/O treated/O with/O PROMACTA/O versus/O less/O than/O 1/O %/O for/O placebo/O )/O ./O
Thrombotic/O thromboembolic/B-AdverseReaction complications/I-AdverseReaction may/B-Factor result/O from/O increases/B-AdverseReaction in/I-AdverseReaction platelet/I-AdverseReaction counts/I-AdverseReaction with/O PROMACTA/O ./O
Reported/O thrombotic/O thromboembolic/B-AdverseReaction complications/I-AdverseReaction included/O both/O venous/O and/O arterial/O events/O and/O were/O observed/O at/O low/O and/O at/O normal/O platelet/O counts/O ./O
Consider/O the/O potential/O for/O an/O increased/O risk/O of/O thromboembolism/O when/O administering/O PROMACTA/O to/O patients/O with/O known/O risk/O factors/O for/O thromboembolism/O (/O e.g./O ,/O Factor/O V/O Leiden/O ,/O ATIII/O deficiency/O ,/O antiphospholipid/O syndrome/O ,/O chronic/O liver/O disease/O )/O ./O
To/O minimize/O the/O risk/O for/O thrombotic/O thromboembolic/O complications/O ,/O do/O not/O use/O PROMACTA/O in/O an/O attempt/O to/O normalize/O platelet/O counts/O ./O
Follow/O the/O dose/O adjustment/O guidelines/O to/O achieve/O and/O maintain/O target/O platelet/O counts/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O ,/O 2.2/O ,/O 2.3/O )/O ]/O ./O
In/O a/O controlled/O trial/O in/O patients/O with/O chronic/O liver/O disease/O and/O thrombocytopenia/O not/O related/O to/O ITP/O undergoing/O elective/O invasive/O procedures/O (/O N/O 292/O )/O ,/O the/O risk/B-Factor of/O thrombotic/B-AdverseReaction events/I-AdverseReaction was/O increased/O in/O patients/O treated/O with/O 75/O mg/O of/O PROMACTA/O once/O daily/O ./O
Seven/O thrombotic/B-AdverseReaction complications/I-AdverseReaction (/O six/O patients/O )/O were/O reported/O in/O the/O group/O that/O received/O PROMACTA/O and/O three/O thrombotic/B-AdverseReaction complications/I-AdverseReaction were/O reported/O in/O the/O placebo/B-Factor group/O (/O two/O patients/O )/O ./O
All/O of/O the/O thrombotic/B-AdverseReaction complications/I-AdverseReaction reported/O in/O the/O group/O that/O received/O PROMACTA/O were/O portal/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction (/O PVT/B-AdverseReaction )/O ./O
Symptoms/O of/O PVT/B-AdverseReaction included/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction ./O
Five/O of/O the/O six/O patients/O in/O the/O group/O that/O received/O PROMACTA/O experienced/O a/O thrombotic/B-AdverseReaction complication/I-AdverseReaction within/O 30/O days/O of/O completing/O treatment/O with/O PROMACTA/O and/O at/O a/O platelet/O count/O above/O 200/O x/O 10/O 9/O /L./O The/O risk/B-Factor of/O portal/B-AdverseReaction venous/I-AdverseReaction thrombosis/I-AdverseReaction was/O increased/O in/O thrombocytopenic/O patients/O with/O chronic/O liver/O disease/O treated/O with/O 75/O mg/O of/O PROMACTA/O once/O daily/O for/O 2/O weeks/O in/O preparation/O for/O invasive/O procedures/O ./O
5.4/O Cataracts/O In/O the/O three/O controlled/O clinical/O trials/O in/O adults/O with/O chronic/O ITP/O ,/O cataracts/B-AdverseReaction developed/O or/O worsened/O in/O 15/O (/O 7/O %/O )/O patients/O who/O received/O 50/O mg/O of/O PROMACTA/O daily/O and/O 8/O (/O 7/O %/O )/O placebo/O -/O group/O patients/O ./O
In/O the/O extension/O trial/O ,/O cataracts/B-AdverseReaction developed/O or/O worsened/O in/O 4/O %/O of/O patients/O who/O underwent/O ocular/O examination/O prior/O to/O therapy/O with/O PROMACTA/O ./O
In/O the/O two/O controlled/O clinical/O trials/O in/O patients/O with/O chronic/O hepatitis/O C/O and/O thrombocytopenia/O ,/O cataracts/B-AdverseReaction developed/O or/O worsened/O in/O 8/O %/O patients/O treated/O with/O PROMACTA/O and/O 5/O %/O patients/O treated/O with/O placebo/O ./O
Cataracts/B-AdverseReaction were/O observed/O in/O toxicology/O studies/O of/O eltrombopag/O in/O rodents/B-Animal [/O see/O Nonclinical/O Toxicology/O (/O 13.2/O )/O ]/O ./O
Perform/O a/O baseline/O ocular/O examination/O prior/O to/O administration/O of/O PROMACTA/O and/O ,/O during/O therapy/O with/O PROMACTA/O ,/O regularly/O monitor/O patients/O for/O signs/O and/O symptoms/O of/O cataracts/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O elsewhere/O in/O the/O labeling/O :/O Application/B-AdverseReaction -/I-AdverseReaction Associated/O Pain/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Increase/B-AdverseReaction in/I-AdverseReaction Blood/I-AdverseReaction Pressure/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 5/O %/O and/O greater/O than/O control/O )/O are/O application/B-AdverseReaction site/I-AdverseReaction erythema/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction pruritus/I-AdverseReaction and/O application/B-AdverseReaction site/I-AdverseReaction papules/I-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Acorda/O Therapeutics/O at/O 1/O -/O 877/O -/O 900/O -/O 6479/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O other/O drugs/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Across/O all/O controlled/O and/O uncontrolled/O trials/O ,/O more/O than/O 1,600/O patients/O have/O received/O Qutenza/O ./O
A/O total/O of/O 394/O patients/O received/O more/O than/O one/O treatment/O application/O and/O 274/O patients/O were/O followed/O for/O 48/O weeks/O or/O longer/O ./O
In/O controlled/O clinical/O studies/O ,/O 98/O %/O of/O patients/O completed/O 90/O %/O of/O the/O intended/O patch/O application/O duration/O ./O
Among/O patients/O treated/O with/O Qutenza/O ,/O 1/O %/O discontinued/O prematurely/O due/O to/O an/O adverse/O event/O ./O
Controlled/O Clinical/O Studies/O Common/O Adverse/O Reactions/O Adverse/O reactions/O occurring/O in/O 5/O %/O of/O patients/O in/O the/O Qutenza/O group/O and/O at/O an/O incidence/O greater/O than/O in/O the/O control/O group/O were/O application/B-AdverseReaction site/I-AdverseReaction erythema/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction pruritus/I-AdverseReaction and/O application/B-AdverseReaction site/I-AdverseReaction papules/I-AdverseReaction ./O
Table/O 1/O summarizes/O all/O adverse/O reactions/O ,/O regardless/O of/O causality/O ,/O occurring/O in/O 1/O %/O of/O patients/O with/O postherpetic/O neuralgia/O in/O the/O Qutenza/O group/O for/O which/O the/O incidence/O was/O greater/O than/O in/O the/O control/O group/O ./O
The/O majority/O of/O application/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction were/O transient/B-Severity and/O self/O -/O limited/O ./O
Transient/B-Severity increases/B-AdverseReaction in/I-AdverseReaction pain/I-AdverseReaction were/O commonly/O observed/O on/O the/O day/O of/O treatment/O in/O patients/O treated/O with/O Qutenza/O ./O
Pain/B-AdverseReaction increases/I-AdverseReaction occurring/O during/O patch/O application/O usually/O began/O to/O resolve/O after/O patch/O removal/O ./O
On/O average/O ,/O pain/O scores/O returned/O to/O baseline/O by/O the/O end/O of/O the/O treatment/O day/O and/O then/O remained/O at/O or/O below/O baseline/O levels/O ./O
A/O majority/O of/O Qutenza/O -/O treated/O patients/O in/O clinical/O studies/O had/O adverse/O reactions/O with/O a/O maximum/O intensity/O of/O "/O mild/O "/O or/O "/O moderate/O "/O ./O
TABLE/O 1/O :/O Treatment/O -/O emergent/O adverse/O reaction/O incidence/O (/O %/O )/O in/O controlled/O trials/O in/O Postherpetic/O Neuralgia/O (/O Events/O in/O 1/O %/O of/O Qutenza/O -/O treated/O patients/O and/O at/O least/O 1/O %/O greater/O in/O the/O Qutenza/O group/O than/O in/O the/O Control/O group/O )/O Body/O SystemPreferred/O Term/O Qutenza60/O minutes(N/O 622)%/O Control60/O minutes(N/O 495)%/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Application/B-AdverseReaction Site/I-AdverseReaction Erythema/I-AdverseReaction 63/O 54/O Application/B-AdverseReaction Site/I-AdverseReaction Pain/I-AdverseReaction 42/O 21/O Application/B-AdverseReaction Site/I-AdverseReaction Pruritus/I-AdverseReaction 6/O 4/O Application/B-AdverseReaction Site/I-AdverseReaction Papules/I-AdverseReaction 6/O 3/O Application/B-AdverseReaction Site/I-AdverseReaction Edema/I-AdverseReaction 4/O 1/O Application/B-AdverseReaction Site/I-AdverseReaction Swelling/I-AdverseReaction 2/O 1/O Application/B-AdverseReaction Site/I-AdverseReaction Dryness/I-AdverseReaction 2/O 1/O Infections/O and/O Infestations/O Nasopharyngitis/B-AdverseReaction 4/O 2/O Bronchitis/B-AdverseReaction 2/O 1/O Sinusitis/B-AdverseReaction 3/O 1/O Gastrointestinal/O Disorders/O Nausea/B-AdverseReaction 5/O 2/O Vomiting/B-AdverseReaction 3/O 1/O Skin/O and/O Subcutaneous/O Tissue/O Disorder/O Pruritus/B-AdverseReaction 2/O 1/O Vascular/O Disorders/O Hypertension/B-AdverseReaction 2/O 1/O Other/O Adverse/O Reactions/O Observed/O During/O the/O Clinical/O Studies/O of/O Qutenza/O General/O Disorders/O and/O Administration/O Site/O Conditions/O :/O Application/B-AdverseReaction site/I-AdverseReaction urticaria/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction paresthesia/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction dermatitis/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction hyperesthesia/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction excoriation/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction warmth/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction anesthesia/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction bruising/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction inflammation/I-AdverseReaction ,/O Application/B-AdverseReaction site/I-AdverseReaction exfoliation/I-AdverseReaction ,/O Peripheral/B-AdverseReaction edema/I-AdverseReaction Nervous/O System/O Disorders/O :/O Headache/B-AdverseReaction ,/O Burning/B-AdverseReaction sensation/I-AdverseReaction ,/O Peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O Dizziness/B-AdverseReaction ,/O Dysgeusia/B-AdverseReaction ,/O Hyperesthesia/B-AdverseReaction ,/O Hypoesthesia/B-AdverseReaction Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O :/O Cough/B-AdverseReaction ,/O Throat/B-AdverseReaction irritation/I-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O Abnormal/B-AdverseReaction skin/I-AdverseReaction odor/I-AdverseReaction 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Do/O not/O use/O near/O eyes/O or/O mucous/O membranes/O ./O
(/O 5.1/O )/O Inhalation/O of/O airborne/O capsaicin/O can/B-Factor result/O in/O coughing/B-AdverseReaction or/O sneezing/B-AdverseReaction ./O
(/O 5.2/O )/O If/O irritation/O of/O eyes/O or/O airway/O occurs/O ,/O remove/O the/O affected/O individual/O from/O the/O vicinity/O of/O Qutenza/O and/O flush/O the/O mucous/O membranes/O or/O eyes/O with/O water/O ./O
If/O skin/O not/O intended/O to/O be/O treated/O comes/O into/O contact/O with/O Qutenza/O ,/O apply/O Cleansing/O Gel/O and/O then/O wipe/O off/O with/O dry/O gauze/O ./O
(/O 5.2/O ,/O 5.3/O )/O Transient/B-Severity increases/B-AdverseReaction in/I-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction may/B-Factor occur/O in/O patients/O during/O and/O shortly/O after/O the/O Qutenza/O treatment/O ./O
Monitor/O blood/O pressure/O during/O and/O following/O the/O treatment/O procedure/O ./O
For/O those/O patients/O who/O require/O the/O use/O of/O opioids/O to/O treat/O pain/O during/O or/O following/O the/O procedure/O ,/O their/O ability/O to/O perform/O potentially/O hazardous/O activities/O such/O as/O driving/O or/O operating/O machinery/O may/O be/O affected/O ./O
(/O 5.4/O ,/O 5.5/O )/O 5.1/O Eye/O and/O Mucous/O Membrane/O Exposure/O Do/O not/O apply/O Qutenza/O to/O the/O face/O or/O scalp/O to/O avoid/O risk/O of/O exposure/O to/O the/O eyes/O or/O mucous/O membranes/O ./O
5.2/O Aerosolization/O of/O Capsaicin/O Aerosolization/O of/O capsaicin/O can/O occur/O upon/O rapid/O removal/O of/O Qutenza/O patches/O ./O
Therefore/O ,/O remove/O Qutenza/O patches/O gently/O and/O slowly/O by/O rolling/O the/O adhesive/O side/O inward/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
If/O irritation/O of/O eyes/O or/O airways/O occurs/O ,/O remove/O the/O affected/O individual/O from/O the/O vicinity/O of/O Qutenza/O ./O
Flush/O eyes/O and/O mucous/O membranes/O with/O cool/O water/O ./O
Inhalation/O of/O airborne/O capsaicin/O can/B-Factor result/O in/O coughing/B-AdverseReaction or/O sneezing/B-AdverseReaction ./O
Provide/O supportive/O medical/O care/O if/O shortness/O of/O breath/O develops/O ./O
5.3/O Unintended/O Skin/O Exposure/O If/O skin/O not/O intended/O to/O be/O treated/O comes/O in/O contact/O with/O Qutenza/O ,/O apply/O Cleansing/O Gel/O for/O one/O minute/O and/O wipe/O off/O with/O dry/O gauze/O ./O
After/O the/O Cleansing/O Gel/O has/O been/O wiped/O off/O ,/O wash/O the/O area/O with/O soap/O and/O water/O ./O
5.4/O Application/O Associated/O Pain/O Even/O following/O use/O of/O a/O local/O anesthetic/O prior/O to/O administration/O of/O Qutenza/O ,/O patients/O may/B-Factor experience/O substantial/B-Severity procedural/B-AdverseReaction pain/I-AdverseReaction ./O
Prepare/O to/O treat/O acute/O pain/O during/O and/O following/O the/O application/O procedure/O with/O local/O cooling/O (/O such/O as/O an/O ice/O pack/O )/O and/or/O appropriate/O analgesic/O medication/O ,/O such/O as/O opioids/O ./O
Opioids/O may/O affect/O the/O ability/O to/O perform/O potentially/O hazardous/O activities/O such/O as/O driving/O or/O operating/O machinery/O ./O
5.5/O Increase/O in/O Blood/O Pressure/O In/O clinical/O trials/O ,/O increases/B-AdverseReaction in/I-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction occurred/O during/O or/O shortly/O after/O exposure/O to/O Qutenza/O ./O
The/O changes/O averaged/O less/O than/O 10/O mm/O Hg/O ,/O although/O some/O patients/O had/O greater/O increases/O and/O these/O changes/O lasted/O for/O approximately/O two/O hours/O after/O patch/O removal/O ./O
Increases/B-AdverseReaction in/I-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction were/O unrelated/O to/O the/O pretreatment/O blood/O pressure/O but/O were/O related/O to/O treatment/O -/O related/O increases/B-AdverseReaction in/I-AdverseReaction pain/I-AdverseReaction ./O
Monitor/O blood/O pressure/O periodically/O during/O the/O treatment/O and/O provide/O adequate/O support/O for/O treatment/O related/O pain/O ./O
Patients/O with/O unstable/O or/O poorly/O controlled/O hypertension/O ,/O a/O recent/O history/O of/O cardiovascular/O or/O cerebrovascular/O events/O may/O be/O at/O an/O increased/O risk/B-Factor of/O adverse/B-AdverseReaction cardiovascular/I-AdverseReaction effects/I-AdverseReaction ./O
Consider/O these/O factors/O prior/O to/O initiating/O Qutenza/O treatment/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O discussed/O elsewhere/O in/O the/O labeling/O :/O Increased/B-AdverseReaction mortality/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O QT/B-AdverseReaction Prolongation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O and/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O Hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Drug/O Interactions/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O The/O most/O common/O adverse/O reactions/O reported/O in/O 10/O %/O or/O more/O of/O patients/O treated/O with/O SIRTURO/O were/O nausea/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O hemoptysis/B-AdverseReaction and/O chest/B-AdverseReaction pain/I-AdverseReaction ./O
(/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Janssen/O Therapeutics/O ,/O Division/O of/O Janssen/O Products/O ,/O LP/O at/O 1/O -/O 800-JANSSEN/O (/O 1/O -/O 800/O -/O 526/O -/O 7736/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Studies/O Experience/O Because/O clinical/O studies/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O studies/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O the/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Adverse/O drug/O reactions/O for/O SIRTURO/O were/O identified/O from/O the/O pooled/O safety/O data/O from/O 335/O SIRTURO/O -/O exposed/O patients/O who/O received/O 8/O weeks/O (/O Study/O 2/O )/O and/O 24/O weeks/O (/O Studies/O 1/O and/O 3/O )/O at/O the/O proposed/O dose/O ./O
Studies/O 1/O and/O 2/O were/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trial/O in/O newly/O diagnosed/O patients/O with/O pulmonary/O MDR/O -/O TB/O ./O
In/O both/O treatment/O arms/O ,/O patients/O received/O SIRTURO/O or/O placebo/O in/O combination/O with/O other/O drugs/O used/O to/O treat/O MDR/O -/O TB/O ./O
Study/O 3/O was/O an/O open/O -/O label/O ,/O noncomparative/O study/O with/O SIRTURO/O administered/O as/O part/O of/O an/O individualized/O pulmonary/O MDR/O -/O TB/O treatment/O regimen/O in/O previously/O treated/O patients/O ./O
In/O Study/O 1/O ,/O 35/O %/O were/O Black/O ,/O 17.5/O %/O were/O Hispanic/O ,/O 12.5/O %/O were/O White/O ,/O 9.4/O %/O were/O Asian/O ,/O and/O 25.6/O %/O were/O of/O another/O race/O ./O
Eight/O of/O 79/O (/O 10.1/O %/O )/O patients/O in/O the/O SIRTURO/O group/O and/O 16/O of/O 81/O (/O 19.8/O %/O )/O patients/O in/O the/O placebo/O treatment/O group/O were/O HIV/O -/O infected/O ./O
Seven/O (/O 8.9/O %/O )/O SIRTURO/O -/O treated/O patients/O and/O six/O (/O 7.4/O %/O )/O placebo/O -/O treated/O patients/O discontinued/O Study/O 1/O because/O of/O an/O adverse/O reaction/O ./O
Table/O 1/O :/O Select/O Adverse/O Reactions/O from/O Study/O 1/O That/O Occurred/O More/O Frequently/O Than/O Placebo/O During/O Treatment/O with/O SIRTURO/O Adverse/O Reactions/O SIRTURO/O Treatment/O GroupN=79n/O (/O %/O )/O Placebo/O Treatment/O GroupN=81n/O (/O %/O )/O Nausea/B-AdverseReaction 30/O (/O 38/O )/O 26/O (/O 32/O )/O Arthralgia/B-AdverseReaction 26/O (/O 33/O )/O 18/O (/O 22/O )/O Headache/B-AdverseReaction 22/O (/O 28/O )/O 10/O (/O 12/O )/O Hemoptysis/B-AdverseReaction 14/O (/O 18/O )/O 9/O (/O 11/O )/O Chest/B-AdverseReaction Pain/I-AdverseReaction 9/O (/O 11/O )/O 6/O (/O 7/O )/O Anorexia/B-AdverseReaction 7/O (/O 9/O )/O 3/O (/O 4/O )/O Transaminases/B-AdverseReaction Increased/I-AdverseReaction 7/O (/O 9/O )/O 1/O (/O 1/O )/O Rash/B-AdverseReaction 6/O (/O 8)/O 3/O (/O 4/O )/O Blood/B-AdverseReaction Amylase/I-AdverseReaction Increased/I-AdverseReaction 2/O (/O 3/O )/O 1/O (/O 1/O )/O No/O additional/O unique/O Adverse/O Reactions/O were/O identified/O from/O the/O uncontrolled/O Study/O 3/O ./O
In/O both/O Studies/O 1/O and/O 2/O ,/O aminotransferase/B-AdverseReaction elevations/I-AdverseReaction of/O at/O least/O 3/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity developed/O more/O frequently/O in/O the/O SIRTURO/O treatment/O group/O (/O 11/102/O [/O 10.8/O %/O ]/O vs/O 6/105/O [/O 5.7/O %/O ]/O )/O than/O in/O the/O placebo/O treatment/O group/O ./O
In/O Study/O 3/O ,/O 22/230/O (/O 9.6/O %/O )/O patients/O had/O alanine/O aminotransferase/O or/O aspartate/O aminotransferase/O greater/O than/O or/O equal/O to/O 3/O times/O the/O upper/O limit/O of/O normal/O during/O the/O overall/O treatment/O period/O ./O
Increased/O Mortality/O In/O Study/O 1/O ,/O there/O was/O a/O statistically/O significant/O increased/B-AdverseReaction mortality/I-AdverseReaction risk/B-Factor by/O Week/O 120/O in/O the/O SIRTURO/O treatment/O group/O compared/O to/O the/O placebo/O treatment/O group/O (/O 9/79/O (/O 11.4/O %/O )/O versus/O 2/81/O (/O 2.5/O %/O )/O ,/O p/O -/O value=0.03/O ,/O an/O exact/O 95/O %/O confidence/O interval/O of/O the/O difference/O [/O 1.1/O %/O ,/O 18.2/O %/O ]/O )/O ./O
Five/O of/O the/O 9/O SIRTURO/O deaths/B-AdverseReaction and/O the/O 2/O placebo/B-Factor deaths/B-AdverseReaction were/O tuberculosis/O -/O related/O ./O
One/O death/B-AdverseReaction occurred/O during/O the/O 24-week/O SIRTURO/O treatment/O period/O ./O
The/O median/O time/O to/O death/B-AdverseReaction for/O the/O remaining/O eight/O subjects/O in/O the/O SIRTURO/O treatment/O group/O was/O 329/O days/O after/O last/O intake/O of/O SIRTURO/O ./O
The/O imbalance/O in/O deaths/B-AdverseReaction is/O unexplained/O ;/O no/O discernible/O pattern/O between/O death/B-AdverseReaction and/O sputum/O conversion/O ,/O relapse/O ,/O sensitivity/O to/O other/O drugs/O used/O to/O treat/O tuberculosis/O ,/O HIV/O status/O ,/O and/O severity/O of/O disease/O was/O observed/O ./O
In/O the/O open/O -/O label/O Study/O 3/O ,/O 6.9/O %/O (/O 16/233/O )/O subjects/O died/B-AdverseReaction ./O
The/O most/O common/O cause/O of/O death/B-AdverseReaction as/O reported/O by/O the/O investigator/O was/O TB/O (/O 9/O subjects/O )/O ./O
All/O but/O one/O subject/O who/O died/B-AdverseReaction of/O TB/O had/O not/O converted/O or/O had/O relapsed/O ./O
The/O causes/O of/O death/B-AdverseReaction in/O the/O remaining/O subjects/O varied/O ./O
BOXED/O WARNING/O :/O WARNINGS/O :/O INCREASED/B-AdverseReaction MORTALITY/I-AdverseReaction ;/O QT/B-AdverseReaction PROLONGATION/I-AdverseReaction WARNINGS/O :/O INCREASED/B-AdverseReaction MORTALITY/I-AdverseReaction ;/O QT/B-AdverseReaction PROLONGATION/I-AdverseReaction EXCERPT/O :/O WARNINGS/O :/O INCREASED/B-AdverseReaction MORTALITY/I-AdverseReaction ;/O QT/B-AdverseReaction PROLONGATION/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Increased/O Mortality/O An/O increased/O risk/B-Factor of/O death/B-AdverseReaction was/O seen/O in/O the/O SIRTURO/O treatment/O group/O (/O 9/79/O ,/O 11.4/O %/O )/O compared/O to/O the/O placebo/O treatment/O group/O (/O 2/81/O ,/O 2.5/O %/O )/O in/O one/O placebo/O -/O controlled/O trial/O ./O
Only/O use/O SIRTURO/O when/O an/O effective/O treatment/O regimen/O can/O not/O otherwise/O be/O provided/O ./O
(/O 5.1/O )/O QT/O Prolongation/O QT/B-AdverseReaction prolongation/I-AdverseReaction can/B-Factor occur/O with/O SIRTURO/O ./O
Use/O with/O drugs/O that/O prolong/O the/O QT/O interval/O may/B-Factor cause/O additive/O QT/B-AdverseReaction prolongation/I-AdverseReaction ./O
Monitor/O ECGs/O ./O
Discontinue/O SIRTURO/O if/O significant/O ventricular/O arrhythmia/O or/O QTcF/O interval/O 500/O ms/O develops/O ./O
(/O 5.2/O )/O Increased/O Mortality/O An/O increased/O risk/B-Factor of/O death/B-AdverseReaction was/O seen/O in/O the/O SIRTURO/O treatment/O group/O (/O 9/79/O ,/O 11.4/O %/O )/O compared/O to/O the/O placebo/O treatment/O group/O (/O 2/81/O ,/O 2.5/O %/O )/O in/O one/O placebo/O -/O controlled/O trial/O ./O
Only/O use/O SIRTURO/O when/O an/O effective/O treatment/O regimen/O can/O not/O otherwise/O be/O provided/O [/O see/O Indications/O and/O Usage/O (/O 1/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
QT/O Prolongation/O QT/B-AdverseReaction prolongation/I-AdverseReaction can/B-Factor occur/O with/O SIRTURO/O ./O
Use/O with/O drugs/O that/O prolong/O the/O QT/O interval/O may/B-Factor cause/O additive/B-AdverseReaction QT/I-AdverseReaction prolongation/I-AdverseReaction ./O
Monitor/O ECGs/O ./O
Discontinue/O SIRTURO/O if/O significant/O ventricular/O arrhythmia/O or/O if/O QTcF/O interval/O prolongation/O of/O greater/O than/O 500/O ms/O develops/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O QT/B-AdverseReaction prolongation/I-AdverseReaction can/B-Factor occur/O with/O SIRTURO/O ./O
Monitor/O ECGs/O and/O discontinue/O SIRTURO/O if/O significant/O ventricular/O arrhythmia/O or/O QTcF/O interval/O 500/O ms/O develops/O ./O
(/O 5.2/O )/O Hepatotoxicity/B-AdverseReaction may/B-Factor occur/O with/O use/O of/O SIRTURO/O ./O
Monitor/O liver/O -/O related/O laboratory/O tests/O ./O
Discontinue/O if/O evidence/O of/O liver/O injury/O ./O
(/O 5.3/O )/O 5.1/O Increased/O Mortality/O An/O increased/O risk/B-Factor of/O death/B-AdverseReaction was/O seen/O in/O the/O SIRTURO/O treatment/O group/O (/O 9/79/O ,/O 11.4/O %/O )/O compared/O to/O the/O placebo/O treatment/O group/O (/O 2/81/O ,/O 2.5/O %/O )/O in/O one/O placebo/O -/O controlled/O trial/O (/O based/O on/O the/O 120-week/O visit/O window/O )/O ./O
One/O death/B-AdverseReaction occurred/O during/O the/O 24/O weeks/O of/O administration/O of/O SIRTURO/O ./O
The/O imbalance/O in/O deaths/B-AdverseReaction is/O unexplained/O ./O
No/O discernible/O pattern/O between/O death/B-AdverseReaction and/O sputum/O culture/O conversion/O ,/O relapse/O ,/O sensitivity/O to/O other/O drugs/O used/O to/O treat/O tuberculosis/O ,/O HIV/O status/O ,/O or/O severity/O of/O disease/O could/O be/O observed/O ./O
Only/O use/O SIRTURO/O when/O an/O effective/O treatment/O regimen/O can/O not/O otherwise/O be/O provided/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.2/O QT/O Prolongation/O SIRTURO/O prolongs/B-AdverseReaction the/I-AdverseReaction QT/I-AdverseReaction interval/I-AdverseReaction ./O
Obtain/O an/O ECG/O before/O initiation/O of/O treatment/O ,/O and/O at/O least/O 2/O ,/O 12/O ,/O and/O 24/O weeks/O after/O starting/O treatment/O with/O SIRTURO/O ./O
Obtain/O serum/O potassium/O ,/O calcium/O ,/O and/O magnesium/O at/O baseline/O and/O correct/O if/O abnormal/O ./O
Monitor/O electrolytes/O if/O QT/O prolongation/O is/O detected/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O and/O Drug/O Interactions/O (/O 7.4/O )/O ]/O ./O
SIRTURO/O has/O not/O been/O studied/O in/O patients/O with/O ventricular/O arrhythmias/O or/O recent/O myocardial/O infarction/O ./O
The/O following/O may/O increase/O the/O risk/B-Factor for/O QT/B-AdverseReaction prolongation/I-AdverseReaction when/O patients/O are/O receiving/O SIRTURO/O :/O use/O with/O other/O QT/O prolonging/O drugs/O including/O fluoroquinolones/O and/O macrolide/O antibacterial/O drugs/O and/O the/O antimycobacterial/O drug/O ,/O clofazimine/O a/O history/O of/O Torsade/O de/O Pointes/O a/O history/O of/O congenital/O long/O QT/O syndrome/O a/O history/O of/O or/O ongoing/O hypothyroidism/O a/O history/O of/O or/O ongoing/O bradyarrhythmias/O a/O history/O of/O uncompensated/O heart/O failure/O serum/O calcium/O ,/O magnesium/O ,/O or/O potassium/O levels/O below/O the/O lower/O limits/O of/O normal/O If/O necessary/O ,/O bedaquiline/O treatment/O initiation/O could/O be/O considered/O in/O these/O patients/O after/O a/O favorable/O benefit/O risk/O assessment/O and/O with/O frequent/O ECG/O monitoring/O ./O
Discontinue/O SIRTURO/O and/O all/O other/O QT/O prolonging/O drugs/O if/O the/O patient/O develops/O :/O Clinically/O significant/O ventricular/O arrhythmia/O A/O QTcF/O interval/O of/O greater/O than/O 500/O ms/O (/O confirmed/O by/O repeat/O ECG/O )/O If/O syncope/O occurs/O ,/O obtain/O an/O ECG/O to/O detect/O QT/O prolongation/O ./O
5.3/O Hepatotoxicity/O More/O hepatic/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O were/O reported/O with/O the/O use/O of/O SIRTURO/O plus/O other/O drugs/O used/O to/O treat/O tuberculosis/O compared/O to/O other/O drugs/O used/O to/O treat/O tuberculosis/O without/O the/O addition/O of/O SIRTURO/O ./O
Alcohol/O and/O other/O hepatotoxic/O drugs/O should/O be/O avoided/O while/O on/O SIRTURO/O ,/O especially/O in/O patients/O with/O impaired/O hepatic/O function/O ./O
Monitor/O symptoms/O (/O such/O as/O fatigue/O ,/O anorexia/O ,/O nausea/O ,/O jaundice/O ,/O dark/O urine/O ,/O liver/O tenderness/O and/O hepatomegaly/O )/O and/O laboratory/O tests/O (/O ALT/O ,/O AST/O ,/O alkaline/O phosphatase/O ,/O and/O bilirubin/O )/O at/O baseline/O ,/O monthly/O while/O on/O treatment/O ,/O and/O as/O needed/O ./O
Test/O for/O viral/O hepatitis/O and/O discontinue/O other/O hepatotoxic/O medications/O if/O evidence/O of/O new/O or/O worsening/O liver/O dysfunction/O occurs/O ./O
Discontinue/O SIRTURO/O if/O :/O aminotransferase/O elevations/O are/O accompanied/O by/O total/O bilirubin/O elevation/O greater/O than/O two/O times/O the/O upper/O limit/O of/O normal/O aminotransferase/O elevations/O are/O greater/O than/O eight/O times/O the/O upper/O limit/O of/O normal/O aminotransferase/O elevations/O are/O greater/O than/O five/O times/O the/O upper/O limit/O of/O normal/O and/O persist/O beyond/O two/O weeks/O 5.4/O Drug/O Interactions/O CYP3A4/O inducers/O inhibitors/O Bedaquiline/O is/O metabolized/O by/O CYP3A4/O and/O its/O systemic/O exposure/O and/O therapeutic/O effect/O may/O therefore/O be/O reduced/O during/O co/O -/O administration/O with/O inducers/O of/O CYP3A4/O ./O
Avoid/O co/O -/O administration/O of/O strong/O CYP3A4/O inducers/O ,/O such/O as/O rifamycins/O (/O i.e./O ,/O rifampin/O ,/O rifapentine/O and/O rifabutin/O )/O ,/O or/O moderate/O CYP3A4/O inducers/O ,/O such/O as/O efavirenz/O ,/O during/O treatment/O with/O SIRTURO/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
Co/O -/O administration/O of/O SIRTURO/O with/O strong/O CYP3A4/O inhibitors/O may/O increase/O the/O systemic/O exposure/O to/O bedaquiline/O ,/O which/O could/O potentially/O increase/O the/O risk/O of/O adverse/O reactions/O ./O
Therefore/O ,/O avoid/O the/O use/O of/O strong/O CYP3A4/O inhibitors/O for/O more/O than/O 14/O consecutive/O days/O while/O on/O SIRTURO/O ,/O unless/O the/O benefit/O of/O treatment/O with/O the/O drug/O combination/O outweighs/O the/O risk/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
Appropriate/O clinical/O monitoring/O for/O SIRTURO/O -/O related/O adverse/O reactions/O is/O recommended/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O greater/O than/O or/O equal/O to/O 2/O %/O )/O include/O headache/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O nasal/B-AdverseReaction congestion/I-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O and/O back/B-AdverseReaction pain/I-AdverseReaction (/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O 1/O -/O 877/O -/O 663/O -/O 0412/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
STENDRA/O was/O administered/O to/O 2215/O men/O during/O clinical/O trials/O ./O
In/O trials/O of/O STENDRA/O for/O use/O as/O needed/O ,/O a/O total/O of/O 493/O patients/O were/O exposed/O for/O greater/O than/O or/O equal/O to/O 6/O months/O ,/O and/O 153/O patients/O were/O treated/O for/O greater/O than/O or/O equal/O to/O 12/O months/O ./O
In/O three/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trials/O lasting/O up/O to/O 3/O months/O in/O duration/O ,/O the/O mean/O age/O of/O patients/O was/O 56.4/O years/O (/O range/O from/O 23/O to/O 88/O years/O )/O ./O
83.9/O %/O of/O patients/O were/O White/O ,/O 13.8/O %/O were/O Black/O ,/O 1.4/O %/O Asian/O ,/O and/O 1/O %/O Hispanic/O ./O
41.1/O %/O were/O current/O or/O previous/O smokers/O ./O
30.6/O %/O had/O diabetes/O mellitus/O ./O
The/O discontinuation/O rate/O due/O to/O adverse/O reactions/O for/O patients/O treated/O with/O STENDRA/O 50/O mg/O ,/O 100/O mg/O ,/O or/O 200/O mg/O was/O 1.4/O %/O ,/O 2.0/O %/O ,/O and/O 2.0/O %/O ,/O respectively/O ,/O compared/O to/O 1.7/O %/O for/O placebo/O -/O treated/O patients/O ./O
Table/O 1/O presents/O the/O adverse/O reactions/O reported/O when/O STENDRA/O was/O taken/O as/O recommended/O (/O on/O an/O as/O -/O needed/O basis/O )/O from/O these/O 3/O clinical/O trials/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Reported/O by/O Greater/O Than/O or/O Equal/O to/O 2/O %/O of/O Patients/O Treated/O with/O STENDRA/O From/O 3/O Placebo/O -/O Controlled/O Clinical/O Trials/O Lasting/O 3/O Months/O for/O STENDRA/O Use/O as/O Needed/O Adverse/O Reaction/O Placebo(N/O 349/O )/O STENDRA/O 50/O mg(N/O 217/O )/O STENDRA/O 100/O mg(N/O 349/O )/O STENDRA/O 200/O mg(N/O 352/O )/O Headache/B-AdverseReaction 1.7/O %/O 5.1/O %/O 6.9/O %/O 10.5/O %/O Flushing/B-AdverseReaction 0.0/O %/O 3.2/O %/O 4.3/O %/O 4.0/O %/O Nasal/B-AdverseReaction congestion/I-AdverseReaction 1.1/O %/O 1.8/O %/O 2.9/O %/O 2.0/O %/O Nasopharyngitis/B-AdverseReaction 2.9/O %/O 0.9/O %/O 2.6/O %/O 3.4/O %/O Back/B-AdverseReaction pain/I-AdverseReaction 1.1/O %/O 3.2/O %/O 2.0/O %/O 1.1/O %/O Adverse/O reactions/O reported/O by/O greater/O than/O or/O equal/O to/O 1/O %/O ,/O but/O less/O than/O 2/O %/O of/O patients/O in/O any/O STENDRA/O dose/O group/O ,/O and/O greater/O than/O placebo/O included/O :/O upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction (/O URI/B-AdverseReaction )/O ,/O bronchitis/B-AdverseReaction ,/O influenza/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O sinus/B-AdverseReaction congestion/I-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O and/O rash/B-AdverseReaction ./O
In/O an/O open/O -/O label/O ,/O long/O -/O term/O extension/O study/O of/O two/O of/O these/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trials/O ,/O the/O total/O duration/O of/O treatment/O was/O up/O to/O 52/O weeks/O ./O
Among/O the/O 712/O patients/O who/O participated/O in/O this/O open/O -/O label/O extension/O study/O ,/O the/O mean/O age/O of/O the/O population/O was/O 56.4/O years/O (/O range/O from/O 23/O to/O 88/O years/O )/O ./O
The/O discontinuation/O rate/O due/O to/O adverse/O reactions/O for/O patients/O treated/O with/O STENDRA/O (/O 50/O mg/O ,/O 100/O mg/O ,/O or/O 200/O mg/O )/O was/O 2.8/O %/O ./O
In/O this/O extension/O trial/O ,/O all/O eligible/O patients/O were/O initially/O assigned/O to/O STENDRA/O 100/O mg/O ./O
At/O any/O point/O during/O the/O trial/O ,/O patients/O could/O request/O to/O have/O their/O dose/O of/O STENDRA/O increased/O to/O 200/O mg/O or/O decreased/O to/O 50/O mg/O based/O on/O their/O individual/O response/O to/O treatment/O ./O
In/O total/O ,/O 536/O (/O approximately/O 75/O %/O )/O patients/O increased/O their/O dose/O to/O 200/O mg/O and/O 5/O (/O less/O than/O 1/O %/O )/O patients/O reduced/O their/O dose/O to/O 50/O mg/O ./O
Table/O 2/O presents/O the/O adverse/O reactions/O reported/O when/O STENDRA/O was/O taken/O as/O recommended/O (/O on/O an/O as/O -/O needed/O basis/O )/O in/O this/O open/O -/O label/O extension/O trial/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Reported/O by/O Greater/O Than/O or/O Equal/O to/O 2/O %/O of/O Patients/O Treated/O With/O STENDRA/O in/O an/O Open/O -/O Label/O Extension/O Trial/O Adverse/O Reaction/O STENDRA(N/O 711/O )/O Headache/B-AdverseReaction 5.6/O %/O Flushing/B-AdverseReaction 3.5/O %/O Nasopharyngitis/B-AdverseReaction 3.4/O %/O Nasal/B-AdverseReaction congestion/I-AdverseReaction 2.1/O %/O Adverse/O reactions/O reported/O by/O greater/O than/O or/O equal/O to/O 1/O %/O ,/O but/O less/O than/O 2/O %/O of/O patients/O in/O the/O open/O -/O label/O extension/O study/O included/O :/O upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction (/O URI/B-AdverseReaction )/O ,/O influenza/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O and/O diarrhea/B-AdverseReaction ./O
The/O following/O events/O occurred/O in/O less/O than/O 1/O %/O of/O patients/O in/O the/O three/O placebo/O -/O controlled/O 3-month/O clinical/O trials/O and/or/O the/O open/O -/O label/O ,/O long/O -/O term/O extension/O study/O lasting/O 12/O months/O ./O
A/O causal/O relationship/O to/O STENDRA/O is/O uncertain/O ./O
Excluded/O from/O this/O list/O are/O those/O events/O that/O were/O minor/O ,/O those/O with/O no/O plausible/O relation/O to/O drug/O use/O ,/O and/O reports/O too/O imprecise/O to/O be/O meaningful/O ./O
Body/O as/O a/O whole/O -/O edema/B-AdverseReaction peripheral/I-AdverseReaction ,/O fatigue/B-AdverseReaction Cardiovascular/O -/O angina/B-AdverseReaction ,/O unstable/B-AdverseReaction angina/I-AdverseReaction ,/O deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction ,/O palpitations/B-AdverseReaction Digestive/O -/O gastritis/B-AdverseReaction ,/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction ,/O hypoglycemia/B-AdverseReaction ,/O blood/B-AdverseReaction glucose/I-AdverseReaction increased/I-AdverseReaction ,/O alanine/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction ,/O oropharyngeal/B-AdverseReaction pain/I-AdverseReaction ,/O stomach/B-AdverseReaction discomfort/I-AdverseReaction ,/O vomiting/B-AdverseReaction Musculoskeletal/O -/O muscle/B-AdverseReaction spasms/I-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction Nervous/O -/O depression/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O vertigo/B-AdverseReaction Respiratory/O -/O cough/B-AdverseReaction ,/O dyspnea/B-AdverseReaction exertional/I-AdverseReaction ,/O epistaxis/B-AdverseReaction ,/O wheezing/B-AdverseReaction Skin/O and/O Appendages/O -/O pruritus/B-AdverseReaction Urogenital/O -/O balanitis/B-AdverseReaction ,/O erection/B-AdverseReaction increased/I-AdverseReaction ,/O hematuria/B-AdverseReaction ,/O nephrolithiasis/B-AdverseReaction ,/O pollakiuria/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction In/O an/O additional/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O study/O lasting/O up/O to/O 3/O months/O in/O 298/O men/O who/O had/O undergone/O bilateral/O nerve/O -/O sparing/O radical/O prostatectomy/O for/O prostate/O cancer/O ,/O the/O mean/O age/O of/O patients/O was/O 58.4/O years/O (/O range/O 40/O -/O 70/O )/O ./O
Table/O 3/O presents/O the/O adverse/O reactions/O reported/O in/O this/O study/O ./O
Table/O 3/O :/O Adverse/O Reactions/O Reported/O by/O Greater/O than/O or/O Equal/O to/O 2/O %/O of/O Patients/O Treated/O with/O STENDRA/O in/O a/O Placebo/O -/O Controlled/O Clinical/O Trial/O Lasting/O 3/O Months/O in/O Patients/O Who/O Underwent/O Bilateral/O Nerve/O -/O Sparing/O Radical/O Prostatectomy/O Adverse/O Reaction/O Placebo(N/O 100/O )/O STENDRA/O 100/O mg(N/O 99/O )/O STENDRA/O 200/O mg(N/O 99/O )/O Headache/B-AdverseReaction 1.0/O %/O 8.1/O %/O 12.1/O %/O Flushing/B-AdverseReaction 0.0/O %/O 5.1/O %/O 10.1/O %/O Nasopharyngitis/B-AdverseReaction 0.0/O %/O 3.0/O %/O 5.1/O %/O Upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction 0.0/O %/O 2.0/O %/O 3.0/O %/O Nasal/B-AdverseReaction congestion/I-AdverseReaction 1.0/O %/O 3.0/O %/O 1.0/O %/O Back/B-AdverseReaction pain/I-AdverseReaction 1.0/O %/O 3.0/O %/O 2.0/O %/O Electrocardiogram/B-AdverseReaction abnormal/I-AdverseReaction 0.0/O %/O 1.0/O %/O 3.0/O %/O Dizziness/B-AdverseReaction 0.0/O %/O 1.0/O %/O 2.0/O %/O A/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O 2/O months/O study/O was/O conducted/O in/O 435/O subjects/O with/O a/O mean/O age/O of/O 58.2/O years/O (/O range/O 24/O to/O 86/O years/O )/O to/O determine/O the/O time/O to/O onset/O of/O effect/O of/O STENDRA/O ,/O defined/O as/O the/O time/O to/O the/O first/O occurrence/O of/O an/O erection/O sufficient/O for/O sexual/O intercourse/O ./O
Table/O 4/O presents/O the/O adverse/O reactions/O occurring/O in/O 2/O %/O of/O subjects/O treated/O with/O STENDRA/O ./O
Table/O 4/O :/O Adverse/O Reactions/O Reported/O by/O 2/O %/O of/O Patients/O Treated/O with/O STENDRA/O in/O a/O Placebo/O -/O Controlled/O Clinical/O Trial/O Lasting/O 2/O Months/O to/O Determine/O the/O Time/O to/O Onset/O of/O Effect/O (/O Study/O 3/O )/O Adverse/O Reaction/O Placebon=143/O STENDRA/O 100/O mgn=146/O STENDRA/O 200/O mgn=146/O Headache/B-AdverseReaction 0.7/O %/O 1.4/O %/O 8.9/O %/O Nasal/B-AdverseReaction congestion/I-AdverseReaction 0.0/O %/O 0.7/O %/O 4.1/O %/O Gastroenteritis/B-AdverseReaction viral/I-AdverseReaction 0.0/O %/O 0.0/O %/O 2.1/O %/O Across/O all/O trials/O with/O any/O STENDRA/O dose/O ,/O 1/O subject/O reported/O a/O change/B-AdverseReaction in/I-AdverseReaction color/I-AdverseReaction vision/I-AdverseReaction ./O
6.2/O Postmarketing/O Experience/O Ophthalmologic/O :/O Non/B-AdverseReaction -/I-AdverseReaction arteritic/I-AdverseReaction anterior/I-AdverseReaction ischemic/I-AdverseReaction optic/O neuropathy/O (/O NAION/B-AdverseReaction )/O ,/O a/O cause/O of/O decreased/B-AdverseReaction vision/I-AdverseReaction including/O permanent/B-AdverseReaction loss/I-AdverseReaction of/I-AdverseReaction vision/I-AdverseReaction ,/O has/O been/O reported/O rarely/O post/O -/O marketing/O in/O temporal/O association/O with/O the/O use/O of/O phosphodiesterase/B-DrugClass type/I-DrugClass 5/I-DrugClass (/I-DrugClass PDE5/I-DrugClass )/O inhibitors/O ./O
Most/O ,/O but/O not/O all/O ,/O of/O these/O patients/O had/O underlying/O anatomic/O or/O vascular/O risk/O factors/O for/O developing/O NAION/O ,/O including/O but/O not/O necessarily/O limited/O to/O :/O low/O cup/O to/O disc/O ratio/O (/O "/O crowded/O disc/O "/O )/O ,/O age/O over/O 50/O ,/O diabetes/O ,/O hypertension/O ,/O coronary/O artery/O disease/O ,/O hyperlipidemia/O ,/O and/O smoking/O ./O
It/O is/O not/O possible/O to/O determine/O whether/O these/O events/O are/O related/O directly/O to/O the/O use/O of/O PDE5/O inhibitors/O ,/O to/O the/O patient/O 's/O underlying/O vascular/O risk/O factors/O or/O anatomical/O defects/O ,/O to/O a/O combination/O of/O these/O factors/O ,/O or/O to/O other/O factors/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4)andPatient/O Counseling/O Information/O (/O 17.6/O )/O ]/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O Evaluation/O of/O erectile/O dysfunction/O (/O ED/O )/O should/O include/O an/O appropriate/O medical/O assessment/O to/O identify/O potential/O underlying/O causes/O ,/O as/O well/O as/O treatment/O options/O ./O
Before/O prescribing/O STENDRA/O ,/O it/O is/O important/O to/O note/O the/O following/O :/O EXCERPT/O :/O Patients/O should/O not/O use/O STENDRA/O if/O sexual/O activity/O is/O inadvisable/O due/O to/O cardiovascular/O status/O or/O any/O other/O reason/O (/O 5.1/O )/O Use/O of/O STENDRA/O with/O alpha/O -/O blockers/O ,/O other/O antihypertensives/O ,/O or/O substantial/O amounts/O of/O alcohol/O (/O greater/O than/O 3/O units/O )/O may/O lead/O to/O hypotension/B-AdverseReaction (/O 2.3,5.6,5.7/O )/O Patients/O should/O seek/O emergency/O treatment/O if/O an/O erection/O lasts/O greater/O than/O 4/O hours/O (/O 5.3/O )/O Patients/O should/O stop/O STENDRA/O and/O seek/O medical/O care/O if/O a/O sudden/O loss/O of/O vision/O occurs/O in/O one/O or/O both/O eyes/O ,/O which/O could/O be/O a/O sign/O of/O Non/O Arteritic/O Ischemic/O Optic/O Neuropathy/O (/O NAION/O )/O ./O
STENDRA/O should/O be/O used/O with/O caution/O ,/O and/O only/O when/O the/O anticipated/O benefits/O outweigh/O the/O risks/O ,/O in/O patients/O with/O a/O history/O of/O NAION/O ./O
Patients/O with/O a/O "/O crowded/O "/O optic/O disc/O may/O also/O be/O at/O an/O increased/O risk/O of/O NAION/O (/O 5.4,6.2/O )/O Patients/O should/O stop/O taking/O STENDRA/O and/O seek/O prompt/O medical/O attention/O in/O the/O event/O of/O sudden/O decrease/O or/O loss/O of/O hearing/O (/O 5.5/O )/O 5.1/O Cardiovascular/O Risks/O There/O is/O a/O potential/B-Factor for/O cardiac/B-AdverseReaction risk/I-AdverseReaction during/O sexual/O activity/O in/O patients/O with/O pre/O -/O existing/O cardiovascular/O disease/O ./O
Therefore/O ,/O treatments/O for/O ED/O ,/O including/O STENDRA/O ,/O should/O not/O be/O used/O in/O men/O for/O whom/O sexual/O activity/O is/O inadvisable/O because/O of/O their/O underlying/O cardiovascular/O status/O ./O
Patients/O with/O left/O ventricular/O outflow/O obstruction/O (/O e.g./O ,/O aortic/O stenosis/O ,/O idiopathic/O hypertrophic/O subaortic/O stenosis/O )/O and/O those/O with/O severely/O impaired/O autonomic/O control/O of/O blood/O pressure/O can/O be/O particularly/O sensitive/O to/O the/O actions/O of/O vasodilators/O ,/O including/O STENDRA/O ./O
The/O following/O groups/O of/O patients/O were/O not/O included/O in/O clinical/O safety/O and/O efficacy/O trials/O for/O STENDRA/O ,/O and/O therefore/O until/O further/O information/O is/O available/O ,/O STENDRA/O is/O not/O recommended/O for/O the/O following/O groups/O :/O Patients/O who/O have/O suffered/O a/O myocardial/O infarction/O ,/O stroke/O ,/O life/O -/O threatening/O arrhythmia/O ,/O or/O coronary/O revascularization/O within/O the/O last/O 6/O months/O ;/O Patients/O with/O resting/O hypotension/O (/O blood/O pressure/O less/O than/O 90/50/O mmHg/O )/O or/O hypertension/O (/O blood/O pressure/O greater/O than/O 170/100/O mmHg/O )/O ;/O Patients/O with/O unstable/O angina/O ,/O angina/O with/O sexual/O intercourse/O ,/O or/O New/O York/O Heart/O Association/O Class/O 2/O or/O greater/O congestive/O heart/O failure/O ./O
As/O with/O other/O PDE5/O inhibitors/O STENDRA/O has/O systemic/O vasodilatory/O properties/O and/O may/O augment/O the/O blood/O pressure/O -/O lowering/O effect/O of/O other/O anti/O -/O hypertensive/O medications/O ./O
STENDRA/O 200/O mg/O resulted/O in/O transient/B-AdverseReaction decreases/I-AdverseReaction in/I-AdverseReaction sitting/I-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction in/O healthy/O volunteers/O of/O 8.0/B-Severity mmHg/I-Severity systolic/I-Severity and/I-Severity 3.3/I-Severity mmHg/I-Severity diastolic/I-Severity [/O seeClinical/O Pharmacology/O (/O 12.2/O )/O ]/O ,/O with/O the/O maximum/O decrease/O observed/O at/O 1/O hour/O after/O dosing/O ./O
While/O this/O normally/O would/O be/O expected/O to/O be/O of/O little/O consequence/O in/O most/O patients/O ,/O prior/O to/O prescribing/O STENDRA/O ,/O physicians/O should/O carefully/O consider/O whether/O patients/O with/O underlying/O cardiovascular/O disease/O could/O be/O affected/O adversely/O by/O such/O vasodilatory/O effects/O ,/O especially/O in/O combination/O with/O sexual/O activity/O ./O
5.2/O Concomitant/O Use/O of/O CYP3A4/O Inhibitors/O STENDRA/O metabolism/O is/O principally/O mediated/O by/O the/O CYP450/O isoform/O 3A4/O (/O CYP3A4/O )/O ./O
Inhibitors/O of/O CYP3A4/O may/O reduce/O STENDRA/O clearance/O and/O increase/O plasma/O concentrations/O of/O avanafil/O ./O
For/O patients/O taking/O concomitant/O strong/O CYP3A4/O inhibitors/O (/O including/O ketoconazole/O ,/O ritonavir/O ,/O atazanavir/O ,/O clarithromycin/O ,/O indinavir/O ,/O itraconazole/O ,/O nefazodone/O ,/O nelfinavir/O ,/O saquinavir/O ,/O and/O telithromycin/O )/O ,/O do/O not/O use/O STENDRA/O [/O seeDrug/O Interactions/O (/O 7.2/O )/O ]/O ./O
For/O patients/O taking/O concomitant/O moderate/O CYP3A4/O inhibitors/O (/O including/O erythromycin/O ,/O amprenavir/O ,/O aprepitant/O ,/O diltiazem/O ,/O fluconazole/O ,/O fosamprenavir/O ,/O and/O verapamil/O )/O ,/O the/O maximum/O recommended/O dose/O of/O STENDRA/O is/O 50/O mg/O ,/O not/O to/O exceed/O once/O every/O 24/O hours/O [/O seeDrug/O Interactions/O (/O 7.2/O )/O ]/O ./O
5.3/O Prolonged/O Erection/O Prolonged/B-AdverseReaction erection/I-AdverseReaction greater/O than/O 4/B-Severity hours/I-Severity and/O priapism/B-AdverseReaction (/O painful/B-AdverseReaction erections/I-AdverseReaction greater/O than/O 6/B-Severity hours/I-Severity in/O duration/O )/O have/O been/O reported/O with/O other/O PDE5/B-DrugClass inhibitors/I-DrugClass ./O
In/O the/O event/O of/O an/O erection/O that/O persists/O longer/O than/O 4/O hours/O ,/O the/O patient/O should/O seek/O immediate/O medical/O assistance/O ./O
If/O not/O treated/O immediately/O ,/O penile/O tissue/O damage/O and/O permanent/O loss/O of/O potency/O could/O result/O ./O
STENDRA/O should/O be/O used/O with/O caution/O in/O patients/O with/O anatomical/O deformation/O of/O the/O penis/O (/O such/O as/O angulation/O ,/O cavernosal/O fibrosis/O ,/O or/O Peyronie/O 's/O disease/O )/O ,/O or/O in/O patients/O who/O have/O conditions/O which/O may/O predispose/O them/O to/O priapism/O (/O such/O as/O sickle/O cell/O anemia/O ,/O multiple/O myeloma/O ,/O or/O leukemia/O )/O ./O
5.4/O Effects/O on/O Eye/O Physicians/O should/O advise/O patients/O to/O stop/O use/O of/O all/O PDE5/O inhibitors/O ,/O including/O STENDRA/O ,/O and/O seek/O medical/O attention/O in/O the/O event/O of/O a/O sudden/O loss/O of/O vision/O in/O one/O or/O both/O eyes/O ./O
Such/O an/O event/O may/O be/O a/O sign/O of/O non/B-AdverseReaction -/I-AdverseReaction arteritic/I-AdverseReaction anterior/I-AdverseReaction ischemic/I-AdverseReaction optic/O neuropathy/O (/O NAION/B-AdverseReaction )/O ,/O a/O rare/O condition/O and/O a/O cause/O of/O decreased/B-AdverseReaction vision/I-AdverseReaction including/O permanent/B-AdverseReaction loss/I-AdverseReaction of/I-AdverseReaction vision/I-AdverseReaction that/O has/O been/O reported/O rarely/O postmarketing/O in/O temporal/O association/O with/O the/O use/O of/O all/O PDE5/B-DrugClass inhibitors/I-DrugClass ./O
Based/O on/O published/O literature/O ,/O the/O annual/O incidence/O of/O NAION/O is/O 2.5/O -/O 11.8/O cases/O per/O 100,000/O in/O males/O aged/O 50/O ./O
An/O observational/O study/O evaluated/O whether/O recent/O use/O of/O PDE5/B-DrugClass inhibitors/I-DrugClass ,/O as/O a/O class/O ,/O was/O associated/O with/O acute/O onset/O of/O NAION/B-AdverseReaction ./O
The/O results/O suggest/O an/O approximate/O 2-fold/O increase/O in/O the/O risk/O of/O NAION/B-AdverseReaction within/O 5/O half/O -/O lives/O of/O PDE5/B-DrugClass inhibitor/I-DrugClass use/O ./O
From/O this/O information/O ,/O it/O is/O not/O possible/O to/O determine/O whether/O these/O events/O are/O related/O directly/O to/O the/O use/O of/O PDE5/O inhibitors/O or/O to/O other/O factors/O [/O seeAdverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
Physicians/O should/O consider/O whether/O their/O patients/O with/O underlying/O NAION/O risk/O factors/O could/O be/O adversely/O affected/O by/O use/O of/O PDE5/O inhibitors/O ./O
Individuals/O who/O have/O already/O experienced/O NAION/O are/O at/O increased/O risk/O of/O NAION/O recurrence/O ./O
Therefore/O ,/O PDE5/O inhibitors/O ,/O including/O STENDRA/O ,/O should/O be/O used/O with/O caution/O in/O these/O patients/O and/O only/O when/O the/O anticipated/O benefits/O outweigh/O the/O risks/O ./O
Individuals/O with/O "/O crowded/O "/O optic/O disc/O are/O also/O considered/O at/O greater/O risk/O for/O NAION/O compared/O to/O the/O general/O population/O ,/O however/O ,/O evidence/O is/O insufficient/O to/O support/O screening/O of/O prospective/O users/O of/O PDE5/O inhibitors/O ,/O including/O STENDRA/O ,/O for/O this/O uncommon/O condition/O ./O
5.5/O Sudden/O Hearing/O Loss/O Use/O of/O PDE5/B-DrugClass inhibitors/I-DrugClass has/O been/O associated/O with/O sudden/O decrease/O or/O loss/B-AdverseReaction of/I-AdverseReaction hearing/I-AdverseReaction ,/O which/O may/O be/O accompanied/O by/O tinnitus/B-AdverseReaction or/O dizziness/B-AdverseReaction ./O
It/O is/O not/O possible/O to/O determine/O whether/O these/O events/O are/O related/O directly/O to/O the/O use/O of/O PDE5/O inhibitors/O or/O to/O other/O factors/O [/O seeAdverse/O Reactions/O (/O 6/O )/O ]/O ./O
Patients/O experiencing/O these/O symptoms/O should/O be/O advised/O to/O stop/O taking/O STENDRA/O and/O seek/O prompt/O medical/O attention/O ./O
5.6/O Alpha/O -/O Blockers/O and/O Other/O Antihypertensives/O Physicians/O should/O discuss/O with/O patients/O the/O potential/O for/O STENDRA/O to/O augment/O the/O blood/O pressure/O -/O lowering/O effect/O of/O alpha/O -/O blockers/O and/O other/O antihypertensive/O medications/O [/O seeDrug/O Interactions/O (/O 7.1)andClinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
Caution/O is/O advised/O when/O PDE5/O inhibitors/O are/O co/O -/O administered/O with/O alpha/O -/O blockers/O ./O
Phosphodiesterase/O type/O 5/O inhibitors/O ,/O including/O STENDRA/O ,/O and/O alpha/O -/O adrenergic/O blocking/O agents/O are/O both/O vasodilators/O with/O blood/O pressure/O -/O lowering/O effects/O ./O
When/O vasodilators/O are/O used/O in/O combination/O ,/O an/O additive/O effect/O on/O blood/O pressure/O may/O be/O anticipated/O ./O
In/O some/O patients/O ,/O concomitant/O use/O of/O these/O two/O drug/O classes/O can/B-Factor lower/O blood/O pressure/O significantly/O leading/O to/O symptomatic/B-AdverseReaction hypotension/I-AdverseReaction (/O e.g./O ,/O dizziness/B-AdverseReaction ,/O lightheadedness/B-AdverseReaction ,/O fainting/B-AdverseReaction )/O ./O
Consideration/O should/O be/O given/O to/O the/O following/O :/O Patients/O should/O be/O stable/O on/O alpha/O -/O blocker/O therapy/O prior/O to/O initiating/O treatment/O with/O a/O PDE5/O inhibitor/O ./O
Patients/O who/O demonstrate/O hemodynamic/O instability/O on/O alpha/O -/O blocker/O therapy/O alone/O are/O at/O increased/O risk/O of/O symptomatic/B-AdverseReaction hypotension/I-AdverseReaction with/O concomitant/O use/O of/O PDE5/B-DrugClass inhibitors/I-DrugClass ./O
In/O those/O patients/O who/O are/O stable/O on/O alpha/O -/O blocker/O therapy/O ,/O PDE5/O inhibitors/O should/O be/O initiated/O at/O the/O lowest/O dose/O (/O STENDRA/O 50/O mg/O )/O ./O
In/O those/O patients/O already/O taking/O an/O optimized/O dose/O of/O a/O PDE5/O inhibitor/O ,/O alpha/O -/O blocker/O therapy/O should/O be/O initiated/O at/O the/O lowest/O dose/O ./O
Stepwise/O increase/O in/O alpha/O -/O blocker/O dose/O may/O be/O associated/O with/O further/O lowering/O of/O blood/O pressure/O when/O taking/O a/O PDE5/O inhibitor/O ./O
Safety/O of/O combined/O use/O of/O PDE5/O inhibitors/O and/O alpha/O -/O blockers/O may/O be/O affected/O by/O other/O variables/O ,/O including/O intravascular/O volume/O depletion/O and/O other/O anti/O -/O hypertensive/O drugs/O [/O see/O Dosage/O and/O Administration/O (/O 2/O )/O and/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
5.7/O Alcohol/O Patients/O should/O be/O made/O aware/O that/O both/O alcohol/O and/O PDE5/O inhibitors/O including/O STENDRA/O act/O as/O vasodilators/O ./O
When/O vasodilators/O are/O taken/O in/O combination/O ,/O blood/O -/O pressure/O -/O lowering/O effects/O of/O each/O individual/O compound/O may/O be/O increased/O ./O
Therefore/O ,/O physicians/O should/O inform/O patients/O that/O substantial/O consumption/O of/O alcohol/O (/O e.g./O ,/O greater/O than/O 3/O units/O )/O in/O combination/O with/O STENDRA/O may/O increase/O the/O potential/O for/O orthostatic/O signs/O and/O symptoms/O ,/O including/O increase/O in/O heart/O rate/O ,/O decrease/O in/O standing/O blood/O pressure/O ,/O dizziness/O ,/O and/O headache/O [/O seeDrug/O Interactions/O (/O 7.1)andClinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
5.8/O Combination/O with/O Other/O PDE5/O Inhibitors/O or/O Erectile/O Dysfunction/O Therapies/O The/O safety/O and/O efficacy/O of/O combinations/O of/O STENDRA/O with/O other/O treatments/O for/O ED/O has/O not/O been/O studied/O ./O
Therefore/O ,/O the/O use/O of/O such/O combinations/O is/O not/O recommended/O ./O
5.9/O Effects/O on/O Bleeding/O The/O safety/O of/O STENDRA/O is/O unknown/O in/O patients/O with/O bleeding/O disorders/O and/O patients/O with/O active/O peptic/O ulceration/O ./O
In/B-Factor vitro/I-Factor studies/O with/O human/O platelets/O indicate/O that/O STENDRA/O potentiates/B-AdverseReaction the/I-AdverseReaction anti/I-AdverseReaction -/I-AdverseReaction aggregatory/I-AdverseReaction effect/I-AdverseReaction of/I-AdverseReaction sodium/O nitroprusside/O (/O a/O nitric/O oxide/O [/O NO/O ]/O donor/O )/O ./O
5.10/O Counseling/O Patients/O about/O Sexually/O Transmitted/O Diseases/O The/O use/O of/O STENDRA/O offers/O no/O protection/O against/O sexually/O transmitted/O diseases/O ./O
Counseling/O patients/O about/O the/O protective/O measures/O necessary/O to/O guard/O against/O sexually/O transmitted/O diseases/O ,/O including/O Human/O Immunodeficiency/O Virus/O (/O HIV/O )/O ,/O should/O be/O considered/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O drug/O reactions/O are/O discussed/O in/O other/O sections/O of/O the/O labeling/O :/O Lactic/B-AdverseReaction Acidosis/I-AdverseReaction Severe/B-Severity Hepatomegaly/B-AdverseReaction with/O Steatosis/B-AdverseReaction [/O see/O Boxed/O Warning/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Severe/B-Severity Acute/B-AdverseReaction Exacerbations/I-AdverseReaction of/I-AdverseReaction Hepatitis/I-AdverseReaction B/I-AdverseReaction [/O see/O Boxed/O Warning/O ,/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
New/O Onset/O or/O Worsening/B-AdverseReaction Renal/I-AdverseReaction Impairment/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Bone/B-AdverseReaction Effects/I-AdverseReaction of/O Tenofovir/O DF/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
Immune/B-AdverseReaction Reconstitution/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O adverse/O drug/O reactions/O to/O STRIBILD/O (/O incidence/O greater/O than/O or/O equal/O to/O 10/O %/O ,/O all/O grades/O )/O are/O nausea/B-AdverseReaction and/O diarrhea/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Gilead/O Sciences/O ,/O Inc./O at/O 1/O -/O 800-GILEAD-5/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Adverse/O Reactions/O from/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
In/O HIV-1-Infected/O Subjects/O With/O No/O Antiretroviral/O Treatment/O History/O The/O safety/O assessment/O of/O STRIBILD/O is/O based/O on/O the/O Week/O 144/O pooled/O data/O from/O 1408/O subjects/O in/O two/O randomized/O ,/O double/O -/O blind/O ,/O active/O -/O controlled/O clinical/O trials/O ,/O Study/O 102/O and/O Study/O 103/O ,/O in/O antiretroviral/O treatment/O -/O naive/O HIV-1/O infected/O adult/O subjects/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
A/O total/O of/O 701/O subjects/O received/O STRIBILD/O once/O daily/O in/O these/O two/O studies/O ./O
The/O proportion/O of/O subjects/O who/O discontinued/O treatment/O with/O STRIBILD/O (/O elvitegravir/O 150/O mg/O cobicistat/O 150/O mg/O emtricitabine/O 200/O mg/O tenofovir/O DF/O 300/O mg/O )/O ;/O ATRIPLA/O (/O efavirenz/O 600/O mg/O emtricitabine/O 200/O mg/O tenofovir/O DF/O 300/O mg/O )/O ;/O or/O atazanavir/O (/O ATV/O )/O +/O ritonavir/O (/O RTV/O )/O +/O TRUVADA/O (/O emtricitabine/O 200/O mg/O tenofovir/O DF/O 300/O mg/O )/O due/O to/O adverse/O events/O ,/O regardless/O of/O severity/O ,/O was/O 6.0/O %/O ,/O 7.4/O %/O and/O 8.5/O %/O ,/O respectively/O ./O
Table/O 2/O displays/O the/O frequency/O of/O adverse/O drug/O reactions/O greater/O than/O or/O equal/O to/O 5/O %/O of/O subjects/O in/O any/O treatment/O arm/O ./O
Table/O 2/O Adverse/O Drug/O ReactionsFrequencies/O of/O adverse/O reactions/O are/O based/O on/O all/O treatment/O -/O emergent/O adverse/O events/O ,/O attributed/O to/O study/O drugs/O ./O
(/O all/O grades/O )/O Reported/O in/O 5/O %/O of/O Subjects/O in/O Any/O Treatment/O Arm/O in/O Studies/O 102/O and/O 103/O (/O Week/O 144/O analysis/O )/O ./O
STRIBILDN=701/O ATRIPLAN=352/O ATV/O +/O RTV/O +/O TRUVADAN=355/O EYE/O DISORDERS/O Ocular/B-AdverseReaction icterus/I-AdverseReaction 1/O %/O 0/O %/O 13/O %/O GASTROINTESTINAL/O DISORDERS/O Diarrhea/B-AdverseReaction 12/O %/O 11/O %/O 17/O %/O Flatulence/B-AdverseReaction 2/O %/O 1/O %/O 8/O %/O Nausea/B-AdverseReaction 16/O %/O 9/O %/O 14/O %/O GENERAL/O DISORDERS/O AND/O ADMINISTRATION/O SITE/O CONDITIONS/O Fatigue/B-AdverseReaction 4/O %/O 8/O %/O 6/O %/O HEPATOBILIARY/O DISORDERS/O Jaundice/B-AdverseReaction 0/O %/O 1/O %/O 9/O %/O NERVOUS/O SYSTEM/O DISORDERS/O Somnolence/B-AdverseReaction 1/O %/O 7/O %/O 1/O %/O Headache/B-AdverseReaction 7/O %/O 4/O %/O 6/O %/O Dizziness/B-AdverseReaction 3/O %/O 21/O %/O 5/O %/O PSYCHIATRIC/O DISORDERS/O Insomnia/B-AdverseReaction 3/O %/O 9/O %/O 1/O %/O Abnormal/B-AdverseReaction dreams/I-AdverseReaction 9/O %/O 27/O %/O 4/O %/O SKIN/O AND/O SUBCUTANEOUS/O TISSUE/O DISORDERS/O Rash/B-AdverseReaction 4/O %/O 15/O %/O 6/O %/O See/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ,/O for/O a/O discussion/O of/O renal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction from/O clinical/O trials/O experience/O with/O STRIBILD/O ./O
Additional/O adverse/O drug/O reactions/O observed/O with/O STRIBILD/O included/O suicidal/B-AdverseReaction ideation/I-AdverseReaction and/O suicide/B-AdverseReaction attempt/I-AdverseReaction (/O 0.3/O %/O )/O ,/O all/O in/O subjects/O with/O a/O pre/O -/O existing/O history/O of/O depression/O or/O psychiatric/O illness/O ./O
In/O Virologically/O -/O Suppressed/O HIV-1-Infected/O Subjects/O No/O new/O adverse/O reactions/O to/O STRIBILD/O through/O Week/O 48/O were/O identified/O in/O 584/O virologically/O stably/O suppressed/O subjects/O switching/O to/O STRIBILD/O from/O a/O regimen/O containing/O a/O RTV/O -/O boosted/O protease/O inhibitor/O (/O PI/O )/O or/O a/O non/O -/O nucleoside/O reverse/O transcriptase/O inhibitor/O (/O NNRTI/O )/O ./O
In/O a/O combined/O analysis/O of/O Studies/O 115/O and/O 121/O ,/O the/O frequency/O of/O adverse/O reactions/O (/O all/O grades/O )/O was/O 24/O %/O in/O subjects/O switching/O to/O STRIBILD/O compared/O to/O 6/O %/O of/O subjects/O in/O either/O group/O who/O stayed/O on/O their/O baseline/O antiretroviral/O regimen/O ,/O RTV/O -/O boosted/O PI/O +/O TRUVADA/O or/O NNRTI/O +/O TRUVADA/O ./O
Common/O adverse/O reactions/O that/O occurred/O in/O greater/O than/O or/O equal/O to/O 2/O %/O of/O subjects/O switching/O to/O STRIBILD/O were/O nausea/B-AdverseReaction (/O 4/O %/O )/O ,/O flatulence/B-AdverseReaction (/O 2/O %/O )/O ,/O and/O headache/B-AdverseReaction (/O 2/O %/O )/O ./O
The/O proportion/O of/O subjects/O who/O discontinued/O treatment/O with/O STRIBILD/O ,/O the/O RTV/O -/O boosted/O PI/O ,/O or/O the/O NNRTI/O due/O to/O adverse/O events/O ,/O was/O 2/O %/O ,/O 3/O %/O and/O 1/O %/O ,/O respectively/O ./O
Adverse/O Reactions/O from/O Clinical/O Trials/O of/O the/O Components/O of/O STRIBILD/O Emtricitabine/O and/O Tenofovir/O Disoproxil/O Fumarate/O :/O In/O addition/O to/O the/O adverse/O reactions/O observed/O with/O STRIBILD/O ,/O the/O following/O adverse/O reactions/O occurred/O in/O at/O least/O 5/O %/O of/O treatment/O -/O experienced/O or/O treatment/O -/O naive/O subjects/O receiving/O emtricitabine/O or/O tenofovir/O DF/O with/O other/O antiretroviral/O agents/O in/O other/O clinical/O trials/O :/O depression/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O fever/B-AdverseReaction ,/O pain/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O myalgia/B-AdverseReaction ,/O paresthesia/B-AdverseReaction ,/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction (/O including/O peripheral/B-AdverseReaction neuritis/I-AdverseReaction and/O neuropathy/O )/O ,/O anxiety/B-AdverseReaction ,/O increased/B-AdverseReaction cough/I-AdverseReaction ,/O and/O rhinitis/B-AdverseReaction ./O
Skin/B-AdverseReaction discoloration/I-AdverseReaction has/O been/O reported/O with/O higher/O frequency/O among/O emtricitabine/O -/O treated/O subjects/O ;/O it/O was/O manifested/O by/O hyperpigmentation/B-AdverseReaction on/I-AdverseReaction the/I-AdverseReaction palms/I-AdverseReaction and/or/O soles/O and/O was/O generally/O mild/B-Severity and/O asymptomatic/O ./O
The/O mechanism/O and/O clinical/O significance/O are/O unknown/O ./O
Laboratory/O Abnormalities/O The/O frequency/O of/O laboratory/O abnormalities/O (/O Grades/O 3/O -/O 4/O )/O occurring/O in/O at/O least/O 2/O %/O of/O subjects/O receiving/O STRIBILD/O in/O Studies/O 102/O and/O 103/O are/O presented/O in/O Table/O 3/O ./O
Table/O 3/O Laboratory/O Abnormalities/O (/O Grades/O 3/O -/O 4/O )/O Reported/O in/O 2/O %/O of/O Subjects/O Receiving/O STRIBILD/O in/O Studies/O 102/O and/O 103/O (/O Week/O 144/O analysis/O )/O STRIBILD/O ATRIPLA/O ATV/O +/O RTV/O +/O TRUVADA/O Laboratory/O Parameter/O Abnormality/O ,/O N=701/O N=352/O N=355/O AST/O (/O 5.0/O ULN/O )/O 3/O %/O 6/O %/O 6/O %/O ALT/O (/O 3.0/O ULN/O )/O 2/O %/O 5/O %/O 4/O %/O Amylase(>2.0/O ULN/O )/O 3/O %/O 3/O %/O 5/O %/O Creatine/O Kinase/O (/O 10.0/O ULN/O )/O 8/O %/O 15/O %/O 11/O %/O Urine/B-AdverseReaction RBC/I-AdverseReaction (/O Hematuria/B-AdverseReaction )/O (/O 75/O RBC/O HPF/O )/O 4/O %/O 2/O %/O 4/O %/O In/O Study/O 103/O ,/O BMD/O was/O assessed/O by/O DEXA/O in/O a/O non/O -/O random/O subset/O of/O 120/O subjects/O (/O STRIBILD/O group/O N/O 54/O ;/O ATV/O +/O RTV/O +/O TRUVADA/O group/O N/O 66/O )/O ./O
Mean/O percentage/O decreases/B-AdverseReaction in/I-AdverseReaction BMD/I-AdverseReaction from/O baseline/O to/O Week/O 144/O in/O the/O STRIBILD/O group/O were/O comparable/O to/O the/O ATV/O +/O RTV/O +/O TRUVADA/O group/O at/O the/O lumbar/O spine/O (/O -1.43/O %/O versus/O -3.68/O %/O ,/O respectively/O )/O and/O at/O the/O hip/O (/O -2.83/O %/O versus/O -3.77/O %/O ,/O respectively/O )/O ./O
In/O Studies/O 102/O and/O 103/O ,/O bone/B-AdverseReaction fractures/I-AdverseReaction occurred/O in/O 27/O subjects/O (/O 3.9/O %/O )/O in/O the/O STRIBILD/O group/O ,/O 8/O subjects/O (/O 2.3/O %/O )/O in/O the/O ATRIPLA/O group/O ,/O and/O 19/O subjects/O (/O 5.4/O %/O )/O in/O the/O ATV/O +/O RTV/O +/O TRUVADA/O group/O ./O
These/O findings/O were/O consistent/O with/O data/O from/O an/O earlier/O 144-week/O trial/O of/O treatment/O -/O naive/O subjects/O receiving/O tenofovir/O DF/O +/O lamivudine/O +/O efavirenz/O ./O
Proteinuria/B-AdverseReaction (/O all/O grades/O )/O occurred/O in/O 52/O %/O of/O subjects/O receiving/O STRIBILD/O ,/O 41/O %/O of/O subjects/O receiving/O ATRIPLA/O ,/O and/O 42/O %/O of/O subjects/O receiving/O ATV/O +/O RTV/O +/O TRUVADA/O ./O
The/O cobicistat/O component/O of/O STRIBILD/O has/O been/O shown/O to/O increase/B-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O decrease/B-AdverseReaction estimated/I-AdverseReaction creatinine/I-AdverseReaction clearance/I-AdverseReaction due/O to/O inhibition/O of/O tubular/O secretion/O of/O creatinine/O without/B-Negation affecting/B-AdverseReaction renal/I-AdverseReaction glomerular/I-AdverseReaction function/I-AdverseReaction ./O
In/O Studies/O 102/O and/O 103/O ,/O increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O decreases/B-AdverseReaction in/I-AdverseReaction estimated/I-AdverseReaction creatinine/I-AdverseReaction clearance/I-AdverseReaction occurred/O early/O in/O treatment/O with/O STRIBILD/O ,/O after/O which/O they/O stabilized/O ./O
Table/O 4/O displays/O the/O mean/O changes/O in/O serum/O creatinine/O and/O eGFR/O levels/O at/O Week/O 144/O and/O the/O percentage/O of/O subjects/O with/O elevations/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction (/O All/O Grades/O )/O ./O
Table/O 4/O Change/O from/O Baseline/O in/O Serum/O Creatinine/O and/O eGFR/O and/O Incidence/O of/O Elevated/B-AdverseReaction Serum/I-AdverseReaction Creatinine/I-AdverseReaction (/O All/O Grades/O )/O in/O Studies/O 102/O and/O 103/O at/O Week/O 144/O STRIBILD(N=701/O )/O ATRIPLA(N=352/O )/O ATV/O +/O RTV/O +/O TRUVADA(N=355/O )/O Serum/O Creatinine/O (/O mg/O dL/O )/O 0.14/O (/O +/O /-0.14/O )/O 0.01/O (/O +/O /-0.12/O )/O 0.09/O (/O +/O /-0.15/O )/O eGFR/O by/O Cockcroft/O -/O Gault/O (/O mL/O minute/O )/O -14.0/O (/O +/O /-16.6/O )/O -1.9/O (/O +/O /-17.9/O )/O -9.8/O (/O +/O /-19.4/O )/O Subjects/O with/O Elevations/B-AdverseReaction in/I-AdverseReaction Serum/I-AdverseReaction Creatinine/I-AdverseReaction (/O All/O Grades)(%/O )/O 12/O 2/O 6/O Emtricitabine/O or/O Tenofovir/O DF/O :/O In/O addition/O to/O the/O laboratory/O abnormalities/O observed/O with/O STRIBILD/O ,/O the/O following/O laboratory/O abnormalities/O have/O been/O previously/O reported/O in/O subjects/O treated/O with/O emtricitabine/O or/O tenofovir/O DF/O with/O other/O antiretroviral/O agents/O in/O other/O clinical/O trials/O :/O Grade/B-Severity 3/I-Severity or/O 4/O laboratory/O abnormalities/B-AdverseReaction of/I-AdverseReaction ALT/I-AdverseReaction (/O M/O :/O greater/O than/O 215/B-Severity U/I-Severity per/I-Severity L/I-Severity ;/O F/O :/O greater/O than/O 170/B-Severity U/I-Severity per/I-Severity L/I-Severity )/O ,/O alkaline/O phosphatase/O (/O greater/O than/O 550/B-Severity U/I-Severity per/I-Severity L/I-Severity )/O ,/O bilirubin/O (/O greater/O than/O 2.5/B-Severity ULN/I-Severity )/O ,/O serum/O glucose/O (/O less/O than/O 40/O or/O greater/O than/O 250/B-Severity mg/I-Severity per/I-Severity dL/I-Severity )/O ,/O glycosuria/O (/O greater/O than/O or/O equal/O to/O 3/B-Severity +/O )/O ,/O neutrophils/O (/O less/O than/O 750/B-Severity per/I-Severity mm/I-Severity 3/O )/O ,/O fasting/O cholesterol/O (/O greater/O than/O 240/B-Severity mg/I-Severity per/I-Severity dL/I-Severity )/O ,/O and/O fasting/O triglycerides/O (/O greater/O than/O 750/B-Severity mg/I-Severity per/I-Severity dL/I-Severity )/O ./O
Serum/O Lipids/O :/O In/O the/O clinical/O trials/O of/O STRIBILD/O ,/O a/O similar/O percentage/O of/O subjects/O receiving/O STRIBILD/O ,/O ATRIPLA/O ,/O and/O ATV/O +/O RTV/O +/O TRUVADA/O were/O on/O lipid/O lowering/O agents/O at/O baseline/O (/O 12/O %/O ,/O 12/O %/O ,/O and/O 13/O %/O ,/O respectively/O )/O ./O
While/O receiving/O study/O drug/O through/O Week/O 144/O ,/O an/O additional/O 11/O %/O of/O STRIBILD/O subjects/O were/O started/O on/O lipid/O lowering/O agents/O ,/O compared/O to/O 13/O %/O of/O ATRIPLA/O and/O 12/O %/O of/O ATV/O +/O RTV/O +/O TRUVADA/O subjects/O ./O
Changes/O from/O baseline/O in/O total/O cholesterol/O ,/O HDL/O -/O cholesterol/O ,/O LDL/O -/O cholesterol/O ,/O and/O triglycerides/O are/O presented/O in/O Table/O 5/O ./O
Table/O 5/O Lipid/O Values/O ,/O Mean/O Change/O from/O Baseline/O at/O Week/O 144/O in/O Subjects/O Receiving/O STRIBILD/O or/O Comparator/O in/O Studies/O 102/O and/O 103/O STRIBILDN=701/O ATRIPLAN=352/O ATV/O +/O RTV/O +/O TRUVADAN=355/O Baseline/O Week/O 144/O Baseline/O Week/O 144/O Baseline/O Week/O 144/O mg/O dL/O Change/O mg/O dL/O Change/O mg/O dL/O Change/O Total/O Cholesterol/O (/O fasted/O )/O 166[N=675/O ]/O +17[N=535/O ]/O 161[N=343/O ]/O +22[N=262/O ]/O 168[N=337/O ]/O +16[N=243/O ]/O HDL/O -/O cholesterol/O (/O fasted/O )/O 43[N=675/O ]/O +7[N=535/O ]/O 43[N=343/O ]/O +9[N=262/O ]/O 42[N=335/O ]/O +7[N=242/O ]/O LDL/O -/O cholesterol/O (/O fasted/O )/O 100[N=675/O ]/O +15[N=535/O ]/O 97[N=343/O ]/O +19[N=262/O ]/O 101[N=337/O ]/O +18[N=242/O ]/O Triglycerides/O (/O fasted/O )/O 122[N=675/O ]/O +12[N=535/O ]/O 121[N=343/O ]/O +5[N=262/O ]/O 132[N=337/O ]/O +22[N=242/O ]/O 6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O tenofovir/O DF/O ./O
Because/O postmarketing/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
No/O additional/O postmarketing/O adverse/O reactions/O specific/O for/O emtricitabine/O have/O been/O identified/O ./O
Immune/O System/O Disorders/O allergic/B-AdverseReaction reaction/I-AdverseReaction ,/O including/O angioedema/B-AdverseReaction Metabolism/O and/O Nutrition/O Disorders/O lactic/B-AdverseReaction acidosis/I-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O dyspnea/B-AdverseReaction Gastrointestinal/O Disorders/O pancreatitis/B-AdverseReaction ,/O increased/B-AdverseReaction amylase/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction Hepatobiliary/O Disorders/O hepatic/B-AdverseReaction steatosis/I-AdverseReaction ,/O hepatitis/B-AdverseReaction ,/O increased/B-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction (/O most/O commonly/O AST/O ,/O ALT/O gamma/O GT/O )/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O rash/B-AdverseReaction Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O rhabdomyolysis/B-AdverseReaction ,/O osteomalacia/B-AdverseReaction (/O manifested/O as/O bone/B-AdverseReaction pain/I-AdverseReaction and/O which/O may/O contribute/O to/O fractures/B-AdverseReaction )/O ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O myopathy/B-AdverseReaction Renal/O and/O Urinary/O Disorders/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction ,/O acute/B-AdverseReaction tubular/I-AdverseReaction necrosis/I-AdverseReaction ,/O Fanconi/B-AdverseReaction syndrome/I-AdverseReaction ,/O proximal/B-AdverseReaction renal/I-AdverseReaction tubulopathy/I-AdverseReaction ,/O interstitial/B-AdverseReaction nephritis/I-AdverseReaction (/O including/O acute/O cases/O )/O ,/O nephrogenic/B-AdverseReaction diabetes/I-AdverseReaction insipidus/I-AdverseReaction ,/O renal/B-AdverseReaction insufficiency/I-AdverseReaction ,/O increased/B-AdverseReaction creatinine/I-AdverseReaction ,/O proteinuria/B-AdverseReaction ,/O polyuria/B-AdverseReaction General/O Disorders/O and/O Administration/O Site/O Conditions/O asthenia/B-AdverseReaction The/O following/O adverse/O reactions/O ,/O listed/O under/O the/O body/O system/O headings/O above/O ,/O may/O occur/O as/O a/O consequence/O of/O proximal/B-AdverseReaction renal/I-AdverseReaction tubulopathy/I-AdverseReaction :/O rhabdomyolysis/B-AdverseReaction ,/O osteomalacia/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O myopathy/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O LACTIC/B-AdverseReaction ACIDOSIS/I-AdverseReaction SEVERE/B-Severity HEPATOMEGALY/B-AdverseReaction WITH/O STEATOSIS/B-AdverseReaction and/O POST/O TREATMENT/O ACUTE/B-AdverseReaction EXACERBATION/I-AdverseReaction OF/I-AdverseReaction HEPATITIS/I-AdverseReaction B/I-AdverseReaction WARNING/O :/O LACTIC/B-AdverseReaction ACIDOSIS/I-AdverseReaction SEVERE/B-Severity HEPATOMEGALY/B-AdverseReaction WITH/O STEATOSIS/B-AdverseReaction and/O POST/O TREATMENT/O ACUTE/B-AdverseReaction EXACERBATION/I-AdverseReaction OF/I-AdverseReaction HEPATITIS/I-AdverseReaction B/I-AdverseReaction Lactic/B-AdverseReaction acidosis/I-AdverseReaction and/O severe/B-Severity hepatomegaly/B-AdverseReaction with/O steatosis/B-AdverseReaction ,/O including/O fatal/B-AdverseReaction cases/O ,/O have/O been/O reported/O with/O the/O use/O of/O nucleoside/O analogs/O ,/O including/O tenofovir/O disoproxil/O fumarate/O ,/O a/O component/O of/O STRIBILD/O ,/O in/O combination/O with/O other/O antiretrovirals/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
STRIBILD/O is/O not/O approved/O for/O the/O treatment/O of/O chronic/O hepatitis/O B/O virus/O (/O HBV/O )/O infection/O and/O the/O safety/O and/O efficacy/O of/O STRIBILD/O have/O not/O been/O established/O in/O patients/O coinfected/O with/O HBV/O and/O HIV-1/O ./O
Severe/B-Severity acute/B-AdverseReaction exacerbations/I-AdverseReaction of/I-AdverseReaction hepatitis/I-AdverseReaction B/I-AdverseReaction have/O been/O reported/O in/O patients/O who/O are/O coinfected/O with/O HBV/O and/O human/O immunodeficiency/O virus-1/O (/O HIV-1/O )/O and/O have/O discontinued/O EMTRIVA/O or/O VIREAD/O ,/O which/O are/O components/O of/O STRIBILD/O ./O
Hepatic/O function/O should/O be/O monitored/O closely/O with/O both/O clinical/O and/O laboratory/O follow/O -/O up/O for/O at/O least/O several/O months/O in/O patients/O who/O are/O coinfected/O with/O HIV-1/O and/O HBV/O and/O discontinue/O STRIBILD/O ./O
If/O appropriate/O ,/O initiation/O of/O anti/O -/O hepatitis/O B/O therapy/O may/O be/O warranted/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O LACTIC/B-AdverseReaction ACIDOSIS/I-AdverseReaction SEVERE/B-Severity HEPATOMEGALY/B-AdverseReaction WITH/O STEATOSIS/B-AdverseReaction and/O POST/O TREATMENT/O ACUTE/B-AdverseReaction EXACERBATION/I-AdverseReaction OF/I-AdverseReaction HEPATITIS/I-AdverseReaction B/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Lactic/B-AdverseReaction acidosis/I-AdverseReaction and/O severe/B-Severity hepatomegaly/B-AdverseReaction with/O steatosis/B-AdverseReaction ,/O including/O fatal/B-AdverseReaction cases/O ,/O have/O been/O reported/O with/O the/O use/O of/O nucleoside/O analogs/O ,/O including/O tenofovir/O disoproxil/O fumarate/O (/O DF/O )/O ,/O a/O component/O of/O STRIBILD/O ./O
(/O 5.1/O )/O STRIBILD/O is/O not/O approved/O for/O the/O treatment/O of/O chronic/O hepatitis/O B/O virus/O (/O HBV/O )/O infection/O ./O
Severe/B-Severity acute/B-AdverseReaction exacerbations/I-AdverseReaction of/I-AdverseReaction hepatitis/I-AdverseReaction B/I-AdverseReaction have/O been/O reported/O in/O patients/O coinfected/O with/O HIV-1/O and/O HBV/O who/O have/O discontinued/O EMTRIVA/O or/O VIREAD/O ,/O two/O of/O the/O components/O of/O STRIBILD/O ./O
Hepatic/O function/O should/O be/O monitored/O closely/O in/O these/O patients/O ./O
If/O appropriate/O ,/O initiation/O of/O anti/O -/O hepatitis/O B/O therapy/O may/O be/O warranted/O ./O
(/O 5.2/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O New/O onset/O or/O worsening/B-AdverseReaction renal/I-AdverseReaction impairment/I-AdverseReaction :/O Can/B-Factor include/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction and/O Fanconi/B-AdverseReaction syndrome/I-AdverseReaction ./O
Assess/O creatinine/O clearance/O (/O CLcr/O )/O ,/O urine/O glucose/O and/O urine/O protein/O before/O initiating/O treatment/O with/O STRIBILD/O ./O
Monitor/O CLcr/O ,/O urine/O glucose/O ,/O and/O urine/O protein/O in/O all/O patients/O ./O
Monitor/O serum/O phosphorus/O in/O patients/O at/O risk/O for/O renal/O impairment/O ./O
Avoid/O administering/O STRIBILD/O with/O concurrent/O or/O recent/O use/O of/O nephrotoxic/O drugs/O ./O
(/O 5.3/O )/O Avoid/O coadministration/O with/O other/O anti/O -/O retroviral/O products/O :/O Do/O not/O use/O with/O products/O containing/O any/O of/O the/O components/O of/O STRIBILD/O (/O cobicistat/O ,/O elvitegravir/O ,/O emtricitabine/O ,/O and/O tenofovir/O disoproxil/O fumarate/O )/O ,/O including/O ATRIPLA/O ,/O COMPLERA/O ,/O EMTRIVA/O ,/O TRUVADA/O ,/O TYBOST/O ,/O VIREAD/O ,/O or/O VITEKTA/O ;/O with/O drugs/O containing/O lamivudine/O ;/O or/O with/O drugs/O or/O regimens/O containing/O ritonavir/O ./O
Do/O not/O administer/O in/O combination/O with/O HEPSERA/O ./O
(/O 5.4/O )/O Risk/O of/O adverse/O reactions/O or/O loss/O of/O virologic/O response/O due/O to/O drug/O interactions/O :/O The/O concomitant/O use/O of/O STRIBILD/O and/O other/O drugs/O may/O result/O in/O known/O or/O potentially/O significant/O drug/O interactions/O ,/O some/O of/O which/O may/O lead/O to/O loss/O of/O therapeutic/O effect/O of/O STRIBILD/O and/O possible/O development/O of/O resistance/O ;/O and/O possible/O clinically/O significant/O adverse/O reactions/O from/O greater/O exposures/O of/O concomitant/O drugs/O ./O
(/O 5.5/O )/O Decreases/B-AdverseReaction in/I-AdverseReaction bone/I-AdverseReaction mineral/I-AdverseReaction density/I-AdverseReaction (/O BMD/O )/O :/O Consider/O monitoring/O BMD/O in/O patients/O with/O a/O history/O of/O pathologic/O fracture/O or/O other/O risk/O factors/O of/O osteoporosis/O or/O bone/O loss/O ./O
(/O 5.6/O )/O Redistribution/O accumulation/B-AdverseReaction of/I-AdverseReaction body/I-AdverseReaction fat/I-AdverseReaction :/O Observed/O in/O patients/O receiving/O antiretroviral/O therapy/O ./O
(/O 5.7/O )/O Immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction :/O May/O necessitate/O further/O evaluation/O and/O treatment/O ./O
(/O 5.8/O )/O 5.1/O Lactic/O Acidosis/O Severe/O Hepatomegaly/O with/O Steatosis/O Lactic/B-AdverseReaction acidosis/I-AdverseReaction and/O severe/B-Severity hepatomegaly/B-AdverseReaction with/O steatosis/B-AdverseReaction ,/O including/O fatal/B-AdverseReaction cases/O ,/O have/O been/O reported/O with/O the/O use/O of/O nucleoside/O analogs/O ,/O including/O tenofovir/O DF/O ,/O a/O component/O of/O STRIBILD/O ,/O in/O combination/O with/O other/O antiretrovirals/O ./O
A/O majority/O of/O these/O cases/O have/O been/O in/O women/O ./O
Obesity/O and/O prolonged/O nucleoside/O exposure/O may/O be/O risk/O factors/O ./O
Particular/O caution/O should/O be/O exercised/O when/O administering/O nucleoside/O analogs/O to/O any/O patient/O with/O known/O risk/O factors/O for/O liver/O disease/O ;/O however/O ,/O cases/O have/O also/O been/O reported/O in/O patients/O with/O no/O known/O risk/O factors/O ./O
Treatment/O with/O STRIBILD/O should/O be/O suspended/O in/O any/O patient/O who/O develops/O clinical/O or/O laboratory/O findings/O suggestive/O of/O lactic/O acidosis/O or/O pronounced/O hepatotoxicity/O (/O which/O may/O include/O hepatomegaly/O and/O steatosis/O even/O in/O the/O absence/O of/O marked/O transaminase/O elevations/O )/O ./O
5.2/O Patients/O Coinfected/O with/O HIV-1/O and/O HBV/O It/O is/O recommended/O that/O all/O patients/O with/O HIV-1/O be/O tested/O for/O the/O presence/O of/O chronic/O hepatitis/O B/O virus/O (/O HBV/O )/O before/O initiating/O antiretroviral/O therapy/O ./O
STRIBILD/O is/O not/O approved/O for/O the/O treatment/O of/O chronic/O HBV/O infection/O and/O the/O safety/O and/O efficacy/O of/O STRIBILD/O have/O not/O been/O established/O in/O patients/O coinfected/O with/O HBV/O and/O HIV-1/O ./O
Severe/O acute/O exacerbations/O of/O hepatitis/O B/O have/O been/O reported/O in/O patients/O who/O are/O coinfected/O with/O HBV/O and/O HIV-1/O and/O have/O discontinued/O emtricitabine/O or/O tenofovir/O DF/O ,/O two/O of/O the/O components/O of/O STRIBILD/O ./O
In/O some/O patients/O infected/O with/O HBV/O and/O treated/O with/O EMTRIVA/O ,/O the/O exacerbations/B-AdverseReaction of/I-AdverseReaction hepatitis/I-AdverseReaction B/I-AdverseReaction were/O associated/O with/O liver/B-AdverseReaction decompensation/I-AdverseReaction and/O liver/B-AdverseReaction failure/I-AdverseReaction ./O
Patients/O who/O are/O coinfected/O with/O HIV-1/O and/O HBV/O should/O be/O closely/O monitored/O with/O both/O clinical/O and/O laboratory/O follow/O -/O up/O for/O at/O least/O several/O months/O after/O stopping/O treatment/O with/O STRIBILD/O ./O
If/O appropriate/O ,/O initiation/O of/O anti/O -/O hepatitis/O B/O therapy/O may/O be/O warranted/O ./O
5.3/O New/O Onset/O or/O Worsening/O Renal/O Impairment/O Renal/B-AdverseReaction impairment/I-AdverseReaction ,/O including/O cases/O of/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction and/O Fanconi/B-AdverseReaction syndrome/I-AdverseReaction (/O renal/B-AdverseReaction tubular/I-AdverseReaction injury/I-AdverseReaction with/O severe/B-Severity hypophosphatemia/B-AdverseReaction )/O ,/O has/O been/O reported/O with/O the/O use/O of/O tenofovir/O DF/O ,/O a/O component/O of/O STRIBILD/O ,/O and/O with/O the/O use/O of/O STRIBILD/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
In/O the/O clinical/O trials/O of/O STRIBILD/O over/O 144/O weeks/O ,/O 13/O (/O 1.9/O %/O )/O subjects/O in/O the/O STRIBILD/O group/O (/O N=701/O )/O ,/O 8/O (/O 2.3/O %/O )/O subjects/O in/O the/O ATV/O +/O RTV/O +/O TRUVADA/O group/O (/O N=355/O )/O and/O no/O subjects/O in/O the/O ATRIPLA/O group/O (/O N/O 352/O )/O discontinued/O study/O drug/O due/O to/O a/O renal/B-AdverseReaction adverse/I-AdverseReaction reaction/I-AdverseReaction ./O
Of/O these/O discontinuations/O ,/O 8/O in/O the/O STRIBILD/O group/O and/O 1/O in/O the/O ATV/O +/O RTV/O +/O TRUVADA/O group/O occurred/O during/O the/O first/O 48/O weeks/O ./O
Four/O (/O 0.6/O %/O )/O subjects/O who/O received/O STRIBILD/O developed/O laboratory/O findings/O consistent/O with/O proximal/B-AdverseReaction renal/I-AdverseReaction tubular/I-AdverseReaction dysfunction/I-AdverseReaction leading/O to/O discontinuation/O of/O STRIBILD/O during/O the/O first/O 48/O weeks/O of/O treatment/O ./O
Two/O of/O the/O four/O subjects/O had/O renal/O impairment/O (/O i.e./O estimated/O creatinine/O clearance/O less/O than/O 70/O mL/O per/O minute/O )/O at/O baseline/O ./O
The/O laboratory/O findings/O in/O these/O 4/O subjects/O improved/O but/O did/O not/O completely/O resolve/O in/O all/O subjects/O upon/O discontinuation/O of/O STRIBILD/O ./O
Renal/O replacement/O therapy/O was/O not/O required/O for/O these/O subjects/O ./O
One/O (/O 0.3/O %/O )/O subject/O who/O received/O ATV/O +/O RTV/O +/O TRUVADA/O developed/O laboratory/O findings/O consistent/O with/O proximal/B-AdverseReaction renal/I-AdverseReaction tubular/I-AdverseReaction dysfunction/I-AdverseReaction leading/O to/O discontinuation/O of/O ATV/O +/O RTV/O +/O TRUVADA/O after/O Week/O 96/O ./O
STRIBILD/O should/O be/O avoided/O with/O concurrent/O or/O recent/O use/O of/O a/O nephrotoxic/O agent/O ./O
(/O e.g./O ,/O high/O -/O dose/O or/O multiple/O non/O -/O steroidal/O anti/O -/O inflammatory/O drugs/O (/O NSAIDs/O )/O )/O [/O see/O Drug/O Interactions/O (/O 7.4/O )/O ]/O ./O
Cases/O of/O acute/O renal/O failure/O after/O initiation/O of/O high/O dose/O or/O multiple/O NSAIDs/O have/O been/O reported/O in/O HIV/O -/O infected/O patients/O with/O risk/O factors/O for/O renal/O dysfunction/O who/O appeared/O stable/O on/O tenofovir/O DF/O ./O
Some/O patients/O required/O hospitalization/O and/O renal/O replacement/O therapy/O ./O
Alternatives/O to/O NSAIDs/O should/O be/O considered/O ,/O if/O needed/O ,/O in/O patients/O at/O risk/O for/O renal/O dysfunction/O ./O
Persistent/O or/O worsening/O bone/O pain/O ,/O pain/O in/O extremities/O ,/O fractures/O and/or/O muscular/O pain/O or/O weakness/O may/O be/O manifestations/O of/O proximal/O renal/O tubulopathy/O and/O should/O prompt/O an/O evaluation/O of/O renal/O function/O in/O at/O -/O risk/O patients/O ./O
Estimated/O creatinine/O clearance/O ,/O urine/O glucose/O and/O urine/O protein/O should/O be/O documented/O in/O all/O patients/O prior/O to/O initiating/O therapy/O ./O
Initiation/O of/O STRIBILD/O in/O patients/O with/O estimated/O creatinine/O clearance/O below/O 70/O mL/O per/O minute/O is/O not/O recommended/O ./O
Routine/O monitoring/O of/O estimated/O creatinine/O clearance/O ,/O urine/O glucose/O ,/O and/O urine/O protein/O should/O be/O performed/O during/O STRIBILD/O therapy/O in/O all/O patients/O ./O
Additionally/O ,/O serum/O phosphorus/O should/O be/O measured/O in/O patients/O at/O risk/O for/O renal/O impairment/O ./O
Although/O cobicistat/O (/O a/O component/O of/O STRIBILD/O )/O may/B-Factor cause/O modest/B-Severity increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction and/O modest/B-Severity declines/B-AdverseReaction in/I-AdverseReaction estimated/I-AdverseReaction creatinine/I-AdverseReaction clearance/I-AdverseReaction without/O affecting/O renal/O glomerular/O function/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ,/O patients/O who/O experience/O a/O confirmed/O increase/O in/O serum/O creatinine/O of/O greater/O than/O 0.4/O mg/O per/O dL/O from/O baseline/O should/O be/O closely/O monitored/O for/O renal/O safety/O ./O
The/O emtricitabine/O and/O tenofovir/O DF/O components/O of/O STRIBILD/O are/O primarily/O excreted/O by/O the/O kidney/O ./O
STRIBILD/O should/O be/O discontinued/O if/O estimated/O creatinine/O clearance/O declines/O below/O 50/O mL/O per/O minute/O as/O dose/O interval/O adjustment/O required/O for/O emtricitabine/O and/O tenofovir/O DF/O can/O not/O be/O achieved/O with/O the/O fixed/O -/O dose/O combination/O tablet/O ./O
5.4/O Avoid/O Use/O with/O Other/O Antiretroviral/O Products/O STRIBILD/O is/O indicated/O for/O use/O as/O a/O complete/O regimen/O for/O the/O treatment/O of/O HIV-1/O infection/O and/O coadministration/O with/O other/O antiretroviral/O products/O is/O not/O recommended/O ./O
STRIBILD/O is/O not/O recommended/O for/O coadministration/O with/O the/O following/O :/O cobicistat/O (/O TYBOST/O )/O ;/O elvitegravir/O (/O VITEKTA/O )/O ;/O products/O containing/O emtricitabine/O or/O tenofovir/O DF/O (/O ATRIPLA/O ,/O COMPLERA/O ,/O EMTRIVA/O ,/O TRUVADA/O ,/O VIREAD/O )/O ;/O products/O containing/O lamivudine/O (/O COMBIVIR/O ,/O EPIVIR/O ,/O EPIVIR/O -/O HBV/O ,/O EPZICOM/O ,/O TRIUMEQ/O ,/O TRIZIVIR/O )/O ;/O adefovir/O dipivoxil/O (/O HEPSERA/O )/O ;/O products/O containing/O ritonavir/O (/O NORVIR/O ,/O KALETRA/O )/O 5.5/O Risk/O of/O Adverse/O Reactions/O or/O Loss/O of/O Virologic/O Response/O Due/O to/O Drug/O Interactions/O The/O concomitant/O use/O of/O STRIBILD/O and/O other/O drugs/O may/O result/O in/O known/O or/O potentially/O significant/O drug/O interactions/O ,/O some/O of/O which/O may/O lead/O to/O [/O see/O Contraindications/O (/O 4/O )/O ,/O Drug/O Interactions/O (/O 7.5/O )/O ]/O :/O Loss/O of/O therapeutic/O effect/O of/O STRIBILD/O and/O possible/O development/O of/O resistance/O ./O
Possible/O clinically/O significant/O adverse/O reactions/O from/O greater/O exposures/O of/O concomitant/O drugs/O ./O
See/O Table/O 6/O for/O steps/O to/O prevent/O or/O manage/O these/O possible/O and/O known/O significant/O drug/O interactions/O ,/O including/O dosing/O recommendations/O [/O see/O Drug/O Interactions/O (/O 7.5/O )/O ]/O ./O
Consider/O the/O potential/O for/O drug/O interactions/O prior/O to/O and/O during/O STRIBILD/O therapy/O ;/O review/O concomitant/O medications/O during/O STRIBILD/O therapy/O ;/O and/O monitor/O for/O the/O adverse/O reactions/O associated/O with/O the/O concomitant/O drugs/O ./O
5.6/O Bone/O Effects/O of/O Tenofovir/O DF/O Bone/O Mineral/O Density/O :/O In/O clinical/O trials/O in/O HIV-1/O infected/O adults/O ,/O tenofovir/O DF/O (/O a/O component/O of/O STRIBILD/O )/O was/O associated/O with/O slightly/O greater/O decreases/B-AdverseReaction in/I-AdverseReaction bone/I-AdverseReaction mineral/I-AdverseReaction density/I-AdverseReaction (/O BMD/O )/O and/O increases/B-AdverseReaction in/I-AdverseReaction biochemical/I-AdverseReaction markers/I-AdverseReaction of/I-AdverseReaction bone/I-AdverseReaction metabolism/I-AdverseReaction ,/O suggesting/O increased/B-AdverseReaction bone/I-AdverseReaction turnover/I-AdverseReaction relative/O to/O comparators/O ./O
Serum/O parathyroid/O hormone/O levels/O and/O 1.25/O Vitamin/O D/O levels/O were/O also/O higher/O in/O subjects/O receiving/O tenofovir/O DF/O ./O
For/O additional/O information/O ,/O see/O Adverse/O Reactions/O (/O 6.1/O )/O and/O consult/O the/O VIREAD/O prescribing/O information/O ./O
The/O effects/O of/O tenofovir/O DF/O -/O associated/O changes/O in/O BMD/O and/O biochemical/O markers/O on/O long/O -/O term/O bone/O health/O and/O future/O fracture/O risk/O are/O unknown/O ./O
Assessment/O of/O BMD/O should/O be/O considered/O for/O HIV-1/O infected/O patients/O who/O have/O a/O history/O of/O pathologic/O bone/O fracture/O or/O other/O risk/O factors/O for/O osteoporosis/O or/O bone/O loss/O ./O
Although/O the/O effect/O of/O supplementation/O with/O calcium/O and/O vitamin/O D/O was/O not/O studied/O ,/O such/O supplementation/O may/O be/O beneficial/O in/O all/O patients/O ./O
If/O bone/O abnormalities/O are/O suspected/O ,/O then/O appropriate/O consultation/O should/O be/O obtained/O ./O
Mineralization/O Defects/O :/O Cases/O of/O osteomalacia/B-AdverseReaction associated/O with/O proximal/B-AdverseReaction renal/I-AdverseReaction tubulopathy/I-AdverseReaction ,/O manifested/O as/O bone/B-AdverseReaction pain/I-AdverseReaction or/O pain/B-AdverseReaction in/I-AdverseReaction extremities/I-AdverseReaction and/O which/O may/B-Factor contribute/O to/O fractures/B-AdverseReaction ,/O have/O been/O reported/O in/O association/O with/O the/O use/O of/O tenofovir/O DF/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
Arthralgias/B-AdverseReaction and/O muscle/B-AdverseReaction pain/I-AdverseReaction or/O weakness/O have/O also/O been/O reported/O in/O cases/O of/O proximal/B-AdverseReaction renal/I-AdverseReaction tubulopathy/I-AdverseReaction ./O
Hypophosphatemia/O and/O osteomalacia/O secondary/O to/O proximal/O renal/O tubulopathy/O should/O be/O considered/O in/O patients/O at/O risk/O of/O renal/O dysfunction/O who/O present/O with/O persistent/O or/O worsening/O bone/O or/O muscle/O symptoms/O while/O receiving/O products/O containing/O tenofovir/O DF/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
5.7/O Fat/O Redistribution/O Redistribution/O accumulation/B-AdverseReaction of/I-AdverseReaction body/I-AdverseReaction fat/I-AdverseReaction including/O central/B-AdverseReaction obesity/I-AdverseReaction ,/O dorsocervical/B-AdverseReaction fat/I-AdverseReaction enlargement/I-AdverseReaction (/O buffalo/B-AdverseReaction hump/I-AdverseReaction )/O ,/O peripheral/O wasting/O ,/O facial/B-AdverseReaction wasting/I-AdverseReaction ,/O breast/B-AdverseReaction enlargement/I-AdverseReaction ,/O and/O "/O cushingoid/B-AdverseReaction appearance/I-AdverseReaction "/O have/O been/O observed/O in/O patients/O receiving/O antiretroviral/O therapy/O ./O
The/O mechanism/O and/O long/O -/O term/O consequences/O of/O these/O events/O are/O currently/O unknown/O ./O
A/O causal/O relationship/O has/O not/O been/O established/O ./O
5.8/O Immune/O Reconstitution/O Syndrome/O Immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction has/O been/O reported/O in/O patients/O treated/O with/O combination/O antiretroviral/O therapy/O ,/O including/O STRIBILD/O ./O
During/O the/O initial/O phase/O of/O combination/O antiretroviral/O treatment/O ,/O patients/O whose/O immune/O system/O responds/O may/B-Factor develop/O an/O inflammatory/O response/O to/O indolent/O or/O residual/B-AdverseReaction opportunistic/I-AdverseReaction infections/I-AdverseReaction [/O such/O as/O Mycobacterium/B-AdverseReaction avium/I-AdverseReaction infection/O ,/O cytomegalovirus/B-AdverseReaction ,/O Pneumocystis/B-AdverseReaction jirovecii/I-AdverseReaction pneumonia/O (/O PCP/B-AdverseReaction )/O ,/O or/O tuberculosis/B-AdverseReaction ]/O ,/O which/O may/O necessitate/O further/O evaluation/O and/O treatment/O ./O
Autoimmune/B-AdverseReaction disorders/I-AdverseReaction (/O such/O as/O Graves/B-AdverseReaction '/I-AdverseReaction disease/O ,/O polymyositis/B-AdverseReaction ,/O and/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O )/O have/O also/O been/O reported/O to/O occur/O in/O the/O setting/O of/O immune/O reconstitution/O ,/O however/O ,/O the/O time/O to/O onset/O is/O more/O variable/O ,/O and/O can/O occur/O many/O months/O after/O initiation/O of/O treatment/O ./O
